,CID,name,smiles,7.1 Drug Indication,8.1 Pharmacodynamics,8.2 MeSH Pharmacological Classification,"8.5 Absorption,Distribution and Excretion",8.6 Metabolism/Metabolites,8.7 Biological Half-Life
0,70001,CID 70001,C1=CC(=CC=C1O)S(=O)(=O)[O-].[Na+],,,,,,
1,70002,"Silane, trichloro(4-chlorophenyl)-",C1=CC(=CC=C1[Si](Cl)(Cl)Cl)Cl,,,,,,
2,70003,1-Benzosuberone,C1CCC(=O)C2=CC=CC=C2C1,,,,,,
3,70004,1-Vinylnaphthalene,C=CC1=CC=CC2=CC=CC=C21,,,,,,
4,70005,"4,6-Dimethylquinoline",CC1=CC2=C(C=CN=C2C=C1)C,,,,,,
5,70006,5-Amino-1-phenylpyrazole,C1=CC=C(C=C1)N2C(=CC=N2)N,,,,,,
6,70007,"1,2-Dibromotetrafluorobenzene",C1(=C(C(=C(C(=C1F)Br)Br)F)F)F,,,,,,
7,70008,Iodopentafluorobenzene,C1(=C(C(=C(C(=C1F)F)I)F)F)F,,,,,,
8,70009,"2,4-Dibromo-6-nitroaniline",C1=C(C=C(C(=C1[N+](=O)[O-])N)Br)Br,,,,,,
9,70010,CID 70010,C1=CC=C(C(=C1)C(=O)O)C(=O)[O-].[Na+],,,,,,
10,70011,"3H-1,2-Dithiol-3-one, 5-phenyl-",C1=CC=C(C=C1)C2=CC(=O)SS2,,,,,,
11,70012,4-Methyl-2-phenyl-1H-imidazole,CC1=CN=C(N1)C2=CC=CC=C2,,,,,,
12,70013,1-(1-Cyclopropylvinyl)-4-fluorobenzene,C=C(C1CC1)C2=CC=C(C=C2)F,,,,,,
13,70014,Sodium 3-nitrobenzoate,C1=CC(=CC(=C1)[N+](=O)[O-])C(=O)[O-].[Na+],,,,,,
14,70015,4-(Trifluoromethoxy)phenol,C1=CC(=CC=C1O)OC(F)(F)F,,,,,,
15,70016,"2',4'-Dimethoxyacetophenone",CC(=O)C1=C(C=C(C=C1)OC)OC,,,,,,
16,70017,Diphenylphosphine,C1=CC=C(C=C1)PC2=CC=CC=C2,,,,,,
17,70018,4-(Trifluoromethyl)benzenesulfonamide,C1=CC(=CC=C1C(F)(F)F)S(=O)(=O)N,,,,,,
18,70019,"2,4,6-Trimethoxybenzaldehyde",COC1=CC(=C(C(=C1)OC)C=O)OC,,,,,,
19,70020,"2',4'-Dimethoxypropiophenone",CCC(=O)C1=C(C=C(C=C1)OC)OC,,,,,,
20,70021,"4-(4-Nitrophenyl)-1,3-thiazolidine",C1C(NCS1)C2=CC=C(C=C2)[N+](=O)[O-],,,,,,
21,70022,CID 70022,C1=C(C=C(C(=O)C1=N)C(=O)O)N(O)O,,,,,,
22,70023,"3-(1,1,2,2-Tetrafluoroethoxy)aniline",C1=CC(=CC(=C1)OC(C(F)F)(F)F)N,,,,,,
23,70024,2-Methyl-3-(4-i-propylphenyl)prop-2-enal,CC(C)C1=CC=C(C=C1)C=C(C)C=O,,,,,,
24,70025,Dicyclohexylphosphinic acid,C1CCC(CC1)P(=O)(C2CCCCC2)O,,,,,,
25,70026,Pentafluorobenzenesulfonyl chloride,C1(=C(C(=C(C(=C1F)F)S(=O)(=O)Cl)F)F)F,,,,,,
26,70027,"(2,3,4,5,6-Pentafluorophenyl)acetyl chloride",C(C1=C(C(=C(C(=C1F)F)F)F)F)C(=O)Cl,,,,,,
27,70028,9-Diazofluorene,C1=CC=C2C(=C1)C3=CC=CC=C3C2=[N+]=[N-],,,,,,
28,70029,"10,11-Dihydro-5H-dibenzo[a,d]cycloheptene",C1CC2=CC=CC=C2CC3=CC=CC=C31,,,,,,
29,70030,2-Phenylbenzoxazole,C1=CC=C(C=C1)C2=NC3=CC=CC=C3O2,,,,,,
30,70031,CID 70031,C1=CC2=C(C=CC(=C2)S(=O)(=O)[O-])C=C1O.[K+],,,,,,
31,70032,5-(4-Methylphenyl)-5-oxopentanoic acid,CC1=CC=C(C=C1)C(=O)CCCC(=O)O,,,,,,
32,70033,"Propiophenone, 3-(1-pyrrolidinyl)-, hydrochloride",C1CCN(C1)CCC(=O)C2=CC=CC=C2.Cl,,,,,,
33,70034,1-Phenyl-3-(pyrrolidin-1-yl)propan-1-one,C1CCN(C1)CCC(=O)C2=CC=CC=C2,,,,,,
34,70035,m-(Benzyloxy)toluene,CC1=CC(=CC=C1)OCC2=CC=CC=C2,,,,,,
35,70036,Benzyl p-tolyl ether,CC1=CC=C(C=C1)OCC2=CC=CC=C2,,,,,,
36,70037,"2',4',6'-Trimethoxypropiophenone",CCC(=O)C1=C(C=C(C=C1OC)OC)OC,,,,,,
37,70038,"2,2'-Dihydroxybenzophenone",C1=CC=C(C(=C1)C(=O)C2=CC=CC=C2O)O,,,,,,
38,70039,"Benzoxazole, 2-(4-methylphenyl)-",CC1=CC=C(C=C1)C2=NC3=CC=CC=C3O2,,,,,,
39,70040,2-Phenethylbenzyl alcohol,C1=CC=C(C=C1)CCC2=CC=CC=C2CO,,,,,,
40,70041,o-(Benzyloxy)anisole,COC1=CC=CC=C1OCC2=CC=CC=C2,,,,,,
41,70042,4-Benzyloxybenzyl chloride,C1=CC=C(C=C1)COC2=CC=C(C=C2)CCl,,,,,,
42,70043,4-Benzyloxybenzyl alcohol,C1=CC=C(C=C1)COC2=CC=C(C=C2)CO,,,,,,
43,70044,"Phenol, 2-[1-(4-hydroxyphenyl)-1-methylethyl]-",CC(C)(C1=CC=C(C=C1)O)C2=CC=CC=C2O,,,,,,
44,70045,"N,N-diethyl-2,4-dinitroaniline",CCN(CC)C1=C(C=C(C=C1)[N+](=O)[O-])[N+](=O)[O-],,,,,,
45,70046,4-Fluorosulfonyl-1-hydroxy-2-naphthoic acid,C1=CC=C2C(=C1)C(=CC(=C2O)C(=O)O)S(=O)(=O)F,,,,,,
46,70047,"Benzoxazole, 2-(4-nitrophenyl)-",C1=CC=C2C(=C1)N=C(O2)C3=CC=C(C=C3)[N+](=O)[O-],,,,,,
47,70048,1-Benzhydrylpiperazine,C1CN(CCN1)C(C2=CC=CC=C2)C3=CC=CC=C3,,,,,['1-Benzhydrylpiperazine is a known human metabolite of cinnarizine.'],
48,70049,"1,3-Naphthalenedisulfonic acid, 7-amino-, disodium salt",C1=CC(=CC2=C(C=C(C=C21)S(=O)(=O)[O-])S(=O)(=O)[O-])N.[Na+].[Na+],,,,,,
49,70050,"Dipotassium 7-hydroxynaphthalene-1,3-disulphonate",C1=CC(=CC2=C(C=C(C=C21)S(=O)(=O)[O-])S(=O)(=O)[O-])O.[K+].[K+],,,,,,
50,70051,"1,3-Naphthalenedisulfonic acid, 7-hydroxy-, disodium salt",C1=CC(=CC2=C(C=C(C=C21)S(=O)(=O)[O-])S(=O)(=O)[O-])O.[Na+].[Na+],,,,,,
51,70052,"2-(4-Methoxyphenyl)-5-phenyl-1,3,4-oxadiazole",COC1=CC=C(C=C1)C2=NN=C(O2)C3=CC=CC=C3,,,,,,
52,70053,"4,4'-(1,4-Cyclohexanediyl)bisphenol",C1CC(CCC1C2=CC=C(C=C2)O)C3=CC=C(C=C3)O,,,,,,
53,70054,"2-[2-Chloro-4-(hydroxyimino)-5-methylcyclohexa-2,5-dien-1-ylidene]-2-(4-chlorophenyl)acetonitrile",CC1=CC(=C(C#N)C2=CC=C(C=C2)Cl)C(=CC1=NO)Cl,,,,,,
54,70055,"2,5-Diphenyl-1,4-benzoquinone",C1=CC=C(C=C1)C2=CC(=O)C(=CC2=O)C3=CC=CC=C3,,,,,,
55,70056,4'-Methoxy-3-(trifluoromethyl)benzophenone,COC1=CC=C(C=C1)C(=O)C2=CC(=CC=C2)C(F)(F)F,,,,,,
56,70057,"Benzo[e][1]benzothiopyrano[4,3-b]indole",C1=CC=C2C(=C1)C=CC3=C2C4=CSC5=CC=CC=C5C4=N3,,,,,,
57,70058,2-(1-Naphthyl)-5-phenyloxazole,C1=CC=C(C=C1)C2=CN=C(O2)C3=CC=CC4=CC=CC=C43,,,,,,
58,70059,"2,5-Bis(4-methoxyphenyl)-1,3,4-oxadiazole",COC1=CC=C(C=C1)C2=NN=C(O2)C3=CC=C(C=C3)OC,,,,,,
59,70060,"Butanamide, N-(4-amino-2-hydroxyphenyl)-2,2,3,3,4,4,4-heptafluoro-",C1=CC(=C(C=C1N)O)NC(=O)C(C(C(F)(F)F)(F)F)(F)F,,,,,,
60,70061,(4-Methoxyphenyl)diphenylmethanol,COC1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3)O,,,,,,
61,70062,"2-(2-(3,4-Dihydro-6-methoxy-1(2H)-naphthylidene)ethyl)-2-ethylcyclopentane-1,3-dione",CCC1(C(=O)CCC1=O)CC=C2CCCC3=C2C=CC(=C3)OC,,,,,,
62,70063,"Phenol, 2,2'-thiobis[4-chloro-6-nitro-",C1=C(C=C(C(=C1[N+](=O)[O-])O)SC2=CC(=CC(=C2O)[N+](=O)[O-])Cl)Cl,,,,,,
63,70064,"5-(1,1'-Biphenyl)-4-yl-2-phenyloxazole",C1=CC=C(C=C1)C2=CC=C(C=C2)C3=CN=C(O3)C4=CC=CC=C4,,,,,,
64,70065,"2-(4-Biphenylyl)-5-phenyl-1,3,4-oxadiazole",C1=CC=C(C=C1)C2=CC=C(C=C2)C3=NN=C(O3)C4=CC=CC=C4,,,,,,
65,70066,Guaiapate,COC1=CC=CC=C1OCCOCCOCCN2CCCCC2,,,,,,
66,70067,"1,5-Anthracenedisulfonic acid, 9,10-dihydro-9,10-dioxo-, disodium salt",C1=CC2=C(C(=C1)S(=O)(=O)[O-])C(=O)C3=C(C2=O)C(=CC=C3)S(=O)(=O)[O-].[Na+].[Na+],,,,,,
67,70068,Decafluorobenzophenone,C1(=C(C(=C(C(=C1F)F)F)F)F)C(=O)C2=C(C(=C(C(=C2F)F)F)F)F,,,,,,
68,70069,"2,7-Anthracenedisulfonic acid, 9,10-dihydro-9,10-dioxo-, disodium salt",C1=CC2=C(C=C1S(=O)(=O)[O-])C(=O)C3=C(C2=O)C=CC(=C3)S(=O)(=O)[O-].[Na+].[Na+],,,,,,
69,70070,"Anthraquinone-2,6-disulfonic acid disodium salt",C1=CC2=C(C=C1S(=O)(=O)[O-])C(=O)C3=C(C2=O)C=C(C=C3)S(=O)(=O)[O-].[Na+].[Na+],,,,,,
70,70071,Tris(4-methoxyphenyl)phosphine,COC1=CC=C(C=C1)P(C2=CC=C(C=C2)OC)C3=CC=C(C=C3)OC,,,,,,
71,70072,"2,4,6-Tris(pentafluoroethyl)-1,3,5-triazine",C1(=NC(=NC(=N1)C(C(F)(F)F)(F)F)C(C(F)(F)F)(F)F)C(C(F)(F)F)(F)F,,,,,,
72,70073,(Benzoylmethylene)triphenylphosphorane,C1=CC=C(C=C1)C(=O)C=P(C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
73,70074,Tris(p-tert-amylphenyl) phosphite,CCC(C)(C)C1=CC=C(C=C1)OP(OC2=CC=C(C=C2)C(C)(C)CC)OC3=CC=C(C=C3)C(C)(C)CC,,,,,,
74,70075,Nitrosomethane,CN=O,,,,,,
75,70076,Iodine trichloride,ClI(Cl)Cl,,,,,,
76,70077,CID 70077,CC(C)(C)[O-].[K+],,,,,,
77,70078,CID 70078,CC(C)(C)[O-].[Na+],,,,,,
78,70079,Tetramethylgermane,C[Ge](C)(C)C,,,,,,
79,70080,"Sulfur, ethenylpentafluoro-",C=CS(F)(F)(F)(F)F,,,,,,
80,70081,"1,1,1,2,2,3,4,4,5,5,5-Undecafluoro-3-(trifluoromethyl)pentane",C(C(C(F)(F)F)(F)F)(C(C(F)(F)F)(F)F)(C(F)(F)F)F,,,,,,
81,70082,"1,1,1,2,3,3,4,4,5,5,6,6,7,7,8,8-Hexadecafluoro-8-iodo-2-(trifluoromethyl)octane",C(C(C(C(C(C(C(F)(F)I)(F)F)(F)F)(F)F)(F)F)(F)F)(C(F)(F)F)(C(F)(F)F)F,,,,,,
82,70083,2-(Perfluorodecyl)ethanol,C(CO)C(C(C(C(C(C(C(C(C(C(F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F,,,,,,
83,70084,Disodium tetrahydroxysuccinate,C(=O)(C(C(C(=O)[O-])(O)O)(O)O)[O-].[Na+].[Na+],,,,,,
84,70085,Diethyl (trichloromethyl)phosphonate,CCOP(=O)(C(Cl)(Cl)Cl)OCC,,,,,,
85,70086,Tetrapentylammonium bromide,CCCCC[N+](CCCCC)(CCCCC)CCCCC.[Br-],,,,,,
86,70087,Dimethyl bromomalonate,COC(=O)C(C(=O)OC)Br,,,,,,
87,70088,"3,6,9,12-Tetraazatetradecanedioic acid, 3,6,9,12-tetrakis(carboxymethyl)-",C(CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O)N(CCN(CC(=O)O)CC(=O)O)CC(=O)O,,,['Chemicals that bind to and remove ions from solutions. Many chelating agents function through the formation of COORDINATION COMPLEXES with METALS. (See all compounds classified as Chelating Agents.)'],,,
88,70089,CID 70089,C(CCCBr)CCC(=NCCN=C(CCCCCCBr)S)S,,,,,,
89,70090,Phosphorisocyanatidic dichloride,C(=NP(=O)(Cl)Cl)=O,,,,,,
90,70091,tert-Butyl carbazate,CC(C)(C)OC(=O)NN,,,,,,
91,70092,"3,3-Dimethylallyl bromide",CC(=CCBr)C,,,,,,
92,70093,Ethyl dithioacetate,CCSC(=S)C,,,,,,
93,70094,"Silane, trichloroheptyl-",CCCCCCC[Si](Cl)(Cl)Cl,,,,,,
94,70095,Octadecanedioic acid,C(CCCCCCCCC(=O)O)CCCCCCCC(=O)O,,,,,,
95,70096,"2,2'-Thiobis(ethylamine)",C(CSCCN)N,,,,,,
96,70097,"N,N'-Diacetylethylenediamine",CC(=O)NCCNC(=O)C,,,,,,
97,70098,N-(2-Aminoethyl)stearamide,CCCCCCCCCCCCCCCCCC(=O)NCCN,,,,,,
98,70099,"1,7-Octadiyne",C#CCCCCC#C,,,,,,
99,70100,7-Octyn-1-ol,C#CCCCCCCO,,,,,,
100,70101,Octyl-silane,CCCCCCCC[SiH3],,,,,,
101,70102,"1-Nonene, 9-chloro-",C=CCCCCCCCCl,,,,,,
102,70103,2-Methyl-1-pyrroline,CC1=NCCC1,,,,,,
103,70104,"2,3-Dihydro-1-methyl-1H-phosphole 1-oxide",CP1(=O)CCC=C1,,,,,,
104,70105,5-Chloro-1-methylimidazole,CN1C=NC=C1Cl,,,,,,
105,70106,Cyclopentanecarbaldehyde,C1CCC(C1)C=O,,,,,,
106,70107,"1,2-Dimethylpyridinium iodide",CC1=CC=CC=[N+]1C.[I-],,,,,,
107,70108,"1,2-Dimethylpyridin-1-ium",CC1=CC=CC=[N+]1C,,,,,,
108,70109,"5,5-Dimethyl-1,3-dioxane",CC1(COCOC1)C,,,,,,
109,70110,2-Bromo-4-chloroaniline,C1=CC(=C(C=C1Cl)Br)N,,,,,,
110,70111,"3,4,5-Trichloropyridazine",C1=C(C(=C(N=N1)Cl)Cl)Cl,,,,,,
111,70112,Cyclopropylbenzene,C1CC1C2=CC=CC=C2,,,,,,
112,70113,CID 70113,C1CCN(CC1)C(=S)[S-].[Na+],,,,,,
113,70114,1-Piperidinecarbodithioic acid,C1CCN(CC1)C(=S)S,,,,,,
114,70115,CID 70115,C1COCCN1C(=S)[S-].[Na+],,,,,,
115,70116,Morpholine-4-carbodithioic acid,C1COCCN1C(=S)S,,,,,,
116,70117,3-Chlorobenzyl alcohol,C1=CC(=CC(=C1)Cl)CO,,,,,,
117,70118,1-Chloro-4-ethynylbenzene,C#CC1=CC=C(C=C1)Cl,,,,,,
118,70119,4-Bromobenzyl alcohol,C1=CC(=CC=C1CO)Br,,,,,,
119,70120,6-Aminouracil,C1=C(NC(=O)NC1=O)N,,,,,,
120,70121,"1,3,2-Dioxaphosphorinane, 2,5,5-trimethyl-, 2-oxide",CC1(COP(=O)(OC1)C)C,,,,,,
121,70122,"1,3-Dimethyluracil",CN1C=CC(=O)N(C1=O)C,,,,,,
122,70123,CID 70123,C=C1C(CCC1=O)C(=O)[O-].[Na+],,,,,,
123,70124,"Cyclopentanecarboxylic acid, 2-methylene-3-oxo-",C=C1C(CCC1=O)C(=O)O,,,,,,
124,70125,Azepane-1-carbodithioic acid,C1CCCN(CC1)C(=S)S,,,,,,
125,70126,"3,5-Dimethylanisole",CC1=CC(=CC(=C1)OC)C,,,,,,
126,70127,4-(Chloromethyl)benzonitrile,C1=CC(=CC=C1CCl)C#N,,,,,,
127,70128,4-(Methylthio)benzyl chloride,CSC1=CC=C(C=C1)CCl,,,,,,
128,70129,4-Methoxybenzonitrile,COC1=CC=C(C=C1)C#N,,,,,,
129,70130,"1,3-Dimethylindole",CC1=CN(C2=CC=CC=C12)C,,,,,,
130,70131,"2,6-Dichloro-4-methylnicotinonitrile",CC1=CC(=NC(=C1C#N)Cl)Cl,,,,,,
131,70132,4-Bromo-2-nitroaniline,C1=CC(=C(C=C1Br)[N+](=O)[O-])N,,,,,,
132,70133,4-Hydroxy-2-methylacetophenone,CC1=C(C=CC(=C1)O)C(=O)C,,,,,,
133,70134,D-(-)-alpha-Phenylglycine,C1=CC=C(C=C1)[C@H](C(=O)O)N,,,,,,
134,70135,4'-Hydroxy-3'-methylacetophenone,CC1=C(C=CC(=C1)C(=O)C)O,,,,,,
135,70136,4-(Chloromethyl)benzoyl chloride,C1=CC(=CC=C1CCl)C(=O)Cl,,,,,,
136,70137,5-Bromo-1H-indole-3-carbaldehyde,C1=CC2=C(C=C1Br)C(=CN2)C=O,,,,,,
137,70138,"7-tert-Butoxybicyclo(2.2.1)hepta-2,5-diene",CC(C)(C)OC1C2C=CC1C=C2,,,,,,
138,70139,Tetrachloro-m-xylene,CC1=C(C(=C(C(=C1Cl)Cl)Cl)C)Cl,,,,,,
139,70140,2-Hydroxy-3-methoxybenzoic acid,COC1=CC=CC(=C1O)C(=O)O,,,,,,
140,70141,"2,5-Dimethylphenyl acetate",CC1=CC(=C(C=C1)C)OC(=O)C,,,,,,
141,70142,(4-(Methylsulfonyl)phenyl)hydrazine,CS(=O)(=O)C1=CC=C(C=C1)NN,,,,,,
142,70143,N-(2-Phenylethyl)acetamide,CC(=O)NCCC1=CC=CC=C1,,,,,,
143,70144,4-Acetoxybenzaldehyde,CC(=O)OC1=CC=C(C=C1)C=O,,,,,,
144,70145,"1,2,3-Trimethylnaphthalene",CC1=CC2=CC=CC=C2C(=C1C)C,,,,,,
145,70146,1-Naphthoyl chloride,C1=CC=C2C(=C1)C=CC=C2C(=O)Cl,,,,,,
146,70147,"Cyclohexylamine, N,N-bis(2-chloroethyl)-, hydrochloride",C1CCC(CC1)N(CCCl)CCCl.Cl,,,,,,
147,70148,"Cyclohexylamine, N,N-bis(2-chloroethyl)-",C1CCC(CC1)N(CCCl)CCCl,,,,,,
148,70149,2-Methoxy-p-tolyl acetate,CC1=CC(=C(C=C1)OC(=O)C)OC,,,,,,
149,70150,"4-tert-Butyl-2,6-dimethylphenol",CC1=CC(=CC(=C1O)C)C(C)(C)C,,,,,,
150,70151,Dipiperidinomethane,C1CCN(CC1)CN2CCCCC2,,,,,,
151,70152,CID 70152,CCOC1=CC=C(C=C1)N=C(N)S,,,,,,
152,70153,2-Octylthiophene,CCCCCCCCC1=CC=CS1,,,,,,
153,70154,Pentafluoronitrobenzene,C1(=C(C(=C(C(=C1F)F)F)F)F)[N+](=O)[O-],,,,,,
154,70155,1-Methyl-4-nitronaphthalene,CC1=CC=C(C2=CC=CC=C12)[N+](=O)[O-],,,,,,
155,70156,3-(4-Nitrophenyl)prop-2-enoic acid,C1=CC(=CC=C1C=CC(=O)O)[N+](=O)[O-],,,,,,
156,70157,"Pyridinium, 1,1'-(1,2-ethanediyl)bis-, dibromide",C1=CC=[N+](C=C1)CC[N+]2=CC=CC=C2.[Br-].[Br-],,,,,,
157,70158,Aqxssjvlmrllqd-uhfffaoysa-,C1=CC=[N+](C=C1)CC[N+]2=CC=CC=C2,,,,,,
158,70159,N-Benzylacetoacetamide,CC(=O)CC(=O)NCC1=CC=CC=C1,,,,,,
159,70160,N-(3-Hydroxypropyl)phthalimide,C1=CC=C2C(=C1)C(=O)N(C2=O)CCCO,,,,,,
160,70161,3-Methoxy-2-naphthoic acid,COC1=CC2=CC=CC=C2C=C1C(=O)O,,,,,,
161,70162,3-(tert-Butyl)-1-methylnaphthalene,CC1=CC(=CC2=CC=CC=C12)C(C)(C)C,,,,,,
162,70163,Methyl 3-hydroxy-2-naphthoate,COC(=O)C1=CC2=CC=CC=C2C=C1O,,,,,,
163,70164,"Methyl 4-hydroxy-3,5-dimethoxybenzoate",COC1=CC(=CC(=C1O)OC)C(=O)OC,,,,,,
164,70165,Cyclododecanecarboxylic acid,C1CCCCCC(CCCCC1)C(=O)O,,,,,,
165,70166,"1,3-Propanediol, 2-(o-chlorophenoxymethyl)-2-hydroxymethyl-",C1=CC=C(C(=C1)OCC(CO)(CO)CO)Cl,,,,,,
166,70167,"1,3,2-Dioxaphosphorinane, 5,5-dimethyl-2-phenoxy-, 2-oxide",CC1(COP(=O)(OC1)OC2=CC=CC=C2)C,,,,,,
167,70168,"Sodium 2,4-dinitrobenzenesulfonate",C1=CC(=C(C=C1[N+](=O)[O-])[N+](=O)[O-])S(=O)(=O)[O-].[Na+],,,,,,
168,70169,"5,11-Dihydropyrido[2,3-b][1,4]benzodiazepin-6-one",C1=CC=C2C(=C1)C(=O)NC3=C(N2)N=CC=C3,,,,,,
169,70170,N-(4-Ethoxy-2-nitrophenyl)acetamide,CCOC1=CC(=C(C=C1)NC(=O)C)[N+](=O)[O-],,,,,,
170,70171,3-Piperidinopropiophenone hydrochloride,C1CCN(CC1)CCC(=O)C2=CC=CC=C2.Cl,,,,,,
171,70172,3-Piperidinopropiophenone,C1CCN(CC1)CCC(=O)C2=CC=CC=C2,,,,,,
172,70173,CID 70173,C1=CC=C(C=C1)NC(=NC2=CC=CC=N2)S,,,,,,
173,70174,"1,4-Diphenylbutadiyne",C1=CC=C(C=C1)C#CC#CC2=CC=CC=C2,,,,,,
174,70175,"2,2-Diphenyltetrahydrofuran",C1CC(OC1)(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
175,70176,"2-Propenal 2,4-Dinitrophenylhydrazone",C=CC=NNC1=C(C=C(C=C1)[N+](=O)[O-])[N+](=O)[O-],,,,,,
176,70177,Declopramide,CCN(CC)CCNC(=O)C1=CC(=C(C=C1)N)Cl,['Investigated for use/treatment in colorectal cancer and inflammatory bowel disease.'],,,,,
177,70178,"1,3-Diazaspiro(4.5)decane-2,4-dione, 3-(morpholinomethyl)-",C1CCC2(CC1)C(=O)N(C(=O)N2)CN3CCOCC3,,,,,,
178,70179,"1,3-Butanedione, 4,4,4-trifluoro-1-(2-naphthalenyl)-",C1=CC=C2C=C(C=CC2=C1)C(=O)CC(=O)C(F)(F)F,,,,,,
179,70180,"2,5-Bis(1,1,3,3-tetramethylbutyl)hydroquinone",CC(C)(C)CC(C)(C)C1=CC(=C(C=C1O)C(C)(C)CC(C)(C)C)O,,,,,,
180,70181,"1,8-Anthracenedisulfonic acid, 9,10-dihydro-9,10-dioxo-, disodium salt",C1=CC2=C(C(=C1)S(=O)(=O)[O-])C(=O)C3=C(C2=O)C=CC=C3S(=O)(=O)[O-].[Na+].[Na+],,,,,,
181,70182,"2,5-Di(1-naphthyl)-1,3,4-oxadiazole",C1=CC=C2C(=C1)C=CC=C2C3=NN=C(O3)C4=CC=CC5=CC=CC=C54,,,,,,
182,70183,2-(Triphenylphosphoranylidene)succinic anhydride,C1C(=P(C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4)C(=O)OC1=O,,,,,,
183,70184,"6,7-Dibenzyloxycoumarin",C1=CC=C(C=C1)COC2=C(C=C3C(=C2)C=CC(=O)O3)OCC4=CC=CC=C4,,,,,,
184,70185,"2,4,6-Tris(heptafluoropropyl)-1,3,5-triazine",C1(=NC(=NC(=N1)C(C(C(F)(F)F)(F)F)(F)F)C(C(C(F)(F)F)(F)F)(F)F)C(C(C(F)(F)F)(F)F)(F)F,,,,,,
185,70186,"5,10,15,20-Tetraphenyl-21,22-dihydroporphyrin",C1=CC=C(C=C1)C2=C3C=CC(=C(C4=CC=C(N4)C(=C5C=CC(=N5)C(=C6C=CC2=N6)C7=CC=CC=C7)C8=CC=CC=C8)C9=CC=CC=C9)N3,,,,,,
186,70187,CID 70187,[Li+].[CH3-],,,,,,
187,70188,CID 70188,[Li+].C=[CH-],,,,,,
188,70189,CID 70189,CC[O-].[K+],,,,,,
189,70190,"2-Propanamine, N,N,2-trimethyl-",CC(C)(C)N(C)C,,,,,,
190,70191,"N,N-Dimethylmethanesulfonamide",CN(C)S(=O)(=O)C,,,,,,
191,70192,"2-Chloro-2,3,3-trimethylbutane",CC(C)(C)C(C)(C)Cl,,,,,,
192,70193,"Phosphorodiamidothioic fluoride, tetramethyl-",CN(C)P(=S)(N(C)C)F,,,,,,
193,70194,"2,2-Dinitropropanol",CC(CO)([N+](=O)[O-])[N+](=O)[O-],,,,,,
194,70195,"1,1,1-Triethoxypentane",CCCCC(OCC)(OCC)OCC,,,,,,
195,70196,"Phosphoric acid, triisoamyl ester",CC(C)CCOP(=O)(OCCC(C)C)OCCC(C)C,,,,,,
196,70197,2-Bromoacrylonitrile,C=C(C#N)Br,,,,,,
197,70198,2-Chloroacrylonitrile,C=C(C#N)Cl,,,,,,
198,70199,Heptamethyldisilazane,CN([Si](C)(C)C)[Si](C)(C)C,,,,,,
199,70200,"N,N-Dimethyl-2-butanamine",CCC(C)N(C)C,,,,,,
200,70201,"1,1-Diisopropylhydrazine",CC(C)N(C(C)C)N,,,,,,
201,70202,"2,2-Dichloro-N,N-diethylacetamide",CCN(CC)C(=O)C(Cl)Cl,,,,,,
202,70203,2-Ethylacrolein,CCC(=C)C=O,,,,,,
203,70204,"1,4-Pentadien-3-ol",C=CC(C=C)O,,,,,,
204,70205,Methyl glyoxylate,COC(=O)C=O,,,,,,
205,70206,CID 70206,CCCCCOC(=O)CC(C(=O)OCCCCC)S(=O)(=O)[O-].[Na+],,,,,,
206,70207,Dipentyl sulfosuccinate,CCCCCOC(=O)CC(C(=O)OCCCCC)S(=O)(=O)O,,,,,,
207,70208,N-methylolmethacrylamide,CC(=C)C(=O)NCO,,,,,,
208,70209,2-Methyloctan-3-one,CCCCCC(=O)C(C)C,,,,,,
209,70210,Tripropyl phosphite,CCCOP(OCCC)OCCC,,,,,,
210,70211,Ethyl glyoxylate,CCOC(=O)C=O,,,,,,
211,70212,"2-Butenedioic acid (2Z)-, mono(1-methylethyl) ester",CC(C)OC(=O)C=CC(=O)O,,,,,,
212,70213,Diisopropyl succinate,CC(C)OC(=O)CCC(=O)OC(C)C,,,,,,
213,70214,Diisobutyl succinate,CC(C)COC(=O)CCC(=O)OCC(C)C,,,,,,
214,70215,Diallyl succinate,C=CCOC(=O)CCC(=O)OCC=C,,,,,,
215,70216,"Diethyl 2,2'-thiodiacetate",CCOC(=O)CSCC(=O)OCC,,,,,,
216,70217,Methyl 4-hydroxybutanoate,COC(=O)CCCO,,,,,,
217,70218,N-(2-(Dimethylamino)ethyl)acrylamide,CN(C)CCNC(=O)C=C,,,,,,
218,70219,Sebacic dihydrazide,C(CCCCC(=O)NN)CCCC(=O)NN,,,,,,
219,70220,tert-Butyl vinyl ether,CC(C)(C)OC=C,,,,,,
220,70221,"Phosphorodiamidothioic fluoride, N,N'-diisopropyl-",CC(C)NP(=S)(NC(C)C)F,,,,,,
221,70222,"S-(2-((1,1-Dimethyl-2-(methylamino)-2-oxoethyl)thio)ethyl) O,O-dimethyl phosphorodithioate",CC(C)(C(=O)NC)SCCSP(=S)(OC)OC,,,,,,
222,70223,2-Aminoethyl hydrogen sulfate,C(COS(=O)(=O)O)N,,,"['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)', 'Agents that promote the excretion of urine through their effects on kidney function. (See all compounds classified as Diuretics.)']",,,
223,70224,2-tert-Butylaminoethanethiol hydrogen sulfate (ester),CC(C)(C)NCCSS(=O)(=O)O,,,,,,
224,70225,4-Bromobutyryl chloride,C(CC(=O)Cl)CBr,,,,,,
225,70226,CID 70226,CCCN=C(N)S,,,,,,
226,70227,"Diazene, bis(1,1-dimethylethyl)-",CC(C)(C)N=NC(C)(C)C,,,,,,
227,70228,Bis(trifluoromethyl) peroxide,C(OOC(F)(F)F)(F)(F)F,,,,,,
228,70229,2-Butoxyethyl hydrogensulphate,CCCCOCCOS(=O)(=O)O,,,,,,
229,70230,CID 70230,C(#CC(=O)[O-])C(=O)O.[K+],,,,,,
230,70231,2-Chloroethyl thiocyanate,C(CCl)SC#N,,,,,,
231,70232,"4,4'-Oxydibutyl diacetate",CC(=O)OCCCCOCCCCOC(=O)C,,,,,,
232,70233,6-Chloro-1-hexene,C=CCCCCCl,,,,,,
233,70234,5-Hexyn-1-ol,C#CCCCCO,,,,,,
234,70235,Hex-4-yn-1-ol,CC#CCCCO,,,,,,
235,70236,"1,5-Pentanedithiol",C(CCS)CCS,,,,,,
236,70237,"Ethanethiol, 2-isopropylamino-, hydrogen sulfate (ester)",CC(C)NCCSS(=O)(=O)O,,,,,,
237,70238,"Ethanethiol, 2-undecylamino-, hydrogen sulfate (ester)",CCCCCCCCCCCNCCSS(=O)(=O)O,,,,,,
238,70239,"Ethanethiol, 2-dodecylamino-, hydrogen sulfate (ester)",CCCCCCCCCCCCNCCSS(=O)(=O)O,,,,,,
239,70240,"Thiosulfuric acid, S-(2-(tridecylamino)ethyl) ester",CCCCCCCCCCCCCNCCSS(=O)(=O)O,,,,,,
240,70241,"Ethanethiol, 2-tetradecylamino-, hydrogen sulfate (ester)",CCCCCCCCCCCCCCNCCSS(=O)(=O)O,,,,,,
241,70242,"Ethanethiol, 2-pentadecylamino-, hydrogen sulfate (ester)",CCCCCCCCCCCCCCCNCCSS(=O)(=O)O,,,,,,
242,70243,"Ethanethiol, 2-hexadecylamino-, hydrogen sulfate (ester)",CCCCCCCCCCCCCCCCNCCSS(=O)(=O)O,,,,,,
243,70244,"Ethanethiol, 2-heptadecylamino-, hydrogen sulfate (ester)",CCCCCCCCCCCCCCCCCNCCSS(=O)(=O)O,,,,,,
244,70245,"Thiosulfuric acid, S-(2-(octadecylamino)ethyl) ester",CCCCCCCCCCCCCCCCCCNCCSS(=O)(=O)O,,,,,,
245,70246,7-Formylheptanoic acid,C(CCCC(=O)O)CCC=O,,,,,,
246,70247,1-Methoxyoctane,CCCCCCCCOC,,,,,,
247,70248,"1,8-Diamino-3,6-dioxaoctane",C(COCCOCCN)N,,,,,,
248,70249,1-(Vinyloxy)octane,CCCCCCCCOC=C,,,,,,
249,70250,"Ethanamine, 2,2'-[oxybis(2,1-ethanediyloxy)]bis-",C(COCCOCCOCCN)N,,,,,,
250,70251,"3,6,9,12-Tetraoxapentacosan-1-ol",CCCCCCCCCCCCCOCCOCCOCCOCCO,,,,,,
251,70252,Chlorocyclopentane,C1CCC(C1)Cl,,,,,,
252,70253,CID 70253,C1=NC(=O)NN1,,,,,,
253,70254,"1,3-Dithiole-2-thione",C1=CSC(=S)S1,,,,,,
254,70255,1-Methylpyrazole,CN1C=CC=N1,,,,,,
255,70256,"2,5-Dihydro-1-methyl-1H-phosphole 1-oxide",CP1(=O)CC=CC1,,,,,,
256,70257,Butylcyclopropane,CCCCC1CC1,,,,,,
257,70258,"4-Cyclopentene-1,3-dione",C1C(=O)C=CC1=O,,,,,,
258,70259,"2,4-Dimethylimidazole",CC1=CN=C(N1)C,,,,,,
259,70260,"1,2,5-Trimethylpyrrole",CC1=CC=C(N1C)C,,,,,,
260,70261,N-Methylmaleimide,CN1C(=O)C=CC1=O,,,,,,
261,70262,2-Ethyl-4-methylimidazole,CCC1=NC=C(N1)C,,,,,,
262,70263,Ethynylcyclohexane,C#CC1CCCCC1,,,,,,
263,70264,1-Methoxycyclohexene,COC1=CCCCC1,,,,,,
264,70265,"5-Amino-1,2,4-triazin-3(2H)-one",C1=NNC(=O)N=C1N,,,,,,
265,70266,N-Acetyl-2-pyrrolidone,CC(=O)N1CCCC1=O,,,,,,
266,70267,2-(Aminomethyl)phenol,C1=CC=C(C(=C1)CN)O,,,,,,
267,70268,CID 70268,C1CN(C(=N1)S)CCO,,,,,,
268,70269,6-Azathymine,CC1=NNC(=O)NC1=O,,,,,,
269,70270,(2-Bromoethylidene)cyclohexane,C1CCC(=CCBr)CC1,,,,,,
270,70271,2-Cyclohexylideneethanol,C1CCC(=CCO)CC1,,,,,,
271,70272,4-Chloro-N-methylaniline,CNC1=CC=C(C=C1)Cl,,,,,,
272,70273,Cyclopentyl acetate,CC(=O)OC1CCCC1,,,,,,
273,70274,"2,4,6-Trichloroborazine",B1(NB(NB(N1)Cl)Cl)Cl,,,,,,
274,70275,7-Methylindole,CC1=C2C(=CC=C1)C=CN2,,,,,,
275,70276,o-Toluoyl chloride,CC1=CC=CC=C1C(=O)Cl,,,,,,
276,70277,3-Hydroxypicolinamide,C1=CC(=C(N=C1)C(=O)N)O,,,,,,
277,70278,"3-Ethylbenzene-1,2-diol",CCC1=C(C(=CC=C1)O)O,,,,,,
278,70279,"Purine, 2-methyl-",CC1=NC=C2C(=N1)N=CN2,,,,,,
279,70280,"3,5-Dimethyl-1H-pyrazole-1-carboxamide",CC1=CC(=NN1C(=O)N)C,,,,,,
280,70281,(1-Chloro-1-methylethyl)benzene,CC(C)(C1=CC=CC=C1)Cl,,,,,,
281,70282,6-Methyl-2-pyridinecarboxylic acid,CC1=NC(=CC=C1)C(=O)O,,,,,,
282,70283,6-Methylpyridine-2-ethanol,CC1=NC(=CC=C1)CCO,,,,,,
283,70284,2-(4-Methylpiperazin-1-yl)ethanamine,CN1CCN(CC1)CCN,,,,,,
284,70285,N-(ethylideneamino)aniline,CC=NNC1=CC=CC=C1,,,,,,
285,70286,3-(2-Furyl)propanoic acid,C1=COC(=C1)CCC(=O)O,,,,,,
286,70287,1-Phenylcyclopropanemethylamine,C1CC1(CN)C2=CC=CC=C2,,,,,,
287,70288,1-Phenylcyclopropanecarbonitrile,C1CC1(C#N)C2=CC=CC=C2,,,,,,
288,70289,Methyl cumyl ether,CC(C)(C1=CC=CC=C1)OC,,,,,,
289,70290,CID 70290,CN(C)C(=S)N1CCN=C1S,,,,,,
290,70291,"2,5-Cyclohexadiene-1,4-dione, 2,3,5-trimethyl-",CC1=CC(=O)C(=C(C1=O)C)C,,,,,,
291,70292,(1-Methyl-2-nitro-1h-imidazol-5-yl)methanol,CN1C(=CN=C1[N+](=O)[O-])CO,,,,,,
292,70293,"2-Phenyl-1,3-dioxolane",C1COC(O1)C2=CC=CC=C2,,,,,,
293,70294,"Morpholine, 4-(1-cyclopenten-1-yl)-",C1CC=C(C1)N2CCOCC2,,,,,,
294,70295,3-Chloropropiophenone,C1=CC=C(C=C1)C(=O)CCCl,,,,,,
295,70296,"2,4-Diethylphenol",CCC1=CC(=C(C=C1)O)CC,,,,,,
296,70297,3-Chloroperoxybenzoic acid,C1=CC(=CC(=C1)Cl)C(=O)OO,,,"['Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant and Hackh&apos;s Chemical Dictionary, 5th ed, p301, p499) (See all compounds classified as Indicators and Reagents.)', 'Electron-accepting molecules in chemical reactions in which electrons are transferred from one molecule to another (OXIDATION-REDUCTION). (See all compounds classified as Oxidants.)']",,,
297,70298,"2,4'-Dichloroacetophenone",C1=CC(=CC=C1C(=O)CCl)Cl,,,,,,
298,70299,p-Chloroperbenzoic acid,C1=CC(=CC=C1C(=O)OO)Cl,,,,,,
299,70300,"[(4,6-Diamino-1,3,5-triazin-2-yl)amino]methanol",C(NC1=NC(=NC(=N1)N)N)O,,,,,,
300,70301,2-Phenylacetohydrazide,C1=CC=C(C=C1)CC(=O)NN,,,,,,
301,70302,3-(Azepan-1-yl)propanenitrile,C1CCCN(CC1)CCC#N,,,,,,
302,70303,(Propoxymethyl)benzene,CCCOCC1=CC=CC=C1,,,,,,
303,70304,p-Tolyl chloroformate,CC1=CC=C(C=C1)OC(=O)Cl,,,,,,
304,70305,O-p-Tolyl chlorothioformate,CC1=CC=C(C=C1)OC(=S)Cl,,,,,,
305,70306,O-p-Chlorophenyl chlorothioformate,C1=CC(=CC=C1OC(=S)Cl)Cl,,,,,,
306,70307,"2-Hexyl-2-methyl-1,3-dioxolane",CCCCCCC1(OCCO1)C,,,,,,
307,70308,"2,2-Dimethylpropiophenone",CC(C)(C)C(=O)C1=CC=CC=C1,,,,,,
308,70309,"Indan-1,2,3-trione",C1=CC=C2C(=C1)C(=O)C(=O)C2=O,,,,,,
309,70310,8-Methoxyquinoline,COC1=CC=CC2=C1N=CC=C2,,,,,,
310,70311,2'-Hydroxy-5'-methylpropiophenone,CCC(=O)C1=C(C=CC(=C1)C)O,,,,,,
311,70312,"2',5'-Dihydroxypropiophenone",CCC(=O)C1=C(C=CC(=C1)O)O,,,,,,
312,70313,1H-Benzotriazole-1-ethanol,C1=CC=C2C(=C1)N=NN2CCO,,,,,,
313,70314,1-Chloro-3-(chloromethyl)-5-nitrobenzene,C1=C(C=C(C=C1[N+](=O)[O-])Cl)CCl,,,,,,
314,70315,1-Methylguanine,CN1C(=O)C2=C(N=CN2)N=C1N,,,,,,
315,70316,2-Methyl-1-phenyl-1-butanone,CCC(C)C(=O)C1=CC=CC=C1,,,,,,
316,70317,"1,3-Dimethyl-1-phenylurea",CNC(=O)N(C)C1=CC=CC=C1,,,,,,
317,70318,5-Phenylisoxazol-3-ol,C1=CC=C(C=C1)C2=CC(=O)NO2,,,,,,
318,70319,"1H-Imidazole, 4,5-dihydro-4-methyl-2-phenyl-",CC1CN=C(N1)C2=CC=CC=C2,,,,,,
319,70320,2-(Bromomethyl)naphthalene,C1=CC=C2C=C(C=CC2=C1)CBr,,,,,,
320,70321,4'-Chlorobutyrophenone,CCCC(=O)C1=CC=C(C=C1)Cl,,,,,,
321,70322,2-Acetylbenzimidazole,CC(=O)C1=NC2=CC=CC=C2N1,,,,,,
322,70323,2-Phenylcyclopropanecarboxylic acid,C1C(C1C(=O)O)C2=CC=CC=C2,,,,,,
323,70324,4-tert-Butylbenzaldehyde,CC(C)(C)C1=CC=C(C=C1)C=O,,,,,,
324,70325,p-Methoxyperbenzoic acid,COC1=CC=C(C=C1)C(=O)OO,,,,,,
325,70326,"Carbamic acid, (4-chlorophenyl)-, methyl ester",COC(=O)NC1=CC=C(C=C1)Cl,,,,,,
326,70327,Phenethyltrichlorosilane,C1=CC=C(C=C1)CC[Si](Cl)(Cl)Cl,,,,,,
327,70328,alpha-Isobutoxytoluene,CC(C)COCC1=CC=CC=C1,,,,,,
328,70329,(4-Methylphenoxy)acetic acid,CC1=CC=C(C=C1)OCC(=O)O,,,,,,
329,70330,CID 70330,N1P(=NP(N=P1(Cl)Cl)(Cl)Cl)(Cl)Cl,,,,,,
330,70331,CID 70331,CP(=O)(C)N=C1SCCCS1,,,,,,
331,70332,"1,3-Dioxolane-2-propanoic acid, 2-methyl-, ethyl ester",CCOC(=O)CCC1(OCCO1)C,,,,,,
332,70333,"4,6,8-Trimethylazulene",CC1=CC(=C2C=CC=C2C(=C1)C)C,,,,,,
333,70334,"4,5-Dichlorophthalic anhydride",C1=C2C(=CC(=C1Cl)Cl)C(=O)OC2=O,,,,,,
334,70335,3-Methyl-1-phenyl-1H-pyrazol-5-ol,CC1=CC(=O)N(N1)C2=CC=CC=C2,,,,,"['Edaravone has known human metabolites that include (2S,3S,4S,5R)-3,4,5-trihydroxy-6-(5-methyl-2-phenylpyrazol-3-yl)oxyoxane-2-carboxylic acid.']",
335,70336,S-(Thiobenzoyl)thioglycolic acid,C1=CC=C(C=C1)C(=S)SCC(=O)O,,,,,,
336,70337,Hexanophenone,CCCCCC(=O)C1=CC=CC=C1,,,,,,
337,70338,5-Chloro-1-phenylpentan-1-one,C1=CC=C(C=C1)C(=O)CCCCCl,,,,,,
338,70339,2-(Dimethylamino)benzothiazol-6-ol,CN(C)C1=NC2=C(S1)C=C(C=C2)O,,,,,,
339,70340,2-Nitro-p-cymene,CC1=C(C=C(C=C1)C(C)C)[N+](=O)[O-],,,,,,
340,70341,Ethyl 5-nitro-2-furoate,CCOC(=O)C1=CC=C(O1)[N+](=O)[O-],,,,,,
341,70342,4-Nitroperoxybenzoic acid,C1=CC(=CC=C1C(=O)OO)[N+](=O)[O-],,,,,,
342,70343,2-Methyl-2-phenoxypropanoic acid,CC(C)(C(=O)O)OC1=CC=CC=C1,,,,,,
343,70344,"Benzonitrile, 3-(((methylamino)carbonyl)oxy)-",CNC(=O)OC1=CC=CC(=C1)C#N,,,,,,
344,70345,"4-Amino-2,3,5,6-tetrafluorobenzoic acid",C1(=C(C(=C(C(=C1F)F)N)F)F)C(=O)O,,,,,,
345,70346,"1,3-Dimethyluric acid",CN1C2=C(C(=O)N(C1=O)C)NC(=O)N2,,,,,"['1,3-Dimethyluric acid is a known human metabolite of theophylline.']",
346,70347,"(2,4-Diaminopteridin-6-yl)methanol",C1=C(N=C2C(=NC(=NC2=N1)N)N)CO,,,,,,
347,70348,Methyldiphenylarsine,C[As](C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
348,70349,"2-Pyrazolin-5-one, 1-benzyl-3-methyl-",CC1=NN(C(=O)C1)CC2=CC=CC=C2,,,,,,
349,70350,Sodium 2-chloro-5-nitrobenzenesulfonate,C1=CC(=C(C=C1[N+](=O)[O-])S(=O)(=O)[O-])Cl.[Na+],,,,,,
350,70351,Carbonylcyanide 4-chlorophenylhydrazone,C1=CC(=CC=C1NN=C(C#N)C#N)Cl,,,['Chemical agents that increase the permeability of CELL MEMBRANES to PROTONS. (See all compounds classified as Proton Ionophores.)'],,,
351,70352,Benzyl phenyl ether,C1=CC=C(C=C1)COC2=CC=CC=C2,,,,,,
352,70353,Cyclohexanone phenylhydrazone,C1CCC(=NNC2=CC=CC=C2)CC1,,,,,,
353,70354,Oxacyclotridecan-2-one,C1CCCCCC(=O)OCCCCC1,,,,,,
354,70355,1-Hydroxycyclohexyl phenyl ketone,C1CCC(CC1)(C(=O)C2=CC=CC=C2)O,,,['Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. (See all compounds classified as Mutagens.)'],,,
355,70356,2-Methoxy-1-naphthoic acid,COC1=C(C2=CC=CC=C2C=C1)C(=O)O,,,,,,
356,70357,2-Biphenylcarboxylic acid,C1=CC=C(C=C1)C2=CC=CC=C2C(=O)O,,,,,,
357,70358,Methyl 1-hydroxy-2-naphthoate,COC(=O)C1=C(C2=CC=CC=C2C=C1)O,,,,,,
358,70359,"1,2,4-Triisopropylbenzene",CC(C)C1=CC(=C(C=C1)C(C)C)C(C)C,,,,,,
359,70360,"Phenoxathiin, 10-oxide",C1=CC=C2C(=C1)OC3=CC=CC=C3S2=O,,,,,,
360,70361,CID 70361,C1=C(N=C2C(=N1)NC(=NC2=O)N)C(=O)O,,,,,,
361,70362,"Morpholine, 4-(phenylthioacetyl)-",C1COCCN1C(=S)CC2=CC=CC=C2,,,,,,
362,70363,"3,7-Dinitro-1,3,5,7-tetraazabicyclo[3.3.1]nonane",C1N2CN(CN1CN(C2)[N+](=O)[O-])[N+](=O)[O-],,,,,,
363,70364,L-Tyrosine ethyl ester,CCOC(=O)[C@H](CC1=CC=C(C=C1)O)N,,,,,,
364,70365,1-Benzylpiperidin-4-one oxime,C1CN(CCC1=NO)CC2=CC=CC=C2,,,,,,
365,70366,Z-Gly-NH2,C1=CC=C(C=C1)COC(=O)NCC(=O)N,,,,,,
366,70367,"Ethanethiol, 2-benzylamino-, hydrogen sulfate (ester)",C1=CC=C(C=C1)CNCCSS(=O)(=O)O,,,,,,
367,70368,"1,1-Dimethoxycyclododecane",COC1(CCCCCCCCCCC1)OC,,,,,,
368,70369,"Phenoxathiin, 10,10-dioxide",C1=CC=C2C(=C1)OC3=CC=CC=C3S2(=O)=O,,,,,,
369,70370,"2,6-Di-tert-butyl-4-mercaptophenol",CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)S,,,,,,
370,70371,"1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carbaldehyde",CC1=C(C(=O)N(N1C)C2=CC=CC=C2)C=O,,,,,,
371,70372,"3,4,5-Trimethoxyphenylacetic acid",COC1=CC(=CC(=C1OC)OC)CC(=O)O,,,,,,
372,70373,2-Acetamido-4-nitrobenzoic acid,CC(=O)NC1=C(C=CC(=C1)[N+](=O)[O-])C(=O)O,,,,,,
373,70374,Morinamide,C1COCCN1CNC(=O)C2=NC=CN=C2,,,,,,
374,70375,2-Cyclooctylaminoethanethiol hydrogen sulfate (ester),C1CCCC(CCC1)NCCSS(=O)(=O)O,,,,,,
375,70376,2-(2-Sulfosulfanylethylamino)ethylbenzene,C1=CC=C(C=C1)CCNCCSS(=O)(=O)O,,,,,,
376,70377,"Phosphorodithioic acid, O,O-diethyl S-(p-tolyl) ester",CCOP(=S)(OCC)SC1=CC=C(C=C1)C,,,,,,
377,70378,1-Benzyl-4-(methylamino)piperidine-4-carbonitrile,CNC1(CCN(CC1)CC2=CC=CC=C2)C#N,,,,,,
378,70379,1-Methylanthraquinone,CC1=C2C(=CC=C1)C(=O)C3=CC=CC=C3C2=O,,,,,,
379,70380,"2,4,6-Trimethylbenzophenone",CC1=CC(=C(C(=C1)C)C(=O)C2=CC=CC=C2)C,,,,,,
380,70381,"N-Methyl-2,2-diphenylacetamide",CNC(=O)C(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
381,70382,9-Nitrophenanthrene,C1=CC=C2C(=C1)C=C(C3=CC=CC=C23)[N+](=O)[O-],,,,,,
382,70383,"2,6-Di-tert-butyl-4-nitrosophenol",CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)N=O,,,,,,
383,70384,CID 70384,C1=C(C=C(C(=C1C(=O)N=N)O)[N+](=O)[O-])N(O)O,,,,,,
384,70385,3-Phenylcoumarin,C1=CC=C(C=C1)C2=CC3=CC=CC=C3OC2=O,,,,,,
385,70386,4-(Bis(2-bromoethyl)amino)benzenesulfonamide,C1=CC(=CC=C1N(CCBr)CCBr)S(=O)(=O)N,,,,,,
386,70387,"2,5-Diphenylfuran",C1=CC=C(C=C1)C2=CC=C(O2)C3=CC=CC=C3,,,,,,
387,70388,6-Benzamidohexanoic acid,C1=CC=C(C=C1)C(=O)NCCCCCC(=O)O,,,,,,
388,70389,2-amino-N-(2-chloropyridin-3-yl)benzamide,C1=CC=C(C(=C1)C(=O)NC2=C(N=CC=C2)Cl)N,,,,,,
389,70390,"2,2'-Dimethylazoxybenzene",CC1=CC=CC=C1N=[N+](C2=CC=CC=C2C)[O-],,,,,,
390,70391,CID 70391,C1=CC(=CC=C1CC2=CC=C(C=C2)C#[N+][O-])C#[N+][O-],,,,,,
391,70392,2-((3-Phenylpropyl)amino)ethanethiol hydrogen sulfate (ester),C1=CC=C(C=C1)CCCNCCSS(=O)(=O)O,,,,,,
392,70393,"3,3-Diphenyldihydrofuran-2(3H)-one",C1COC(=O)C1(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
393,70394,"4,4'-Dimethoxythiobenzophenone",COC1=CC=C(C=C1)C(=S)C2=CC=C(C=C2)OC,,,,,,
394,70395,"3,3'-Dinitrobiphenyl",C1=CC(=CC(=C1)[N+](=O)[O-])C2=CC(=CC=C2)[N+](=O)[O-],,,,,,
395,70396,4-Nitrophenyl benzoate,C1=CC=C(C=C1)C(=O)OC2=CC=C(C=C2)[N+](=O)[O-],,,,,,
396,70397,"1,3,5-Triacryloylhexahydro-1,3,5-triazine",C=CC(=O)N1CN(CN(C1)C(=O)C=C)C(=O)C=C,,,,,,
397,70398,2-Benzoylacetanilide,C1=CC=C(C=C1)C(=O)CC(=O)NC2=CC=CC=C2,,,,,,
398,70399,Famoxon,CN(C)S(=O)(=O)C1=CC=C(C=C1)OP(=O)(OC)OC,,,,,,
399,70400,Triphenylborane,B(C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
400,70401,5-Hydroxybenz(a)anthracene,C1=CC=C2C=C3C4=CC=CC=C4C(=CC3=CC2=C1)O,,,,,,
401,70402,"2,4,6-Tri-tert-butylaniline",CC(C)(C)C1=CC(=C(C(=C1)C(C)(C)C)N)C(C)(C)C,,,,,,
402,70403,Chlorcyclohexamide,C1CCC(CC1)NC(=O)NS(=O)(=O)C2=CC=C(C=C2)Cl,,,,,,
403,70404,1-Benzyl-4-(butylamino)piperidine-4-carbonitrile,CCCCNC1(CCN(CC1)CC2=CC=CC=C2)C#N,,,,,,
404,70405,Dicyclohexyl succinate,C1CCC(CC1)OC(=O)CCC(=O)OC2CCCCC2,,,,,,
405,70406,"Benz(a)anthracene, 5-methoxy-7-methyl-",CC1=C2C=C(C3=CC=CC=C3C2=CC4=CC=CC=C14)OC,,,,,,
406,70407,"3-(6,11-Dihydro-5H-dibenzo[b,e]azepin-11-yl)-N,N-dimethylpropan-1-amine--hydrogen chloride (1/1)",CN(C)CCCC1C2=CC=CC=C2CNC3=CC=CC=C13.Cl,,,,,,
407,70408,"5,6-Dihydro-11-(3-dimethylaminopropyl)dibenz(b,e)azepine",CN(C)CCCC1C2=CC=CC=C2CNC3=CC=CC=C13,,,,,,
408,70409,"2-(2-Naphthyl)-5-phenyl-1,3,4-oxadiazole",C1=CC=C(C=C1)C2=NN=C(O2)C3=CC4=CC=CC=C4C=C3,,,,,,
409,70410,Leucyltyrosine,CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N,,,,,,
410,70411,1-Benzyl-4-(cyclohexylamino)piperidine-4-carbonitrile,C1CCC(CC1)NC2(CCN(CC2)CC3=CC=CC=C3)C#N,,,,,,
411,70412,4-Anilino-1-benzylpiperidine-4-carbonitrile,C1CN(CCC1(C#N)NC2=CC=CC=C2)CC3=CC=CC=C3,,,,,,
412,70413,Chlorpromazine sulfoxide,CN(C)CCCN1C2=CC=CC=C2S(=O)C3=C1C=C(C=C3)Cl,,,,,['Chlorpromazine S-oxide is a known human metabolite of chlorpromazine.'],
413,70414,Dipentamethylenethiuram hexasulfide,C1CCN(CC1)C(=S)SSSSSSC(=S)N2CCCCC2,,,,,,
414,70415,1-Benzyl-4-(o-toluidino)piperidine-4-carbonitrile,CC1=CC=CC=C1NC2(CCN(CC2)CC3=CC=CC=C3)C#N,,,,,,
415,70416,1-Benzyl-4-(m-toluidino)piperidine-4-carbonitrile,CC1=CC(=CC=C1)NC2(CCN(CC2)CC3=CC=CC=C3)C#N,,,,,,
416,70417,1-Benzyl-4-(p-toluidino)piperidine-4-carbonitrile,CC1=CC=C(C=C1)NC2(CCN(CC2)CC3=CC=CC=C3)C#N,,,,,,
417,70418,1-Benzyl-4-[(4-chlorophenyl)amino]piperidine-4-carbonitrile,C1CN(CCC1(C#N)NC2=CC=C(C=C2)Cl)CC3=CC=CC=C3,,,,,,
418,70419,"8-Benzyl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one",C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CC4=CC=CC=C4,,,,,,
419,70420,Fluorone black,C1=CC=C(C=C1)C2=C3C=C(C(=O)C=C3OC4=CC(=C(C=C42)O)O)O,,,,,,
420,70421,"Diethyl 3,5-di-tert-butyl-4-hydroxybenzylphosphonate",CCOP(=O)(CC1=CC(=C(C(=C1)C(C)(C)C)O)C(C)(C)C)OCC,,,,,,
421,70422,4-Tritylphenol,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=C(C=C4)O,,,,,,
422,70423,"2,9-Dimethylquinacridone",CC1=CC2=C(C=C1)NC3=CC4=C(C=C3C2=O)NC5=C(C4=O)C=C(C=C5)C,,,,,,
423,70424,"Diazene, phenyl(triphenylmethyl)-",C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3)N=NC4=CC=CC=C4,,,,,,
424,70425,p-tert-Butylphenyl diphenyl phosphate,CC(C)(C)C1=CC=C(C=C1)OP(=O)(OC2=CC=CC=C2)OC3=CC=CC=C3,,,,,,
425,70426,"N,N'-Bis(2-chlorobenzyl)-2,6-spiro(3.3)heptanebis(methylamine) dihydrochloride",C1CC2(C1CNCC3=CC=CC=C3Cl)CCC2CNCC4=CC=CC=C4Cl.Cl.Cl,,,,,,
426,70427,N-[(2-chlorophenyl)methyl]-1-[3-[[(2-chlorophenyl)methylamino]methyl]spiro[3.3]heptan-7-yl]methanamine,C1CC2(C1CNCC3=CC=CC=C3Cl)CCC2CNCC4=CC=CC=C4Cl,,,,,,
427,70428,"16-Methyl-20-oxopregna-5,16-dien-3-yl acetate",CC1=C(C2(CCC3C(C2C1)CC=C4C3(CCC(C4)OC(=O)C)C)C)C(=O)C,,,,,,
428,70429,"(Z)-1,2-Bis(diphenylphosphino)ethene",C1=CC=C(C=C1)P(C=CP(C2=CC=CC=C2)C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
429,70430,Einecs 213-576-5,CC(C)OP1(=NP(=NP(=N1)(OC(C)C)OC(C)C)(OC(C)C)OC(C)C)OC(C)C,,,,,,
430,70431,"4-((4,6-Bis(octylthio)-1,3,5-triazin-2-yl)amino)-2,6-di-tert-butylphenol",CCCCCCCCSC1=NC(=NC(=N1)NC2=CC(=C(C(=C2)C(C)(C)C)O)C(C)(C)C)SCCCCCCCC,,,,,,
431,70432,Hexaphenylbenzene,C1=CC=C(C=C1)C2=C(C(=C(C(=C2C3=CC=CC=C3)C4=CC=CC=C4)C5=CC=CC=C5)C6=CC=CC=C6)C7=CC=CC=C7,,,,,,
432,70433,"4,4'-((6-(Octylthio)-1,3,5-triazine-2,4-diyl)bis(oxy))bis(2,6-di-tert-butylphenol)",CCCCCCCCSC1=NC(=NC(=N1)OC2=CC(=C(C(=C2)C(C)(C)C)O)C(C)(C)C)OC3=CC(=C(C(=C3)C(C)(C)C)O)C(C)(C)C,,,,,,
433,70434,Methylsilane,C[SiH3],,,,,,
434,70435,Trimethylsilane,C[SiH](C)C,,,,,,
435,70436,Methylgermanium trichloride,C[Ge](Cl)(Cl)Cl,,,,,,
436,70437,Methyldimethoxychlorosilane,CO[Si](C)(OC)Cl,,,,,,
437,70438,Triethylgermanium chloride,CC[Ge](CC)(CC)Cl,,,,,,
438,70439,"N,N-Diethyl-N-methylethanaminium iodide",CC[N+](C)(CC)CC.[I-],,,,,,
439,70440,"n,n-Diethyl-n-methylethanaminium",CC[N+](C)(CC)CC,,,,,,
440,70441,"Germanium, triethylpropyl-",CCC[Ge](CC)(CC)CC,,,,,,
441,70442,Hexaethyldisiloxane,CC[Si](CC)(CC)O[Si](CC)(CC)CC,,,,,,
442,70443,Tetrabutylsilane,CCCC[Si](CCCC)(CCCC)CCCC,,,,,,
443,70444,Diethyl ((diethylamino)methyl)phosphonate,CCN(CC)CP(=O)(OCC)OCC,,,,,,
444,70445,Chlorotripropylsilane,CCC[Si](CCC)(CCC)Cl,,,,,,
445,70446,Tetraethyl ethylenediphosphonate,CCOP(=O)(CCP(=O)(OCC)OCC)OCC,,,,,,
446,70447,"Butyl 4,4-bis(tert-butyldioxy)valerate",CCCCOC(=O)CCC(C)(OOC(C)(C)C)OOC(C)(C)C,,,,,,
447,70448,Tributylchlorosilane,CCCC[Si](CCCC)(CCCC)Cl,,,,,,
448,70449,"S,S-Dipropyl methylphosphonodithioate",CCCSP(=O)(C)SCCC,,,,,,
449,70450,"Phosphonotrithioic acid, methyl-, dipropyl ester",CCCSP(=S)(C)SCCC,,,,,,
450,70451,"Silane, dibutylchloromethyl-",CCCC[Si](C)(CCCC)Cl,,,,,,
451,70452,"N,N-Dimethylisopropylamine",CC(C)N(C)C,,,,,,
452,70453,"Silanamine, 1,1,1-trimethyl-N-(trimethylsilyl)-N-(trimethylstannyl)-",C[Si](C)(C)N([Si](C)(C)C)[Sn](C)(C)C,,,,,,
453,70454,"N,N-Diethyl-1,1,1-trimethylsilylamine",CCN(CC)[Si](C)(C)C,,,,,,
454,70455,Tetrakis(dimethylamino)ethylene,CN(C)C(=C(N(C)C)N(C)C)N(C)C,,,,,,
455,70456,"N,N-Diethyloctanamide",CCCCCCCC(=O)N(CC)CC,,,,,,
456,70457,4-Hydroxybutyl methacrylate,CC(=C)C(=O)OCCCCO,,,,,,
457,70458,"3-Hydroxymethylpentane-1,5-diol",C(CO)C(CCO)CO,,,,,,
458,70459,Tripropyl-silane,CCC[SiH](CCC)CCC,,,,,,
459,70460,4-Bromoheptane,CCCC(CCC)Br,,,,,,
460,70461,Thiophosphonic acid diethyl ester,CCOP(=S)OCC,,,,,,
461,70462,"N,N''-Ethylenebis(N-methylpropane-1,3-diamine)",CNCCCNCCNCCCNC,,,,,,
462,70463,"Phosphonodithious acid, methyl-, dipropyl ester",CCCSP(C)SCCC,,,,,,
463,70464,"Propanamide, 3,3'-dithiobis[n-methyl-",CNC(=O)CCSSCCC(=O)NC,,,,,,
464,70465,"1,1,3,3,5,5,7,7-Octamethylheptanetetrasiloxane",C[SiH](C)O[Si](C)(C)O[Si](C)(C)O[SiH](C)C,,,,,,
465,70466,"Phosphorofluoridothioic acid, O,O-diisopropyl ester",CC(C)OP(=S)(OC(C)C)F,,,,,,
466,70467,"2,2,5-Trimethylhex-4-enal",CC(=CCC(C)(C)C=O)C,,,,,,
467,70468,CID 70468,CCCOS(=O)(=O)[O-].[Na+],,,,,,
468,70469,"Sulfuric acid, monopropyl ester",CCCOS(=O)(=O)O,,,,,,
469,70470,CID 70470,CCCCOS(=O)(=O)[O-].[Na+],,,,,,
470,70471,"Sulfuric acid, monobutyl ester",CCCCOS(=O)(=O)O,,,,,,
471,70472,1-(Methylamino)-2-sulfosulfanylethane,CNCCSS(=O)(=O)O,,,,,,
472,70473,Bis(trimethylsilyl)carbodiimide,C[Si](C)(C)N=C=N[Si](C)(C)C,,,,,,
473,70474,CID 70474,C(N=C(N)S)O,,,,,,
474,70475,Zinc isopropylxanthate,CC(C)OC(=S)[S-].CC(C)OC(=S)[S-].[Zn+2],,,,,,
475,70476,6-Pentadecanone,CCCCCCCCCC(=O)CCCCC,,,,,,
476,70477,"Propanenitrile, 3-mercapto-",C(CS)C#N,,,,,,
477,70478,1-(Ethylamino)-2-sulfosulfanylethane,CCNCCSS(=O)(=O)O,,,,,,
478,70479,"1-Chloro-2,3-dihydro-1H-phosphole 1-oxide",C1CP(=O)(C=C1)Cl,,,,,,
479,70480,4-Methyloxazole-5-carbonitrile,CC1=C(OC=N1)C#N,,,,,,
480,70481,2-Hydroxy-3-methylpyridine,CC1=CC=CNC1=O,,,,,,
481,70482,2-Hydroxy-5-methylpyridine,CC1=CNC(=O)C=C1,,,,,,
482,70483,"2,4-Dimethylsulfolane",CC1CC(S(=O)(=O)C1)C,,,,,,
483,70484,"2,3,4,5-Tetramethyl-1H-pyrrole",CC1=C(NC(=C1C)C)C,,,,,,
484,70485,CID 70485,C1=C(N=C(N=C1N)S)N,,,,,,
485,70486,CID 70486,C1C(=NC(=NC1=O)S)N,,,,,,
486,70487,"2,4,5,6-Tetraaminopyrimidine",C1(=C(N=C(N=C1N)N)N)N,,,,,,
487,70488,CID 70488,C1(=C(NC(=NC1=O)N)N)N,,,,,,
488,70489,CID 70489,C1(=C(NC(=NC1=O)S)N)N,,,,,,
489,70490,2-Isopropylcyclohexanone,CC(C)C1CCCCC1=O,,,,,,
490,70491,"1,2-Diethenylcyclohexane",C=CC1CCCCC1C=C,,,,,,
491,70492,Methyl 3-methylisoxazole-5-carboxylate,CC1=NOC(=C1)C(=O)OC,,,,,,
492,70493,Picolinimidohydrazide,C1=CC=NC(=C1)C(=NN)N,,,,,,
493,70494,Cyclohexylphosphonic acid,C1CCC(CC1)P(=O)(O)O,,,,,,
494,70495,3-Carbamyl-1-methylpyridinium chloride,C[N+]1=CC=CC(=C1)C(=O)N.[Cl-],,,,,,
495,70496,4-Amino-6-chloro-2-(methylthio)pyrimidine,CSC1=NC(=CC(=N1)Cl)N,,,,,,
496,70497,"2-(Methylthio)pyrimidine-4,6-diamine",CSC1=NC(=CC(=N1)N)N,,,,,,
497,70498,O-Phenyl chlorothioformate,C1=CC=C(C=C1)OC(=S)Cl,,,,,,
498,70499,4-Butylmorpholine,CCCCN1CCOCC1,,,,,,
499,70500,"1,3,2-Dioxaphosphorinane, 2-methoxy-5,5-dimethyl-",CC1(COP(OC1)OC)C,,,,,,
500,70501,"2,2,6,6-Tetramethyl-1,2,3,6-tetrahydropyridine hydrochloride",CC1(CC=CC(N1)(C)C)C.Cl,,,,,,
501,70502,"Piperidine, 3,4-didehydro-2,2,6,6-tetramethyl-",CC1(CC=CC(N1)(C)C)C,,,,,,
502,70503,CID 70503,CN1C=NC2=C1N=CN=C2S,,,,,,
503,70504,"5-Nitroso-2,4,6-triaminopyrimidine",C1(=C(N=C(N=C1N)N)N)N=O,,,,,,
504,70505,"2,4(1H,3H)-Pyrimidinedione, 3-ethyl-6-methyl-",CCN1C(=O)C=C(NC1=O)C,,,,,,
505,70506,1-Methoxyindan,COC1CCC2=CC=CC=C12,,,,,,
506,70507,"2,6-Diethylphenol",CCC1=C(C(=CC=C1)CC)O,,,,,,
507,70508,3'-Bromo-4'-fluoroacetophenone,CC(=O)C1=CC(=C(C=C1)F)Br,,,,,,
508,70509,3-Bromo-4-fluorobenzoic acid,C1=CC(=C(C=C1C(=O)O)Br)F,,,,,,
509,70510,"1,6-Dihydro-N-methyl-6-oxonicotinamide",CNC(=O)C1=CNC(=O)C=C1,,,,,,
510,70511,Pyridin-4-ylmethyl acetate,CC(=O)OCC1=CC=NC=C1,,,,,,
511,70512,"1,3,2-Dioxaphosphorinane, 2-ethoxy-5,5-dimethyl-",CCOP1OCC(CO1)(C)C,,,,,,
512,70513,"Imidazole, 1-(cyanomethyl)-2-methyl-5-nitro-",CC1=NC=C(N1CC#N)[N+](=O)[O-],,,,,,
513,70514,CID 70514,C1=CC=C(C(=C1)C=O)S(=O)(=O)[O-].[Na+],,,,,,
514,70515,Dihydro-4-phenylfuran-2(3H)-one,C1C(COC1=O)C2=CC=CC=C2,,,,,,
515,70516,"4-Pyrazolin-3-one, 1-phenyl-",C1C(=O)N=CN1C2=CC=CC=C2,,,,,,
516,70517,1-(4-Pyridyl)piperazine,C1CN(CCN1)C2=CC=NC=C2,,,,,,
517,70518,4-(Pyrrolidin-1-yl)phenol,C1CCN(C1)C2=CC=C(C=C2)O,,,,,,
518,70519,2-Chloro-5-nitroanisole,COC1=C(C=CC(=C1)[N+](=O)[O-])Cl,,,,,,
519,70520,"2,2-Dimethyl-3-phenylpropanal",CC(C)(CC1=CC=CC=C1)C=O,,,,,,
520,70521,"N-Phenyl-4,5-dihydro-1,3-thiazol-2-amine",C1CSC(=N1)NC2=CC=CC=C2,,,,,,
521,70522,"1,4-Bis(2-chloroethyl)piperazine",C1CN(CCN1CCCl)CCCl,,,,,,
522,70523,Azacycloundecan-2-one,C1CCCCC(=O)NCCCC1,,,,,,
523,70524,Triethylphenylammonium iodide,CC[N+](CC)(CC)C1=CC=CC=C1.[I-],,,,,,
524,70525,Triethylphenylammonium,CC[N+](CC)(CC)C1=CC=CC=C1,,,,,,
525,70526,N-(1-hydroxyquinolin-4-ylidene)hydroxylamine;hydrochloride,C1=CC=C2C(=C1)C(=NO)C=CN2O.Cl,,,,,,
526,70527,"1,2,3,4,6,7,8,9-Octahydrodibenzofuran",C1CCC2=C(C1)C3=C(O2)CCCC3,,,,,,
527,70528,"Uracil, 3-butyl-6-methyl-",CCCCN1C(=O)C=C(NC1=O)C,,,,,,
528,70529,1-(2-Fluorophenyl)piperazine,C1CN(CCN1)C2=CC=CC=C2F,,,,,,
529,70530,1-(2-Hydroxyphenyl)piperazine,C1CN(CCN1)C2=CC=CC=C2O,,,,,,
530,70531,"1-(2,3-Dihydro-1,4-benzodioxin-2-yl)ethanone",CC(=O)C1COC2=CC=CC=C2O1,,,,,,
531,70532,2-(2-Hydroxyethyl)quinoline,C1=CC=C2C(=C1)C=CC(=N2)CCO,,,,,,
532,70533,"Sodium 2,4-dinitrophenolate",C1=CC(=C(C=C1[N+](=O)[O-])[N+](=O)[O-])[O-].[Na+],,,,,,
533,70534,2-Cyano-3-phenylprop-2-enoic acid,C1=CC=C(C=C1)C=C(C#N)C(=O)O,,,,,,
534,70535,Diphenyltin,C1=CC=C(C=C1)[Sn]C2=CC=CC=C2,,,,,,
535,70536,p-((Trimethylsilyl)oxy)benzaldehyde,C[Si](C)(C)OC1=CC=C(C=C1)C=O,,,,,,
536,70537,7-Hydroxytheophylline,CN1C2=C(C(=O)N(C1=O)C)N(C=N2)O,,,,,,
537,70538,"1-(2,6-Dimethylphenyl)piperazine",CC1=C(C(=CC=C1)C)N2CCNCC2,,,,,,
538,70539,azanium;N-naphthalen-2-yl-N-oxidonitrous amide,C1=CC=C2C=C(C=CC2=C1)N(N=O)[O-].[NH4+],,,,,,
539,70540,N-naphthalen-2-yl-N-oxidonitrous amide,C1=CC=C2C=C(C=CC2=C1)N(N=O)[O-],,,,,,
540,70541,"1-(2,3-Dimethylphenyl)piperazine",CC1=C(C(=CC=C1)N2CCNCC2)C,,,,,,
541,70542,"1-(2,5-Dimethylphenyl)piperazine",CC1=CC(=C(C=C1)C)N2CCNCC2,,,,,,
542,70543,CID 70543,CC1=CC(=C2C(=CC(=O)C=C2O1)O)O,,,,,,
543,70544,"1-(2,4-Dimethylphenyl)Piperazine",CC1=CC(=C(C=C1)N2CCNCC2)C,,,,,,
544,70545,"Silane, trimethyl(4-nitrophenoxy)-",C[Si](C)(C)OC1=CC=C(C=C1)[N+](=O)[O-],,,,,,
545,70546,"3,4-Dihydro-5,8-dimethoxynaphthalen-1(2H)-one",COC1=C2CCCC(=O)C2=C(C=C1)OC,,,,,,
546,70547,N-Acetyltryptamine,CC(=O)NCCC1=CNC2=CC=CC=C21,,,,,,
547,70548,3-Bromobenzophenone,C1=CC=C(C=C1)C(=O)C2=CC(=CC=C2)Br,,,,,,
548,70549,Trimethylolmelamine,C(NC1=NC(=NC(=N1)NCO)NCO)O,,,,,,
549,70550,"Phosphorodithioic acid, O,O-diethyl S-((2-methyl-1,3-dithiolan-2-yl)methyl) ester",CCOP(=S)(OCC)SCC1(SCCS1)C,,,,,,
550,70551,"2,5-Dihydro-1-((p-tolyl)sulphonyl)-1H-pyrazol-3-amine",CC1=CC=C(C=C1)S(=O)(=O)N2CC=C(N2)N,,,,,,
551,70552,"4-Hydroxy-3,5-dinitrobenzoic acid",C1=C(C=C(C(=C1[N+](=O)[O-])O)[N+](=O)[O-])C(=O)O,,,,,,
552,70553,"Acetaldehyde 2,4-Dinitrophenylhydrazone",CC=NNC1=C(C=C(C=C1)[N+](=O)[O-])[N+](=O)[O-],,,,,,
553,70554,"4-Phenyl-2-pyridinecarboximidic acid, hydrazide",C1=CC=C(C=C1)C2=CC(=NC=C2)C(=NN)N,,,,,,
554,70555,"Benzenamine, 4-ethoxy-N-phenyl-",CCOC1=CC=C(C=C1)NC2=CC=CC=C2,,,,,,
555,70556,"1-Phenyl-1,3,8-triazaspiro[4.5]decan-4-one",C1CNCCC12C(=O)NCN2C3=CC=CC=C3,,,,,,
556,70557,7-Butyltheophylline,CCCCN1C=NC2=C1C(=O)N(C(=O)N2C)C,,,,,,
557,70558,1-Benzyl-4-(ethylamino)piperidine-4-carbonitrile,CCNC1(CCN(CC1)CC2=CC=CC=C2)C#N,,,,,,
558,70559,Dibutyl phenylphosphonate,CCCCOP(=O)(C1=CC=CC=C1)OCCCC,,,,,,
559,70560,"1-Phenyl-1,3-bis(trimethylsilyl)urea",C[Si](C)(C)NC(=O)N(C1=CC=CC=C1)[Si](C)(C)C,,,,,,
560,70561,"1-Isoamyl-3,7-dimethylxanthine",CC(C)CCN1C(=O)C2=C(N=CN2C)N(C1=O)C,,,,,,
561,70562,"2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-methyl-, 1,1-dioxide",CC1=NS(=O)(=O)C2=CC(=C(C=C2N1)Cl)S(=O)(=O)N,,,,,,
562,70563,"Propiophenone, 4'-methoxy-3-piperidino-, hydrochloride",COC1=CC=C(C=C1)C(=O)CCN2CCCCC2.Cl,,,,,,
563,70564,1-(4-Methoxyphenyl)-3-(piperidin-1-yl)propan-1-one,COC1=CC=C(C=C1)C(=O)CCN2CCCCC2,,,,,,
564,70565,"2-(Acetylamino)-3-(4-hydroxy-3,5-diiodophenyl)propanoic acid",CC(=O)NC(CC1=CC(=C(C(=C1)I)O)I)C(=O)O,,,,,,
565,70566,Bis(dimethylamino)diphenylsilane,CN(C)[Si](C1=CC=CC=C1)(C2=CC=CC=C2)N(C)C,,,,,,
566,70567,1-Benzyl-4-(ethylamino)piperidine-4-carboxamide,CCNC1(CCN(CC1)CC2=CC=CC=C2)C(=O)N,,,,,,
567,70568,1-Benzyl-4-(isopropylamino)piperidine-4-carbonitrile,CC(C)NC1(CCN(CC1)CC2=CC=CC=C2)C#N,,,,,,
568,70569,Pentifylline,CCCCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,,,,,,
569,70570,n-(2-Chloropyridin-3-yl)-2-nitrobenzamide,C1=CC=C(C(=C1)C(=O)NC2=C(N=CC=C2)Cl)[N+](=O)[O-],,,,,,
570,70571,2-[Nitroso(phenylmethyl)amino]benzoic acid,C1=CC=C(C=C1)CN(C2=CC=CC=C2C(=O)O)N=O,,,,,,
571,70572,"3,3'-(Benzylidenedithio)dipropanoic acid",C1=CC=C(C=C1)C(SCCC(=O)O)SCCC(=O)O,,,,,,
572,70573,1-Benzyl-4-(isopropylamino)piperidine-4-carboxamide,CC(C)NC1(CCN(CC1)CC2=CC=CC=C2)C(=O)N,,,,,,
573,70574,1-Benzyl-4-(propylamino)piperidine-4-carboxamide,CCCNC1(CCN(CC1)CC2=CC=CC=C2)C(=O)N,,,,,,
574,70575,Diphenyl(p-tolyl)phosphine,CC1=CC=C(C=C1)P(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
575,70576,Ethyl 4-oxo-1-phenethylpiperidine-3-carboxylate hydrochloride,CCOC(=O)C1CN(CCC1=O)CCC2=CC=CC=C2.Cl,,,,,,
576,70577,4-Oxo-1-(2-phenylethyl)-3-piperidinecarboxylic acid ethyl ester,CCOC(=O)C1CN(CCC1=O)CCC2=CC=CC=C2,,,,,,
577,70578,"N,N-Dimethyl-2,2-diphenoxyacetamide",CN(C)C(=O)C(OC1=CC=CC=C1)OC2=CC=CC=C2,,,,,,
578,70579,Triphenylphosphine dibromide,C1=CC=C(C=C1)P(C2=CC=CC=C2)(C3=CC=CC=C3)(Br)Br,,,,,,
579,70580,"Spiro(5H-dibenzo(a,d)cycloheptene-5,3'-pyrrolidine)-2',5'-dione, 10,11-dihydro-",C1CC2=CC=CC=C2C3(CC(=O)NC3=O)C4=CC=CC=C41,,,,,,
580,70581,"Spiro(dibenzo(a,d)cyclooctene-5,4'-imidazolidine)-2',5'-dione, 10,11,12-trihydro-",C1CC2=CC=CC=C2C3(C4=CC=CC=C4C1)C(=O)NC(=O)N3,,,,,,
581,70582,"4,4'-Diaminooctafluorobiphenyl",C1(=C(C(=C(C(=C1F)F)N)F)F)C2=C(C(=C(C(=C2F)F)N)F)F,,,,,,
582,70583,Thiomethylpromazine,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)SC,,,,,,
583,70584,1-Benzyl-4-(cyclohexylamino)piperidine-4-carboxamide,C1CCC(CC1)NC2(CCN(CC2)CC3=CC=CC=C3)C(=O)N,,,,,,
584,70585,"Ethanone, 2-(1-methylnaphtho[1,2-d]thiazol-2(1h)-ylidene)-1-phenyl-",CN1C(=CC(=O)C2=CC=CC=C2)SC3=C1C4=CC=CC=C4C=C3,,,,,,
585,70586,Pentafluorophenyl sulfide,C1(=C(C(=C(C(=C1F)F)SC2=C(C(=C(C(=C2F)F)F)F)F)F)F)F,,,,,,
586,70587,1-Benzyl-4-[(4-chlorophenyl)amino]piperidine-4-carboxamide,C1CN(CCC1(C(=O)N)NC2=CC=C(C=C2)Cl)CC3=CC=CC=C3,,,,,,
587,70588,"3-(2-Pyridyl)-5,6-diphenyl-1,2,4-triazine",C1=CC=C(C=C1)C2=C(N=NC(=N2)C3=CC=CC=N3)C4=CC=CC=C4,,,,,,
588,70589,O-2-Naphthyl methyl-2-naphthylthiocarbamate,CN(C1=CC2=CC=CC=C2C=C1)C(=S)OC3=CC4=CC=CC=C4C=C3,,,,,,
589,70590,Tyrosyltyrosine,C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N)O,,,,,,
590,70591,"8-Benzyl-3-(hydroxymethyl)-1-phenyl-1,3,8-triazaspiro[4,5]decan-4-one",C1CN(CCC12C(=O)N(CN2C3=CC=CC=C3)CO)CC4=CC=CC=C4,,,,,,
591,70592,CID 70592,CN1CCC(CC1)OC2C3=CC=CC=C3CCC4=CC=CC=C24.C(=CC(=O)O)C(=O)O,,,,,,
592,70593,Hepzidine,CN1CCC(CC1)OC2C3=CC=CC=C3CCC4=CC=CC=C24,,,,,,
593,70594,"3-(4-Phenyl-2-pyridyl)-5,6-diphenyl-1,2,4-triazine",C1=CC=C(C=C1)C2=CC(=NC=C2)C3=NC(=C(N=N3)C4=CC=CC=C4)C5=CC=CC=C5,,,,,,
594,70595,Octaphenylcyclotetrasilane,C1=CC=C(C=C1)[Si]2([Si]([Si]([Si]2(C3=CC=CC=C3)C4=CC=CC=C4)(C5=CC=CC=C5)C6=CC=CC=C6)(C7=CC=CC=C7)C8=CC=CC=C8)C9=CC=CC=C9,,,,,,
595,70596,Ethylphosphonic dichloride,CCP(=O)(Cl)Cl,,,,,,
596,70597,Tetrakis(trimethylsilyl)methane,C[Si](C)(C)C([Si](C)(C)C)([Si](C)(C)C)[Si](C)(C)C,,,,,,
597,70598,Tris(hydroxymethyl)phosphine oxide,C(O)P(=O)(CO)CO,,,,,,
598,70599,Tetrabutylgermane,CCCC[Ge](CCCC)(CCCC)CCCC,,,,,,
599,70600,Tetraallyloxysilane,C=CCO[Si](OCC=C)(OCC=C)OCC=C,,,,,,
600,70601,Butyltrimethoxysilane,CCCC[Si](OC)(OC)OC,,,,,,
601,70602,"2-Oxa-7,10-diaza-3-silatridecan-13-oic acid, 3,3-dimethoxy-, methyl ester",COC(=O)CCNCCNCCC[Si](OC)(OC)OC,,,,,,
602,70603,"Butanenitrile, 4-(diethoxymethylsilyl)-",CCO[Si](C)(CCCC#N)OCC,,,,,,
603,70604,Diethyl octylphosphonate,CCCCCCCCP(=O)(OCC)OCC,,,,,,
604,70605,Diethyl phosphoramidate,CCOP(=O)(N)OCC,,,,,,
605,70606,S-Methylisothiourea hydrobromide,CSC(=N)N.Br,,,,,,
606,70607,2-Bromoethyldiethylammonium bromide,CCN(CC)CCBr.Br,,,,,,
607,70608,"2-Bromo-N,N-diethylethanamine",CCN(CC)CCBr,,,,,,
608,70609,2-Propylacrolein,CCCC(=C)C=O,,,,,,
609,70610,4-Ethoxy-4-oxobutanoic acid,CCOC(=O)CCC(=O)O,,,,,,
610,70611,Bis(2-chloroethyl) phosphonate,C(CCl)OP(O)OCCCl,,,,,,
611,70612,2-Methylenehexanal,CCCCC(=C)C=O,,,,,,
612,70613,"1,4-Butanediol diacrylate",C=CC(=O)OCCCCOC(=O)C=C,,,,,,
613,70614,"Propanenitrile, 3-(dichloromethylsilyl)-",C[Si](CCC#N)(Cl)Cl,,,,,,
614,70615,Ethyl hydrogen malonate,CCOC(=O)CC(=O)O,,,,,,
615,70616,3-Dichlorosilylpropanenitrile,C(C[SiH](Cl)Cl)C#N,,,,,,
616,70617,CID 70617,CCCCCC[SiH3],,,,,,
617,70618,CID 70618,CCCCCCCCCOS(=O)(=O)[O-].[Na+],,,,,,
618,70619,Monononyl sulfate,CCCCCCCCCOS(=O)(=O)O,,,,,,
619,70620,Adipaldehyde,C(CCC=O)CC=O,,,,,,
620,70621,"2,5,8,11,14,17,20-Heptaoxahenicosane",COCCOCCOCCOCCOCCOCCOC,,,,,,
621,70622,2-Amino-5-bromopyridine,C1=CC(=NC=C1Br)N,,,,,,
622,70623,Trimethylene sulfate,C1COS(=O)(=O)OC1,,,,,,
623,70624,4-Chlorophenylhydrazine,C1=CC(=CC=C1NN)Cl,,,,,,
624,70625,"2-(1,3,2-Dioxaphospholan-2-yloxy)ethanol",C1COP(O1)OCCO,,,,,,
625,70626,"2,6-Dimethyldihydro-2H-pyran-4(3H)-one",CC1CC(=O)CC(O1)C,,,,,,
626,70627,5-Hydroxymaltol,CC1=C(C(=O)C(=CO1)O)O,,,,,,
627,70628,1-Benzylaziridine,C1CN1CC2=CC=CC=C2,,,,,,
628,70629,2-(Piperazin-1-yl)propan-1-ol,CC(CO)N1CCNCC1,,,,,,
629,70630,3-(1H-imidazol-4-yl)propanoic acid,C1=C(NC=N1)CCC(=O)O,,,,,,
630,70631,[4-(Aminomethyl)cyclohexyl]methanol,C1CC(CCC1CN)CO,,,,,,
631,70632,6-Methoxypurine,COC1=NC=NC2=C1NC=N2,,,,,,
632,70633,3-Methyl-4-nitropyridine 1-oxide,CC1=C(C=C[N+](=C1)[O-])[N+](=O)[O-],,,,,,
633,70634,"4-Phenyl-1,3-dioxolane",C1C(OCO1)C2=CC=CC=C2,,,,,,
634,70635,"1H-Indene, 2,3-dihydro-5,6-dimethyl-",CC1=CC2=C(CCC2)C=C1C,,,,,,
635,70636,5-Chloro-2-methylindole,CC1=CC2=C(N1)C=CC(=C2)Cl,,,,,,
636,70637,"1-(2,3-Dichloroprop-2-enyl)pyridin-1-ium;chloride",C1=CC=[N+](C=C1)CC(=CCl)Cl.[Cl-],,,,,,
637,70638,"1-(2,3-Dichloroprop-2-enyl)pyridin-1-ium",C1=CC=[N+](C=C1)CC(=CCl)Cl,,,,,,
638,70639,3-Methylxanthine,CN1C2=C(C(=O)NC1=O)NC=N2,,,,,['3-Methylxanthine is a known human metabolite of theobromine and theophylline.'],
639,70640,"3-Hydroxy-N,N-dimethylpyridine-2-carboxamide",CN(C)C(=O)C1=C(C=CC=N1)O,,,,,,
640,70641,"5(4H)-Isoxazolone, 3-phenyl-",C1C(=NOC1=O)C2=CC=CC=C2,,,,,,
641,70642,5-Methoxy-2-methylindole,CC1=CC2=C(N1)C=CC(=C2)OC,,,,,,
642,70643,2-(4-Methoxyphenyl)-2-oxoacetaldehyde,COC1=CC=C(C=C1)C(=O)C=O,,,,,,
643,70644,"1,4-Benzenedicarbothioic acid",C1=CC(=CC=C1C(=O)S)C(=O)S,,,,,,
644,70645,"Pyridine-2,6-diethanol",C1=CC(=NC(=C1)CCO)CCO,,,,,,
645,70646,3-(Dichlorophenylsilyl)propiononitrile,C1=CC=C(C=C1)[Si](CCC#N)(Cl)Cl,,,,,,
646,70647,"3,4-Dihydro-6-methyl-2H-1-benzothiopyran 1,1-dioxide",CC1=CC2=C(C=C1)S(=O)(=O)CCC2,,,,,,
647,70648,6-Methoxy-2-methylquinoline,CC1=NC2=C(C=C1)C=C(C=C2)OC,,,,,,
648,70649,"Butanenitrile, 4-(dichlorophenylsilyl)-",C1=CC=C(C=C1)[Si](CCCC#N)(Cl)Cl,,,,,,
649,70650,"1,4-Bis(dimethylchlorosilyl)benzene",C[Si](C)(C1=CC=C(C=C1)[Si](C)(C)Cl)Cl,,,,,,
650,70651,N-Butyl-3-hydroxypyridine-2-carboxamide,CCCCNC(=O)C1=C(C=CC=N1)O,,,,,,
651,70652,Methyl L-tyrosinate,COC(=O)[C@H](CC1=CC=C(C=C1)O)N,,,,,,
652,70653,N-p-Tosylglycine,CC1=CC=C(C=C1)S(=O)(=O)NCC(=O)O,,,,,,
653,70654,"3,5-Diacetyl-2,4,6-trimethyl-1,4-dihydropyridine",CC1C(=C(NC(=C1C(=O)C)C)C)C(=O)C,,,,,,
654,70655,"Methanal 2,4-dinitrophenylhydrazone",C=NNC1=C(C=C(C=C1)[N+](=O)[O-])[N+](=O)[O-],,,,,,
655,70656,2-(4-Chloro-2-methylphenoxy)-N-methoxyacetamide,CC1=C(C=CC(=C1)Cl)OCC(=O)NOC,,,,,,
656,70657,1-(2-(4-Bromophenoxy)ethyl)pyrrolidine,C1CCN(C1)CCOC2=CC=C(C=C2)Br,,,,,,
657,70658,"2-(Diethoxyphosphorylsulfanylmethyl)-2-methyl-1,3-dithiolane",CCOP(=O)(OCC)SCC1(SCCS1)C,,,,,,
658,70659,6-Amino-N-methylnaphthalene-1-sulphonamide,CNS(=O)(=O)C1=CC=CC2=C1C=CC(=C2)N,,,,,,
659,70660,"1-(4-Acetylphenyl)-1H-pyrrole-2,5-dione",CC(=O)C1=CC=C(C=C1)N2C(=O)C=CC2=O,,,,,,
660,70661,"3,4-Dihydro-6-methyl-2H-1-benzothiopyran-7-sulphonyl chloride 1,1-dioxide",CC1=CC2=C(C=C1S(=O)(=O)Cl)S(=O)(=O)CCC2,,,,,,
661,70662,"Phosphonothioic acid, methyl-, O-(4-nitrophenyl) O-propyl ester",CCCOP(=S)(C)OC1=CC=C(C=C1)[N+](=O)[O-],,,,,,
662,70663,2-(2-Sulfosulfanylethylamino)ethoxybenzene,C1=CC=C(C=C1)OCCNCCSS(=O)(=O)O,,,,,,
663,70664,"1,4-Dicyclohexylbenzene",C1CCC(CC1)C2=CC=C(C=C2)C3CCCCC3,,,,,,
664,70665,"N,N-Dimethylphenothiazine-2-sulphonamide",CN(C)S(=O)(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2,,,,,,
665,70666,Dansylglycine,CN(C)C1=CC=CC2=C1C=CC=C2S(=O)(=O)NCC(=O)O,,,,,,
666,70667,Triphenyl trithiophosphite,C1=CC=C(C=C1)SP(SC2=CC=CC=C2)SC3=CC=CC=C3,,,,,,
667,70668,4-Anilino-1-benzylpiperidine-4-carboxamide,C1CN(CCC1(C(=O)N)NC2=CC=CC=C2)CC3=CC=CC=C3,,,,,,
668,70669,"9,10-Anthracenedione, 1-(cyclohexylamino)-",C1CCC(CC1)NC2=CC=CC3=C2C(=O)C4=CC=CC=C4C3=O,,,,,,
669,70670,Ethyl (triphenylphosphoranylidene)acetate,CCOC(=O)C=P(C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
670,70671,Benzyltriphenylphosphonium chloride,C1=CC=C(C=C1)C[P+](C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4.[Cl-],,,,,,
671,70672,Benzyltriphenylphosphonium,C1=CC=C(C=C1)C[P+](C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
672,70673,Tetraphenyldiphosphine,C1=CC=C(C=C1)P(C2=CC=CC=C2)P(C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
673,70674,"2-(1,1'-Biphenyl)-4-yl-5-(2-naphthyl)-1,3,4-oxadiazole",C1=CC=C(C=C1)C2=CC=C(C=C2)C3=NN=C(O3)C4=CC5=CC=CC=C5C=C4,,,,,,
674,70675,Tris(4-dimethylaminophenyl)phosphine,CN(C)C1=CC=C(C=C1)P(C2=CC=C(C=C2)N(C)C)C3=CC=C(C=C3)N(C)C,,,,,,
675,70676,Sulfinpyrazone sulfone,C1=CC=C(C=C1)N2C(=O)C(C(=O)N2C3=CC=CC=C3)CCS(=O)(=O)C4=CC=CC=C4,,,,,['Sulfinpyrazone sulfone is a known human metabolite of Sulfinpyrazone.'],
676,70677,"1,3-Isobenzofurandione, 5,5'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]bis-",C1=CC2=C(C=C1C(C3=CC4=C(C=C3)C(=O)OC4=O)(C(F)(F)F)C(F)(F)F)C(=O)OC2=O,,,,,,
677,70678,"Germane, triiodomethyl-",C[Ge](I)(I)I,,,,,,
678,70679,3-Chloro-3-methyl-1-butyne,CC(C)(C#C)Cl,,,,,,
679,70680,Bromotriethylsilane,CC[Si](CC)(CC)Br,,,,,,
680,70681,Tetrabutylammonium chloride,CCCC[N+](CCCC)(CCCC)CCCC.[Cl-],,,"['Purifying or cleansing agents, usually salts of long-chain aliphatic bases or acids, that exert cleansing (oil-dissolving) and antimicrobial effects through a surface action that depends on possessing both hydrophilic and hydrophobic properties. (See all compounds classified as Detergents.)']",,,
681,70682,"Ethanaminium, N-ethyl-2-hydroxy-N,N-dimethyl-, iodide",CC[N+](C)(C)CCO.[I-],,,,,,
682,70683,Ethyl 2-amino-2-methylpropanoate,CCOC(=O)C(C)(C)N,,,,,,
683,70684,3-Bromopyruvic acid,C(C(=O)C(=O)O)Br,,,"['Analogs of those substrates or compounds which bind naturally at the active sites of proteins, enzymes, antibodies, steroids, or physiological receptors. These analogs form a stable covalent bond at the binding site, thereby acting as inhibitors of the proteins or steroids. (See all compounds classified as Affinity Labels.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)']",,,
684,70685,"2,4-Dimethylpentan-3-one oxime",CC(C)C(=NO)C(C)C,,,,,,
685,70686,"1,1-Diethylguanidine hydrochloride",CCN(CC)C(=N)N.Cl,,,,,,
686,70687,"Propanamide, N,N-dipropyl-",CCCN(CCC)C(=O)CC,,,,,,
687,70688,"Octane-2,4,5,7-tetrone",CC(=O)CC(=O)C(=O)CC(=O)C,,,,,,
688,70689,"Ethenamine, N,N-diethenyl-",C=CN(C=C)C=C,,,,,,
689,70690,"N,N-Dipropylacetamide",CCCN(CCC)C(=O)C,,,,,,
690,70691,Triisobutylborane,B(CC(C)C)(CC(C)C)CC(C)C,,,,,,
691,70692,Bis(2-cyanoethyl)nitrosamine,C(CN(CCC#N)N=O)C#N,,,,,,
692,70693,tert-Butyl cyanoacetate,CC(C)(C)OC(=O)CC#N,,,,,,
693,70694,Hexyl valerate,CCCCCCOC(=O)CCCC,,,,,,
694,70695,Diazoethane,CC=[N+]=[N-],,,,,,
695,70696,Isocyanatotrimethylsilane,C[Si](C)(C)N=C=O,,,,,,
696,70697,"1,3-Disiloxanediol, 1,1,3,3-tetramethyl-",C[Si](C)(O)O[Si](C)(C)O,,,,,,
697,70698,"Butanenitrile, 3-imino-",CC(=N)CC#N,,,,,,
698,70699,"2-Butenenitrile, 3-amino-",CC(=CC#N)N,,,,,,
699,70700,"2,2,6,6-Tetramethylheptane-3,5-dione",CC(C)(C)C(=O)CC(=O)C(C)(C)C,,,,,,
700,70701,Allyl acetoacetate,CC(=O)CC(=O)OCC=C,,,,,,
701,70702,(S)-(+)-Nerolidol,CC(=CCCC(=CCC[C@@](C)(C=C)O)C)C,,,,,,
702,70703,4-(Methylamino)butanoic acid,CNCCCC(=O)O,,,,,,
703,70704,5-Bromo-1-pentene,C=CCCCBr,,,,,,
704,70705,6-Heptenoic acid,C=CCCCCC(=O)O,,,,,,
705,70706,Dioctadecyl adipate,CCCCCCCCCCCCCCCCCCOC(=O)CCCCC(=O)OCCCCCCCCCCCCCCCCCC,,,,,,
706,70707,2-Chloroethyl stearate,CCCCCCCCCCCCCCCCCC(=O)OCCCl,,,,,,
707,70708,Trimethyloctadecylammonium bromide,CCCCCCCCCCCCCCCCCC[N+](C)(C)C.[Br-],,,,,,
708,70709,Nonanamide,CCCCCCCCC(=O)N,,,,,,
709,70710,"1,2-Bis(n-propylthio)ethene",CCCSC=CSCCC,,,,,,
710,70711,"N,N-Dimethyldecylamine",CCCCCCCCCCN(C)C,,,,,,
711,70712,Chlorocyclobutane,C1CC(C1)Cl,,,,,,
712,70713,2-Methyl-2-oxazoline,CC1=NCCO1,,,,,,
713,70714,3-Iodopyridine,C1=CC(=CN=C1)I,,,,,,
714,70715,"1,2,4-Triazin-3-amine",C1=CN=NC(=N1)N,,,,,,
715,70716,"3-Methyl-1,2-oxathiolane 2,2-dioxide",CC1CCOS1(=O)=O,,,,,,
716,70717,N-Methylsuccinimide,CN1C(=O)CCC1=O,,,,,,
717,70718,2-Mercaptophenol,C1=CC=C(C(=C1)O)S,,,,,,
718,70719,3-Hydroxy-2-methylpyridine,CC1=C(C=CC=N1)O,,,,,,
719,70720,"1,2-Dimethylpyridinium chloride",CC1=CC=CC=[N+]1C.[Cl-],,,,,,
720,70721,Dicyclopropyl ketone,C1CC1C(=O)C2CC2,,,,,,
721,70722,3-Cyclohepten-1-one,C1CC=CCC(=O)C1,,,,,,
722,70723,2-Cyclohepten-1-one,C1CCC(=O)C=CC1,,,,,,
723,70724,4-Chloropyridine N-oxide,C1=C[N+](=CC=C1Cl)[O-],,,,,,
724,70725,1-Fluoro-3-iodobenzene,C1=CC(=CC(=C1)I)F,,,,,,
725,70726,Glutarimide,C1CC(=O)NC(=O)C1,,,"['Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. (See all compounds classified as Protein Synthesis Inhibitors.)']",,,
726,70727,Dibromomaleic anhydride,C1(=C(C(=O)OC1=O)Br)Br,,,,,,
727,70728,Dichloromaleic anhydride,C1(=C(C(=O)OC1=O)Cl)Cl,,,,,,
728,70729,"1H-Imidazole-4,5-dicarbonitrile",C1=NC(=C(N1)C#N)C#N,,,,,,
729,70730,"2,4-Dichlorobenzenethiol",C1=CC(=C(C=C1Cl)Cl)S,,,,,,
730,70731,"2-Iodo-1,4-dimethylbenzene",CC1=CC(=C(C=C1)C)I,,,,,,
731,70732,"2,6-Dimethyl-3-hydroxypyridine",CC1=NC(=C(C=C1)O)C,,,,,,
732,70733,"2,4-Dimethylpyridine 1-oxide",CC1=CC(=[N+](C=C1)[O-])C,,,,,,
733,70734,4-Nitropyridine,C1=CN=CC=C1[N+](=O)[O-],,,,,,
734,70735,6-Methyl-2-vinylpyridine,CC1=NC(=CC=C1)C=C,,,,,,
735,70736,6-Methyl-2-pyridinemethanol,CC1=NC(=CC=C1)CO,,,,,,
736,70737,6-Methyl-2-pyridinecarboxaldehyde,CC1=NC(=CC=C1)C=O,,,,,,
737,70738,4-Propylpyridine,CCCC1=CC=NC=C1,,,,,,
738,70739,N-Thionylaniline,C1=CC=C(C=C1)N=S=O,,,,,,
739,70740,Phenyl cyanate,C1=CC=C(C=C1)OC#N,,,,,,
740,70741,4-Bromobenzaldehyde,C1=CC(=CC=C1C=O)Br,,,,,,
741,70742,CID 70742,COC1=CC=C(C=C1)[O-].[K+],,,,,,
742,70743,4-Methoxypyridine N-oxide,COC1=CC=[N+](C=C1)[O-],,,,,,
743,70744,1-Methylcyclohexanecarboxylic acid,CC1(CCCCC1)C(=O)O,,,,,,
744,70745,1-(1-Hydroxycyclohexyl)ethanone,CC(=O)C1(CCCCC1)O,,,,,,
745,70746,8-Azaadenine,C1=NC2=NNN=C2C(=N1)N,,,,,,
746,70747,"4-Chloro-2,6-dimethylphenol",CC1=CC(=CC(=C1O)C)Cl,,,,,,
747,70748,1-Cyclohexylpropan-1-one,CCC(=O)C1CCCCC1,,,,,,
748,70749,"1,3-Benzothiazol-5-amine",C1=CC2=C(C=C1N)N=CS2,,,,,,
749,70750,4-Ethyl-m-cresol,CCC1=C(C=C(C=C1)O)C,,,,,,
750,70751,5-Hydroxymethylcytosine,C1=NC(=O)NC(=C1CO)N,,,,,,
751,70752,"2-Ethyl-3,5-dimethylpyridine",CCC1=C(C=C(C=N1)C)C,,,,,,
752,70753,2-Fluorobenzothiazole,C1=CC=C2C(=C1)N=C(S2)F,,,,,,
753,70754,"2-Chloro-4,5-dimethylphenol",CC1=CC(=C(C=C1C)Cl)O,,,,,,
754,70755,"2,5-Dichloro-p-xylene",CC1=CC(=C(C=C1Cl)C)Cl,,,,,,
755,70756,"4-Chloro-2,5-xylenol",CC1=CC(=C(C=C1Cl)C)O,,,,,,
756,70757,"2,4-Dichloro-5-methylphenol",CC1=CC(=C(C=C1Cl)Cl)O,,,,,,
757,70758,"2,4,5-Trihydroxytoluene",CC1=CC(=C(C=C1O)O)O,,,,,,
758,70759,"alpha,3-Dimethylstyrene",CC1=CC(=CC=C1)C(=C)C,,,,,,
759,70760,"Pyridine, 2-ethyl-4,6-dimethyl-",CCC1=CC(=CC(=N1)C)C,,,,,,
760,70761,4-Ethylcatechol,CCC1=CC(=C(C=C1)O)O,,,,,,
761,70762,(3-Chloropropyl)cyclohexane,C1CCC(CC1)CCCCl,,,,,,
762,70763,3-Cyclohexylpropan-1-ol,C1CCC(CC1)CCCO,,,,,,
763,70764,CID 70764,C1CCC=CCCC=CC1,,,,,,
764,70765,1-Methylhypoxanthine,CN1C=NC2=C(C1=O)NC=N2,,,,,,
765,70766,5-Aminoisoquinoline,C1=CC2=C(C=CN=C2)C(=C1)N,,,,,,
766,70767,1-Cyclohexyl-2-methylpropan-1-one,CC(C)C(=O)C1CCCCC1,,,,,,
767,70768,1-Pyrrolidino-1-cyclohexene,C1CCC(=CC1)N2CCCC2,,,,,,
768,70769,1-Phenylpyrazole,C1=CC=C(C=C1)N2C=CC=N2,,,,,,
769,70770,Ethyl 4-piperidinecarboxylate,CCOC(=O)C1CCNCC1,,,,,,
770,70771,2-Butylcyclohexanone,CCCCC1CCCCC1=O,,,,,,
771,70772,2-(Allyloxy)phenol,C=CCOC1=CC=CC=C1O,,,,,,
772,70773,"Pyridinium, 1-(2-hydrazino-2-oxoethyl)-, chloride",C1=CC=[N+](C=C1)CC(=O)NN.[Cl-],,,,,,
773,70774,1-(2-Hydrazinyl-2-oxoethyl)pyridinium,C1=CC=[N+](C=C1)CC(=O)NN,,,,,,
774,70775,4-Allylpyrocatechol,C=CCC1=CC(=C(C=C1)O)O,,,,,['Hydroxychavicol is a known human metabolite of eugenol.'],
775,70776,Hexahydro-2H-azocine-1-ethylamine,C1CCCN(CCC1)CCN,,,,,,
776,70777,4-Acetamidothiophenol,CC(=O)NC1=CC=C(C=C1)S,,,,,,
777,70778,"Glutarimide, 3-methyl-3-isopropyl-",CC(C)C1(CC(=O)NC(=O)C1)C,,,,,,
778,70779,"2,2,4,4-Tetramethylcyclobutane-1,3-dione dioxime",CC1(C(=NO)C(C1=NO)(C)C)C,,,,,,
779,70780,"Benzo[b]thiophene-3(2H)-one 1,1-dioxide",C1C(=O)C2=CC=CC=C2S1(=O)=O,,,,,,
780,70781,4-Amino-2-isopropyl-5-methylphenol,CC1=CC(=C(C=C1N)C(C)C)O,,,,,,
781,70782,"2,3-Dimethoxy-5-methylphenol",CC1=CC(=C(C(=C1)OC)OC)O,,,,,,
782,70783,3-Methyl-1-phenyl-1H-pyrazole,CC1=NN(C=C1)C2=CC=CC=C2,,,,,,
783,70784,6-Fluoro-2-methylquinoline,CC1=NC2=C(C=C1)C=C(C=C2)F,,,,,,
784,70785,Ethyl 3-chlorobenzoate,CCOC(=O)C1=CC(=CC=C1)Cl,,,,,,
785,70786,"Carbamic acid, methyl-, 2-methylphenyl ester",CC1=CC=CC=C1OC(=O)NC,,,,,,
786,70787,"Phenol, o-(3-methyl-2-butenyl)-",CC(=CCC1=CC=CC=C1O)C,,,,,,
787,70788,"2,4-Dichloro-6-(trichloromethyl)pyridine",C1=C(C=C(N=C1C(Cl)(Cl)Cl)Cl)Cl,,,,,,
788,70789,4-Methoxybenzenesulfonamide,COC1=CC=C(C=C1)S(=O)(=O)N,,,,,,
789,70790,"2,6-Diacetylpyridine",CC(=O)C1=NC(=CC=C1)C(=O)C,,,,,,
790,70791,Methyl 4-cyanobenzoate,COC(=O)C1=CC=C(C=C1)C#N,,,,,,
791,70792,"Propanoic acid, 2-methyl-, cyclohexyl ester",CC(C)C(=O)OC1CCCCC1,,,,,,
792,70793,"Carbamic acid, methyl-, 4-methylphenyl ester",CC1=CC=C(C=C1)OC(=O)NC,,,,,,
793,70794,"2,4,6-Tris(chloromethyl)-1,3,5-trioxane",C(C1OC(OC(O1)CCl)CCl)Cl,,,,,,
794,70795,"2-(3,4-Dihydroxyphenyl)acetamide",C1=CC(=C(C=C1CC(=O)N)O)O,,,,,,
795,70796,Cyclohexylpropyl formate,C1CCC(CC1)CCCOC=O,,,,,,
796,70797,2-Hexylpyridine,CCCCCCC1=CC=CC=N1,,,,,,
797,70798,"2-Chloro-N-(2,6-dimethylphenyl)acetamide",CC1=C(C(=CC=C1)C)NC(=O)CCl,,,,,,
798,70799,Benzo[b]thiophene-3-acetic acid,C1=CC=C2C(=C1)C(=CS2)CC(=O)O,,,,,,
799,70800,"3,5-Dimethyl-1-phenyl-1H-pyrazole",CC1=CC(=NN1C2=CC=CC=C2)C,,,,,,
800,70801,3-Methyl-1-phenyl-1H-pyrazol-5-amine,CC1=NN(C(=C1)N)C2=CC=CC=C2,,,,,,
801,70802,"2-Bromo-1,3,5-trimethoxybenzene",COC1=CC(=C(C(=C1)OC)Br)OC,,,,,,
802,70803,4-Phenylpyridine N-oxide,C1=CC=C(C=C1)C2=CC=[N+](C=C2)[O-],,,,,,
803,70804,"5,6,7,8-Tetrahydro-2-naphthoic acid",C1CCC2=C(C1)C=CC(=C2)C(=O)O,,,,,,
804,70805,N-Cyclohexylacetoacetamide,CC(=O)CC(=O)NC1CCCCC1,,,,,,
805,70806,1-Piperidinepropanesulfonic acid,C1CCN(CC1)CCCS(=O)(=O)O,,,,,,
806,70807,3[N-Morpholino]propane sulfonic acid,C1COCCN1CCCS(=O)(=O)O,,,,,,
807,70808,"Benzenesulfonamide, 4-methyl-N-propyl-",CCCNS(=O)(=O)C1=CC=C(C=C1)C,,,,,,
808,70809,"1,2,3,5-Tetrachloro-4,6-bis(chloromethyl)benzene",C(C1=C(C(=C(C(=C1Cl)Cl)Cl)CCl)Cl)Cl,,,,,,
809,70810,"2-Acetyl-1H-indene-1,3(2H)-dione",CC(=O)C1C(=O)C2=CC=CC=C2C1=O,,,,,,
810,70811,"2,3,4,5-Tetrachloro-6-(trichloromethyl)pyridine",C1(=C(C(=NC(=C1Cl)Cl)C(Cl)(Cl)Cl)Cl)Cl,,,,,,
811,70812,"2,3,6,7-Tetramethylnaphthalene",CC1=CC2=C(C=C1C)C=C(C(=C2)C)C,,,,,,
812,70813,"5-(3-Buten-1-ynyl)-2,2'-bithiophene",C=CC#CC1=CC=C(S1)C2=CC=CS2,,,,,,
813,70814,CID 70814,C1=C(C=C(C(=O)C1=N)[N+](=O)[O-])N(O)[O-].[NH4+],,,,,,
814,70815,3-Cyclohexyl-1-propylsulfonic acid,C1CCC(CC1)NCCCS(=O)(=O)O,,,,,,
815,70816,"1,3,2-Dioxaborolane, 2,2'-[1,2-ethanediylbis(oxy)]bis-",B1(OCCO1)OCCOB2OCCO2,,,,,,
816,70817,1-Phenylcyclohexanecarboxylic acid,C1CCC(CC1)(C2=CC=CC=C2)C(=O)O,,,,,,
817,70818,"(2,2,8-trimethyl-4H-[1,3]dioxino[4,5-c]pyridin-5-yl)methanol",CC1=NC=C(C2=C1OC(OC2)(C)C)CO,,,,,,
818,70819,"4,6-Dimethyldibenzofuran",CC1=C2C(=CC=C1)C3=CC=CC(=C3O2)C,,,,,,
819,70820,"4-Hydroxy-3,5-dichlorobiphenyl",C1=CC=C(C=C1)C2=CC(=C(C(=C2)Cl)O)Cl,,,,,,
820,70821,2-(2-Pyridyl)benzimidazole,C1=CC=C2C(=C1)NC(=N2)C3=CC=CC=N3,,,,,,
821,70822,Diphenylnitrone,C1=CC=C(C=C1)C=[N+](C2=CC=CC=C2)[O-],,,,,,
822,70823,N-cinnamoylimidazole,C1=CC=C(C=C1)C=CC(=O)N2C=CN=C2,,,,,,
823,70824,"1,2-Diphenylcyclopropane",C1C(C1C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
824,70825,"3,5-Di-tert-butylphenol",CC(C)(C)C1=CC(=CC(=C1)O)C(C)(C)C,,,,,,
825,70826,"Isopropyl 3,4,5-trihydroxybenzoate",CC(C)OC(=O)C1=CC(=C(C(=C1)O)O)O,,,,,,
826,70827,Trifluorodiphenylphosphorane,C1=CC=C(C=C1)P(C2=CC=CC=C2)(F)(F)F,,,,,,
827,70828,"4-(1,1,3,3-Tetramethylbutyl)pyrocatechol",CC(C)(C)CC(C)(C)C1=CC(=C(C=C1)O)O,,,,,,
828,70829,"4-Bromo-2,6-di-tert-butylphenol",CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)Br,,,,,,
829,70830,"2,6-Dimethylbenzophenone",CC1=C(C(=CC=C1)C)C(=O)C2=CC=CC=C2,,,,,,
830,70831,"2,4-Dimethylbenzophenone",CC1=CC(=C(C=C1)C(=O)C2=CC=CC=C2)C,,,,,,
831,70832,N-Cbz-d-alanine,C[C@H](C(=O)O)NC(=O)OCC1=CC=CC=C1,,,,,,
832,70833,p-Nitrophenyl dimethylsulphamate,CN(C)S(=O)(=O)OC1=CC=C(C=C1)[N+](=O)[O-],,,,,,
833,70834,4-Hexyloxybenzoic acid,CCCCCCOC1=CC=C(C=C1)C(=O)O,,,,,,
834,70835,1-Butyltheobromine,CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,,,,,,
835,70836,"5H-Dibenzo[b,e]azepine-6,11-dione",C1=CC=C2C(=C1)C(=O)C3=CC=CC=C3NC2=O,,,,,,
836,70837,"2,3,4-Trihydroxybenzophenone",C1=CC=C(C=C1)C(=O)C2=C(C(=C(C=C2)O)O)O,,,,,,
837,70838,Ethyl 5-methyl-3-phenylisoxazole-4-carboxylate,CCOC(=O)C1=C(ON=C1C2=CC=CC=C2)C,,,,,,
838,70839,4-Nitrobenzophenone,C1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)[N+](=O)[O-],,,,,,
839,70840,"3,5-Diphenylpyrazole",C1=CC=C(C=C1)C2=CC(=NN2)C3=CC=CC=C3,,,,,,
840,70841,N-Chloroacetyl-L-tyrosine,C1=CC(=CC=C1CC(C(=O)O)NC(=O)CCl)O,,,,,,
841,70842,"Benzene, 1-nitro-4-(phenylmethoxy)-",C1=CC=C(C=C1)COC2=CC=C(C=C2)[N+](=O)[O-],,,,,,
842,70843,Einecs 214-548-5,CCOOP(CC1=CC=C(C=C1)OC)OCC,,,,,,
843,70844,5-Furfuryl-5-isopropylbarbituric acid,CC(C)C1(C(=O)NC(=O)NC1=O)CC2=CC=CO2,,,,,,
844,70845,N-(4-hydroxyphenyl)-4-methylbenzenesulfonamide,CC1=CC=C(C=C1)S(=O)(=O)NC2=CC=C(C=C2)O,,,,,,
845,70846,Clorindione,C1=CC=C2C(=C1)C(=O)C(C2=O)C3=CC=C(C=C3)Cl,,,,,,
846,70847,2-(2-Aminobenzoyl)benzoic acid,C1=CC=C(C(=C1)C(=O)C2=CC=CC=C2N)C(=O)O,,,,,,
847,70848,"2,2':6',2''-Terpyridine",C1=CC=NC(=C1)C2=NC(=CC=C2)C3=CC=CC=N3,,,,,,
848,70849,"Diethyl 1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate",CCOC(=O)C1=C(NC(=C(C1)C(=O)OCC)C)C,,,,,,
849,70850,N-(4-methoxyphenyl)-4-methylbenzenesulfonamide,CC1=CC=C(C=C1)S(=O)(=O)NC2=CC=C(C=C2)OC,,,,,,
850,70851,9-Phenylcarbazole,C1=CC=C(C=C1)N2C3=CC=CC=C3C4=CC=CC=C42,,,,,,
851,70852,2-(4-Ethylbenzoyl)benzoic acid,CCC1=CC=C(C=C1)C(=O)C2=CC=CC=C2C(=O)O,,,,,,
852,70853,"Benzamide, 3,5-dichloro-N-(4-chlorophenyl)-2-hydroxy-",C1=CC(=CC=C1NC(=O)C2=C(C(=CC(=C2)Cl)Cl)O)Cl,,,,,,
853,70854,"2-(2,4-Dinitrobenzyl)pyridine",C1=CC=NC(=C1)CC2=C(C=C(C=C2)[N+](=O)[O-])[N+](=O)[O-],,,,,,
854,70855,Z-DL-Asp-OH,C1=CC=C(C=C1)COC(=O)NC(CC(=O)O)C(=O)O,,,,,,
855,70856,"Phosphoric acid, dipropyl p-nitrophenyl ester",CCCOP(=O)(OCCC)OC1=CC=C(C=C1)[N+](=O)[O-],,,,,,
856,70857,"3,5-Dicarbethoxy-2,6-dimethyl-4-ethyl-1,4-dihydropyridine",CCC1C(=C(NC(=C1C(=O)OCC)C)C)C(=O)OCC,,,,,,
857,70858,"(dimethyl)[3-thieno[2,3-c][2]benzothiepin-4(9H)-ylidenepropyl]ammonium chloride",CN(C)CCC=C1C2=C(SCC3=CC=CC=C31)SC=C2.Cl,,,,,,
858,70859,"N,N-dimethyl-3-(5H-thieno[2,3-c][2]benzothiepin-10-ylidene)propan-1-amine",CN(C)CCC=C1C2=C(SCC3=CC=CC=C31)SC=C2,,,,,,
859,70860,"N-Trimethylsilyl-N,N'-diphenylurea",C[Si](C)(C)N(C1=CC=CC=C1)C(=O)NC2=CC=CC=C2,,,,,,
860,70861,Bis(2-nitrophenyl) disulfide,C1=CC=C(C(=C1)[N+](=O)[O-])SSC2=CC=CC=C2[N+](=O)[O-],,,,,,
861,70862,"4-(4-Hydroxyphenoxy)-3,5-diiodophenylacetic acid",C1=CC(=CC=C1O)OC2=C(C=C(C=C2I)CC(=O)O)I,,,,,,
862,70863,Propipocaine hydrochloride,CCCOC1=CC=C(C=C1)C(=O)CCN2CCCCC2.Cl,,,,,,
863,70864,Propipocaine,CCCOC1=CC=C(C=C1)C(=O)CCN2CCCCC2,,,,,,
864,70865,1-Benzyl-N-phenylpiperidin-4-amine,C1CN(CCC1NC2=CC=CC=C2)CC3=CC=CC=C3,,,,,,
865,70866,N-Carbobenzoxy-L-glutamic acid,C1=CC=C(C=C1)COC(=O)N[C@@H](CCC(=O)O)C(=O)O,,,,,,
866,70867,"trans-N,N'-Bis(cyclobutylmethyl)-1,4-cyclohexanebis(methylamine) dihydrochloride",C1CC(C1)CNCC2CCC(CC2)CNCC3CCC3.Cl.Cl,,,,,,
867,70868,1-cyclobutyl-N-[[4-[(cyclobutylmethylamino)methyl]cyclohexyl]methyl]methanamine,C1CC(C1)CNCC2CCC(CC2)CNCC3CCC3,,,,,,
868,70869,"1,4-Cyclohexanebis(methylamine), N,N'-dicyclopentyl-, dihydrochloride, (E)-",C1CCC(C1)NCC2CCC(CC2)CNC3CCCC3.Cl.Cl,,,,,,
869,70870,N-[[4-[(cyclopentylamino)methyl]cyclohexyl]methyl]cyclopentanamine,C1CCC(C1)NCC2CCC(CC2)CNC3CCCC3,,,,,,
870,70871,Bis(4-nitrophenyl) sulfone,C1=CC(=CC=C1[N+](=O)[O-])S(=O)(=O)C2=CC=C(C=C2)[N+](=O)[O-],,,,,,
871,70872,"2,2-Bis-(4-cyanatophenyl)propane",CC(C)(C1=CC=C(C=C1)OC#N)C2=CC=C(C=C2)OC#N,,,,,,
872,70873,"Benzenamine, 4-methyl-N,N-bis(4-methylphenyl)-",CC1=CC=C(C=C1)N(C2=CC=C(C=C2)C)C3=CC=C(C=C3)C,,,,,,
873,70874,Tris(4-chlorophenyl)phosphine,C1=CC(=CC=C1P(C2=CC=C(C=C2)Cl)C3=CC=C(C=C3)Cl)Cl,,,,,,
874,70875,"1,2-Dibenzoylbenzene",C1=CC=C(C=C1)C(=O)C2=CC=CC=C2C(=O)C3=CC=CC=C3,,,,,,
875,70876,"Quinoline, 8,8'-dithiobis-",C1=CC2=C(C(=C1)SSC3=CC=CC4=C3N=CC=C4)N=CC=C2,,,,,,
876,70877,Carbobenzoxyglycyl-L-proline,C1CC(N(C1)C(=O)CNC(=O)OCC2=CC=CC=C2)C(=O)O,,,,,,
877,70878,Carbobenzoxyphenylalanine,C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)OCC2=CC=CC=C2,,,,,,
878,70879,"1,4-Cyclohexanebis(methylamine), N,N'-dicyclohexyl-, dihydrochloride, (E)-",C1CCC(CC1)NCC2CCC(CC2)CNC3CCCCC3.Cl.Cl,,,,,,
879,70880,N-[[4-[(cyclohexylamino)methyl]cyclohexyl]methyl]cyclohexanamine,C1CCC(CC1)NCC2CCC(CC2)CNC3CCCCC3,,,,,,
880,70881,Moxaverine hydrochloride,CCC1=NC(=C2C=C(C(=CC2=C1)OC)OC)CC3=CC=CC=C3.Cl,,,['Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)'],,,
881,70882,Moxaverine,CCC1=NC(=C2C=C(C(=CC2=C1)OC)OC)CC3=CC=CC=C3,,,['Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)'],,,
882,70883,"2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-phenyl-, 1,1-dioxide",C1=CC=C(C=C1)C2=NS(=O)(=O)C3=CC(=C(C=C3N2)Cl)S(=O)(=O)N,,,,,,
883,70884,1-Benzyl-4-(p-toluidino)piperidine-4-carboxamide,CC1=CC=C(C=C1)NC2(CCN(CC2)CC3=CC=CC=C3)C(=O)N,,,,,,
884,70885,"1,1':2',1'':3'',1'''-Quaterphenyl",C1=CC=C(C=C1)C2=CC(=CC=C2)C3=CC=CC=C3C4=CC=CC=C4,,,,,,
885,70886,"1,1':2',1'':4'',1'''-Quaterphenyl",C1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC=CC=C3C4=CC=CC=C4,,,,,,
886,70887,"1,1':3',1'':4'',1'''-Quaterphenyl",C1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC=CC(=C3)C4=CC=CC=C4,,,,,,
887,70888,"1,4-Cyclohexanebis(methylamine), N,N'-bis(1-methylpiperid-4-yl)-, (E)-",CN1CCC(CC1)NCC2CCC(CC2)CNC3CCN(CC3)C,,,,,,
888,70889,N-[(benzyloxy)carbonyl]glycylphenylalanine,C1=CC=C(C=C1)CC(C(=O)O)NC(=O)CNC(=O)OCC2=CC=CC=C2,,,,,,
889,70890,"1,4-Cyclohexanebis(methylamine), N,N'-dibenzyl-N,N'-dimethyl-, dihydrochloride, (E)-",CN(CC1CCC(CC1)CN(C)CC2=CC=CC=C2)CC3=CC=CC=C3.Cl.Cl,,,,,,
890,70891,N-benzyl-1-[4-[[benzyl(methyl)amino]methyl]cyclohexyl]-N-methylmethanamine,CN(CC1CCC(CC1)CN(C)CC2=CC=CC=C2)CC3=CC=CC=C3,,,,,,
891,70892,"N,N'-Bis(phenethyl)-1,4-cyclohexanebis(methylamine) dihydrochloride",C1CC(CCC1CNCCC2=CC=CC=C2)CNCCC3=CC=CC=C3.Cl.Cl,,,,,,
892,70893,2-phenyl-N-[[4-[(2-phenylethylamino)methyl]cyclohexyl]methyl]ethanamine,C1CC(CCC1CNCCC2=CC=CC=C2)CNCCC3=CC=CC=C3,,,,,,
893,70894,"9-Dicyanomethylene-2,4,7-trinitrofluorene",C1=CC2=C(C=C1[N+](=O)[O-])C(=C(C#N)C#N)C3=C2C(=CC(=C3)[N+](=O)[O-])[N+](=O)[O-],,,,,,
894,70895,"1,2-Dimethyl-1,1,2,2-tetraphenyldisilane",C[Si](C1=CC=CC=C1)(C2=CC=CC=C2)[Si](C)(C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
895,70896,Tetraphenoxysilane,C1=CC=C(C=C1)O[Si](OC2=CC=CC=C2)(OC3=CC=CC=C3)OC4=CC=CC=C4,,,,,,
896,70897,"Phosphorothioic acid, O,O'-(sulfonyldi-1,4-phenylene) O,O,O',O'-tetramethyl ester",COP(=S)(OC)OC1=CC=C(C=C1)S(=O)(=O)C2=CC=C(C=C2)OP(=S)(OC)OC,,,,,,
897,70898,"Stannane, chlorotris(2-methyl-2-phenylpropyl)-",CC(C)(C[Sn](CC(C)(C)C1=CC=CC=C1)(CC(C)(C)C2=CC=CC=C2)Cl)C3=CC=CC=C3,,,,,,
898,70899,2-Fluoropropene,CC(=C)F,,,,,,
899,70900,CID 70900,Cl[GeH](Cl)Cl,,,,,,
900,70901,CID 70901,C(=O)(C(Br)(Br)Br)[O-].[Na+],,,,,,
901,70902,CID 70902,CC(C)(C)C(=O)[O-].[Na+],,,,,,
902,70903,"Propylamine, N,1,1-triethyl-, hydrochloride",CCC(CC)(CC)NCC.Cl,,,,,,
903,70904,"N,3-diethylpentan-3-amine",CCC(CC)(CC)NCC,,,,,,
904,70905,"N,1-Diethyl-1-methylpropylamine hydrochloride",CCC(C)(CC)NCC.Cl,,,,,,
905,70906,N-ethyl-3-methylpentan-3-amine,CCC(C)(CC)NCC,,,,,,
906,70907,(2-Cyanoethyl)methyldiethoxysilane,CCO[Si](C)(CCC#N)OCC,,,,,,
907,70908,Bis(dimethylamino)methoxymethane,CN(C)C(N(C)C)OC,,,,,,
908,70909,"Propanamide, N,N-dibutyl-",CCCCN(CCCC)C(=O)CC,,,,,,
909,70910,Leucyl-glycyl-glycine,CC(C)C[C@@H](C(=O)NCC(=O)NCC(=O)O)N,,,,,,
910,70911,"1,3-Propanediol dimethacrylate",CC(=C)C(=O)OCCCOC(=O)C(=C)C,,,,,,
911,70912,N-Acetyl-L-leucine,CC(C)C[C@@H](C(=O)O)NC(=O)C,,,,,,
912,70913,"1,1-Diethoxy-N,N-dimethylmethanamine",CCOC(N(C)C)OCC,,,,,,
913,70914,N-Acetyl-L-glutamic acid,CC(=O)N[C@@H](CCC(=O)O)C(=O)O,,,,,,
914,70915,Trioctyl ammonium chloride,CCCCCCCC[NH+](CCCCCCCC)CCCCCCCC.[Cl-],,,,,,
915,70916,"1,3-Butyleneglycol dimethacrylate",CC(CCOC(=O)C(=C)C)OC(=O)C(=C)C,,,,,,
916,70917,"Methyl-3,7-dimethyl-2,6-octadienoate",CC(=CCCC(=CC(=O)OC)C)C,,,,,,
917,70918,Chlorosulfonyl isocyanate,C(=NS(=O)(=O)Cl)=O,,,,,,
918,70919,3-tert-Butylamino-3-methyl-1-butyne hydrochloride,CC(C)(C)NC(C)(C)C#C.Cl,,,,,,
919,70920,"N-tert-Butyl-1,1-dimethylpropargylamine",CC(C)(C)NC(C)(C)C#C,,,,,,
920,70921,Bis(dimethylsilyloxy)-dimethylsilane,C[SiH](C)O[Si](C)(C)O[SiH](C)C,,,,,,
921,70922,Formylurea,C(=O)NC(=O)N,,,,,,
922,70923,N(6)-Formyl-L-lysine,C(CCNC=O)C[C@@H](C(=O)O)N,,,,,,
923,70924,Cetyl stearate,CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC,,,,,,
924,70925,2-Propylaminoethanethiol hydrogen sulfate (ester),CCCNCCSS(=O)(=O)O,,,,,,
925,70926,1-(2-Sulfosulfanylethylamino)butane,CCCCNCCSS(=O)(=O)O,,,,,,
926,70927,"Ethanethiol, 2-pentylamino-, hydrogen sulfate (ester)",CCCCCNCCSS(=O)(=O)O,,,,,,
927,70928,N-Dodecylmethacrylamide,CCCCCCCCCCCCNC(=O)C(=C)C,,,,,,
928,70929,Dibutylmagnesium,CCC[CH2-].CCC[CH2-].[Mg+2],,,,,,
929,70930,1-(2-Sulfosulfanylethylamino)heptane,CCCCCCCNCCSS(=O)(=O)O,,,,,,
930,70931,"2,5,8,11,14,17-Hexaoxaoctadecane",COCCOCCOCCOCCOCCOC,,,,,,
931,70932,"2,5,8,11,14,17,20,23-Octaoxatetracosane",COCCOCCOCCOCCOCCOCCOCCOC,,,,,,
932,70933,Ethylcyclopropane,CCC1CC1,,,,,,
933,70934,"2,3-Dihydrofuran",C1COC=C1,,,,,,
934,70935,"1,3-Dihydro-4-methyl-2H-imidazol-2-one",CC1=CNC(=O)N1,,,,,,
935,70936,"4,5-Dihydro-2-methyl-1-vinyl-1H-imidazole",CC1=NCCN1C=C,,,,,,
936,70937,1-Pyrrolidinecarbonyl chloride,C1CCN(C1)C(=O)Cl,,,,,,
937,70938,"4-Methyloxazolidine-2,5-dione",CC1C(=O)OC(=O)N1,,,,,,
938,70939,"3,4-Dihydro-2-cyano-2H-pyran",C1CC(OC=C1)C#N,,,,,,
939,70940,Hexahydro-1-methyl-1H-azepine,CN1CCCCCC1,,,,,,
940,70941,"3-Methyl-2,5-dihydrothiophene 1,1-dioxide",CC1=CCS(=O)(=O)C1,,,,,,
941,70942,"3,3-Dimethylpiperidine",CC1(CCCNC1)C,,,,,,
942,70943,"4,6-Dichloropyrimidine",C1=C(N=CN=C1Cl)Cl,,,,,,
943,70944,CID 70944,C1=C(NC=NC1=O)N,,,,,,
944,70945,"2-Methylcyclohexane-1,3-dione",CC1C(=O)CCCC1=O,,,,,,
945,70946,"5-Chloropyrimidine-4,6-diol",C1=NC(=C(C(=O)N1)Cl)O,,,,,,
946,70947,"1-Bromo-2,4-dichlorobenzene",C1=CC(=C(C=C1Cl)Cl)Br,,,,,,
947,70948,CID 70948,C1=C(NC(=NC1=O)N)Cl,,,,,,
948,70949,"2,5-Dihydroxybenzaldehyde",C1=CC(=C(C=C1O)C=O)O,,,,,,
949,70950,"4-Ethylbenzene-1,3-diamine",CCC1=C(C=C(C=C1)N)N,,,,,,
950,70951,Orotaldehyde,C1=C(NC(=O)NC1=O)C=O,,,,,,
951,70952,2-Methylbenzo[b]thiophene,CC1=CC2=CC=CC=C2S1,,,,,,
952,70953,"3-Methyl-5-(trichloromethyl)-1,2,4-oxadiazole",CC1=NOC(=N1)C(Cl)(Cl)Cl,,,,,,
953,70954,"Cyclohexene, 1-methyl-4-(1-methylethyl)-, (R)-",CC1=CC[C@@H](CC1)C(C)C,,,,,,
954,70955,4-Fluorophenyl isocyanate,C1=CC(=CC=C1N=C=O)F,,,,,,
955,70956,"Pyridine-3,5-dicarbonitrile",C1=C(C=NC=C1C#N)C#N,,,,,,
956,70957,"2,6-Pyridinedimethanol",C1=CC(=NC(=C1)CO)CO,,,,,,
957,70958,"1,3-Cyclohexanedione, 2-bromo-5,5-dimethyl-",CC1(CC(=O)C(C(=O)C1)Br)C,,,,,,
958,70959,"1,3,5-Trichloro-2-nitrosobenzene",C1=C(C=C(C(=C1Cl)N=O)Cl)Cl,,,,,,
959,70960,2-Methyl-6-oxocyclopent-1-enyl acetate,CC1=C(C(=O)CC1)OC(=O)C,,,,,,
960,70961,3-Hydroxy-N-methylpyridine-2-carboxamide,CNC(=O)C1=C(C=CC=N1)O,,,,,,
961,70962,(+)-Isomenthone,C[C@@H]1CC[C@@H](C(=O)C1)C(C)C,,,,,,
962,70963,CID 70963,C1=NC2=C(NC(=NC2=N1)Br)Br,,,,,,
963,70964,(2-Hydroxyphenyl)urea,C1=CC=C(C(=C1)NC(=O)N)O,,,,,,
964,70965,"2,5-Dimethyl-1H-indole",CC1=CC2=C(C=C1)NC(=C2)C,,,,,,
965,70966,Vanillylamine,COC1=C(C=CC(=C1)CN)O,,,,,,
966,70967,4-(Dimethylamino)benzonitrile,CN(C)C1=CC=C(C=C1)C#N,,,,,,
967,70968,"1-(5-Methyl-2-furanyl)-1,2-propanedione",CC1=CC=C(O1)C(=O)C(=O)C,,,,,,
968,70969,Phentermine hydrochloride,CC(C)(CC1=CC=CC=C1)N.Cl,,,"['Drugs that act on adrenergic receptors or affect the life cycle of adrenergic transmitters. Included here are adrenergic agonists and antagonists and agents that affect the synthesis, storage, uptake, metabolism, or release of adrenergic transmitters. (See all compounds classified as Adrenergic Agents.)', 'Agents that are used to suppress appetite. (See all compounds classified as Appetite Depressants.)', 'A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here. (See all compounds classified as Central Nervous System Stimulants.)', 'Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters. (See all compounds classified as Sympathomimetics.)']",,,
969,70970,N-Phenylmethanesulfonamide,CS(=O)(=O)NC1=CC=CC=C1,,,,,,
970,70971,alpha-Methylcinnamonitrile,CC(=CC1=CC=CC=C1)C#N,,,,,,
971,70972,"Furan, 2,2'-methylenebis-",C1=COC(=C1)CC2=CC=CO2,,,,,,
972,70973,"Ammonium, (5-methylfurfuryl)trimethyl-, iodide",CC1=CC=C(O1)C[N+](C)(C)C.[I-],,,"['Drugs that mimic the effects of parasympathetic nervous system activity. Included here are drugs that directly stimulate muscarinic receptors and drugs that potentiate cholinergic activity, usually by slowing the breakdown of acetylcholine (CHOLINESTERASE INHIBITORS). Drugs that stimulate both sympathetic and parasympathetic postganglionic neurons (GANGLIONIC STIMULANTS) are not included here. (See all compounds classified as Parasympathomimetics.)']",,,
973,70974,5-Bromoquinolin-8-ol,C1=CC2=C(C=CC(=C2N=C1)O)Br,,,,,,
974,70975,9-Methylxanthine,CN1C=NC2=C1NC(=O)NC2=O,,,,,,
975,70976,6-Methylthioguanine,CSC1=NC(=NC2=C1NC=N2)N,,,,,,
976,70977,"1,3-Dichlorotetrafluorobenzene",C1(=C(C(=C(C(=C1F)Cl)F)Cl)F)F,,,,,,
977,70978,"1,3-Diaminotetrafluorobenzene",C1(=C(C(=C(C(=C1F)F)F)N)F)N,,,,,,
978,70979,"1,4-Benzenediamine, 2,3,5,6-tetrafluoro-",C1(=C(C(=C(C(=C1F)F)N)F)F)N,,,,,,
979,70980,"2-Butenoic acid, 3-phenyl-",CC(=CC(=O)O)C1=CC=CC=C1,,,,,,
980,70981,1-Chloro-4-(methylthio)-2-nitrobenzene,CSC1=CC(=C(C=C1)Cl)[N+](=O)[O-],,,,,,
981,70982,2-Amino-4-tert-butylphenol,CC(C)(C)C1=CC(=C(C=C1)O)N,,,,,,
982,70983,4-Dimethylamino-o-tolualdehyde,CC1=C(C=CC(=C1)N(C)C)C=O,,,,,,
983,70984,1-Ethyl-4-(methoxycarbonyl)pyridinium iodide,CC[N+]1=CC=C(C=C1)C(=O)OC.[I-],,,,,,
984,70985,1-Ethyl-4-(methoxycarbonyl)pyridinium,CC[N+]1=CC=C(C=C1)C(=O)OC,,,,,,
985,70986,(4-Bromobutoxy)benzene,C1=CC=C(C=C1)OCCCCBr,,,,,,
986,70987,4-Methoxyphenyl acetate,CC(=O)OC1=CC=C(C=C1)OC,,,,,,
987,70988,4-Butylbenzaldehyde,CCCCC1=CC=C(C=C1)C=O,,,,,,
988,70989,3-Indolylacetone,CC(=O)CC1=CNC2=CC=CC=C21,,,,,,
989,70990,"3,4,5-Trichloro-2-(trichloromethyl)pyridine",C1=C(C(=C(C(=N1)C(Cl)(Cl)Cl)Cl)Cl)Cl,,,,,,
990,70991,"2',5'-Dimethoxyacetophenone",CC(=O)C1=C(C=CC(=C1)OC)OC,,,,,,
991,70992,Methyl 1H-indole-2-carboxylate,COC(=O)C1=CC2=CC=CC=C2N1,,,,,,
992,70993,5'-Isopropyl-2'-methylacetophenone,CC1=C(C=C(C=C1)C(C)C)C(=O)C,,,,,,
993,70994,Methyl 4-(dimethylamino)benzoate,CN(C)C1=CC=C(C=C1)C(=O)OC,,,,,,
994,70995,Diphenyltellurium,C1=CC=C(C=C1)[Te]C2=CC=CC=C2,,,,,,
995,70996,"1,2-Benzenedicarboperoxoic acid",C1=CC=C(C(=C1)C(=O)OO)C(=O)OO,,,,,,
996,70997,"2-Bromo-2',5'-dimethoxyacetophenone",COC1=CC(=C(C=C1)OC)C(=O)CBr,,,,,,
997,70998,Trimellitic anhydride chloride,C1=CC2=C(C=C1C(=O)Cl)C(=O)OC2=O,,,,,,
998,70999,"1-Ethyl-2,4-dinitrobenzene",CCC1=C(C=C(C=C1)[N+](=O)[O-])[N+](=O)[O-],,,,,,
999,71000,4-[Bis(2-chloroethyl)amino]phenol,C1=CC(=CC=C1N(CCCl)CCCl)O,,,,,,
1000,71001,3-Hydroxyquinoxaline-2-carboxylic acid,C1=CC=C2C(=C1)NC(=O)C(=N2)C(=O)O,,,,,,
1001,71002,N-Benzoyl-DL-alanine,CC(C(=O)O)NC(=O)C1=CC=CC=C1,,,,,,
1002,71003,Ethyl 4-isothiocyanatobenzoate,CCOC(=O)C1=CC=C(C=C1)N=C=S,,,,,,
1003,71004,Methyl 3-chloro-4-hydroxy-5-methoxybenzoate,COC1=C(C(=CC(=C1)C(=O)OC)Cl)O,,,,,,
1004,71005,CID 71005,CC1=CC=C(C=C1)NC(=NCC=C)S,,,,,,
1005,71006,"1,4-Diacetoxybenzene",CC(=O)OC1=CC=C(C=C1)OC(=O)C,,,,,,
1006,71007,1-(4-Methylphenyl)cyclohexanecarbonitrile,CC1=CC=C(C=C1)C2(CCCCC2)C#N,,,,,,
1007,71008,1-(4-Methoxyphenyl)cyclopentanecarbonitrile,COC1=CC=C(C=C1)C2(CCCC2)C#N,,,,,,
1008,71009,6-Amino-1-naphthalenesulfonamide,C1=CC2=C(C=CC(=C2)N)C(=C1)S(=O)(=O)N,,,,,,
1009,71010,1-((3-Hydroxy-2-pyridyl)carbonyl)piperidine,C1CCN(CC1)C(=O)C2=C(C=CC=N2)O,,,,,,
1010,71011,4-((3-Hydroxy-2-pyridyl)carbonyl)morpholine,C1COCCN1C(=O)C2=C(C=CC=N2)O,,,,,,
1011,71012,"1,8-Dimethyldibenzothiophene",CC1=CC2=C(C=C1)SC3=CC=CC(=C32)C,,,,,,
1012,71013,9-Chloroacridine,C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)Cl,,,,,,
1013,71014,10H-phenothiazine 5-oxide,C1=CC=C2C(=C1)NC3=CC=CC=C3S2=O,,,,,,
1014,71015,10-Methylphenothiazine,CN1C2=CC=CC=C2SC3=CC=CC=C31,,,,,,
1015,71016,"3-(2-hydroxyethyl)quinazoline-2,4(1H,3H)-dione",C1=CC=C2C(=C1)C(=O)N(C(=O)N2)CCO,,,,,,
1016,71017,3-Chloro-10H-phenothiazine,C1=CC=C2C(=C1)NC3=C(S2)C=C(C=C3)Cl,,,,,,
1017,71018,4-[Bis(2-chloroethyl)amino]benzaldehyde,C1=CC(=CC=C1C=O)N(CCCl)CCCl,,,,,,
1018,71019,"Benzenesulfinothioic acid, S-phenyl ester",C1=CC=C(C=C1)SS(=O)C2=CC=CC=C2,,,,,,
1019,71020,CID 71020,CC(=C)COC1=CC=C(C=C1)S(=O)(=O)[O-].[Na+],,,,,,
1020,71021,p-Sulfophenyl methallyl ether,CC(=C)COC1=CC=C(C=C1)S(=O)(=O)O,,,,,,
1021,71022,1-(Chloromethyl)-4-(phenylthio)benzene,C1=CC=C(C=C1)SC2=CC=C(C=C2)CCl,,,,,,
1022,71023,4-(Phenylthio)benzaldehyde,C1=CC=C(C=C1)SC2=CC=C(C=C2)C=O,,,,,,
1023,71024,"10H-Phenothiazine 5,5-dioxide",C1=CC=C2C(=C1)NC3=CC=CC=C3S2(=O)=O,,,,,,
1024,71025,2-((Carboxymethyl)sulphonyl)benzoic acid,C1=CC=C(C(=C1)C(=O)O)S(=O)(=O)CC(=O)O,,,,,,
1025,71026,"1,8-Naphthalenedicarboxylic acid, dipotassium salt",C1=CC2=C(C(=C1)C(=O)[O-])C(=CC=C2)C(=O)[O-].[K+].[K+],,,,,,
1026,71027,"3,3-Diphenylacrylaldehyde",C1=CC=C(C=C1)C(=CC=O)C2=CC=CC=C2,,,,,,
1027,71028,Adrenoglomerulotropin,CC1C2=C(CCN1)C3=C(N2)C=CC(=C3)OC,,,,,,
1028,71029,6-Anilinopurine,C1=CC=C(C=C1)NC2=NC=NC3=C2NC=N3,,,,,,
1029,71030,2-(o-Aminophenyl)-2H-benzotriazole,C1=CC=C(C(=C1)N)N2N=C3C=CC=CC3=N2,,,,,,
1030,71031,"Benzenesulfonothioic acid, S-phenyl ester",C1=CC=C(C=C1)SS(=O)(=O)C2=CC=CC=C2,,,,,,
1031,71032,CID 71032,C1=CC=NC(=C1)NC(=NC2=CC=CC=N2)S,,,,,,
1032,71033,Methyl N-benzyloxycarbonylglycinate,COC(=O)CNC(=O)OCC1=CC=CC=C1,,,,,,
1033,71034,2-Methoxy-9H-xanthen-9-one,COC1=CC2=C(C=C1)OC3=CC=CC=C3C2=O,,,,,,
1034,71035,"9,10-Dicyanoanthracene",C1=CC=C2C(=C1)C(=C3C=CC=CC3=C2C#N)C#N,,,,,,
1035,71036,"Acetic acid, (2,3-dichloro-4-(1-oxobutyl)phenoxy)-",CCCC(=O)C1=C(C(=C(C=C1)OCC(=O)O)Cl)Cl,,,,,,
1036,71037,CID 71037,COP(=S)(OC)SCN1C=CC2=CC=CC=C2O1,,,,,,
1037,71038,Bicyclo[2.2.1]hept-5-en-2-ylmethyl bicyclo[2.2.1]hept-5-ene-2-carboxylate,C1C2CC(C1C=C2)COC(=O)C3CC4CC3C=C4,,,,,,
1038,71039,Ethyl [2-[[(2-hydroxyethyl)amino]carbonyl]phenyl]carbamate,CCOC(=O)NC1=CC=CC=C1C(=O)NCCO,,,,,,
1039,71040,"Methyl 2-(2,3-dimethylanilino)benzoate",CC1=C(C(=CC=C1)NC2=CC=CC=C2C(=O)OC)C,,,,,,
1040,71041,Nibufin,CCCCP(=O)(CCCC)OC1=CC=C(C=C1)[N+](=O)[O-],,,,,,
1041,71042,"6,7-Dichloro-1,4-dihydroxyanthraquinone",C1=CC(=C2C(=C1O)C(=O)C3=CC(=C(C=C3C2=O)Cl)Cl)O,,,,,,
1042,71043,"4,4'-Dimethoxybenzil",COC1=CC=C(C=C1)C(=O)C(=O)C2=CC=C(C=C2)OC,,,,,,
1043,71044,"N'-Benzoyl-N,N'-dimethylbenzohydrazide",CN(C(=O)C1=CC=CC=C1)N(C)C(=O)C2=CC=CC=C2,,,,,,
1044,71045,"4,4'-Bis(dimethylamino)thiobenzophenone",CN(C)C1=CC=C(C=C1)C(=S)C2=CC=C(C=C2)N(C)C,,,,,,
1045,71046,4-Hydroxy Triamterene,C1=CC(=CC=C1C2=NC3=C(N=C(N=C3N=C2N)N)N)O,,,,,['4p-Hydroxytriamterene has known human metabolites that include Hydroxytriamterene sulfate.'],
1046,71047,CID 71047,COC1=CC=C(C=C1)NC(=NC2=CC=C(C=C2)OC)S,,,,,,
1047,71048,"N,N'-Diisopentyl-1,4-cyclohexanebis(methylamine) dihydrochloride",CC(C)CCNCC1CCC(CC1)CNCCC(C)C.Cl.Cl,,,,,,
1048,71049,3-methyl-N-[[4-[(3-methylbutylamino)methyl]cyclohexyl]methyl]butan-1-amine,CC(C)CCNCC1CCC(CC1)CNCCC(C)C,,,,,,
1049,71050,Bis(3-nitrophenyl)sulfone,C1=CC(=CC(=C1)S(=O)(=O)C2=CC=CC(=C2)[N+](=O)[O-])[N+](=O)[O-],,,,,,
1050,71051,"p,p'-Octylidenebisphenol",CCCCCCCC(C1=CC=C(C=C1)O)C2=CC=C(C=C2)O,,,,,,
1051,71052,"Phenol, p-(bis(2-chloroethyl)amino)-, benzoate",C1=CC=C(C=C1)C(=O)OC2=CC=C(C=C2)N(CCCl)CCCl,,,,,,
1052,71053,"Cyclohexane, 1,4-bis(hexahydroazepinylmethyl)-, dihydrochloride, (E)-",C1CCCN(CC1)CC2CCC(CC2)CN3CCCCCC3.Cl.Cl,,,,,,
1053,71054,1-[[4-(Azepan-1-ylmethyl)cyclohexyl]methyl]azepane,C1CCCN(CC1)CC2CCC(CC2)CN3CCCCCC3,,,,,,
1054,71055,"L-Arginine, N2-[(phenylmethoxy)carbonyl]-",C1=CC=C(C=C1)COC(=O)N[C@@H](CCCN=C(N)N)C(=O)O,,,,,,
1055,71056,"1,4-Cyclohexanebis(methylamine), N,N'-bis(2-thienylmethyl)-, dihydrochloride",C1CC(CCC1CNCC2=CC=CS2)CNCC3=CC=CS3.Cl.Cl,,,,,,
1056,71057,N-(thiophen-2-ylmethyl)-1-[4-[(thiophen-2-ylmethylamino)methyl]cyclohexyl]methanamine,C1CC(CCC1CNCC2=CC=CS2)CNCC3=CC=CS3,,,,,,
1057,71058,N-Phenyl-N-(1-(phenylmethyl)-4-piperidinyl)acetamide,CC(=O)N(C1CCN(CC1)CC2=CC=CC=C2)C3=CC=CC=C3,,,,,,
1058,71059,"1,3,5-Triazine, 2-chloro-4,6-bis(2,4-dimethylphenyl)-",CC1=CC(=C(C=C1)C2=NC(=NC(=N2)Cl)C3=C(C=C(C=C3)C)C)C,,,,,,
1059,71060,Naphthol AS-BI,COC1=CC=CC=C1NC(=O)C2=C(C=C3C=CC(=CC3=C2)Br)O,,,,,,
1060,71061,CID 71061,C1=CC=C2C(=C1)C=CC=C2NC(=NC3=CC=CC4=CC=CC=C43)S,,,,,,
1061,71062,"1,4-Cyclohexanebis(methylamine), N,N'-bis(3-norbornyl)-, dihydrochloride, (E)-",C1CC(CCC1CNC2CC3CCC2C3)CNC4CC5CCC4C5.Cl.Cl,,,,,,
1062,71063,N-[[4-[(2-bicyclo[2.2.1]heptanylamino)methyl]cyclohexyl]methyl]bicyclo[2.2.1]heptan-2-amine,C1CC(CCC1CNC2CC3CCC2C3)CNC4CC5CCC4C5,,,,,,
1063,71064,"1,4-Cyclohexanebis(methylamine), N,N'-diheptyl-, dihydrochloride, (E)-",CCCCCCCNCC1CCC(CC1)CNCCCCCCC.Cl.Cl,,,,,,
1064,71065,N-[[4-[(heptylamino)methyl]cyclohexyl]methyl]heptan-1-amine,CCCCCCCNCC1CCC(CC1)CNCCCCCCC,,,,,,
1065,71066,"Piperazine, 1-(m-chlorophenyl)-4-(3,4-dimethoxyphenethyl)-",COC1=C(C=C(C=C1)CCN2CCN(CC2)C3=CC(=CC=C3)Cl)OC,,,,,,
1066,71067,N-Tetradecyl-p-toluenesulphonamide,CCCCCCCCCCCCCCNS(=O)(=O)C1=CC=C(C=C1)C,,,,,,
1067,71068,"[2,2'-Biquinoline]-4,4'-dicarboxylic acid",C1=CC=C2C(=C1)C(=CC(=N2)C3=NC4=CC=CC=C4C(=C3)C(=O)O)C(=O)O,,,"['Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant and Hackh&apos;s Chemical Dictionary, 5th ed, p301, p499) (See all compounds classified as Indicators and Reagents.)']",,,
1068,71069,CID 71069,COC1=C(C=C(C=C1)C2=C(C(=C3C(=CC(=CC3=O)OC)O2)O)OC)OC,,,,,,
1069,71070,D-Arginine,C(C[C@H](C(=O)O)N)CN=C(N)N,,,,,,
1070,71071,Dibenzofluorene,C1C2=CC=CC=C2C3=C1C4=CC=CC=C4C5=CC=CC=C53,,,,,,
1071,71072,"Benzo[b]naphtho[2,3-d]furan",C1=CC=C2C=C3C(=CC2=C1)C4=CC=CC=C4O3,,,,,,
1072,71073,"1,2-Benzisoxazole",C1=CC=C2C(=C1)C=NO2,,,,,,
1073,71074,Tremorine dihydrochloride,C1CCN(C1)CC#CCN2CCCC2.Cl.Cl,,,,,,
1074,71075,Decamethylenediguanidine dihydrochloride,C(CCCCCN=C(N)N)CCCCN=C(N)N.Cl.Cl,,,,,,
1075,71076,"Barbituric acid, 5-ethyl-5-(4-fluorobutyl)-",CCC1(C(=O)NC(=O)NC1=O)CCCCF,,,,,,
1076,71077,D-serine,C([C@H](C(=O)O)N)O,,,,,,
1077,71078,CID 71078,CCC(=O)[O-].[K+],,,,,,
1078,71079,Silver perfluorooctanoate,C(=O)(C(C(C(C(C(C(C(F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)[O-].[Ag+],,,,,,
1079,71080,D-alanine,C[C@H](C(=O)O)N,,,,,,
1080,71081,Oxalate,C(=O)(C(=O)[O-])[O-],,,,,,
1081,71082,D-ornithine,C(C[C@H](C(=O)O)N)CN,,,,,,
1082,71083,D-Histidine,C1=C(NC=N1)C[C@H](C(=O)O)N,,,,,,
1083,71084,Trichlorofluoroethylene,C(=C(Cl)Cl)(F)Cl,,,,,,
1084,71085,Silver difluoroacetate,C(C(=O)[O-])(F)F.[Ag+],,,,,,
1085,71086,CID 71086,C(C(F)(F)F)[O-].[Na+],,,,,,
1086,71087,Zolimidine hydrochloride,CS(=O)(=O)C1=CC=C(C=C1)C2=CN3C=CC=CC3=N2.Cl,,,,,,
1087,71088,"Boron, trifluoro(tetrahydrofuran)-, (T-4)-",B(F)(F)F.C1CCOC1,,,,,,
1088,71089,CID 71089,CC(=O)OC1=CC=CC=C1C(=O)[O-].[Na+],,,,,,
1089,71090,1-Phenylbut-2-en-1-one,CC=CC(=O)C1=CC=CC=C1,,,,,,
1090,71091,Azane;phthalic acid,C1=CC=C(C(=C1)C(=O)O)C(=O)O.N.N,,,,,,
1091,71092,Ammonium hippurate,C1=CC=C(C=C1)C(=O)NCC(=O)O.N,,,,,,
1092,71093,Calcium diisobutyrate,CC(C)C(=O)[O-].CC(C)C(=O)[O-].[Ca+2],,,,,,
1093,71094,CID 71094,COC1=CC=C(C=C1)C(=O)[O-].[Na+],,,,,,
1094,71095,Diisopentylammonium chloride,CC(C)CCNCCC(C)C.Cl,,,,,,
1095,71096,"Zinc bis(4-hydroxy-3,5-diiodobenzenesulphonate)",C1=C(C=C(C(=C1I)O)I)S(=O)(=O)[O-].C1=C(C=C(C(=C1I)O)I)S(=O)(=O)[O-].[Zn+2],,,,,,
1096,71097,2-Naphthylammonium acetate,CC(=O)O.C1=CC=C2C=C(C=CC2=C1)N,,,,,,
1097,71098,D-tyrosine,C1=CC(=CC=C1C[C@H](C(=O)O)N)O,,,,,,
1098,71099,CID 71099,C1=CC=C(C=C1)C(=O)NCC(=O)[O-].[K+],,,,,,
1099,71100,N-(2-Methylphenyl)benzamide,CC1=CC=CC=C1NC(=O)C2=CC=CC=C2,,,,,,
1100,71101,Amiperone,CN(C)C(=O)C1(CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F)C3=CC=C(C=C3)Cl,,,,,,
1101,71102,Menadiol sodium sulfate,CC1=C(C2=CC=CC=C2C(=C1)OS(=O)(=O)[O-])OS(=O)(=O)[O-].[Na+].[Na+],,,,,,
1102,71103,Menadiol disulfate,CC1=C(C2=CC=CC=C2C(=C1)OS(=O)(=O)O)OS(=O)(=O)O,,,,,,
1103,71104,6-[2-(5-Nitrofuran-2-yl)ethenyl]pyridazin-3-amine,C1=CC(=NN=C1C=CC2=CC=C(O2)[N+](=O)[O-])N,,,,,,
1104,71105,Azintamide,CCN(CC)C(=O)CSC1=NN=C(C=C1)Cl,,,,,,
1105,71106,Doxibetasol,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)C)O)C)O)F)C,,,,,,
1106,71107,Fenbenicillin,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C(C3=CC=CC=C3)OC4=CC=CC=C4)C(=O)O)C,,,,,,
1107,71108,Felipyrine,C1CCN(CC1)C2CCN(C2=O)C3=CC=CC=C3,,,,,,
1108,71109,Perisoxal,C1CCN(CC1)CC(C2=NOC(=C2)C3=CC=CC=C3)O,,,,,,
1109,71110,CID 71110,CC(COC1=CC=CC=C1C2=CC=CC=C2)N3CCCCC3,,,,,,
1110,71111,Salazosulfadimidine,CC1=CC(=NC(=N1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O)C,,,,,,
1111,71112,Foscolic acid,CC(C(=O)O)(O)P(=O)(C(C)(C(=O)O)O)O,,,,,,
1112,71113,Valpromide,CCCC(CCC)C(=O)N,,,['Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)'],,,
1113,71114,Pibecarb,CC(C)(C)C(=O)OCC(=O)C1=CC=CC=C1,,,,,,
1114,71115,Prothixene,CN(C)CCC=C1C2=CC=CC=C2SC3=CC=CC=C31,,,,,,
1115,71116,"2,3-Dimethoxy-6-{[2-(pyridine-4-carbonyl)hydrazinylidene]methyl}benzoic acid",COC1=C(C(=C(C=C1)C=NNC(=O)C2=CC=NC=C2)C(=O)O)OC,,,,,,
1116,71117,Roxoperone,CN1C(=O)CC2(C1=O)CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F,,,,,,
1117,71118,Acetergamine,CC(=O)NC[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)C,,,,,,
1118,71119,Febuprol,CCCCOCC(COC1=CC=CC=C1)O,,,['Gastrointestinal agents that stimulate the flow of bile into the duodenum (cholagogues) or stimulate the production of bile by the liver (choleretic). (See all compounds classified as Cholagogues and Choleretics.)'],,,
1119,71120,N-Acetyl-1-aspartylglutamic acid,CC(=O)N[C@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O,,,"['Agents that cause an increase in the expansion of a bronchus or bronchial tubes. (See all compounds classified as Bronchodilator Agents.)', 'Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. (See all compounds classified as Histamine H1 Antagonists.)', 'Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475) (See all compounds classified as Anti-Allergic Agents.)', 'Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids. (See all compounds classified as Neuroprotective Agents.)', 'Toxic substances from microorganisms, plants or animals that interfere with the functions of the nervous system. Most venoms contain neurotoxic substances. Myotoxins are included in this concept. (See all compounds classified as Neurotoxins.)']",,,
1120,71121,"N-cyclohexyloctadeca-9,12-dienamide",CCCCCC=CCC=CCCCCCCCC(=O)NC1CCCCC1,,,,,,
1121,71122,Valofane,CC1CC(C(=O)O1)(CC=C)C(=O)NC(=O)N,,,,,,
1122,71123,"3-{[2,6-Dideoxyhexopyranosyl-(1->4)-2,6-dideoxyhexopyranosyl-(1->4)-2,6-dideoxyhexopyranosyl]oxy}-16-(formyloxy)-14-hydroxycard-20(22)-enolide",CC1C(C(CC(O1)OC2C(OC(CC2O)OC3C(OC(CC3O)OC4CCC5(C(C4)CCC6C5CCC7(C6(CC(C7C8=CC(=O)OC8)OC=O)O)C)C)C)C)O)O,,,,,,
1123,71124,Bisibuthiamine,CC1=NC=C(C(=N1)N)CN(C=O)C(=C(CCOC(=O)C(C)C)SSC(=C(C)N(CC2=CN=C(N=C2N)C)C=O)CCOC(=O)C(C)C)C,,,,,,
1124,71125,Deanol aceglumate,CC(=O)N[C@@H](CCC(=O)O)C(=O)O.CN(C)CCO,,,,,,
1125,71126,"3-[(Morpholin-4-yl)methyl]-1-{[(5-nitrofuran-2-yl)methylidene]amino}imidazolidine-2,4-dione",C1COCCN1CN2C(=O)CN(C2=O)N=CC3=CC=C(O3)[N+](=O)[O-],,,,,,
1126,71127,Prozapine,C1CCCN(CC1)CCC(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
1127,71128,Aprofene,CCN(CC)CCOC(=O)C(C)(C1=CC=CC=C1)C2=CC=CC=C2,,,['Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)'],,,
1128,71129,Zylofuramine,CCN[C@H](CC1=CC=CC=C1)[C@H]2CCCO2,,,,,,
1129,71130,Denaverine,CCC(CC)COC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OCCN(C)C,,,,,,
1130,71131,CID 71131,CCN(CC)CC(CN(C)C)C(C1CCCCC1)C2=CC=CC=C2,,,,,,
1131,71132,Cloridarol,C1=CC=C2C(=C1)C=C(O2)C(C3=CC=C(C=C3)Cl)O,,,,,,
1132,71133,Promolate,CC(C)(C(=O)OCCN1CCOCC1)OC2=CC=CC=C2,,,,,,
1133,71134,Dimetazin,CC1CC2(C(CCC3C2CCC4(C3CCC4(C)O)C)CC1=NN=C5CC6CCC7C8CCC(C8(CCC7C6(CC5C)C)C)(C)O)C,,,,,,
1134,71135,Decloxizine,C1CN(CCN1CCOCCO)C(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
1135,71136,Cianergoline,CN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CC(C#N)C(=O)N,,,,,,
1136,71137,Docarpamine,CCOC(=O)OC1=C(C=C(C=C1)CCNC(=O)[C@H](CCSC)NC(=O)C)OC(=O)OCC,,,['Drugs that bind to and activate dopamine receptors. (See all compounds classified as Dopamine Agonists.)'],,,
1137,71138,"1,1,4,4-Tetramethyl-6-(1-phenylprop-1-EN-2-YL)-2,3-dihydronaphthalene",CC(=CC1=CC=CC=C1)C2=CC3=C(C=C2)C(CCC3(C)C)(C)C,,,,,,
1138,71139,Milverine,C1=CC=C(C=C1)C(CCNC2=CC=NC=C2)C3=CC=CC=C3,,,,,,
1139,71140,Tienocarbine,CC1=CSC2=C1C3=C(C=C2)NC4=C3CN(CC4)C,,,,,,
1140,71141,Cefminox,CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@](C3=O)(NC(=O)CSC[C@H](C(=O)O)N)OC)SC2)C(=O)O,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
1141,71142,Dulozafone,CN(C1=C(C=C(C=C1)Cl)C(=O)C2=CC=CC=C2Cl)C(=O)CN(CCO)CCO,,,,,,
1142,71143,Mopidralazine,CC1=CC=C(N1NC2=NN=C(C=C2)N3CCOCC3)C,,,,,,
1143,71144,Pafenolol,CC(C)NCC(COC1=CC=C(C=C1)CCNC(=O)NC(C)C)O,,,,,,
1144,71145,"[(1R,2S,3R,6R,7S)-6-methyl-5-oxo-4-oxatricyclo[5.2.1.02,6]dec-8-en-3-yl] N-methylcarbamate",C[C@@]12[C@H]3C[C@@H]([C@@H]1[C@H](OC2=O)OC(=O)NC)C=C3,,,,,,
1145,71146,Dazoquinast,C1=CC=C2C(=C1)N=CC3=NC(=CN23)C(=O)O,,,,,,
1146,71147,Nicainoprol,CC(C)NCC(COC1=CC=CC2=C1N(CCC2)C(=O)C3=CN=CC=C3)O,,,,,,
1147,71148,Tropapride,COC1=CC=CC(=C1OC)C(=O)NC2C[C@H]3CC[C@@H](C2)N3CC4=CC=CC=C4,,,,,,
1148,71149,Broxaterol,CC(C)(C)NCC(C1=CC(=NO1)Br)O,,,['Drugs that selectively bind to and activate beta-adrenergic receptors. (See all compounds classified as Adrenergic beta-Agonists.)'],,,
1149,71150,CID 71150,CCC[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]([C@]4(CC3)C)(CCC(=O)[O-])O)C.[K+],,,,,,
1150,71151,"3-[(9S,10R,13S,14S,17R)-17-hydroxy-10,13-dimethyl-3-oxo-7-propyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl]propanoic acid",CCCC1CC2=CC(=O)CC[C@@]2([C@@H]3C1[C@@H]4CC[C@]([C@]4(CC3)C)(CCC(=O)O)O)C,,,,,,
1151,71152,Rofelodine,C1CN=C2CC(CN2C1=O)C3=CC=CC=C3,,,,,,
1152,71153,Fluprazine,C1CN(CCN1CCNC(=O)N)C2=CC=CC(=C2)C(F)(F)F,,,"['A loosely defined grouping of drugs that have effects on psychological function. Here the psychotropic agents include the antidepressive agents, hallucinogens, and tranquilizing agents (including the antipsychotics and anti-anxiety agents). (See all compounds classified as Psychotropic Drugs.)']",,,
1153,71154,CID 71154,CN=C(C1(CCCS1)C2=CC=CC=N2)S,,,,,,
1154,71155,Trigevolol,COCCOC1=CC=C(C=C1)OCC(CNCCOC2=CC(=C(C=C2)O)C(=O)N)O,,,,,,
1155,71156,CID 71156,CC(C)OC[C@@H](COC1=CC=CC=C1OC)O,,,,,,
1156,71157,Nefiracetam,CC1=C(C(=CC=C1)C)NC(=O)CN2CCCC2=O,,,"['A class of drugs producing both physiological and psychological effects through a variety of mechanisms. They can be divided into &quot;specific&quot; agents, e.g., affecting an identifiable molecular mechanism unique to target cells bearing receptors for that agent, and &quot;nonspecific&quot; agents, those producing effects on different target cells and acting by diverse molecular mechanisms. Those with nonspecific mechanisms are generally further classed according to whether they produce behavioral depression or stimulation. Those with specific mechanisms are classed by locus of action or specific therapeutic use. (From Gilman AG, et al., Goodman and Gilman&apos;s The Pharmacological Basis of Therapeutics, 8th ed, p252) (See all compounds classified as Central Nervous System Agents.)', 'Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids. (See all compounds classified as Neuroprotective Agents.)', 'A loosely defined grouping of drugs that have effects on psychological function. Here the psychotropic agents include the antidepressive agents, hallucinogens, and tranquilizing agents (including the antipsychotics and anti-anxiety agents). (See all compounds classified as Psychotropic Drugs.)', 'Drugs used to specifically facilitate learning or memory, particularly to prevent the cognitive deficits associated with dementias. These drugs act by a variety of mechanisms. (See all compounds classified as Nootropic Agents.)']",,,
1157,71158,Acamprosate,CC(=O)NCCCS(=O)(=O)O,['Acamprosate is indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation. It is also indicated for the maintenance of alcohol abstinence in patients who have undergone alcohol detoxification. This drug should be used with a psychosocial support program providing adequate support.'],"['Acamprosate acts on the CNS, aiding in the restoration of normal glutaminergic neuron activity. Pharmacodynamic studies have shown that acamprosate calcium reduces alcohol intake in alcohol-dependent individuals, likely through effects on NMDA receptors and calcium channels.   It is a safe and well-tolerated drug for patients with alcohol dependency and improves the likelihood of alcohol abstinence.']","['Substances interfering with the metabolism of ethyl alcohol, causing unpleasant side effects thought to discourage the drinking of alcoholic beverages. Alcohol deterrents are used in the treatment of alcoholism. (See all compounds classified as Alcohol Deterrents.)']","['Acamprosate is absorbed in the gastrointestinal tract. The absolute bioavailability of acamprosate after oral administration is about 11%. The effect of food absorption is clinically insignificant and no adjustment of the dose is necessary with regard to meals. After repeated oral doses of 666 mg 3 times a day, steady-state concentrations are achieved within 5 to 7 days, with plasma concentration ranging between 370 to 650 micrograms/L.', 'Half of acamprosate excretion occurs as unchanged acetyl-homotaurine in urine, and the other half possibly by biliary excretion. The kidneys are primarily responsible for the elimination of acamprosate.', 'At steady state concentrations, the distribution of acamprosate is about 20L. Following intravenous administration, the volume of distribution is about 72-109 L (an estimated 1 L/kg).', 'Severe renal insufficiency decreases the elimination of acamprosate, and is a contraindication. An acamprosate dose of 333mg, three times daily, is recommended for moderate renal impairment (creatinine clearance of 30-50 mL/min).', 'Protein binding: Negligible.', 'Volume of distribution (VolD): 72 to 109 liters (approximately 1 L/kg) following intravenous administration.', 'The absolute bioavailability following oral administration is about 11%. Food decreases bioavailability as measured by Cmax and AUC, 42% and 23% respectively. The effect of food on absorption is not clinically significant.', 'Elimination: Via the kidneys as unchanged drug.', 'For more Absorption, Distribution and Excretion (Complete) data for ACAMPROSATE (8 total), please visit the HSDB record page.']","['Acamprosate is not metabolized.', 'Acamprosate does not undergo metabolism.']","['In pharmacokinetic studies, enteric-coated acamprosate tablets demonstrate a terminal elimination half-life 10-fold higher than reported 3 hour half-life after intravenous infusion of acamprosate. After two oral doses of acamprosate 333mg, the terminal half-life ranges between 20 - 33 hours.', 'Terminal: 20 to 33 hours following oral dosing of 2 x 333 mg.']"
1158,71159,"(6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[2-[[5,6-dioxo-4-(2-oxoethyl)-1H-1,2,4-triazin-3-yl]sulfanyl]ethenyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid",CON=C(C1=CSC(=N1)N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C=CSC4=NNC(=O)C(=O)N4CC=O)C(=O)O,,,,,,
1159,71160,Valproate pivoxil,CCCC(CCC)C(=O)OCOC(=O)C(C)(C)C,,,,,,
1160,71161,Asocainol,CN1CCC2=C(C=C(C=C2)OC)C3=C(CC1CCC4=CC=CC=C4)C=CC(=C3O)OC,,,,,,
1161,71162,Exepanol,CN[C@H]1C[C@H](C2=CC=CC=C2OC1)O,,,,,,
1162,71163,CID 71163,C=C1C(C(=O)N2CCSC2=N1)CC3=CC=C(C=C3)Cl,,,,,,
1163,71164,Defosfamide,C(CNP(=O)(N(CCCl)CCCl)OCCCl)CO,,,,,,
1164,71165,Morsuximide,CC1(CC(=O)N(C1=O)CN2CCOCC2)C3=CC=CC=C3,,,,,,
1165,71166,Aminoquinuride,CC1=CC(=C2C=C(C=CC2=N1)NC(=O)NC3=CC4=C(C=C(N=C4C=C3)C)N)N,,,,,,
1166,71167,Fenharmane,C1CNC(C2=C1C3=CC=CC=C3N2)CC4=CC=CC=C4,,,,,,
1167,71168,Sulfaclomide,CC1=C(C(=NC(=N1)C)NS(=O)(=O)C2=CC=C(C=C2)N)Cl,,,['Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. (See all compounds classified as Anti-Infective Agents.)'],,,
1168,71169,Isaxonine,CC(C)NC1=NC=CC=N1,,,,,,
1169,71170,Fencibutirol,CCC(C(=O)O)C1(CCC(CC1)C2=CC=CC=C2)O,,,,,,
1170,71171,Dihydroergotamine mesylate,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C.CS(=O)(=O)O,,,"['Drugs used to cause constriction of the blood vessels. (See all compounds classified as Vasoconstrictor Agents.)', 'Drugs that bind to and activate dopamine receptors. (See all compounds classified as Dopamine Agonists.)', 'A subclass of analgesic agents that typically do not bind to OPIOID RECEPTORS and are not addictive. Many non-narcotic analgesics are offered as NONPRESCRIPTION DRUGS. (See all compounds classified as Analgesics, Non-Narcotic.)']",,,
1171,71172,Oxprenolol hydrochloride,CC(C)NCC(COC1=CC=CC=C1OCC=C)O.Cl,,,"['Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. (See all compounds classified as Adrenergic beta-Antagonists.)', 'Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)', 'Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'Drugs that inhibit the actions of the sympathetic nervous system by any mechanism. The most common of these are the ADRENERGIC ANTAGONISTS and drugs that deplete norepinephrine or reduce the release of transmitters from adrenergic postganglionic terminals (see ADRENERGIC AGENTS). Drugs that act in the central nervous system to reduce sympathetic activity (e.g., centrally acting alpha-2 adrenergic agonists, see ADRENERGIC ALPHA-AGONISTS) are included here. (See all compounds classified as Sympatholytics.)', 'Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)']",,,
1172,71173,N-[5-[[5-[(3-amino-3-iminopropyl)carbamoyl]-1-methylpyrrol-3-yl]carbamoyl]-1-methylpyrrol-3-yl]-4-(hydroxymethylamino)-1-methylpyrrole-2-carboxamide;hydrochloride,CN1C=C(C=C1C(=O)NC2=CN(C(=C2)C(=O)NC3=CN(C(=C3)C(=O)NCCC(=N)N)C)C)NCO.Cl,,,,,,
1173,71174,N-[5-[[5-[(3-amino-3-iminopropyl)carbamoyl]-1-methylpyrrol-3-yl]carbamoyl]-1-methylpyrrol-3-yl]-4-(hydroxymethylamino)-1-methylpyrrole-2-carboxamide,CN1C=C(C=C1C(=O)NC2=CN(C(=C2)C(=O)NC3=CN(C(=C3)C(=O)NCCC(=N)N)C)C)NCO,,,,,,
1174,71175,Perhexiline maleate salt,C1CCC(CC1)C(CC2CCCCN2)C3CCCCC3.C(=CC(=O)O)C(=O)O,,,,,,
1175,71176,Talopram hydrochloride,CC1(C2=CC=CC=C2C(O1)(CCCNC)C3=CC=CC=C3)C.Cl,,,,,,
1176,71177,Methixene hydrochloride,CN1CCCC(C1)CC2C3=CC=CC=C3SC4=CC=CC=C24.O.Cl,,,,,,
1177,71178,CID 71178,C1=CC=C(C(=C1)C(=O)NCC(=O)[O-])[125I].[Na+],,,,,,
1178,71179,Iodohippuric acid I-125,C1=CC=C(C(=C1)C(=O)NCC(=O)O)[125I],,,,,,
1179,71180,Sodium phosphate P 32,O[32P](=O)([O-])[O-].[Na+].[Na+],,,,,,
1180,71181,(32P)Phosphoric acid,O[32P](=O)(O)O,,,,,,
1181,71182,Mesuprine hydrochloride,CC(C(C1=CC(=C(C=C1)O)NS(=O)(=O)C)O)NCCC2=CC=C(C=C2)OC.Cl,,,,,,
1182,71183,Methscopolamine,C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C,,"['Methscopolamine bromide is an anticholinergic agent which possesses most of the pharmacologic actions of that drug class. These include reduction in volume and total acid content of gastric secretion, inhibition of gastrointestinal motility, inhibition of salivary excretion, dilation of the pupil and inhibition of accommodation with resulting blurring of vision. Large doses may result in tachycardia [Dailymed].']",['Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)'],"['Methscopolamine bromide is a quaternary ammonium derivative of scopolamine. As a class, these agents are poorly and unreliably absorbed. Total absorption of quaternary ammonium derivatives of the alkaloids is 10-25%. Rate of absorption is not available. Quaternary ammonium salts have limited absorption from intact skin, and conjunctival penetration is poor. Little is known of the fate and excretion of most of these agents. Following oral administration, drug effects appear in about one hour and persist for 4 to 6 hours. Methscopolamine bromide has limited ability to cross the blood-brain barrier. The drug is excreted primarily in the urine and bile, or as unabsorbed drug in feces. There is no data on the presence of methscopolamine in breast milk; traces of atropine have been found after administration of atropine. /Methscopolamine bromide/', 'Methscopolamine bromide, like other quaternary ammonium drugs, is incompletely absorbed from the GI tract since it is completely ionized.  Little information is available on the distribution or metabolic fate of methscopolamine bromide in the body. Quaternary ammonium antimuscarinics are completely ionized and possess poor lipid solubility. Accordingly, they do not readily penetrate the CNS or the eye. Methscopolamine bromide, like other quaternary ammonium compounds, is believed to be excreted principally in urine as unchanged drug and metabolites and in the feces as unabsorbed drug. Substantial amounts of orally administered drug are probably eliminated in feces as unabsorbed drug. /Methscopolamine bromide/']","['... Little information is available on the distribution or metabolic fate of methscopolamine bromide in the body. ... Methscopolamine bromide, like other quaternary ammonium compounds, is believed to be excreted principally in urine as unchanged drug and metabolites and in the feces as unabsorbed drug. ... /Methscopolamine bromide/']",
1183,71184,Iobenguane (131I),C1=CC(=CC(=C1)[131I])CN=C(N)N,,,"['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)', 'Compounds that are used in medicine as sources of radiation for radiotherapy and for diagnostic purposes. They have numerous uses in research and industry. (Martindale, The Extra Pharmacopoeia, 30th ed, p1161) (See all compounds classified as Radiopharmaceuticals.)']",,,
1184,71185,CID 71185,C[C@H]1C(C(=O)N1OCC(=O)O)NC(=O)C(=NOC)C2=CSC(=N2)N,,,,,,
1185,71186,Ibafloxacin,CC1CCC2=C3N1C=C(C(=O)C3=CC(=C2C)F)C(=O)O,['* Dogs: :'],,,,,
1186,71187,Ipsapirone hydrochloride,C1CN(CCN1CCCCN2C(=O)C3=CC=CC=C3S2(=O)=O)C4=NC=CC=N4.Cl,,,"['Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)', 'Endogenous compounds and drugs that bind to and activate SEROTONIN RECEPTORS. Many serotonin receptor agonists are used as ANTIDEPRESSANTS; ANXIOLYTICS; and in the treatment of MIGRAINE DISORDERS. (See all compounds classified as Serotonin Receptor Agonists.)']",,,
1187,71188,Enrofloxacin,CCN1CCN(CC1)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4CC4)F,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],"['Pharmacokinetics and bioavailability of enrofloxacin were determined after single intravenous (IV) and intramuscular (IM) administrations of 5 mg/kg body weight (BW) to 5 healthy adult Angora goats. Plasma enrofloxacin concentrations were measured by high performance liquid chromatography. Pharmacokinetics were best described by a 2-compartment open model. The elimination half-life and volume of distribution after IV and IM administrations were similar (t1/2beta, 4.0 to 4.7 hr and Vd(ss),1.2 to 1.5 L/kg, respectively). Enrofloxacin was rapidly (t1/2a, 0.25 hr) and almost completely absorbed (F, 90%) after IM administration. Mean plasma concentrations of enrofloxacin at 24 hr after IV and IM administration (0.07 and 0.09 microg/mL, respectively) were higher than the minimal inhibitory concentration (MIC) values for most pathogens. In conclusion, once-daily IV and IM administration of enrofloxacin (5 mg/kg BW) in Angora goats may be useful in treatment of infectious diseases caused by sensitive pathogens.', 'Plasma, urine, and skin drug concentrations were determined for dogs (n=12) given five daily oral doses of marbofloxacin (MAR) (2.75 mg/kg), enrofloxacin (ENR) (5.0 mg/kg) or difloxacin (DIF) (5.0 mg/kg). Concentrations of the active metabolite of ENR, ciprofloxacin (CIP), were also determined. The three-period, three-treatment crossover experimental design included a 21-day washout period between treatments. Area under the plasma drug concentration vs. time curve (AUC0-last, microg/mlxhr of MAR was greater than for ENR, CIP, ENR/CIP combined, and DIF. Maximum concentration (Cmax) of MAR was greater than ENR, CIP, and DIF. Time of maximum plasma concentration (Tmax) was similar for MAR and DIF; Tmax occurred earlier for ENR and later for CIP. Plasma half-life (t1/2) of MAR was longer than for ENR, CIP, and DIF. Urine concentrations of DIF were less than MAR or ENR/CIP combined, but urine concentrations of MAR and ENR/CIP combined did not differ. DIF skin concentrations were less than the concentrations of MAR or ENR/CIP combined 2 h after dosing, but skin concentrations of MAR and ENR/CIP combined did not differ.', 'Serum concentrations and pharmacokinetics of enrofloxacin were studied in 6 mares after intravenous (IV) and intragastric (IG) administration at a single dose rate of 7.5 mg/kg body weight. In experiment 1, an injectable formulation of enrofloxacin (100 mg/ml) was given IV. At 5 min after injection, mean serum concentration was 9.04 microg/mL and decreased to 0.09 microg/mL by 24 hr. Elimination half-life was 5.33 +/- 1.05 hr and the area under the serum concentration vs time curve (AUC) was 21.03 +/- 5.19 mg x hr/L. In experiment 2, the same injectable formulation was given IG. The mean peak serum concentration was 0.94 +/- 0.97 microg/ml at 4 hr after administration and declined to 0.29 +/- 0.12 microg/ml by 24 hr. Absorption of this enrofloxacin preparation after IG administration was highly variable, and for this reason, pharmacokinetic values for each mare could not be determined. In experiment 3, a poultry formulation (32.3 mg/ml) was given IG. The mean peak serum concentration was 1.85 +/- 1.47 microg/ml at 45 min after administration and declined to 0.19 +/- 0.06 microg/mL by 24 h. Elimination half-life was 10.62 +/- 5.33 h and AUC was 16.30 +/- 4.69 mg x h/L. Bioavailability was calculated at 78.29 +/- 16.55%. Minimum inhibitory concentrations of enrofloxacin were determined for equine bacterial culture specimens submitted to the microbiology laboratory over an 11-month period. The minimum inhibitory concentration of enrofloxacin required to inhibit 90% of isolates (MIC90) was 0.25 microg/ml for Staphylococcus aureus, Escherichia coli, Salmonella spp., Klebsiella spp., and Pasteurella spp. The poultry formulation was well tolerated and could be potentially useful in the treatment of susceptible bacterial infections in adult horses. The injectable enrofloxacin solution should not be used orally.', 'Concentrations of enrofloxacin equivalent activity were determined by microbiological assay in the plasma of healthy and E. coli-infected broilers following single intravenous and oral administrations at 10 mg/kg. Tissue distribution and residue-depletion following multiple oral doses (10 mg/kg for 3 successive days) were investigated. Pharmacokinetic variables were determined using compartmental and non-compartmental analytical methods. Plasma enrofloxacin concentrations after intravenous dosing to healthy and infected birds were best described by a two-compartments model. Enrofloxacin concentrations in plasma of infected birds were lower than those of healthy ones. The disposition kinetics of intravenously administered drug in healthy and infected birds were somewhat different. The elimination half-life (t1/2 beta) was 4.75 vs. 3.63 hr; mean residence time (MRT) was 6.72 vs 4.90 hr; apparent volume of the central compartment (Vc) was 1.11 vs 1.57 l/kg; rate constant for transfer from peripheral to central compartment (k21) was 1.15 vs 1.41 hr-1 and total body clearance (ClB) was 0.35 vs 0.53 l/hr/kg in healthy and infected birds, respectively. After oral administration, the absorption half-life (t1/2abs) in the infected birds was significantly longer than in healthy birds, while elimination half-life (t1/2el) and MRT were significantly shorter. Bioavailability was higher in infected birds (72.50%) as compared to healthy ones (69.78%). Enrofloxacin was detected in the tissues of healthy and infected birds after daily oral dosing of 10 mg/kg for 3 days. It was more concentrated in liver, kidney, and breast muscle. The minimal inhibitory concentration (MIC) of enrofloxacin against E. coli was 0.064 microgram/ml. On the basis of maintaining enrofloxacin plasma concentrations over the MIC, a dose of 10 mg/kg given intravenously every 20.14 hr or orally every 20.86 hr should provide tissue concentrations effective against E. coli infection in chickens.', 'For more Absorption, Distribution and Excretion (Complete) data for ENROFLOXACIN (6 total), please visit the HSDB record page.']","['The pharmacokinetics of enrofloxacin and its active metabolite ciprofloxacin were investigated in goats after a single intramuscular administration of enrofloxacin at 2.5 mg/kg body weight. The plasma concentrations of enrofloxacin and ciprofloxacin were determined simultaneously by a HPLC method. The peak concentrations (Cmax) of enrofloxacin (1.13 microg/ml) and ciprofloxacin (0.24 microg/ml) were observed at 0.8 and 1.2 hr, respectively. The elimination half-life (t1/2beta), volume of distribution (Vd(area)), total body clearance (Cl(B)) and mean residence time (MRT) of enrofloxacin were 0.74 hr, 1.42 l/kg, 1329 ml/hr per kg and 1.54 hr, respectively. The t1/2beta, area under the plasma concentration-time curve (AUC) and the MRT of ciprofloxacin were 1.38 h, 0.74 microg h/ml and 2.73 h, respectively. The metabolic conversion of enrofloxacin to ciprofloxacin was appreciable (36%) and the sum of the plasma concentrations of enrofloxacin and ciprofloxacin was maintained at or above 0.1 microg/ml for up to 4 hr. Enrofloxacin appears to be useful for the treatment of goat diseases associated with pathogens sensitive to this drug.']",
1188,71189,CI 946; Go 4942; Goe 4942; PD 117818,CC1=C(C(=CC=C1)Cl)NC(=O)C=C2N(C(=O)CS2)C,,,,,,
1189,71190,CID 71190,CCN(CC)C(=NNC=C1C(=C2C3=C(C1=NC(=O)C(=CC=CC(C(C(C(C(C(C(C(C=COC4(C(=O)C2=C(O4)C(=C3O)C)C)OC)C)OC(=O)C)C)O)C)O)C)C)O)O)C,,,,,,
1190,71191,Cromakalim,CC1([C@@H]([C@H](C2=C(O1)C=CC(=C2)C#N)N3CCCC3=O)O)C,,,"['Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)', 'Agents that cause an increase in the expansion of a bronchus or bronchial tubes. (See all compounds classified as Bronchodilator Agents.)', 'Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)']",,,
1191,71192,"7-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-1,4-dithiaspiro[4.4]nonane-8-carboxylic acid;hydrochloride",CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)C2CC3(CC2C(=O)O)SCCS3.Cl,,,,,,
1192,71193,"7-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-1,4-dithiaspiro[4.4]nonane-8-carboxylic acid",CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)C2CC3(CC2C(=O)O)SCCS3,,,,,,
1193,71194,Clofenamic acid,C1=CC=C(C(=C1)C(=O)O)NC2=C(C(=CC=C2)Cl)Cl,,,,,,
1194,71195,Meprotixol,CN(C)CCCC1(C2=CC=CC=C2SC3=C1C=C(C=C3)OC)O,,,,,,
1195,71196,Barbexaclone,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2.C[C@@H](CC1CCCCC1)NC,"['Created for the treatment for epilepsy, with the intent of creating an antiepileptic with less sedative properties than phenobarbital.']",,,"['After oral administration of barbexaclone in mice the maximum plasma levels of  prophylhexedrine appeared after 4 minutes, and propylhexedrine was seen to penetrate the blood brain barrier rapidly.  Bioavailability (AUC oral / AUC iv) = 0.37. [3] Phenobarbital was observed to reach the blood more slowly, and brain uptake was a slow process.  Equilibrium concentrations with plasma reached after 30 minutes after i.v injection. [3]', 'In mice, the volume of distribution was 0.78L/kg of phenobarbital, and 19.3L/kg for propylhexedrine, after i.v. administration. [3] High but unequal tissue accumulation of propylhexedrine was observed in mice:  lung = kidney > liver = brain > spleen > heart > skeletal muscle.  [3]']",,"['After IV administration in mice, levels of phenobarbital declined exponentially with a half life of 7.5h. [3] For propylhexedrine t0.5a = 0.31h and t0.5b = 2.5h.']"
1196,71197,Levopropylhexedrine,C[C@@H](CC1CCCCC1)NC,,,,,,
1197,71198,Amikhelline,CCN(CC)CCOC1=C2C(=C(C3=C1OC(=CC3=O)C)O)C=CO2,,,,,,
1198,71199,Persilic acid,C1=C(C(=CC(=C1S(=O)(=O)O)O)S(=O)(=O)O)O,,,,,,
1199,71200,"(1alpha,4alpha)-N,N,N',N'-Tetraethylbicyclo[2.2.1]hept-5-ene-2beta,3alpha-dicarboxamide",CCN(CC)C(=O)[C@@H]1[C@@H]2C[C@H]([C@H]1C(=O)N(CC)CC)C=C2,,,,,,
1200,71201,"(2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(1R,2S,4R,6S)-4,6-diamino-3-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxyoxane-3,4-diol",C1[C@@H]([C@H]([C@@H](C([C@@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CN)O)O)N)N,,,,,,
1201,71202,Botiacrine,CC1(C2=CC=CC=C2N(C3=CC=CC=C31)C(=O)SCCN(C)C)C,,,,,,
1202,71203,Vinburnine,CC[C@@]12CCCN3[C@@H]1C4=C(CC3)C5=CC=CC=C5N4C(=O)C2,,,['Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)'],,,
1203,71204,Apovincamine,CC[C@@]12CCCN3[C@@H]1C4=C(CC3)C5=CC=CC=C5N4C(=C2)C(=O)OC,,,,,,
1204,71205,Danosteine,C(CSCC(=O)O)C(=O)O,,,,,,
1205,71206,Prednisolone steaglate,CCCCCCCCCCCCCCCCCC(=O)OCC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)C=C[C@]34C)O)C)O,,,,,,
1206,71207,CID 71207,C1=NNC2=C1C(=NC=N2)S,,,,,,
1207,71208,Tiliquinol,CC1=C2C=CC=NC2=C(C=C1)O,,,,,,
1208,71209,Dichlormezanone,CN1C(S(=O)(=O)CCC1=O)C2=CC(=C(C=C2)Cl)Cl,,,,,,
1209,71210,Paxamate,CNC(=O)OC1=CC=C(C=C1)C2=CC=CC=C2,,,,,,
1210,71211,Nicoxamat,C1=CC(=CN=C1)C(=O)NO,,,,,,
1211,71212,Detrothyronine,C1=CC(=C(C=C1OC2=C(C=C(C=C2I)C[C@H](C(=O)O)N)I)I)O,,,,,,
1212,71213,Moprolol,CC(C)NCC(COC1=CC=CC=C1OC)O,,,,,,
1213,71214,CID 71214,CN1CC(=O)N=C1NP(=O)(O)O,,,,,,
1214,71215,Toloxychlorinol,CC1=CC=CC=C1OCC(COC(C(Cl)(Cl)Cl)O)OC(C(Cl)(Cl)Cl)O,,,,,,
1215,71216,CID 71216,CC1(CC(=O)C2=CC=CC=C2C1=O)S(=O)(=O)[O-].O.O.O.[Na+],,,,,,
1216,71217,n-[1-(Dimethylamino)-1-oxobutan-2-yl]-n-ethylbut-2-enamide,CCC(C(=O)N(C)C)N(CC)C(=O)C=CC,,,,,,
1217,71218,Anaxirone,C1C(O1)CN2C(=O)N(N(C2=O)CC3CO3)CC4CO4,,,['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)'],,,
1218,71219,Pipequaline,C1CNCCC1CCC2=CC(=NC3=CC=CC=C32)C4=CC=CC=C4,,,['Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)'],,,
1219,71220,Tolpadol,CC1=CC=CC=C1C(=O)NC(C2=CC=NC=C2)C(C3=CC=NC=C3)NC(=O)C4=CC=CC=C4C,,,,,,
1220,71221,"4-[(2S)-2-aminopropyl]-N,N,3-trimethylaniline",CC1=C(C=CC(=C1)N(C)C)C[C@H](C)N,,,"['A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman&apos;s The Pharmacological Basis of Therapeutics, 8th ed, p414) (See all compounds classified as Monoamine Oxidase Inhibitors.)']",,,
1221,71222,Falipamil,CN(CCCN1CC2=CC(=C(C=C2C1=O)OC)OC)CCC3=CC(=C(C=C3)OC)OC,,,"['Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)', 'A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)', 'Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume. (See all compounds classified as Cardiovascular Agents.)', 'Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)']",,,
1222,71223,Picoprazole,CC1=C(N=CC=C1)CS(=O)C2=NC3=C(N2)C=C(C(=C3)C(=O)OC)C,,,,,,
1223,71224,Filenadol,C[C@@H]([C@@H](C1=CC2=C(C=C1)OCO2)N3CCOCC3)O,,,,,,
1224,71225,Emopamil,CC(C)C(CCCN(C)CCC1=CC=CC=C1)(C#N)C2=CC=CC=C2,,,['A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)'],,,
1225,71226,Ociltide,C1CSC(=O)C1NC(=O)C(CC2=CC=CC=C2)NC(=O)CNC(=O)C(CCCCNC=O)NC(=O)C(CC3=CC=C(C=C3)O)N,,,,,,
1226,71227,Adimolol,CC(C)(CCN1C2=CC=CC=C2NC1=O)NCC(COC3=CC=CC4=CC=CC=C43)O,,,,,,
1227,71228,Razobazam,CC1=C2C(=NN1)N(C(=O)CC(=O)N2C3=CC=CC=C3)C,,,,,,
1228,71229,Dicresulene,CC1=CC(=C(C=C1CC2=CC(=C(C=C2C)O)S(=O)(=O)O)S(=O)(=O)O)O,,,,,,
1229,71230,Posatirelin,CC(C)C[C@@H](C(=O)N1CCC[C@H]1C(=O)N)NC(=O)[C@@H]2CCCC(=O)N2,,,,,,
1230,71231,Sarmazenil,CCOC(=O)C1=C2CN(C(=O)C3=C(N2C=N1)C=CC=C3Cl)C,,,,,,
1231,71232,Rosterolone,CCC[C@@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3([C@H](CC(=O)C4)C)C)C)O,,,,,,
1232,71233,Icospiramide,C1CC(CCC1N2CCC3(CC2)C(=O)N(CN3C4=CC=C(C=C4)F)CC(=O)N)(C#N)C5=CC=C(C=C5)F,,,,,,
1233,71234,Nicaraven,CC(CNC(=O)C1=CN=CC=C1)NC(=O)C2=CN=CC=C2,['Investigated for use/treatment in cerebrovascular disease (unspecified).'],,['Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. (See all compounds classified as Antioxidants.)'],,,
1234,71235,Vebufloxacin,CC1CCC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O,,,,,,
1235,71236,Dopropidil,CC#CC1(CCCCC1)OCC(COCC(C)C)N2CCCC2,,,,,,
1236,71237,Neridronic acid,C(CCC(O)(P(=O)(O)O)P(=O)(O)O)CCN,,,,,,
1237,71238,CID 71238,COCC1=C(N2[C@@H]([C@@H](C2=O)NC(=C(C3=CSC(=N3)N)N=O)O)SC1)C(=O)O,,,,,,
1238,71239,CID 71239,CCCCC[C@H](C=C[C@@H]1[C@H](C[C@@H]2[C@H]1CC(=N2)SCCCC(=O)OC)O)O,,,,,,
1239,71240,Tefludazine,C1CN(CCN1CCO)[C@@H]2C[C@H](C3=C2C=C(C=C3)C(F)(F)F)C4=CC=C(C=C4)F,,,,,,
1240,71241,Mafoprazine,CC(=O)NC1=CC(=C(C=C1)OCCCN2CCN(CC2)C3=CC=CC=C3F)OC,,,,,,
1241,71242,1-[3-(Benzyloxy)oct-1-en-1-yl]-1H-imidazole,CCCCCC(C=CN1C=CN=C1)OCC2=CC=CC=C2,,,,,,
1242,71243,"2-Deoxy-2-{[hydroxy(pyridin-3-yl)methylidene]amino}-1,3,4,6-tetra-O-(pyridine-3-carbonyl)hexopyranose",C1=CC(=CN=C1)C(=O)N[C@@H]2[C@H]([C@@H](C(O[C@H]2OC(=O)C3=CN=CC=C3)COC(=O)C4=CN=CC=C4)OC(=O)C5=CN=CC=C5)OC(=O)C6=CN=CC=C6,,,,,,
1243,71244,Rentiapril,C1[C@H](N([C@H](S1)C2=CC=CC=C2O)C(=O)CCS)C(=O)O,,,"['A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. (See all compounds classified as Angiotensin-Converting Enzyme Inhibitors.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)']",,,
1244,71245,Etofenprox,CCOC1=CC=C(C=C1)C(C)(C)COCC2=CC(=CC=C2)OC3=CC=CC=C3,,,,,,
1245,71246,Flosulide,CS(=O)(=O)NC1=C(C=C2C(=C1)CCC2=O)OC3=C(C=C(C=C3)F)F,,,"['Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)', 'Compounds or agents that combine with cyclooxygenase (PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES) and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes. (See all compounds classified as Cyclooxygenase Inhibitors.)']",,,
1246,71247,Iodecimol,C(CO)N(C1=C(C(=C(C(=C1I)C(=O)NC(CO)CO)I)C(=O)NC(CO)CO)I)C(=O)CC(=O)N(CCO)C2=C(C(=C(C(=C2I)C(=O)NC(CO)CO)I)C(=O)NC(CO)CO)I,,,,,,
1247,71248,Taltrimide,CC(C)NS(=O)(=O)CCN1C(=O)C2=CC=CC=C2C1=O,,,,,,
1248,71249,Diprafenone,CCC(C)(C)NCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O,,,"['Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)']",,,
1249,71250,Guaimesal,CC1(OC2=CC=CC=C2C(=O)O1)OC3=CC=CC=C3OC,,,,,,
1250,71251,CID 71251,CN1C2C(C(=O)N(C1=O)C)N(C=N2)CCCN[C@H]3CO[C@H]4[C@@H]3OC[C@@H]4O[N+](=O)[O-],,,,,,
1251,71252,Batebulast,CC(C)(C)C1=CC=C(C=C1)OC(=O)C2CCC(CC2)CN=C(N)N,,,"['Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. (See all compounds classified as Histamine H1 Antagonists.)', 'Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES). (See all compounds classified as Protease Inhibitors.)', 'Serine proteinase inhibitors which inhibit trypsin. They may be endogenous or exogenous compounds. (See all compounds classified as Trypsin Inhibitors.)']",,,
1252,71253,Alpiropride,CNS(=O)(=O)C1=C(C=C(C(=C1)C(=O)NCC2CCCN2CC=C)OC)N,,,,,,
1253,71254,Flerobuterol,CC(C)(C)NCC(C1=CC=CC=C1F)O,,,,,,
1254,71255,Flufylline,CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CCN3CCC(CC3)C(=O)C4=CC=C(C=C4)F,,,,,,
1255,71256,"(7R)-3-((1,2,3-thiadiazol-5-ylthio)methyl)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid",CON=C(C1=CSC(=N1)N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)CSC4=CN=NS4)C(=O)O,,,,,,
1256,71257,Girisopam,CC1=NN=C(C2=CC(=C(C=C2C1)OC)OC)C3=CC(=CC=C3)Cl,,,,,,
1257,71258,Moxiraprine,CC1=CC(=NN=C1NCCN2CCOCC2)C3=CC=C(C=C3)O,,,,,['4-Hydroxyminaprine is a known human metabolite of minaprine.'],
1258,71259,CID 71259,CC1=NN(N=N1)CC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)O,,,,,,
1259,71260,Flurithromycin,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)(C)F)C)O)(C)O,,,['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)'],,,
1260,71261,Mabuprofen,CC(C)CC1=CC=C(C=C1)C(C)C(=O)NCCO,,,,,,
1261,71262,Zabicipril,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@@H](C3CCC2CC3)C(=O)O,,,,,,
1262,71263,Mifentidine,CC(C)N=CNC1=CC=C(C=C1)C2=CN=CN2,,,"['Drugs that selectively bind to but do not activate histamine H2 receptors, thereby blocking the actions of histamine. Their clinically most important action is the inhibition of acid secretion in the treatment of gastrointestinal ulcers. Smooth muscle may also be affected. Some drugs in this class have strong effects in the central nervous system, but these actions are not well understood. (See all compounds classified as Histamine H2 Antagonists.)', 'Compounds which inhibit or antagonize the biosynthesis or actions of androgens. (See all compounds classified as Androgen Antagonists.)']",,,
1263,71264,Tiracizine,CCOC(=O)NC1=CC2=C(CCC3=CC=CC=C3N2C(=O)CN(C)C)C=C1,,,"['A loosely defined grouping of drugs that have effects on psychological function. Here the psychotropic agents include the antidepressive agents, hallucinogens, and tranquilizing agents (including the antipsychotics and anti-anxiety agents). (See all compounds classified as Psychotropic Drugs.)', 'Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)']",,,
1264,71265,Ridazolol,C1=CC=C(C(=C1)OCC(CNCCNC2=C(C(=O)NN=C2)Cl)O)Cl,,,,,,
1265,71266,Bromerguride,CCN(CC)C(=O)N[C@@H]1CN([C@@H]2CC3=C(NC4=CC=CC(=C34)C2=C1)Br)C,,,,,,
1266,71267,Pincainide,CC1=C(C(=CC=C1)C)NC(=O)CN2CCCCCC2,,,,,,
1267,71268,Ipramidil,CC(C)NC(=O)C1=NO[N+](=C1C(=O)NC(C)C)[O-],,,,,,
1268,71269,"(1R,3S)-5-[2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-7,7,7-trifluoro-6-hydroxy-6-(trifluoromethyl)heptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol",C[C@H](CCCC(C(F)(F)F)(C(F)(F)F)O)[C@H]1CC[C@@H]2[C@@]1(CCCC2=CC=C3C[C@H](C[C@@H](C3=C)O)O)C,,,,,,
1269,71270,Ambasilide,C1C2CN(CC1CN(C2)C(=O)C3=CC=C(C=C3)N)CC4=CC=CC=C4,,,,,,
1270,71271,"5-[(3aS,4R,5R,6aS)-4-[(3S)-3-cyclopentyl-3-hydroxyprop-1-enyl]-5-hydroxy-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid",C1CCC(C1)[C@@H](C=C[C@H]2[C@@H](C[C@H]3[C@@H]2CC(=CCCCC(=O)O)C3)O)O,,,,,,
1271,71272,Metaclazepam,CN1C(CN=C(C2=C1C=CC(=C2)Br)C3=CC=CC=C3Cl)COC,,,,,,
1272,71273,"N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide",CCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C,,,"['Drugs that block nerve conduction when applied locally to nerve tissue in appropriate concentrations. They act on any part of the nervous system and on every type of nerve fiber. In contact with a nerve trunk, these anesthetics can cause both sensory and motor paralysis in the innervated area. Their action is completely reversible. (From Gilman AG, et. al., Goodman and Gilman&apos;s The Pharmacological Basis of Therapeutics, 8th ed) Nearly all local anesthetics act by reducing the tendency of voltage-dependent sodium channels to activate. (See all compounds classified as Anesthetics, Local.)']",,,
1273,71274,Ramixotidine,CN(C)CC1=CC=C(O1)CSCCNC(=O)C2=C[N+](=CC=C2)[O-],,,,,,
1274,71275,CID 71275,C=C(C1=CC=CC=C1C(=O)O)N2CCSC2,,,,,,
1275,71276,Erythromycin stinoprate,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)OC(=O)CC)(C)O)C)C)O)(C)O.CC(=O)N[C@@H](CS)C(=O)O,,,,,,
1276,71277,Erythromycin propionate,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)OC(=O)CC)(C)O)C)C)O)(C)O,,,,,,
1277,71278,"4-Oxo-4-(3,4,5-trimethoxyphenyl)but-2-enoic acid",COC1=CC(=CC(=C1OC)OC)C(=O)C=CC(=O)O,,,,,,
1278,71279,Ranolazine dihydrochloride,CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CC(COC3=CC=CC=C3OC)O.Cl.Cl,,,"['Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume. (See all compounds classified as Cardiovascular Agents.)', 'A class of drugs that act by inhibition of sodium influx through cell membranes. Blockade of sodium channels slows the rate and amplitude of initial rapid depolarization, reduces cell excitability, and reduces conduction velocity. (See all compounds classified as Sodium Channel Blockers.)']",,,
1279,71280,"[(2S,3R,4S,6R)-4-(dimethylamino)-2-[[(3R,5S,6R,7R,9R,11R,12R,13S,14R)-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-2,10-dioxo-oxacyclotetradec-6-yl]oxy]-6-methyloxan-3-yl] acetate;octadecanoic acid",CCCCCCCCCCCCCCCCCC(=O)O.CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)OC(=O)C)(C)O)C)C)O)(C)O,,,,,,
1280,71281,"[(2S,3R,4S,6R)-4-(dimethylamino)-2-[[(3R,5S,6R,7R,9R,11R,12R,13S,14R)-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-2,10-dioxo-oxacyclotetradec-6-yl]oxy]-6-methyloxan-3-yl] acetate",CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)OC(=O)C)(C)O)C)C)O)(C)O,,,,,,
1281,71282,Guanidine Monohydrobromide,C(=N)(N)N.Br,,,,,,
1282,71283,Liothyronine hydrochloride,C1=CC(=C(C=C1OC2=C(C=C(C=C2I)C[C@@H](C(=O)O)N)I)I)O.Cl,,,,,,
1283,71284,Thiamine bromide,CC1=C(SC=[N+]1CC2=CN=C(N=C2N)C)CCO.[Br-],,,,,,
1284,71285,MDMA hydrochloride,CC(CC1=CC2=C(C=C1)OCO2)NC.Cl,,,"['Drugs capable of inducing illusions, hallucinations, delusions, paranoid ideations, and other alterations of mood and thinking. Despite the name, the feature that distinguishes these agents from other classes of drugs is their capacity to induce states of altered perception, thought, and feeling that are not experienced otherwise. (See all compounds classified as Hallucinogens.)', 'Drugs used for their effects on serotonergic systems. Among these are drugs that affect serotonin receptors, the life cycle of serotonin, and the survival of serotonergic neurons. (See all compounds classified as Serotonin Agents.)', 'Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin. (See all compounds classified as Adrenergic Uptake Inhibitors.)']",,,
1285,71286,Ephedrine camsilate,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.CC1([C@@H]2CC[C@]1(C(=O)C2)CS(=O)(=O)O)C,,,,,,
1286,71287,2-(Methylamino)-1-phenylpropyl dihydrogen phosphate,CC(C(C1=CC=CC=C1)OP(=O)(O)O)NC,,,,,,
1287,71288,alpha-(1-(Methylamino)ethyl)benzyl alcohol hydrogen sulfate,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.OS(=O)(=O)O,,,,,,
1288,71289,Ephedrine acefyllinate,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(=O)O,,,,,,
1289,71290,2-Methylamino-1-phenylpropan-2-ol hydrochloride,C[C@H]([C@H](C1=CC=CC=C1)O)NC.Cl,,,,,,
1290,71291,"[(1R,2S)-2-(methylamino)-1-phenylpropyl] acetate",C[C@@H]([C@@H](C1=CC=CC=C1)OC(=O)C)NC,,,,,,
1291,71292,D-alpha-(1-(Methylamino)ethyl)benzyl phosphate,C[C@H]([C@H](C1=CC=CC=C1)OP(=O)(O)O)NC,,,,,,
1292,71293,DL-alpha-(1-(Methylamino)ethyl)benzyl phosphate,C[C@@H]([C@@H](C1=CC=CC=C1)OP(=O)(O)O)NC,,,,,,
1293,71294,"1-Propanethiol, 2-(methylamino)-1-phenyl-, hydrochloride",C[C@@H]([C@@H](C1=CC=CC=C1)S)NC.Cl,,,,,,
1294,71295,CID 71295,C[C@@H](C(C1=CC=CC=C1)S)NC,,,,,,
1295,71296,"Ephedrine, thiocyanate",CC(C(C1=CC=CC=C1)O)NC.C(#N)S,,,,,,
1296,71297,CID 71297,CC1=C(C(=O)N(N1C)C2=CC=CC=C2)C(C)C.C[C@H]([C@@H](C1=CC=CC=C1)O)NC,,,,,,
1297,71298,CID 71298,CCCCCCCCCCC[C@@H](C[C@H]1C(C(=O)O1)CCCCCC)OC(=O)C(CC(C)C)NCO,,,,,,
1298,71299,"3-[(1S,2R)-1-hydroxy-1-[3-(2H-tetrazol-5-yl)phenyl]pentadeca-3,5-dien-2-yl]sulfanylpropanoic acid",CCCCCCCCCC=CC=C[C@H]([C@H](C1=CC=CC(=C1)C2=NNN=N2)O)SCCC(=O)O,,,,,,
1299,71300,Barmastine,CC1=C(C(=O)N2C=CC=CC2=N1)CCN3CCC(CC3)NC4=NC5=C(N4CC6=CC=CO6)N=CC=C5,,,,,,
1300,71301,Nebivolol,C1CC2=C(C=CC(=C2)F)OC1C(CNCC(C3CCC4=C(O3)C=CC(=C4)F)O)O,['Nebivolol is indicated to treat hypertension.'],"['Nebivolol is a selective beta-1 adrenergic receptor antagonist that decreases vascular resistance, increases stroke volume and cardiac output, and does not negatively affect left ventricular function. It has a long duration of action as effects can be seen 48 hours after stopping the medication and a wide therapeutic window as patients generally take 5-40mg daily. Patients should not abruptly stop taking this medication as this may lead to exacerbation of coronary artery disease. Diabetic patients should monitor their blood glucose levels as beta blockers may mask signs of hypoglycemia.']","['Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'Compounds that bind to and activate ADRENERGIC BETA-1 RECEPTORS. (See all compounds classified as Adrenergic beta-1 Receptor Agonists.)', 'Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)']","['The absorption of nebivolol is not affected by food. Nebivolol has a T<sub>max</sub> of 1.5-4 hours. Bioavailability can range from 12-96% for extensive to poor CYP2D6 metabolizers. For a 20mg dose, d-nebivolol has a C<sub>max</sub> of 2.75±1.55ng/mL, l-nebivolol has a C<sub>max</sub> of 5.29±2.06ng/mL, both enantiomers have a C<sub>max</sub> of 8.02±3.47ng/mL, and nebivolol glucuronides have a C<sub>max</sub> of 68.34±44.68ng/mL. For a 20mg dose, d-nebivolol has an AUC of 13.78±15.27ng\\*h/mL, l-nebivolol has an AUC of 27.72±15.32ng\\*h/mL, both enantiomers have an AUC of 41.50±29.76ng\\*h/mL, and nebivolol glucuronides have an AUC of 396.78±297.94ng\\*h/mL.', 'In extensive CYP2D6 metabolizers, 38% is eliminated in the urine and 44% in the feces. In poor CYP2D6 metabolizers, 67% is eliminated in the urine and 13% in the feces. <1% of a dose is excreted as the unmetabolized drug.', 'For a 20mg dose, d-nebivolol has an apparent volume of distribution of 10,290.81±3911.72L, l-nebivolol has an apparent volume of distribution of 8,066.66±4,055.50L, and both enantiomers together have a volume of distribution of 10,423.42±6796.50L.', 'For a 20mg dose, the clearance of d-nebivolol is 1241.63±749.77L/h, l-nebivolol is 435.53±180.93L/h, and both enantiomers is 635.31±300.25L/h.']","['Nebivolol is metabolized mainly by glucuronidation and CYP2D6 mediated hydroxylation. Metabolism involves n-dealkylation, hydroxylation, oxidation, and glucuronidation. Aromatic hydroxyl and acyclic oxide metabolites are active, while n-dealkylated and glucuronides are inactive.']",['d-nebivolol has a half life of 12 hours in CYP2D6 extensive metabolizers and 19 hours in poor metabolizers.']
1301,71302,Tiqueside,C[C@@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)C[C@@H]4[C@@]3(CC[C@H]5[C@H]4CC[C@@H]6[C@@]5(CCC(C6)O[C@H]7[C@@H]([C@H](C([C@H](O7)CO)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)O)O)C)C)C)OC1,,,,,,
1302,71303,"(1R,4S,4'S,5'S,6R,6'S,8R,13R,20R,21R,24S)-4',21,24-trihydroxy-5',11,13,22-tetramethyl-6'-(4-methylpent-2-en-2-yl)spiro[3,7,19-trioxatetracyclo[15.6.1.14,8.020,24]pentacosa-10,14,16,22-tetraene-6,2'-oxane]-2-one",C[C@@H]1CC(=CC[C@@H]2C[C@@H](C[C@@]3(O2)C[C@@H]([C@@H]([C@H](O3)C(=CC(C)C)C)C)O)OC(=O)[C@@H]4C=C([C@H]([C@@H]5[C@]4(C(=CC=C1)CO5)O)O)C)C,,,,,,
1303,71304,Tameridone,CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CCN3CCC(CC3)C4=CNC5=CC=CC=C54,,,,,,
1304,71305,Nanterinone,CC1=CC(=CC2=C1NC(=O)C=C2)N3C=C(N=C3C)C,,,,,,
1305,71306,Ccris 6495,CC(C)C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CC6=CNC7=CC=CC=C76)C(=O)N,,,"['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)', 'Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)']",,,
1306,71307,Lazabemide,C1=CC(=NC=C1Cl)C(=O)NCCN,,,"['A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman&apos;s The Pharmacological Basis of Therapeutics, 8th ed, p414) (See all compounds classified as Monoamine Oxidase Inhibitors.)', 'Agents used in the treatment of Parkinson&apos;s disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. (See all compounds classified as Antiparkinson Agents.)']",,,
1307,71308,CID 71308,CON=C(C1=CSC(=N1)N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)CSC(=O)C4=CC=CO4)C(=O)[O-].[Na+],,,,,,
1308,71309,Ceftiofur,CON=C(C1=CSC(=N1)N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)CSC(=O)C4=CC=CO4)C(=O)O,['* Pigs:'],,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],"['A study of 4 male and 4 female Sprague-Dawley rats treated intramuscularly with (14)C-ceftiofur (2 mg/kg bw) revealed that 55% of the administered dose was excreted in the urine and about 30% in the GI tract and feces. The major urinary metabolite was desfuroylceftiofur (DFC). The metabolism of ceftiofur was similar in calves administered (14)C-ceftiofur (2 mg/kg bw) via the i.m. route. Unmetabolized ceftiofur was also present in the urine (4.4-21% of total radioactivity).', 'A group of Sprague-Dawley rats (7/sex) received single oral doses of (14)C-ceftiofur (200 mg/kg bw) in a comparative study with calves. Approximately 55% of the total dose was recovered in the urine and the rest was present in the feces and GI tract. Plasma concentration at 6 hr was 1 mg/kg and trace amounts of ceftiofur were present in all tissues (i.e. liver, muscle and fat). The highest residue levels (0.7 mg/kg) were present in kidney.', 'A study of lactating cows treated with (14)C-ceftiofur (2.3 mg/kg bw/day for 5 days) revealed that 32-38% of the radioactivity was present in the milk as free metabolites. The major metabolite was desfuroylceftiofur cysteine disulfide representing 7-9% of the total radioactivity. No parent compound was detected in the milk.', 'A study of im administration of (14)C-ceftiofur in a bull revealed that 55% of the administered dose was excreted in the urine and approximately 30% in the GI tract and feces. The initial metabolite in both urine and plasma was desfuroylceftiofur. HPLC analysis of radioactive metabolites was similar to the results found in the rat studies. A number of metabolites were produced, the major metabolite (87% of total urinary metabolites) being desfuroylceftiofur acetamide conjugates. No parent compound was observed in the urine.', 'For more Absorption, Distribution and Excretion (Complete) data for CEFTIOFUR (13 total), please visit the HSDB record page.']","['A study of 4 male and 4 female Sprague-Dawley rats treated intramuscularly with (14)C-ceftiofur (2 mg/kg bw) revealed that 55% of the administered dose was excreted in the urine and about 30% in the GI tract and faeces. The major urinary metabolite was desfuroylceftiofur (DFC). The metabolism of ceftiofur was similar in calves administered (14)C-ceftiofur (2 mg/kg bw) via the i.m. route. Unmetabolized ceftiofur was also present in the urine (4.4-21% of total radioactivity).', 'A group of Sprague-Dawley rats (7/sex) received single oral doses of (14)C-ceftiofur (200 mg/kg bw) in a comparative study with calves. Approximately 55% of the total dose was recovered in the urine and the rest was present in the feces and GI tract. ... The major urinary metabolite was ceftiofursulfoxide cysteine thioester.', 'HPLC analysis of metabolites of (14)C-ceftiofur formed by arochlor-induced rat liver S-9 fractions  in vitro revealed that desfuroylceftiofur was the major metabolite. Low doses (119 mg/kg bw) of ceftiofur were completely metabolized within 15 minutes. Higher doses (857 mg/kg bw) were converted to desfuroylceftiofur after 60 minutes of incubation.', 'A study in 8-week old Sprague-Dawley rats (7/sex) treated with (14)C-ceftiofur (800 mg/kg bw/day) by oral gavage for 5 days revealed several urinary metabolites, including desfuroylceftiofur,  ceftiofur sulfoxide, and cysteine disulfide.', 'For more Metabolism/Metabolites (Complete) data for CEFTIOFUR (15 total), please visit the HSDB record page.']","['Six Friesian calves (3/sex) were treated with ceftiofur according to different protocols including one single im and iv injection at 1 mg/kg bw, and 5 i.m. injections at 1 mg/kg bw at 24 hr intervals. ...  The half life (0.07 hr) was short due to rapid metabolism to desfuroylceftiofur. The t1/2 of desfuroylceftiofur after im and iv administration were similar (9.7 and 8.6 hr, respectively).', 'A study of 4 calves (sex and breed unspecified) administered ceftiofur intramuscularly daily for 4 days at 2 dose levels (2.2 or 4.4 mg/kg bw/day) demonstrated a plasma half life of 3.5 hr. ... Plasma half life of the metabolite desfuroylceftiofur was 9.7 h after im administration.', 'A study of 4- to 5-month old Yorkshire-Hampshire pigs (6/sex) treated with 3 daily im injections of (14)C-ceftiofur (5.2 mg/kg bw) produced similar results to those observed in rats and cattle. ... The half life of desfuroylceftiofur was 13.5 hr after im treatment and 12.2 hr after iv treatment. /Desfuroylceftiofur/']"
1309,71310,Atipamezole,CCC1(CC2=CC=CC=C2C1)C3=CN=CN3,['For the reversal of the sedative and analgesic effects of dexmedetomidine and medetomidine in dogs.'],,['Drugs that bind to and block the activation of ADRENERGIC ALPHA-2 RECEPTORS. (See all compounds classified as Adrenergic alpha-2 Receptor Antagonists.)'],,,
1310,71311,7-[2-Methoxyimino-2-(2-aminothiazol-4-yl)acetamido]-3-[2-(4-methylthiazol-5-yl)vinyl]-3-cephem-4-carboxylic acid,CC1=C(SC=N1)C=CC2=C(N3[C@@H](C(C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)O,,,,,,
1311,71312,3-Chloro-6-[4-(3-phenylprop-2-en-1-yl)piperazin-1-yl]pyridazine,C1CN(CCN1CC=CC2=CC=CC=C2)C3=NN=C(C=C3)Cl,,,,,,
1312,71313,CID 71313,C[C@H](C(=NO)C)NCC(C)(C)CN[C@@H](C)C(=NO)C,,,,,,
1313,71314,"6-{1-[4-(Methanesulfonyl)phenyl]prop-1-en-2-yl}-1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphthalene",CC(=CC1=CC=C(C=C1)S(=O)(=O)C)C2=CC3=C(C=C2)C(CCC3(C)C)(C)C,,,,,,
1314,71315,"bis[3-[(1R)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] oct-4-enedioate;dichloride",C[N+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)CCCOC(=O)CCC=CCCC(=O)OCCC[N+]4(CCC5=CC(=C(C=C5[C@H]4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)C.[Cl-].[Cl-],,,,,,
1315,71316,"bis[3-[(1R)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] oct-4-enedioate",C[N+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)CCCOC(=O)CCC=CCCC(=O)OCCC[N+]4(CCC5=CC(=C(C=C5[C@H]4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)C,,,,,,
1316,71317,CID 71317,CC[C@@H]1[C@H](C=C(C=CC(=O)[C@@H](C[C@@H]([C@@H]([C@H](C(CC(=O)O1)O)C)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C)O)N(C)C)O)CCN3CC(CC(C3)C)C)C)C)CO[C@H]4[C@@H]([C@@H]([C@@H]([C@H](O4)C)O)OC)OC,,,,,,
1317,71318,CID 71318,CN(C)CCC=C1C2=CC=CN2CCC3=C1C=C(C=C3)Cl.C(=CC(=O)O)C(=O)O,,,,,,
1318,71319,"3-(9-Chloro-5,6-dihydro-11H-pyrrolo[2,1-b][3]benzazepin-11-ylidene)-N,N-dimethylpropan-1-amine",CN(C)CCC=C1C2=CC=CN2CCC3=C1C=C(C=C3)Cl,,,,,,
1319,71320,Libenzapril,C1CC2=CC=CC=C2N(C(=O)[C@H]1N[C@@H](CCCCN)C(=O)O)CC(=O)O,,,"['A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. (See all compounds classified as Angiotensin-Converting Enzyme Inhibitors.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)']",,,
1320,71321,Romazarit,CC1=C(OC(=N1)C2=CC=C(C=C2)Cl)COC(C)(C)C(=O)O,,,,,,
1321,71322,"1,4-Thiazepine-4(5H)-aceticacid,6-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]tetrahydro-5-oxo-2-(2-thienyl)-,hydrochloride (1:1), (2S,6R)-",CCOC(=O)[C@H](CCC1=CC=CC=C1)NC2CS[C@@H](CN(C2=O)CC(=O)O)C3=CC=CS3.Cl,,,,,,
1322,71323,"2-[(2s)-6-[[(1s)-1-Ethoxycarbonyl-3-phenylpropyl]amino]-5-oxo-2-thiophen-2-yl-1,4-thiazepan-4-yl]acetic acid",CCOC(=O)[C@H](CCC1=CC=CC=C1)NC2CS[C@@H](CN(C2=O)CC(=O)O)C3=CC=CS3,,,,,,
1323,71324,"(2S)-2-[[(2S)-4-(carboxymethyl)-5-oxo-2-thiophen-2-yl-1,4-thiazepan-6-yl]amino]-4-phenylbutanoic acid",C1[C@H](SCC(C(=O)N1CC(=O)O)N[C@@H](CCC2=CC=CC=C2)C(=O)O)C3=CC=CS3,,,,,,
1324,71325,"(1R,3S)-5-[2-[(1R,7aR)-1-[(2R,5S)-5-cyclopropyl-5-hydroxypent-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol",C[C@H](C=C[C@H](C1CC1)O)[C@H]2CCC3[C@@]2(CCCC3=CC=C4C[C@H](C[C@@H](C4=C)O)O)C,,,,,,
1325,71326,"2-(Diethylamino)-5,6,18,20-tetrahydroxy-14-methoxy-7,9,15,17,19,21,25-heptamethyl-10,26-dioxo-9,10-dihydro-9,4-(epoxypentadeca[1,11,13]trienoimino)furo[2',3':7,8]naphtho[1,2-d][1,3]thiazol-16-yl acetate",CCN(CC)C1=NC2=C(S1)C3=C(C4=C2C5=C(C(=C4O)C)OC(C5=O)(OC=CC(C(C(C(C(C(C(C(C=CC=C(C(=O)N3)C)C)O)C)O)C)OC(=O)C)C)OC)C)O,,,,,,
1326,71327,Semduramicin,C[C@H]1C[C@H]([C@@](O[C@@H]1[C@H]2C[C@@H]([C@@H](O2)[C@@]3(CC[C@@H](O3)[C@@]4(CC[C@@]5(O4)C[C@@H]([C@H]([C@H](O5)[C@@H](C)[C@H]6[C@@H]([C@H]([C@@H]([C@](O6)(CC(=O)O)O)C)O)OC)C)O)C)C)O[C@H]7CC[C@@H]([C@H](O7)C)OC)(C)O)C,,,,,,
1327,71328,Fosquidone,CC1C2=CC=CC=C2CN3C1=C4C(=C3)C(=O)C5=C(C4=O)C=CC=C5OP(=O)(O)OCC6=CC=CC=C6,,,,,,
1328,71329,Dofetilide,CN(CCC1=CC=C(C=C1)NS(=O)(=O)C)CCOC2=CC=C(C=C2)NS(=O)(=O)C,['For the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter [AF/AFl]) in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm'],"['Dofetilide is an antiarrhythmic drug with Class III (cardiac action potential duration prolonging) properties and is indicated for the maintenance of normal sinus rhythm. Dofetilide increases the monophasic action potential duration in a predictable, concentration-dependent manner, primarily due to delayed repolarization. At concentrations covering several orders of magnitude, Dofetilide blocks only IKr with no relevant block of the other repolarizing potassium currents (e.g., IKs, IK1). At clinically relevant concentrations, Dofetilide has no effect on sodium channels (associated with Class I effect), adrenergic alpha-receptors, or adrenergic beta-receptors.']","['A class of drugs that act by inhibition of potassium efflux through cell membranes. Blockade of potassium channels prolongs the duration of ACTION POTENTIALS. They are used as ANTI-ARRHYTHMIA AGENTS and VASODILATOR AGENTS. (See all compounds classified as Potassium Channel Blockers.)', 'Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)']","['>90%', '3 L/kg', 'Approximately 80% of a single dose of dofetilide is excreted in urine, of which approximately 80% is excreted as unchanged dofetilide with the remaining 20% consisting of inactive or minimally active metabolites. Renal elimination involves both glomerular filtration and active tubular secretion (via the cation transport system, a process that can be inhibited by cimetidine, trimethoprim, prochlorperazine, megestrol and ketoconazole). ...', 'The oral bioavailability of dofetilide is >90%, with maximal plasma concentrations occurring at about 2-3 hours in the fasted state. Oral bioavailability is unaffected by food or antacid. The terminal half life of Tikosyn is approximately 10 hours; steady state plasma concentrations are attained within 2-3 days, with an accumulation index of 1.5 to 2.0. Plasma concentrations are dose proportional. Plasma protein binding of dofetilide is 60-70%, is independent of plasma concentration, and is unaffected by renal impairment. Volume of distribution is 3 L/kg.', '1. Pharmacokinetics of dofetilide were studied in man, dog, rat and mouse after single IV and oral doses of dofetilide or (14)C-dofetilide. 2. Dofetilide was absorbed completely in all species. Low metabolic clearance in man resulted in complete bioavailability following oral administration. Higher metabolic clearance in rodents, and to a lesser extent dogs, resulted in decreased bioavailability because of first-pass metabolism. 3. Following IV administration, the volume of distribution showed only moderate variation in all species (2.8-6.3 l/kg). High plasma clearance in rodents resulted in short half-life values (mouse 0.32, male rat 0.5 and female rat 1.2 hr), while lower clearance in dog and man gave longer terminal elimination half-lives (4.6 and 7.6 hr respectively). 4. After single IV doses of (14)C-dofetilide, unchanged drug was the major component excreted in urine of all species with several metabolites also present. 5. Metabolites identified in urine from all species were formed by N-oxidation or N-dealkylation of the tertiary nitrogen atom of dofetilide. 6. After oral and IV administration of (14)C-dofetilide to man, parent compound was the only detectable component present in plasma and represented 75% of plasma radioactivity. No single metabolite accounted for greater than 5% of plasma radioactivity.']","['Hepatic', ""Dofetilide, a class III antidysrhythmic agent, undergoes both renal and metabolic clearance. Characterization of the metabolism in vitro allows explanation of species differences, whereas identification of the human enzymes involved permits assessment of potential drug interaction. In liver microsomes, the rate of oxidative metabolism of dofetilide is in the order: male rat > female rat > dog >  humans, which correlates with the metabolic clearance seen in vivo. In vitro products of oxidative metabolism, formed by N-dealkylation, are the same as those formed in vivo, with the N-desmethyl being the major product. This route of dofetilide metabolism is mediated by cytochrome P450 (CYP). In humans, N-demethylation has a high KM of 657 +/- 116 uM, indicating low affinity for the enzyme's active site. In a number of human liver microsomal preparations, this rate correlated (r = 0.903) with the activity of CYP3A4. There was no correlation with the activities of other isozymes. Specific isozyme inhibitors also indicated the involvement of CYP3A4, with partial inhibition being observed with ketoconazole and troleandeomycin, whereas the activator, alpha-naphthaflavone, caused increased turnover. No inhibition was observed with specific inhibitors or competing substrates for other isozymes. Dofetilide did not significantly inhibit CYP2C9, CYP2D6, or CYP3A4 at concentrations up to 100 microM in vitro. In contrast, amiodarone (IC50, 25 uM) and flecainide (49 microM) inhibited CYP2C9 and quinidine (0.26 uM), and flecainide (0.44 uM) inhibited CYP2D6. Many antidysrhythmic drugs have active, circulating metabolites, complicating the relationship of dose and clinical response. In vitro pharmacology studies allow assessment of the potential contribution to the pharmacological profile by metabolites. Potency of dofetilide and metabolites has been compared for class III (K+ channel blockade) and class I (Na+ channel blockade) antidysrhythmic activities. Three of the metabolites of dofetilide displayed class III activity but at concentrations at least 20-fold higher  than dofetilide. Dofetilide N-oxide showed class I activity, but only at high concentration. Neither resting membrane potential or action potential amplitude were affected by any metabolite. This lack of biologically relevant activity is in accord with the close correlation between plasma concentrations of dofetilide and pharmacological response."", 'Approximately 80% of a single dose of dofetilide is excreted in urine, of which approximately 80% is excreted as unchanged dofetilide with the remaining 20% consisting of inactive or minimally active metabolites. ... In vitro studies with human liver microsomes show that dofetilide can be metabolized by CYP3A4, but it has a low affinity for this isoenzyme. Metabolites are formed by N-dealkylation and N-oxidation. There are no quantifiable metabolites circulating in plasma, but 5 metabolites have been identified in urine']","['10 hours', 'Following IV administration, ... high plasma clearance in rodents resulted in short half-life values (mouse 0.32, male rat 0.5 and female rat 1.2 hr), while lower clearance in dog and man gave longer terminal elimination half-lives (4.6 and 7.6 hr respectively). ...', 'The terminal half life of Tikosyn is approximately 10 hours']"
1329,71330,Irtemazole,CC1=NC2=C(N1)C=C(C=C2)C(C3=CC=CC=C3)N4C=CN=C4,,,,,,
1330,71331,"Pyrrolidine, 1-[2-[4-[(1E)-1-(4-iodophenyl)-2-phenyl-1-buten-1-yl]phenoxy]ethyl]-",CCC(=C(C1=CC=C(C=C1)OCCN2CCCC2)C3=CC=C(C=C3)I)C4=CC=CC=C4,,,,,,
1331,71332,"(1'R,2R,3S,4'S,6S,8'R,13'S,20'R,21'R,24'S)-2-cyclohexyl-21',24'-dihydroxy-12'-[(2R,4S,6S)-5-[(2S,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-4-methoxy-6-methyloxan-2-yl]oxy-3,11',13',22'-tetramethylspiro[2,3-dihydropyran-6,6'-3,7,19-trioxatetracyclo[15.6.1.14,8.020,24]pentacosa-10,14,16,22-tetraene]-2'-one",C[C@H]1C=C[C@]2(C[C@@H]3C[C@H](O2)CC=C(C([C@H](C=CC=C4CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H](C([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)C)O[C@@H]1C8CCCCC8,,,,,,
1332,71333,"1-[2-Chloro-2-(2,4-dichlorophenyl)ethenyl]-1,2,4-triazole",C1=CC(=C(C=C1Cl)Cl)C(=CN2C=NC=N2)Cl,,,,,,
1333,71334,Danofloxacin mesylate,CN1C[C@@H]2C[C@H]1CN2C3=C(C=C4C(=C3)N(C=C(C4=O)C(=O)O)C5CC5)F.CS(=O)(=O)O,,,['Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. (See all compounds classified as Anti-Infective Agents.)'],,,
1334,71335,Danofloxacin,CN1C[C@@H]2C[C@H]1CN2C3=C(C=C4C(=C3)N(C=C(C4=O)C(=O)O)C5CC5)F,,,['Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. (See all compounds classified as Anti-Infective Agents.)'],,,
1335,71336,Lifarizine,CC1=CC=C(C=C1)C2=NC(=C(N2)C)CN3CCN(CC3)C(C4=CC=CC=C4)C5=CC=CC=C5,,,,,,
1336,71337,"N-[2-[(8S)-4-[anilino(hydroxy)methoxy]-8-(chloromethyl)-1-methyl-7,8-dihydro-3H-pyrrolo[3,2-e]indole-6-carbonyl]-1H-indol-5-yl]-6-(diethylamino)-1-benzofuran-2-carboxamide",CCN(CC)C1=CC2=C(C=C1)C=C(O2)C(=O)NC3=CC4=C(C=C3)NC(=C4)C(=O)N5C[C@H](C6=C7C(=CNC7=C(C=C65)OC(NC8=CC=CC=C8)O)C)CCl,,,,,,
1337,71338,"N-[25-(1-azabicyclo[2.2.2]octan-3-ylsulfanylmethyl)-3-[[4-(dimethylamino)phenyl]methyl]-12-ethyl-4,16-dimethyl-2,5,11,14,18,21,24-heptaoxo-19-phenyl-17-oxa-1,4,10,13,20-pentazatricyclo[20.4.0.06,10]hexacosan-15-yl]-3-hydroxypyridine-2-carboxamide",CCC1C(=O)N2CCCC2C(=O)N(C(C(=O)N3CC(C(=O)CC3C(=O)NC(C(=O)OC(C(C(=O)N1)NC(=O)C4=C(C=CC=N4)O)C)C5=CC=CC=C5)CSC6CN7CCC6CC7)CC8=CC=C(C=C8)N(C)C)C,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],"['Quinupristin and dalfopristin is distributed into milk in rats ... .', 'The pharmacokinetics of quinupristin/dalfopristin have been studied in rats, monkeys and humans following intravenous infusion of radiolabelled and unlabelled drug. In rats and monkeys quinupristin and dalfopristin undergo rapid elimination from the blood and wide tissue distribution. Nevertheless, they do not penetrate the central nervous system or cross the placenta to any significant degree and they do not appear to be subject to significant body retention following cessation of administration. The blood elimination half-life of quinupristin was approximately 0.6 hr in rats and 0.5 hr in monkeys, and that of dalfopristin was approximately 0.6 hr and 0.2 hr, respectively. Both compounds are primarily eliminated through the bile into the faeces; quinupristin is mainly excreted unchanged whereas dalfopristin is extensively metabolized beforehand. The metabolites include the microbiologically active pristinamycin PIIA for dalfopristin and the microbiologically active glutathione- and cysteine-conjugated derivatives for quinupristin. Quinupristin and dalfopristin appear to be handled in a similar manner by humans. Following intravenous administration both compounds are rapidly cleared from the blood with elimination half-lives of approximately 1 hr for quinupristin and 0.4-0.5 hr for dalfopristin. The pharmacokinetic profile of quinupristin is dose-independent and so is that of dalfopristin and RP 12536 when considered together. Extravascular diffusion of quinupristin/dalfopristin has been assessed in human non-inflammatory interstitial fluid.', 'Fecal excretion constitutes the main elimination route for both parent drugs and their metabolites (75 to 77% of dose). Urinary excretion accounts for approximately 15% of the quinupristin and 19% of the dalfopristin dose. Preclinical data in rats have demonstrated that approximately 80% of the dose is excreted in the bile and suggest that in man, biliary excretion is probably the principal route for fecal elimination.']","['Quinupristin and dalfopristin are converted to several major active metabolites: 2 conjugated (with glutathione and cysteine) metabolites for quinupristin and one nonconjugated (formed by hydrolysis) metabolite for dalfopristin, which also act synergistically with the complementary parent drug. This conversion occurs in vitro by nonenzymatic reactions independent of cytochrome P-450 (CYP) and glutathione transferase enzymes.']","['The elimination half-life of quinupristin and dalfopristin is approximately 0.85 and 0.70 hours, respectively.', 'The pharmacokinetics of quinupristin/dalfopristin have been studied in rats, monkeys and humans following intravenous infusion of radiolabelled and unlabelled drug. ... The blood elimination half-life of quinupristin was approximately 0.6 hr in rats and 0.5 hr in monkeys, and that of dalfopristin was approximately 0.6 hr and 0.2 hr, respectively. ... Following intravenous administration both compounds are rapidly cleared from the blood with elimination half-lives of approximately 1 hr for quinupristin and 0.4-0.5 hr for dalfopristin.']"
1338,71339,Biapenem,C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1SC3CN4C=NC=[N+]4C3)C(=O)[O-])[C@@H](C)O,,,['Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. (See all compounds classified as Anti-Infective Agents.)'],,,
1339,71340,"(4R,5S,6S)-3-(6,7-dihydro-5H-pyrazolo[1,2-a][1,2,4]triazol-4-ium-6-ylsulfanyl)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid",C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1SC3CN4C=NC=[N+]4C3)C(=O)O)[C@@H](C)O,,,,,,
1340,71341,"(5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-(1-oxothiolan-3-yl)sulfanyl-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid",C[C@H]([C@@H]1[C@@H]2N(C1=O)C(=C(S2)SC3CCS(=O)C3)C(=O)O)O,,,,,,
1341,71342,Pancopride,C1CC1COC2=CC(=C(C=C2C(=O)NC3CN4CCC3CC4)Cl)N,,,,,,
1342,71343,"(6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;chloride;hydrate;hydrochloride",C[N+]1(CCCC1)CC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)O.O.Cl.[Cl-],,,,,,
1343,71344,CID 71344,C[C@H]1[C@@H]2C[C@H](CC1=O)[C@](OO2)(C)C=CC3=C(C=C(C=C3)C(F)(F)F)C(F)(F)F,,,,,,
1344,71345,Pirodavir,CCOC(=O)C1=CC=C(C=C1)OCCC2CCN(CC2)C3=NN=C(C=C3)C,,,,,,
1345,71346,Binospirone mesylate,CS(=O)(=O)O.C1CCC2(C1)CC(=O)N(C(=O)C2)CCNCC3COC4=CC=CC=C4O3,,,"['Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or SEROTONIN RECEPTOR AGONISTS. (See all compounds classified as Serotonin Antagonists.)', 'Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)', 'Endogenous compounds and drugs that bind to and activate SEROTONIN RECEPTORS. Many serotonin receptor agonists are used as ANTIDEPRESSANTS; ANXIOLYTICS; and in the treatment of MIGRAINE DISORDERS. (See all compounds classified as Serotonin Receptor Agonists.)']",,,
1346,71347,"ethyl N-[4-[[(2R)-2-(imidazol-1-ylmethyl)-2-(4-methoxyphenyl)-1,3-dioxolan-4-yl]methylsulfanyl]phenyl]carbamate",CCOC(=O)NC1=CC=C(C=C1)SCC2CO[C@](O2)(CN3C=CN=C3)C4=CC=C(C=C4)OC,,,,,,
1347,71348,Somatuline (TN),CC(C)C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC6=CC=CC=C6C=C5)N)C(=O)NC(C(C)O)C(=O)N.CC(=O)O,,,,,,
1348,71349,Lanreotide,CC(C)C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC6=CC=CC=C6C=C5)N)C(=O)NC(C(C)O)C(=O)N,['Lanreotide is a somatostatin analog approved for treatment of neuroendocrine tumours and acromegaly.'],"['Lanreotide exhibits antisecretory effects through cAMP suppression, and activation of ion currents such as K+ and Ca2+ which leads to hyperpolarization of the membrane and inhibition of Ca2+ mediated depolarization.  Furthermore, through direct and indirect mechanisms, Lanreotide has potent antiproliferative effects.']",['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)'],"['Lanreotide forms a drug depot at the site of injection; therefore, there are 2 phases that describe the absorption of Lanreotide: 1. Initial rapid subcutaneous release during the first few days of treatment where drug that has not precipitated is rapidly absorbed.    2. Slow release of drug from the depot via passive diffusion. Absorption is independent of body weight, gender, and dosage.', '<5% of lanreotide is excreted in urine, and less than 0.5% is excreted unchanged in the feces suggesting biliary excretion involvement.', 'Estimated Volume of Distribution = 15.1 L', 'Estimated Clearance = 23.1 L/h']",,['Half-life is approximately 22 days']
1349,71350,"4-[3-[2-(4-Cyclobutyl-2-thiazolyl)ethenyl]anilino]-2,2-diethyl-4-oxobutanoic acid",CCC(CC)(CC(=O)NC1=CC=CC(=C1)C=CC2=NC(=CS2)C3CCC3)C(=O)O,,,,,,
1350,71351,Ocaperidone,CC1=CC=CN2C1=NC(=C(C2=O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F)C,['Investigated for use/treatment in schizophrenia and schizoaffective disorders.'],,,,,
1351,71352,Dapoxetine hydrochloride,CN(C)[C@@H](CCOC1=CC=CC2=CC=CC=C21)C3=CC=CC=C3.Cl,,,,,,
1352,71353,Dapoxetine,CN(C)[C@@H](CCOC1=CC=CC2=CC=CC=C21)C3=CC=CC=C3,['For the treatment of premature ejaculation.'],"['Dapoxetine is a selective serotonin reuptake inhibitor currently undergoing trials through Alza (under license from GenuPro, a collaboration between Eli Lilly and PPD). Dapoxetine is a short-acting SSRI drug currently being considered for approval by the Food and Drug Administration (FDA) for the treatment of premature ejaculation in men, which would make it the first drug approved for such treatment. Despite two clinical trials finished in 2006, experts doubt it will be approved by the FDA soon because SSRIs come with undesirable side-effects after long-term use, such as psychiatric problems, dermatological reactions, increase in body weight, lower sex-drive, nausea, headache, upset stomach and weakness, thus not significantly outweighing the benefit of premature ejaculation medication versus the risks. By contrast with SSRIs approved for depression, which take 2 weeks or longer to reach steady-state concentration, dapoxetine has a unique pharmacokinetic profile, with a short time to maximum serum concentration (about 1 h) and rapid elimination (initial half-life of 1-2 h).']",,['Rapidly absorbed.'],,['Initial half-life of 1-2 hours.']
1353,71354,Bindarit,CC(C)(C(=O)O)OCC1=NN(C2=CC=CC=C21)CC3=CC=CC=C3,,,"['Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. (See all compounds classified as Protein Synthesis Inhibitors.)', 'Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)']",,,
1354,71355,Lecimibide,CCCCCCCN(CCCCCSC1=NC(=C(N1)C2=CC=CC=C2)C3=CC=CC=C3)C(=O)NC4=C(C=C(C=C4)F)F,,,,,,
1355,71356,Cipamfylline,C1CC1CN2C3=C(C(=O)N(C2=O)CC4CC4)NC(=N3)N,,,,,,
1356,71357,Cardiogen-82,[Cl-].[82Rb+],['Visualisation of myocardial perfusion for diagnostic purposes'],,,,,
1357,71358,Pirsidomine,C[C@@H]1CCC[C@@H](N1[N+]2=NOC(=C2)N=C(C3=CC=C(C=C3)OC)[O-])C,,,,,,
1358,71359,"N-[3-[(2S,6R)-2,6-dimethylpiperidin-1-yl]oxadiazol-3-ium-5-yl]-4-methoxybenzamide",C[C@@H]1CCC[C@@H](N1[N+]2=NOC(=C2)NC(=O)C3=CC=C(C=C3)OC)C,,,,,,
1359,71360,Iloperidone,CC(=O)C1=CC(=C(C=C1)OCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)OC,['Treatment of acute schizophrenia.'],"[""Iloperidone shows high affinity and maximal receptor occupancy for dopamine D2 receptors in the caudate nucleus and putamen of the brains of schizophrenic patients. The improvement in cognition is attributed to iloperidone's high affinity for  α adrenergic receptors. Iloperidone also binds with high affinity to serotonin 5-HT2a and dopamine 3 receptors. Iloperidone binds with moderate affinity to dopamine D4, serotonin 5-HT6 and 5-HT7, and norepinephrine NEα1 receptors. Furthermore, iloperidone binds with weak affinity to serotonin 5-HT1A, dopamine D1, and histamine H1 receptors.""]","['Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)']","['Well absorbed from the GI tract and Cmax is reached within 2-4 hours. Steady-state concentration is achieved in 3-4 days post-administration of iloperidone. Relative bioavailability of the tablet formulation compared to oral solution is 96%. Accumulation occurs in a predictable fashion.', 'Renal (in which <1% of iloperidone is excreted unchanged).', 'Apparent Vd = 1340-2800 L', 'Apparent clearance (clearance/bioavilability) = 47-102 L/h.', 'Iloperidone has an apparent clearance (clearance/bioavailability) of 47 to 102 L/hr, with an apparent volume of distribution of 1340 to 2800 L. At therapeutic concentrations, the unbound fraction of iloperidone in plasma is approximately 3% and of each metabolite (P88 and P95) it is approximately 8%.', 'The majority of radiolabeled iloperidone was recovered in the urine (mean 58.2% and 45.1% in extensive  and poor metabolizers of CYP2D6, respectively), with feces accounting for 19.9% (extensive metabolizers) and 22.1% (poor metabolizers) of the radiolabeled dose.', 'Iloperidone is well absorbed after administration of the tablet with peak plasma concentrations occurring within 2 to 4 hours; while the relative bioavailability of the tablet formulation compared to oral solution is 96%. Administration of iloperidone with a standard high-fat meal did not significantly affect the Cmax or AUC of iloperidone, P88, or P95, but delayed Tmax by 1 hour for iloperidone, 2 hours for P88 and 6 hours for P95. Fanapt can be administered without regard to meals.', ""... The P88 metabolite penetrates the CNS and is thought to contribute to the drug's antipsychotic activity whereas the P95 metabolite does not readily penetrate the CNS ... .""]","['Iloperidone is hepatically metabolized by cytochrome enzymes which mediates O-dealkylation (CYP3A4), hydroxylation (CYP2D6), and decarboxylation/reduction processes. Metabolites formed are P89, P95, and P88. The minor metabolite is P89, whereas P95 and P88 are the major ones. The affinity of the iloperidone metabolite P88 is generally equal or less than that of the parent compound. In contrast, the metabolite P95 only shows affinity for 5-HT2A (Ki value of 3.91) and the NEα1A, NEα1B, NEα1D, and NEα2C receptors (Ki values of 4.7, 2.7, 8.8 and 4.7 nM respectively).', ""Iloperidone is primarily metabolized by carbonyl reduction, cytochrome P-450 (CYP) isoenzyme 2D6-mediated hydroxylation, and CYP3A4-mediated O-demethylation; the drug's two principal metabolites, P88 and P95, undergo further oxidation and/or conjugation with glucuronic acid. The P88 metabolite penetrates the CNS and is thought to contribute to the drug's antipsychotic activity whereas the P95 metabolite does not readily penetrate the CNS and primarily contributes to the adverse effect profile of the drug."", 'Iloperidone is metabolized primarily by 3 biotransformation pathways: carbonyl reduction, hydroxylation (mediated by CYP2D6) and O-demethylation (mediated by CYP3A4). There are 2 predominant iloperidone metabolites, P95 and P88. The iloperidone metabolite P95 represents 47.9% of the AUC of iloperidone and its metabolites in plasma at steady-state for extensive metabolizers (EM) and 25% for poor metabolizers (PM). The active metabolite P88 accounts for 19.5% and 34.0% of total plasma exposure in EM and PM, respectively.  Approximately 7% to 10% of Caucasians and 3% to 8% of black/African Americans lack the capacity to metabolize CYP2D6 substrates and are classified as poor metabolizers (PM), whereas the rest are intermediate, extensive or ultrarapid metabolizers. Co-administration of Fanapt with known strong inhibitors of CYP2D6 like fluoxetine results in a 2.3-fold increase in iloperidone plasma exposure, and therefore one-half of the Fanapt dose should be administered.  Similarly, PMs of CYP2D6 have higher exposure to iloperidone compared with EMs and PMs should have their dose reduced by one-half.', 'Iloperidone has known human metabolites that include 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]- propoxy]-3-hydroxyphenyl]ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]-2-hydroxyethanone, and 4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy-a-methylbenzene methanol.']","['The observed mean elimination half-lives for iloperidone, P88 and P95 in CYP2D6 extensive metabolizers (EM) are 18, 26 and 23 hours, respectively, and in poor metabolizers (PM) are 33, 37 and 31 hours, respectively.', 'The mean elimination half-lives of iloperidone, P88, and P95 are 18, 26, and 23 hours, respectively, in extensive metabolizers of CYP2D6 and 33, 37, and 31 hours, respectively, in poor metabolizers of CYP2D6.']"
1360,71361,CID 71361,CC1=CC=C(C=C1)C(=O)C2=CC(=O)C(=O)C(=C2)N(O)O,,,,,,
1361,71362,H-D-Arg-DL-Arg-DL-Pro-DL-Hyp-Gly-2Thi-Ser-DL-Tic-DL-Oic-Arg-OH.CH3CO2H,CC(=O)O.C1CC[C@H]2[C@@H](C1)CC(N2C(=O)C3CC4=CC=CC=C4CN3C(=O)[C@H](CO)NC(=O)[C@H](CC5=CC=CS5)NC(=O)CNC(=O)C6C[C@H](CN6C(=O)C7CCCN7C(=O)C(CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)N)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O,,,,,,
1362,71363,CID 71363,C1CCC2CC(N([C@H]2C1)C(=O)C3CC4=CC=CC=C4CN3C(=O)[C@H](CO)NC(=O)[C@H](CC5=CC=CS5)NC(=O)CNC(=O)C6C[C@H](CN6C(=O)C7CCCN7C(=O)C(CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)N)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O,,,,,,
1363,71364,Icatibant,C1CC[C@H]2[C@@H](C1)CC(N2C(=O)C3CC4=CC=CC=C4CN3C(=O)[C@H](CO)NC(=O)[C@H](CC5=CC=CS5)NC(=O)CNC(=O)C6C[C@H](CN6C(=O)C7CCCN7C(=O)C(CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)N)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O,['Firazyr is indicated for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency).'],,"['Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)', 'Compounds and drugs that inhibit ligand binding or cellular signaling by BRADYKININ B2 RECEPTORS. (See all compounds classified as Bradykinin B2 Receptor Antagonists.)']",,,
1364,71365,Almecillin,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)CSCC=C)C(=O)O)C,,,,,,
1365,71366,CID 71366,O.O.O.O.[AlH3],,,,,,
1366,71367,Pentapiperium methylsulfate,CCC(C)C(C1=CC=CC=C1)C(=O)OC2CC[N+](CC2)(C)C.COS(=O)(=O)[O-],,,,,,
1367,71368,Sodium iodide I 131,[Na+].[131I-],,,,,,
1368,71369,"Parachlorophenol, Camphorated",CC1(C2CCC1(C(=O)C2)C)C.C1=CC(=CC=C1O)Cl,,,"['Substances used on inanimate objects that destroy harmful microorganisms or inhibit their activity. Disinfectants are classed as complete, destroying SPORES as well as vegetative forms of microorganisms, or incomplete, destroying only vegetative forms of the organisms. They are distinguished from ANTISEPTICS, which are local anti-infective agents used on humans and other animals. (From Hawley&apos;s Condensed Chemical Dictionary, 11th ed) (See all compounds classified as Disinfectants.)', 'Substances used on humans and other animals that destroy harmful microorganisms or inhibit their activity. They are distinguished from DISINFECTANTS, which are used on inanimate objects. (See all compounds classified as Anti-Infective Agents, Local.)']",,,
1369,71370,Trimethylammonium bromide,CN(C)C.Br,,,,,,
1370,71371,Liotrix,C1=CC(=C(C=C1OC2=C(C=C(C=C2I)C[C@@H](C(=O)[O-])N)I)I)O.C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)[O-])N.[Na+].[Na+],"['May be used to treat primary, secondary or tertiary hypothyroidism. May also be used to suppress thyroid stimulating hormone (TSH) secretion in patients with simple (nontoxic) goiter, subacute or chronic lymphocytic thyroiditis multinodular goiter, and in the management of thyroid cancer. May be used in conjunction with other antithyroid agents to treat thyrotoxicosis to prevent goitrogenesis and hypothyroidism. May also be used for differential diagnosis of suspected mild hyperthyroidism or thyroid gland autonomy.']","['Thyroid hormone drugs are natural or synthetic preparations containing T<sub>4</sub> or T<sub>3</sub> or both. T<sub>4</sub> and T<sub>3</sub> are produced in the human thyroid gland by the iodination and coupling of the amino acid tyrosine. Liotrix is a synthetic preparation of T4 and T3 in a 4:1 weight-based ratio. These hormones enhance oxygen consumption by most tissues of the body and increase the basal metabolic rate and the metabolism of carbohydrates, lipids and proteins. Thus, they exert a profound influence on every organ system in the body and are of particular importance in the development of the central nervous system.']",,['Thyroid hormones are primarily eliminated by the kidneys.'],,
1371,71372,"Iron(2+);2,3,4,5,6-pentahydroxyhexanoate;dihydrate",C(C(C(C(C(C(=O)[O-])O)O)O)O)O.C(C(C(C(C(C(=O)[O-])O)O)O)O)O.O.O.[Fe+2],,,,,,
1372,71373,Sodium sulfate S-35,[O-][35S](=O)(=O)[O-].[Na+].[Na+],,,,,,
1373,71374,CID 71374,O[35S](=O)(=O)O,,,,,,
1374,71375,Potassium Aspartate and Magnesium Aspartate,C([C@@H](C(=O)[O-])N)C(=O)O.C(C(C(=O)[O-])N)C(=O)O.C(C(C(=O)[O-])N)C(=O)O.[Mg+2].[K+],,,,,,
1375,71376,Magnesium carbonate hydrate,C(=O)([O-])[O-].O.[Mg+2],,,"['Chemicals that are used to oxidize pigments and thus effect whitening. (See all compounds classified as Bleaching Agents.)', 'Materials that readily absorb moisture from their surroundings. (See all compounds classified as Hygroscopic Agents.)']",,,
1376,71377,Suncillin sodium,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)NS(=O)(=O)[O-])C(=O)[O-])C.[Na+].[Na+],,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
1377,71378,"7-Hydroxy-1,4,10,19-tetramethyl-17,18-dioxo-2-(2-oxopropanamido)-16-oxabicyclo[13.2.2]nonadeca-3,5,9,11-tetraen-13-yl acetate",CC1C2CC(C=CC(=CCC(C=CC(=CC(C(C1=O)(C(=O)O2)C)NC(=O)C(=O)C)C)O)C)OC(=O)C,,,,,,
1378,71379,Hydroxyguanabenz,C1=CC(=C(C(=C1)Cl)C=NN=C(N)NO)Cl,,,,,,
1379,71380,Strontium chloride Sr 85,[Cl-].[Cl-].[85Sr+2],,,,,,
1380,71381,Zinc chloride Zn 65,Cl[65Zn]Cl,,,,,,
1381,71382,Sodium iodide (125I),[Na+].[125I-],,,,,,
1382,71383,Phosphocol P32,[O-][32P](=O)([O-])[O-].[Cr+3],,,,,,
1383,71384,Dexrazoxane,C[C@@H](CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2,['For reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin hydrochloride dose of 300 mg/m^2 and would benefit from continued doxorubicin therapy. Also approved for the treatment of extravasation from intravenous anthracyclines.'],"['Dexrazoxane is a cardioprotective agent for use in conjunction with doxorubicin indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose. Patients receiving anthracycline-derivative antineoplastic agents may experience three types of cardiotoxicity: acute transient type; chronic, subacute type (related to cumulative dose and has a more indolent onset later on); and a late-onset type that manifests years after therapy, mainly in patients that have been exposed to the drug as a child. Although the exact mechanism of anthracycline-induced cardiotoxicity is not known, it has shown to exert a variety of actions that may result in the development of cardiotoxicity. In animals, anthracyclines cause a selective inhibition of cardiac muscle gene expression for α-actin, troponin, myosin light-chain 2, and the M isoform of creatine kinase. This may lead to myofibrillar loss associated with anthracycline-induced cardiotoxicity. Anthracyclines may also cause myocyte damage via calcium overload, altered myocardial adrenergic function, release of vasoactive amines, and proinflammatory cytokines. Furthermore, it has been suggested that the main cause of anthracycline-induced cardiotoxicity is associated with free-radical damage to DNA. The drugs intercalate DNA, chelate metal ions to produce drug-metal complexes, and generate superoxide radicals via oxidation-reduction reactions. Anthracyclines also contain a quinone structure that can undergo reduction via NADPH-dependent reactions to produce a semiquinone free radical that initiates a cascade of superoxide and hydroxide radical generation. Chelation of metal ions, particularly iron, by anthracyclines results in an anthracycline-metal complex that catalyzes the generation of reactive oxygen free radicals. This complex is a powerful oxidant that can initiate lipid peroxidation in the absence of oxygen free radicals. The toxicity induced by antrhacyclines may be exacerbated in cardiac cells, as these cells do not possess sufficient amounts of certain enzymes (e.g., superoxide dismutase, catalase, glutathione peroxidase) involved in detoxifying free radicals and protecting the cells from subsequent damage.']","['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)', 'Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). (See all compounds classified as Cardiotonic Agents.)', 'Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)']","['IV administration results in complete bioavailability.', 'Urinary excretion plays an important role in the elimination of dexrazoxane. Forty-two percent of the 500 mg/m2 dose of dexrazoxane was excreted in the urine.', '9 to 22.6 L/m^2', '7.88 L/h/m2 [dose of 50 mg/m2 Doxorubicin and 500 mg/m2 Dexrazoxane]', 'After intravenous administration, the drug is rapidly distributed into tissue fluids, the highest concentrations of the parent drug and its hydrolysis product being found in hepatic and renal tissues.', 'The mean peak plasma concentration of dexrazoxane was 36.5 mcg/mL at the end of the 15-minute infusion of a 500 mg/sq m doxorubicin dose. Following a rapid distributive phase, dexrazoxane reaches post-distributive equilibrium within 2 to 4 hours.', 'The estimated steady-state volume of distribution of dexrazoxane suggests its distribution primarily in the total body water (25 L/sq m ).', 'In vitro studies have shown that /dexrazoxane/ is not bound to plasma proteins.', 'For more Absorption, Distribution and Excretion (Complete) data for DEXRAZOXANE (9 total), please visit the HSDB record page.']","['Dexrazoxane is hydrolysed by the enzyme dihydropyrimidine amidohydrolase in the liver and kidney to active metabolites that are capable of binding to metal ions.', 'Metabolic products include the unchanged drug, a diacid-diamide cleavage product, and two monoacid-monoamide ring products of unknown concentrations.', 'In vitro studies have shown dexrazoxane to be hydrolysed by DHPase in liver and kidney, but not heart extracts.', '/This/ study was undertaken to determine the metabolism of dexrazoxane (ICRF-187) to its one-ring open hydrolysis products and its two-rings opened metal-chelating product ADR-925 in cancer patients with brain metastases treated with high-dose etoposide. In this phase I/II trial dexrazoxane was used as a rescue agent to reduce the extracerebral toxicity of etoposide. Dexrazoxane and its one-ring open hydrolysis products were determined by HPLC and ADR-925 was determined by a fluorescence flow injection assay. The two one-ring open hydrolysis intermediates of dexrazoxane appeared in the plasma at low levels upon completion of dexrazoxane infusion and then rapidly decreased with half-lives of 0.6 and 2.5 hr. A plasma concentration of 10 micro M ADR-925 was also detected at the completion of the dexrazoxane i.v. infusion period, indicating that dexrazoxane was rapidly metabolized in vivo. A plateau level of 30 micro M ADR-925 was maintained for 4 hr and then slowly decreased. The pharmacokinetics of dexrazoxane were found to be similar to other reported data in other settings and at lower doses. The rapid appearance of ADR-925 in plasma may make ADR-925 available to be taken up by heart tissue and bind free iron. These results suggest that the dexrazoxane intermediates are enzymatically metabolized to ADR-925 and provide a pharmacodynamic basis for the antioxidant cardioprotective activity of dexrazoxane.']","['2.5 hours', 'The distribution half-life has ranged from about 12 to 60 minutes ...', 'Elimination - 2.5 hours.']"
1384,71385,Licryfilcon A,CC(=C)C(=O)OCCO.CC(=C)C(=O)OCCOC(=O)C(=C)C,,,,,,
1385,71386,Clobetasone butyrate,CCCC(=O)O[C@@]1([C@H](C[C@@H]2[C@@]1(CC(=O)[C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)C)C)C(=O)CCl,,,"['Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)', 'A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. (See all compounds classified as Glucocorticoids.)']",,,
1386,71387,Clobetasone,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3(C(=O)C[C@@]2([C@]1(C(=O)CCl)O)C)F)C,"[""In dermatology, topical clobestasone butyrate helps to reduce the itchiness and erythema associated with eczema and dermatitis. In ophthalmology, clobetasone butyrate 0.1% eye drops have been shown to be safe and effective in the treatment of dry eyes in Sjögren's Syndrome.""]","['Topical corticosteroid like clobetasone are synthetic derivatives of cortisone which produce anti-inflammatory, antiproliferative, immunosuppressive and vasoconstrictor effects when applied to the skin.']",,"['Absorption is dependent on many drug-related factors including: intrinsic properties of the steroid itself; concentration of the drug (increased concentration generally leads to more drug being absorbed but may plateau at higher concentrations); vehicle used (optimized or augmented vehicles > ointments or gels > creams or lotions); duration of exposure; frequency of application; combination with other products that break down the skin barrier and increase absorption (e.g., salicylic acid, urea). Patient-related factors that influence absorption include: patient age (infants and children absorb topical medications more quickly and to a greater degree than adults, and have a greater total skin surface to body weight ratio; the elderly have thinner skin and absorb drug more readily); disruption of the skin due to inflammation or disease (e.g., absorption increased in atopic dermatitis); total skin area treated; skin site treated (absorption is much greater from thin-skinned areas such as scalp, face, eyelid, axilla, and scrotum than from areas with thicker skin such as forearm, knee, elbow, palm and sole); absorption is increased with increased temperature or humidity of the skin or the environment; occlusion of the treated skin (via plastic wrap, oily vehicles, dressings, tape, diapers, tight-fitting clothing, etc.) can increase absorption up to 10-fold.', 'Clobetasone and its metabolites are excreted in urine.', 'The use of pharmacodynamic endpoints for assessing the systemic exposure of  topical corticosteroids is necessary due to the fact that circulating levels are well below the level of detection.']","['Once absorbed through the skin, topical corticosteroids are handled through  pharmacokinetic pathways similar to systemically administered corticosteroids. They  are metabolised, primarily in the liver.']",['N/A']
1387,71388,Macrocyclon,CC(C)(C)CC(C)(C)C1=CC=C(C=C1)O.C=O.C1CO1,['Tyloxapol is an inhaled surfactant that assists in removing and liquefying and removing bronchopulmonary secretions with mucus and pus. Tyloxapol is administered either through nebulized solution or a stream of oxygen. Also investigated for use/treatment in cystic fibrosis and pediatric indications.'],"['It is used as a surfactant to aid liquefaction and removal of mucopurulent (containing mucus and pus) bronchopulmonary secretions. Tyloxapol also blocks plasma lipolytic activity, and thus the breakdown of triglyceride-rich lipoproteins.']","['Purifying or cleansing agents, usually salts of long-chain aliphatic bases or acids, that exert cleansing (oil-dissolving) and antimicrobial effects through a surface action that depends on possessing both hydrophilic and hydrophobic properties. (See all compounds classified as Detergents.)', 'Agents that modify interfacial tension of water; usually substances that have one lipophilic and one hydrophilic group in the molecule; includes soaps, detergents, emulsifiers, dispersing and wetting agents, and several groups of antiseptics. (See all compounds classified as Surface-Active Agents.)']",,,
1388,71389,"2-Propenoic acid, 2-methyl-, methyl ester, polymer with 1-ethenyl-2-pyrrolidinone",CC(=C)C(=O)OC.C=CN1CCCC1=O,,,,,,
1389,71390,CID 71390,C[C@H](C(=O)N[C@@H](CC(C)C)[C@H](CC(=O)O)O)NC(=O)C[C@@H](C(CC(C)C)NC(=O)C(C(C)C)NC(=O)C(C(C)C)NC(=O)CC(C)C)O,,,,,,
1390,71391,Vicryl,CC1C(=O)OC(C(=O)O1)C.C1C(=O)OCC(=O)O1,,,,,,
1391,71392,Epicillin,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CCC=CC3)N)C(=O)O)C,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
1392,71393,Tilidine Hydrochloride,CCOC(=O)[C@@]1(CCC=C[C@H]1N(C)C)C2=CC=CC=C2.Cl,,,"['Agents that induce NARCOSIS. Narcotics include agents that cause somnolence or induced sleep (STUPOR); natural or synthetic derivatives of OPIUM or MORPHINE or any substance that has such effects. They are potent inducers of ANALGESIA and OPIOID-RELATED DISORDERS. (See all compounds classified as Narcotics.)', 'Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. (See all compounds classified as Analgesics, Opioid.)']",,,
1393,71394,CID 71394,CCOC(=O)[C@@]1(CCC=CC1N(C)C)C2=CC=CC=C2,,,,,,
1394,71395,"but-2-enedioic acid;ethyl (1S,2R)-2-(dimethylamino)-1-phenylcyclohex-3-ene-1-carboxylate",CCOC(=O)[C@@]1(CCC=C[C@H]1N(C)C)C2=CC=CC=C2.C(=CC(=O)O)C(=O)O,,,,,,
1395,71396,Intriptyline hydrochloride,CN(C)CC#CC=C1C2=CC=CC=C2C=CC3=CC=CC=C31.Cl,,,,,,
1396,71397,Intriptyline,CN(C)CC#CC=C1C2=CC=CC=C2C=CC3=CC=CC=C31,,,,,,
1397,71398,Masoprocol,C[C@H](CC1=CC(=C(C=C1)O)O)[C@@H](C)CC2=CC(=C(C=C2)O)O,['Used for the treatment of actinic keratoses (precancerous skin growths that can become malignant if left untreated).'],['Masoprocol is a novel antineoplastic agent. It is not known exactly how masoprocol works. Laboratory experiments have shown that masoprocol prevents cells similar to the ones found in actinic keratoses from multiplying. Masoprocol was withdrawn from the U.S. market in June 1996.'],"['Compounds or agents that combine with cyclooxygenase (PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES) and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes. (See all compounds classified as Cyclooxygenase Inhibitors.)', 'Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. (See all compounds classified as Antioxidants.)', 'Compounds that bind to and inhibit that enzymatic activity of LIPOXYGENASES. Included under this category are inhibitors that are specific for lipoxygenase subtypes and act to reduce the production of LEUKOTRIENES. (See all compounds classified as Lipoxygenase Inhibitors.)']",['Less than 1%-2% is absorbed through the skin over a 4-day period following application.'],,
1398,71399,Loxapine succinate,CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl.C(CC(=O)O)C(=O)O,,,"['Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)', 'Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME. (See all compounds classified as Dopamine Antagonists.)']",,,
1399,71400,Loxapine hydrochloride,CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl.Cl,,,"['Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)', 'Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME. (See all compounds classified as Dopamine Antagonists.)']",,,
1400,71401,Guanfacine hydrochloride,C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl.Cl,"['Intuniv is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective.']",,"['Compounds that bind to and activate ADRENERGIC ALPHA-2 RECEPTORS. (See all compounds classified as Adrenergic alpha-2 Receptor Agonists.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)']",,,
1401,71402,Cetocycline,CC1=C(C2=C(C3=C(C[C@H]4[C@H](C(=O)C(=C([C@]4(C3=O)O)O)C(=O)C)N)C(=C2C=C1)C)O)O,,,,,,
1402,71403,"2-Propenoic acid, 2-methyl-, 2-ethoxyethyl ester, polymer with 2-hydroxyethyl 2-methyl-2-propenoate",CCOCCOC(=O)C(=C)C.CC(=C)C(=O)OCCO,,,,,,
1403,71404,2-Ethoxyethyl methacrylate,CCOCCOC(=O)C(=C)C,,,,,,
1404,71405,Pirenzepine hydrochloride,CN1CCN(CC1)CC(=O)N2C3=CC=CC=C3C(=O)NC4=C2N=CC=C4.Cl.Cl,,,"['Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. (See all compounds classified as Muscarinic Antagonists.)', 'Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. (See all compounds classified as Anti-Ulcer Agents.)']",,,
1405,71406,Tocophersolan,CC1=C(C(=C(C2=C1OC(CC2)(C)CCCC(C)CCCC(C)CCCC(C)C)C)OC(=O)CCC(=O)OCCO)C,,,,,,
1406,71407,Bamnidazole,CC1=NC=C(N1CCOC(=O)N)[N+](=O)[O-],,,,,,
1407,71408,"2-Propenoic acid, 2-methyl-, polymer with 2-hydroxyethyl 2-methyl-2-propenoate",CC(=C)C(=O)O.CC(=C)C(=O)OCCO,,,,,,
1408,71409,"4-[(S)-hydroxy-[(2R)-piperidin-2-yl]methyl]benzene-1,2-diol;hydrobromide",C1CCN[C@H](C1)[C@H](C2=CC(=C(C=C2)O)O)O.Br,,,,,,
1409,71410,"4-[(S)-hydroxy(piperidin-2-yl)methyl]benzene-1,2-diol",C1CCNC(C1)[C@H](C2=CC(=C(C=C2)O)O)O,,,,,,
1410,71411,CID 71411,CC1CCCC(N1C(=NC2=CC=CC(=C2)C(F)(F)F)S)C,,,,,,
1411,71412,Labetalol hydrochloride,CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O.Cl,,,"['Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. (See all compounds classified as Adrenergic beta-Antagonists.)', 'Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters. (See all compounds classified as Sympathomimetics.)', 'Drugs that bind to and block the activation of ADRENERGIC ALPHA-1 RECEPTORS. (See all compounds classified as Adrenergic alpha-1 Receptor Antagonists.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)']",,,
1412,71413,Aprindine hydrochloride,CCN(CC)CCCN(C1CC2=CC=CC=C2C1)C3=CC=CC=C3.Cl,,,"['Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)', 'A class of drugs that inhibit the activation of VOLTAGE-GATED SODIUM CHANNELS. (See all compounds classified as Voltage-Gated Sodium Channel Blockers.)']",,,
1413,71414,Diflorasone diacetate,C[C@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COC(=O)C)OC(=O)C)C)O)F)C)F,,,"['Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)', 'A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. (See all compounds classified as Glucocorticoids.)']",,,
1414,71415,Diflorasone,C[C@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C)F,['For relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.'],"['Like other topical corticosteroids, diflorasone has anti-inflammatory, antipruritic, and vasoconstrictive properties. Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Diflorasone is a potent topical corticosteroid that should not be used with occlusive dressings. It is recommended that treatment should be limited to 2 consecutive weeks and therapy should be discontinued when adequate results have been achieved.']","['Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)', 'A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. (See all compounds classified as Glucocorticoids.)']","['Topical corticosteroids can be absorbed from intact healthy skin. The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier. Occlusion, inflammation and/or other disease processes in the skin may also increase percutaneous absorption.']","['Metabolized, primarily in the liver, and then excreted by the kidneys.']",
1415,71416,Zolazepam hydrochloride,CC1=NN(C2=C1C(=NCC(=O)N2C)C3=CC=CC=C3F)C.Cl,,,"['Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)', 'Substances that do not act as agonists or antagonists but do affect the GAMMA-AMINOBUTYRIC ACID receptor-ionophore complex. GABA-A receptors (RECEPTORS, GABA-A) appear to have at least three allosteric sites at which modulators act: a site at which BENZODIAZEPINES act by increasing the opening frequency of GAMMA-AMINOBUTYRIC ACID-activated chloride channels; a site at which BARBITURATES act to prolong the duration of channel opening; and a site at which some steroids may act. GENERAL ANESTHETICS probably act at least partly by potentiating GABAergic responses, but they are not included here. (See all compounds classified as GABA Modulators.)']",,,
1416,71417,Acecainide hydrochloride,CCN(CC)CCNC(=O)C1=CC=C(C=C1)NC(=O)C.Cl,,,"['Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)']",,,
1417,71418,"Sulfuric acid--bis(1,2,2,6,6-pentamethylpiperidin-4-yl) butanedioate (1/1)",CC1(CC(CC(N1C)(C)C)OC(=O)CCC(=O)OC2CC(N(C(C2)(C)C)C)(C)C)C.OS(=O)(=O)O,,,,,,
1418,71419,Suxemerid,CC1(CC(CC(N1C)(C)C)OC(=O)CCC(=O)OC2CC(N(C(C2)(C)C)C)(C)C)C,,,,,,
1419,71420,Loperamide hydrochloride,CN(C)C(=O)C(CCN1CCC(CC1)(C2=CC=C(C=C2)Cl)O)(C3=CC=CC=C3)C4=CC=CC=C4.Cl,,,"['Miscellaneous agents found useful in the symptomatic treatment of diarrhea. They have no effect on the agent(s) that cause diarrhea, but merely alleviate the condition. (See all compounds classified as Antidiarrheals.)']",,,
1420,71421,Loperamide oxide,CN(C)C(=O)C(CC[N+]1(CCC(CC1)(C2=CC=C(C=C2)Cl)O)[O-])(C3=CC=CC=C3)C4=CC=CC=C4,,,"['Miscellaneous agents found useful in the symptomatic treatment of diarrhea. They have no effect on the agent(s) that cause diarrhea, but merely alleviate the condition. (See all compounds classified as Antidiarrheals.)']",,,
1421,71422,Endrisone,C[C@H]1C[C@H]2[C@@H]3CC[C@@H]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)C=C4)C)O)C)C(=O)C,,,,,,
1422,71423,Tiazuril,CC1=CC(=CC(=C1SC2=CC=C(C=C2)Cl)C)N3C(=O)NC(=O)C=N3,,,,,,
1423,71424,Viloxazine hydrochloride,CCOC1=CC=CC=C1OCC2CNCCO2.Cl,,,"['Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin. (See all compounds classified as Adrenergic Uptake Inhibitors.)', 'A structurally and mechanistically diverse group of drugs that are not tricyclics or monoamine oxidase inhibitors. The most clinically important appear to act selectively on serotonergic systems, especially by inhibiting serotonin reuptake. (See all compounds classified as Antidepressive Agents, Second-Generation.)']",,,
1424,71425,"9-[4-(Dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-3-ethyl-7-hydroxy-10-(2-hydroxyethyl)-2,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadec-14-ene-5,13-dione",CCC1C(C2C(O2)(C=CC(=O)C(CC(C(C(C(CC(=O)O1)O)C)OC3C(C(CC(O3)C)N(C)C)O)CCO)C)C)C,,,,,,
1425,71426,CID 71426,CC1[C@H]2C(=O)C3=C([C@@]1(CCN2CC4CC4)C)C=C(C=C3)O,,,,,,
1426,71427,"9-Octadecen-1-amine, hydrofluoride, (9Z)-",CCCCCCCCC=CCCCCCCCCN.F,,,,,,
1427,71428,"D-Streptamine, O-4-amino-4-deoxy-alpha-D-glucopyranosyl-(1-8)-O-(8R)-2-amino-2,3,7-trideoxy-7-(methylamino)-D-glycero-alpha-D-allo-octadialdo-1,5:8,4-dipyranosyl-(1-4)-2-deoxy-",CN[C@H]1[C@H]([C@@H]2[C@H](C[C@H](C(O2)O[C@@H]3[C@H](C[C@H]([C@@H]([C@H]3O)O)N)N)N)O[C@@H]1O[C@@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)N)O)O)O,,,,,,
1428,71429,"1-ethoxycarbonyloxyethyl (2S,5R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate;hydrochloride",CCOC(=O)OC(C)OC(=O)[C@H]1C(S[C@H]2N1C(=O)C2NC(=O)[C@@H](C3=CC=CC=C3)N)(C)C.Cl,,,,,,
1429,71430,"(2R,4R,5R)-11-fluoro-4-(hydroxymethyl)-10-imino-3,7-dioxa-1,9-diazatricyclo[6.4.0.02,6]dodeca-8,11-dien-5-ol",C1=C(C(=N)N=C2N1[C@H]3C(O2)[C@@H]([C@H](O3)CO)O)F,,,,,,
1430,71431,Difenoximide hydrochloride,C1CC(=O)N(C1=O)OC(=O)C2(CCN(CC2)CCC(C#N)(C3=CC=CC=C3)C4=CC=CC=C4)C5=CC=CC=C5.Cl,,,,,,
1431,71432,Iosumetic acid,CCN(C1=C(C=C(C(=C1I)NC)I)I)C(=O)CCC(=O)O,,,,,,
1432,71433,Trientine hydrochloride,C(CNCCNCCN)N.Cl.Cl,"['Cufence is indicated for the treatment of Wilson’s disease in patients intolerant to D-Penicillamine therapy, in adults and children aged 5 years or older.']",,['Chemicals that bind to and remove ions from solutions. Many chelating agents function through the formation of COORDINATION COMPLEXES with METALS. (See all compounds classified as Chelating Agents.)'],,,
1433,71434,Trientine tetrahydrochloride,C(CNCCNCCN)N.Cl.Cl.Cl.Cl,"[""Cuprior is indicated for the treatment of Wilson's disease in adults, adolescents and children ≥ 5 years intolerant to D-penicillamine therapy.""]",,,,,
1434,71435,Metastron,[Cl-].[Cl-].[89Sr+2],,,,,,
1435,71436,"2-amino-2-(hydroxymethyl)propane-1,3-diol;7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3S)-3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoic acid",CCCCC[C@@H](C=C[C@H]1[C@@H](C[C@@H]([C@@H]1CC=CCCCC(=O)O)O)O)O.C(C(CO)(CO)N)O,,,,,,
1436,71437,CID 71437,CCCCC[C@@H](C=C[C@H]1[C@@H](C[C@@H]([C@@H]1CC=CCCCC(=O)OCC)O)O)O,,,,,,
1437,71438,CID 71438,CCCCC[C@@H](C=C[C@H]1[C@@H](C[C@@H]([C@@H]1CC=CCCCC(=O)OC(C)C)O)O)O,,,,,,
1438,71439,"methyl 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3S)-3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoate",CCCCC[C@@H](C=C[C@H]1[C@@H](C[C@@H]([C@@H]1CC=CCCCC(=O)OC)O)O)O,,,,,,
1439,71440,Surfilcon A,CC(=C)C(=O)OC.CC(=C)C(=O)OCC=C.C=CN1CCCC1=O,,,,,,
1440,71441,Rodocaine,CC1=C(C(=CC=C1)Cl)NC(=O)CCN2CCC[C@@H]3[C@@H]2CCC3,,,,,,
1441,71442,Pirolazamide,C1CC2CN(CCN2C1)CCC(C3=CC=CC=C3)(C4=CC=CC=C4)C(=O)N,,,,,,
1442,71443,Gold sodium thiomalate,C(C(C(=O)[O-])[S-])C(=O)[O-].O.[Na+].[Na+].[Au+],,,['Drugs that are used to treat RHEUMATOID ARTHRITIS. (See all compounds classified as Antirheumatic Agents.)'],"['Higher tissue levels occur with parenteral gold salts, with a mean steady state plasma level of 1 to 5 ug/ml. Drug is distributed widely throughout the body in lymph nodes, bone marrow, kidneys, liver, spleen, and tissues. About 85% to 90% is protein-bound.', 'Gold has been shown to cross the placenta in pregnant women receiving gold sodium thiomalate. Small amounts of gold have been shown to be distributed into milk in women receiving ... gold sodium thiomalate.', 'Gold sodium thiomalate solutions are rapidly absorbed following IM injection, with peak serum concentrations occurring in 3-6 hours.', 'Following single 10-mg doses of gold sodium thiomalate, serum gold concentrations showed a biphasic decline with a relatively rapid early phase (serum half-life about 43 hours) and a slow late phase (serum half-life about 6 days). The slow phase of decline may result from excretion and the rapid phase of decline may result from tissue distribution. The true potential of gold compounds, including ... gold sodium thiomalate, to cumulate has not been clearly defined, but it is clear that substantially larger amounts of gold are retained in the body during therapy with parenteral gold compounds than during therapy with auranofin.', 'For more Absorption, Distribution and Excretion (Complete) data for GOLD SODIUM THIOMALATE (8 total), please visit the HSDB record page.']","['For a patient receiving gold sodium thiomalate the principal gold species in the urine is [Au(CN)2]-, which is also seen in a low molecular weight infiltrate of the blood']","['Following single 10-mg doses of gold sodium thiomalate, serum gold concentrations showed a biphasic decline with a relatively rapid early phase (serum half-life about 43 hours) and a slow late phase (serum half-life about 6 days).', '...Terminal log-linear phases corresponded to a mean disposition half-life of 25 days...', '... the mean alpha half-lives were 0.738 and 1.78 hr for the iv and im routes, respectively. The corresponding terminal (beta) half-lives were 54.1 and 63.0 hr...', 'Four normal male volunteers participated in a study designed to examine the disposition of gold given intramuscularly as gold sodium thiomalate. Blood samples were collected for 32 days following the administration of 10 mg of gold sodium thiomalate. .... Terminal log-linear phases corresponded to a mean disposition half-life of 25 days. ...']"
1443,71444,CID 71444,C[C@H](C(=O)O)NC(=O)C1CCCN1C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC.CC(=O)O,,,,,,
1444,71445,CID 71445,C[C@H](C(=O)O)NC(=O)C1CCCN1C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC,,,,,,
1445,71446,Talampicillin hydrochloride,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)OC4C5=CC=CC=C5C(=O)O4)C.Cl,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
1446,71447,Talampicillin,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)OC4C5=CC=CC=C5C(=O)O4)C,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
1447,71448,Minocromil,CCCC1=C2C(=CC3=C1OC(=CC3=O)C(=O)O)C(=CC(=N2)C(=O)O)NC,,,,,,
1448,71449,Netobimin,CCCSC1=CC(=C(C=C1)[N+](=O)[O-])NC(=NCCS(=O)(=O)O)NC(=O)OC,,,['Agents that kill parasitic worms. They are used therapeutically in the treatment of HELMINTHIASIS in man and animal. (See all compounds classified as Anthelmintics.)'],,,
1449,71450,Gusanlung A,COC1=C(C2=C(C[C@H]3C4=CC5=C(C=C4CCN3C2=O)OCO5)C=C1)O,,,,,,
1450,71451,CID 71451,C[C@H]([C@@H]1[C@H]2[C@H]3CCC[C@@H](C3=C(N2C1=O)C(=O)[O-])OC)O.[Na+],,,,,,
1451,71452,Sanfetrinem,C[C@H]([C@@H]1[C@H]2[C@H]3CCC[C@@H](C3=C(N2C1=O)C(=O)O)OC)O,,,,,,
1452,71453,2-[1-[2-[(4-Carbamimidoylbenzoyl)amino]-3-(4-hydroxyphenyl)propanoyl]piperidin-4-yl]oxyacetic acid,C1CN(CCC1OCC(=O)O)C(=O)C(CC2=CC=C(C=C2)O)NC(=O)C3=CC=C(C=C3)C(=N)N,,,,,,
1453,71454,Liarozole hydrochloride,C1=CC(=CC(=C1)Cl)C(C2=CC3=C(C=C2)N=CN3)N4C=CN=C4.Cl,,,"['Compounds which inhibit or antagonize the biosynthesis or actions of androgens. (See all compounds classified as Androgen Antagonists.)', 'Drugs used to treat or prevent skin disorders or for the routine care of skin. (See all compounds classified as Dermatologic Agents.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)', 'Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079) (See all compounds classified as Antineoplastic Agents, Hormonal.)']",,,
1454,71455,Premafloxacin,C[C@@H]([C@@H]1CCN(C1)C2=C(C=C3C(=C2OC)N(C=C(C3=O)C(=O)O)C4CC4)F)NC,,,,,,
1455,71456,Xanomeline tartrate,CCCCCCOC1=NSN=C1C2=CCCN(C2)C.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,,,"['Drugs that mimic the effects of parasympathetic nervous system activity. Included here are drugs that directly stimulate muscarinic receptors and drugs that potentiate cholinergic activity, usually by slowing the breakdown of acetylcholine (CHOLINESTERASE INHIBITORS). Drugs that stimulate both sympathetic and parasympathetic postganglionic neurons (GANGLIONIC STIMULANTS) are not included here. (See all compounds classified as Parasympathomimetics.)', 'Drugs that bind to and activate muscarinic cholinergic receptors (RECEPTORS, MUSCARINIC). Muscarinic agonists are most commonly used when it is desirable to increase smooth muscle tone, especially in the GI tract, urinary bladder and the eye. They may also be used to reduce heart rate. (See all compounds classified as Muscarinic Agonists.)', 'A loosely defined grouping of drugs that have effects on psychological function. Here the psychotropic agents include the antidepressive agents, hallucinogens, and tranquilizing agents (including the antipsychotics and anti-anxiety agents). (See all compounds classified as Psychotropic Drugs.)']",,,
1456,71457,CID 71457,C1=CC(=CC(=C1)Cl)C(C2=CC3=C(C=C2)N=CN3)N4C=CN=C4.C(=CC(=O)O)C(=O)O,,,,,,
1457,71458,Ontazolast,CC1=CC2=C(C=C1)OC(=N2)N[C@@H](CC3CCCCC3)C4=CC=CC=N4,,,,,,
1458,71459,2-[[(2S)-4-[(1-carbamimidoylpiperidin-3-yl)methylamino]-2-(naphthalen-2-ylsulfonylamino)-4-oxobutanoyl]-cyclopropylamino]acetic acid,C1CC(CN(C1)C(=N)N)CNC(=O)C[C@@H](C(=O)N(CC(=O)O)C2CC2)NS(=O)(=O)C3=CC4=CC=CC=C4C=C3,,,,,,
1459,71460,N-Hydroxy-N-(4-(5-(4-fluorophenoxy)-2-furyl)-3-butyn-2-yl)urea,CC(C#CC1=CC=C(O1)OC2=CC=C(C=C2)F)N(C(=O)N)O,,,,,,
1460,71461,CID 71461,C1N(CSC(=S)N1CC2=CC=CC=C2)CC(=O)[O-].[Na+],,,,,,
1461,71462,Bensuldazic Acid,C1N(CSC(=S)N1CC2=CC=CC=C2)CC(=O)O,,,,,,
1462,71463,Paratensiol,C[C@H]1[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2C(=CO1)C(=O)OCCN(C)C)NC5=CC(=C(C=C45)OC)OC.Cl.Cl,,,,,,
1463,71464,Dimethylaminoethyl reserpilinate dihydrochloride,C[C@H]1[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2C(=CO1)C(=O)OCCN(C)C)NC5=CC(=C(C=C45)OC)OC,,,,,,
1464,71465,Bronkosol,CC[C@H]([C@H](C1=CC(=C(C=C1)O)O)O)NC(C)C.Cl,,,,,,
1465,71466,Isoetarine,CC[C@H]([C@H](C1=CC(=C(C=C1)O)O)O)NC(C)C,,,"['Agents that cause an increase in the expansion of a bronchus or bronchial tubes. (See all compounds classified as Bronchodilator Agents.)', 'Compounds bind to and activate ADRENERGIC BETA-2 RECEPTORS. (See all compounds classified as Adrenergic beta-2 Receptor Agonists.)']",,,
1466,71467,Phenoxypropazine,CC(COC1=CC=CC=C1)NN,['For the treatment of depression.'],,,,,
1467,71468,Pyruvic acid calcium isoniazid,CC(=NNC(=O)C1=CC=NC=C1)C(=O)[O-].CC(=NNC(=O)C1=CC=NC=C1)C(=O)[O-].[Ca+2],,,,,,
1468,71469,Erythromycin lactobionate,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O.C([C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@H]([C@@H](CO)O)[C@@H]([C@H](C(=O)O)O)O)O)O)O)O,,,"['Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion. (See all compounds classified as Gastrointestinal Agents.)', 'Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)']",,,
1469,71470,Betamethasone butyrate propionate,CCCC(=O)O[C@@]1([C@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)O)C)C)C(=O)COC(=O)CC,,,,,,
1470,71471,1-(2-methoxyphenyl)-N-methylpropan-1-amine hydrochloride,CCC(C1=CC=CC=C1OC)NC.Cl,,,,,,
1471,71472,[1-(2-Methoxyphenyl)propyl](methyl)amine,CCC(C1=CC=CC=C1OC)NC,,,,,,
1472,71473,Cyclizine lactate,CC(C(=O)O)O.CN1CCN(CC1)C(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
1473,71474,Trisodium citrate dihydrate,C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.O.O.[Na+].[Na+].[Na+],,,"['Agents that prevent BLOOD CLOTTING. (See all compounds classified as Anticoagulants.)', 'A chemical system that functions to control the levels of specific ions in solution. When the level of hydrogen ion in solution is controlled the system is called a pH buffer. (See all compounds classified as Buffers.)', 'Substances capable of inhibiting, retarding or arresting the process of fermentation, acidification or other deterioration of foods. (See all compounds classified as Food Preservatives.)']",,,
1474,71475,CID 71475,CN1CC[C@]23[C@@H]4[C@@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O.OS(=O)(=O)O,,,,,,
1475,71476,Lincomycin hydrochloride monohydrate,CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@@H](C)O.O.Cl,,,"['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)', 'Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. (See all compounds classified as Protein Synthesis Inhibitors.)']",,,
1476,71477,Migrenine,CC1=CC(=O)N(N1C)C2=CC=CC=C2.CN1C=NC2=C1C(=O)N(C(=O)N2C)C.C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O,,,,,,
1477,71478,Maprotiline hydrochloride,CNCCCC12CCC(C3=CC=CC=C31)C4=CC=CC=C24.Cl,,,"['Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin. (See all compounds classified as Adrenergic Uptake Inhibitors.)', 'A structurally and mechanistically diverse group of drugs that are not tricyclics or monoamine oxidase inhibitors. The most clinically important appear to act selectively on serotonergic systems, especially by inhibiting serotonin reuptake. (See all compounds classified as Antidepressive Agents, Second-Generation.)']",,,
1478,71479,Bencyclane (fumarate),CN(C)CCCOC1(CCCCCC1)CC2=CC=CC=C2.C(=CC(=O)O)C(=O)O,,,,,,
1479,71480,CID 71480,C(=O)[C@@H]([C@H]([C@@H]([C@@H](C(=O)[O-])O)O)O)O.[Na+],,,,,,
1480,71481,CID 71481,CCCC(=O)OCCC(=C(C)N(CC1=CN=C(N=C1N)C)C=C)SSC(=C(C)N(CC2=CN=C(N=C2N)C)C=O)CCOC(=O)CCC,,,,,,
1481,71482,Azamethiphos,COP(=O)(OC)SCN1C2=C(C=C(C=N2)Cl)OC1=O,,,['Drugs used to treat or prevent parasitic infections. (See all compounds classified as Antiparasitic Agents.)'],,,
1482,71483,"3-(2,4-Dinitrostyryl)-(6r,7r)-7-(2-thienylacetamido)-ceph-3-em-4-carboxylic acid",C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CS3)C(=O)O)C=CC4=C(C=C(C=C4)[N+](=O)[O-])[N+](=O)[O-],,,,,,
1483,71484,Protoporphyrin disodium,CC1=C(C2=CC3=NC(=CC4=NC(=CC5=C(C(=C(N5)C=C1N2)C=C)C)C(=C4CCC(=O)[O-])C)C(=C3C)CCC(=O)[O-])C=C.[Na+].[Na+],,,['Drugs that are pharmacologically inactive but when exposed to ultraviolet radiation or sunlight are converted to their active metabolite to produce a beneficial reaction affecting the diseased tissue. These compounds can be administered topically or systemically and have been used therapeutically to treat psoriasis and various types of neoplasms. (See all compounds classified as Photosensitizing Agents.)'],,,
1484,71485,Sucralose,C([C@@H]1[C@@H]([C@@H]([C@H]([C@H](O1)O[C@]2([C@H]([C@@H]([C@H](O2)CCl)O)O)CCl)O)O)Cl)O,,,"['Substances that sweeten food, beverages, medications, etc., such as sugar, saccharine or other low-calorie synthetic products. (From Random House Unabridged Dictionary, 2d ed) (See all compounds classified as Sweetening Agents.)']","['After single intravenous doses of (14)C-trichlorogalactosucrose to dogs at a dose level of 2 mg/kg (5.8 uCi/kg) radioactivity was rapidly excreted mainly in the urine. Urinary excretion accounted for means of 29.3%, 63.9% and 74.1% of the dose during 3, 6 and 12 hours after dosing respectively, increasing to 80.9% of the dose after 5 days. Fecal excretion accounted for a mean of 10.4% dose after 24 hours, increasing to 11.9% dose after 5 days. Plasma radioactivity was maximal at 5 minutes after dosing (the first time of sampling, 8.46 ug equivalents/mL). Radioactivity in plasma declined in a multi-exponential fashion; concentrations decreased rapidly to a mean of 0.057 ug equivalents/ml at 12 hours after dosing but thereafter declined more slowly, and were still detectable in all animals at 120 hours after dosing (mean, 0.013 ug equivalents/ml). Consideration of whole-blood and plasma concentrations indicated that radioactivity was cleared more slowly from blood cells than from plasma.', ""(14)C-trichlorogalactosucrose (1 mg/kg; 100 uCi > 98% pure) was given orally dissolved in water to 8 normal, healthy male volunteers and blood, urine and feces collected for up to 5 days after the dose. The total recovery of (14)C-activity was 92.7% (range 87.8-99.2%) with most of the radioactivity 78.3% (range 69.4-89.6%) in the feces, and the remainder 14.4% (range 8.8-21.7%) in the urine.  The plasma concentrations of (14)C-activity reached a peak at about 2 hr after the dose, with levels of (14)C equivalent to approximately 250 ng/mL of trichlorogalactosucrose. The plasma concentrations fell rapidly between 2 and 12 hr followed by a more gradual decrease until 72 hr by which time the levels of radioactivity were near or below the limit of accurate determination. The mean 'effective half-life' calculated on the basis of a mean residence time (MRT) of 18.8 hr gives a value of 13.0 hr."", 'Three male subjects given a single oral dose (1.11 mg/kg b.w., 0.3 uCi/kg) of trichlorogalactosucrose uniformly labelled with carbon-14 excreted an average of 13.5% of the radioactivity in urine and 82.1% in feces in 5 days. No (14)CO2 was detected in expired air collected during the initial 8 hours after dosing. Maximum levels of radioactivity in the blood occurred within 2-3 hours and in two of the subjects declined with a half-life of approximately 2.5 hours. Chromatographic examination of the 0-3 hours urines indicated the presence of only a single radioactive component.', 'After single oral doses of (14)C-trichlorogalactosucrose to non-pregnant and pregnant rabbits at a dose level of 10 mg/kg, radioactivity was excreted mainly in the feces. During 24 hours after dosing, a mean of 16.8% of the dose was excreted in the feces of non-pregnant animals, increasing to 31.8% during 48 hours and 54.7% during 120 hours. Excretion of radioactivity in the feces of pregnant rabbits was similar, with means of 27.8%, 43.0% and 65.2% of the dose excreted by this route during 24, 48 and 120 hours after dosing, respectively. Means of 5.3% and 4.2% dose were excreted in the feces of non-pregnant and pregnant rabbits respectively during 96-120 hours after dosing, indicating that excretion of radioactivity was not completed after 5 days, probably because of the coprophagic behavior of rabbits. During 24 hours, means of 8.3% and 8.6% of the dose were excreted in the urine of non-pregnant and pregnant rabbits, respectively. Mean totals of 22.3% (non-pregnant rabbits) and 21.5% (pregnant rabbits) of the dose was gradually excreted in the urine during 5 days after dosing. Radioactivity was still being excreted in the urine of rabbits (up to 2.9% dose) during 96-120 hours after dosing. Mean total recoveries of radioactivity from the urine and feces of non- pregnant and pregnant rabbits after 5 days accounted for 80.3% and 87.0% of the dose respectively. The dose not accounted for was presumably still to be excreted since a total of up to 8.4% of the dose was excreted during 96-120 hours after dosing. There were no notable differences in the absorption and excretion of single oral doses of (14)C-trichlorogalactosucrose between non-pregnant and pregnant rabbits.', 'For more Absorption, Distribution and Excretion (Complete) data for Sucralose (14 total), please visit the HSDB record page.']","['Following a single oral dose of (14)C-sucralose (1mg/kg, 100 microCi) to eight male subjects, a mean of 14.5% (range 8.9 to 21.8%) of the radioactivity was excreted in urine and 78.3% (range 69.4 to 89.6%) in the feces, within 5 days. The total recovery of radioactivity averaged 92.8%. Plasma concentrations of radioactivity were maximal at about 2 hours after dosing. The mean residence time (MRT) for sucralose was 18.8 hr, while the effective half-life for the decline of plasma radioactivity was 13 hr. Two volunteers given a higher oral dose (10 mg/kg, 22.7 uCi) excreted a mean of 11.2% (9.6 and 12.7%) of the radioactivity in urine, and 85.5% (84.1 and 86.8%) in feces over 5 days. The total recovery of radioactivity was 96.7%. The radiolabelled material present in feces was essentially unchanged sucralose. Sucralose was the principal component in the urine together with two more polar components which accounted for only 2.6% of the administered dose (range 1.5 to 5.1% of dose); both metabolites possessed characteristics of glucuronide conjugates of sucralose.']","['Three male subjects given a single oral dose (1.11 mg/kg b.w., 0.3 uCi/kg) of trichlorogalactosucrose uniformly labelled with carbon-14 excreted an average of 13.5% of the radioactivity in urine and 82.1% in feces in 5 days. ... Maximum levels of radioactivity in the blood occurred within 2-3 hours and in two of the subjects declined with a half-life of approximately 2.5 hours.']"
1485,71486,Dipivefrin hydrochloride,CC(C)(C)C(=O)OC1=C(C=C(C=C1)C(CNC)O)OC(=O)C(C)(C)C.Cl,,,['Drugs that bind to and activate adrenergic receptors. (See all compounds classified as Adrenergic Agonists.)'],,,
1486,71487,Copovithane,CNC(=O)OCC(=C)COC(=O)NC.C=CN1CCCC1=O,,,,,,
1487,71488,"2-Methylenepropane-1,3-diyl bis(methylcarbamate)",CNC(=O)OCC(=C)COC(=O)NC,,,,,,
1488,71489,Fenpiverinium bromide,C[N+]1(CCCCC1)CCC(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N.[Br-],,,,,,
1489,71490,Fenpiverinium,C[N+]1(CCCCC1)CCC(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N,,,,,,
1490,71491,"3-{[Hydroxy(diphenyl)acetyl]oxy}-6-methoxy-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide",C[N+]1(C2CC(CC1C(C2)OC)OC(=O)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)C.[Br-],,,,,,
1491,71492,"3-[(Hydroxydiphenylacetyl)oxy]-6-methoxy-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane",C[N+]1(C2CC(CC1C(C2)OC)OC(=O)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)C,,,,,,
1492,71493,Propyromazine bromide,CC(C(=O)N1C2=CC=CC=C2SC3=CC=CC=C31)[N+]4(CCCC4)C.[Br-],,,,,,
1493,71494,1-Methyl-1-(1-phenothiazin-10-ylcarbonylethyl)pyrrolidinium,CC(C(=O)N1C2=CC=CC=C2SC3=CC=CC=C31)[N+]4(CCCC4)C,,,,,,
1494,71495,Hexcarbacholine bromide,C[N+](C)(C)CCOC(=O)NCCCCCCNC(=O)OCC[N+](C)(C)C.[Br-].[Br-],,,,,,
1495,71496,Hexcarbacholine,C[N+](C)(C)CCOC(=O)NCCCCCCNC(=O)OCC[N+](C)(C)C,,,,,,
1496,71497,Dicolinium iodide,CC[N+](C)(CC)CCOC(=O)C1CCCC([N+]1(C)C)C.[I-].[I-],,,,,,
1497,71498,Dicolinium,CC[N+](C)(CC)CCOC(=O)C1CCCC([N+]1(C)C)C,,,,,,
1498,71499,"6-Amino-2-[2-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)ethenyl]-1-methylquinolin-1-ium chloride",CC1=CC(=C(N1C2=CC=CC=C2)C)C=CC3=[N+](C4=C(C=C3)C=C(C=C4)N)C.[Cl-],,,,,,
1499,71500,"6-Amino-2-[2-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)ethenyl]-1-methylquinolin-1-ium",CC1=CC(=C(N1C2=CC=CC=C2)C)C=CC3=[N+](C4=C(C=C3)C=C(C=C4)N)C,,,,,,
1500,71501,Methylguanidine sulfate,CN=C(N)N.CN=C(N)N.OS(=O)(=O)O,,,,,,
1501,71502,Trifluoroacetic acid-d,[2H]OC(=O)C(F)(F)F,,,,,,
1502,71503,Toloconium metilsulfate,CCCCCCCCCCCC(C1=CC=C(C=C1)C)[N+](C)(C)C.COS(=O)(=O)[O-],,,,,,
1503,71504,Toloconium,CCCCCCCCCCCC(C1=CC=C(C=C1)C)[N+](C)(C)C,,,,,,
1504,71505,"disodium;(1S,2R,3S,4R,5R)-2,3,4,5,6-pentahydroxy-1-[4-[4-[[(1S,2R,3S,4R,5R)-2,3,4,5,6-pentahydroxy-1-sulfonatohexyl]amino]phenyl]sulfonylanilino]hexane-1-sulfonate",C1=CC(=CC=C1N[C@H]([C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)S(=O)(=O)[O-])S(=O)(=O)C2=CC=C(C=C2)N[C@H]([C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)S(=O)(=O)[O-].[Na+].[Na+],,,,,,
1505,71506,CID 71506,C1=CC(=CC=C1NC(C(C(C([C@@H](CO)O)O)O)O)S(=O)(=O)O)S(=O)(=O)C2=CC=C(C=C2)NC(C(C(C([C@@H](CO)O)O)O)O)S(=O)(=O)O,,,,,,
1506,71507,Oxypyrronium bromide,C[N+]1(CCCC1COC(=O)C(C2CCCCC2)(C3=CC=CC=C3)O)C.[Br-],,,,,,
1507,71508,Oxypyrronium,C[N+]1(CCCC1COC(=O)C(C2CCCCC2)(C3=CC=CC=C3)O)C,,,,,,
1508,71509,Cyheptropine,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C3C4=CC=CC=C4CCC5=CC=CC=C35,,,,,,
1509,71510,Sulfarsphenamine,C1=CC(=C(C=C1[As]=[As]C2=CC(=C(C=C2)O)NCS(=O)(=O)[O-])NCS(=O)(=O)[O-])O.[Na+].[Na+],,,,,,
1510,71511,"[1,2-Diarsenediylbis[(6-hydroxy-3,1-phenylene)imino]]bis-methanesulfonic acid",C1=CC(=C(C=C1[As]=[As]C2=CC(=C(C=C2)O)NCS(=O)(=O)O)NCS(=O)(=O)O)O,,,,,,
1511,71512,Trepirium iodide,C[N+]1(CCCC1C(=O)OCC[N+](C)(C)C)C.[I-].[I-],,,,,,
1512,71513,Trepirium,C[N+]1(CCCC1C(=O)OCC[N+](C)(C)C)C,,,,,,
1513,71514,Trethinium tosilate,CC[N+]1(CCC2=CC=CC=C2C1)C.CC1=CC=C(C=C1)S(=O)(=O)[O-],,,,,,
1514,71515,Trethinium,CC[N+]1(CCC2=CC=CC=C2C1)C,,,,,,
1515,71516,Laurcetium bromide,CCCCCCCCCCCC[N+](C)(C)CC(=O)OCC.[Br-],,,,,,
1516,71517,Laurcetium,CCCCCCCCCCCC[N+](C)(C)CC(=O)OCC,,,,,,
1517,71518,Metocinium iodide,C[N+](C)(C)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O.[I-],,,"['Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)', 'Agents that dilate the pupil. They may be either sympathomimetics or parasympatholytics. (See all compounds classified as Mydriatics.)', 'Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. (See all compounds classified as Muscarinic Antagonists.)']",,,
1518,71519,Dimecolonium iodide,CC1CCCC([N+]1(C)C)C(=O)OCC[N+](C)(C)C.[I-].[I-],,,,,,
1519,71520,Dimecolonium,CC1CCCC([N+]1(C)C)C(=O)OCC[N+](C)(C)C,,,,,,
1520,71521,Etipirium iodide,C[N+]1(CCCC1)CCOC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O.[I-],,,,,,
1521,71522,Etipirium,C[N+]1(CCCC1)CCOC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O,,,,,,
1522,71523,Oxysonium iodide,C[S+](C)CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O.[I-],,,,,,
1523,71524,Oxysonium,C[S+](C)CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O,,,,,,
1524,71525,Hexasonium iodide,C[S+](C)CCOC(=O)C(C1CCCCC1)C2=CC=CC=C2.[I-],,,,,,
1525,71526,Hexasonium,C[S+](C)CCOC(=O)C(C1CCCCC1)C2=CC=CC=C2,,,,,,
1526,71527,Troxypyrrolium tosilate,CC[N+]1(CCCC1)CCOC(=O)C2=CC(=C(C(=C2)OC)OC)OC.CC1=CC=C(C=C1)S(=O)(=O)[O-],,,,,,
1527,71528,Troxypyrrolidinium,CC[N+]1(CCCC1)CCOC(=O)C2=CC(=C(C(=C2)OC)OC)OC,,,,,,
1528,71529,Fubrogonium iodide,CC[N+](C)(CC)CCC(C)OC(=O)C1=CC=C(O1)Br.[I-],,,,,,
1529,71530,Fubrogonium,CC[N+](C)(CC)CCC(C)OC(=O)C1=CC=C(O1)Br,,,,,,
1530,71531,Trantelinium bromide,C[N+]1([C@@H]2CC[C@H]1CC(C2)OC(=O)C3C4=CC=CC=C4OC5=CC=CC=C35)C.[Br-],,,,,,
1531,71532,Trantelinium,C[N+]1([C@@H]2CC[C@H]1CC(C2)OC(=O)C3C4=CC=CC=C4OC5=CC=CC=C35)C,,,,,,
1532,71533,Mefenidramium metilsulfate,C[N+](C)(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2.COS(=O)(=O)[O-],,,,,,
1533,71534,Fentonium (bromide),C[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)CC(=O)C4=CC=C(C=C4)C5=CC=CC=C5.[Br-],,,,,,
1534,71535,[8-Methyl-8-[2-oxo-2-(4-phenylphenyl)ethyl]-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate bromide,C[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)CC(=O)C4=CC=C(C=C4)C5=CC=CC=C5,,,,,,
1535,71536,CID 71536,CCC12CN3CCC4=C(C(CC(C3)C1O2)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)NC1=CC=CC=C41,,,,,,
1536,71537,Candocuronium iodide,C[C@]12CC[C@@H](CC1=CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC[N+]4(C)C)C)[N+]5(CCCC5)C.[I-].[I-],,,,,,
1537,71538,Candocuronium,C[C@]12CC[C@@H](CC1=CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC[N+]4(C)C)C)[N+]5(CCCC5)C,,,,,,
1538,71539,"3,5,5-Trimethylhexanoyl ferrocene",CC(CC(=C1C=CC=C1)[O-])CC(C)(C)C.[CH-]1C=CC=C1.[Fe+2],,,,,,
1539,71540,"1-Cyclopenta-2,4-dien-1-ylidene-3,5,5-trimethylhexan-1-ol",CC(CC(=C1C=CC=C1)O)CC(C)(C)C,,,,,,
1540,71541,Ditercalinium chloride,COC1=CC2=C(C=C1)NC3=C2C4=C(C=C3)C=C[N+](=C4)CCN5CCC(CC5)C6CCN(CC6)CC[N+]7=CC8=C(C=CC9=C8C1=C(N9)C=CC(=C1)OC)C=C7.[Cl-].[Cl-],,,"['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)', 'Agents that are capable of inserting themselves between the successive bases in DNA, thus kinking, uncoiling or otherwise deforming it and therefore preventing its proper functioning. They are used in the study of DNA. (See all compounds classified as Intercalating Agents.)']",,,
1541,71542,(6-Ethoxyquinolin-4-yl)-(5-ethyl-1-azabicyclo[2.2.2]octan-2-yl)methanol,CCC1CN2CCC1CC2C(C3=C4C=C(C=CC4=NC=C3)OCC)O,,,,,,
1542,71543,"3,6,9,12-Tetraazaheneicosan-21-amide, 1-amino-N-(2-((2-((2-((2-aminoethyl)amino)ethyl)amino)ethyl)amino)ethyl)-13-(1-hydroxynonyl)-",CCCCCCCCC(C(CCCCCCCC(=O)NCCNCCNCCNCCN)NCCNCCNCCNCCN)O,,,,,,
1543,71544,"[2,2-Bis(2-methylpropoxy)ethyl]benzene",CC(C)COC(CC1=CC=CC=C1)OCC(C)C,,,,,,
1544,71545,2-Phenylquinoline,C1=CC=C(C=C1)C2=NC3=CC=CC=C3C=C2,,,,,,
1545,71546,(S)-3-Hydroxy-alpha-((methylamino)methyl)benzyl alcohol,CNC[C@H](C1=CC(=CC=C1)O)O,,,,,,
1546,71547,Triethylstibine,CC[Sb](CC)CC,,,,,,
1547,71548,Methenamine salicylate,C1N2CN3CN1CN(C2)C3.C1=CC=C(C(=C1)C(=O)O)O,,,,,,
1548,71549,Phenamidine isethionate,C1=CC(=CC=C1C(=N)N)OC2=CC=C(C=C2)C(=N)N.C(CS(=O)(=O)O)O.C(CS(=O)(=O)O)O,,,,,,
1549,71550,Anhaline sulfate,CN(C)CCC1=CC=C(C=C1)O.CN(C)CCC1=CC=C(C=C1)O.OS(=O)(=O)O,,,,,,
1550,71551,Metoquinone,CNC1=CC=C(C=C1)O.CNC1=CC=C(C=C1)O.C1=CC(=CC=C1O)O,,,,,,
1551,71552,Heptadecanal,CCCCCCCCCCCCCCCCC=O,,,,,,
1552,71553,"Spiro(isobenzofuran-1(3H),9'-(9H)xanthen)-3-one, 4,5,6,7-tetrachloro-3',6'-dihydroxy-2',4',5',7'-tetraiodo-, dipotassium salt",C1=C2C(=C(C(=C1I)[O-])I)OC3=C(C(=C(C=C3C24C5=C(C(=C(C(=C5Cl)Cl)Cl)Cl)C(=O)O4)I)[O-])I.[K+].[K+],,,,,,
1553,71554,o-Tolylhydrazine hydrochloride,CC1=CC=CC=C1NN.Cl,,,,,,
1554,71555,Homoveratrylamine hydrochloride,COC1=C(C=C(C=C1)CCN)OC.Cl,,,,,,
1555,71556,CID 71556,[Li+].C1=CC=C(C=C1)C(=O)NCC(=O)[O-],,,,,,
1556,71557,"2,4-Diaminotoluene dihydrochloride",CC1=C(C=C(C=C1)N)N.Cl.Cl,,,,,,
1557,71558,Niacin hydrochloride,C1=CC(=CN=C1)C(=O)O.Cl,,,"['Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS. (See all compounds classified as Hypolipidemic Agents.)', 'Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)', 'A group of water-soluble vitamins, some of which are COENZYMES. (See all compounds classified as Vitamin B Complex.)']",,,
1558,71559,Picolinic Acid Hydrochloride,C1=CC=NC(=C1)C(=O)O.Cl,,,,,,
1559,71560,CID 71560,C1=CC(=CC(=C1)N(O)O)N=N.Cl,,,,,,
1560,71561,"N,N,N',N'-Tetramethyl-p-phenylenediamine dihydrochloride",CN(C)C1=CC=C(C=C1)N(C)C.Cl.Cl,,,,,,
1561,71562,3-Methylphenylhydrazine hydrochloride,CC1=CC(=CC=C1)NN.Cl,,,,,,
1562,71563,D-Valine,CC(C)[C@H](C(=O)O)N,,,,,,
1563,71564,Dopamine hydrobromide,C1=CC(=C(C=C1CCN)O)O.Br,,,,,,
1564,71565,"Methanesulfonic acid, trifluoro-, compd. with N,N-diethylethanamine (1:1)",CCN(CC)CC.C(F)(F)(F)S(=O)(=O)O,,,,,,
1565,71566,CID 71566,[Li+].C1=C(C=C(C(=C1C(=O)[O-])O)I)I,,,,,,
1566,71567,D-phenylalanine,C1=CC=C(C=C1)C[C@H](C(=O)O)N,,,,,,
1567,71568,Methanol-d4,[2H]C([2H])([2H])O[2H],,,,,,
1568,71569,Lead dipropionate,CCC(=O)[O-].CCC(=O)[O-].[Pb+2],,,,,,
1569,71570,"Copper O,O'-diethyl bis(dithiocarbonate)",CCOC(=S)[S-].CCOC(=S)[S-].[Cu+2],,,,,,
1570,71571,Calcium nicotinate,C1=CC(=CN=C1)C(=O)[O-].C1=CC(=CN=C1)C(=O)[O-].[Ca+2],,,,,,
1571,71572,4-Fluorobenzamide,C1=CC(=CC=C1C(=O)N)F,,,,,,
1572,71573,CID 71573,C1(=N[O-])C(=O)NC(=O)NC1=O.[Na+],,,,,,
1573,71574,CID 71574,CC1=CC(=C(C=C1)S(=O)(=O)[O-])C.[Na+],,,,,,
1574,71575,CID 71575,C12=C(NC(=O)N1)NC(=NC2=O)[O-].C12=C(NC(=O)N1)NC(=NC2=O)[O-].[Ca+2],,,,,,
1575,71576,CID 71576,C1=C(OC(=C(C1=O)O)C(=O)[O-])C(=O)[O-].[Ca+2],,,,,,
1576,71577,"Disodium 1,3-benzenedisulfonate",C1=CC(=CC(=C1)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+],,,,,,
1577,71578,CID 71578,C1=CC=C2C(=C1)C=CC(=C2O)S(=O)(=O)[O-].[K+],,,,,,
1578,71579,CID 71579,C1=CC=C2C(=C1)C=CC(=C2O)S(=O)(=O)[O-].[Na+],,,,,,
1579,71580,Mescaline hydrochloride,COC1=CC(=CC(=C1OC)OC)CCN.Cl,,,,,,
1580,71581,CID 71581,CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(=O)[O-].[Na+],,,,,,
1581,71582,CID 71582,C1=CC(=CC2=C(C=C(C=C21)S(=O)(=O)O)S(=O)(=O)[O-])N.[K+],,,,,,
1582,71583,Chloroform-D,[2H]C(Cl)(Cl)Cl,,,,,,
1583,71584,5-Aminomethyl-2-methylpyrimidin-4-ylamine dihydrochloride,CC1=NC=C(C(=N1)N)CN.Cl.Cl,,,,,,
1584,71585,CID 71585,C1=CC=C2C=C(C=CC2=C1)[O-].[Na+],,,,,,
1585,71586,Indigo White,C1=CC=C2C(=C1)C(=C(N2)C3=C(C4=CC=CC=C4N3)[O-])[O-].[Na+].[Na+],,,,,,
1586,71587,Opipramol dihydrochloride,C1CN(CCN1CCCN2C3=CC=CC=C3C=CC4=CC=CC=C42)CCO.Cl.Cl,,,"['Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin. (See all compounds classified as Adrenergic Uptake Inhibitors.)', 'Substances that contain a fused three-ring moiety and are used in the treatment of depression. These drugs block the uptake of norepinephrine and serotonin into axon terminals and may block some subtypes of serotonin, adrenergic, and histamine receptors. However, the mechanism of their antidepressant effects is not clear because the therapeutic effects usually take weeks to develop and may reflect compensatory changes in the central nervous system. (See all compounds classified as Antidepressive Agents, Tricyclic.)']",,,
1587,71588,Phosphocreatine sodium,CN(CC(=O)O)C(=NP(=O)([O-])[O-])N.[Na+].[Na+],,,,,,
1588,71589,"Ethyl hydrogen sulphate, calcium salt",CCOS(=O)(=O)[O-].CCOS(=O)(=O)[O-].[Ca+2],,,,,,
1589,71590,"4-Heptenal, (4Z)-",CCC=CCCC=O,,,,,,
1590,71591,Calcium di(benzenesulphonate),C1=CC=C(C=C1)S(=O)(=O)[O-].C1=CC=C(C=C1)S(=O)(=O)[O-].[Ca+2],,,,,,
1591,71592,CID 71592,C1=CC=C(C=C1)S(=O)(=O)[O-].[K+],,,,,,
1592,71593,7-Methyladenine,CN1C=NC2=NC=NC(=C21)N,,,,,,
1593,71594,CID 71594,C1=CC=C2C(=C1)N=CC(=N2)[N-]S(=O)(=O)C3=CC=C(C=C3)N.[Na+],,,,,,
1594,71595,Pridinol hydrochloride,C1CCN(CC1)CCC(C2=CC=CC=C2)(C3=CC=CC=C3)O.Cl,,,,,,
1595,71596,CID 71596,CN1C=NC2=C1C(=O)N=C(N2C)[O-].[Na+],,,,,,
1596,71597,CID 71597,COC1=NC(=NC(=C1)[N-]S(=O)(=O)C2=CC=C(C=C2)N)OC.[Na+],,,,,,
1597,71598,DL-Ornithine hydrochloride,C(CC(C(=O)O)N)CN.Cl,,,,,,
1598,71599,CID 71599,C[Si](C)(C)[N-][Si](C)(C)C.[Na+],,,,,,
1599,71600,4-Chlorophenylhydrazine hydrochloride,C1=CC(=CC=C1NN)Cl.Cl,,,,,,
1600,71601,Benzene-d6,[2H]C1=C(C(=C(C(=C1[2H])[2H])[2H])[2H])[2H],,,,,,
1601,71602,Acetylisoniazid,CC(=O)NNC(=O)C1=CC=NC=C1,,,,,['Isoniazid N-acetyl is a known human metabolite of isoniazid.'],
1602,71603,Benzoic acid-d5,[2H]C1=C(C(=C(C(=C1[2H])[2H])C(=O)O)[2H])[2H],,,,,,
1603,71604,CID 71604,C([C@@H](C(=O)[O-])N)C(=O)O.[K+],,,,,,
1604,71605,CID 71605,C1=CC(=CC=C1[O-])Cl.[K+],,,,,,
1605,71606,Cyclopentylacetic acid,C1CCC(C1)CC(=O)O,,,,,,
1606,71607,"cis-1,2-Diphenylcyclopropane",C1[C@H]([C@H]1C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
1607,71608,"5-Hydroxy-6-methylpyridine-3,4-dimethanol phosphate",CC1=NC=C(C(=C1O)CO)CO.OP(=O)(O)O,,,,,,
1608,71609,Mescaline sulfate,COC1=CC(=CC(=C1OC)OC)CCN.OS(=O)(=O)O,,,,,,
1609,71610,CID 71610,C1=CC(=CC=C1CN)S(=O)(=O)N.C1=CC(=CC=C1N)S(=O)(=O)N=C(N)S,,,,,,
1610,71611,Mephentermine sulfate,CC(C)(CC1=CC=CC=C1)NC.CC(C)(CC1=CC=CC=C1)NC.OS(=O)(=O)O,,,"['Compounds that bind to and activate ADRENERGIC ALPHA-1 RECEPTORS. (See all compounds classified as Adrenergic alpha-1 Receptor Agonists.)', 'Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters. (See all compounds classified as Sympathomimetics.)', 'Drugs used to cause constriction of the blood vessels. (See all compounds classified as Vasoconstrictor Agents.)']",,,
1611,71612,Hydroxyzine Hcl,C1CN(CCN1CCOCCO)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl.Cl,,,"['Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. (See all compounds classified as Histamine H1 Antagonists.)', 'Agents, usually topical, that relieve itching (pruritus). (See all compounds classified as Antipruritics.)']",,,
1612,71613,16alpha-Bromoepiandrosterone,C[C@]12CC[C@@H](C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3C[C@H](C4=O)Br)C)O,"['Investigated for use/treatment in cystic fibrosis, HIV infection, hepatitis (viral, B), and malaria.']",,,,,
1613,71614,"Ethyl 5,11,16,21-tetraethyl-12,17,22,27-tetramethyl-7,23,25,26-tetraza-24lambda2-stannaheptacyclo[11.9.3.15,8.115,18.02,6.010,25.020,23]heptacosa-1(22),2(6),3,7,9,11,13,15(26),16,18,20-undecaene-4-carboxylate",CCC1=C(C2=CC3=C(C(=C4N3[Sn]N5C(=CC6=NC7=C4C=C(C7(C6C)CC)C(=O)OCC)C(=C(C5=CC1=N2)C)CC)C)CC)C,,,,,,
1614,71615,CID 71615,CCC1=C2C=C3C(C4(C(=C(O)OCC)C=C(C4=N3)C5=NC(=CC6=NC(=CC(=C1C)N2)C(=C6C)CC)C(=C5C)CC)CC)C,,,,,,
1615,71616,Voriconazole,C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,"['For the treatment of esophageal candidiasis, cadidemia, invasive pulmonary aspergillosis, and serious fungal infections caused by <i>Scedosporium apiospermum</i> and <i>Fusarium</i> spp.']",['Voriconazole is a fungistatic triazole antifungal used to treat infections by inhibiting fungal growth. It is known to cause hepatotoxic and photosensitivity reactions in some patients.'],"['Compounds that specifically inhibit STEROL 14-DEMETHYLASE. A variety of azole-derived ANTIFUNGAL AGENTS act through this mechanism. (See all compounds classified as 14-alpha Demethylase Inhibitors.)', 'Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)', 'Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP3A. (See all compounds classified as Cytochrome P-450 CYP3A Inhibitors.)']","['The oral bioavailability is estimated to be 96% in healthy adults. Population pharmacokinetic studies report a reduced bioavailability pediatric patients with a mean of 61.8% (range 44.6–64.5%) thought to be due to differences in first-pass metabolism or due to differences in diet. Of note, transplant patients also have reduced bioavailability but this is known to increase with time after transplantation and may be due in part to gastrointestinal upset from surgery and some transplant medications. Tmax is 1-2 hours with oral administration. When administered with a high-fat meal Cmax decreases by 34% and AUC by 24%. pH does not have an effect on absorption of voriconazole. Differences in Cmax and AUC have been observed between healthy adult males and females with Cmax increasing by 83% and AUC by 113% although this has not been observed to significantly impact medication safety profiles.', 'Voriconazole is eliminated via hepatic metabolism with less than 2% of the dose excreted unchanged in the urine.', 'The estimated volume of distribution of voriconazole is 4.6 L/kg. Population pharmacokinetic studies estimate the median volume of distribution to be 77.6 L with the central compartment estimated at 1.07 L/kg Voriconazole is known to achieve therapeutic concentrations in many tissues including the  brain, lungs, liver, spleen, kidneys, and heart.', ""The clearance of voriconazole is estimated to be a mean of 5.25-7 L/h in healthy adults for the linear portion of the drug's kinetics.""]","['Voriconazole undergoes extensive hepatic metabolism through cytochrome enzymes CYP2C9, CYP2C19, and CYP3A4. CYP2C19 mediates N-oxidation with an apparent Km of 14 μM and an apparent Vmax of 0.22 nmol/min/nmol CYP2C19. Voriconazole N-oxide is the major circulating metabolite, accounting for 72% of radiolabeled metabolites found. CYP3A4 contributes to N-oxidation with a Km of 16 μM and Vmax of 0.05 nmol/min/nmol CYP3A4 as well as 4-hydroxylation with a Km of 11 μM and a Vmax of 0.10 nmol/min/nmol CYP3A4. CYP3A5 and CYP3A7 provide minor contributions to N-oxidation and 4-hydroxylation. The N-oxide and 4-hydroxylated metabolites undergo  glucuronidation and are excreted through the urine with other minor glucuronidated metabolites.', 'Voriconazole has known human metabolites that include Hydroxymethyl Voriconazole and Voriconazole N-Oxide.']",['Voriconazole follows non-linear kinetics and has a terminal half-life of elimination which is dose-dependent.']
1616,71617,CID 71617,C(S(=O)(=O)[O-])(I)I.[Na+],,,,,,
1617,71618,Dimethiodal,C(S(=O)(=O)O)(I)I,,,,,,
1618,71619,CID 71619,C1=CC(=CC=C1N)S(=O)(=O)C2=CC=C(C=C2)NCC(=O)[O-].[Na+],,,,,,
1619,71620,Methestrol,CCC(C1=CC(=C(C=C1)O)C)C(CC)C2=CC(=C(C=C2)O)C,,,,,,
1620,71621,Clorindanic Acid,C1CC2=C(C=C(C(=C2C1)O)C(=O)O)Cl,,,,,,
1621,71622,Simetride,CCCC1=CC(=C(C=C1)OCC(=O)N2CCN(CC2)C(=O)COC3=C(C=C(C=C3)CCC)OC)OC,,,,,,
1622,71623,1-(p-Chloro-alpha-phenylbenzyl)-4-cinnamylpiperazine,C1CN(CCN1CC=CC2=CC=CC=C2)C(C3=CC=CC=C3)C4=CC=C(C=C4)Cl,,,,,,
1623,71624,CID 71624,C[C@@H]1CC2C(CC[C@H]3[C@@]2(CCC(=O)C3)C)C4C1[C@H](CC4)C(=O)COC(=O)CCC(=O)[O-].[Na+],,,,,,
1624,71625,CID 71625,C[C@@H]1CC2C(CC[C@H]3[C@@]2(CCC(=O)C3)C)C4C1[C@H](CC4)C(=O)COC(=O)CCC(=O)O,,,,,,
1625,71626,(8-Methyl-8-azabicyclo[3.2.1]octan-3-yl) 3-hydroxy-2-methyl-2-phenylpropanoate,CC(CO)(C1=CC=CC=C1)C(=O)OC2CC3CCC(C2)N3C,,,,,,
1626,71627,Inproquone,CCCOC1=C(C(=O)C(=C(C1=O)N2CC2)OCCC)N3CC3,,,,,,
1627,71628,"(2R,3R,4S,5S,6R)-2-[[(8S,9S,10R,13R,14S)-17-[(2R,5R)-5-ethyl-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol",CC[C@H](CC[C@@H](C)C1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CCC(C4)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)C)C)C(C)C,,,,,,
1628,71629,Leucocyanidin,C1=CC(=C(C=C1C2C(C(C3=C(C=C(C=C3O2)O)O)O)O)O)O,,,,,,
1629,71630,Hydroxytetracaine,CCCCNC1=CC(=C(C=C1)C(=O)OCCN(C)C)O,,,,,,
1630,71631,Propanocaine,CCN(CC)CCC(C1=CC=CC=C1)OC(=O)C2=CC=CC=C2,,,,,,
1631,71632,Dioxethedrin,CCNC(C)C(C1=CC(=C(C=C1)O)O)O,,,,,,
1632,71633,Mercurobutol,CC(C)(C)C1=CC(=C(C=C1)O)[Hg]Cl,,,,,,
1633,71634,CID 71634,C[C@@]1(CC[C@H]2[C@@H]3CC4=C5[C@]2([C@H]1OC5=C(C=C4)O)CCN3C)O,,,,,,
1634,71635,"N-(2,2,2-Trichloro-1-hydroxyethyl)formamide",C(=O)NC(C(Cl)(Cl)Cl)O,,,,,,
1635,71636,Chlorbenzoxamine,CC1=CC=CC=C1CN2CCN(CC2)CCOC(C3=CC=CC=C3)C4=CC=CC=C4Cl,,,,,,
1636,71637,"(1R,5R)-3-benzhydryloxy-8-ethyl-8-azabicyclo[3.2.1]octane",CCN1[C@@H]2CC[C@@H]1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
1637,71638,Mercuderamide,C1=CC=C(C(=C1)C(=O)NCC(C[Hg])O)OCC(=O)O.O,,,,,,
1638,71639,[3-[[2-(Carboxymethoxy)benzoyl]amino]-2-hydroxypropyl]mercury,C1=CC=C(C(=C1)C(=O)NCC(C[Hg])O)OCC(=O)O,,,,,,
1639,71640,Piprinhydrinate,CN1CCC(CC1)OC(C2=CC=CC=C2)C3=CC=CC=C3.CN1C2=C(C(=O)N(C1=O)C)NC(=N2)Cl,,,,,,
1640,71641,CID 71641,CN1CC[C@]23[C@@H]4[C@@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](CC4)OC(=O)C6=CN=CC=C6,,,,,,
1641,71642,CID 71642,CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C(=CC=C4)O)C(=C3C(=O)[C@@]2(C(=O)C(=C(N)O)C1=O)O)O,,,,,,
1642,71643,Norletimol,C1=CC=C(C=C1)CN=CC2=CC=CC=C2O,,,,,,
1643,71644,Damotepine,CN(C)CC1=CC2=CC=CC=C2SC3=CC=CC=C31,,,,,,
1644,71645,Mexenone,CC1=CC=C(C=C1)C(=O)C2=C(C=C(C=C2)OC)O,,,,,,
1645,71646,Dimabefylline,CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC3=CC=C(C=C3)N(C)C,,,,,,
1646,71647,"1,4-Dihydro-3,5-diiodo-4-oxopyridine-2,6-dicarboxylic acid",C1(=C(NC(=C(C1=O)I)C(=O)O)C(=O)O)I,,,,,,
1647,71648,5-Methoxyresorcinol,COC1=CC(=CC(=C1)O)O,,,,,,
1648,71649,CID 71649,CC1=NC=C(C(=N1)N)CN(C=O)C(=C(CCOC(=O)C2=CC=CC=C2)SSC(=C(C)N(CC3=CN=C(N=C3N)C)C=O)CCOC(=O)C4=CC=CC=C4)C,,,,,,
1649,71650,Nicametate,CCN(CC)CCOC(=O)C1=CN=CC=C1,,,['Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)'],,,
1650,71651,Betamipron,C1=CC=C(C=C1)C(=O)NCCC(=O)O,,,,,,
1651,71652,Mebutizide,CCC(C)C(C)C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,,,,,,
1652,71653,Hydracarbazine,C1=CC(=NN=C1C(=O)N)NN,['Was used for the treatment of hypertension.'],['Relaxes vascular smooth muscle.'],,,,
1653,71654,Fenocinol,CC(C1=CC=CC=C1)(C2=C(C=C(C=C2)OC)OC)O,,,,,,
1654,71655,Moroxydine,C1COCCN1C(=N)N=C(N)N,,,['Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)'],,,
1655,71656,Teclothiazide,C1=C2C(=CC(=C1Cl)S(=O)(=O)N)S(=O)(=O)NC(N2)C(Cl)(Cl)Cl,,,,,,
1656,71657,CID 71657,COCC(C1=C(OC2=CC=CC=C2C1=O)O)C3=C(OC4=CC=CC=C4C3=O)O,,,,,,
1657,71658,Dexoxadrol Hydrochloride,C1CCN[C@@H](C1)[C@H]2COC(O2)(C3=CC=CC=C3)C4=CC=CC=C4.Cl,,,['Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)'],,,
1658,71659,"2-[(4S)-2,2-diphenyl-1,3-dioxolan-4-yl]piperidine",C1CCNC(C1)[C@H]2COC(O2)(C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
1659,71660,Leptacline,C1CCC(CC1)CN2CCCCC2,,,,,,
1660,71661,Pentalamide,CCCCCOC1=CC=CC=C1C(=O)N,,,,,,
1661,71662,Cyclomenol,CC1=CC(=C(C(=C1)O)C2CCCCC2)C,,,,,,
1662,71663,Picloxydine,C1CN(CCN1C(=NC(=NC2=CC=C(C=C2)Cl)N)N)C(=NC(=NC3=CC=C(C=C3)Cl)N)N,,,,,,
1663,71664,CID 71664,C=CCN=C(NC1=CC=CC(=C1)C(=O)[O-])[S-].[Na+].[Cu+],,,,,,
1664,71665,CID 71665,C=CCN=C(NC1=CC=CC(=C1)C(=O)O)S,,,,,,
1665,71666,Cycotiamine,CC1=NC=C(C(=N1)N)CN(C=O)C(=C2CCOC(=O)S2)C,,,,,,
1666,71667,Cloprothiazole,CC1=C(SC=N1)CCCCl,,,,,,
1667,71668,Mepiroxol,C1=CC(=C[N+](=C1)[O-])CO,,,,,,
1668,71669,Naphthonone,C1CCC(=O)C(C1)C2=C(C=CC3=CC=CC=C32)O,,,,,,
1669,71670,Cloquinate,CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl.C1=CC2=C(C(=C(C=C2S(=O)(=O)O)I)O)N=C1.C1=CC2=C(C(=C(C=C2S(=O)(=O)O)I)O)N=C1,,,,,,
1670,71671,Benmoxin,CC(C1=CC=CC=C1)NNC(=O)C2=CC=CC=C2,['For the treatment of depression.'],,,,,
1671,71672,Prethcamide,CCCN(C(CC)C(=O)N(C)C)C(=O)C=CC.CCC(C(=O)N(C)C)N(CC)C(=O)C=CC,,,,,,
1672,71673,Cicliomenol,CC1=CC(=C(C(=C1I)C)C2CCCCC2)O,,,,,,
1673,71674,Avilamycin,C[C@@H]1[C@H]([C@@H](C[C@@H](O1)O[C@@H]2[C@H](OC3(C[C@H]2O)O[C@@H]4[C@H](O[C@H](C[C@]4(O3)C)O[C@@H]5[C@H]([C@@H](O[C@@H]([C@@H]5OC)C)O[C@@H]6[C@H](O[C@H]([C@H]([C@H]6O)OC)OC7[C@@H]([C@H]8[C@H](CO7)O[C@@]9(O8)[C@H]1[C@H]([C@@]([C@H](O9)C)(C(=O)C)O)OCO1)OC(=O)C(C)C)COC)O)C)C)O)OC(=O)C1=C(C(=C(C(=C1OC)Cl)O)Cl)C,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],"['(14)C-Avilamycin was fed to growing swine at a level of 60-80 ppm (1.5-2 times the recommended use level), and tissues were assayed for radioactivity (RA). At a practical zero withdrawal swine fed 60 ppm of uniformly labeled (U-14)C-avilamycin for 14 days had RA residues of 0.14, 0.66, 0.34, and 0.55 ppm in muscle, liver, kidney, and fat, respectively. Swine fed 80 ppm of (14)C-avilamycin labeled in the dichloroisoeverninic acid portion had residues 3-5 times lower, indicative that most of the residue was derived from the oligosaccharide portion of avilamycin. The primary metabolite in liver and feces was flambic acid. Most of the RA in fat from swine fed (U-14)C-avilamycin was in the fatty acids. (14)C-Avilamycin was excreted rapidly and nearly quantitatively by swine, with 5% of the dose in the murine and the remainder in feces. The excretion pattern and metabolic profile of (14)C-avilamycin in the rat were similar to swine.', 'Seven female and four to five male starter pigs weighing 7-12 kg were fed standard diets containing 20 mg avilamycin/kg in three different product forms (crystalline, micronized and non-micronized) for 6 days. The feces collected from pigs that were fed crystalline, micronized and non-micronized product had microbiologically active residues that represented 2.0%, 4.5% and 15.0%, respectively, of the residues of avilamycin and its degradation products, as determined by gas chromatographic assays. The faeces contained an average of 0.94, 2.28 and 8.45 ug of microbiologically active residues per gram for pigs fed crystalline, micronized and non-micronized avilamycin, respectively. The gas chromatographic assay, which determined the total residues of avilamycin plus any degradation products that hydrolyse to DIA, indicated that the faeces contained 43.3, 40.1 and 43.4 ug/g for pigs fed the crystalline, micronized and non-micronized product forms, respectively.', '... Two crossbred female pigs weighing approximately 40 kg each received 0.9 kg of feed containing unlabelled avilamycin at 60 mg activity/kg in the diet twice daily for 7 days. After being fed the unlabelled drug, each pig received a one-time dose of 120 mg of (14)C-avilamycin (9.3 kBq/mg) incorporated into 450 g of diet. After the consumption of the diet containing (14)C-avilamycin, the animals were given an additional 450 g of unmedicated diet. The female pigs were then fed twice daily with 0.9 kg of unmedicated feed for the duration of the experiment. Most of the (14)C residues in both pigs were excreted in the first 4 days, with over 91% eliminated on days 2 and 3. The peak excretion of (14)C residues in urine occurred in the first 24-hr collection period, with 2.75% and 3.30% recovery for the two animals. During the 9-day collection period, the two pigs excreted 96.9% and 99.0%, respectively, of the total dose administered. An average of 93.4% of the excreted dose was found in the feces, and 4.54% was found in the urine.', 'Six male and six female 7-week-old broiler chickens (Hubbard-White Mountain Cross) were fed a standard broiler finishing ration containing 14.16 mg (14)C-avilamycin/kg diet (equivalent to 15 mg avilamycin activity/kg in the diet) for 4, 7 or 10 days. Medicated ration was provided ad libitum throughout the dosing phase. At the end of each dosing period, two birds of each sex were deprived of food and water for 6 h, and then samples of muscle, liver, abdominal fat, kidney and skin with subcutaneous fat were collected for radiochemical analysis. Radioactive residue levels in muscle and kidney were lower than the detection limits of 0.008 and 0.024 ug/g, respectively, at all sampling times. The mean peak level of 0.039 ug/g was attained in liver after 7 days of dosing. After 10 days of dosing, the mean total radioactive residues in skin, liver and fat, expressed as avilamycin equivalents, were 0.018, 0.022 and 0.024 ug/g, respectively. Steady-state concentrations of radioactivity were attained in all tissues within 4-7 days after the initiation of dosing.', 'For more Absorption, Distribution and Excretion (Complete) data for AVILAMYCIN (6 total), please visit the HSDB record page.']","['Six rats (three males and three females) were fed a ration containing uniformly radiolabelled (14)C- avilamycin at a concentration of 550 mg/kg diet for 4.5 days. Urine and feces were collected during the dosing period, and livers were collected at zero withdrawal. Avilamycin A constituted approximately 19% of the fecal radioactivity. There were three major metabolites derived from the oligosaccharide and eurekanate portion of avilamycin in fecal samples. The most abundant metabolite in feces was flambic acid (metabolite B). Flambic acid was relatively unstable and readily converted to flambalactone (metabolite A).', 'The minimum inhibitory concentrations (MIC) of eight antibiotics and two anticoccidial agents were determined for Clostridium perfringens strains isolated from 26 commercial broiler farms and 22 commercial turkey farms. Isolates were obtained from the intestines of birds on the farm or as the processing plant using standard culture and identification techniques. The microbroth dilution test was used to determine the MIC for each compound. Most isolates from chickens had MICs in the range of 2-16 mg/L for tilmicosin, tylosin and virginiamycin, whereas the MICs for avilamycin, avoparcin, monensin, narasin and penicillin were < or = 1 mg/L. Most strains from chickens had high MICs (> or = 64 mg/L) and appeared to be resistant to bacitracin and lincomycin. Most turkey isolates had MICs in the range of 2-16 mg/L for bacitracin, tilmicosin, tylosin and virginiamycin, with strains exhibiting MICs < or = 1 mg/L for avilamycin, avoparcin, monensin, narasin and penicillin. Several turkey isolates had MICs > or = 64 mg/L to lincomycin. No attempt was made to associate farm usage of a particular antibiotic to the antibiograms.', '... Nine crossbred pigs (five males and four females) weighing approximately 44 kg each were fed a ration containing 76.19 mg (14)C-avilamycin/kg in the diet (equivalent to 80 mg avilamycin activity/kg in the diet) at 12-hr intervals for 4, 7 or 10 days. ... One major metabolite observed in the extracts of both liver and excreta was flambic acid, which was formed as a result of cleavage of the ortho ester linking the C and D rings of avilamycin. Flambic acid represented 40-50% of the total radioactive residue in urine and feces and 15-20% of the residue in liver.', 'Avilamycin is poorly absorbed and is extensively metabolized in the gut of pigs. Only about 8% of total radioactivity in pig feces was attributable to parent avilamycin. Metabolites were found in liver, whereas they were not detected in other tissues. The primary metabolite is flambic acid, representing 40-50% of the total radioactive residue in urine and feces and 15-20% of the residue in liver. No microbiologically active residues were detected in liver. Avilamycin is unlikely to be persistent in the environment following excretion from treated animals, as it is highly metabolized or degraded in animals.']",
1674,71675,Clobenzorex,CC(CC1=CC=CC=C1)NCC2=CC=CC=C2Cl,,,,,,
1675,71676,CID 71676,CC1=CC2=C(C=C1C)N(C=N2)[C@@H]3C(C([C@H](O3)CO)OP(=O)([O-])OC(C)CNC(=O)CC[C@@]4([C@@H](C5[C@]6([C@@]([C@@H](C(=N6)C(=C7[C@@]([C@@H](C(=N7)C=C8C([C@H](C(=N8)C(=C4[N-]5)C)CCC(=O)N)(C)C)CCC(=O)N)(C)CC(=O)N)C)CCC(=O)N)(C)CC(=O)N)C)CC(=O)N)C)O.[CH2-]C1[C@@H]([C@@H]([C@H](O1)N2C=NC3=C(N=CN=C32)N)O)O.[Co+3],,,,,,
1676,71677,CID 71677,CC1=CC2=C(C=C1C)N(C=N2)[C@@H]3C(C([C@H](O3)CO)OP(=O)(O)OC(C)CNC(=O)CC[C@@]4([C@H](C5[C@]6([C@@]([C@@H](C(=N6)C(=C7[C@@]([C@@H](C(=CC8=NC(=C(C4=N5)C)[C@H](C8(C)C)CCC(=O)N)N7)CCC(=O)N)(C)CC(=O)N)C)CCC(=O)N)(C)CC(=O)N)C)CC(=O)N)C)O,,,,,,
1677,71678,"(2S,3S,4R)-2-(6-aminopurin-9-yl)-5-methyloxolane-3,4-diol",CC1[C@@H]([C@@H]([C@H](O1)N2C=NC3=C(N=CN=C32)N)O)O,,,,,,
1678,71679,Meladrazine,CCN(CC)C1=NC(=NC(=N1)NN)N(CC)CC,,,,,,
1679,71680,"(3R,5S,9S,14S)-3-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,3,4,5,6,7,8,9,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-11-one",CC12CC[C@H](C[C@@H]1CCC3[C@@H]2C(=O)CC4([C@H]3CCC4C(=O)CO)C)O,,,,,,
1680,71681,Pramiverine,CC(C)NC1CCC(CC1)(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
1681,71682,CID 71682,CCNC1=NC(=O)C(O1)C2=CC=CC=C2,,,,,,
1682,71683,CID 71683,CCN(CC)CCN1C=NC2=C1C(=O)N(C(=O)N2C)C.CC1=C2C=C(C(=O)C=C2OC(=C1)O)OCC(=O)O,,,,,,
1683,71684,Pipratecol,COC1=CC=CC=C1N2CCN(CC2)CC(C3=CC(=C(C=C3)O)O)O,,,,,,
1684,71685,Cloracetadol,CC(=O)NC1=CC=C(C=C1)OC(C(Cl)(Cl)Cl)O,,,,,,
1685,71686,Dodeclonium Bromide,CCCCCCCCCCCC[N+](C)(C)CCOC1=CC=C(C=C1)Cl.[Br-],,,,,,
1686,71687,Dodeclonium,CCCCCCCCCCCC[N+](C)(C)CCOC1=CC=C(C=C1)Cl,,,,,,
1687,71688,Naftazone,C1=CC=C2C(=C1)C=CC(=C2O)N=NC(=O)N,,,['Agents acting to arrest the flow of blood. Absorbable hemostatics arrest bleeding either by the formation of an artificial clot or by providing a mechanical matrix that facilitates clotting when applied directly to the bleeding surface. These agents function more at the capillary level and are not effective at stemming arterial or venous bleeding under any significant intravascular pressure. (See all compounds classified as Hemostatics.)'],,,
1688,71689,CID 71689,CC1(C2CC3C(C(=O)C(=C(NCN4CCN(CC4)C(=N)N=C(N)N)O)C(=O)C3(C(=O)C2=C(C5=C1C=CC=C5O)O)O)N(C)C)O,,,,,,
1689,71690,Penoctonium Bromide,CCCCCCCC[N+](CC)(CC)CCOC(=O)C(C1CCCC1)C2CCCC2.[Br-],,,,,,
1690,71691,Penoctonium,CCCCCCCC[N+](CC)(CC)CCOC(=O)C(C1CCCC1)C2CCCC2,,,,,,
1691,71692,Diniprofylline,CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(COC(=O)C3=CN=CC=C3)OC(=O)C4=CN=CC=C4,,,"['Agents that cause an increase in the expansion of a bronchus or bronchial tubes. (See all compounds classified as Bronchodilator Agents.)', 'Compounds which inhibit or antagonize the biosynthesis or actions of phosphodiesterases. (See all compounds classified as Phosphodiesterase Inhibitors.)']",,,
1692,71693,Fomocaine,C1COCCN1CCCC2=CC=C(C=C2)COC3=CC=CC=C3,,,,,,
1693,71694,Pranosal,CC1CCC(N1CCCOC(=O)C2=CC=CC=C2O)C,,,,,,
1694,71695,Aptocaine,CC1=CC=CC=C1NC(=O)C(C)N2CCCC2,,,,,,
1695,71696,2-ethyl-3-[3-(2-piperidin-1-ylethoxy)anilino]-3H-isoindol-1-one,CCN1C(C2=CC=CC=C2C1=O)NC3=CC(=CC=C3)OCCN4CCCCC4,,,,,,
1696,71697,Clobuzarit,CC(C)(C(=O)O)OCC1=CC=C(C=C1)C2=CC=C(C=C2)Cl,,,,,,
1697,71698,Mepindolol,CC1=CC2=C(N1)C=CC=C2OCC(CNC(C)C)O,,,"['Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. (See all compounds classified as Adrenergic beta-Antagonists.)']",,,
1698,71699,CID 71699,CC1=CC2=C(C(=C1)O)N=CC=C2.O.O.[BiH3],,,,,,
1699,71700,6-Methylquinolin-8-ol,CC1=CC2=C(C(=C1)O)N=CC=C2,,,,,,
1700,71701,CID 71701,CC(C)CC1=CN=C(N=C1)[N-]S(=O)(=O)C2=CC=C(C=C2)CC(=O)NC3=C(C=CC(=C3)Cl)OC.[Na+],,,,,,
1701,71702,Glicetanile,CC(C)CC1=CN=C(N=C1)NS(=O)(=O)C2=CC=C(C=C2)CC(=O)NC3=C(C=CC(=C3)Cl)OC,,,,,,
1702,71703,Hexaprofen,CC(C1=CC=C(C=C1)C2CCCCC2)C(=O)O,,,,,,
1703,71704,Cicrotoic Acid,CC(=CC(=O)O)C1CCCCC1,,,,,,
1704,71705,"[(2S,3S,5S,10S,13S)-17-hydroxy-10,13-dimethyl-2,16-bis(1-methylpiperidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate;dibromide",CC(=O)O[C@H]1C[C@@H]2CCC3C([C@]2(C[C@@H]1[N+]4(CCCCC4)C)C)CC[C@]5(C3CC(C5O)[N+]6(CCCCC6)C)C.[Br-].[Br-],,,"['Drugs that interrupt transmission at the skeletal neuromuscular junction without causing depolarization of the motor end plate. They prevent acetylcholine from triggering muscle contraction and are used as muscle relaxants during electroshock treatments, in convulsive states, and as anesthesia adjuvants. (See all compounds classified as Neuromuscular Nondepolarizing Agents.)']",,,
1705,71706,"[(2S,3S,5S,10S,13S)-17-hydroxy-10,13-dimethyl-2,16-bis(1-methylpiperidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate",CC(=O)O[C@H]1C[C@@H]2CCC3C([C@]2(C[C@@H]1[N+]4(CCCCC4)C)C)CC[C@]5(C3CC(C5O)[N+]6(CCCCC6)C)C,,,,,,
1706,71707,Procinolol,CC(C)NCC(COC1=CC=CC=C1C2CC2)O,,,,,,
1707,71708,Phenisonone,CC(C)NC(C)C(=O)C1=CC(=C(C=C1)O)O,,,,,,
1708,71709,Lofendazam,C1CNC2=C(C=C(C=C2)Cl)N(C1=O)C3=CC=CC=C3,,,,,,
1709,71710,4-[2-(1-Ethenyl-5-nitro-1h-imidazol-2-yl)ethenyl]benzoic acid,C=CN1C(=CN=C1C=CC2=CC=C(C=C2)C(=O)O)[N+](=O)[O-],,,,,,
1710,71711,N(1)Tyr-Ile-Gln-Asn-DL-Asu(1)-Gly-Leu-Gly-NH2,CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)NC(CCCCCC(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N,,,,,,
1711,71712,"4-Butyl-5-oxo-1,2-diphenylpyrazol-3-olate;dimethyl-(2-methyl-3,4-diphenyl-3-propanoyloxybutyl)azanium",CCCCC1=C(N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3)[O-].CCC(=O)OC(CC1=CC=CC=C1)(C2=CC=CC=C2)C(C)C[NH+](C)C,,,,,,
1712,71713,Bifluranol,CCC(C1=CC(=C(C=C1)O)F)C(C)C2=CC(=C(C=C2)O)F,,,,,,
1713,71714,CID 71714,CC12CC(C3C(C1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O)OC,,,,,,
1714,71715,"(2s)-1-[(3s,6s,9s,12s,15s)-12-[(2s)-butan-2-yl]-9-(2-carbamoylethyl)-6-(carbamoylmethyl)-15-[(4-hy-droxyphenyl)methyl]-16-methyl-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentazacycloicosane-3-carbonyl]-N-[(1s)-1-(carbamoylmethylcarbamoyl)-3-methyl-butyl]pyrrolidine-2-carboxamide",CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSCCCC(=O)N([C@H](C(=O)N1)CC2=CC=C(C=C2)O)C)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N,,,,,,
1715,71716,Terbucromil,CC(C)(C)C1=CC2=C(C(=C1)C(C)(C)C)OC(=CC2=O)C(=O)O,,,,,,
1716,71717,"(8R,9S,13S,14S)-17-methoxy-13-methyl-3-propoxy-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene",CCCOC1=CC2=C(C=C1)[C@H]3CC[C@]4([C@H]([C@@H]3CC2)CCC4OC)C,,,,,,
1717,71718,Nitroclofene,C1=C(C=C(C(=C1CC2=C(C(=CC(=C2)Cl)[N+](=O)[O-])O)O)Cl)[N+](=O)[O-],,,,,,
1718,71719,"(6R,7R)-3-Acetoxymethyl-7-[2-methoxyimino-2-(fur-2-yl) acetamido]ceph-3-em-4-carboxylic acid",CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)C(=NOC)C3=CC=CO3)SC1)C(=O)O,,,,,,
1719,71720,Tazolol Hydrochloride,CC(C)NCC(COC1=NC=CS1)O.Cl,,,,,,
1720,71721,Tazolol,CC(C)NCC(COC1=NC=CS1)O,,,,,,
1721,71722,CID 71722,C[N+]1([C@H]2CC(C[C@H]1[C@H]3[C@H]2O3)OC(=O)[C@@H](CO)C4=CC=CC=C4)CC5CC5.[Br-],,,,,,
1722,71723,"[(1S,2S,4S,5S)-9-(cyclopropylmethyl)-9-methyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] (2R)-3-hydroxy-2-phenylpropanoate",C[N+]1([C@H]2CC(C[C@H]1[C@H]3[C@H]2O3)OC(=O)[C@@H](CO)C4=CC=CC=C4)CC5CC5,,,,,,
1723,71724,Adicillin,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)CCC[C@H](C(=O)O)N)C(=O)O)C,,,,,,
1724,71725,CID 71725,CC(=O)OCC(=O)[C@@]1(CCC2[C@@]1(CC(=O)C3C2C[C@@H](C4=CC(=O)C=C[C@]34C)Cl)C)O,,,,,,
1725,71726,Tetrantoin,C1CC2(CC3=CC=CC=C31)C(=O)NC(=O)N2,,,,,,
1726,71727,CID 71727,C[C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)OC2=CC=C(C=C2)C=CC(=O)NCCCNCCCCN)N=C(N)N)O)NC(=O)N[C@@H]3[C@@H]([C@H]([C@@H](CO3)O[C@H]4[C@@H]([C@@H]5[C@@H](CO4)OC(=O)N5)NC(=O)N)O)NC(=O)N.Cl,,,,,,
1727,71728,"3-[4-[(2R,3R,4S,5S,6R)-5-[[(2S,3R,4R,5R)-5-[[(3aS,6S,7R,7aR)-7-(carbamoylamino)-2-oxo-1,3a,4,6,7,7a-hexahydropyrano[4,3-d][1,3]oxazol-6-yl]oxy]-3-(carbamoylamino)-4-hydroxyoxan-2-yl]carbamoylamino]-3-(diaminomethylideneamino)-4-hydroxy-6-methyloxan-2-yl]oxyphenyl]-N-[3-(4-aminobutylamino)propyl]prop-2-enamide",C[C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)OC2=CC=C(C=C2)C=CC(=O)NCCCNCCCCN)N=C(N)N)O)NC(=O)N[C@@H]3[C@@H]([C@H]([C@@H](CO3)O[C@H]4[C@@H]([C@@H]5[C@@H](CO4)OC(=O)N5)NC(=O)N)O)NC(=O)N,,,,,,
1728,71729,Pyridofylline,CC1=NC=C(C(=C1O)CO)CO.CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CCOS(=O)(=O)O,,,,,,
1729,71730,"2-(1,3-Dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7h-purin-7-yl)ethyl hydrogen sulfate",CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CCOS(=O)(=O)O,,,,,,
1730,71731,Fenoxedil,CCCCOC1=CC=C(C=C1)OCC(=O)N(CCN(CC)CC)C2=C(C=CC(=C2)OCC)OCC,,,,,,
1731,71732,Suxethonium Chloride,CC[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)CC.[Cl-].[Cl-],,,,,,
1732,71733,Bufuralol,CCC1=CC=CC2=C1OC(=C2)C(CNC(C)(C)C)O,,,"['Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. (See all compounds classified as Adrenergic beta-Antagonists.)']",,"[""Bufuralol has known human metabolites that include 1'2'-Ethenylbufuralol, 4-Hydroxybufuralol, and 6-Hydroxubufuralol.""]",
1733,71734,Enocitabine,CCCCCCCCCCCCCCCCCCCCCC(=O)NC1=NC(=O)N(C=C1)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O,,,"['Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)', 'Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)']",,,
1734,71735,Butopiprine,CCCCOCCOC(=O)C(C1=CC=CC=C1)N2CCCCC2,,,,,,
1735,71736,Cefazedone,CC1=NN=C(S1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)CN4C=C(C(=O)C(=C4)Cl)Cl)SC2)C(=O)O,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
1736,71737,Isoprazone,CC1=C(C(=C(N1)C2=CC=CC=C2)N)C(=O)C(C)C,,,,,,
1737,71738,Adosterol,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C[C@H](C4=C3CC[C@@H](C4)O)CI)C,,,,,,
1738,71739,Carazolol,CC(C)NCC(COC1=CC=CC2=C1C3=CC=CC=C3N2)O,,,"['Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. (See all compounds classified as Adrenergic beta-Antagonists.)']",,,
1739,71740,Cafedrine,CC(C(C1=CC=CC=C1)O)NCCN2C=NC3=C2C(=O)N(C(=O)N3C)C,,,"['Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)']",,,
1740,71741,Ranimustine,CO[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CNC(=O)N(CCCl)N=O)O)O)O,,,['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)'],,,
1741,71742,Lombazole,C1=CC=C(C=C1)C2=CC=C(C=C2)C(C3=CC=CC=C3Cl)N4C=CN=C4,,,,,,
1742,71743,Quinfamide,C1CC2=C(C=CC(=C2)OC(=O)C3=CC=CO3)N(C1)C(=O)C(Cl)Cl,,,,,,
1743,71744,Declenperone,C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCCN3C4=CC=CC=C4NC3=O,,,,,,
1744,71745,Etibendazole,COC(=O)NC1=NC2=C(N1)C=C(C=C2)C3(OCCO3)C4=CC=C(C=C4)F,,,,,,
1745,71746,"11beta,14,17,21-Tetrahydroxypregn-4-ene-3,20-dione cyclic 14,17-acetal with crotonaldehyde, 21-isonicotinate",CC=CC1O[C@@]23CC[C@]([C@]2(C[C@@H]([C@H]4[C@H]3CCC5=CC(=O)CC[C@]45C)O)C)(O1)C(=O)COC(=O)C6=CC=NC=C6,,,,,,
1746,71747,Murocainide,CNC(=O)NC1=C(C2=C(C(=C1OCCN3CCCCC3)OC)OC=C2)OC,,,,,,
1747,71748,CID 71748,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)NC(=O)N4CCN(C4=O)N=CC5=CC=CO5)C(=O)O)C,,,,,,
1748,71749,Almagate,C(=O)([O-])[O-].O.O.[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Al+3],,,['Substances that counteract or neutralize acidity of the GASTROINTESTINAL TRACT. (See all compounds classified as Antacids.)'],,,
1749,71750,Daniquidone,C1C2=C(C=CC(=C2)N)N=C3N1C(=O)C4=CC=CC=C43,,,,,"['8-aminoisoindolo (1,2-b)quinazolin-12(10H)-one has known human metabolites that include N-(12-Oxo-10H-isoindolo[1,2-b]quinazolin-8-yl)acetamide.']",
1750,71751,Prifelone,CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)C(=O)C2=CC=CS2,,,,,,
1751,71752,"methyl 7-[(1R,2R,3R)-3-hydroxy-2-[(4R)-4-hydroxy-4-(1-propylcyclobutyl)but-1-enyl]-5-oxocyclopentyl]heptanoate",CCCC1(CCC1)[C@@H](CC=C[C@H]2[C@@H](CC(=O)[C@@H]2CCCCCCC(=O)OC)O)O,,,,,,
1752,71753,"methyl 7-[(1R,2R,3R)-3-hydroxy-2-[(3S,5S)-3-hydroxy-5-methylnon-1-enyl]-5-oxocyclopentyl]-6-oxoheptanoate",CCCC[C@H](C)C[C@@H](C=C[C@H]1[C@@H](CC(=O)[C@@H]1CC(=O)CCCCC(=O)OC)O)O,,,,,,
1753,71754,(S)-Denopamine,COC1=C(C=C(C=C1)CCNC[C@H](C2=CC=C(C=C2)O)O)OC,,,,,,
1754,71755,Spizofurone,CC(=O)C1=CC2=C(C=C1)OC3(C2=O)CC3,,,,,,
1755,71756,Fosarilate,CCOP(=O)(CCCCCCOC1=C(C=C(C=C1)OC)Cl)OCC,,,,,,
1756,71757,CID 71757,CC[C@@H]1[C@]([C@H]2[C@H](O2)C=CC(=O)[C@@H](C[C@@H]([C@@H]([C@H](C=CC(=O)O1)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)C)C)(CO[C@H]4[C@@H]([C@@H]([C@@H]([C@H](O4)C)O)OC)OC)O,,,,,,
1757,71758,Flumeridone,C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=C(C=C(C=C5)F)NC4=O,,,,,,
1758,71759,Ciamexon,CC1=NC(=C(C=C1)CN2CC2C#N)OC,,,"['Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund&apos;s adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)']",,,
1759,71760,CID 71760,CCCCCCC([C@H](C)O)[N+]1=C=NC2=C1NC=NC2=O,,,,,,
1760,71761,CID 71761,CCCCCCCCCCCCCCCCCC(=O)NCCCC[C@H](C(=O)O)NC(=O)CC[C@H](C(=O)N)NC(=O)[C@@H](C)NC(=O)[C@@H](C)O[C@H]1[C@@H]([C@H](OC([C@@H]1NC(=O)C)O)CO)O,,,,,,
1761,71762,"1-[(4R,5R)-4,5-Dihydroxy-N2-[4-(octyloxy)benzoyl]-L-ornithine]echinocandin B",CCCCCCCCOC1=CC=C(C=C1)C(=O)NC2C[C@H]([C@H](NC(=O)C3[C@H]([C@H](CN3C(=O)C(NC(=O)C(NC(=O)C4C[C@H](CN4C(=O)C(NC2=O)C(C)O)O)[C@@H]([C@H](C5=CC=C(C=C5)O)O)O)C(C)O)C)O)O)O,,,,,,
1762,71763,Sufotidine,CN1C(=NC(=N1)CS(=O)(=O)C)NCCCOC2=CC=CC(=C2)CN3CCCCC3,,,,,,
1763,71764,Alfuzosin Hydrochloride,CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC.Cl,,,"['Drugs used in the treatment of urological conditions and diseases such as URINARY INCONTINENCE and URINARY TRACT INFECTIONS. (See all compounds classified as Urological Agents.)', 'Drugs that bind to and block the activation of ADRENERGIC ALPHA-1 RECEPTORS. (See all compounds classified as Adrenergic alpha-1 Receptor Antagonists.)']",,,
1764,71765,Flusoxolol,CC(C)NC[C@@H](COC1=CC=C(C=C1)OCCOCCC2=CC=C(C=C2)F)O,,,,,,
1765,71766,Mitozolomide,C1=NC(=C2N1C(=O)N(N=N2)CCCl)C(=O)N,,,['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)'],,,
1766,71767,Seganserin,CC1=C(C(=O)N2C=CC=CC2=N1)CCN3CCC(=C(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F)CC3,,,,,,
1767,71768,Buparvaquone,CC(C)(C)C1CCC(CC1)CC2=C(C3=CC=CC=C3C(=O)C2=O)O,,,['Substances that are destructive to protozoans. (See all compounds classified as Antiprotozoal Agents.)'],,,
1768,71769,CID 71769,CCN1CCN([C@H]2[C@H]1C3=C(C4=CC=CC=C4N3CC2)C)C(C)C.C(=CC(=O)O)C(=O)O,,,,,,
1769,71770,"(2S,7R)-3-ethyl-17-methyl-6-propan-2-yl-3,6,10-triazatetracyclo[8.7.0.02,7.011,16]heptadeca-1(17),11,13,15-tetraene",CCN1CCN([C@H]2[C@H]1C3=C(C4=CC=CC=C4N3CC2)C)C(C)C,,,,,,
1770,71771,Aceclofenac,C1=CC=C(C(=C1)CC(=O)OCC(=O)O)NC2=C(C=CC=C2Cl)Cl,"['Aceclofenac is indicated for the relief of pain and inflammation in osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.']","[""Aceclofenac is a NSAID that inhibits both isoforms of COX enzyme, a key enzyme involved in the inflammatory cascade. COX-1 enzyme is a constitutive enzyme involved in prostacyclin production and protective functions of gastric mucosa whereas COX-2 is an inducible enzyme involved in the production of inflammatory mediators in response to inflammatory stimuli. Aceclofenac displays more selectivity towards COX-2 (IC50 of 0.77uM) than COX-1 (IC50 of >100uM), which promotes its gastric tolerance compared to other NSAIDs. The primary metabolite, 4'-hydroxyaceclofenac, also minimally inhibits COX-2 with IC50 value of 36uM. Although the mode of action of aceclofenac is thought to mainly arise from the inhibition of synthesis of prostaglandins (PGE2), aceclofenac also inhibits the production of inflammatory cytokines, interleukins (IL-1β, IL-6), and tumor necrosis factors (TNF). It is also reported that aceclofenac also affects the cell adhesion molecules from neutrophils. Aceclofenac also targets the synthesis of glycosaminoglycan and mediates chrondroprotective effects.""]","['Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)']","['Aceclofenac is rapidly and completely absorbed from the gastrointestinal tract and circulates mainly as unchanged drug following oral administration. Peak plasma concentrations are reached around 1.25 to 3 hours post-ingestion, and the drug penetrates into the synovial fluid where the concentration may reach up to 60% of that in the plasma. There is no accumulation in regular dosing, with similar maximum plasma concentration (Cmax) and time to reach peak plasma concentration (Tmax) after single and multiple doses.', 'The main route of elimination is via the urine where the elimination accounts for 70-80% of clearance of the drug. Approximately two thirds of the administered dose is excreted via the urine, mainly as glucuronidated and hydroxylated forms of aceclofenac. About 20% of the dose is excreted into feces.', 'The volume of distribution is approximately 25 L.', 'The mean clearance rate is approximately 5 L/h.']","[""4'-hydroxyaceclofenac is the main metabolite detected in plasma however other minor metabolites include diclofenac, 5-hydroxyaceclofenac, 5-hydroxydiclofenac, and 4'-hydroxydiclofenac. It is probable that the metabolism of aceclofenac is mediated by CYP2C9."", ""Aceclofenac has known human metabolites that include 4'-hydroxy-aceclofenac, 5-hydroxy-aceclofenac, and diclofenac.""]",['The mean plasma elimination half-life is approximately 4 hours.']
1771,71772,Mitoquidone,C1C2=CC=CC=C2CN3C1=C4C(=C3)C(=O)C5=CC=CC=C5C4=O,,,,,,
1772,71773,Suplatast Tosilate,CCOCC(COC1=CC=C(C=C1)NC(=O)CC[S+](C)C)O.CC1=CC=C(C=C1)S(=O)(=O)[O-],,,"['Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475) (See all compounds classified as Anti-Allergic Agents.)', 'Drugs that bind to but do not activate histamine receptors, thereby blocking the actions of histamine or histamine agonists. Classical antihistaminics block the histamine H1 receptors only. (See all compounds classified as Histamine Antagonists.)']",,,
1773,71774,Suplatast,CCOCC(COC1=CC=C(C=C1)NC(=O)CC[S+](C)C)O,,,,,,
1774,71775,CID 71775,CCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O[C@H]2[C@H]3[C@H]([C@H]([C@H](O2)CO)O[C@H]4[C@@H]([C@H]([C@H]([C@H](O4)CO)O)O[C@H]5[C@@H]([C@H]([C@H]([C@H](O5)CO)O)O)O)NC(=O)C)O[C@@]6(C[C@H]([C@@H](C(O6)[C@H]([C@H](CO)O)O)NC(=O)C)O)C(=O)O3)O)O)[C@H](C=CCCCCCCCCCCCCC)O,,,,,,
1775,71776,CID 71776,CC[C@@H](C)C(=O)O[C@@H](C)[C@@]1([C@@H](OC(C[C@H]1OC)O[C@@H]2[C@@H]([C@@H](O[C@H]([C@@H]2OC(=O)C(C(C)SC[C@@H](C(=O)O)NC(=O)C)N=C(S)SC[C@@H](C(=O)O)NC(=O)C)COC(=O)C)[C@@]3(CC(=O)C(=C(C3=O)C(=O)O)N)O)O)C)O,,,,,,
1776,71777,Lufenuron,C1=CC(=C(C(=C1)F)C(=O)NC(=O)NC2=CC(=C(C=C2Cl)OC(C(C(F)(F)F)F)(F)F)Cl)F,,,"['Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)']",,,
1777,71778,Rilopirox,CC1=CC(=O)N(C(=C1)COC2=CC=C(C=C2)OC3=CC=C(C=C3)Cl)O,,,,,,
1778,71779,CID 71779,CON=C(C1=NSC(=N1)N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]45CCC(CC4)(CC5)C(=O)N)C(=O)[O-],,,,,,
1779,71780,"(6R)-7-[[2-(5-amino-1,2,4-thiadiazol-3-yl)-2-methoxyiminoacetyl]amino]-3-[(4-carbamoyl-1-azoniabicyclo[2.2.2]octan-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid",CON=C(C1=NSC(=N1)N)C(=O)NC2[C@@H]3N(C2=O)C(=C(CS3)C[N+]45CCC(CC4)(CC5)C(=O)N)C(=O)O,,,,,,
1780,71781,Glemanserin,C1CN(CCC1C(C2=CC=CC=C2)O)CCC3=CC=CC=C3,,,,,,
1781,71782,"3-[[(3aR,4R,5R,6aS)-4-[(3S)-3-cyclohexyl-3-hydroxyprop-1-enyl]-5-hydroxy-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]methyl]benzoic acid",C1CCC(CC1)[C@@H](C=C[C@H]2[C@@H](C[C@H]3[C@@H]2CC(=CC4=CC(=CC=C4)C(=O)O)O3)O)O,,,,,,
1782,71783,"(6R,7R)-3-((1H-imidazo[1,2-b]pyridazin-4-ium-1-yl)methyl)-7-((Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate",CON=C(C1=NSC(=N1)N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4=C5C=CC=NN5C=C4)C(=O)[O-],,,,,,
1783,71784,"(6R,7R)-7-[[2-(5-amino-1,2,4-thiadiazol-3-yl)-2-methoxyiminoacetyl]amino]-3-(imidazo[1,2-b]pyridazin-1-ium-1-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid",CON=C(C1=NSC(=N1)N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4=C5C=CC=NN5C=C4)C(=O)O,,,,,,
1784,71785,"3,3-dimethyl-N-[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]-2H-indole-1-carboxamide",CC1(CN(C2=CC=CC=C21)C(=O)NC3C[C@H]4CC[C@@H](C3)N4C)C,,,,,,
1785,71786,Gallium;2-[bis[2-[carboxylatomethyl-(2-morpholin-4-yl-2-oxoethyl)amino]ethyl]amino]acetate,C1COCCN1C(=O)CN(CCN(CCN(CC(=O)N2CCOCC2)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].[Ga+3],,,,,,
1786,71787,"n,n-Bis(2-{(carboxymethyl)[2-(morpholin-4-yl)-2-oxoethyl]amino}ethyl)glycine",C1COCCN1C(=O)CN(CCN(CCN(CC(=O)N2CCOCC2)CC(=O)O)CC(=O)O)CC(=O)O,,,,,,
1787,71788,Beciparcil,C1[C@H]([C@@H]([C@H]([C@@H](S1)SC2=CC=C(C=C2)C#N)O)O)O,,,,,,
1788,71789,CID 71789,C1COC(O1)(COC2=CC(=CC=C2)Cl)C=C[C@@H]3[C@H](C[C@H]([C@H]3CC=CCCCC(=O)O)O)O,,,,,,
1789,71790,CID 71790,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)COCCO)C)CC(C)C)C)C(C)C)CC(C)C)C)C,,,,,,
1790,71791,CID 71791,C#CCO[C@H]1CN2CCC1CC2.C(=CC(=O)O)C(=O)O,,,,,,
1791,71792,Talsaclidine,C#CCO[C@H]1CN2CCC1CC2,,,,,,
1792,71793,Glyclopyramide,C1CCN(C1)NC(=O)NS(=O)(=O)C2=CC=C(C=C2)Cl,,,,,,
1793,71794,Quinine Salicylate,COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O.C1=CC=C(C(=C1)C(=O)O)O,,,,,,
1794,71795,"[(2S,4S)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol",COC1=CC2=C(C=CN=C2C=C1)C([C@@H]3C[C@@H]4CCN3CC4C=C)O,,,,,,
1795,71796,Penethamate Hydriodide,CCN(CC)CCOC(=O)[C@H]1C(S[C@H]2N1C(=O)[C@H]2NC(=O)CC3=CC=CC=C3)(C)C.I,,,,,,
1796,71797,Penethamate,CCN(CC)CCOC(=O)[C@H]1C(S[C@H]2N1C(=O)[C@H]2NC(=O)CC3=CC=CC=C3)(C)C,,,,,,
1797,71798,Methoserpidine,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=C(C=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC,,,,,,
1798,71799,CID 71799,C1=CC=C(C(=C1)C(=O)NCC(=O)[O-])[131I].[Na+],,,,,,
1799,71800,Iodohippuric acid i-131,C1=CC=C(C(=C1)C(=O)NCC(=O)O)[131I],,,,,,
1800,71801,CID 71801,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C(NCO)O)C(=O)[C@]3(C(=O)C2=C(C4=C(C=CC(=C41)Cl)O)O)O)N(C)C)O,,,,,,
1801,71802,Propiomazine hydrochloride,CCC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CC(C)N(C)C.Cl,,,,,,
1802,71803,CID 71803,C1=CC(=CC=C1N[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)[Sb](=O)(O)O[Sb](=O)(C3=CC=C(C=C3)N[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O[Sb](=O)(C5=CC=C(C=C5)N[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)[O-].[Na+],,,,,,
1803,71804,CID 71804,C1=CC(=CC=C1N[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)[SbH](=O)O[Sb](=O)(C3=CC=C(C=C3)N[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O[Sb](=O)(C5=CC=C(C=C5)N[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)[O-].O,,,,,,
1804,71805,Paraflutizide,C1=CC(=CC=C1CC2NC3=CC(=C(C=C3S(=O)(=O)N2)S(=O)(=O)N)Cl)F,,,,,,
1805,71806,Amphotalide,C1=CC=C2C(=C1)C(=O)N(C2=O)CCCCCOC3=CC=C(C=C3)N,,,,,,
1806,71807,Clometocillin,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C(C3=CC(=C(C=C3)Cl)Cl)OC)C(=O)O)C,,,,,,
1807,71808,Mecloralurea,CNC(=O)NC(C(Cl)(Cl)Cl)O,,,,,,
1808,71809,Diponium bromide,CC[N+](CC)(CC)CCOC(=O)C(C1CCCC1)C2CCCC2.[Br-],,,,,,
1809,71810,Dipenine,CC[N+](CC)(CC)CCOC(=O)C(C1CCCC1)C2CCCC2,,,,,,
1810,71811,Clofenetamine hydrochloride,CCN(CC)CCOC(C)(C1=CC=CC=C1)C2=CC=C(C=C2)Cl.Cl,,,,,,
1811,71812,Clofenetamine,CCN(CC)CCOC(C)(C1=CC=CC=C1)C2=CC=C(C=C2)Cl,,,,,,
1812,71813,Loprodiol,C(C(CO)(CCl)CCl)O,,,,,,
1813,71814,Fluoresone,CCS(=O)(=O)C1=CC=C(C=C1)F,,,,,,
1814,71815,Secnidazole,CC1=NC=C(N1CC(C)O)[N+](=O)[O-],['Secnidazole is indicated for the treatment of trichomoniasis in adults and bacterial vaginosis in adult women.'],"['Secnidazole is a nitroimidazole antimicrobial drug that displays selectivity against many anaerobic Gram-positive and Gram-negative bacteria and protozoa. In vitro studies demonstrates the effectiveness of the drug against *Bacteroides fragilis*, *Trichomonas vaginalis*, *Entamoeba histolytica* and *Giardia lamblia*. There is no significant bacterial or protozoal resistance reported from secnidazole treatment.']",['Substances that are destructive to protozoans. (See all compounds classified as Antiprotozoal Agents.)'],"['Secnidazole is rapidly and completely absorbed after oral administration. Following a single oral dose of 2 g in healthy adult female subjects, the mean (SD) secnidazole peak plasma concentration (Cmax) of 45.4 (7.64) mcg/mL and mean (SD) systemic exposure (AUC0-inf) of 1331.6 (230.16) mcg x hr/mL was reached. Median (range) time to peak concentration (Tmax) was 4.0 (3.0-4.0) hours.', 'The predominant route of elimination is renal elimination. Following a single oral dose of 2g secnidazole, approximately 15% of the drug is excreted as unchanged compoung in the urine.', 'The apparent volume of distribution of secnidazole is approximately 42-49 L.', 'The total body clearance of secnidazole is approximately 25 mL/min. The renal clearance of secnidazole is approximately 3.9 mL/min.']","['According to *in vitro* studies, secnidazole is metabolized via oxidation by human hepatic CYP450 enzyme system with ≤ 1% conversion to metabolites.']",['The plasma elimination half-life for secnidazole is approximately 17 hours.']
1815,71816,Clociguanil,CC1(N=C(N=C(N1OCC2=CC(=C(C=C2)Cl)Cl)N)N)C,,,,,,
1816,71817,Benfurodil hemisuccinate,CC1=C(OC2=C1C=C(C=C2)C3=CC(=O)OC3)C(C)OC(=O)CCC(=O)O,,,,,,
1817,71818,Menbutone,COC1=CC=C(C2=CC=CC=C21)C(=O)CCC(=O)O,,,,,,
1818,71819,Clefamide,C1=CC(=CC=C1CN(CCO)C(=O)C(Cl)Cl)OC2=CC=C(C=C2)[N+](=O)[O-],,,,,,
1819,71820,Emepronium Bromide,CC[N+](C)(C)C(C)CC(C1=CC=CC=C1)C2=CC=CC=C2.[Br-],,,"['Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. (See all compounds classified as Muscarinic Antagonists.)', 'Drugs used in the treatment of urological conditions and diseases such as URINARY INCONTINENCE and URINARY TRACT INFECTIONS. (See all compounds classified as Urological Agents.)', 'Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)']",,,
1820,71821,Chlormidazole,CC1=NC2=CC=CC=C2N1CC3=CC=C(C=C3)Cl,,,,,,
1821,71822,Etymemazine hydrochloride,CCC1=CC2=C(C=C1)SC3=CC=CC=C3N2CC(C)CN(C)C.Cl,,,,,,
1822,71823,Etymemazine,CCC1=CC2=C(C=C1)SC3=CC=CC=C3N2CC(C)CN(C)C,,,,,,
1823,71824,Cimemoxin,C1CCC(CC1)CNN,,,,,,
1824,71825,Parvaquone,C1CCC(CC1)C2=C(C3=CC=CC=C3C(=O)C2=O)O,,,"['Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585) (See all compounds classified as Antimalarials.)']",,,
1825,71826,Cletoquine,CC(CCCNCCO)NC1=C2C=CC(=CC2=NC=C1)Cl,,,,,,
1826,71827,Nixylic acid,CC1=C(C(=CC=C1)NC2=C(C=CC=N2)C(=O)O)C,,,,,,
1827,71828,CID 71828,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C(NCN4CCN(CC4)CCO)O)C(=O)[C@]3(C(=O)C2=C(C5=C1C=CC=C5O)O)O)N(C)C)O.CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)COC3=CC=CC=C3)C(=O)O)C,,,,,,
1828,71829,Chlorproethazine hydrochloride,CCN(CC)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl.Cl,,,"['A heterogeneous group of drugs used to produce muscle relaxation, excepting the neuromuscular blocking agents. They have their primary clinical and therapeutic uses in the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. They have been used also for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in MULTIPLE SCLEROSIS. (From Smith and Reynard, Textbook of Pharmacology, 1991, p358) (See all compounds classified as Muscle Relaxants, Central.)']",,,
1829,71830,Camphotamide,CCN(CC)C(=O)C1=C[N+](=CC=C1)C.CC1(C2CCC1(C(=O)C2S(=O)(=O)[O-])C)C,,,,,,
1830,71831,3-(Diethylcarbamoyl)-1-methylpyridinium,CCN(CC)C(=O)C1=C[N+](=CC=C1)C,,,,,,
1831,71832,"4,7,7-Trimethyl-3-oxobicyclo[2.2.1]heptane-2-sulfonic acid",CC1(C2CCC1(C(=O)C2S(=O)(=O)O)C)C,,,,,,
1832,71833,Hydrastinine Hydrochloride,CN1CCC2=CC3=C(C=C2C1O)OCO3.Cl,,,,,,
1833,71834,Vatensol,C1=CC(=C(C(=C1)Cl)OCCNN=C(N)N)Cl.OS(=O)(=O)O,,,,,,
1834,71835,Guanoclor,C1=CC(=C(C(=C1)Cl)OCCNN=C(N)N)Cl,,,,,,
1835,71836,Flualamide,CCN(CC)CCNC(=O)C1=C(C=C(C=C1)C(F)(F)F)OCC=C,,,,,,
1836,71837,Alloclamide,CCN(CC)CCNC(=O)C1=C(C=C(C=C1)Cl)OCC=C,,,,,,
1837,71838,CID 71838,C1(C(=O)NC(=O)N1)NC(=O)N.O.O.[AlH3],,,,,,
1838,71839,Penthrichloral,C1C(COC(O1)C(Cl)(Cl)Cl)(CO)CO,,,,,,
1839,71840,Oletimol,CC(=NCC1=CC=CC=C1)C2=CC=CC=C2O,,,,,,
1840,71841,Fenabutene,CC=C(C)C1=CC=C(C=C1)OC(=O)C,,,,,,
1841,71842,CID 71842,C1=CC(=CN=C1)C(=O)OCC(C(C(C(COC(=O)C2=CN=CC=C2)OC(=O)C3=CN=CC=C3)OC(=O)C4=CN=CC=C4)OC(=O)C5=CN=CC=C5)OC(=O)C6=CN=CC=C6,,,,,,
1842,71843,CID 71843,C1(=C(C(=C(C(=C1Br)Br)Br)Br)O)O.O.[BiH3],,,,,,
1843,71844,Chloroserpidine,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=C(C=C5)Cl)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC,,,,,,
1844,71845,Phenyracillin,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C.CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C.C1C(NCC(N1)C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
1845,71846,"2,5-Diphenylpiperazine",C1C(NCC(N1)C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
1846,71847,"5-Amino-2-[2-(4-amino-2-sulfophenyl)ethenyl]benzenesulfonate;(2,4-dichlorophenoxy)methyl-dimethyl-octylazanium",CCCCCCCC[N+](C)(C)COC1=C(C=C(C=C1)Cl)Cl.C1=CC(=C(C=C1N)S(=O)(=O)O)C=CC2=C(C=C(C=C2)N)S(=O)(=O)[O-],,,,,,
1847,71848,Chlorphenoctium,CCCCCCCC[N+](C)(C)COC1=C(C=C(C=C1)Cl)Cl,,,,,,
1848,71849,Mebezonium Iodide,C[N+](C)(C)C1CCC(CC1)CC2CCC(CC2)[N+](C)(C)C.[I-].[I-],,,,,,
1849,71850,Mebezonium,C[N+](C)(C)C1CCC(CC1)CC2CCC(CC2)[N+](C)(C)C,,,,,,
1850,71851,Myrtecaine,CCN(CC)CCOCCC1=CCC2CC1C2(C)C,,,,,,
1851,71852,Furterene,C1=COC(=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,,,,,,
1852,71853,Chitosan,COC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O[C@@H]2[C@H](O[C@H]([C@@H]([C@H]2O)N)O[C@@H]3[C@H](O[C@H]([C@@H]([C@H]3O)N)O)CO)CO)CO)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)N)O)N)O)N)O)N)O)N)O)N)O,,,"['Chemicals that bind to and remove ions from solutions. Many chelating agents function through the formation of COORDINATION COMPLEXES with METALS. (See all compounds classified as Chelating Agents.)', 'Synthetic or natural materials, other than DRUGS, that are used to replace or repair any body TISSUES or bodily function. (See all compounds classified as Biocompatible Materials.)', 'Substances used to lower plasma cholesterol levels. (See all compounds classified as Anticholesteremic Agents.)', 'Agents acting to arrest the flow of blood. Absorbable hemostatics arrest bleeding either by the formation of an artificial clot or by providing a mechanical matrix that facilitates clotting when applied directly to the bleeding surface. These agents function more at the capillary level and are not effective at stemming arterial or venous bleeding under any significant intravascular pressure. (See all compounds classified as Hemostatics.)']",,,
1853,71854,Nicoclonate,CC(C)C(C1=CC=C(C=C1)Cl)OC(=O)C2=CN=CC=C2,,,,,,
1854,71855,Cuproxoline,CCNCC.CCNCC.CCNCC.CCNCC.C1=CC2=C(C(=C(C=C2S(=O)(=O)O)S(=O)(=O)O)[O-])N=C1.C1=CC2=C(C(=C(C=C2S(=O)(=O)O)S(=O)(=O)O)[O-])N=C1.[Cu+2],,,,,,
1855,71856,"8-Hydroxyquinoline-5,7-disulphonic acid",C1=CC2=C(C(=C(C=C2S(=O)(=O)O)S(=O)(=O)O)O)N=C1,,,,,,
1856,71857,Theodrenaline,CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CCNCC(C3=CC(=C(C=C3)O)O)O,,,"['Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)']",,,
1857,71858,Beclotiamine,CC1=C(SC=[N+]1CC2=CN=C(N=C2N)C)CCCl.[Cl-],,,,,,
1858,71859,"3-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-5-(2-chloroethyl)-4-methyl-1,3-thiazol-3-ium",CC1=C(SC=[N+]1CC2=CN=C(N=C2N)C)CCCl,,,,,,
1859,71860,Benzopyrronium Bromide,C[N+]1(CCC(C1)OC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O)C.[Br-],,,,,,
1860,71861,Benzopyrronium,C[N+]1(CCC(C1)OC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O)C,,,,,,
1861,71862,Protizinic Acid,CC(C1=CC2=C(C=C1)SC3=C(N2C)C=CC(=C3)OC)C(=O)O,,,,,,
1862,71863,Minepentate,CN(C)CCOCCOC(=O)C1(CCCC1)C2=CC=CC=C2,,,,,,
1863,71864,Hydrobentizide,C1=CC=C(C=C1)CSCC2NC3=CC(=C(C=C3S(=O)(=O)N2)S(=O)(=O)N)Cl,,,,,,
1864,71865,Prothidium,CC1=CC(=NC(=[N+]1C)N)NC2=CC3=C([N+](=C4C=C(C=CC4=C3C=C2)N)C)C5=CC=C(C=C5)N.[Br-].[Br-],,,,,,
1865,71866,Pyritidium,CC1=CC(=NC(=[N+]1C)N)NC2=CC3=C([N+](=C4C=C(C=CC4=C3C=C2)N)C)C5=CC=C(C=C5)N,,,,,,
1866,71867,Phenylmercury;3-[(3-sulfonaphthalen-2-yl)methyl]naphthalene-2-sulfonic acid,C1=CC=C(C=C1)[Hg].C1=CC=C(C=C1)[Hg].C1=CC=C2C=C(C(=CC2=C1)CC3=CC4=CC=CC=C4C=C3S(=O)(=O)O)S(=O)(=O)O,,,,,,
1867,71868,3-[3-(3-Hydroxy-2-phenylpropanoyl)oxy-8-methyl-8-azoniabicyclo[3.2.1]octan-8-yl]propane-1-sulfonate,C[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)CCCS(=O)(=O)[O-],,,,,,
1868,71869,3-[(3-Hydroxy-2-phenylpropanoyl)oxy]-8-methyl-8-(3-sulfopropyl)-8-azabicyclo[3.2.1]octan-8-ium,C[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)CCCS(=O)(=O)O,,,,,,
1869,71870,Ferrotrenine,CC=NC(C(C)O)C(=O)[O-].CC=NC(C(C)O)C(=O)[O-].O.O.[Fe+2],,,,,,
1870,71871,N-Ethylidenethreonine,CC=NC(C(C)O)C(=O)O,,,,,,
1871,71872,Metamfepramone,CC(C(=O)C1=CC=CC=C1)N(C)C,,,,,,
1872,71873,Myralact,CCCCCCCCCCCCCCNCCO.CC(C(=O)O)O,,,,,,
1873,71874,2-(Tetradecylamino)ethanol,CCCCCCCCCCCCCCNCCO,,,,,,
1874,71875,Cyprodenate,CN(C)CCOC(=O)CCC1CCCCC1,,,,,,
1875,71876,CID 71876,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C(NCN(C)CCN(C)CNC(=C4C(=O)[C@H]([C@@H]5C[C@H]6C(=C(C7=C([C@@]6(C)O)C=CC=C7O)O)C(=O)[C@@]5(C4=O)O)N(C)C)O)O)C(=O)[C@]3(C(=O)C2=C(C8=C1C=CC=C8O)O)O)N(C)C)O,,,,,,
1876,71877,Amfepentorex,CCCCCC1=CC=C(C=C1)CC(C)NC,,,,,,
1877,71878,Biclotymol,CC1=C(C=C(C(=C1CC2=C(C(=CC(=C2C)Cl)C(C)C)O)O)C(C)C)Cl,,,,,,
1878,71879,Dextrofemine,CC(CC1=CC=CC=C1)NC(C)COC2=CC=CC=C2,,,,,,
1879,71880,Difebarbamate,CCCCOCC(CN1C(=O)C(C(=O)N(C1=O)CC(COCCCC)OC(=O)N)(CC)C2=CC=CC=C2)OC(=O)N,,,,,,
1880,71881,"(6S,10R,13S,17S)-17-acetyl-17-hydroxy-10,13-dimethyl-6-(trifluoromethyl)-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one",CC(=O)[C@@]1(CCC2[C@@]1(CCC3C2C[C@@H](C4=CC(=O)CC[C@]34C)C(F)(F)F)C)O,,,,,,
1881,71882,CID 71882,C1COCCN1CC2=C3C=C(C(=O)C=C3OC(=C2)O)O,,,,,,
1882,71883,CID 71883,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C(NCNC(C4=CC=CC=C4)C(=O)NC5C6N(C5=O)C(C(S6)(C)C)C(=O)O)O)C(=O)[C@]3(C(=O)C2=C(C7=C1C=CC=C7O)O)O)N(C)C)O,,,,,,
1883,71884,Amogastrin,CCC(C)(C)OC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N,,,,,,
1884,71885,Nonabine,CCCCCC(C)C(C)C1=CC(=C2C(=C1)OC(C=C2C3=CC=NC=C3)(C)C)O,,,,,,
1885,71886,BRL 2351; BRL 2534; D-(-)-alpha-Azidobenzylpenicillin; DAN 10510; SPC 297D; SPC 97D,CC1(C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=CC=C3)N=[N+]=[N-])C(=O)O)C,,,,,,
1886,71887,Taloximine,CN(C)CCOC1=NN=C(C2=CC=CC=C21)NO,,,,,,
1887,71888,"(17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-16-methylidene-1,2,8,9,11,12,14,15-octahydrocyclopenta[a]phenanthren-3-one",CC12CCC(=O)C=C1C=CC3C2C(CC4(C3CC(=C)[C@@]4(C(=O)CO)O)C)O,,,,,,
1888,71889,Cyclobutoic Acid,CC(CC(=O)O)(C1CCCCC1)O,,,,,,
1889,71890,Picodralazine,C1=CC=C2C(=C1)C(=NN=C2NN)CC3=CC=NC=C3,,,,,,
1890,71891,Oxitefonium Bromide,CC[N+](C)(CC)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CS2)O.[Br-],,,,,,
1891,71892,Oxitefonium,CC[N+](C)(CC)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CS2)O,,,,,,
1892,71893,Rolziracetam,C1CC(=O)N2C1CCC2=O,,,,,,
1893,71894,"1-(2,4-Dimethoxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one",COC1=CC=C(C=C1)C=CC(=O)C2=C(C=C(C=C2)OC)OC,,,,,,
1894,71895,Ftaxilide,CC1=C(C(=CC=C1)C)NC(=O)C2=CC=CC=C2C(=O)O,,,,,,
1895,71896,CID 71896,CCCC(C=C(C)C=CC=CC(=O)N1CCCC1=O)O,,,,,,
1896,71897,Mepiprazole,CC1=CC(=NN1)CCN2CCN(CC2)C3=CC(=CC=C3)Cl,['For the treatment of anxiety neuroses.'],,,,,
1897,71898,Fenoxazoline hydrochloride,CC(C)C1=CC=CC=C1OCC2=NCCN2.Cl,,,,,,
1898,71899,Fenoxazoline,CC(C)C1=CC=CC=C1OCC2=NCCN2,,,,,,
1899,71900,Nitrefazole,CC1=NC(=CN1C2=CC=C(C=C2)[N+](=O)[O-])[N+](=O)[O-],,,,,,
1900,71901,N-[(2S)-1-phenoxypropan-2-yl]-1-phenylpropan-2-amine,C[C@@H](COC1=CC=CC=C1)NC(C)CC2=CC=CC=C2,,,,,,
1901,71902,Sicanina,CC1=CC(=C2[C@H]3[C@H]4[C@](CC[C@@H]5[C@]4(CCCC5(C)C)CO3)(OC2=C1)C)O,,,,,,
1902,71903,CID 71903,C[C@@]1([C@H]2C[C@H]3[C@H](C(=O)C(=C(N)O)C(=O)[C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)N(C)C)O.Cl,,,,,,
1903,71904,CID 71904,C[C@@]1([C@H]2C[C@H]3[C@H](C(=O)C(=C(N)O)C(=O)[C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)N(C)C)O,,,,,,
1904,71905,Olaquindox,CC1=C([N+](=O)C2=CC=CC=C2N1[O-])C(=O)NCCO,,,,"['Experiments with (3-1)4C-olaquindox intraduodenally administered to rats with bile duct fistulas suggested that around 18% of the dose was excreted in the bile.  Similar findings were made after intravenous dosing.  Distribution occurred in a generalized manner throughout the body after oral dosing and most of the radioactivity had disappeared by 24 hours.  Autoradiography revealed the highest amount in the rat kidney at 4 hours, indicative of the extent of urinary excretion already noted.  Slightly elevated concentrations were also observed in liver, testes, adrenals and hair follicles.', 'After pigs were given diets containing up to 45 ppm olaquindox for the duration of the fattening period, the highest levels were found in the liver (0.14 ppm) and kidney (0.28 ppm) 6 hours after withdrawal.  By 24 hours the levels were below the limit of detection (0.1 ppm).  Similar results were noted when pigs were given diets containing 10 ppm olaquindox.', 'When pigs were dosed at levels in the range of those recommended in use (up to 100 ppm in the diet) for up to 20 weeks, relatively high levels were found in the kidney (around 2000 ppb) with relatively moderate levels in the liver (300 ppb) when the animals were killed six hours after drug withdrawal.  When killed 2 days after withdrawal, levels had fallen to below the limits of detection (50 ppb) in liver,  kidney and muscle.  Pigs given diets containing olaquindox at levels in excess of those recommended (160 or 250 ppm) for up to 4 weeks also had high initial levels in kidney, liver and muscle but these had fallen to below the limits of detection by day 2 after withdrawal.', 'Olaquindox was rapidly absorbed when given orally to pigs.  Over 90% of an oral dose of 2 mg/kg bw was eliminated in the urine within 24 hours, which is indicative of rapid and extensive absorption.  The remainder was excreted in the feces.  Maximum plasma levels were attained within 1-2 hours of dosing (1-2 ppm).  This was followed by a rapid decline in plasma levels reaching around 0.03 ppm by 24 hours and 0.005-0.01 ppm by 48 hours.  Radioactivity was present in all tissues when examined 2 days after dosing, but the levels were extremely low.  In the kidney and liver, levels of 110 and 52 ppb were found, while levels in muscle were only 9 ppb.  After 8 days, levels in liver and kidney had fallen to 27 and 12 ppb, respectively, while those in muscle were in the range of 2.5 ppb.  By 28 days after dosing only low levels were found in kidney and muscle (0.9 and 0.5-0.8 ppb, respectively) with slightly higher concentrations in the liver (2 ppb).', 'For more Absorption, Distribution and Excretion (Complete) data for OLAQUINDOX (6 total), please visit the HSDB record page.']","['The biotransformation of olaquindox has been investigated only in the pig.  The majority of an oral dose of olaquindox (70%) was excreted in the urine unchanged.  The major metabolites appeared to be the reduced compounds, the 1- or 4-mono-N-oxides (16%).  Three other compounds thought to be carboxylic acid derivatives made up the remainder.  Later work led to the elucidation of the structures of these metabolites in the pig.  Again the major urinary component after oral dosing was olaquindox with about 7% present as the 4-mono-N-oxide.  Omega oxidation produced the 2-carboxymethylaminocarbonyl compound and its 4-mono-N-oxide derivative (6%).  Some of the corresponding 1-mono-N-oxide moiety of the 2-carboxymethylaminocarbonyl was also noted (1%).  The remaining metabolite was the di-desoxy derivative of 2-carboxymethylaminocarbonyl compound, 2-carboxymethylaminocarbonyl-3- methyl quinoxaline (>1%).']",
1905,71906,Proligestone,CCC1O[C@@]23CC[C@]([C@]2(CC[C@H]4[C@H]3CCC5=CC(=O)CC[C@]45C)C)(O1)C(=O)C,,,,,,
1906,71907,"2-[4,5-Bis(hydroxymethyl)-2-methylpyridin-1-ium-3-yl]oxy-2-hydroxyacetate;2-hydroxy-2-[[5-hydroxy-4-(hydroxymethyl)-6-methylpyridin-1-ium-3-yl]methoxy]acetate",CC1=[NH+]C=C(C(=C1O)CO)COC(C(=O)[O-])O.CC1=[NH+]C=C(C(=C1OC(C(=O)[O-])O)CO)CO,,,,,,
1907,71908,Hydroxy[[5-hydroxy-4-(hydroxymethyl)-6-methylpyridin-3-yl]methoxy]acetic acid,CC1=NC=C(C(=C1O)CO)COC(C(=O)O)O,,,,,,
1908,71909,"{[4,5-Bis(hydroxymethyl)-2-methylpyridin-3-yl]oxy}(hydroxy)acetic acid",CC1=NC=C(C(=C1OC(C(=O)O)O)CO)CO,,,,,,
1909,71910,Diisopromine hydrochloride,CC(C)N(CCC(C1=CC=CC=C1)C2=CC=CC=C2)C(C)C.Cl,,,,,,
1910,71911,Amixetrine,CC(C)CCOC(CN1CCCC1)C2=CC=CC=C2,,,,,,
1911,71912,Duometacin,CC1=C(C2=C(N1CC(=O)O)C=C(C=C2)OC)C(=O)C3=CC=C(C=C3)OC,,,,,,
1912,71913,Dotefonium Bromide,CN(CC[N+]1(CCCC1)C)C(=O)C(C2=CC=CC=C2)(C3=CC=CS3)O.[Br-],,,,,,
1913,71914,Dotefonium,CN(CC[N+]1(CCCC1)C)C(=O)C(C2=CC=CC=C2)(C3=CC=CS3)O,,,,,,
1914,71915,"Morpholine, 4-(1-methylethyl)-2-[4-(trifluoromethyl)phenyl]-",CC(C)N1CCOC(C1)C2=CC=C(C=C2)C(F)(F)F,,,,,,
1915,71916,Alibendol,COC1=CC(=CC(=C1O)C(=O)NCCO)CC=C,,,,,,
1916,71917,Pipebuzone,CCCCC1(C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3)CN4CCN(CC4)C,,,,,,
1917,71918,Floverine,COC1=CC(=CC(=C1)OCCO)OC,,,,,,
1918,71919,Niaprazine,CC(CCN1CCN(CC1)C2=CC=C(C=C2)F)NC(=O)C3=CN=CC=C3,,,,,,
1919,71920,L-alpha-Glycerylphosphorylcholine (GPC),C[N+](C)(C)CCOP(=O)([O-])OC[C@H](CO)O,,,,,,
1920,71921,D-Glycerophosphocholine,C[N+](C)(C)CCOP(=O)(O)OC[C@H](CO)O,,,,,,
1921,71922,Droclidinium Bromide,C[N+]12CCC(CC1)C(C2)OC(=O)C(C3CCCCC3)(C4=CC=CC=C4)O.[Br-],,,,,,
1922,71923,Droclidinium,C[N+]12CCC(CC1)C(C2)OC(=O)C(C3CCCCC3)(C4=CC=CC=C4)O,,,,,,
1923,71924,Stercuronium Iodide,CC[N+](C)(C)[C@H]1CC[C@@]2([C@H]3CC[C@]45CN([C@H]([C@H]4CC[C@H]5[C@@H]3C=CC2=C1)C)C)C.[I-],,,,,,
1924,71925,Stercuronium,CC[N+](C)(C)[C@H]1CC[C@@]2([C@H]3CC[C@]45CN([C@H]([C@H]4CC[C@H]5[C@@H]3C=CC2=C1)C)C)C,,,,,,
1925,71926,Amezinium metilsulfate,COC1=[N+](N=CC(=C1)N)C2=CC=CC=C2.COS(=O)(=O)[O-],,,"['A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman&apos;s The Pharmacological Basis of Therapeutics, 8th ed, p414) (See all compounds classified as Monoamine Oxidase Inhibitors.)', 'Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters. (See all compounds classified as Sympathomimetics.)']",,,
1926,71927,Amezinium,COC1=[N+](N=CC(=C1)N)C2=CC=CC=C2,,,"['Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters. (See all compounds classified as Sympathomimetics.)', 'A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman&apos;s The Pharmacological Basis of Therapeutics, 8th ed, p414) (See all compounds classified as Monoamine Oxidase Inhibitors.)']",,,
1927,71928,Fenclexonium metilsulfate,C[N+]1(CCCCC1)CCC(C2=CCCCC2)C3=CC=CC=C3.COS(=O)(=O)[O-],,,,,,
1928,71929,Fenclexonium,C[N+]1(CCCCC1)CCC(C2=CCCCC2)C3=CC=CC=C3,,,,,,
1929,71930,CID 71930,CC(=O)O[C@H]1CC[C@]2([C@H](C1(C)C)CC[C@@]3([C@@]2(C(=O)C=C4[C@]3(CC[C@@]5([C@H]4C[C@@](CC5)(C)C(=O)OC=CC6=CC=CC=C6)C)C)C)C)C,,,,,,
1930,71931,Dimethyltubocurarinium chloride,C[N+]1(CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C6[C@@H](CC7=CC(=C(C=C7)OC)O3)[N+](CCC6=CC(=C5OC)OC)(C)C)OC)C.[Cl-].[Cl-],,,,,,
1931,71932,CID 71932,CC(CC1=CC=CC=C1)[N+]2=NOC(=C2)N=C(NC3=CC=CC=C3)[O-],,,,,,
1932,71933,1-Phenyl-3-[3-(1-phenylpropan-2-yl)oxadiazol-3-ium-5-yl]urea,CC(CC1=CC=CC=C1)[N+]2=NOC(=C2)NC(=O)NC3=CC=CC=C3,,,,,,
1933,71934,Fenalcomine,CCC(C1=CC=C(C=C1)OCCNC(C)CC2=CC=CC=C2)O,,,,,,
1934,71935,Cotriptyline,CN(C)CC(=O)C=C1C2=CC=CC=C2CCC3=CC=CC=C31,,,"['Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. (See all compounds classified as Antidepressive Agents.)']",,,
1935,71936,Azaspirium Chloride,COC1=C2C(=C(C3=C1C=CO3)OC)OC4=C(C2=O)C[N+]5(CCCCC5)CC4=C.[Cl-],,,,,,
1936,71937,Azaspirium,COC1=C2C(=C(C3=C1C=CO3)OC)OC4=C(C2=O)C[N+]5(CCCCC5)CC4=C,,,,,,
1937,71938,"[6-[(2S,3R,4R,5S,6R)-4-(dimethylamino)-3-hydroxy-5-[(2S,4R,5R,6R)-4-hydroxy-4,6-dimethyl-5-propanoyloxyoxan-2-yl]oxy-6-methyloxan-2-yl]oxy-10-hydroxy-5-methoxy-9,16-dimethyl-2-oxo-7-(2-oxoethyl)-1-oxacyclohexadeca-11,13-dien-4-yl] propanoate",CCC(=O)O[C@@H]1[C@H](O[C@H](C[C@@]1(C)O)O[C@@H]2[C@H](O[C@H]([C@@H]([C@H]2N(C)C)O)OC3C(CC(C(C=CC=CCC(OC(=O)CC(C3OC)OC(=O)CC)C)O)C)CC=O)C)C,,,,,,
1938,71939,Rimazolium Metilsulfate,CCOC(=O)C1=C[N+](=C2CCCC(N2C1=O)C)C.COS(=O)(=O)[O-],,,,,,
1939,71940,Rimazolium,CCOC(=O)C1=C[N+](=C2CCCC(N2C1=O)C)C,,,,,,
1940,71941,CID 71941,CCCCOC1=C(C=C(C=C1)C=CC(=O)O)OC,,,,,,
1941,71942,Dicobalt Edetate,C(CN(CC(=O)[O-])CC(=O)[O-])N(CC(=O)[O-])CC(=O)[O-].[Co+2].[Co+2],,,['Chemicals that bind to and remove ions from solutions. Many chelating agents function through the formation of COORDINATION COMPLEXES with METALS. (See all compounds classified as Chelating Agents.)'],,,
1942,71943,Polybutester,C1=CC(=CC=C1C(=O)O)C(=O)OCCCCOC(=O)C2=CC=C(C=C2)C(=O)OCCCCO,,,,,,
1943,71944,Flavodic Acid,C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=C(C=C3OCC(=O)O)OCC(=O)O,,,,,,
1944,71945,Taurultam,C1CS(=O)(=O)NCN1,,,,,,
1945,71946,Nifuroquine,C1=CC=C2C(=C1)C(=CC(=[N+]2[O-])C(=O)O)C3=CC=C(O3)[N+](=O)[O-],,,,,,
1946,71947,Potassium sucrose octasulfate,C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@]2([C@H]([C@@H]([C@H](O2)COS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])COS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-].[K+].[K+].[K+].[K+].[K+].[K+].[K+].[K+],,,,,,
1947,71948,CID 71948,C(C1[C@H]([C@@H]([C@H]([C@H](O1)O[C@]2([C@H]([C@@H](C(O2)COS(=O)(=O)O)OS(=O)(=O)O)OS(=O)(=O)O)COS(=O)(=O)O)OS(=O)(=O)O)OS(=O)(=O)O)OS(=O)(=O)O)OS(=O)(=O)O,,,,,,
1948,71949,Ciclotizolam,C1CCC(CC1)C2=NN=C3N2C4=C(C=C(S4)Br)C(=NC3)C5=CC=CC=C5Cl,,,,,,
1949,71950,Ambicromil,CCCC1=C2C(=CC3=C1OC(=CC3=O)C(=O)O)C(=O)C=C(O2)C(=O)O,,,,,,
1950,71951,3-(2-(3-t-Butylamino-2-hydroxy-propoxy)phenyl)-6-hydrazinopyridazine,CC(C)(C)NCC(COC1=CC=CC=C1C2=NN=C(C=C2)NN)O.Cl.Cl,,,"['Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. (See all compounds classified as Adrenergic beta-Antagonists.)', 'Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)']",,,
1951,71952,Prizidilol,CC(C)(C)NCC(COC1=CC=CC=C1C2=NN=C(C=C2)NN)O,,,"['Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. (See all compounds classified as Adrenergic beta-Antagonists.)', 'Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)']",,,
1952,71953,Buquineran,CCCCNC(=O)NC1CCN(CC1)C2=NC=NC3=CC(=C(C=C32)OC)OC,,,,,,
1953,71954,Bibenzonium,C[N+](C)(C)CCOC(CC1=CC=CC=C1)C2=CC=CC=C2,,,,,,
1954,71955,Indenolol,CC(C)NCC(COC1=CC=CC2=C1C=CC2)O,,,"['Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. (See all compounds classified as Adrenergic beta-Antagonists.)', 'Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)']",,,
1955,71956,Nilprazole,CC(C)NC(=O)CN1CCN(CC1)CC2=NC3=CC=CC=C3N2CCC(=O)C4=CC=CC=C4,,,,,,
1956,71957,Alafosfalin,C[C@@H](C(=O)N[C@@H](C)P(=O)(O)O)N,,,,,,
1957,71958,Butoprozine Hydrochloride,CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C2=C(C=C3N2C=CC=C3)CC.Cl,,,,,,
1958,71959,Butoprozine,CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C2=C(C=C3N2C=CC=C3)CC,,,,,,
1959,71960,Minaxolone,CCO[C@H]1C[C@]2([C@@H](CC[C@@H]3[C@@H]2[C@@H](C[C@]4([C@H]3CC[C@@H]4C(=O)C)C)N(C)C)C[C@@H]1O)C,,,"['Agents capable of inducing a total or partial loss of sensation, especially tactile sensation and pain. They may act to induce general ANESTHESIA, in which an unconscious state is achieved, or may act locally to induce numbness or lack of sensation at a targeted site. (See all compounds classified as Anesthetics.)', 'Endogenous compounds or drugs that affect neuronal excitability through modulation of specific ionotropic receptors (e.g., GABA-A RECEPTORS). Endogenous neurosteroids are steroid hormones de novo synthesized by neurons and glial cells from steroid metabolite precursors (e.g., PREGNENOLONE). (See all compounds classified as Neurosteroids.)']",,,
1960,71961,Aspoxicillin,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)NC(=O)[C@@H](CC(=O)NC)N)C(=O)O)C,,,,,,
1961,71962,"[(1R,5R)-8-(2-fluoroethyl)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 2-hydroxy-2,2-diphenylacetate;bromide",C[N+]1([C@@H]2CC[C@@H]1CC(C2)OC(=O)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCF.[Br-],,,,,,
1962,71963,"[(1R,5R)-8-(2-fluoroethyl)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 2-hydroxy-2,2-diphenylacetate",C[N+]1([C@@H]2CC[C@@H]1CC(C2)OC(=O)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCF,,,,,,
1963,71964,Ioglucomide,CNC(=O)C1=C(C(=C(C(=C1I)NC(=O)[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)I)NC(=O)[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)I,,,,,,
1964,71965,CID 71965,C[C@H]1C=CC2(C[C@@H]3C[C@H](O2)CC=C(C([C@H](C=CC=C4CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)C)O[C@@H]1C(C)C,,,,,,
1965,71966,Lofemizole hydrochloride,CC1=C(N=CN1)C2=CC=C(C=C2)Cl.Cl,,,,,,
1966,71967,Lofemizole,CC1=C(N=CN1)C2=CC=C(C=C2)Cl,,,,,,
1967,71968,Avizafone,CN(C1=C(C=C(C=C1)Cl)C(=O)C2=CC=CC=C2)C(=O)CNC(=O)[C@H](CCCCN)N,,,,,,
1968,71969,Romifidine,C1CN=C(N1)NC2=C(C=CC=C2Br)F,,,"['Agents capable of inducing a total or partial loss of sensation, especially tactile sensation and pain. They may act to induce general ANESTHESIA, in which an unconscious state is achieved, or may act locally to induce numbness or lack of sensation at a targeted site. (See all compounds classified as Anesthetics.)', 'Compounds that bind to and activate ADRENERGIC ALPHA-2 RECEPTORS. (See all compounds classified as Adrenergic alpha-2 Receptor Agonists.)']",,,
1969,71970,Carocainide,CNC(=O)NC1=C(C2=C(C(=C1OCCN3CCCC3)OC)OC=C2)OC,,,,,,
1970,71971,Ifoxetine,CC1=C(C(=CC=C1)O[C@H]2CCNC[C@H]2O)C,,,,,,
1971,71972,N-(3-morpholin-4-yloxadiazol-3-ium-5-yl)cyclohexanecarboximidate,C1CCC(CC1)C(=NC2=C[N+](=NO2)N3CCOCC3)[O-],,,,,,
1972,71973,"5-[(Cyclohexanecarbonyl)amino]-3-(morpholin-4-yl)-1,2,3-oxadiazol-3-ium",C1CCC(CC1)C(=O)NC2=C[N+](=NO2)N3CCOCC3,,,,,,
1973,71974,CID 71974,C[C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)OC2=CC=C(C=C2)C=CC(=O)NCCCNCCCCNC(C)C)N=C(N)N)O)NC(=O)N[C@@H]3[C@@H]([C@H]([C@@H](CO3)O[C@H]4[C@@H]([C@@H]5[C@@H](CO4)OC(=O)N5)NC(=O)N)O)NC(=O)N.Cl,,,,,,
1974,71975,CID 71975,C[C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)OC2=CC=C(C=C2)C=CC(=O)NCCCNCCCCNC(C)C)N=C(N)N)O)NC(=O)N[C@@H]3[C@@H]([C@H]([C@@H](CO3)O[C@H]4[C@@H]([C@@H]5[C@@H](CO4)OC(=O)N5)NC(=O)N)O)NC(=O)N,,,,,,
1975,71976,Palmoxiric acid,CCCCCCCCCCCCCCC1(CO1)C(=O)O,,,['Substances which lower blood glucose levels. (See all compounds classified as Hypoglycemic Agents.)'],,,
1976,71977,CID 71977,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)NC(=O)C4=CC=C(NC4=O)C5=CC=C(C=C5)S(=O)(=O)N(CCO)CCO)C(=O)[O-])C.[Na+],,,,,,
1977,71978,Piridicillin,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)NC(=O)C4=CC=C(NC4=O)C5=CC=C(C=C5)S(=O)(=O)N(CCO)CCO)C(=O)O)C,,,,,,
1978,71979,"3-Pyridinemethanamine, alpha-1,3-dioxan-5-yl-N,N-dimethyl-, monohydrochloride, (-)-",CN(C)C(C1COCOC1)C2=CN=CC=C2.Cl,,,,,,
1979,71980,"1-(1,3-dioxan-5-yl)-N,N-dimethyl-1-(pyridin-3-yl)methanamine",CN(C)C(C1COCOC1)C2=CN=CC=C2,,,,,,
1980,71981,Oxoprostol,C1CC(=O)[C@@H]([C@H]1CCC(=O)COC2=CC=CC=C2)CCCCCCCO,,,,,,
1981,71982,CID 71982,C[C@H]1CC[C@]2(C[C@@H]3C[C@H](O2)CC=C([C@H]([C@H](C=CC=C4CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@H]([C@H]([C@@H](O7)C)O)OC)OC)C)O[C@@H]1C(C)C,,,,,,
1982,71983,Carbazeran,CCNC(=O)OC1CCN(CC1)C2=NN=CC3=CC(=C(C=C32)OC)OC,,,,,,
1983,71984,Iotasul,CN(CC(CO)O)C(=O)C1=C(C(=C(C(=C1I)NC(=O)CCSCCC(=O)NC2=C(C(=C(C(=C2I)C(=O)N(C)CC(CO)O)I)C(=O)N(C)CC(CO)O)I)I)C(=O)N(C)CC(CO)O)I,,,,,,
1984,71985,Clemeprol,CN(C)CC(C(C1=CC=CC=C1)C2=CC=C(C=C2)Cl)O,,,,,,
1985,71986,Indorenate Hydrochloride,COC1=CC2=C(C=C1)NC=C2C(CN)C(=O)OC.Cl,,,"['Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)', 'Endogenous compounds and drugs that bind to and activate SEROTONIN RECEPTORS. Many serotonin receptor agonists are used as ANTIDEPRESSANTS; ANXIOLYTICS; and in the treatment of MIGRAINE DISORDERS. (See all compounds classified as Serotonin Receptor Agonists.)']",,,
1986,71987,Indorenate,COC1=CC2=C(C=C1)NC=C2C(CN)C(=O)OC,,,"['Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)', 'Endogenous compounds and drugs that bind to and activate SEROTONIN RECEPTORS. Many serotonin receptor agonists are used as ANTIDEPRESSANTS; ANXIOLYTICS; and in the treatment of MIGRAINE DISORDERS. (See all compounds classified as Serotonin Receptor Agonists.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)']",,,
1987,71988,Lamtidine,CN1C(=NC(=N1)N)NCCCOC2=CC=CC(=C2)CN3CCCCC3,,,,,,
1988,71989,CID 71989,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3CC2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C=CC6=CC(=C(C=C6)O)OC,,,,,,
1989,71990,"[(2S,3S,4R,6S)-6-[(2R,3S,4R,5R,6S)-6-[[(4R,5S,6S,7R,9R,10R,16R)-4,10-dihydroxy-5-methoxy-9,16-dimethyl-2-oxo-7-(2-oxoethyl)-1-oxacyclohexadeca-11,13-dien-6-yl]oxy]-4-(dimethylamino)-5-hydroxy-2-methyloxan-3-yl]oxy-2,4-dimethyl-4-propanoyloxyoxan-3-yl] butanoate",CCCC(=O)O[C@H]1[C@@H](O[C@H](C[C@@]1(C)OC(=O)CC)O[C@@H]2[C@H](O[C@H]([C@@H]([C@H]2N(C)C)O)O[C@H]3[C@H](C[C@H]([C@H](C=CC=CC[C@H](OC(=O)C[C@H]([C@@H]3OC)O)C)O)C)CC=O)C)C,,,,,,
1990,71991,Tebuquine,CC(C)(C)NCC1=C(C(=CC(=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)C4=CC=C(C=C4)Cl)O,,,,,,
1991,71992,Alacepril,C[C@H](CSC(=O)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)O,,,"['Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. (See all compounds classified as Angiotensin-Converting Enzyme Inhibitors.)']",,,
1992,71993,Spiroplatin,C1CCC(CC1)(C[NH-])C[NH-].OS(=O)(=O)O.[Pt+2],,,['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)'],,,
1993,71994,[1-(Aminomethyl)cyclohexyl]methanamine,C1CCC(CC1)(CN)CN,,,,,,
1994,71995,Moxadolen,CNC(=O)O[C@H]1[C@@H]2[C@@H]3C[C@H]([C@@H]2C(=O)O1)C=C3,,,,,,
1995,71996,"(9S,10S,13S,14S)-13-methyl-10-prop-2-ynyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-3,17-dione",C[C@]12CC[C@H]3C([C@@H]1CCC2=O)CCC4=CC(=O)CC[C@]34CC#C,,,,,,
1996,71997,"Methyl 7-chloro-6,7,8-trideoxy-6-{[(4-ethylpiperidin-2-yl)(hydroxy)methylidene]amino}-1-thiooctopyranoside--hydrogen chloride--water (1/1/1)",CC[C@@H]1CCN[C@@H](C1)C(=O)NC([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)C(C)Cl.O.Cl,,,,,,
1997,71998,CID 71998,CC[C@@H]1CCN[C@@H](C1)C(=O)NC([C@@H]2C([C@@H]([C@H]([C@H](O2)SC)O)O)O)C(C)Cl,,,,,,
1998,71999,Proterguride,CCCN1C[C@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)NC(=O)N(CC)CC,,,,,,
1999,72000,"(2S,5R,6R)-6-[[(2S)-2-(furan-2-ylmethylideneamino)-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid",CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@H](C3=CC=C(C=C3)O)N=CC4=CC=CO4)C(=O)O)C,,,,,,
2000,72001,Mioflazine,C1CN(C(CN1CC(=O)NC2=C(C=CC=C2Cl)Cl)C(=O)N)CCCC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,,,"['Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume. (See all compounds classified as Cardiovascular Agents.)']",,,
2001,72002,Panuramine,C1CN(CCC1NC(=O)NC(=O)C2=CC=CC=C2)CC3=CC4=CC=CC=C4C=C3,,,,,,
2002,72003,Ipsalazide,C1=CC(=CC=C1C(=O)NCC(=O)O)N=NC2=CC(=C(C=C2)O)C(=O)O,,,,,,
2003,72004,Emiglitate,CCOC(=O)C1=CC=C(C=C1)OCCN2C[C@@H]([C@H]([C@@H]([C@H]2CO)O)O)O,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
2004,72005,Metrenperone,CC1=CN2C(=NC(=C(C2=O)CCN3CCC(CC3)C(=O)C4=CC=C(C=C4)F)C)C=C1,,,,,,
2005,72006,Nipradilol,CC(C)NCC(COC1=CC=CC2=C1OCC(C2)O[N+](=O)[O-])O,,,"['Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. (See all compounds classified as Adrenergic alpha-Antagonists.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)', 'Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. (See all compounds classified as Adrenergic beta-Antagonists.)']",,,
2006,72007,Carbetimer,CC(C1C(C(=O)NC1=O)CCC(C(CCC(CC(=O)[O-])C(=O)N)C(=O)[O-])C(=O)N)C2=CC=CC=C2.[NH4+].[NH4+],,,"['Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund&apos;s adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)', 'Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)']",,,
2007,72008,"2-{1-Amino-4-[2,5-dioxo-4-(1-phenylethyl)pyrrolidin-3-yl]-1-oxobutan-2-yl}-5-carbamoylheptanedioic acid",CC(C1C(C(=O)NC1=O)CCC(C(CCC(CC(=O)O)C(=O)N)C(=O)O)C(=O)N)C2=CC=CC=C2,,,,,,
2008,72009,Dembrexine,C1CC(CCC1NCC2=C(C(=CC(=C2)Br)Br)O)O,,,,,,
2009,72010,3-{[Cyclopentyl(phenyl)acetyl]oxy}-8-methyl-8-(propan-2-yl)-8-azabicyclo[3.2.1]octan-8-ium bromide,CC(C)[N+]1([C@@H]2CC[C@@H]1CC(C2)OC(=O)C(C3CCCC3)C4=CC=CC=C4)C.[Br-],,,,,,
2010,72011,"[(1R,5R)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 2-cyclopentyl-2-phenylacetate",CC(C)[N+]1([C@@H]2CC[C@@H]1CC(C2)OC(=O)C(C3CCCC3)C4=CC=CC=C4)C,,,,,,
2011,72012,Beperidium Iodide,CC[N+]1(CCC(CC1)OC(=O)C(C2=NOC3=CC=CC=C32)N4CCCCCC4)C.[I-],,,,,,
2012,72013,"4-{[(Azepan-1-yl)(1,2-benzoxazol-3-yl)acetyl]oxy}-1-ethyl-1-methylpiperidin-1-ium",CC[N+]1(CCC(CC1)OC(=O)C(C2=NOC3=CC=CC=C32)N4CCCCCC4)C,,,,,,
2013,72014,Epanolol,C1=CC=C(C(=C1)C#N)OCC(CNCCNC(=O)CC2=CC=C(C=C2)O)O,,,"['Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. (See all compounds classified as Adrenergic beta-Antagonists.)', 'Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters. (See all compounds classified as Sympathomimetics.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)']",,,
2014,72015,Panipenem,C[C@H]([C@@H]1[C@H]2CC(=C(N2C1=O)C(=O)O)S[C@H]3CCN(C3)C(=N)C)O,,,,,,
2015,72016,Efaroxan,CCC1(CC2=CC=CC=C2O1)C3=NCCN3,,,"['Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. (See all compounds classified as Adrenergic alpha-Antagonists.)']",,,
2016,72017,(4S)-3-[(2R)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-1-methyl-2-oxoimidazolidine-4-carboxylic acid,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H](C)C(=O)N2[C@@H](CN(C2=O)C)C(=O)O,,,,,,
2017,72018,(4S)-3-[(2R)-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]propanoyl]-1-methyl-2-oxoimidazolidine-4-carboxylic acid,C[C@H](C(=O)N1[C@@H](CN(C1=O)C)C(=O)O)N[C@@H](CCC2=CC=CC=C2)C(=O)O,,,,,,
2018,72019,Luxabendazole,COC(=O)NC1=NC2=C(N1)C=C(C=C2)OS(=O)(=O)C3=CC=C(C=C3)F,,,,,,
2019,72020,CID 72020,CN=C([C@@]1(CCCCS1=O)C2=CN=CC=C2)S,,,,,,
2020,72021,CID 72021,CN=C([C@@]1(CCCC[S+]1O)C2=CN=CC=C2)S,,,,,,
2021,72022,Perindoprilat,CCC[C@@H](C(=O)O)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O,,,"['A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. (See all compounds classified as Angiotensin-Converting Enzyme Inhibitors.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)']",,,
2022,72023,"2-[2-[(3aS,4S,5R,6aS)-5-hydroxy-4-[(3S,4S)-3-hydroxy-4-methylnona-1,6-diynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]ethoxy]acetic acid",CCC#CC[C@H](C)[C@@H](C#C[C@H]1[C@@H](C[C@H]2[C@@H]1CC(=CCOCC(=O)O)C2)O)O,,,,,,
2023,72024,Revospirone,C1CN(CCN1CCCN2C(=O)C3=CC=CC=C3S2(=O)=O)C4=NC=CC=N4,,,,,,
2024,72025,Fomidacillin,CCN1CCN(C(=O)C1=O)C(=O)N[C@H](C2=CC(=C(C=C2)O)O)C(=O)N[C@]3([C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O)NC=O,,,,,,
2025,72026,Epsiprantel,C1CCC(CC1)C(=O)N2CC3C4=CC=CC=C4CCCN3C(=O)C2,,,,,,
2026,72027,Levemopamil,CC(C)[C@](CCCN(C)CCC1=CC=CC=C1)(C#N)C2=CC=CC=C2,,,['A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)'],,,
2027,72028,Mequitamium Iodide,C[N+]12CCC(CC1)C(C2)CN3C4=CC=CC=C4SC5=CC=CC=C53.[I-],,,,,,
2028,72029,Mequitamium,C[N+]12CCC(CC1)C(C2)CN3C4=CC=CC=C4SC5=CC=CC=C53,,,,,,
2029,72030,CID 72030,C[C@H]1[C@]([C@@H](CC(O1)O[C@@H]2[C@@H]([C@@H](O[C@H]([C@@H]2OC(=O)C(C(C)SC[C@@H](C(=O)O)NC(=O)C)N=C(S)SC[C@@H](C(=O)O)NC(=O)C)COC(=O)C)[C@@]3(CC(=O)C(=C(C3=O)C(=O)O)N)O)O)OC)([C@H](C)OC(=O)C(C)C)O,,,,,,
2030,72031,Miboplatin,C1C[C@@H](NC1)CN.C1CC(C1)(C(=O)[O-])C(=O)[O-].[Pt+2],,,['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)'],,,
2031,72032,Pyrrolidin-2-ylmethanamine,C1CC(NC1)CN,,,,,,
2032,72033,Asobamast,CCOCCOC(=O)C(=O)NC1=NC(=CS1)C2=CC(=NO2)C,,,,,,
2033,72034,Datelliptium Chloride,CCN(CC)CC[N+]1=CC2=C(C3=C(C(=C2C=C1)C)NC4=C3C=C(C=C4)O)C.[Cl-],,,,,,
2034,72035,Datelliptium,CCN(CC)CC[N+]1=CC2=C(C3=C(C(=C2C=C1)C)NC4=C3C=C(C=C4)O)C,,,,,,
2035,72036,Fluparoxan,C1[C@H]2[C@H](CN1)OC3=C(O2)C=CC=C3F,,,,,,
2036,72037,Carvotroline Hydrochloride,C1CN(CC2=C1NC3=C2C=C(C=C3)F)CCC4=CC=NC=C4.Cl,,,,,,
2037,72038,Carvotroline,C1CN(CC2=C1NC3=C2C=C(C=C3)F)CCC4=CC=NC=C4,,,,,,
2038,72039,"Diethyl 2-[(dimethylamino)methyl]-6-methyl-4-[2-[3-[(2-methylpropan-2-yl)oxy]-3-oxoprop-1-enyl]phenyl]-1,4-dihydropyridine-3,5-dicarboxylate;hydrochloride",CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2C=CC(=O)OC(C)(C)C)C(=O)OCC)CN(C)C)C.Cl,,,,,,
2039,72040,"Diethyl 2-[(dimethylamino)methyl]-6-methyl-4-[2-[3-[(2-methylpropan-2-yl)oxy]-3-oxoprop-1-enyl]phenyl]-1,4-dihydropyridine-3,5-dicarboxylate",CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2C=CC(=O)OC(C)(C)C)C(=O)OCC)CN(C)C)C,,,,,,
2040,72041,Acemannan,CC(=O)N[C@H]1[C@H]([C@@H]([C@H](O[C@@H]1O[C@@H]2[C@H](O[C@@H]([C@H]([C@H]2OC(=O)C)O)O[C@@H]3[C@H](O[C@@H]([C@H]([C@H]3OC(=O)C)O)O[C@@H]4[C@H](O[C@@H]([C@H]([C@H]4OC(=O)C)O)OC)CO)CO)CO)CO)O[C@@H]5[C@H]([C@H]([C@@H]([C@H](O5)CO)O[C@@H]6[C@H]([C@H]([C@@H]([C@H](O6)C(=O)[O-])O[C@@H]7[C@H]([C@H]([C@@H]([C@H](O7)CO)O[C@@H]8[C@H]([C@H]([C@@H]([C@H](O8)CO)OC)OC(=O)C)O)OC(=O)C)O)OC(=O)C)O)OC(=O)C)O)O,,,"['Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund&apos;s adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)', 'Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)', 'Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion. (See all compounds classified as Gastrointestinal Agents.)', 'Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)']",,,
2041,72042,"(2S,3S,4R,5S,6S)-6-[(2R,3R,4R,5S,6R)-6-[(2R,3S,4R,5S,6R)-5-acetamido-6-[(2R,3R,4R,5S,6R)-4-acetyloxy-6-[(2R,3R,4R,5S,6R)-4-acetyloxy-6-[(2R,3R,4R,5S,6S)-4-acetyloxy-5-hydroxy-2-(hydroxymethyl)-6-methoxyoxan-3-yl]oxy-5-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-5-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4-acetyloxy-5-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4-acetyloxy-3-[(2R,3S,4R,5R,6R)-4-acetyloxy-5-[(2R,3S,4R,5R,6R)-4-acetyloxy-3-hydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy-3-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxyoxane-2-carboxylic acid",CC(=O)N[C@H]1[C@H]([C@@H]([C@H](O[C@@H]1O[C@@H]2[C@H](O[C@@H]([C@H]([C@H]2OC(=O)C)O)O[C@@H]3[C@H](O[C@@H]([C@H]([C@H]3OC(=O)C)O)O[C@@H]4[C@H](O[C@@H]([C@H]([C@H]4OC(=O)C)O)OC)CO)CO)CO)CO)O[C@@H]5[C@H]([C@H]([C@@H]([C@H](O5)CO)O[C@@H]6[C@H]([C@H]([C@@H]([C@H](O6)C(=O)O)O[C@@H]7[C@H]([C@H]([C@@H]([C@H](O7)CO)O[C@@H]8[C@H]([C@H]([C@@H]([C@H](O8)CO)OC)OC(=O)C)O)OC(=O)C)O)OC(=O)C)O)OC(=O)C)O)O,,,"['Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund&apos;s adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)', 'Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)', 'Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)', 'Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion. (See all compounds classified as Gastrointestinal Agents.)']",,,
2042,72043,CID 72043,CC=CC=C[C@H]1C([C@H]([C@H]([C@](O1)(C(CO[C@H]2C[C@H](C([C@H](O2)C)O[C@H]3C[C@@H]([C@@H]([C@H](O3)C)O[C@@H]4C[C@H]([C@H]([C@H](O4)C)O)OC)OC)OC)C(=O)NCC=CC=C(C)C([C@@H](C)C5C[C@H]([C@H](O5)C=CC=CC=CC(=O)O)O)OC)O)OC(=O)CC6=CC=CC=C6)O)(C)C,,,,,,
2043,72044,CID 72044,CC[N+](C)(CC=CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)C(=NOCF)C3=NSC(=N3)N)SC1)C(=O)[O-])CC(=O)N,,,,,,
2044,72045,"(2-amino-2-oxoethyl)-[3-[(6R,7R)-7-[[2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(fluoromethoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]prop-2-enyl]-ethyl-methylazanium",CC[N+](C)(CC=CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)C(=NOCF)C3=NSC(=N3)N)SC1)C(=O)O)CC(=O)N,,,,,,
2045,72046,Ilatreotide,C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)[C@@H](CC5=CC=CC=C5)NC[C@@]6([C@H]([C@@H]([C@@H](CO6)O)O[C@@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)O)O)C(=O)N[C@H](CO)[C@@H](C)O)O,,,,,,
2046,72047,CID 72047,CCOC(=O)[C@H](C[S-])NCC[N-][C@@H](C[S-])C(=O)OCC.O=[99Tc+3],,,,,,
2047,72048,Bicisate,CCOC(=O)[C@H](CS)NCCN[C@@H](CS)C(=O)OCC,['Bicisate as a complex with technetium Tc-99m is used in single photon emission computerized tomography (SPECT) as an adjunct to conventional CT or MRI in the localization of stroke in patients whom the presence of a stroke has already been diagnosed. It is not indicated to assess the functional viability of brain tissue or to distinguish between a stroke and other brain lesions.  A stroke is defined as a condition in which the blood stops flowing to any part of the brain causing a damage to brain cells. The potential effect of a stroke depends on the part of the brain that was affected by it as well as the extension of the damage.'],['The neutral and lipophilic nature of bicisate provides it with high stability. This property is given by its N2S2 core. This characteristic has been proven to allow bicisate to be used even several hours after preparation and to present an easy passage through the blood-brain barrier.'],,"['After intravenous administration, bicisate presents a very large brain extraction. About 5% of the administered dose remains in the blood one hour after administration. The highest concentration of radioactivity in blood was attained 0.5 minutes after intravenous injection and it represented 13.9% of the injected dose. After intravenous administration of bicisate, the permeability surface area was 0.48 ml.g/min.', 'Bicisate is primarily excreted by the kidneys. It has been reported that 50% of the dose is excreted in urine two hours after initial administration and even 74% of the administered dose is excreted in urine after 24 hours. Fecal excretion just accounts for 12.5% of the administered dose 48 hours after initial administration.', 'After intravenous administration of bicisate, the distribution volume was 0.74 L.', 'The clearance of bicisate from 1 to 24 hours, studied as a loss of hydrophilic tracer, is of approximate 3.5% per hour.']",['Bicisate is metabolized to form mono- and di-acids by the action of esterases. The exact metabolic transformation has not been elucidated.'],"['The stability of bicisate is superior when compared to other brain radiopharmaceuticals. Thus, the reported half-life of bicisate is of 6.02 hours. When broadly studied in clinical trials, the pharmacokinetic profile fits a three-compartment model with half-lives of 43 seconds, 49.5 minutes and 533 minutes.']"
2048,72049,"Carsatrin, (S)-",C1CN(CCN1C[C@@H](CSC2=NC=NC3=C2NC=N3)O)C(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F,,,,,,
2049,72050,Basifungin,CC[C@@H](C)[C@@H]1C(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)O[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N2CCC[C@H]2C(=O)N1)CC3=CC=CC=C3)C)CC4=CC=CC=C4)C(C)C)C)[C@H](C)CC)C(C)(C)O)C)CC(C)C)C(C)C)C,,,"['Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)']",,,
2050,72051,Eberconazole,C1CC2=C(C(C3=CC=CC=C31)N4C=CN=C4)C(=CC(=C2)Cl)Cl,,,,,,
2051,72052,Sprodiamide,CNC(=O)CN(CCN(CCN(CC(=O)NC)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].[Dy+3],,,['Substances used to allow enhanced visualization of tissues. (See all compounds classified as Contrast Media.)'],,,
2052,72053,CID 72053,CCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)CO)O[C@H]3[C@@H]([C@H]([C@H]([C@H](O3)CO)O)O[C@H]4[C@@H]([C@H]([C@H]([C@H](O4)CO)O)O)O)NC(=O)C)O[C@]5(C[C@H]([C@@H]([C@H](O5)[C@@H]([C@@H](CO)O)O)NC(=O)C)O)C(=O)OC(C)C)O)O)O)[C@@H](C=CCCCCCCCCCCCCC)O,,,,,,
2053,72054,"2-(1-(2-(2,3-Dihydrobenzofuran-5-yl)ethyl)pyrrolidin-3-yl)-2,2-diphenylacetamide",C1CN(CC1C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N)CCC4=CC5=C(C=C4)OCC5,,,,,,
2054,72055,CID 72055,C[C@@H]1CCC[C@@H](N1[N+]2=NOC(=[N-])C2)C,,,,,,
2055,72056,"3-[(2R,6S)-2,6-dimethylpiperidin-1-yl]-4H-oxadiazol-3-ium-5-imine",C[C@@H]1CCC[C@@H](N1[N+]2=NOC(=N)C2)C,,,,,,
2056,72057,"Gadolinium,[10-[2,3-dihydroxy-1-(hydroxymethyl)propyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3-)-kN1,kN4,kN7,kN10,kO1,kO4,kO7]-",C1CN(CCN(CCN(CCN1CC(=O)[O-])CC(=O)[O-])[C@H](CO)[C@@H](CO)O)CC(=O)[O-].[Ga+3],,,,,,
2057,72058,Butrol,C1CN(CCN(CCN(CCN1CC(=O)O)CC(=O)O)[C@H](CO)[C@@H](CO)O)CC(=O)O,,,,,,
2058,72059,Fenleuton,CC(C#CC1=CC(=CC=C1)OC2=CC=C(C=C2)F)N(C(=O)N)O,,,,,,
2059,72060,Pheneturide,CCC(C1=CC=CC=C1)C(=O)NC(=O)N,,,['Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)'],,,
2060,72061,Oxymesterone,C[C@]12CCC(=O)C(=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(C)O)C)O,,,,,,
2061,72062,Anthiolimine,[Li+].[Li+].[Li+].[Li+].[Li+].[Li+].C(C(C(=O)[O-])S[Sb](SC(CC(=O)[O-])C(=O)[O-])SC(CC(=O)[O-])C(=O)[O-])C(=O)[O-],,,,,,
2062,72063,Bietamiverine hydrochloride,CCN(CC)CCOC(=O)C(C1=CC=CC=C1)N2CCCCC2.Cl,,,,,,
2063,72064,Bietamiverine,CCN(CC)CCOC(=O)C(C1=CC=CC=C1)N2CCCCC2,,,,,,
2064,72065,Cyclobutyrol,CCC(C(=O)O)C1(CCCCC1)O,,,,,,
2065,72066,"(6S,9R,13R,16S)-N,N,6,7,13-pentamethyl-7-azapentacyclo[10.8.0.02,9.05,9.013,18]icos-18-en-16-amine",C[C@H]1C2CCC3[C@@]2(CCC4C3CC=C5[C@@]4(CC[C@@H](C5)N(C)C)C)CN1C,,,,,,
2066,72067,Coltramyl,CC(=O)NC1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)SC)OC)OC)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O,,,,,,
2067,72068,"2,6-Bis(thiophen-2-ylmethylidene)cyclohexan-1-one",C1CC(=CC2=CC=CS2)C(=O)C(=CC3=CC=CS3)C1,,,,,,
2068,72069,Quintiofos,CCOP(=S)(C1=CC=CC=C1)OC2=CC=CC3=C2N=CC=C3,,,,,,
2069,72070,Bemetizide,CC(C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl)C3=CC=CC=C3,,,,,,
2070,72071,Dipiproverine hydrochloride,C1CCN(CC1)CCOC(=O)C(C2=CC=CC=C2)N3CCCCC3.Cl.Cl,,,,,,
2071,72072,Dipiproverine,C1CCN(CC1)CCOC(=O)C(C2=CC=CC=C2)N3CCCCC3,,,,,,
2072,72073,Quindoxin,C1=CC=C2C(=C1)N(C=C[N+]2=O)[O-],,,,,,
2073,72074,Amicarbalide,C1=CC(=CC(=C1)NC(=O)NC2=CC=CC(=C2)C(=N)N)C(=N)N,,,,,,
2074,72075,Bamipine,CN1CCC(CC1)N(CC2=CC=CC=C2)C3=CC=CC=C3,,,"['Drugs that bind to but do not activate histamine receptors, thereby blocking the actions of histamine or histamine agonists. Classical antihistaminics block the histamine H1 receptors only. (See all compounds classified as Histamine Antagonists.)']",,,
2075,72076,Cyclarbamate,C1CCC(C1)(COC(=O)NC2=CC=CC=C2)COC(=O)NC3=CC=CC=C3,,,,,,
2076,72077,Prednazoline,CC(C)C1=CC=CC=C1OCC2=NCCN2.C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)COP(=O)(O)O)O)CCC4=CC(=O)C=C[C@]34C)O,,,,,,
2077,72078,Prednisolone phosphate,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)COP(=O)(O)O)O)CCC4=CC(=O)C=C[C@]34C)O,"['Prednisolone phosphate is indication to a number of conditions including treat allergic states, dermatologic diseases, edematous states, endocrine disorders, gastrointestinal diseases, hematologic disorders, neoplastic diseases, nervous system, ophthalmic diseases, respiratory diseases, rheumatic disorders.']","['Corticosteroids bind to the glucocorticoid receptor, inhibiting pro-inflammatory signals, and promoting anti-inflammatory signals. Prednisolone has a short duration of action as the half life is 2-4 hours. Corticosteroids have a wide therapeutic window as patients make require doses that are multiples of what the body naturally produces. Patients taking corticosteroids should be counselled regarding the risk of hypothalamic-pituitary-adrenal axis suppression and increased susceptibility to infections.']","['A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. (See all compounds classified as Glucocorticoids.)']","['A 30mg prednisolone oral solution reaches a C<sub>max</sub> of 461.33±77.94ng/mL with an AUC of 2426.1±360.0ng\\*h/mL. A 30mg prednisolone orally disintegrating tablet reaches a C<sub>max</sub> of 420.91±78.28ng/mL with an AUC of 2408.1±361.5ng\\*h/mL.', 'Prednisolone is predominantly eliminated in the urine as sulfate and glucuronide conjugate metabolites.', 'The volume of distribution of prednisolone phosphate has been reported as 0.22-0.7L/kg.']","['Prednisolone phosphate undergoes ester hydrolysis to [prednisolone]. After this step, the drug undergoes the normal metabolism of prednisolone.']",['The half life of prednisolone is 2-4 hours.']
2078,72079,Etisazole,CCNC1=NSC2=CC=CC=C21,,,,,,
2079,72080,Panidazole,CC1=NC=C(N1CCC2=CC=NC=C2)[N+](=O)[O-],,,,,,
2080,72081,Terlipressin,C1C[C@H](N(C1)C(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N,['Commonly used to stop bleeding of varices in the food pipe (oesophagus).'],"['Terlipressin is a medicine similar to a naturally occurring hormone present in the body, known as antidiuretic hormone (ADH) or vasopressin. ADH has two main effects in the body. Firstly, it causes narrowing of blood vessels (vasoconstriction), thereby limiting blood flow to a particular area of the body. It also acts on receptors in the kidney to retain water in the body, which helps to prevent excessive loss of water in the urine.']","['Drugs used to cause constriction of the blood vessels. (See all compounds classified as Vasoconstrictor Agents.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)']",,,
2081,72082,Cyclopyrronium Bromide,CC[N+]1(CCC(C1)OC(=O)C(C2CCCC2)C3=CC=CC=C3)C.[Br-],,,,,,
2082,72083,Cyclopyrronium,CC[N+]1(CCC(C1)OC(=O)C(C2CCCC2)C3=CC=CC=C3)C,,,,,,
2083,72084,CID 72084,CCCCNC(C)(C)P(=O)O,,,,,,
2084,72085,(-)-Diacetone-2-keto-L-gulonic acid monohydrate,CC1(OCC2C(O1)C3C(O2)(OC(O3)(C)C)C(=O)O)C,,,,,,
2085,72086,"3-(hydroxymethyl)-1-[(E)-3-(5-nitrofuran-2-yl)prop-2-enylideneamino]imidazolidine-2,4-dione",C1C(=O)N(C(=O)N1/N=C/C=CC2=CC=C(O2)[N+](=O)[O-])CO,,,,,,
2086,72087,Bufeniode,CC(CCC1=CC=CC=C1)NC(C)C(C2=CC(=C(C(=C2)I)O)I)O,,,,,,
2087,72088,Feprosidnine,CC(CC1=CC=CC=C1)[N+]2=CC(=N)O[N-]2,,,,,,
2088,72089,"5-Imino-3-(1-phenylpropan-2-yl)-2,5-dihydro-1,2,3-oxadiazol-3-ium",CC(CC1=CC=CC=C1)[N+]2=NOC(=C2)N,,,,,,
2089,72090,"14-(2-Hydroxypentan-2-yl)-7-methoxy-3-(prop-2-en-1-yl)-1,2,3,4,7,7a-hexahydro-4a,7-ethano-4,12-methano[1]benzofuro[3,2-e]isoquinolin-9-ol",CCC[C@](C)(C1CC23C=CC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O)O4)CC=C)OC)O,,,,,,
2090,72091,Moxipraquine,CC(CCN1CCN(CC1)CCCCCCNC2=C3C(=CC(=C2)OC)C=CC=N3)O,,,,,,
2091,72092,Otilonium Bromide,CCCCCCCCOC1=CC=CC=C1C(=O)NC2=CC=C(C=C2)C(=O)OCC[N+](C)(CC)CC.[Br-],,,"['A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)', 'Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion. (See all compounds classified as Gastrointestinal Agents.)', 'Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. (See all compounds classified as Muscarinic Antagonists.)', 'Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)']",,,
2092,72093,Otilonium,CCCCCCCCOC1=CC=CC=C1C(=O)NC2=CC=C(C=C2)C(=O)OCC[N+](C)(CC)CC,,,"['Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. (See all compounds classified as Muscarinic Antagonists.)', 'Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion. (See all compounds classified as Gastrointestinal Agents.)', 'A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)', 'Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)']",,,
2093,72094,Suclofenide,C1C(C(=O)N(C1=O)C2=C(C=C(C=C2)S(=O)(=O)N)Cl)C3=CC=CC=C3,,,,,,
2094,72095,Parsalmide,CCCCNC(=O)C1=C(C=CC(=C1)N)OCC#C,,,,,,
2095,72096,Pendecamaine,CCCCCCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC(=O)[O-],,,,,,
2096,72097,3-(Hexadecanoylamino)propyl(carboxymethyl)dimethylammonium,CCCCCCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC(=O)O,,,,,,
2097,72098,Fenoverine,C1CN(CCN1CC2=CC3=C(C=C2)OCO3)CC(=O)N4C5=CC=CC=C5SC6=CC=CC=C64,,,['Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)'],,,
2098,72099,Esflurbiprofen,C[C@@H](C1=CC(=C(C=C1)C2=CC=CC=C2)F)C(=O)O,,,,,['(s)-flurbiprofen has known human metabolites that include 4-hydroxy-S-flurbiprofen.'],
2099,72100,CID 72100,CC1=CC=CC=C1OCCCCN2C(CCC2(C)C)(C)C,,,,,,
2100,72101,Dofamium Chloride,CCCCCCCCCCCC(=O)N(C)CC[N+](C)(C)CC(=O)NC1=CC=CC=C1.[Cl-],,,,,,
2101,72102,Dofamium,CCCCCCCCCCCC(=O)N(C)CC[N+](C)(C)CC(=O)NC1=CC=CC=C1,,,,,,
2102,72103,Bufrolin,CCCCC1=CC2=C(C3=C1NC(=CC3=O)C(=O)O)NC(=CC2=O)C(=O)O,,,,,,
2103,72104,Premazepam,CC1=C2C(=CN1C)NC(=O)CN=C2C3=CC=CC=C3,,,,,,
2104,72105,4-[2-(1-Methyl-5-nitro-1H-imidazol-2-yl)ethenyl]pyrimidin-2-amine,CN1C(=CN=C1C=CC2=NC(=NC=C2)N)[N+](=O)[O-],,,,,,
2105,72106,Morniflumate,C1COCCN1CCOC(=O)C2=C(N=CC=C2)NC3=CC=CC(=C3)C(F)(F)F,"['Morniflumate is indicated for the treatment of inflammatory conditions affecting the airways, ENT system, urogenital tract and bone and joint systems in adults. In Italy, morniflumate is also indicated for the treatment of pain associated with ear, nose, throat (ENT) and gastrointestinal inflammatory conditions in children.  Morniflumate is a well established NSAID that has been in use for over three decades in Italy (particularly for the treatment of upper respiratory tract infections in children), France, Belgium, Austria, Switzerland, Spain and Portugal; it has a generally favorable tolerability profile.']","['Morniflumate, given at therapeutic dosages to healthy human volunteers, on leukotriene B4 (LTB4) and thromboxane (TXB2) synthesis, both in purified PMNs (polymorphnuclear neutrophils)  and in whole blood.  In whole blood experiments, morniflumate reduced blood leukotriene B4 (LTB4) synthesis induced by Ca-ionophore A23187 Bx approximately 50%, both after a single dose and at steady state; the level of inhibition showed a pattern similar to the plasma levels of the bioactive metabolite of morniflumate (M1). The inhibition of serum thromboxane B2 (TXB2) levels was higher than 85%. Hence, morniflumate is demonstrated to reduce arachidonic acid metabolism, by exerting its effects on cyclooxygenase and 5-lipoxygenase. This characteristic might provide a better approach for anti-inflammatory therapy.  In several animal models orally administered morniflumate, the beta-morpholinoethyl ester of niflumic acid, proved almost equal to the parent compound in anti-inflammatory, analgesic and antipyretic activity with the absence of gastric irritating/ulcerogenic effects of its acidic parent compound.']",,"['0.12 L /kg on average', '45 ml/min']","['The pharmacokinetic availability of niflumic acid in two different pharmaceutical preparations have been studied in 12 subjects after oral administration.   Bioavailability and pharmacokinetics studies after oral and intravenous (IV) administration demonstrate that morniflumate is absorbed as from the gastrointestinal tract, followed by rapid hydrolysis in the plasma, releasing the free acidic form, the molecule responsible for its anti-inflammatory effects. The ester displays gastroprotective effect against the ulcerogenic effects of niflumic acid.']",['2h']
2106,72107,CID 72107,CC(=O)NC1=CC=C(C=C1)C(=O)C(CCSC)NC(=O)C,,,,,,
2107,72108,Icotidine,CC1=NC=C(C=C1)CC2=CN=C(NC2=O)NCCCCC3=C(C=CC=N3)OC,,,,,,
2108,72109,CID 72109,COC(=O)CCCC=CC[C@H]1[C@H](C[C@H](C1C#C[C@H](CCC2CCCCC2)O)O)O,,,,,,
2109,72110,Manozodil,CC1=NC2=C(S1)CCC(C2)CNC,,,,,,
2110,72111,Rifaximin (Xifaxan),C[C@H]1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)O[C@@](C4=O)(OC=C[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,,,"['Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion. (See all compounds classified as Gastrointestinal Agents.)', 'Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)']",,,
2111,72112,CID 72112,CON=C(C1=CSC(=N1)N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4=CC=CC5=C4CCCC5)C(=O)[O-].OS(=O)(=O)O,,,,,,
2112,72113,"(7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-3-(5,6,7,8-tetrahydroquinolin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid",CON=C(C1=CSC(=N1)N)C(=O)N[C@H]2C3N(C2=O)C(=C(CS3)C[N+]4=CC=CC5=C4CCCC5)C(=O)O,,,,,,
2113,72114,Dibrospidium Chloride,C1C[N+]2(CCN1C(=O)CCBr)CC[N+]3(CCN(CC3)C(=O)CCBr)CC2.[Cl-].[Cl-],,,,,,
2114,72115,Dibrospidium,C1C[N+]2(CCN1C(=O)CCBr)CC[N+]3(CCN(CC3)C(=O)CCBr)CC2,,,,,,
2115,72116,Losoxantrone,C1=CC2=C(C(=C1)O)C(=O)C3=C(C=CC4=C3C2=NN4CCNCCO)NCCNCCO,,,['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)'],,,
2116,72117,"4-chloro-3-sulfamoyl-N-(2,4,6-trimethylpyridin-1-ium-1-yl)benzenecarboximidate",CC1=CC(=[N+](C(=C1)C)N=C(C2=CC(=C(C=C2)Cl)S(=O)(=O)N)[O-])C,,,,,,
2117,72118,"1-[(4-Chloro-5-aminosulfonylbenzoyl)amino]-2,4,6-trimethylpyridinium",CC1=CC(=[N+](C(=C1)C)NC(=O)C2=CC(=C(C=C2)Cl)S(=O)(=O)N)C,,,,,,
2118,72119,Bazinaprine,C1COCCN1CCNC2=NN=C(C=C2C#N)C3=CC=CC=C3,,,,,,
2119,72120,Nedaplatin,C(C(=O)O)O.[NH2-].[NH2-].[Pt+2],,,['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)'],,,
2120,72121,"5-{[8-(Ethylamino)-7-methylquinolin-5-yl]methyl}pyrimidine-2,4-diamine",CCNC1=C2C(=C(C=C1C)CC3=CN=C(N=C3N)N)C=CC=N2,,,,,,
2121,72122,Belfosdil,CCCCOP(=O)(CC(CCOC1=CC=CC=C1)CP(=O)(OCCCC)OCCCC)OCCCC,,,,,,
2122,72123,H-D-Met(O2)-Glu-D-His-Phe-D-Lys-Phe-NHOctNH2,CS(=O)(=O)CC[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](CC1=CN=CN1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@H](CCCCN)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)NCCCCCCCCN)N,,,,,,
2123,72124,Siguazodan,CC1CC(=O)NN=C1C2=CC=C(C=C2)NC(=NC)NC#N,,,"['Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)', 'Compounds which inhibit or antagonize the biosynthesis or actions of phosphodiesterases. (See all compounds classified as Phosphodiesterase Inhibitors.)']",,,
2124,72125,Aprosulate Sodium,C(CNC(=O)[C@@H]([C@H]([C@@H]([C@@H](COS(=O)(=O)[O-])OS(=O)(=O)[O-])O[C@H]1[C@@H]([C@H]([C@H]([C@H](O1)COS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])CNC(=O)[C@@H]([C@H]([C@@H]([C@@H](COS(=O)(=O)[O-])OS(=O)(=O)[O-])O[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)COS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+],,,"['Agents that prevent BLOOD CLOTTING. (See all compounds classified as Anticoagulants.)', 'Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. (See all compounds classified as Fibrinolytic Agents.)']",,,
2125,72126,Aprosulate,C(CNC(=O)[C@@H]([C@H]([C@@H]([C@@H](COS(=O)(=O)O)OS(=O)(=O)O)O[C@H]1[C@@H]([C@H]([C@H]([C@H](O1)COS(=O)(=O)O)OS(=O)(=O)O)OS(=O)(=O)O)OS(=O)(=O)O)OS(=O)(=O)O)OS(=O)(=O)O)CNC(=O)[C@@H]([C@H]([C@@H]([C@@H](COS(=O)(=O)O)OS(=O)(=O)O)O[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)COS(=O)(=O)O)OS(=O)(=O)O)OS(=O)(=O)O)OS(=O)(=O)O)OS(=O)(=O)O)OS(=O)(=O)O,,,"['Agents that prevent BLOOD CLOTTING. (See all compounds classified as Anticoagulants.)', 'Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. (See all compounds classified as Fibrinolytic Agents.)']",,,
2126,72127,"2-[2-[[2-[[(2R)-1-[[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-16-benzyl-4-[[(2R,3R)-1,3-dihydroxybutan-2-yl]carbamoyl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]-(carboxylatomethyl)amino]ethyl-[2-[carboxylatomethyl(carboxymethyl)amino]ethyl]amino]acetate;indium(3+)",C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)[C@@H](CC5=CC=CC=C5)NC(=O)CN(CCN(CCN(CC(=O)O)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])C(=O)N[C@H](CO)[C@@H](C)O)O.[In+3],,,,,,
2127,72128,Pentetreotide,C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)[C@@H](CC5=CC=CC=C5)NC(=O)CN(CCN(CCN(CC(=O)O)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)N[C@H](CO)[C@@H](C)O)O,,,,,,
2128,72129,CID 72129,CC(C)COC1=CC=C(C=C1)NC(=NC2=CC=C(C=C2)C3=CC=CC=N3)S,,,,,,
2129,72130,CID 72130,CC=C(C)C(=O)OC1C[C@H]2CC[C@H](C1)N2C,,,,,,
2130,72131,Yohimbic Acid,C1C[C@@H]([C@@H]([C@@H]2[C@@H]1CN3CCC4=C([C@@H]3C2)NC5=CC=CC=C45)C(=O)O)O,,,,,,
2131,72132,"beta,beta-Carotene-3,3'-diol, dihexadecanoate",CCCCCCCCCCCCCCCC(=O)OC1CC(=C(C(C1)(C)C)C=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)C=CC2=C(CC(CC2(C)C)OC(=O)CCCCCCCCCCCCCCC)C)C)C)C,,,,,,
2132,72133,"Xenyhexenic acid, (+)-",CC=CCC(C1=CC=C(C=C1)C2=CC=CC=C2)C(=O)O,,,,,,
2133,72134,Tolboxane,B1(OCC(CO1)(C)CCC)C2=CC=C(C=C2)C,,,,,,
2134,72135,Vinylbital,CCCC(C)C1(C(=O)NC(=O)NC1=O)C=C,,,,,,
2135,72136,Trifluomeprazine,CC(CN1C2=CC=CC=C2SC3=C1C=C(C=C3)C(F)(F)F)CN(C)C,,,,,,
2136,72137,Tolycaine,CCN(CC)CC(=O)NC1=C(C=CC=C1C(=O)OC)C,,,,,,
2137,72138,Tolonidine,CC1=CC(=C(C=C1)NC2=NCCN2)Cl,,,,,,
2138,72139,Tioxolone,C1=CC2=C(C=C1O)OC(=O)S2,,,,,,
2139,72140,"(9R,10S,13S,17S)-17-acetyl-6-chloro-10,13-dimethyl-8,9,11,12,14,15,16,17-octahydrocyclopenta[a]phenanthren-3-one",CC(=O)[C@H]1CCC2[C@@]1(CC[C@@H]3C2C=C(C4=CC(=O)C=C[C@@]34C)Cl)C,,,,,,
2140,72141,Tolpropamine,CC1=CC=C(C=C1)C(CCN(C)C)C2=CC=CC=C2,,,,,,
2141,72142,Tiemonium iodide,C[N+]1(CCOCC1)CCC(C2=CC=CC=C2)(C3=CC=CS3)O.[I-],,,,,,
2142,72143,Thiacetarsamide sodium,C1=CC(=CC=C1C(=O)N)[As](SCC(=O)[O-])SCC(=O)[O-].[Na+].[Na+],,,['Pharmacological agents destructive to nematodes in the superfamily Filarioidea. (See all compounds classified as Filaricides.)'],,,
2143,72144,"(exo)-4,5-Dimethyl-2-(1,7,7-trimethylbicyclo(2.2.1)hept-2-yl)phenol",CC1=CC(=C(C=C1C)O)[C@@H]2C[C@H]3CC[C@@]2(C3(C)C)C,,,,,,
2144,72145,Tritoqualine,CCOC1=C(C(=C(C2=C1C(OC2=O)C3C4=C(C5=C(C=C4CCN3C)OCO5)OC)N)OCC)OCC,,,"['Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. (See all compounds classified as Histamine H1 Antagonists.)']",,,
2145,72146,Vanitiolide,COC1=C(C=CC(=C1)C(=S)N2CCOCC2)O,,,,,,
2146,72147,CID 72147,C1=CC=C2C(=C1)C(=O)C(=C(O2)O)C(CC(C3=CC=C(C=C3)Cl)O)C4=CC=C(S4)Cl,,,,,,
2147,72148,"(1S,5S)-3-(6H-benzo[c][1]benzothiepin-11-ylidene)-8-methyl-8-azabicyclo[3.2.1]octane",CN1[C@H]2CC[C@H]1CC(=C3C4=CC=CC=C4CSC5=CC=CC=C53)C2,,,,,,
2148,72149,Tofisoline,CCC1=C([N+](=C(C2=CC(=C(C=C21)OC)OC)C3=CC(=C(C=C3)OC)OC)[NH-])C,,,,,,
2149,72150,Tidiacic,C1C(NC(S1)C(=O)O)C(=O)O,,,,,,
2150,72151,Truxipicurium Iodide,CC[N+]1(CCCCC1)CCCOC(=O)C2C(C(C2C3=CC=CC=C3)C(=O)OCCC[N+]4(CCCCC4)CC)C5=CC=CC=C5.[I-].[I-],,,,,,
2151,72152,Anatruksonium,CC[N+]1(CCCCC1)CCCOC(=O)C2C(C(C2C3=CC=CC=C3)C(=O)OCCC[N+]4(CCCCC4)CC)C5=CC=CC=C5,,,,,,
2152,72153,Tolmesoxide,CC1=CC(=C(C=C1S(=O)C)OC)OC,,,,,,
2153,72154,Tioxaprofen,CC(C(=O)O)SC1=NC(=C(O1)C2=CC=C(C=C2)Cl)C3=CC=C(C=C3)Cl,,,,,,
2154,72155,Zetidoline,CC1(CN(C1)CCN2CCN(C2=O)C3=CC(=CC=C3)Cl)C,,,"['Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)', 'Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)']",,,
2155,72156,Tizolemide,CN=C1N(C(CS1)(C2=CC(=C(C=C2)Cl)S(=O)(=O)N)O)C,,,,,,
2156,72157,Tioxidazole,CCCOC1=CC2=C(C=C1)N=C(S2)NC(=O)OC,,,,,,
2157,72158,Vedaprofen,CC(C1=CC=C(C2=CC=CC=C21)C3CCCCC3)C(=O)O,"['Reduction of inflammation and relief of pain associated with musculoskeletal disorders and soft-tissue lesions (traumatic injuries and surgical trauma). In cases of anticipated surgical trauma, Quadrisol can be given prophylactically at least three hours prior to elective surgery.']",,['Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)'],,,
2158,72159,Tiquizium bromide,C[N@+]12CCCC[C@@H]1CCC(=C(C3=CC=CS3)C4=CC=CS4)C2.[Br-],,,,,,
2159,72160,Tiquizium,C[N@+]12CCCC[C@@H]1CCC(=C(C3=CC=CS3)C4=CC=CS4)C2,,,,,,
2160,72161,Timefurone,COC1=C2C(=O)C=C(OC2=C(C3=C1C=CO3)OC)CSC,,,,,,
2161,72162,Velaresol,C1=CC(=C(C(=C1)OCCCCC(=O)O)C=O)O,,,"['Drugs used to protect against ionizing radiation. They are usually of interest for use in radiation therapy but have been considered for other purposes, e.g. military. (See all compounds classified as Radiation-Protective Agents.)', 'Agents used to prevent or reverse the pathological events leading to sickling of erythrocytes in sickle cell conditions. (See all compounds classified as Antisickling Agents.)']",,,
2162,72163,Vinleucinol,CC[C@H](C)[C@@H](C(=O)OCC)NC(=O)[C@@]1([C@H]2[C@]3(CCN4[C@H]3[C@]([C@H]1O)(C=CC4)CC)C5=CC(=C(C=C5N2C)OC)[C@]6(C[C@H]7C[C@](CN(C7)CCC8=C6NC9=CC=CC=C89)(CC)O)C(=O)OC)O,,,,,,
2163,72164,Trifenagrel,CN(C)CCOC1=CC=CC=C1C2=NC(=C(N2)C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
2164,72165,"[(1S,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 1H-indole-3-carboxylate",CN1[C@H]2CC[C@H]1CC(C2)OC(=O)C3=CNC4=CC=CC=C43,,,,,,
2165,72166,Trazium Esilate,CCS(=O)(=O)[O-].C1=CC=C2C(=C1)C=C[N+]3=C2C(N=CN3)(C4=CC=C(C=C4)Cl)O,,,,,,
2166,72167,Trazium,C1=CC=C2C(=C1)C=C[N+]3=C2C(N=CN3)(C4=CC=C(C=C4)Cl)O,,,,,,
2167,72168,Zolasartan,CCCCC1=NC(=C(N1CC2=CC3=C(C=C2)OC(=C3Br)C4=CC=CC=C4C5=NNN=N5)C(=O)O)Cl,,,['Agents that antagonize ANGIOTENSIN II TYPE 1 RECEPTOR. Included are ANGIOTENSIN II analogs such as SARALASIN and biphenylimidazoles such as LOSARTAN. Some are used as ANTIHYPERTENSIVE AGENTS. (See all compounds classified as Angiotensin II Type 1 Receptor Blockers.)'],,,
2168,72169,Tricyclamol Chloride,C[N+]1(CCCC1)CCC(C2CCCCC2)(C3=CC=CC=C3)O.[Cl-],,,,,,
2169,72170,Thallous chloride tl 201,[Cl-].[201Tl+],,,,,,
2170,72171,Timoprazole,C1=CC=C2C(=C1)NC(=N2)S(=O)CC3=CC=CC=N3,,,['Compounds that inhibit H(+)-K(+)-EXCHANGING ATPASE. They are used as ANTI-ULCER AGENTS and sometimes in place of HISTAMINE H2 ANTAGONISTS for GASTROESOPHAGEAL REFLUX. (See all compounds classified as Proton Pump Inhibitors.)'],,,
2171,72172,Ubenimex,CC(C)C[C@@H](C(=O)O)NC(=O)[C@H]([C@@H](CC1=CC=CC=C1)N)O,"['An adjuvant therapy used  for acute and chronic myelonous leukemia, lung cancer and nasopharyngeal cancer. It is also used to treat hypercholesterolaemia.']",,"['Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund&apos;s adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)', 'Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. (See all compounds classified as Anti-HIV Agents.)', 'Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. (See all compounds classified as Antibiotics, Antineoplastic.)', 'Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES). (See all compounds classified as Protease Inhibitors.)', 'Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)', 'Biologically active substances whose activities affect or play a role in the functioning of the immune system. (See all compounds classified as Immunologic Factors.)']",,,
2172,72173,"[(2R,3S,4S,5R,6R)-2-[(2S,3S,4S,5S,6S)-2-[3-[[5-[[1-[[2-[4-[4-[[4-amino-6-[3-(4-aminobutylamino)propylamino]-6-oxohexyl]carbamoyl]-1,3-thiazol-2-yl]-1,3-thiazol-2-yl]-1-[(2S,3R,4R,5S,6S)-5-amino-3,4-dihydroxy-6-methyloxan-2-yl]oxy-2-hydroxyethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-hydroxy-5-oxopentan-2-yl]amino]-2-[[6-amino-2-[3-amino-1-[(2,3-diamino-3-oxopropyl)amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-1-(1H-imidazol-5-yl)-3-oxopropoxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl] carbamate",C[C@H]1[C@H]([C@H]([C@H]([C@@H](O1)OC(C(C2=NC(=CS2)C3=NC(=CS3)C(=O)NCCCC(CC(=O)NCCCNCCCCN)N)O)NC(=O)C(C(C)O)NC(=O)CC(C(C)NC(=O)C(C(C4=CN=CN4)O[C@@H]5[C@H]([C@H]([C@@H]([C@@H](O5)CO)O)O)O[C@@H]6[C@H]([C@H]([C@@H]([C@H](O6)CO)O)OC(=O)N)O)NC(=O)C7=C(C(=NC(=N7)C(CC(=O)N)NCC(C(=O)N)N)N)C)O)O)O)N,,,,,,
2173,72174,Tiprostanide,CCCCCC(C)(CS[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)OC2=CC=C(C=C2)NC(=O)C3=CC=CC=C3)O)O,,,,,,
2174,72175,Tipropidil Hydrochloride,CCCCCCCCNCC(COC1=CC=C(C=C1)SC(C)C)O.Cl,,,,,,
2175,72176,Tipropidil,CCCCCCCCNCC(COC1=CC=C(C=C1)SC(C)C)O,,,,,,
2176,72177,Tonazocine,CCCCCC(=O)CC[C@@]1([C@@H]2CC3=C([C@]1(CCN2C)C)C=C(C=C3)O)C,,,,,,
2177,72178,CID 72178,C[C@@H]1CCC[C@@H]([C@H]1[C@H](C)C(=O)C2=C(OCC2=O)O)C=C(CO)[C@H]3[C@@H](CC[C@H](O3)C=C[C@H](C)C4[C@H](C[C@@H](O4)[C@H](C)OC)C)C,,,,,,
2178,72179,"(2S,4S)-1-[(2R)-3-benzoylsulfanyl-2-methylpropanoyl]-4-phenylsulfanylpyrrolidine-2-carboxylic acid",C[C@@H](CSC(=O)C1=CC=CC=C1)C(=O)N2C[C@H](C[C@H]2C(=O)O)SC3=CC=CC=C3,,,,,,
2179,72180,Lodenosine,C1[C@H](O[C@H]([C@H]1F)N2C=NC3=C(N=CN=C32)N)CO,,,,,,
2180,72181,CID 72181,C1[C@@H]([C@H](O[C@H]1N2C=NC3=C2NC(=NC3=O)N)CO)N=[N+]=[N-],,,,,,
2181,72182,Azdddapr,C1[C@@H]([C@H](O[C@H]1N2C=NC3=C(N=C(N=C32)N)N)CO)N=[N+]=[N-],,,,,,
2182,72183,CID 72183,C1[C@@H]([C@H](O[C@H]1N2C=NC3=C2NC(=NC3=O)N)CO)F,,,,,,
2183,72184,"5'-(1,4-Dihydro-1-methyl-3-pyridinylcarbonyl)-3'-azido-3'-deoxythymidine",CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COC(=O)C3=CN(C=CC3)C)N=[N+]=[N-],,,,,,
2184,72185,Avarol,C[C@H]1CC[C@]2([C@H]([C@]1(C)CC3=C(C=CC(=C3)O)O)CCC=C2C)C,,,"['Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)', 'Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)']",,,
2185,72186,Avarone,C[C@H]1CC[C@]2([C@H]([C@]1(C)CC3=CC(=O)C=CC3=O)CCC=C2C)C,,,,,,
2186,72187,Combivir,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)N=[N+]=[N-],['Combivir is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection.'],,"['Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)', 'Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. (See all compounds classified as Anti-HIV Agents.)']",,,
2187,72188,Ara-ttp,CC1=CN(C(=O)NC1=O)[C@H]2[C@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O,,,,,,
2188,72189,CID 72189,C1CC(O[C@H]1N2C=NC3=C2NC(=NC3=O)N)COP(=O)(O)OP(=O)(O)OP(=O)(O)O,,,,,,
2189,72190,"2',3'-Dideoxy-2'-fluoroarabinofuranosyladenine",C1[C@H]([C@H](O[C@H]1N2C=NC3=C(N=CN=C32)N)CO)F,,,,,,
2190,72191,"7-Methoxy-1,6-dimethyl-5,8-dihydroisoquinoline-5,8-dione",CC1=C(C(=O)C2=C(C1=O)C=CN=C2C)OC,,,,,,
2191,72192,CID 72192,C1C(C=CC1N2C=NC3=C2NC(=NC3=O)N)CO,,,,,,
2192,72193,CID 72193,CCN(CC)C(=S)[S-].O.O.O.[Na+],,,,,,
2193,72194,2-Chlorodideoxyadenosine,C1C[C@@H](O[C@@H]1CO)N2C=NC3=C(N=C(N=C32)Cl)N,,,,,,
2194,72195,"2-Fluoro-2',3'-dideoxyadenosine",C1C[C@@H](O[C@@H]1CO)N2C=NC3=C(N=C(N=C32)F)N,,,,,,
2195,72196,Pentamidine mesylate,CS(=O)(=O)O.CS(=O)(=O)O.C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N,,,"['Substances that are destructive to protozoans. (See all compounds classified as Antiprotozoal Agents.)', 'Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)', 'Agents destructive to the protozoal organisms belonging to the suborder TRYPANOSOMATINA. (See all compounds classified as Trypanocidal Agents.)']",,,
2196,72197,"1-[(2S,4R,5R)-4-(hydroxymethyl)-5-iodooxolan-2-yl]-5-methylpyrimidine-2,4-dione",CC1=CN(C(=O)NC1=O)[C@@H]2C[C@@H]([C@H](O2)I)CO,,,,,,
2197,72198,CID 72198,C1=NC(=C2C(=N1)N(C=N2)C=C=CCO)N,,,,,,
2198,72199,CID 72199,C1=CN(C(=O)N=C1N)C=C=CCO,,,,,,
2199,72200,2-Aminoadenosine,C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)N)N,,,,,,
2200,72201,"2-Chloro-2',3'-didehydro-2',3'-dideoxyadenosine",C1=C[C@@H](O[C@@H]1CO)N2C=NC3=C(N=C(N=C32)Cl)N,,,,,,
2201,72202,C.I. Acid Violet 19,CC1=CC(=C(C2=CC(=C(C=C2)N)S(=O)(=O)O)C3=CC(=C(C=C3)N)S(=O)(=O)[O-])C=C(C1=N)S(=O)(=O)[O-].[Na+].[Na+],,,,,,
2202,72203,Acidal fuchsine,CC1=CC(=C(C2=CC(=C(C=C2)N)S(=O)(=O)O)C3=CC(=C(C=C3)N)S(=O)(=O)O)C=C(C1=N)S(=O)(=O)O,,,,,,
2203,72204,CID 72204,C[C@H]1[C@@H]([C@@H]([C@H]([C@H](O1)O[C@@H]2[C@@H](C3=CC4=C(C(=C3C5=C2C=C(C(=C5O)C(=O)N[C@@H](C)C(=O)O)C)O)C(=O)C6=C(C4=O)C(=CC(=C6)OC)O)O)O)O[C@H]7[C@@H]([C@H]([C@H](CO7)O)O)O)NC,,,,,,
2204,72205,"2-[[(4R)-4-[(3R,5R,10S,13R,17R)-10,13-dimethyl-3-sulfooxy-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonic acid",C[C@H](CCC(=O)NCCS(=O)(=O)O)[C@H]1CCC2[C@@]1(CCC3C2CC[C@H]4[C@@]3(CC[C@H](C4)OS(=O)(=O)O)C)C,,,,,,
2205,72206,CID 72206,C[C@H](CCC(=O)NCCS(=O)(=O)[O-])[C@H]1CC[C@@H]2[C@@]1(CCC3[C@H]2CC[C@H]4[C@@]3(CC[C@H](C4)O)C)C.[Na+],,,,,,
2206,72207,CID 72207,C[C@H](CCC(=O)NCCS(=O)(=O)O)C1CC[C@@H]2[C@@]1(CCC3C2CC[C@H]4[C@@]3(CC[C@H](C4)O)C)C,,,,,,
2207,72208,"2,5'-Anhydro-3'-azido-3'-deoxythymidine",CC1=CN2[C@H]3C[C@@H]([C@H](O3)COC2=NC1=O)N=[N+]=[N-],,,,,,
2208,72209,"2,5'-Anhydro-3'-azido-2',3'-dideoxy-5-bromouridine",C1[C@@H]([C@H]2COC3=NC(=O)C(=CN3[C@@H]1O2)Br)N=[N+]=[N-],,,,,,
2209,72210,"2,5'-Anhydro-3'-azido-2',3'-dideoxy-5-iodouridine",C1[C@@H]([C@H]2COC3=NC(=O)C(=CN3[C@@H]1O2)I)N=[N+]=[N-],,,,,,
2210,72211,CID 72211,C1[C@H](CO[C@H]1CO)N2C=NC3=C2NC(=NC3=O)N,,,,,,
2211,72212,CID 72212,C1[C@H](O[C@H]([C@H]1F)N2C=NC3=C2NC=NC3=O)CO,,,,,,
2212,72213,"9-(2,3-dideoxy-2-fluoropentofuranosyl)-N-methyl-9H-purin-6-amine",CNC1=C2C(=NC=N1)N(C=N2)[C@H]3[C@H](CC(O3)CO)F,,,,,,
2213,72214,Oxetanocin A,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@H](O3)CO)CO)N,,,"['Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)', 'Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)']",,,
2214,72215,CID 72215,C1=NC2=C(N1[C@H]3[C@@H]([C@H](O3)CO)CO)NC(=NC2=O)N,,,,,,
2215,72216,"[(2R,3R,4R)-2-(2,6-diaminopurin-9-yl)-4-(hydroxymethyl)oxetan-3-yl]methanol",C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H](O3)CO)CO)N)N,,,,,,
2216,72217,"2',3'-Didehydro-2',3'-dideoxy-5-chlorocytidine",C1=C[C@@H](O[C@@H]1CO)N2C=C(C(=NC2=O)N)Cl,,,,,,
2217,72218,Dexylosylbenanomicin B,C[C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](C3=CC4=C(C(=C3C5=C2C=C(C(=C5O)C(=O)N[C@H](C)C(=O)O)C)O)C(=O)C6=C(C4=O)C(=CC(=C6)OC)O)O)O)O)N,,,,,,
2218,72219,CID 72219,C[C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](C3=CC4=C(C(=C3C5=C2C=C(C(=C5O)C(=O)N[C@@H](C)C(=O)O)C)O)C(=O)C6=C(C4=O)C(=CC(=C6)OC)O)O)O)O[C@H]7[C@@H]([C@H]([C@@H](CO7)O)O)O)N,,,,,,
2219,72220,"N-[[[(5S)-5alpha-[(3-O-beta-D-Xylopyranosyl-6-deoxy-beta-D-galactopyranosyl)oxy]-5,6,8,13-tetrahydro-1,6beta,9,14-tetrahydroxy-11-methoxy-3-methyl-8,13-dioxobenzo[a]naphthacen]-2-yl]carbonyl]-L-alanine",C[C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](C3=CC4=C(C(=C3C5=C2C=C(C(=C5O)C(=O)N[C@@H](C)C(=O)O)C)O)C(=O)C6=C(C4=O)C(=CC(=C6)OC)O)O)O)O[C@H]7[C@@H]([C@H]([C@@H](CO7)O)O)O)O,,,,,,
2220,72221,CID 72221,C1[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)O)O)O)OC(=O)C3=CC(=C(C(=C3C4=C(C(=O)C5=C6C4=C(OC7=C6C(=C(O5)O)C(=C(C7=O)O)C8=C(C(=C(C=C8C(=O)O1)O)O)O)O)O)O)O)O,,,,,,
2221,72222,Sulfoglycolithocholic acid,C[C@H](CCC(=O)NCC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@H]4[C@@]3(CC[C@H](C4)OS(=O)(=O)O)C)C,,,,,,
2222,72223,CID 72223,C1=CC(=CC=C1C2=CC(=O)C3=C(O2)C(=C(C=C3)O)C4=C(C=CC(=C4)C5=CC(=C6C(=CC(=O)C=C6O5)O)O)O)O,,,,,,
2223,72224,CID 72224,C1=CC(=CC=C1C2=CC(=C3C(=CC(=O)C(=C3O)O)O2)O)O,,,,,,
2224,72225,CID 72225,CCCCCOC1=C2C3=C(C(=C1C)O)C(=O)C(=C(C3=O)C)NC(=O)C(=CC=C[C@H]([C@@H]4C([C@H]([C@H]([C@@H]([C@@H]([C@H]([C@](C=C(C2=O)C)(C)O)O)C)O)C(=O)O4)O)C)C)C,,,,,,
2225,72226,"Methanone, (5-amino-2-(4-methyl-1-piperidinyl)phenyl)(4-chlorophenyl)-",CC1CCN(CC1)C2=C(C=C(C=C2)N)C(=O)C3=CC=C(C=C3)Cl,,,,,,
2226,72227,Bz-Ddcn,C1=CC=C(C=C1)C(=O)NC2=NC(=O)N(C=C2)[C@H]3C=C[C@H](O3)CO,,,,,,
2227,72228,CID 72228,C[C@@H]1C=CC=C(C(=O)NC2=C(C(=C3C(=C(C(=C4C3=C(C(=C[C@@]([C@@H]([C@@H]([C@H]([C@@H]([C@@H]([C@@H](C1O)C)O)C(=O)OC)O)C)O)(C)O)C)OCO4)C)O)C2=O)OC(=O)C)C)C,,,,,,
2228,72229,CID 72229,C[C@H]1[C@@H]2C=C[C@]3(CO3)[C@@](O2)(O[C@H]1[C@H](C)C=C(C)C=CC(=O)C4=C(N([C@H](C4=O)[C@H](C)C(=O)NC)[C@@H]5CC[C@@H]([C@@H](O5)C)O)O)C,,,,,,
2229,72230,5'-O-Benzoyl-3'-deoxythymidine,CC1=CN(C(=O)NC1=O)[C@H]2CC[C@H](O2)COC(=O)C3=CC=CC=C3,,,,,,
2230,72231,CID 72231,C([C@@H]1[C@H]([C@H]([C@@H](O1)N2C3=C(C(=O)N=C(N3)N)SC2=O)O)O)O,,,,,,
2231,72232,"6-cyclohexyl-5-(3,3-dimethylbutanoylamino)-4-hydroxy-N-[3-methyl-1-oxo-1-(pyridin-2-ylmethylamino)pentan-2-yl]-2-propan-2-ylhexanamide",CCC(C)C(C(=O)NCC1=CC=CC=N1)NC(=O)C(CC(C(CC2CCCCC2)NC(=O)CC(C)(C)C)O)C(C)C,,,,,,
2232,72233,CID 72233,C1=CC(=C(C=C1Br)S(=O)(=O)O)NN=C2C(=CC3=C(C2=O)C(=O)C(=NNC4=C(C=C(C=C4)Br)S(=O)(=O)O)C(=C3)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+],,,,,,
2233,72234,CID 72234,C1=CC(=C(C=C1Br)S(=O)(=O)O)NN=C2C(=CC3=C(C2=O)C(=O)C(=NNC4=C(C=C(C=C4)Br)S(=O)(=O)O)C(=C3)S(=O)(=O)O)S(=O)(=O)O,,,,,,
2234,72235,Procion Red H7B,C1=CC=C(C=C1)C(=O)NC2=C3C(=CC(=C2)S(=O)(=O)[O-])C=C(C(=C3O)N=NC4=C(C=CC(=C4)NC5=NC(=NC(=N5)NC6=CC=C(C=C6)S(=O)(=O)[O-])Cl)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+],,,,,,
2235,72236,Cibacron Brilliant Red 3B-A,C1=CC=C(C=C1)C(=O)NC2=C3C(=CC(=C2)S(=O)(=O)O)C=C(C(=C3O)N=NC4=C(C=CC(=C4)NC5=NC(=NC(=N5)NC6=CC=C(C=C6)S(=O)(=O)O)Cl)S(=O)(=O)O)S(=O)(=O)O,,,,,,
2236,72237,Disodium 8-hydroxy-7-[(4-sulphonato-1-naphthyl)azo]quinoline-5-sulphonate,C1=CC=C2C(=C1)C(=CC=C2S(=O)(=O)[O-])N=NC3=CC(=C4C=CC=NC4=C3O)S(=O)(=O)[O-].[Na+].[Na+],,,,,,
2237,72238,CID 72238,C1=CC=C(C(=C1)NN=C2C(=CC3=C(C2=O)C(=O)C(=NNC4=CC=CC=C4S(=O)(=O)[O-])C(=C3)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+],,,,,,
2238,72239,CID 72239,C1=CC=C(C(=C1)NN=C2C(=CC3=C(C2=O)C(=O)C(=NNC4=CC=CC=C4S(=O)(=O)O)C(=C3)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O,,,,,,
2239,72240,Valyl-seryl-glutaminyl-asparaginyl-leucyl-hydroxyethyl-valyl-isoleucyl-valine,CC[C@H](C)[C@@H](C(=O)NC(C(C)C)C(=O)O)NC(=O)C(C[C@@H]([C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N)O)C(C)C,,,,,,
2240,72241,rac-3-Octadecanamido-2-ethoxypropan-1-ol Phosphocholine,CCCCCCCCCCCCCCCCCC(=O)NCC(COP(=O)([O-])OCC[N+](C)(C)C)OCC,,,,,,
2241,72242,2-[[2-Ethoxy-3-(octadecanoylamino)propoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium,CCCCCCCCCCCCCCCCCC(=O)NCC(COP(=O)(O)OCC[N+](C)(C)C)OCC,,,,,,
2242,72243,"2-Acetonyl-2,4,9-trihydroxy-6-methoxy-7-methyl-1H-phenalene-1,3(2H)-dione",CC1=CC(=C2C3=C(C(=CC(=C13)OC)O)C(=O)C(C2=O)(CC(=O)C)O)O,,,,,,
2243,72244,"1-(4-Chlorobenzoyl)-1,2-dihydro-2-quinolinecarbonitrile",C1=CC=C2C(=C1)C=CC(N2C(=O)C3=CC=C(C=C3)Cl)C#N,,,,,,
2244,72245,ddUTP,C1C[C@@H](O[C@@H]1COP(=O)(O)OP(=O)(O)OP(=O)(O)O)N2C=CC(=O)NC2=O,,,,,,
2245,72246,"(2R,3R,5R)-5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol",C1[C@H]([C@H](O[C@H]1N2C=NC3=C(N=CN=C32)N)CO)O,,,,,,
2246,72247,"2,4(1H,3H)-Pyrimidinedione, 1-(2-deoxy-beta-D-threo-pentofuranosyl)-5-methyl-",CC1=CN(C(=O)NC1=O)[C@H]2C[C@H]([C@H](O2)CO)O,,,,,,
2247,72248,"2'-Fluoro-2',3'-dideoxyadenosine",C1[C@H](O[C@H]([C@@H]1F)N2C=NC3=C(N=CN=C32)N)CO,,,,,,
2248,72249,3'-Chloro-3'-deoxythymidine,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)Cl,,,,,,
2249,72250,3'-O-Methylthymidine,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)OC,,,,,,
2250,72251,"2',3'-Dideoxy-5-methylcytidine",CC1=CN(C(=O)N=C1N)[C@H]2CC[C@H](O2)CO,,,,,,
2251,72252,"2',3'-Anhydroadenosine",C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@H]4[C@H](O4)[C@H](O3)CO)N,,,,,,
2252,72253,Hpmpa,C1=NC(=C2C(=N1)N(C=N2)C[C@@H](CO)OCP(=O)(O)O)N,,,"['Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)', 'Agents destructive to the protozoal organisms belonging to the suborder TRYPANOSOMATINA. (See all compounds classified as Trypanocidal Agents.)']",,,
2253,72254,"9-(3-Hydroxy-2-phosphonomethoxypropyl)-2,6-diaminopurine",C1=NC2=C(N=C(N=C2N1C[C@@H](CO)OCP(=O)(O)O)N)N,,,,,,
2254,72255,CID 72255,C1=NC2=C(N1CC=CCO)NC(=NC2=O)N,,,,,,
2255,72256,1-(1-(2-Hydroxyethoxy)-3-azidopropyl)thymine,CC1=CN(C(=O)NC1=O)C(CCN=[N+]=[N-])OCCO,,,,,,
2256,72257,"3',3'-Difluoro-3'-deoxythymidine",CC1=CN(C(=O)NC1=O)[C@H]2CC([C@H](O2)CO)(F)F,,,,,,
2257,72258,1-Deoxymannojirimycin,C1[C@H]([C@H]([C@@H]([C@H](N1)CO)O)O)O,,,"['Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)']",,,
2258,72259,Fagomine,C1CN[C@@H]([C@H]([C@@H]1O)O)CO,,,,,,
2259,72260,"5-Fluoro-2',3'-dideoxy-3'-fluorouridine",C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)F)CO)F,,,,,,
2260,72261,"9-(2',3'-Dideoxy-2'-fluoroarabinofuranosyl)purine",C1[C@H](O[C@H]([C@H]1F)N2C=NC3=CN=CN=C32)CO,,,,,,
2261,72262,CID 72262,C1[C@H]([C@H](O[C@H]1N2C=NC3=C2NC(=NC3=O)N)CO)F,,,,,,
2262,72263,"3'-C-Methylidene-2',3'-dideoxy-5-methyluridine",CC1=CN(C(=O)NC1=O)[C@H]2CC(=C)[C@H](O2)CO,,,,,,
2263,72264,"4-amino-1-[(2R,3S,4R,5R)-3,4-difluoro-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one",C1=CN(C(=O)N=C1N)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)F)F,,,,,,
2264,72265,Cyanothymidine,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)C#N,,,,,,
2265,72266,"(2R,4S,5R)-2-[6-(dimethylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol",CN(C)C1=NC=NC2=C1N=CN2[C@H]3C([C@@H]([C@H](O3)CO)O)O,,,,,,
2266,72267,"2',3'-Dideoxy-2',3'-didehydro-2'-fluorocytidine",C1=CN(C(=O)N=C1N)[C@H]2C(=C[C@H](O2)CO)F,,,,,,
2267,72268,Carbonyldiphosphonate,C(=O)(P(=O)(O)O)P(=O)(O)O,,,['Compounds that inhibit cell production of DNA or RNA. (See all compounds classified as Nucleic Acid Synthesis Inhibitors.)'],,,
2268,72269,CID 72269,CC1=CN(C(=O)N=C1S)[C@H]2CC[C@H](O2)CO,,,,,,
2269,72270,CID 72270,CC1=CN(C(=O)N=C1S)[C@H]2C[C@@H]([C@H](O2)CO)N=[N+]=[N-],,,,,,
2270,72271,7-Hydroxystaurosporine,C[C@@]12[C@@H]([C@@H](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)[C@H](NC6=O)O)NC)OC,,,"['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)', 'Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)']",,,
2271,72272,3'-Isocyano-3'-deoxythymidine,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)[N+]#[C-],,,,,,
2272,72273,"3'-Isocyano-2',3'-dideoxyuridine",[C-]#[N+][C@H]1C[C@@H](O[C@@H]1CO)N2C=CC(=O)NC2=O,,,,,,
2273,72274,"1-[(2R,5S)-3-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione",CC1=CN(C(=O)NC1=O)[C@H]2C(C[C@H](O2)CO)N=[N+]=[N-],,,,,,
2274,72275,"8,11a-Methano-11aH-cyclohepta[a]naphthalene-4-carboxylic acid, 5-(benzoyloxy)tetradecahydro-9-hydroxy-4,9,11b-trimethyl-, (4R,4aR,6aR,8R,9R,11aS,11bS)-",C[C@]1(CC[C@]23C[C@H]1C[C@@H]2C[C@H]([C@@H]4[C@@]3(CCC[C@@]4(C)C(O)O)C)OC(=O)C5=CC=CC=C5)O,,,,,,
2275,72276,(-)-Epicatechin,C1[C@H]([C@H](OC2=CC(=CC(=C21)O)O)C3=CC(=C(C=C3)O)O)O,,,,,"[""Epicatechin has known human metabolites that include 5-(3',4'-dihydroxyphenyl)-gamma-valerolactone and Phloroglucinol.""]",
2276,72277,Epigallocatechin,C1[C@H]([C@H](OC2=CC(=CC(=C21)O)O)C3=CC(=C(C(=C3)O)O)O)O,,,,,"['(-)-Epigallocatechin has known human metabolites that include (-)-Epigallocatechin, 3p-hydroxy-glucuronide.']",
2277,72278,Acid Blue 45,C1=C(C2=C(C(=C1S(=O)(=O)[O-])O)C(=O)C3=C(C2=O)C(=C(C=C3N)S(=O)(=O)[O-])O)N.[Na+].[Na+],,,,,,
2278,72279,6-Hydroxyflavone,C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=CC(=C3)O,,,,,"['6-Hydroxyflavone has known human metabolites that include (2S,3S,4S,5R)-3,4,5-trihydroxy-6-(4-oxo-2-phenylchromen-6-yl)oxyoxane-2-carboxylic acid.']",
2279,72280,CID 72280,C1=CC=C(C=C1)C2=CC(=C3C=CC(=O)C=C3O2)O,,,,,,
2280,72281,Hesperetin,COC1=C(C=C(C=C1)[C@@H]2CC(=O)C3=C(C=C(C=C3O2)O)O)O,"['For lowering cholesterol and, possibly, otherwise favorably affecting lipids. <i>In vitro</i> research also suggests the possibility that hesperetin might have some anticancer effects and that it might have some anti-aromatase activity, as well as activity again.']","['Hesperetin is a cholesterol lowering flavanoid found in a number of citrus juices. It appears to reduce cholesteryl ester mass and inhibit apoB secretion by up to 80%. Hesperetin may have antioxidant, anti-inflammatory, anti-allergic, hypolipidemic, vasoprotective and anticarcinogenic actions.']",,,['Hesperetin has known human metabolites that include Hesperetin 3p-O-glucuronide and Hesperetin 7-O-glucuronide.'],
2281,72282,"(2S,3R)-2-(3,4-dihydroxyphenyl)-3,7-dihydroxy-2,3-dihydrochromen-4-one",C1=CC(=C(C=C1[C@H]2[C@H](C(=O)C3=C(O2)C=C(C=C3)O)O)O)O,,,,,,
2282,72283,"3'-Deoxy-2',3'-didehydro-2'fluorothymidine",CC1=CN(C(=O)NC1=O)[C@H]2C(=C[C@H](O2)CO)F,,,,,,
2283,72284,Chebulinic acid,C1=C(C=C(C(=C1O)O)O)C(=O)OC[C@@H]2[C@@H]3[C@@H]([C@H]([C@@H](O2)OC(=O)C4=CC(=C(C(=C4)O)O)O)OC(=O)C5=CC(=C(C6=C5[C@H]([C@@H](C(=O)O3)CC(=O)O)[C@@H](C(=O)O6)O)O)O)OC(=O)C7=CC(=C(C(=C7)O)O)O,,,,,,
2284,72285,JW8L3F5IW9,C1[C@@H]2C3[C@@H]([C@H]([C@@H](O2)OC(=O)C4=CC(=C(C(=C4)O)O)O)OC(=O)C5=CC(=C(C6=C5[C@H]([C@@H](C(=O)O3)CC(=O)O)[C@@H](C(=O)O6)O)O)O)OC(=O)C7=CC(=C(C(=C7C8=C(C(=C(C=C8C(=O)O1)O)O)O)O)O)O,,,"['Compounds that bind to and inhibit that enzymatic activity of LIPOXYGENASES. Included under this category are inhibitors that are specific for lipoxygenase subtypes and act to reduce the production of LEUKOTRIENES. (See all compounds classified as Lipoxygenase Inhibitors.)', 'Compounds that inhibit the activity of DNA TOPOISOMERASE I. (See all compounds classified as Topoisomerase I Inhibitors.)']",,,
2285,72286,CID 72286,C[C@@H](CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C.C(=CC(=O)O)C(=O)O,,,,,,
2286,72287,Levomepromazine,C[C@@H](CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C,"['For the treatment of psychosis, particular those of schizophrenia, and manic phases of bipolar disorder.']","['Methotrimeprazine is a phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604)']","['Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)', 'Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME. (See all compounds classified as Dopamine Antagonists.)', 'A subclass of analgesic agents that typically do not bind to OPIOID RECEPTORS and are not addictive. Many non-narcotic analgesics are offered as NONPRESCRIPTION DRUGS. (See all compounds classified as Analgesics, Non-Narcotic.)']","['Methotrimeprazine has an incomplete oral bioavailability, because it undergoes considerable first-pass-metabolism in the liver. Oral bioavailability is approximately 50 to 60%.']","['Hepatic. Methotrimeprazine is metabolized in the liver and degraded to a sulfoxid-, a glucuronid- and a demethyl-moiety.']",['Approximately 20 hours.']
2287,72288,"2-(1,1-Dimethylpiperidin-1-ium-3-yl)oxy-2-oxo-1,1-diphenylethanolate",C[N+]1(CCCC(C1)OC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)[O-])C,,,,,,
2288,72289,"Benzyl [(1r,4s,6s,9r)-4,6-Dibenzyl-5-Hydroxy-1,9-Bis(1-Methylethyl)-2,8,11-Trioxo-13-Phenyl-12-Oxa-3,7,10-Triazatridec-1-Yl]carbamate",CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C([C@H](CC2=CC=CC=C2)NC(=O)[C@H](C(C)C)NC(=O)OCC3=CC=CC=C3)O)NC(=O)OCC4=CC=CC=C4,,,,,,
2289,72290,"L-Iditol, 1,2,5,6-tetradeoxy-2,5-bis[[(2S)-3-methyl-1-oxo-2-[[(phenylmethoxy)carbonyl]amino]butyl]amino]-1,6-diphenyl-",CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H]([C@@H]([C@H](CC2=CC=CC=C2)NC(=O)[C@H](C(C)C)NC(=O)OCC3=CC=CC=C3)O)O)NC(=O)OCC4=CC=CC=C4,,,,,,
2290,72291,Ilimaquinone,C[C@H]1CC[C@]2([C@H]([C@]1(C)CC3=C(C(=O)C=C(C3=O)OC)O)CCCC2=C)C,,,,,,
2291,72292,4-O-Methyl-12-O-tetradecanoylphorbol 13-acetate,CCCCCCCCCCCCCC(=O)O[C@@H]1[C@H]([C@]2([C@@H](C=C(C[C@]3([C@H]2C=C(C3=O)C)OC)CO)[C@H]4[C@@]1(C4(C)C)OC(=O)C)O)C,,,,,,
2292,72293,"Phorbol 12,13-diacetate",C[C@@H]1[C@H]([C@@]2([C@@H](C2(C)C)[C@H]3[C@]1([C@@H]4C=C(C(=O)[C@]4(CC(=C3)CO)O)C)O)OC(=O)C)OC(=O)C,,,,,,
2293,72294,"Phorbol-12,13-dibenzoate",C[C@@H]1[C@H]([C@@]2([C@@H](C2(C)C)[C@H]3[C@]1([C@@H]4C=C(C(=O)[C@]4(CC(=C3)CO)O)C)O)OC(=O)C5=CC=CC=C5)OC(=O)C6=CC=CC=C6,,,,,,
2294,72295,CID 72295,CCCCCCCCCC(=O)O[C@@H]1C[C@]2([C@@H](C=C(C[C@@]3([C@H]2C=C(C3=O)C)O)CO)C4[C@@]1(C4(C)C)OC(=O)CCCCCCCCC)O,,,,,,
2295,72296,4'-Azidothymidine,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@](O2)(CO)N=[N+]=[N-])O,,,,,,
2296,72297,3'-Azido-3'-deoxy-5'-(3-octadecanamido-2-ethoxypropyl)phosphothymidine,CCCCCCCCCCCCCCCCCC(=O)NCC(COP(=O)([O-])OC[C@@H]1[C@H](C[C@@H](O1)N2C=C(C(=O)NC2=O)C)N=[N+]=[N-])OCC.[Na+],,,,,,
2297,72298,"[(2S,3S,5R)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl [2-ethoxy-3-(octadecanoylamino)propyl] hydrogen phosphate",CCCCCCCCCCCCCCCCCC(=O)NCC(COP(=O)(O)OC[C@@H]1[C@H](C[C@@H](O1)N2C=C(C(=O)NC2=O)C)N=[N+]=[N-])OCC,,,,,,
2298,72299,Nucleocidin,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@](O3)(COS(=O)(=O)N)F)O)O)N,,,,,,
2299,72300,Magnolol,C=CCC1=CC(=C(C=C1)O)C2=C(C=CC(=C2)CC=C)O,,,"['Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)', 'Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)', 'Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)']","[""To investigate the relationship between magnolol and the clinical effects of Saiboku-To, urinary magnolol excretion was compared in responders and non-responders under long-term Saiboku-To treatment. The clinical outcome of the Saiboku-To treatment was evaluated in nine asthmatic patients at 52 weeks after the onset of the treatment, using individual fluctuation of asthmatic points obtained from the patients' diary cards. Three patients whose clinical conditions were improved by the treatment were termed responders and six others were termed non-responders. The difference in the amounts of the total magnolol excreted were not significant; however, free (or non-conjugated) amounts of magnolol excreted in the responders were 7 times those in the non-responders (P < 0.05). These results suggest that the magnolol might be responsible for the therapeutic effect of Saiboku-To, indicating practical bioavailability in the responders.""]","['Magnolol has known human metabolites that include (2S,3S,4S,5R)-3,4,5-trihydroxy-6-[2-(2-hydroxy-5-prop-2-enylphenyl)-4-prop-2-enylphenoxy]oxane-2-carboxylic acid.']",
2300,72301,Tetrahydropalmatine,COC1=C(C2=C(C[C@H]3C4=CC(=C(C=C4CCN3C2)OC)OC)C=C1)OC,,,"['Drugs that act on adrenergic receptors or affect the life cycle of adrenergic transmitters. Included here are adrenergic agonists and antagonists and agents that affect the synthesis, storage, uptake, metabolism, or release of adrenergic transmitters. (See all compounds classified as Adrenergic Agents.)', 'Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)', 'A subclass of analgesic agents that typically do not bind to OPIOID RECEPTORS and are not addictive. Many non-narcotic analgesics are offered as NONPRESCRIPTION DRUGS. (See all compounds classified as Analgesics, Non-Narcotic.)', 'Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME. (See all compounds classified as Dopamine Antagonists.)', 'A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)']",,,
2301,72302,"4H-1-Benzopyran-4-one, 3-[(6-deoxy-alpha-L-mannopyranosyl)oxy]-7-(beta-D-glucopyranosyloxy)-5-hydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-butenyl)-",C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)COC2=C(OC3=C(C2=O)C=CC(=C3CC=C(C)C)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)C5=CC=C(C=C5)OC)O)O)O,,,,,,
2302,72303,Honokiol,C=CCC1=CC(=C(C=C1)O)C2=CC(=C(C=C2)O)CC=C,,,"['Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475) (See all compounds classified as Anti-Allergic Agents.)', 'Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)', 'Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. (See all compounds classified as Antineoplastic Agents, Phytogenic.)', 'Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion. (See all compounds classified as Gastrointestinal Agents.)', 'Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)', 'Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. (See all compounds classified as Anti-Infective Agents.)', 'A very loosely defined group of drugs that tend to reduce the activity of the central nervous system. The major groups included here are ethyl alcohol, anesthetics, hypnotics and sedatives, narcotics, and tranquilizing agents (antipsychotics and antianxiety agents). (See all compounds classified as Central Nervous System Depressants.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)']",,,
2303,72304,Isoflavone,C1=CC=C(C=C1)C2=COC3=CC=CC=C3C2=O,['Indicated for over-the-counter use as a dietary supplement for increasing bone density and regulating blood fat.'],"['Isolated soy protein with isoflavones was shown to decrease LDL cholesterol levels in randomized trials assessed by the American Heart Association. In a study of postmenopausal women, daily dietary intake of 101 mg of aglycone isoflavones (indicating [DB01645] and [DB13182]) was associated with lowered LDL cholesterol and apolipoprotein B levels by 8% and reduced systolic and diastolic blood pressure by 6.8% in hypertensive women. In a meta-analysis of randomized controlled trials of menopausal women, soy isoflavones attenuated bone loss of the spine and decreased the levels of deoxypyridinoline, a bone resorption marker, while increasing serum bone-specific alkaline phosphatase, a bone formation marker. The findings from studies investigating the effects of soy consumption on menopausal symptoms, breast cancer, and prostate cancer remain somewhat controversial and inconclusive. Consumption of soy isoflavones may decrease the markers of cancer development and progression in prostate cells, including prostate-specific antigen (PSA), testosterone, and androgen receptor in patients with prostate cancer but not in normal subjects. Although epidemiologic data in Asian women demonstrate that high soy food intake is associated with protection against breast cancer, soy foods have little effect on intermediary markers of breast cancer risk and postmenopausal soy intake may not reduce the risk of developing breast cancer. However, preliminary studies  show that soy food intake reduces tumor recurrence in breast cancer patients. Soy isoflavones reported to interfere with thyroid peroxidase, which are involved in the production of thyroid hormones.']",,"['Following oral ingestion, serum isoflavone concentrations increase in a dose-dependent manner. Isoflavones are metabolized by gut microflora, where they need to undergo deglycosylation in order to be absorbed in the intestine. After oral ingestion, glycosylated isoflavones are rapidly deglycosylated, absorbed and metabolized in intestinal enterocytes and liver, entering the systemic circulation predominantly as conjugates with limited bioavailability. In humans, the mean time to reach peak plasma concentrations (Tmax) for conjugated and unconjugated genistein and daidzein are approximately 5-6 and 6-8 hours, respectively.', 'Renal excretion is the predominant route of elimination for dietary isoflavones, where approximately 10-60% of total administered dose is excreted in urine. Glucuronide conjugates account for the majority (70-90%) of the isoflavone content in urine, followed by sulphate conjugates (10-25%) and aglycone forms (1-10%). Fecal excretion is minimal, which accounts for 1-4% of the dietary isoflavone ingested.', 'Isoflavones are readily distributed to all tissues, and they are known to cross the placental barrier and blood brain barrier. They are also distributed to the extra-vascular compartments. In a human study, the volume of distribution of daidzein and genistein were 336.25 L and 258.76 L, respectively.', 'In a human study, the clearance rate for daidzein and genistein were 30.09 L/h and 21.85 L/h, respectively.']","['The conversion of glycosylated isoflavones to de glycosylated isoflavones begins in the oral cavity, wherein oral microflora and oral epithelium exhibit β-glucosidase activity. Further conversion is mediated by intestinal lactase phlorizin hydrolase on the luminal side of the intestinal brush border to form aglycones that diffuses into the enterocytes. The glycosylated isoflavones may also be converted to aglycone in the large intestines by the resident intestinal microflora. Isoflavone aglycones that enter the intestinal cell via passive diffusion are rapidly conjugated into sulfate or glucuronide conjugates.   Under the anaerobic, reductive conditions of the colon, genistein undergoes reduction to form dihydrogenistein and further to 5-hydroxyequol, while daidzein is reduced to dihydrodaidzein and equol. Microbial cleavage of the Ring-C of isoflavones produces deoxybenzoin metabolites (DOBs), which retains similar biological activity as unchanged isoflavones and are passively absorbed. There is a large interindividual variation in isoflavone metabolism, leading to circulating concentrations of isoflavone metabolites and parent isoflavones varying up to hundreds-fold. About 25% of the non-Asian and 50% of the Asian population host the intestinal bacteria that convert the daidzein into the isoflavonoid equol, which is a beneficial isoflavonoid.']","['The half-life of isoflavones is between 4 and 8 h. Daidzein has a longer intestinal half-life than genistein due to more rapid degradation of genistein. Individual half-life of daidzein and genistein in a human pharmacokinetic study were 7.75 h and 7.77 h, respectively.']"
2304,72305,CID 72305,C1=CN(C2=C1C(=O)N=C(N2)N)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O,,,,,,
2305,72306,Methyl 7-but-2-enylidene-1-oxocyclopenta[c]pyran-4-carboxylate,CC=CC=C1C=CC2=C1C(=O)OC=C2C(=O)OC,,,,,,
2306,72307,Sesamin,C1[C@H]2[C@H](CO[C@@H]2C3=CC4=C(C=C3)OCO4)[C@H](O1)C5=CC6=C(C=C5)OCO6,,,"['Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. (See all compounds classified as Antioxidants.)', 'Substances used to lower plasma cholesterol levels. (See all compounds classified as Anticholesteremic Agents.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)']",,,
2307,72308,5-Ethyl-1-benzyloxymethyl-6-(phenylthio)uracil,CCC1=C(N(C(=O)NC1=O)COCC2=CC=CC=C2)SC3=CC=CC=C3,,,,,,
2308,72309,Columbamine iodide,COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC(=C(C=C4CC3)OC)O)OC.[I-],,,,,,
2309,72310,Columbamine,COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC(=C(C=C4CC3)OC)O)OC,,,,,,
2310,72311,Chelerythrine chloride,C[N+]1=C2C(=C3C=CC(=C(C3=C1)OC)OC)C=CC4=CC5=C(C=C42)OCO5.[Cl-],,,"['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)', 'Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)']",,,
2311,72312,Isopilosine,CN1C=NC=C1C[C@H]2COC(=O)[C@@H]2[C@H](C3=CC=CC=C3)O,,,,,,
2312,72313,Pubescine,C[C@H]1[C@@H]2CN3CCC4=C([C@@H]3C[C@@H]2C(=CO1)C(=O)OC)NC5=C4C=CC(=C5)OC,,,,,,
2313,72314,"methyl (1R)-17-ethyl-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4,6,8,16-pentaene-1-carboxylate;hydrochloride",CCC1=CC2C[C@]3(C1N(C2)CCC4=C3NC5=CC=CC=C45)C(=O)OC.Cl,,,,,,
2314,72315,"(+)-3,4-Didehydrocoronaridine",CCC1=CC2C[C@]3(C1N(C2)CCC4=C3NC5=CC=CC=C45)C(=O)OC,,,,,,
2315,72316,"methyl 2-[(2S,3R,12bS)-3-ethenyl-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-2-yl]-3-methoxyprop-2-enoate",COC=C([C@H]1C[C@H]2C3=C(CCN2C[C@@H]1C=C)C4=CC=CC=C4N3)C(=O)OC,,,,,,
2316,72317,CID 72317,CC=C1CN[C@H]2CC3=C(C(=O)C[C@@H]1[C@H]2C(=O)OC)NC4=CC=CC=C34,,,,,,
2317,72318,"(1S,12S,13R,14S)-15-ethylidene-13-(hydroxymethyl)-3-aza-17-azoniapentacyclo[12.3.1.02,10.04,9.012,17]octadeca-2(10),4(9),5,7,16-pentaen-7-ol",CC=C1C=[N+]2[C@H]3C[C@H]1[C@H]([C@@H]2CC4=C3NC5=C4C=C(C=C5)O)CO,,,,,,
2318,72319,Plumieride,C[C@@H](C1=C[C@@]2(C=C[C@H]3[C@@H]2[C@@H](OC=C3C(=O)OC)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)OC1=O)O,,,,,,
2319,72320,"1-(Acetyloxy)-1,2-dihydroobacunoic acid e-lactone",CC(=O)O[C@H]1CC(=O)OC([C@H]2[C@]1([C@H]3CC[C@]4([C@@H](OC(=O)[C@@H]5[C@@]4([C@@]3(C(=O)C2)C)O5)C6=COC=C6)C)C)(C)C,,,,,,
2320,72321,Coptisine chloride,C1C[N+]2=C(C=C3C=CC4=C(C3=C2)OCO4)C5=CC6=C(C=C51)OCO6.[Cl-],,,,,,
2321,72322,Coptisine,C1C[N+]2=C(C=C3C=CC4=C(C3=C2)OCO4)C5=CC6=C(C=C51)OCO6,,,,"['Corydalis saxicola Bunting (Yanhuanglian) is an important component in various prescriptions in traditional Chinese medicine. Yanhuanglian has been demonstrated to possess many pharmacological activities, including antibacterial, antiviral, and anticancer activities. The active fractions are dehydrocavidine, coptisine, dehydroapocavidine, and tetradehydroscoulerine. The purpose of the present study was to examine in vivo pharmacokinetics and tissue distribution in rats by using high-performance liquid chromatography (HPLC) coupled with tandem mass spectrometry. Systemic clearance of the four active alkaloids in plasma was over 93% of hepatic blood flow, indicating they may be quickly eliminated via hepatic clearance. Less than 10% drugs was excreted via urine following intravenous and oral administration, suggesting that these four alkaloids may undergo significant metabolism in the body or the drug may be excreted via other routes other than urine. There was significantly lower excretion of these four alkaloids following oral than intravenous administration, suggesting a significant first pass effect after oral administration. There appeared to be wide distribution of those four alkaloids in rats as demonstrated by the higher apparent volume of distribution. Our results have also demonstrated that the four alkaloids can be absorbed following oral administration although there were less than 15% of drugs absorbed into systemic circulation. In summary, the favorable oral bioavailability properties of those four active alkaloids in rats make Yanhuanglian extract worth further investigation for improving oral bioavailability.', 'To study the absorption of coptisine chloride (COP) and berberrubine (BRB) as chemical constituents of some traditional Chinese medicines in human intestinal epithelial. By using Caco-2 (the human colonic adenocarcinoma cell lines) cell monolayers as an intestinal epithelial cell model, the permeability of COP and BRB were studied from apical side (AP side) to basolateral side (BL side) or from BL side to AP side. The two alkaloids were measured by reversed-phase high performance liquid chromatography (HPLC) coupled with UV detector. Transport parameters and apparent permeability coefficients (P(app)) were then calculated and compared with those of propranolol and atenolol. P(app) values were also compared with the reported values for model compounds (propranolol and atenolol). The P(app) values of COP, BRB were (1.103 +/- 0.162) x 10(-5), (1.309 +/- 0.102) x 10(-5) cm x s(-1 from AP side to BL side, and (0.300 +/- 0.041) x 10(-5) and (1.955 +/- 0.055) x 10(-5) cm x s(-1) from BL side to AP side, respectively. Their P(app) values were identical with those of propranolol [(2.23 +/- 0.10) x 10(-5 cm x s(-1)], which is a transcellular transport marker and as a control substance for high permeability. On the other hand, the efflux transport of BRB was higher 1.49 times more than its influx transport with 0.67 rate of P(app A-->B)/P(app B-->A). But P(app A-->B)/P(app B-->A value of COP was 3.67, which suggested that the efflux transport have not been involved in its absorbed mechanism in Caco-2 cells monolayers. COP and BRB can be absorbed across intestinal epithelial cells, and they are completely absorbed compounds. BRB may have been involved in efflux mechanism in Caco-2 cells monolayers model from the basolateral-to-apical direction.', 'To determine the pharmacokinetics, distribution, and mutual transformation of the total alkaloids, jatrorrhizine, coptisine, berberine, and palmatine from Coptis chinensis in rats. After the total alkaloids and berberine were fed into rats, their contents in plasma, tissues and gastrointestinal tract were determined by reversed-phase HPLC. The peak times of berberine in blood were 2.0 hr (Cmax 3.7 mg x L(-1)) and 5.0 hr Cmax 2.8 mg x L(-1)), respectively. Berberine in rat blood can be transformed into jatrorrhizine. After the rats were fed with the total alkaloids by gavage, the content of berberine was decreased monotonously, while coptisine, palmatine, and jatrorrhizine contents were increased gradually in the stomach, it speculated that berberine may be transformed into jatrorrhizine in the stomach. Animal experiments showed that berberine and palmatine were mainly distributed in the lungs of animals, followed by the distribution in the liver, while jatrorrhizine and coptisine was mainly in the liver, then in the lungs. Berberine could transform into jatrorrhizine. The mechanism on the appearance of two maximum blood concentration of berberine in blood could be explained with the propulsion of the gastrointestinal tract partly.', 'The absorption and transport mechanisms of berberine, palmatine, jateorhizine, and coptisine were studied using a Caco-2 cells uptake and transport model, with the addition of cyclosporin A and verapamil as P-glycoprotein (P-gp) inhibitors and MK-571 as a multidrug resistance-associated protein 2 (MRP(2)) inhibitor. In the uptake experiment, berberine, palmatine, jateorhizine, and coptisine were all taken into Caco-2 cells, and their uptakes were increased in the presence of cyclosporin A or verapamil. In the transport experiment, P(app) (AP-BL) was between 0.1 and 1.0 x 10(6) cm/sec for berberine, palmatine, jateorhizine, and coptisine and was lower than P(app) (BL-AB). ER values were all >2. Cyclosporin A and verapamil both increased P(app) (AP-BL) but decreased P(app) (BL-AB) for berberine, palmatine, jateorhizine, and coptisine; ER values were decreased by >50%. MK-571 had no influence on the transmembrane transport of berberine, palmatine, jateorhizine, and coptisine. At a concentration of 1-100 uM, berberine, palmatine, jateorhizine, and coptisine had no significant effects on the bidirection transport of Rho123. Berberine, palmatine, jateorhizine, and coptisine were all P-gp substrates; and at the range of 1-100 uM, berberine, palmatine, jateorhizine, and coptisine had no inhibitory effects on P-gp.', ""Jiao-Tai-Wan (JTW), an important herbal formula consists of Rhizoma coptidis and Cortex cinnamomi powder, is a famous prescription which has been used for centuries to treat insomnia in Traditional Chinese Medicine. The purpose of this study is to compare the pharmacokinetic properties of five protoberberine-type alkaloids (i.e. berberine, palmatine, coptisine, epiberberine and jatrorrhizine), the main bioactive constituents in JTW, between normal and insomnic rats. We also investigate the differences between single-dose and multiple-dose pharmacokinetics of five protoberberine-type alkaloids. The insomnic rat models were induced by intraperitoneal injection of one-dose para-chlorophenylalanine acid (PCPA). Quantification of five protoberberine-type alkaloids in rat plasma was achieved by using a rapid LC-MS/MS method. Plasma samples were collected at different time points to construct pharmacokinetic profiles by plotting drug concentration versus time and estimate pharmacokinetic parameters. An unpaired Student's t test was used for comparisons with SPSS 17.0. The five protoberberine-type alkaloids of single-dose normal groups had slow absorption and low bioavailability, as well as a delay of peak time. In the single-dose oral administration, the Cmax and Tmax of five ingredients in insomnic rats had significant differences compared with those of normal rats. In the multiple-dose oral administration, the pharmacokinetic parameters of five protoberberine-type alkaloids varied greatly in insomnic rats. In the normal rats, there were significant differences (p<0.05) in the principal pharmacokinetic parameters such as Cmax and Tmax between single-dose and multiple-dose oral administration. In the insomnic rats, the five ingredients of multiple-dose groups showed better absorption than the single-dose groups. Particularly, three peaks were observed in multiple-dose model group of plasma-concentration curves. The pharmacokinetic behavior of five protoberberine-type alkaloids was described in this paper. In both normal groups and model groups, the pharmacokinetic behavior of multiple-dose had significant differences comparing with the single-dose; either single-dose or multiple-dose, the pharmacokinetic behavior of insomnic rats had significant differences comparing the normal rats. Multiple dosing may improve the absorption of JTW in insomnic rats, which will increase the bioavailability and bring into active role in therapeutical effect.""]",,
2322,72323,Jatrorrhizine,COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC(=C(C=C4CC3)O)OC)OC,,,,,,
2323,72324,Sulfuric acid--6'-methoxycinchonan-9-ol--water (2/1/7),COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3CC4CCN3C[C@@H]4C=C)O.O.O.O.O.O.O.O.OS(=O)(=O)O.OS(=O)(=O)O,,,,,,
2324,72325,Sparteine sulphate,C1CCN2C[C@H]3C[C@@H]([C@H]2C1)CN4[C@H]3CCCC4.O.O.O.O.O.OS(=O)(=O)O,,,,,,
2325,72326,Betulin,CC(=C)[C@@H]1CC[C@]2([C@H]1[C@H]3CC[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)O)C)CO,,,,,,
2326,72327,Clevudine,CC1=CN(C(=O)NC1=O)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)F,,,['Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)'],,,
2327,72328,"tert-butyl N-[(2S,3S,5S)-6-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-benzyl-3-hydroxy-6-oxo-1-phenylhexan-2-yl]carbamate",CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N)NC(=O)[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OC(C)(C)C)O,,,,,,
2328,72329,Melosmine,CC1(C2=C(C=CC(=C2)O)C3=C(C(=C(C4=C3C1=NC=C4)OC)OC)O)C,,,,,,
2329,72330,"3,8,9-Trimethoxybenzo[c]phenanthridin-2(5h)-one",COC1=CC2=CNC3=C4C=C(C(=O)C=C4C=CC3=C2C=C1OC)OC,,,,,,
2330,72331,"Cephalotaxine, 4-methyl (2R)-2-hydroxy-2-(3-hydroxy-3-methylbutyl)butanedioate (ester)",CC(C)(CC[C@](CC(=O)OC)(C(=O)O[C@H]1[C@@H]2C3=CC4=C(C=C3CCN5[C@@]2(CCC5)C=C1OC)OCO4)O)O,,,,,,
2331,72332,"Cephalotaxine, 4-methyl (2R)-2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate (ester)",CC(C)(CCCC(CC(=O)OC)(C(=O)O[C@H]1[C@@H]2C3=CC4=C(C=C3CCN5[C@@]2(CCC5)C=C1OC)OCO4)O)O,,,,,,
2332,72333,CID 72333,C1=CC(=CC=C1C=CC(=O)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=C(OC4=CC(=O)C=C(C4=C3O)O)C5=CC=C(C=C5)O)O)O)O)O,,,,,,
2333,72334,CID 72334,COC1=CC(=O)C2=C(C=C(OC2=C1)C3=CC(=C(C=C3)O)OC)O,,,,,,
2334,72335,CID 72335,COC1=CC2=C(C3=C(NC2=CC1=O)OC=C3)OC,,,,,,
2335,72336,"[(1S,12S,13R,14R)-15-ethylidene-7-methoxy-3,17-diazapentacyclo[12.3.1.02,10.04,9.012,17]octadeca-2(10),4(9),5,7-tetraen-13-yl]methanol",CC=C1CN2[C@H]3C[C@@H]1[C@H]([C@@H]2CC4=C3NC5=C4C=C(C=C5)OC)CO,,,,,,
2336,72337,CID 72337,CC=C1C=[N+]2[C@H]3C[C@H]1[C@@H]([C@@H]2CC4=C3NC5=C4C=C(C=C5)O)C(=O)OC,,,,,,
2337,72338,Rauniticine,C[C@@H]1[C@@H]2CN3CCC4=C([C@@H]3C[C@@H]2C(=CO1)C(=O)OC)NC5=CC=CC=C45,,,,,,
2338,72339,Raunitidine,C[C@@H]1[C@@H]2CN3CCC4=C([C@@H]3C[C@@H]2C(=CO1)C(=O)OC)NC5=C4C=CC(=C5)OC,,,,,,
2339,72340,Tetrahydroalstonine,C[C@H]1[C@@H]2CN3CCC4=C([C@@H]3C[C@@H]2C(=CO1)C(=O)OC)NC5=CC=CC=C45,,,['Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)'],,,
2340,72341,Tubulosine,CC[C@H]1CN2CCC3=CC(=C(C=C3[C@@H]2C[C@@H]1C[C@@H]4C5=C(CCN4)C6=C(N5)C=CC(=C6)O)OC)OC,,,,,,
2341,72342,CID 72342,CC=C1CN2[C@H]3C[C@@]45C(C2CC1C3(C4O)C(=O)OC)N(C6=CC=CC=C56)C,,,,,,
2342,72343,Hernandezine,CN1CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)C[C@H]6C7=C(CCN6C)C(=C(C(=C7O3)OC)OC)OC)OC)OC,,,,,,
2343,72344,Nobiletin,COC1=C(C=C(C=C1)C2=CC(=O)C3=C(O2)C(=C(C(=C3OC)OC)OC)OC)OC,,,['Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. (See all compounds classified as Antioxidants.)'],,,
2344,72345,CID 72345,C1=CC(=CC=C1C2=CC(=C3C(=CC(=O)C(=C3O)OC4=CC=C(C=C4)C5=CC(=C6C(=CC(=O)C=C6O5)O)O)O2)O)O,,,,,,
2345,72346,"Piperazine, 1-(1H-indol-2-ylcarbonyl)-4-(3-((1-methylethyl)amino)-2-pyridinyl)-",CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=CC=CC=C4N3,,,,,,
2346,72347,"9-Azido-11-ethyl-6,11-dihydro-6-methyl-5H-pyrido(2,3-b)(1,5)benzodiazepin-5-one",CCN1C2=CC(=NN=[N-])C=CC2=[N+](C(=O)C3=C1N=CC=C3)C,,,,,,
2347,72348,N-Myristoylglycine,CCCCCCCCCCCCCC(=O)NCC(=O)O,,,,,,
2348,72349,"Piperazine, 1-[(4-chlorophenyl)sulfonyl]-4-[4-[[7-(trifluoromethyl)-4-quinolinyl]amino]benzoyl]-",C1CN(CCN1C(=O)C2=CC=C(C=C2)NC3=C4C=CC(=CC4=NC=C3)C(F)(F)F)S(=O)(=O)C5=CC=C(C=C5)Cl,,,,,,
2349,72350,Berberine iodide,COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OC.[I-],,,,,,
2350,72351,Pseudocoralyne,CC(=O)C1=CC(=C(C=C1CC2=NC=CC3=CC(=C(C=C32)OC)OC)OC)OC,,,,,,
2351,72352,3-(2-(Benzoxazol-2-yl)ethyl)-5-ethyl-6-methylpyridin-2(1H)-one,CCC1=C(NC(=O)C(=C1)CCC2=NC3=CC=CC=C3O2)C,,,,,,
2352,72353,"(7S,12R,13R,15S)-12,15-dihydroxy-7-methyl-8-oxabicyclo[11.3.0]hexadeca-2,10-dien-9-one",C[C@H]1CCCC=CC2C[C@@H](C[C@H]2[C@@H](C=CC(=O)O1)O)O,,,,,,
2353,72354,CID 72354,CC1=C(OC(=C(C1=O)C)OC)[C@H]2CCC(=CC(=CC3=CC=C(C=C3)[N+](=O)[O-])C)O2,,,,,,
2354,72355,"L-Valinamide, N(sup 2)-(((1-carboxy-2-phenylethyl)amino)carbonyl)-L-arginyl-N-(1-formyl-2-phenylethyl)-, (1(S),2(S))-",CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@@H](CC2=CC=CC=C2)C(=O)O,,,,,,
2355,72356,"5-Iodo-6-amino-1,2-benzopyrone",C1=CC(=O)OC2=C1C(=C(C=C2)N)I,,,,,,
2356,72357,"N-{1-Benzyl-(2R,3R)-2,3-dihydroxy-4-[3-methyl-2-(3-methyl-3-pyridin-2-ylmethyl-ureido)-butyrylamino]-5-phenyl-pentyl}-3-methyl-2-(3-methyl-3-pyridin-2-ylmethyl-ureido)-butyramide",CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H]([C@@H]([C@H](CC2=CC=CC=C2)NC(=O)[C@H](C(C)C)NC(=O)N(C)CC3=CC=CC=N3)O)O)NC(=O)N(C)CC4=CC=CC=N4,,,,,,
2357,72358,1-(2-Hydroxyethoxy)methyl-5-methyluracil,CC1=CN(C(=O)NC1=O)COCCO,,,,,,
2358,72359,5-Fluoro-1-((2-hydroxyethoxy)methyl)uracil,C1=C(C(=O)NC(=O)N1COCCO)F,,,,,,
2359,72360,"3-(Hydroxymethyl)-1,2,7-trihydroxypyrrolizidine",C1CN2[C@@H]([C@H]([C@@H]([C@H]2[C@@H]1O)O)O)CO,,,,,,
2360,72361,Glucosamine 6-sulfate,C([C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)N)O)O)OS(=O)(=O)O,,,,,,
2361,72362,H-Glu-Glu-Glu-OH,C(CC(=O)O)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N,,,,,,
2362,72363,Lysyllysyllysine,C(CCN)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O)N,,,,,,
2363,72364,H-Arg-Arg-Arg-OH.HCl,C(C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N)CN=C(N)N.Cl,,,,,,
2364,72365,CID 72365,C(C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)C(CCCN=C(N)N)N)CN=C(N)N,,,,,,
2365,72366,CID 72366,CC1=CC(=CC(=C1)SC2=C(C(=O)N=C(N2COCCO)S)C(C)C)C,,,,,,
2366,72367,"(1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,33R,35S,36R,37S)-33-[(2R,3S,4S,5S,6R)-3,5-dihydroxy-4-[[(3S)-3-hydroxy-3-[(4R,5R)-5-hydroxy-2-phenyl-1,3-dioxan-4-yl]-2-oxopropyl]amino]-6-methyloxan-2-yl]oxy-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid;(2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol",C[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@@H](C[C@H]2[C@@H]([C@H](C[C@](O2)(C[C@H](C[C@H]([C@@H](CC[C@H](C[C@H](CC(=O)O[C@H]([C@@H]([C@@H]1O)C)C)O)O)O)O)O)O)O)C(=O)O)O[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)C)O)NCC(=O)[C@H]([C@H]4[C@@H](COC(O4)C5=CC=CC=C5)O)O)O.CNC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O,,,,,,
2367,72368,"(1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,33R,35S,36R,37S)-33-[(2R,3S,4S,5S,6R)-3,5-dihydroxy-4-[[(3S)-3-hydroxy-3-[(4R,5R)-5-hydroxy-2-phenyl-1,3-dioxan-4-yl]-2-oxopropyl]amino]-6-methyloxan-2-yl]oxy-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid",C[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@@H](C[C@H]2[C@@H]([C@H](C[C@](O2)(C[C@H](C[C@H]([C@@H](CC[C@H](C[C@H](CC(=O)O[C@H]([C@@H]([C@@H]1O)C)C)O)O)O)O)O)O)O)C(=O)O)O[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)C)O)NCC(=O)[C@H]([C@H]4[C@@H](COC(O4)C5=CC=CC=C5)O)O)O,,,,,,
2368,72369,Tripterifordin,C[C@@]12CCC[C@@]3([C@@H]1CC[C@]45[C@H]3CC[C@H](C4)[C@](C5)(C)O)COC2=O,,,,,,
2369,72370,"(2R)-2-[(5S,6R)-6-[(2S,3S,4S,6R)-6-[(3S,5R,7S,9S,10S,12R,15R)-3-[(2R,5R,6S)-5-ethyl-5-hydroxy-6-methyloxan-2-yl]-15-hydroxy-3,10,12-trimethyl-4,6,8-trioxadispiro[4.1.57.35]pentadec-13-en-9-yl]-3-hydroxy-4-methyl-5-oxooctan-2-yl]-5-methyloxan-2-yl]butanoic acid",CC[C@H]([C@@H]1[C@H](C[C@H]([C@@]2(O1)C=C[C@H]([C@]3(O2)CC[C@@](O3)(C)[C@H]4CC[C@@]([C@@H](O4)C)(CC)O)O)C)C)C(=O)[C@@H](C)[C@H]([C@H](C)[C@H]5[C@H](CCC(O5)[C@@H](CC)C(=O)O)C)O,,,,"['Salinomycin was administered to chickens orally and intravenously to determine blood concentration, kinetic behavior, bioavailability and tissue residues. The drug was given by intracrop and intravenous routes in a single dose of 20 mg kg-1 body-weight. The highest serum concentrations of salinomycin were reached half an hour after oral dosage with an absorption half-life (t0.5(ab)) of 3.64 hours and elimination half-life (t0.5(beta)) of 1.96 hours. The systemic bioavailability percentage was 73.02 per cent after intracrop administration, indicating the high extent of salinomycin absorption from this route in chickens. Following intravenous injection the kinetics of salinomycin can be described by a two-compartment open model with a t1/2(alpha) of 0.48 hours, Vd ss (volume of distribution) of 3.28 litre kg-1 and Cl(beta) (total body clearance) of 27.39 ml kg-1 min-1. The serum protein-binding tendency of salinomycin as calculated in vitro was 19.78 per cent. Salinomycin concentrations in the serum and tissues of birds administered salinomycin premix (60 ppm) for two weeks were lower than those after administration of a single intracrop dose of pure salinomycin (20 mg kg-1 bodyweight). The highest concentration of salinomycin residues were present in the liver followed by the kidneys, muscles, fat, heart and skin. No salinomycin residues were detected in tissues after 48 hours except in the liver and these had disappeared completely by 72 hours.']","['... Salinomycin (SAL), a broad spectrum antibiotic and a coccidiostat has been found to counter tumour resistance and kill cancer stem cells with better efficacy than the existing chemotherapeutic agents; paclitaxel and doxorubicin. This refocused its importance for treatment of human cancers. In this study, we studied the in vitro drug metabolism and pharmacokinetic parameters of SAL. SAL undergoes rapid metabolism in liver microsomes and has a high intrinsic clearance. SAL metabolism is mainly mediated by CYP enzymes; CYP3A4 the major enzyme metabolising SAL. The percent plasma protein binding of SAL in human was significantly lower as compared to mouse and rat plasma. CYP inhibition was carried out by chemical inhibition and recombinant enzyme studies. SAL was found to be a moderate inhibitor of CYP2D6 as well as CYP3A4. As CYP3A4 was the major enzyme responsible for metabolism of SAL, in vivo pharmacokinetic study in rats was done to check the effect of concomitant administration of Ketoconazole (KTC) on SAL pharmacokinetics. KTC, being a selective CYP3A4 inhibitor increased the systemic exposure of SAL significantly to 7-fold in AUC0-a and 3-fold increase in Cmax of SAL in rats with concomitant KTC administration.']",['... The drug was given by intracrop and intravenous routes in a single dose of 20 mg kg-1 body-weight. The highest serum concentrations of salinomycin were reached half an hour after oral dosage with an absorption half-life (t0.5(ab)) of 3.64 hours and elimination half-life (t0.5(beta)) of 1.96 hours. ...']
2370,72371,4'-Thiothymidine,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](S2)CO)O,,,,,,
2371,72372,"[(1R,4S,5R)-4-(6-aminopurin-9-yl)-5-(hydroxymethyl)cyclopent-2-en-1-yl]methanol",C1=C[C@@H]([C@@H]([C@@H]1CO)CO)N2C=NC3=C(N=CN=C32)N,,,,,,
2372,72373,Acuagel; Adjoen,C=CCSSC=CCS(=O)CC=C,,,"['Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)', 'Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)', 'Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)']",,,
2373,72374,"Dibenz[b,f][1,4]oxazepin-11(10H)-one",C1=CC=C2C(=C1)C(=O)NC3=CC=CC=C3O2,,,,,,
2374,72375,Methyl blue free acid,C1=CC(=NC2=CC=C(C=C2)S(=O)(=O)O)C=CC1=C(C3=CC=C(C=C3)NC4=CC=C(C=C4)S(=O)(=O)O)C5=CC=C(C=C5)NC6=CC=C(C=C6)S(=O)(=O)O,,,"['Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant and Hackh&apos;s Chemical Dictionary, 5th ed, p301, p499) (See all compounds classified as Indicators and Reagents.)']",,,
2375,72376,Narciclasine,C1OC2=C(O1)C(=C3C(=C2)C4=C[C@@H]([C@H]([C@H]([C@@H]4NC3=O)O)O)O)O,,,,,,
2376,72377,"(1R,2S,3S,4S,4aR)-1,2,3,4,7-pentahydroxy-2,3,4,4a,5,11b-hexahydro-1H-[1,3]dioxolo[4,5-j]phenanthridin-6-one",C1OC2=C(O1)C(=C3C(=C2)C4[C@H]([C@@H]([C@@H]([C@H]([C@@H]4O)O)O)O)NC3=O)O,,,,,,
2377,72378,Lycorine,C1CN2CC3=CC4=C(C=C3[C@H]5[C@H]2C1=C[C@@H]([C@H]5O)O)OCO4,,,,,,
2378,72379,"Galanthan-1,2,10-triol, 3,12-didehydro-9-methoxy-, (1-alpha,2-beta)-",COC1=C(C=C2[C@H]3[C@H]([C@@H](C=C4[C@@H]3N(CC4)CC2=C1)O)O)OC,,,,,,
2379,72380,"Cyclo(L-alanyl-2-mercapto-L-tryptophanyl-4,5-dihydroxy-L-leucyl-L-valyl-erythro-3-hydroxy-D-alpha-aspartyl-L-cysteinyl-cis-4-hydroxy-L-prolyl, cyclic (2, 6)-sulfide",C[C@H]1C(=O)N[C@H]2CC3=C(NC4=CC=CC=C34)SC[C@@H](C(=O)N5CC(C[C@H]5C(=O)N1)O)NC(=O)[C@H](NC(=O)C(NC(=O)[C@@H](NC2=O)C[C@@](C)(CO)O)C(C)C)C(=O)O,,,,,,
2380,72381,3-[N-[(5-Ethyl-2-methoxy-6-methyl-3-pyridyl)methyl]amino]-5-ethyl-6-methylpyridin-2(1H)-one,CCC1=CC(=C(N=C1C)OC)CNC2=CC(=C(NC2=O)C)CC,,,,,,
2381,72382,"2-[4-[2-[[2-[4-(Carboxymethoxy)-2,3-dichlorophenyl]-1-[5-(2-chlorophenyl)dithiol-3-ylidene]-2-oxoethyl]disulfanyl]-2-[5-(2-chlorophenyl)dithiol-3-ylidene]acetyl]-2,3-dichlorophenoxy]acetic acid",C1=CC=C(C(=C1)C2=CC(=C(C(=O)C3=C(C(=C(C=C3)OCC(=O)O)Cl)Cl)SSC(=C4C=C(SS4)C5=CC=CC=C5Cl)C(=O)C6=C(C(=C(C=C6)OCC(=O)O)Cl)Cl)SS2)Cl,,,,,,
2382,72383,"2-[4-[2-[[2-[4-(Carboxymethoxy)-2,3-dichlorophenyl]-1-[5-(4-chlorophenyl)dithiol-3-ylidene]-2-oxoethyl]disulfanyl]-2-[5-(4-chlorophenyl)dithiol-3-ylidene]acetyl]-2,3-dichlorophenoxy]acetic acid",C1=CC(=CC=C1C2=CC(=C(C(=O)C3=C(C(=C(C=C3)OCC(=O)O)Cl)Cl)SSC(=C4C=C(SS4)C5=CC=C(C=C5)Cl)C(=O)C6=C(C(=C(C=C6)OCC(=O)O)Cl)Cl)SS2)Cl,,,,,,
2383,72384,"23-(Nonylphenoxy)-3,6,9,12,15,18,21-heptaoxatricosan-1-ol",CCCCCCCCCC1=CC=C(C=C1)OCCOCCOCCOCCOCCOCCOCCOCCO,,,,,,
2384,72385,Nonoxynol-9,CCCCCCCCCC1=CC=C(C=C1)OCCOCCOCCOCCOCCOCCOCCOCCOCCO,"['Nonoxynol 9 is a surfactant spermicide used for contraception in spermicidal creams, jellies, foams, gel, and lubricants. It is also used in conjuction with other methods of contraception, including condoms, cervical caps and diaphragms.']",,"['Chemical substances that are destructive to spermatozoa used as topically administered vaginal contraceptives. (See all compounds classified as Spermatocidal Agents.)', 'Agents that modify interfacial tension of water; usually substances that have one lipophilic and one hydrophilic group in the molecule; includes soaps, detergents, emulsifiers, dispersing and wetting agents, and several groups of antiseptics. (See all compounds classified as Surface-Active Agents.)']","['In mice intravenously injected with (14)C-Nonoxynol-9, the highest amounts of radioactivity were reported for the small and large intestines. (14)C radioactivity was excreted mainly in the urine and feces. An HPLC analysis of the urine and bile indicated that no intact Nonoxynol-9 was present in the bile or urine, and that Nonoxynol-9 was metabolized to highly polar species.', 'In in vitro skin penetration studies using cadaver skin (rinse off and leave-on protocols), the total skin penetration of Nonoxynol-2, -4, and -9 was less than 1 % over a period of 48 hours.', 'The disposition of nonoxynol-9 labeled with (14)C at the ethylene oxide units was studied following an iv or vaginal administration to female Sprague-Dawley rats. The results from the vaginal administration studies indicate 12.8% absorption of (14)C radioactivity in 6.0 hr and 37.7% in 24.0 hr. Tissue distribution studies showed that the small and large intestines, including their contents, had the highest (14)C activity by either route of administration. Radiomonitored HPLC of bile collected at 6.0 hr and urine at 6.0, 24.0, and 48.0 hr following an iv injection of (14)C nonoxynol-9 showed that the compound was completely metabolized in the body of the rat. The metabolites were primarily excreted in the feces and secondarily in the urine. Analysis of urinary metabolites containing the (14)C label, 6.0 hr following an iv dose, indicated the presence of highly polar neutral (53.27%) and acidic (39.23%) species.']",,
2385,72386,Thiarubrine A,CC#CC1=CC=C(SS1)C#CC#CC=C,,,,,,
2386,72387,"2-[4-(6-Prop-1-ynyldithiin-3-yl)buta-1,3-diynyl]oxirane",CC#CC1=CC=C(SS1)C#CC#CC2CO2,,,,,,
2387,72388,Anolignan B,C=C(CC1=CC=C(C=C1)O)C(=C)CC2=CC=C(C=C2)O,,,,,,
2388,72389,"(16-Benzyl-12-hydroxy-5,7,14-trimethyl-13-methylidene-18-oxo-17-azatricyclo[9.7.0.01,15]octadeca-3,9-dien-2-yl) acetate",CC1CC=CC2C(C(=C)C(C3C2(C(C=CC(C1)C)OC(=O)C)C(=O)NC3CC4=CC=CC=C4)C)O,,,,,,
2389,72390,Procysteine,C1[C@H](NC(=O)S1)C(=O)O,,,,,,
2390,72391,Anolignan A,C=C(CC1=CC2=C(C=C1)OCO2)C(=C)CC3=C(C=C(C=C3)O)O,,,,,,
2391,72392,Neamine,C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)N)O)O)N,,,,,,
2392,72393,Butirosin,C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1NC(=O)[C@@H](CCN)O)O)O[C@@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CN)O)O)N)N,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
2393,72394,lividomycin A,C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H](C[C@@H]([C@H](O2)CO)O)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O[C@@H]4[C@@H]([C@H]([C@@H]([C@@H](O4)CN)O[C@@H]5[C@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)O)N)O)O)N,,,,,,
2394,72395,Gentamicin C1,C[C@H]([C@@H]1CC[C@H]([C@H](O1)O[C@@H]2[C@H](C[C@H]([C@@H]([C@H]2O)O[C@@H]3[C@@H]([C@H]([C@@](CO3)(C)O)NC)O)N)N)N)NC,,,,"['/MILK/ Gentamicin is distributed into milk following IM administration.', 'Gentamicin is distributed into cerebrospinal fluid (CSF) in low concentrations following IM or IV administration. CSF concentrations of gentamicin following intrathecal administration depend on the dose administered, the site of injection, the volume in which the dose is diluted, and the presence or absence of obstruction to CSF flow. There may be considerable interpatient variation in concentrations achieved. In one study, intrathecal administration of 4 mg of gentamicin resulted in CSF concentrations of the drug of 19-46 ug/mL for 8 hours and less than 3 ug/mL at 20 hours. Gentamicin crosses the placenta.', 'Following parenteral administration of usual dosages of gentamicin, the drug can be detected in lymph, subcutaneous tissue, lung, sputum, and bronchial, pleural, pericardial, synovial, ascitic, and peritoneal fluids. Concentrations in bile may be low, suggesting minimal biliary excretion. In patients with ventilator-associated pneumonia receiving IV gentamicin (240 mg once daily), drug concentrations in alveolar lining fluid were 32% of serum concentrations and averaged 4.24 ug/mL 2 hours after a dose. Only minimal concentrations of gentamicin are attained in ocular tissue following IM or IV administration.', 'Accumulation of gentamicin does not appear to occur in patients with normal renal function receiving 1-mg/kg doses every 8 hours for 7-10 days. However, accumulation may occur with higher doses and/or when the drug is given for prolonged periods, especially in patients with renal impairment.', 'For more Absorption, Distribution and Excretion (Complete) data for Gentamicin (18 total), please visit the HSDB record page.']","['Gentamicin is not metabolized. It is excreted by glomerular filtration in an active, unchanged form.']","['The plasma elimination half-life of gentamicin is usually 2-4 hours in adults with normal renal function and is reported to range from 24-60 hours in adults with severe renal impairment. The serum half-life of gentamicin averages 3-3.5 hours in infants 1 week to 6 months of age and 5.5 hours in full-term infants and large premature infants less than 1 week of age. In small premature infants, the plasma half-life is approximately 5 hours in those weighing over 2 kg, 8 hours in those weighing 1.5-2 kg, and 11.5 hours in those weighing less than 1.5 kg.', '... terminal elimination half-lives of greater than 100 hours have been reported in adults with normal renal function following repeated IM or IV administration of the drug.']"
2395,72396,Gentamicin C1a,C[C@@]1(CO[C@@H]([C@@H]([C@H]1NC)O)O[C@H]2[C@@H](C[C@@H]([C@H]([C@@H]2O)O[C@@H]3[C@@H](CC[C@H](O3)CN)N)N)N)O,,,,,,
2396,72397,Gentamicin C2,C[C@H]([C@@H]1CC[C@H]([C@H](O1)O[C@@H]2[C@H](C[C@H]([C@@H]([C@H]2O)O[C@@H]3[C@@H]([C@H]([C@@](CO3)(C)O)NC)O)N)N)N)N,,,,,,
2397,72398,"(7S,9S)-7-[(2R,5S,6S)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione",C[C@H]1[C@H](C(C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)O)O,,,,,,
2398,72399,5-Iminodaunorubicin hydrochloride,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=N)C(=CC=C5)OC)O)(C(=O)C)O)N)O.Cl,,,"['Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. (See all compounds classified as Antibiotics, Antineoplastic.)']",,,
2399,72400,5-Iminodaunorubicin,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=N)C(=CC=C5)OC)O)(C(=O)C)O)N)O,,,"['Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. (See all compounds classified as Antibiotics, Antineoplastic.)']",,,
2400,72401,Adriamycinone,COC1=CC=CC2=C1C(=O)C3=C(C4=C(C[C@](C[C@@H]4O)(C(=O)CO)O)C(=C3C2=O)O)O,,,,,,
2401,72402,9-Aminocamptothecin,CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC=C5N=C4C3=C2)N)O,,,['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)'],,,
2402,72403,"10,11-Methylenedioxy-20S-camptothecin",CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=C(C3=C2)N=C5C=C6C(=CC5=C4)OCO6)O,,,,,,
2403,72404,"(4r,5s,6s,7r)-4,7-Dibenzyl-5,6-dihydroxy-1,3-bis[4-(hydroxymethyl)benzyl]-1,3-diazepan-2-one",C1=CC=C(C=C1)C[C@@H]2[C@@H]([C@H]([C@H](N(C(=O)N2CC3=CC=C(C=C3)CO)CC4=CC=C(C=C4)CO)CC5=CC=CC=C5)O)O,,,"['Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly. (See all compounds classified as HIV Protease Inhibitors.)']",,,
2404,72405,CID 72405,C([C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)[S-])O)O)O)O.[Na+],,,,,,
2405,72406,CID 72406,CC(C)CCCC(C)[C@H]1CCC2[C@@]1(CCC3C2CCC4[C@@]3(CC[C@@H](C4)CCC=C(C5=CC(=C(C(=C5)Cl)O)C(=O)O)C6=CC(=C(C(=C6)Cl)O)C(=O)[O-])C)C.[NH4+],,,,,,
2406,72407,"5-{1-(3-Carboxy-5-chloro-4-hydroxyphenyl)-4-[1-(1,5-dimethylhexyl)-9a,11a-dimethylperhydrocyclopenta[a]phenanthren-7-yl]-1-butenyl}-3-chloro-2-hydroxybenzoic acid",CC(C)CCCC(C)[C@H]1CCC2[C@@]1(CCC3C2CCC4[C@@]3(CC[C@@H](C4)CCC=C(C5=CC(=C(C(=C5)Cl)O)C(=O)O)C6=CC(=C(C(=C6)Cl)O)C(=O)O)C)C,,,,,,
2407,72408,"4-amino-5-bromo-1-[(2S,5R)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one",C1[C@@H](O[C@@H](S1)CO)N2C=C(C(=NC2=O)N)Br,,,,,,
2408,72409,CID 72409,C1[C@@H](O[C@@H](S1)CO)N2C=NC3=C2NC=NC3=O,,,,,,
2409,72410,"1,3-Oxathiolane-2-methanol, 5-(2-amino-6-chloro-9H-purin-9-yl)-, (2S-cis)-",C1[C@@H](O[C@@H](S1)CO)N2C=NC3=C2N=C(N=C3Cl)N,,,,,,
2410,72411,"(3S,4S)-4-[8-[[(1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-9-hydroxy-5a,5b,8,8,11a-pentamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carbonyl]amino]octanoylamino]-3-hydroxy-6-methylheptanoic acid",CC(C)C[C@@H]([C@H](CC(=O)O)O)NC(=O)CCCCCCCNC(=O)[C@]12CC[C@H]([C@@H]1[C@H]3CC[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)O)C)C(=C)C,,,,,,
2411,72412,Inophyllum B,C[C@@H]1[C@H](OC2=C([C@H]1O)C3=C(C(=CC(=O)O3)C4=CC=CC=C4)C5=C2C=CC(O5)(C)C)C,,,,,,
2412,72413,"2',3'-Dideoxy-beta-5-fluorocytidine",C1C[C@H](O[C@H]1CO)N2C=C(C(=NC2=O)N)F,,,,,,
2413,72414,Suksdorfin,CC(C)CC(=O)O[C@H]1[C@H](C(OC2=C1C3=C(C=C2)C=CC(=O)O3)(C)C)OC(=O)C,,,,,,
2414,72415,Deoxoqinghaosu,C[C@H]1CC2C[C@@](OCC23C(=C[C@H](COO3)C)C1)(C)O,,,,,,
2415,72416,Artemotil,CCO[C@@H]1[C@@H]([C@@H]2CC[C@H]([C@H]3[C@]24[C@H](O1)OC(CC3)(OO4)C)C)C,,,"['Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585) (See all compounds classified as Antimalarials.)', 'Agents which are destructive to amebae, especially the parasitic species causing AMEBIASIS in man and animal. (See all compounds classified as Amebicides.)', 'Agents that act systemically to kill adult schistosomes. (See all compounds classified as Schistosomicides.)']",,,
2416,72417,"6-Chloro-4(S)-cyclopropyl-3,4-dihydro-4-((2-pyridyl)ethynyl)quinazolin-2(1H)-one",C1CC1[C@@]2(C3=C(C=CC(=C3)Cl)NC(=O)N2)C#CC4=CC=CC=N4,,,,,,
2417,72418,"1,2-Dithiolane-3-carboxylic acid",C1CSSC1C(=O)O,,,,,,
2418,72419,"3-hydroxy-N-[6-hydroxy-9-(8-hydroxy-1,5,7-trimethyl-3,6-dioxo-2-oxa-5-azaspiro[3.4]octan-8-yl)-9-methoxy-7-methylnona-2,4-dienyl]-2,2,4-trimethyl-10-(2-methyl-1,3-oxazol-5-yl)deca-4,6,8-trienamide",CC1C(=O)N(C2(C1(C(CC(C)C(C=CC=CCNC(=O)C(C)(C)C(C(=CC=CC=CCC3=CN=C(O3)C)C)O)O)OC)O)C(OC2=O)C)C,,,,,,
2419,72420,CID 72420,C[C@@]12C[C@H](C([C@]1(CC(=O)[C@@]3([C@H]2CC=C4[C@H]3C[C@@H]([C@H](C4(C)C)O)O)C)C)[C@](C)(C(=O)C=CC(C)(C)O)O)O,,,,,,
2420,72421,"(2S,3S,8S,9R,10R,13R,14S,16R)-17-[(1R)-1,5-dihydroxy-1,5-dimethyl-2-oxo-hexyl]-2,3,16-trihydroxy-4,4,9,13,14-pentamethyl-1,2,3,7,8,10,12,15,16,17-decahydrocyclopenta[a]phenanthren-11-one",C[C@@]12C[C@H](C([C@]1(CC(=O)[C@@]3([C@H]2CC=C4[C@H]3C[C@@H]([C@H](C4(C)C)O)O)C)C)[C@](C)(C(=O)CCC(C)(C)O)O)O,,,,,,
2421,72422,Mesoporphyrin IX,CCC1=C(C2=CC3=C(C(=C(N3)C=C4C(=C(C(=N4)C=C5C(=C(C(=N5)C=C1N2)C)CCC(=O)O)CCC(=O)O)C)C)CC)C,,,,,,
2422,72423,uroporphyrin III,C1=C2C(=C(C(=CC3=NC(=CC4=NC(=CC5=C(C(=C1N5)CCC(=O)O)CC(=O)O)C(=C4CCC(=O)O)CC(=O)O)C(=C3CCC(=O)O)CC(=O)O)N2)CC(=O)O)CCC(=O)O,,,,,,
2423,72424,Uroporphyrin I,C1=C2C(=C(C(=CC3=NC(=CC4=NC(=CC5=C(C(=C1N5)CC(=O)O)CCC(=O)O)C(=C4CCC(=O)O)CC(=O)O)C(=C3CCC(=O)O)CC(=O)O)N2)CC(=O)O)CCC(=O)O,,,,,,
2424,72425,Teleocidin B4,CC(C)[C@H]1C(=O)N[C@@H](CC2=CNC3=C4C(=CC(=C23)N1C)[C@@](CC[C@]4(C)C=C)(C)C(C)C)CO,,,"['Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)', 'Drugs that act locally on cutaneous or mucosal surfaces to produce inflammation; those that cause redness due to hyperemia are rubefacients; those that raise blisters are vesicants and those that penetrate sebaceous glands and cause abscesses are pustulants; tear gases and mustard gases are also irritants. (See all compounds classified as Irritants.)']",,,
2425,72426,Daphnodorin A,C1CC2=C(C3=C(C=C2O)OC(=C3C(=O)C4=C(C=C(C=C4O)O)O)C5=CC=C(C=C5)O)O[C@@H]1C6=CC=C(C=C6)O,,,,,,
2426,72427,Daphnodorin B,C1[C@@H]([C@H](OC2=C1C(=CC3=C2C(=C(O3)C4=CC=C(C=C4)O)C(=O)C5=C(C=C(C=C5O)O)O)O)C6=CC=C(C=C6)O)O,,,,,,
2427,72428,Daphnodorin C,C1CC2=C(C3=C(C=C2O)O[C@H]([C@]34C(=O)C5=C(C=C(C=C5O4)O)O)C6=CC=C(C=C6)O)O[C@@H]1C7=CC=C(C=C7)O,,,,,,
2428,72429,Leupeptin,CC(C)C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C=O)NC(=O)C,,,['Exogenous and endogenous compounds which inhibit CYSTEINE ENDOPEPTIDASES. (See all compounds classified as Cysteine Proteinase Inhibitors.)'],,,
2429,72430,Calpain Inhibitor III,CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C=O)NC(=O)OCC2=CC=CC=C2,,,['Exogenous and endogenous compounds which inhibit CYSTEINE ENDOPEPTIDASES. (See all compounds classified as Cysteine Proteinase Inhibitors.)'],,,
2430,72431,"2-methyl-2-butenoic acid [(9R,10R)-9-acetyloxy-8,8-dimethyl-2-oxo-9,10-dihydropyrano[2,3-f][1]benzopyran-10-yl] ester",CC=C(C)C(=O)O[C@H]1[C@H](C(OC2=C1C3=C(C=C2)C=CC(=O)O3)(C)C)OC(=O)C,,,,,,
2431,72432,3-S-Glucopyranosyl-3-thioglucose,C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O)O)S[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O)O,,,,,,
2432,72433,CID 72433,COC1=CC(=O)C2=C(C3=C(C(=CC(=C3OC2=C1)O)C4=C5C(=C(C(=C4O)[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)O)C(=O)C=C(O5)C7=CC(=C(C=C7)O)O)O)O,,,,,,
2433,72434,Isodeoxypodophyllotoxin,COC1=CC(=CC(=C1OC)OC)[C@H]2[C@@H]3C(CC4=CC5=C(C=C24)OCO5)COC3=O,,,"['Semisynthetic conjugates of various toxic molecules, including RADIOACTIVE ISOTOPES and bacterial or plant toxins, with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; and ANTIGENS. The antitumor or antiviral immune substance carries the toxin to the tumor or infected cell where the toxin exerts its poisonous effect. (See all compounds classified as Immunotoxins.)', 'Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)']",,,
2434,72435,Picropodophyllin,COC1=CC(=CC(=C1OC)OC)[C@H]2[C@H]3[C@H](COC3=O)[C@H](C4=CC5=C(C=C24)OCO5)O,,,,,,
2435,72436,"2,2'-(1,4-Butanediylbis(oxy(3-methoxy-4,1-phenylene)))bis(4,5-dihydro)-1H-imidazole",COC1=C(C=CC(=C1)C2=NCCN2)OCCCCOC3=C(C=C(C=C3)C4=NCCN4)OC,,,,,,
2436,72437,"1,3-Bis(4-amidino-2-methoxyphenoxy)propane",COC1=C(C=CC(=C1)C(=N)N)OCCCOC2=C(C=C(C=C2)C(=N)N)OC,,,,,,
2437,72438,Methylbenzoprim,CCC1=C(C(=NC(=N1)N)N)C2=CC(=C(C=C2)N(C)CC3=CC=CC=C3)[N+](=O)[O-],,,"['Inhibitors of the enzyme, dihydrofolate reductase (TETRAHYDROFOLATE DEHYDROGENASE), which converts dihydrofolate (FH2) to tetrahydrofolate (FH4). They are frequently used in cancer chemotherapy. (From AMA, Drug Evaluations Annual, 1994, p2033) (See all compounds classified as Folic Acid Antagonists.)']",,,
2438,72439,Bromochloromethotrexate,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=C(C=C(C=C3Br)C(=O)N[C@@H](CCC(=O)O)C(=O)O)Cl,,,,,,
2439,72440,D-Amethopterin,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@H](CCC(=O)O)C(=O)O,,,,,,
2440,72441,Deoxyaminopteroic acid,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)O,,,,,,
2441,72442,"4-Morpholineethanamine, N-(4,5-dimethoxy-2-nitrophenyl)-",COC1=C(C=C(C(=C1)NCCN2CCOCC2)[N+](=O)[O-])OC,,,,,,
2442,72443,CID 72443,C1=NC(=O)C2=NNC(=C2N1)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O,,,,,,
2443,72444,CID 72444,C[C@H]([C@@H]1[C@@H]2N(C1=O)C(=C(S2)SCCOC(=O)N)C(=O)[O-])O.[Na+],,,,,,
2444,72445,2-Carbamoyloxyethylthio-6-(1-hydroxyethyl)penem-3-carboxylic acid,C[C@H]([C@@H]1[C@@H]2N(C1=O)C(=C(S2)SCCOC(=O)N)C(=O)O)O,,,,,,
2445,72446,"(3S)-3,6-diamino-N-[[(2S,5S,11S,15S)-15-amino-11-[(6R)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-methyl-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide",C[C@H]1C(=O)N[C@H](C(=O)NC(=CNC(=O)N)C(=O)N[C@H](C(=O)NC[C@@H](C(=O)N1)N)[C@H]2CCN=C(N2)N)CNC(=O)C[C@H](CCCN)N,,,,,,
2446,72447,"N-(alpha-Guanidino-3,5-dihydroxy-4-isopropylphenylacetyl)glycine",CC(C)C1=C(C=C(C=C1O)[C@@H](C(=O)NCC(=O)O)N=C(N)N)O,,,,,,
2447,72448,"(S)-7-(3-Amino-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid",C1CN(C[C@H]1N)C2=C(C=C3C(=O)C(=CN(C3=N2)C4CC4)C(=O)O)F,,,,,,
2448,72449,CID 72449,CC[C@H]1[C@](C2[C@@H]([C@@H]([C@@H](C[C@@]([C@@H]([C@@H]([C@@H]([C@@H](C(=O)O1)C)O[C@@H]3C[C@@]([C@@H]([C@@H](O3)C)O)(C)OC)C)O[C@@H]4[C@@H]([C@@H](C[C@@H](O4)C)N(C)C)O)(C)O)C)N[C@H](O2)COCCOC)C)(C)O,,,,,,
2449,72450,"6-N-(2-amino-1,6-dimethylpyrimidin-1-ium-4-yl)-1,2-dimethylquinolin-1-ium-4,6-diamine;chloride;hydrochloride",CC1=CC(=C2C=C(C=CC2=[N+]1C)NC3=NC(=[N+](C(=C3)C)C)N)N.Cl.[Cl-],,,,,,
2450,72451,"6-N-(2-amino-1,6-dimethylpyrimidin-1-ium-4-yl)-1,2-dimethylquinolin-1-ium-4,6-diamine",CC1=CC(=C2C=C(C=CC2=[N+]1C)NC3=NC(=[N+](C(=C3)C)C)N)N,,,,,,
2451,72452,Isometamidium,CC[N+]1=C2C=C(C=CC2=C3C=CC(=CC3=C1C4=CC=CC=C4)N=NNC5=CC=CC(=C5)C(=N)N)N,,,['Agents destructive to the protozoal organisms belonging to the suborder TRYPANOSOMATINA. (See all compounds classified as Trypanocidal Agents.)'],,,
2452,72453,"1,7-Heptanediamine, N,N'-bis(3-((phenylmethyl)amino)propyl)-",C1=CC=C(C=C1)CNCCCNCCCCCCCNCCCNCC2=CC=CC=C2,,,,,,
2453,72454,Halofantrina,CCCCN(CCCC)CC[C@@H](C1=C2C=CC(=CC2=C3C=C(C=C(C3=C1)Cl)Cl)C(F)(F)F)O,,,,,,
2454,72455,9-((2-Chloro-6-fluorophenyl)methyl)-9H-purin-6-amine 1-oxide,C1=CC(=C(C(=C1)Cl)CN2C=NC3=C2N=CN(C3=N)O)F,,,,,,
2455,72456,Amicarbalide isethionate,C1=CC(=CC(=C1)NC(=O)NC2=CC=CC(=C2)C(=N)N)C(=N)N.C(CS(=O)(=O)O)O,,,,,,
2456,72457,Topsentin,C1=CC=C2C(=C1)C(=CN2)C3=CN=C(N3)C(=O)C4=CNC5=C4C=CC(=C5)O,,,,,,
2457,72458,Einecs 239-293-7,C[C@@]1(C2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)[O-])O)[O-])C(=O)N)N(C)C)O)O.[Ca+2],,,,,,
2458,72459,CID 72459,C[C@@]1(C2[C@@H]([C@H]3[C@@H](C(=O)C(=C(N)O)C(=O)[C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)N(C)C)O)O,,,,,,
2459,72460,"2-[[5-[5-Amino-3-hydroxy-6-methyl-4-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]oxy-1,6,9,14-tetrahydroxy-11-methoxy-3-methyl-8,13-dioxo-5,6-dihydrobenzo[a]tetracene-2-carbonyl]amino]acetic acid",CC1C(C(C(C(O1)OC2C(C3=CC4=C(C(=C3C5=C2C=C(C(=C5O)C(=O)NCC(=O)O)C)O)C(=O)C6=C(C4=O)C(=CC(=C6)OC)O)O)O)OC7C(C(C(CO7)O)O)O)N,,,,,,
2460,72461,CID 72461,C[C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](C3=CC4=C(C(=C3C5=C2C=C(C(=C5O)C(=O)N[C@@H](C)C(=O)O)C)O)C(=O)C6=C(C4=O)C(=CC(=C6)OC)O)O)O)O)NC,,,,,,
2461,72462,Chlorsulfaquinoxaline,C1=CC2=NC(=CN=C2C(=C1)Cl)NS(=O)(=O)C3=CC=C(C=C3)N,,,,,,
2462,72463,CID 72463,CON=C(C1=CSC(=N1)N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)CSC4=NN=NN4CCNS(=O)(=O)O)C(=O)O,,,,,,
2463,72464,CID 72464,C[C@H]1C=CC=C(C(=O)N=C2C(=CNN=CN3CCCCC3)C(=O)C4=C(C2=O)C(=C(C5=C4C(=O)[C@](O5)(OC=C[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)C,,,,,,
2464,72465,CID 72465,CCCC(CC=CC=CC(=O)OC[C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](O[C@@]3([C@@H]([C@H]2OC(=O)C=CC=CCC(C(=CC=CCCC(C)CC)C)O)O)C4=C(CO3)C=C(C=C4O)O)CO)O)O)O)O,,,,,,
2465,72466,Blenoxane,CC1=C(N=C(N=C1N)C(CC(=O)N)NCC(C(=O)N)N)C(=O)NC(C(C2=CN=CN2)O[C@H]3[C@H]([C@H]([C@@H]([C@@H](O3)CO)O)O)O[C@@H]4[C@H]([C@H]([C@@H]([C@H](O4)CO)O)OC(=O)N)O)C(=O)NC(C)C(C(C)C(=O)NC(C(C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O.OS(=O)(=O)[O-],,,"['Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. (See all compounds classified as Antibiotics, Antineoplastic.)']",,,
2466,72467,"3-[[2-[2-[2-[[2-[[4-[[2-[[6-amino-2-[3-amino-1-[(2,3-diamino-3-oxopropyl)amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2R,3S,4S,5S,6S)-3-[(2R,3S,4S,5R,6R)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium",CC1=C(N=C(N=C1N)C(CC(=O)N)NCC(C(=O)N)N)C(=O)NC(C(C2=CN=CN2)O[C@H]3[C@H]([C@H]([C@@H]([C@@H](O3)CO)O)O)O[C@@H]4[C@H]([C@H]([C@@H]([C@H](O4)CO)O)OC(=O)N)O)C(=O)NC(C)C(C(C)C(=O)NC(C(C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O,,,,,,
2467,72468,"6-(((2,5-Dimethoxyphenyl)amino)methyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine",CC1=C2C(=NC(=NC2=NC=C1CNC3=C(C=CC(=C3)OC)OC)N)N,,,,,,
2468,72469,Pradimicin FA 1,C[C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](C3=CC4=C(C(=C3C5=C2C=C(C(=C5O)C(=O)N[C@@H](CO)C(=O)O)C)O)C(=O)C6=C(C4=O)C(=CC(=C6)OC)O)O)O[C@H]7[C@@H]([C@H]([C@@H](CO7)O)O)O)O)NC,,,,,,
2469,72470,Pradimicin FA 2,CC1C(C(C(C(O1)OC2C(C3=CC4=C(C(=C3C5=C2C=C(C(=C5O)C(=O)NC(CO)C(=O)O)C)O)C(=O)C6=C(C4=O)C(=CC(=C6)OC)O)O)O)OC7C(C(C(CO7)O)O)O)N,,,,,,
2470,72471,CID 72471,CCC(C)N1CCN(CC1)C2=CC(=O)C3=NC4=C(C5=C(C6=C4C7=C(C(=C6O)C)O[C@@](C7=O)(OC=C[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]([C@H](C=CC=C(C(=O)N5)C)C)O)C)O)C)OC(=O)C)C)OC)C)O)OC3=C2,,,,,,
2471,72472,CID 72472,CCCN1CCN(CC1)C2=CC(=O)C3=NC4=C(C5=C(C6=C4C7=C(C(=C6O)C)O[C@@](C7=O)(OC=C[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]([C@H](C=CC=C(C(=O)N5)C)C)O)C)O)C)OC(=O)C)C)OC)C)O)OC3=C2,,,,,,
2472,72473,Meridine,C1=CC=C2C(=C1)C3=C4C(=N2)C5=C(C(=O)C4=NC=C3)NC=CC5=O,,,,,,
2473,72474,Grepafloxacin,CC1CN(CCN1)C2=C(C(=C3C(=C2)N(C=C(C3=O)C(=O)O)C4CC4)C)F,"['For treatment of adults with mild to moderate infections caused by susceptible strains of <i>Haemophilus influenzae</i>, <i>Streptococcus pneumoniae</i>, or <i>Moraxella catarrhalis</i>.']","['Grepafloxacin has in vitro activity against a wide range of gram-positive and gram-negative aerobic microorganisms, as well as some atypical microorganisms.']","['Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)', 'Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)']",['Rapidly and extensively absorbed following oral administration. The absolute bioavailability is approximately 70%.'],"['Primarily hepatic via CYP1A2 and CYP3A4. The major metabolite is a glucuronide conjugate; minor metabolites include sulfate conjugates and oxidative metabolites. The oxidative metabolites are formed mainly by the cytochrome P450 enzyme CYP1A2, while the cytochrome P450 enzyme CYP3A4 plays a minor role. The nonconjugated metabolites have little antimicrobial activity compared with the parent drug, and the conjugated metabolites have no antimicrobial activity']",['15 &plusmn; 3 hours']
2474,72475,Pneumocandin B0,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@H]([C@H](NC(=O)[C@@H]2[C@H](CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@@H](NC1=O)[C@H](C)O)O)[C@@H]([C@H](C4=CC=C(C=C4)O)O)O)[C@H](CC(=O)N)O)O)O)O,,,,,,
2475,72476,Polyoxin d,C1=C(C(=O)NC(=O)N1[C@H]2[C@@H]([C@@H]([C@H](O2)[C@@H](C(=O)O)NC(=O)[C@H]([C@@H]([C@H](COC(=O)N)O)O)N)O)O)C(=O)O,,,"['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)', 'Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)']",,,
2476,72477,Chryscandin,COC1=CC=C(C=C1)C[C@@H](C(=O)N[C@H]2[C@H]([C@@H](O[C@@H]2C(=O)O)N3C=NC4=C(N=CN=C43)N)O)N,,,,,,
2477,72478,"(2S)-2-[(2R,3S,4R,5R)-5-(5-acetyl-2-oxo-1H-imidazol-3-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]-2-[[(2S,3S,4S)-2-amino-4-hydroxy-4-(5-hydroxy-2-pyridyl)-3-methyl-butanoyl]amino]acetic acid",C[C@H]([C@@H](C1=NC=C(C=C1)O)O)[C@@H](C(=O)N[C@@H]([C@@H]2[C@H]([C@H]([C@@H](O2)N3C=C(NC3=O)C(=O)C)O)O)C(=O)O)N,,,,,,
2478,72479,"(2S)-2-[[(2S,3S,4S)-2-amino-4-hydroxy-4-(5-hydroxypyridin-2-yl)-3-methylbutanoyl]amino]-2-[(2R,3S,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]acetic acid",C[C@H]([C@@H](C1=NC=C(C=C1)O)O)[C@@H](C(=O)N[C@@H]([C@@H]2[C@H](C([C@@H](O2)N3C=CC(=O)NC3=O)O)O)C(=O)O)N,,,,,,
2479,72480,CID 72480,CCC(C)CCC=CC=C(C)C(CC=CC=CC(=O)O[C@H]1[C@@H]([C@H](O[C@]2([C@@H]1O)C3=C(CO2)C=C(C=C3O)O)CO)O[C@H]4[C@@H]([C@H]([C@H]([C@H](O4)COC(=O)C=CC=CC=CC(CC)O)O)O)O)O,,,,,,
2480,72481,"N-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-6-[(1S,2S)-1,2-Dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,21,25-tetrahydroxy-3,15-bis[(1S)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-18-yl]octadeca-9,12-dienamide",CCCCCC=CCC=CCCCCCCCC(=O)N[C@H]1C[C@H]([C@H](NC(=O)[C@@H]2[C@H]([C@H](CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@@H](NC1=O)[C@H](C)O)O)[C@@H]([C@H](C4=CC=C(C=C4)O)O)O)[C@H](C)O)C)O)O)O,,,,,,
2481,72482,3-Hydroxypyrazin-1(2H)-olate,C1C(=O)NC=CN1[O-],,,,,,
2482,72483,CID 72483,CCC1CCC2CN(CCN2C1)NC=C3C(=C4C5=C(C3=NC(=O)C(=CC=CC(C(C(C(C(C(C(C(C=COC6(C(=O)C4=C(O6)C(=C5O)C)C)OC)C)OC(=O)C)C)O)C)O)C)C)O)O,,,,,,
2483,72484,CID 72484,C[C@H]1C=CC=C(C(=O)N=C2C(=CNN3CCN4CCCCC4C3)C(=C5C(=C2O)C(=C(C6=C5C(=O)[C@](O6)(OC=C[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C,,,,,,
2484,72485,"5-[(1R,7S,8R,9R)-4,7-bis(methoxycarbonyl)-9-methyl-11-oxo-10-oxatricyclo[6.3.2.01,7]tridec-3-en-9-yl]-2-methylpenta-2,4-dienoic acid",CC(=CC=C[C@@]1([C@@H]2CC[C@@]3([C@@]2(CCC(=CC3)C(=O)OC)C(=O)OC)C(=O)O1)C)C(=O)O,,,,,,
2485,72486,Eupolauridine,C1=CC=C2C(=C1)C3=NC=CC4=C3C2=NC=C4,,,,,,
2486,72487,1'(Or 2')-(isopropylidene)isonicotinohydrazide,CC(=NNC(=O)C1=CC=NC=C1)C,,,,,,
2487,72488,2-Phenylquinoline-4-carbohydrazide,C1=CC=C(C=C1)C2=NC3=CC=CC=C3C(=C2)C(=O)NN,,,,,,
2488,72489,"1,2-Diisonicotinoylhydrazine",C1=CN=CC=C1C(=O)NNC(=O)C2=CC=NC=C2,,,,,,
2489,72490,p-Aminosalicylic acid hydrazide,C1=CC(=C(C=C1N)O)C(=O)NN,,,,,,
2490,72491,Succinic dihydrazide,C(CC(=O)NN)C(=O)NN,,,,,,
2491,72492,Oleandomycin phosphate,C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)O)OC)C)C)C)O)C)C)O)N(C)C.OP(=O)(O)O,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
2492,72493,Oleandomycin,C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)O)OC)C)C)C)O)C)C)O)N(C)C,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],"['Macrolides become widely distributed in tissues, and concentrations are about the same as in plasma, or even higher in some instances. They actually accumulate within many cells, including macrophages, in which they may be > or = 20 times the plasma concentration. This accumulation accounts in part for the long dosing interval that characterizes some macrolides (eg, tilmicosin). ... Macrolides tend to concentrate in the spleen, liver, kidneys, and particularly the lungs. They enter pleural and ascitic fluids but not the CSF (only 2-13% of plasma concentration unless the meninges are inflamed). They concentrate in the bile and milk. Up to 75% of the dose is bound to plasma proteins, and they bind to alpha1-acid glycoproteins rather than to albumin. /Macrolides/', 'Macrolides are readily absorbed from the GI tract if not inactivated by gastric acid. ... Plasma levels peak within 1-2 hours in most cases, although absorption patterns may be erratic due to the presence of food and may depend on the salt or ester used. Absorption from the ruminoreticulum is usualy delayed and is unreliable. /Macrolides/', 'Macrolide antibiotics and their metabolites are excreted mainly in the bile (> 60%) and often undergo enterohepatic cycling. Urinary clearance may be slow and variable (often <10%) but my represent a more significant route of elimination after parenteral administration. The concentration of macrolides in milk often is several times greater than in plasma, especially in mastitis. /Macrolide/', 'The pharmacokinetics of oleandomycin (OLD) after intravenous and oral administration, both alone and after intramuscular pretreatment with metamizole or dexamethasone, were studied in healthy dogs. After intravenous injection of oleandomycin alone (10 mg/kg as bolus), the elimination half-life (t 1/2 beta, volume of distribution (Vd, area), body clearance (ClB) and area under the concentration time curve (AUC) were 1.60 hr, 1.11 L/kg. 7.36 (ml/kg)/min and 21.66 ug hr/ml, respectively. There were no statistically significant differences following pretreatment with metamizole or dexamethasone. After oral administration of oleandomycin alone, the t 1/2 beta, maximum plasma concentrations (Cmax), time of Cmax (tmax), mean absorption time and absolute bioavailability (Fabs) were 1.6 hr, 5.34 ug/ml, 1.5 hr, 1.34 hr and 84.29%, respectively. Pretreatment with metamizole caused a significantly decreased value for Cmax (2.93 ug/ml) but the mean absorption time value (2.23 hr) was significantly increased. Statistically significant changes in the pharmacokinetic parameters of oleandomycin following oral administration were also observed as a result of pretreatment with dexamethasone. The Cmax was increased (8.24 ug/ml) and the tmax (0.5 hr) and mean absorption time (0.45 hr) were lower.', 'Knowledge of the disposition of macrolides in a single animal species has been insufficient for the prediction of the pharmacokinetics of macrolides in humans. To better understand the species differences in the pharmacokinetics of macrolide antibiotics, the disposition of erythromycin, oleandomycin, and tylosin in several mammalian species was examined. Generally, the serum concentration versus time profiles of these drugs after intravenous administration were described by two-compartment kinetic models and were similar within each species. These drugs were rapidly cleared, resulting in terminal half-lives of less than 2 h. Comparison of their pharmacokinetics showed greater variation in antibiotic disposition among animal species than noted for the differences within a species. When the pharmacokinetic data was fitted to an allometric model, the logarithms of volume of distribution, clearance, and half-life were linearly related to the logarithms of body weight. From these relationships, the human pharmacokinetics of erythromycin and oleandomycin were extrapolated and found to approximate observed human pharmacokinetics.']","['Metabolic inactivation of the macrolides is usually extensive, but the relative proportion depends on the route of administration and th particular antibiotic. ... /Macrolides/']","['The plasma half-lives of macrolides usually are 1-3 hr, ... /Macrolides/']"
2493,72494,"2,3-Dihydro-2-ethyl-6-nitroimidazo(2,1-b)oxazole",CCC1CN2C=C(N=C2O1)[N+](=O)[O-],,,,,,
2494,72495,Squalamine,C[C@H](CC[C@H](C(C)C)OS(=O)(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@@H](C[C@@H]4[C@@]3(CC[C@@H](C4)NCCCNCCCCN)C)O)C,"['Investigated for use/treatment in ovarian cancer, lung cancer, and macular degeneration.']",,"['Agents and endogenous substances that antagonize or inhibit the development of new blood vessels. (See all compounds classified as Angiogenesis Inhibitors.)', 'Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)', 'Agents that reduce the frequency or rate of spontaneous or induced tumors independently of the mechanism involved. (See all compounds classified as Anticarcinogenic Agents.)']",,,
2495,72496,"N-[[(2S)-2-[(2R,3R,4S)-3,4-dihydroxy-5-oxooxolan-2-yl]-2-hydroxyethylidene]amino]pyridine-4-carboxamide",C1=CN=CC=C1C(=O)NN=C[C@@H]([C@@H]2[C@@H]([C@@H](C(=O)O2)O)O)O,,,,,,
2496,72497,N-[(2-methyl-5-prop-1-en-2-ylcyclohex-2-en-1-ylidene)amino]pyridine-4-carboxamide,CC1=CCC(CC1=NNC(=O)C2=CC=NC=C2)C(=C)C,,,,,,
2497,72498,"4-Pyridinecarboxylic acid, 2,2-bis((2-thioxo-3(2H)-benzothiazolyl)methyl)hydrazide",C1=CC=C2C(=C1)N(C(=S)S2)CN(CN3C4=CC=CC=C4SC3=S)NC(=O)C5=CC=NC=C5,,,,,,
2498,72499,"3-(3,5-Ditert-butyl-4-oxo-cyclohexa-2,5-dien-1-ylidene)tetralin-1,2,4-trione",CC(C)(C)C1=CC(=C2C(=O)C3=CC=CC=C3C(=O)C2=O)C=C(C1=O)C(C)(C)C,,,,,,
2499,72500,"2-(3-methylbut-2-enyl)-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynaphthalene-1,4-dione",CC(=CCC1=C(C(=O)C2=CC=CC=C2C1=O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)C,,,,,,
2500,72501,3-Deazaaristeromycin,C1[C@@H]([C@H]([C@H]([C@@H]1N2C=NC3=C2C=CN=C3N)O)O)CO,,,['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)'],,,
2501,72502,Warburganal,C[C@]12CCCC([C@@H]1CC=C([C@@]2(C=O)O)C=O)(C)C,,,,,,
2502,72503,Polygodial,C[C@]12CCCC([C@@H]1CC=C([C@@H]2C=O)C=O)(C)C,,,"['Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)']",,,
2503,72504,Nagilactone E,CC(C)[C@@H]1C23[C@H](O2)[C@@H]4[C@@H]5[C@@](C3=CC(=O)O1)(CC[C@@H]([C@@]5(C(=O)O4)C)O)C,,,,,,
2504,72505,Nagilactone C,CC(C)C1=C2[C@H]([C@@H]3[C@H]4[C@]([C@H]([C@@H]5[C@H]([C@@]4(C2=CC(=O)O1)C)O5)O)(C(=O)O3)C)O,,,,,,
2505,72506,Conidendrin,COC1=C(C=C2[C@H]([C@@H]3COC(=O)[C@@H]3CC2=C1)C4=CC(=C(C=C4)O)OC)O,,,,,,
2506,72507,Propyl pyrazine-2-carboxylate,CCCOC(=O)C1=NC=CN=C1,,,,,,
2507,72508,Piperidinium pentamethylenedithiocarbamate,C1CCNCC1.C1CCN(CC1)C(=S)S,,,,,,
2508,72509,"6-[[2-Methoxy-5-(trifluoromethyl)anilino]methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine",CC1=C2C(=NC(=NC2=NC=C1CNC3=C(C=CC(=C3)C(F)(F)F)OC)N)N,,,,,,
2509,72510,CID 72510,COC1=CC=CC2=C1N(C3=CC=CC(=O)C3=[N+]2[O-])O,,,,,,
2510,72511,Phleomycin,CC1=C(N=C(N=C1N)C(CC(=O)N)NCC(C(=O)N)N)C(=O)NC(C(C2=CN=CN2)O[C@H]3[C@@]([C@H]([C@@H]([C@@H](O3)CO)O)O)(C)O[C@H]4[C@@H]([C@]([C@H](C(O4)CO)O)(C(=O)N)O)O)C(=O)NC(C)C(C(C)C(=O)NC(C(=O)C)C(=O)NCCC5=NC(CS5)C6=NC(=CS6)C(=O)N)O,,,"['Compounds that inhibit cell production of DNA or RNA. (See all compounds classified as Nucleic Acid Synthesis Inhibitors.)', 'Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. (See all compounds classified as Antibiotics, Antineoplastic.)']",,,
2511,72512,9-Methoxyellipticine,CC1=C2C=CN=CC2=C(C3=C1NC4=C3C=C(C=C4)OC)C,,,,,,
2512,72513,CID 72513,C1=NC(=O)C2=C(N1)N(C=N2)[C@@H](C=O)O[C@@H](CO)C=O,,,,,,
2513,72514,"(3S,6S)-3,6-bis[(2S,5R)-5-chloropiperidin-2-yl]piperazine-2,5-dione;dihydrochloride",C1C[C@H](NC[C@@H]1Cl)[C@H]2C(=O)N[C@H](C(=O)N2)[C@@H]3CC[C@H](CN3)Cl.Cl.Cl,,,,,,
2514,72515,"3,6-bis[(5R)-5-chloropiperidin-2-yl]piperazine-2,5-dione",C1CC(NC[C@@H]1Cl)C2C(=O)NC(C(=O)N2)C3CC[C@H](CN3)Cl,,,,,,
2515,72516,CID 72516,C1=NN(C(=NC1=O)S)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O,,,,,,
2516,72517,"1-(2,5-Dichlorophenyl)ethanol",CC(C1=C(C=CC(=C1)Cl)Cl)O,,,,,,
2517,72518,3'-Hydroxydaunorubicin,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)O)O,,,,,,
2518,72519,Nonactin,C[C@@H]1C[C@H]2CC[C@H](O2)[C@@H](C(=O)O[C@H](C[C@@H]3CC[C@@H](O3)[C@H](C(=O)O[C@@H](C[C@H]4CC[C@H](O4)[C@@H](C(=O)O[C@H](C[C@@H]5CC[C@@H](O5)[C@H](C(=O)O1)C)C)C)C)C)C)C,,,,,,
2519,72520,"(1R,2S,5S,7R,10S,11S,14R,16S,19R,20S,23S,25R,28S,29S,32R,34S)-5,23-diethyl-2,11,14,20,29,32-hexamethyl-4,13,22,31,37,38,39,40-octaoxapentacyclo[32.2.1.17,10.116,19.125,28]tetracontane-3,12,21,30-tetrone",CC[C@H]1C[C@H]2CC[C@H](O2)[C@@H](C(=O)O[C@@H](C[C@@H]3CC[C@@H](O3)[C@@H](C(=O)O[C@H](C[C@H]4CC[C@H](O4)[C@@H](C(=O)O[C@@H](C[C@@H]5CC[C@@H](O5)[C@@H](C(=O)O1)C)C)C)CC)C)C)C,,,,,,
2520,72521,Alkannin,CC(=CC[C@@H](C1=CC(=O)C2=C(C=CC(=C2C1=O)O)O)O)C,,,,,,
2521,72522,CID 72522,CC1=C(C(=O)C2=C(C1=O)N3C[C@]4([C@@H]([C@@]3([C@@H]2COC(=O)N)O)N4C)C)N,,,,,,
2522,72523,"(2R,6R)-2-methyl-6-undecylpiperidine",CCCCCCCCCCC[C@@H]1CCC[C@H](N1)C,,,,,,
2523,72524,"[(1R,2S,3S,4S)-2,4-diacetyloxy-5-cyano-3,7-dihydroxy-3-methyl-6,11-dioxo-2,4-dihydro-1H-benzo[b]carbazol-1-yl] acetate",CC(=O)O[C@H]1[C@@H]([C@@]([C@H](C2=C1C3=C(N2C#N)C(=O)C4=C(C3=O)C=CC=C4O)OC(=O)C)(C)O)OC(=O)C,,,,,,
2524,72525,CID 72525,C[C@H]1C(C(C(C(C(C(C=C(C2=C3C4=C(C(=C(C(=O)C4=C(C(=C3OCO2)C)O)NC(=O)C(=CC=C[C@](C1O)(C)O)C)C)OC(=O)C)C)(C)O)O)C)OC(=O)C)C(=O)OC)O,,,,,,
2525,72526,CID 72526,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=NNC(=O)C6=CC=C(C=C6)Cl)C)O)N)O.Cl,,,,,,
2526,72527,CID 72527,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=NNC(=O)C6=CC=C(C=C6)Cl)C)O)N)O,,,,,,
2527,72528,CID 72528,C[C@H]1[C@H](C(C[C@@H](O1)O[C@@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=NNC(=O)C6=CC(=CC=C6)[N+](=O)[O-])C)O)N)O.Cl,,,,,,
2528,72529,CID 72529,C[C@H]1[C@H](C(C[C@@H](O1)O[C@@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=NNC(=O)C6=CC(=CC=C6)[N+](=O)[O-])C)O)N)O,,,,,,
2529,72530,CID 72530,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=NNC(=O)C6=CC(=C(C=C6)Cl)Cl)C)O)N)O.Cl,,,,,,
2530,72531,CID 72531,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=NNC(=O)C6=CC(=C(C=C6)Cl)Cl)C)O)N)O,,,,,,
2531,72532,CID 72532,CCC1=CC=C(C=C1)C(=O)NN=C(C)[C@]2(C[C@H](C3=C(C2)C(=C4C(=C3O)C(=O)C5=C(C4=O)C=CC=C5OC)O)O[C@H]6C[C@@H]([C@@H]([C@@H](O6)C)O)N)O.Cl,,,,,,
2532,72533,CID 72533,CCC1=CC=C(C=C1)C(=O)NN=C(C)[C@]2(CC(C3=C(C2)C(=C4C(=C3O)C(=O)C5=C(C4=O)C=CC=C5OC)O)O[C@H]6C[C@@H]([C@@H]([C@@H](O6)C)O)N)O,,,,,,
2533,72534,CID 72534,C[C@H]1C(=O)N([C@@H]2CSSC[C@H](C(=O)N([C@H](C(=O)OC[C@H](C(=O)N1)NC(=O)C3=NC4=CC=CC=C4N=C3)C(C)C)C)N(C(=O)[C@@H](NC(=O)[C@@H](COC(=O)[C@@H](N(C2=O)C)C(C)C)NC(=O)C5=NC6=CC=CC=C6N=C5)C)C)C,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
2534,72535,Grisellimycin,CCC(C)[C@H]1C(=O)N([C@@H](C(=O)N2CCC[C@H]2C(=O)N([C@@H](C(=O)NCC(=O)O[C@@H]([C@@H](C(=O)N[C@H](C(=O)N3C[C@@H](C[C@@H]3C(=O)N1)C)C(C)CC)N(C)C(=O)C4C[C@H](CN4C(=O)[C@H](C(C)C)N(C)C(=O)C)C)C)C(C)CC)C)C(C)C)C,,,,,,
2535,72536,"(4aS,6aS,12aR,12bS)-10-hydroxy-4,4,6a,12b-tetramethyl-2,3,4a,5,6,12a-hexahydro-1H-benzo[a]xanthen-9-one",C[C@]12CCCC([C@@H]1CC[C@]3([C@@H]2C=C4C=C(C(=O)C=C4O3)O)C)(C)C,,,,,,
2536,72537,Rubrofusarin,CC1=CC(=O)C2=C(C3=C(C=C(C=C3C=C2O1)OC)O)O,,,,,,
2537,72538,CID 72538,C[C@@H](C(=O)N[C@@H]1[C@@H]2[C@H]([C@@H](CC(=O)C2=C(O[C@]1(C)C(Cl)Cl)O)O)O)N,,,,,,
2538,72539,CID 72539,CC1=C[C@H]2C[C@@H](C(=C2C(=O)C[C@H](CCC=CC[C@@H](NC(=O)C=CC=C1)C3=CC=CC=C3)O)O)OC,,,,,,
2539,72540,Encelin,C[C@@]12C[C@@H]3[C@H](C[C@H]1C(=C)C(=O)C=C2)C(=C)C(=O)O3,,,,,,
2540,72541,"6H-Benzo(d)naphtho(1,2-b)pyran-6-one, 4-(6-deoxy-3-C-methyl-beta-L-gulopyranosyl)-1-hydroxy-10,12-dimethoxy-8-methyl-",C[C@@H]1[C@@H]([C@@](C([C@@H](O1)C2=C3C(=C(C=C2)O)C(=CC4=C3OC(=O)C5=C4C(=CC(=C5)C)OC)OC)O)(C)O)O,,,,,,
2541,72542,Echinosporin,C1=C[C@@]2([C@@H]3[C@@H]1[C@@H](OC(=C3)C(=O)N)OC2=O)O,,,,,,
2542,72543,"(6S)-3-[[4-(3,7-dimethylocta-2,6-dienoxy)phenyl]methylidene]-1,4-dihydroxy-6-methylpiperazine-2,5-dione",C[C@H]1C(=O)N(C(=CC2=CC=C(C=C2)OCC=C(C)CCC=C(C)C)C(=O)N1O)O,,,,,,
2543,72544,CID 72544,C1=CC(=CC=C1N=C(S)S)Cl.N,,,,,,
2544,72545,CID 72545,C1=CC(=CC=C1N=C(S)S)Cl,,,,,,
2545,72546,CID 72546,CCCCN=C(S)[S-].[Na+],,,,,,
2546,72547,CID 72547,CCCCN=C(S)S,,,,,,
2547,72548,N-(2-hydroxyethyl)-N'-[(5-nitrofuran-2-yl)methylideneamino]oxamide,C1=C(OC(=C1)[N+](=O)[O-])C=NNC(=O)C(=O)NCCO,,,,,,
2548,72549,CID 72549,C1=C(OC(=C1)N(O)O)C(=O)N=N,,,,,,
2549,72550,4-[[butyl(methyl)amino]diazenyl]-1H-imidazole-5-carboxamide,CCCCN(C)N=NC1=C(NC=N1)C(=O)N,,,,,,
2550,72551,2-(Phenylazo)-1H-imidazole,C1=CC=C(C=C1)N=NC2=NC=CN2,,,,,,
2551,72552,"Benzamide, 2,2'-dithiobis-",C1=CC=C(C(=C1)C(=O)N)SSC2=CC=CC=C2C(=O)N,,,,,,
2552,72553,"Benzamide, 2,2'-dithiobis(N-(hydroxymethyl)-",C1=CC=C(C(=C1)C(=O)NCO)SSC2=CC=CC=C2C(=O)NCO,,,,,,
2553,72554,"Benzamide, 2,2'-dithiobis(N-(2-hydroxyethyl)-",C1=CC=C(C(=C1)C(=O)NCCO)SSC2=CC=CC=C2C(=O)NCCO,,,,,,
2554,72555,"2,2'-dithiobis(N-2-hydroxypropylbenzamide)",CC(CNC(=O)C1=CC=CC=C1SSC2=CC=CC=C2C(=O)NCC(C)O)O,,,,,,
2555,72556,"2,2'-Dithiobis(5-chloro-N-(2-hydroxyethyl)benzamide)",C1=CC(=C(C=C1Cl)C(=O)NCCO)SSC2=C(C=C(C=C2)Cl)C(=O)NCCO,,,,,,
2556,72557,"Piperazine, 1,1'-(dithiobis(2,1-phenylenecarbonyl))bis(4-(phenylmethyl)-, dihydrochloride",C1CN(CCN1CC2=CC=CC=C2)C(=O)C3=CC=CC=C3SSC4=CC=CC=C4C(=O)N5CCN(CC5)CC6=CC=CC=C6.Cl.Cl,,,,,,
2557,72558,CID 72558,C1CN(CCN1CC2=CC=CC=C2)C(=O)C3=CC=CC=C3SSC4=CC=CC=C4C(=O)N5CCN(CC5)CC6=CC=CC=C6,,,,,,
2558,72559,"Morpholine, 4,4'-(dithiobis(2,1-phenylenecarbonyl))bis-",C1COCCN1C(=O)C2=CC=CC=C2SSC3=CC=CC=C3C(=O)N4CCOCC4,,,,,,
2559,72560,"2-(Hydroxymethyl)-1,2-benzisothiazol-3(2H)-one 1,1-dioxide",C1=CC=C2C(=C1)C(=O)N(S2(=O)=O)CO,,,,,,
2560,72561,"4-Thiomorpholinamine,N-[[2-(5-nitro-2-furanyl)-4-thiazolyl]methylene]-, 1,1-dioxide",C1CS(=O)(=O)CCN1N=CC2=CSC(=N2)C3=CC=C(O3)[N+](=O)[O-],,,,,,
2561,72562,CID 72562,C1=CN=CC=C1C2=NC(=NN2)S,,,,,,
2562,72563,"9H-Thioxanthen-9-one, 6-chloro-1-((2-(ethyl(2-hydroxyethyl)amino)ethyl)amino)-4-(hydroxymethyl)-",CCN(CCNC1=C2C(=C(C=C1)CO)SC3=C(C2=O)C=CC(=C3)Cl)CCO,,,,,,
2563,72564,"5-Methoxy-6-[1-(4-methoxyphenyl)ethyl]-1,3-benzodioxole",CC(C1=CC=C(C=C1)OC)C2=CC3=C(C=C2OC)OCO3,,,,,,
2564,72565,"2,4-Diamino-5-phenyl-6-methylpyrimidine",CC1=C(C(=NC(=N1)N)N)C2=CC=CC=C2,,,,,,
2565,72566,8-(6-(4-Benzylpiperazinyl)hexylamino)-6-methoxyquinoline dioxalate,COC1=CC(=C2C(=C1)C=CC=N2)NCCCCCCN3CCN(CC3)CC4=CC=CC=C4.C(=O)(C(=O)O)O.C(=O)(C(=O)O)O,,,,,,
2566,72567,N-[6-(4-benzylpiperazin-1-yl)hexyl]-6-methoxyquinolin-8-amine,COC1=CC(=C2C(=C1)C=CC=N2)NCCCCCCN3CCN(CC3)CC4=CC=CC=C4,,,,,,
2567,72568,8-((4-(Diethylamino)-1-methylbutyl)amino)-6-methoxyquinoline hydriodide,CCN(CC)CCCC(C)NC1=C2C(=CC(=C1)OC)C=CC=N2.I,,,,,,
2568,72569,CID 72569,CC1(C=CC2=C3C(=C(C4=CC=CC=C4N3C)O)C(=O)C=C2O1)C,,,,,,
2569,72570,CID 72570,CC(=C)C1CC2=C3C(=C(C4=CC=CC=C4N3C)O)C(=O)C=C2O1,,,,,,
2570,72571,Redoxal,COC1=C(C=CC(=C1)C2=CC(=C(C=C2)NC3=CC=CC=C3C(=O)O)OC)NC4=CC=CC=C4C(=O)O,,,,,,
2571,72572,8-(2-(3-Pentylamino)ethylamino)-6-methoxyquinoline dihydrobromide,CCC(CC)NCCNC1=C2C(=CC(=C1)OC)C=CC=N2.Br,,,,,,
2572,72573,"N-(6-methoxyquinolin-8-yl)-N'-pentan-3-ylethane-1,2-diamine",CCC(CC)NCCNC1=C2C(=CC(=C1)OC)C=CC=N2,,,,,,
2573,72574,7-Oxo-7H-benzo[e]perimidine-4-carboxylic acid,C1=CC=C2C(=C1)C3=NC=NC4=C(C=CC(=C43)C2=O)C(=O)O,,,,,,
2574,72575,CID 72575,C[C@@H]1[C@@H]([C@@H]([C@H]([C@H](O1)CCOC2[C@H]([C@H]([C@H](O[C@H]2OC3=CC=CC4=C3C5=C6C7=C(C=CC(=C7C(=O)O5)C)OC(=C6C4=O)O)C)O)O)O)OC)O,,,,,,
2575,72576,CID 72576,C1=CC2=C3C(=C1)N=NN=C3C(=NN=C4C=C(C=C(C4=O)Cl)N(O)O)C=C2S(=O)(=O)[O-].[Na+],,,,,,
2576,72577,CID 72577,C1=CC2=C3C(=C1)N=NN=C3C(=NN=C4C=C(C=C(C4=O)Cl)N(O)O)C=C2S(=O)(=O)O,,,,,,
2577,72578,CID 72578,CC1=CC(=C(C=C1)NC2=C3C4=C(C=C2)N(C(=O)C=C4C5=CC=CC=C5C3=O)C)S(=O)(=O)[O-].[Na+],,,,,,
2578,72579,"3-Methyl-6-(2-sulfo-4-methylanilino)-7H-dibenz[f,ij]isoquinoline-2,7(3H)-dione",CC1=CC(=C(C=C1)NC2=C3C4=C(C=C2)N(C(=O)C=C4C5=CC=CC=C5C3=O)C)S(=O)(=O)O,,,,,,
2579,72580,"6-Bromo-1-(ethoxycarbonyl)-3-methyl-7H-dibenz(f,ij)isoquinoline-2,7(3H)-dione",CCOC(=O)C1=C2C3=CC=CC=C3C(=O)C4=C(C=CC(=C42)N(C1=O)C)Br,,,,,,
2580,72581,CID 72581,C1=C2C3=C4C(=C(OC3=C(C1=O)O)O)C(=C(C(=C4OC2=O)O)O)O,,,,,,
2581,72582,"1,4,7,9b-Tetraazaphenalene, dodecahydro-2,5,8-trimethyl-",CC1CC2NC(CC3N2C(N1)CC(N3)C)C,,,,,,
2582,72583,Pradimicin L,C[C@H]1[C@H]([C@H]([C@@H]([C@H](O1)O[C@@H]2[C@H](C3=CC4=C(C(=C3C5=C2C=C(C(=C5O)C(=O)N[C@H](C)C(=O)OC)C)O)C(=O)C6=C(C4=O)C(=CC(=C6)OC)O)O)O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)NC,,,,,,
2583,72584,Onychine,CC1=C2C(=NC=C1)C3=CC=CC=C3C2=O,,,,,,
2584,72585,CID 72585,CSC(=NN)S,,,,,,
2585,72586,Acid Blue 120,CC1=CC=C(C=C1)NC2=C3C(=C(C=C2)N=NC4=CC=C(C5=CC=CC=C54)N=NC6=CC(=CC=C6)S(=O)(=O)[O-])C=CC=C3S(=O)(=O)[O-].[Na+].[Na+],,,,,,
2586,72587,Acid Blue 120 parent,CC1=CC=C(C=C1)NC2=C3C(=C(C=C2)N=NC4=CC=C(C5=CC=CC=C54)N=NC6=CC(=CC=C6)S(=O)(=O)O)C=CC=C3S(=O)(=O)O,,,,,,
2587,72588,CID 72588,C(CO)N=C(S)SSC(=NCCO)S,,,,,,
2588,72589,Hexa(methylamino)cyclotriphosphazene,CNP1(=NP(=NP(=N1)(NC)NC)(NC)NC)NC,,,,,,
2589,72590,Hexakis(dimethylamino)cyclotriphosphazene,CN(C)P1(=NP(=NP(=N1)(N(C)C)N(C)C)(N(C)C)N(C)C)N(C)C,,,,,,
2590,72591,Trisodium 3-((4-((4-((4-aminophenyl)azo)-6-sulphonatonaphthyl)azo)-6-sulphonatonaphthyl)azo)-4-hydroxynaphthalene-1-sulphonate,C1=CC=C2C(=C1)C(=CC(=C2O)N=NC3=C4C=CC(=CC4=C(C=C3)N=NC5=C6C=CC(=CC6=C(C=C5)N=NC7=CC=C(C=C7)N)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+],,,,,,
2591,72592,Azogen Blue BR,C1=CC=C2C(=C1)C(=CC(=C2O)N=NC3=C4C=CC(=CC4=C(C=C3)N=NC5=C6C=CC(=CC6=C(C=C5)N=NC7=CC=C(C=C7)N)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O,,,,,,
2592,72593,"C.I. Direct Brown 101, trisodium salt",C1=CC(=CC=C1C2=CC=C(C=C2)N=NC3=C4C=CC(=CC4=C(C=C3)N=NC5=CC(=C(C=C5)O)C(=O)[O-])S(=O)(=O)[O-])N=NC6=CC(=C(C=C6)O)C(=O)[O-].[Na+].[Na+].[Na+],,,,,,
2593,72594,C.I. Direct Brown 101,C1=CC(=CC=C1C2=CC=C(C=C2)N=NC3=C4C=CC(=CC4=C(C=C3)N=NC5=CC(=C(C=C5)O)C(=O)O)S(=O)(=O)O)N=NC6=CC(=C(C=C6)O)C(=O)O,,,,,,
2594,72595,Triphenylboroxin,B1(OB(OB(O1)C2=CC=CC=C2)C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
2595,72596,Methyl apholate,CC1CN1P2(=NP(=NP(=N2)(N3CC3C)N4CC4C)(N5CC5C)N6CC6C)N7CC7C,,,,,,
2596,72597,"Disodium 1,4-piperazinedicarbodithioate",C1CN(CCN1C(=S)[S-])C(=S)[S-].[Na+].[Na+],,,,,,
2597,72598,"Piperazine-1,4-dicarbodithioic acid",C1CN(CCN1C(=S)S)C(=S)S,,,,,,
2598,72599,"Phenothiazine-10-carbodithioic acid, 2-(diethylamino)ethyl ester",CCN(CC)CCSC(=S)N1C2=CC=CC=C2SC3=CC=CC=C31,,,,,,
2599,72600,"4-Morpholinecarbo(dithioperoxo)thioic acid, 2-carboxyphenyl ester",C1COCCN1C(=S)SSC2=CC=CC=C2C(=O)O,,,,,,
2600,72601,Pentazirinocyclodiphosphathiazene,C1CN1P2(=NP(=NS(=N2)(=O)N3CC3)(N4CC4)N5CC5)N6CC6,,,,,,
2601,72602,tert-Butylsulfenyl dimethyldithiocarbamate,CC(C)(C)SSC(=S)N(C)C,,,,,,
2602,72603,CID 72603,CN=C(S)SC1=NS(=O)(=O)C2=CC=CC=C2N1,,,,,,
2603,72604,Lanatoside B,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]4[C@@H]3CC[C@]5([C@@]4(C[C@@H]([C@@H]5C6=CC(=O)OC6)O)O)C)C)O)O[C@H]7C[C@@H]([C@@H]([C@H](O7)C)O[C@H]8C[C@@H]([C@@H]([C@H](O8)C)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O)OC(=O)C)O,,,,,,
2604,72605,"2,3-Dihydroxy-5-isopropylcyclohepta-2,4,6-trienone",CC(C)C1=CC(=O)C(=C(C=C1)O)O,,,,,,
2605,72606,CID 72606,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC2=C(OC3=CC(=O)C=C(C3=C2O)O)C4=CC(=C(C(=C4)O)O)O)O)O)O,,,,,,
2606,72607,"2-[(3r,5s,8r)-3,8-Dimethyl-1,2,3,4,5,6,7,8-octahydroazulen-5-yl]propan-2-ol",C[C@@H]1CC[C@@H](CC2=C1CC[C@H]2C)C(C)(C)O,,,,,,
2607,72608,"4-Hydroxy-3-(4-hydroxy-3-methylbut-2-enyl)naphthalene-1,2-dione",CC(=CCC1=C(C2=CC=CC=C2C(=O)C1=O)O)CO,,,,,,
2608,72609,L-Histidine dihydrochloride,C1=C(NC=N1)C[C@@H](C(=O)O)N.Cl.Cl,,,,,,
2609,72610,Peganine,C1CN2CC3=CC=CC=C3N=C2C1O,,,,,,
2610,72611,"1H-Pyrrolizine-7-methanol, 2,3,5,7a-tetrahydro-1-hydroxy-, hydrochloride, (1R-trans)-",C1CN2CC=C([C@H]2[C@H]1O)CO.Cl,,,,,,
2611,72612,"(1S)-7-(hydroxymethyl)-2,3,5,8-tetrahydro-1H-pyrrolizin-1-ol",C1CN2CC=C(C2[C@H]1O)CO,,,,,,
2612,72613,"(15-alpha,20R)-20-Chloro-15,20-dihydro-12,15-dihydroxysenecionan-11,16-dione hydrochloride",C[C@@H]1C[C@@](C(=O)O[C@@H]2CCN3[C@@H]2C(=CC3)COC(=O)[C@]1(C)O)(C(C)Cl)O.Cl,,,,,,
2613,72614,Jaconine,C[C@@H]1C[C@@](C(=O)O[C@@H]2CCN3[C@@H]2C(=CC3)COC(=O)[C@]1(C)O)(C(C)Cl)O,,,,,,
2614,72615,Corlumine,CN1CCC2=CC(=C(C=C2C1C3C4=C(C5=C(C=C4)OCO5)C(=O)O3)OC)OC,,,,,,
2615,72616,Cryptopine,CN1CCC2=CC(=C(C=C2C(=O)CC3=C(C1)C4=C(C=C3)OCO4)OC)OC,,,,,,
2616,72617,"3,6-Diphenylfuro[3,2-b]furan-2,5-dione",C1=CC=C(C=C1)C2=C3C(=C(C(=O)O3)C4=CC=CC=C4)OC2=O,,,,,,
2617,72618,"(1S,9S,10R)-3-hydroxy-4-methoxy-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-13-one",CN1CC[C@]23CC(=O)CC[C@H]2[C@@H]1CC4=C3C(=C(C=C4)OC)O,,,,,,
2618,72619,Sanguinarine nitrate,C[N+]1=C2C(=C3C=CC4=C(C3=C1)OCO4)C=CC5=CC6=C(C=C52)OCO6.[N+](=O)([O-])[O-],,,"['Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). (See all compounds classified as Cardiotonic Agents.)', 'Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. (See all compounds classified as Anti-Infective Agents.)']",,,
2619,72620,Thujic acid,CC1(C=CC=C(C=C1)C(=O)O)C,,,,,,
2620,72621,CID 72621,COC1=CC=C(C=C1)C2=CC(=C3C(=CC(=O)C(=C3O2)C4=C(C=CC(=C4)C5=CC(=C6C(=CC(=CC6=O)OC)O5)O)OC)O)O,,,,,,
2621,72622,Duazomycin,CC(=O)N[C@@H](CCC(=O)C=[N+]=[N-])C(=O)O,,,,,,
2622,72623,CID 72623,CC(=O)N[C@@H](CCC(=C[N+]#N)O)C(=O)O,,,,,,
2623,72624,Lumicolchicine,CC(=O)N[C@@H]1CCC2=CC(=C(C(=C2C3=C1[C@@H]4[C@H]3C=C(C4=O)OC)OC)OC)OC,,,,,,
2624,72625,Humulone,CC(C)CC(=O)C1=C(C(=C([C@](C1=O)(CC=C(C)C)O)O)CC=C(C)C)O,,,,,,
2625,72626,Cinnabarin,C1=CC(=C2C(=C1)OC3=CC(=O)C(=C(C3=N2)C(=O)O)N)CO,,,,,,
2626,72627,"(2R,7S,10R,11S,13S,14S,15R,16S,17R,20S,23S)-10,14,16,20-tetramethyl-22-azahexacyclo[12.10.0.02,11.05,10.015,23.017,22]tetracos-4-ene-7,13-diol",C[C@H]1CC[C@@H]2[C@H]([C@H]3[C@@H](N2C1)CC4[C@@]3([C@H](C[C@H]5[C@H]4CC=C6[C@@]5(CC[C@@H](C6)O)C)O)C)C,,,,,,
2627,72628,"2,2-Dimethyl-2,3-dihydroperimidine",CC1(NC2=CC=CC3=C2C(=CC=C3)N1)C,,,,,,
2628,72629,Epoxydon,C1=C(C(=O)[C@H]2[C@@H]([C@@H]1O)O2)CO,,,,,,
2629,72630,CID 72630,CN1C(=O)C2=NC=NNC2=NC1=O,,,,,,
2630,72631,Bostrycoidin,CC1=CC2=C(C=N1)C(=O)C3=C(C2=O)C(=C(C=C3O)OC)O,,,,,,
2631,72632,CID 72632,CC1(C=CC2=C(C3=C(C(=C2O1)C(C)(C)C=C)OC4=C(C(=O)C=CC4=C3O)O)O)C,,,,,,
2632,72633,"(2S,3S)-3-hydroxy-2-methyl-7-prop-1-enyl-2,3-dihydropyrano[3,2-c]pyran-4,5-dione",CC=CC1=CC2=C(C(=O)[C@H]([C@@H](O2)C)O)C(=O)O1,,,,,,
2633,72634,CID 72634,C[C@]1([C@@H]2C[C@@H]3[C@H](C(=O)C(=C(NCN4CCN(CC4)C(=N)N=C(N)N)O)C(=O)[C@@]3(C(=O)C2=C(C5=C1C=CC=C5O)O)O)N(C)C)O.Cl.Cl,,,,,,
2634,72635,CID 72635,C[C@]1([C@@H]2C[C@@H]3[C@H](C(=O)C(=C(NCN4CCN(CC4)C(=N)N=C(N)N)O)C(=O)[C@@]3(C(=O)C2=C(C5=C1C=CC=C5O)O)O)N(C)C)O,,,,,,
2635,72636,CID 72636,COC1=C(C=C(C=C1)C2=C(C(=C3C(=CC(=C(C3=O)OC)OC)O2)O)O)O,,,,,,
2636,72637,Actinomine,CCN(CC)CCNC(=O)C1=C2C(=C(C=C1)C)OC3=C(C(=O)C(=C(C3=N2)C(=O)NCCN(CC)CC)N)C,,,,,,
2637,72638,CID 72638,CC=CC1=C(C(=O)[C@@H]([C@@]1(C(=O)OC)O)Cl)Cl,,,,,,
2638,72639,4-Aminoantipyrine hydrochloride,CC1=C(C(=O)N(N1C)C2=CC=CC=C2)N.Cl,,,,,,
2639,72640,"1,4-Piperazinediacetic acid",C1CN(CCN1CC(=O)O)CC(=O)O,,,,,,
2640,72641,CID 72641,CC1=CC=C(C=C1)S(=O)(=O)OC2=CC=C(C=C2)N=NC3C(=NN(C3=O)C4=C(C=C(C=C4)Cl)S(=O)(=O)[O-])C.[Na+],,,,,,
2641,72642,5-chloro-2-[3-methyl-4-[[4-(4-methylphenyl)sulfonyloxyphenyl]diazenyl]-5-oxo-4H-pyrazol-1-yl]benzenesulfonic acid,CC1=CC=C(C=C1)S(=O)(=O)OC2=CC=C(C=C2)N=NC3C(=NN(C3=O)C4=C(C=C(C=C4)Cl)S(=O)(=O)O)C,,,,,,
2642,72643,CID 72643,CC1=C(C(=O)N(N1C)C2=CC=CC=C2)N=C(NC3=CC=CC=C3)S,,,,,,
2643,72644,"Dimethyl(3-(((2'-methyl(2,4'-bithiazol)-4-yl)carbonyl)amino)propyl)sulfonium chloride",CC1=NC(=CS1)C2=NC(=CS2)C(=O)NCCC[S+](C)C.[Cl-],,,,,,
2644,72645,"Dimethyl-[3-[[2-(2-methyl-1,3-thiazol-4-yl)-1,3-thiazole-4-carbonyl]amino]propyl]sulfanium",CC1=NC(=CS1)C2=NC(=CS2)C(=O)NCCC[S+](C)C,,,,,,
2645,72646,Zaluzanin C,C=C1CC[C@@H]2[C@@H]([C@@H]3[C@H]1C[C@@H](C3=C)O)OC(=O)C2=C,,,,,,
2646,72647,Anticapsin,C1CC(=O)[C@H]2[C@@H]([C@H]1C[C@@H](C(=O)O)N)O2,,,,,,
2647,72648,CID 72648,COC1=C2C(=C(C3=C(C=C4C(=C3O2)[C@@H]5C=CO[C@H]5O4)OC)O)C(=O)C=C1,,,,,,
2648,72649,CID 72649,CC1=C(C(=O)O[C@@H](C1)C(C)([C@@]2(CC[C@@]3([C@@]2(CC[C@H]4[C@H]3C[C@@H]5[C@]6([C@@]4(C(=O)C=CC6)C)O5)C)O)O)O)C,,,,,,
2649,72650,"[(1R,2S,4R,9S,10S,11R,12R)-11-acetyloxy-4,10-dihydroxy-1,5-dimethylspiro[8-oxatricyclo[7.2.1.02,7]dodec-5-ene-12,2'-oxirane]-2-yl]methyl acetate",CC1=CC2[C@@](C[C@H]1O)([C@@]3([C@H]([C@@H]([C@@H]([C@]34CO4)O2)O)OC(=O)C)C)COC(=O)C,,,,,,
2650,72651,CID 72651,CC1(C=CC2=C3C(=C(C4=CC=CC=C4N3C)S)C(=O)C=C2O1)C,,,,,,
2651,72652,Coumarin 153,C1CC2=CC3=C(C4=C2N(C1)CCC4)OC(=O)C=C3C(F)(F)F,,,,,,
2652,72653,Coumarin 314,CCOC(=O)C1=CC2=CC3=C4C(=C2OC1=O)CCCN4CCC3,,,,,,
2653,72654,Coumarin 337,C1CC2=C3C(=C4C(=C2)C=C(C(=O)O4)C#N)CCCN3C1,,,,,,
2654,72655,Coumarin 334,CC(=O)C1=CC2=CC3=C4C(=C2OC1=O)CCCN4CCC3,,,,,,
2655,72656,3-Aminopyrazine-2-carboxylic acid,C1=CN=C(C(=N1)C(=O)O)N,,,,,,
2656,72657,3-Hydroxycarbamoyl-1-methylpyridinium iodide,C[N+]1=CC=CC(=C1)C(=O)NO.[I-],,,,,,
2657,72658,3-[(Hydroxyamino)carbonyl]-1-methylpyridinium,C[N+]1=CC=CC(=C1)C(=O)NO,,,,,,
2658,72659,"2,3-Dimethylquinoxaline 1,4-dioxide",CC1=C([N+](=O)C2=CC=CC=C2N1[O-])C,,,,,,
2659,72660,3-Carbamoyl-1-methylpyridinium iodide,C[N+]1=CC=CC(=C1)C(=O)N.[I-],,,,,,
2660,72661,Nicotinamide N-oxide,C1=CC(=C[N+](=C1)[O-])C(=O)N,,,,,,
2661,72662,Methyl 2-pyrazinecarboxylate,COC(=O)C1=NC=CN=C1,,,,,,
2662,72663,N-(2-Hydroxyethyl)nicotinamide,C1=CC(=CN=C1)C(=O)NCCO,,,,,,
2663,72664,CID 72664,CC1=NN(C(=O)C1N=NC2=C(C=C(C3=CC=CC=C32)S(=O)(=O)[O-])O)C4=CC=CC=C4.[Na+],,,,,,
2664,72665,"1-Naphthalenesulfonic acid, 4-((4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)azo)-3-hydroxy-",CC1=NN(C(=O)C1N=NC2=C(C=C(C3=CC=CC=C32)S(=O)(=O)O)O)C4=CC=CC=C4,,,,,,
2665,72666,4-Formylaminoantipyrine,CC1=C(C(=O)N(N1C)C2=CC=CC=C2)NC=O,,,,,,
2666,72667,CID 72667,C1=CC(=NC=C1C(=O)N)S,,,,,,
2667,72668,"5-Methylpyrazine-2,3-dicarboxylic acid",CC1=CN=C(C(=N1)C(=O)O)C(=O)O,,,,,,
2668,72669,Methyl 3-aminopyrazine-2-carboxylate,COC(=O)C1=NC=CN=C1N,,,,,,
2669,72670,"2,5-Dimethylene-3,6-diketopiperazine",C=C1C(=O)NC(=C)C(=O)N1,,,,,,
2670,72671,"3-Pyridinecarboxamide, 5-nitro-2-(2-pyrimidinylthio)-",C1=CN=C(N=C1)SC2=C(C=C(C=N2)[N+](=O)[O-])C(=O)N,,,,,,
2671,72672,CID 72672,CC1=NN(C(=O)C1N=NC2=C(C(=CC(=C2)Cl)S(=O)(=O)[O-])O)C3=CC=CC=C3.[Na+],,,,,,
2672,72673,"5-Chloro-3-((4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)azo)-2-hydroxybenzenesulphonic acid",CC1=NN(C(=O)C1N=NC2=C(C(=CC(=C2)Cl)S(=O)(=O)O)O)C3=CC=CC=C3,,,,,,
2673,72674,Cyclo(tyrosylarginyl),C1=CC(=CC=C1C[C@@H]2C(=O)N[C@@H](C(=O)N2)CCCN=C(N)N)O,,,,,,
2674,72675,Morpholine-N-dithiocarbamate,C1COCCN1.C1COCCN1C(=S)S,,,,,,
2675,72676,CID 72676,CC(C)N(C(C)C)C(=S)[S-].[Na+],,,,,,
2676,72677,Diisopropyldithiocarbamate,CC(C)N(C(C)C)C(=S)S,,,,,,
2677,72678,CID 72678,CCN=C(S)[S-].[Na+],,,,,,
2678,72679,CID 72679,CCN=C(S)S,,,,,,
2679,72680,CID 72680,CCN.CCN=C(S)S,,,,,,
2680,72681,CID 72681,C1=CC(=CC=C1N=C(S)S)O.N,,,,,,
2681,72682,CID 72682,C1=CC(=CC=C1N=C(S)S)O,,,,,,
2682,72683,Dibenzylammonium dibenzyldithiocarbamate,C1=CC=C(C=C1)CNCC2=CC=CC=C2.C1=CC=C(C=C1)CN(CC2=CC=CC=C2)C(=S)S,,,,,,
2683,72684,Dibenzyldithiocarbamate,C1=CC=C(C=C1)CN(CC2=CC=CC=C2)C(=S)S,,,,,,
2684,72685,Orcein,CC1=CC(=CC(=C1NC2=C(C3=C(C=C2O)OC4=CC(=O)C(=NC5=C(C=C(C=C5C)O)O)C(=C43)C)C)O)O,,,['Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. (See all compounds classified as Coloring Agents.)'],,,
2685,72686,"2-Methoxy-5-[2-(3,4,5-trimethoxyphenyl)ethenyl]phenol",COC1=C(C=C(C=C1)C=CC2=CC(=C(C(=C2)OC)OC)OC)O,,,,,,
2686,72687,"1H-imidazole-4,5-dicarbohydrazide",C1=NC(=C(N1)C(=O)NN)C(=O)NN,,,,,,
2687,72688,"4,5-Dihydro-5-oxo-1-phenyl-1H-pyrazole-3-carbohydrazide",C1C(=NN(C1=O)C2=CC=CC=C2)C(=O)NN,,,,,,
2688,72689,1-Naphthohydrazide,C1=CC=C2C(=C1)C=CC=C2C(=O)NN,,,,,,
2689,72690,Orotic acid hydrazide,C1=C(NC(=O)NC1=O)C(=O)NN,,,,,,
2690,72691,2-{2-[(4-Chlorophenyl)methylidene]hydrazinyl}-5-nitropyridine,C1=CC(=CC=C1C=NNC2=NC=C(C=C2)[N+](=O)[O-])Cl,,,,,,
2691,72692,CID 72692,C1=CC(=CN=NC2=NC=C(C=C2)N(O)O)C(=O)C=C1,,,,,,
2692,72693,"1,3-Naphthalenedisulfonic acid, 7-((4-((4-aminobenzoyl)amino)-2-methylphenyl)azo)-, disodium salt",CC1=C(C=CC(=C1)NC(=O)C2=CC=C(C=C2)N)N=NC3=CC4=C(C=C(C=C4C=C3)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+],,,,,,
2693,72694,"7-[[4-[(4-Aminobenzoyl)amino]-2-methylphenyl]diazenyl]naphthalene-1,3-disulfonic acid",CC1=C(C=CC(=C1)NC(=O)C2=CC=C(C=C2)N)N=NC3=CC4=C(C=C(C=C4C=C3)S(=O)(=O)O)S(=O)(=O)O,,,,,,
2694,72695,Benzamin Red 7B,C1=CC(=CC(=C1)N)C(=O)NC2=CC3=CC(=C(C(=C3C=C2)O)N=NC4=CC=C(C=C4)N=NC5=CC=C(C=C5)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+],,,,,,
2695,72696,7-[(3-Aminobenzoyl)amino]-4-hydroxy-3-[[4-[(4-sulfophenyl)diazenyl]phenyl]diazenyl]naphthalene-2-sulfonic acid,C1=CC(=CC(=C1)N)C(=O)NC2=CC3=CC(=C(C(=C3C=C2)O)N=NC4=CC=C(C=C4)N=NC5=CC=C(C=C5)S(=O)(=O)O)S(=O)(=O)O,,,,,,
2696,72697,Benzamin Red 5B,C1=CC(=CC(=C1)NC(=O)C2=CC=C(C=C2)N)C(=O)NC3=CC4=CC(=C(C(=C4C=C3)O)N=NC5=CC=C(C=C5)N=NC6=CC=C(C=C6)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+],,,,,,
2697,72698,7-[[3-[(4-Aminobenzoyl)amino]benzoyl]amino]-4-hydroxy-3-[[4-[(4-sulfophenyl)diazenyl]phenyl]diazenyl]naphthalene-2-sulfonic acid,C1=CC(=CC(=C1)NC(=O)C2=CC=C(C=C2)N)C(=O)NC3=CC4=CC(=C(C(=C4C=C3)O)N=NC5=CC=C(C=C5)N=NC6=CC=C(C=C6)S(=O)(=O)O)S(=O)(=O)O,,,,,,
2698,72699,3-Hydroxy-2-naphthohydrazide,C1=CC=C2C=C(C(=CC2=C1)C(=O)NN)O,,,,,,
2699,72700,Isophthalic dihydrazide,C1=CC(=CC(=C1)C(=O)NN)C(=O)NN,,,,,,
2700,72701,"2'-(2,4-Dichlorobenzoyl)-1-naphthohydrazide",C1=CC=C2C(=C1)C=CC=C2C(=O)NNC(=O)C3=C(C=C(C=C3)Cl)Cl,,,,,,
2701,72702,CID 72702,CC(=O)NC1=CC=C(C=C1)C=NNC(=NCCCN2CCN(CC2)CCCN=C(NN=CC3=CC=C(C=C3)NC(=O)C)S)S,,,,,,
2702,72703,Berberrubine chloride,COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)O.[Cl-],,,,,,
2703,72704,Berberrubine,COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)O,,,,,,
2704,72705,"Phenol, 4-((2,6-diamino-3-pyridinyl)azo)-",C1=CC(=CC=C1N=NC2=C(N=C(C=C2)N)N)O,,,,,,
2705,72706,"3H-1,2-Benzodithiole-3-thione",C1=CC=C2C(=C1)C(=S)SS2,,,,,,
2706,72707,"3H-1,2-Benzodithiol-3-one",C1=CC=C2C(=C1)C(=O)SS2,,,,,,
2707,72708,Trimethyl-[2-(5-nitrofuran-2-yl)ethenyl]azanium;bromide,C[N+](C)(C)C=CC1=CC=C(O1)[N+](=O)[O-].[Br-],,,,,,
2708,72709,Trimethyl-[2-(5-nitrofuran-2-yl)ethenyl]azanium,C[N+](C)(C)C=CC1=CC=C(O1)[N+](=O)[O-],,,,,,
2709,72710,"Indole-3-acetic acid, (2-oxo-3-indolinylidene)hydrazide",C1=CC=C2C(=C1)C(=CN2)CC(=O)N=NC3=C(NC4=CC=CC=C43)O,,,,,,
2710,72711,4-Chloropicolinohydrazide,C1=CN=C(C=C1Cl)C(=O)NN,,,,,,
2711,72712,"Thioxanthen-9-one, 4-(hydroxymethyl)-1-((2-(2-methylpiperidino)ethyl)amino)-",CC1CCCCN1CCNC2=C3C(=C(C=C2)CO)SC4=CC=CC=C4C3=O,,,,,,
2712,72713,Desethylhycanthone,CCNCCNC1=C2C(=C(C=C1)CO)SC3=CC=CC=C3C2=O,,,,,,
2713,72714,"9H-Thioxanthen-9-one, 1-((2-(ethyl(2-hydroxy-2-methylpropyl)amino)ethyl)amino)-4-(hydroxymethyl)-",CCN(CCNC1=C2C(=C(C=C1)CO)SC3=CC=CC=C3C2=O)CC(C)(C)O,,,,,,
2714,72715,CID 72715,CC(=O)NN=C(N)S,,,,,,
2715,72716,CID 72716,CC1=C(NON1O)C(=O)N=N,,,,,,
2716,72717,CID 72717,CC1=C(N(ON1)O)C(=O)N=N,,,,,,
2717,72718,4-Biphenylcarboxylic acid hydrazide,C1=CC=C(C=C1)C2=CC=C(C=C2)C(=O)NN,,,,,,
2718,72719,Nitrazine,C(C(=O)NN)N(CC(=O)NN)CC(=O)NN,,,,,,
2719,72720,"1,2,3-Thiadiazole-4-carbohydrazide",C1=C(N=NS1)C(=O)NN,,,,,,
2720,72721,"2,6,7-Trihydroxy-9-methylxanthen-3-one",CC1=C2C=C(C(=O)C=C2OC3=CC(=C(C=C13)O)O)O,,,,,,
2721,72722,9-Hydroxyphenylfluoron,C1=CC=C(C(=C1)C2=C3C=C(C(=O)C=C3OC4=CC(=C(C=C42)O)O)O)O,,,,,,
2722,72723,"2-Amino-3-oxo-3H-phenoxazine-4,6-dicarboxylic acid dimethyl ester",COC(=O)C1=C2C(=CC=C1)N=C3C=C(C(=O)C(=C3O2)C(=O)OC)N,,,,,,
2723,72724,Alantolactone,C[C@H]1CCC[C@]2(C1=C[C@H]3[C@@H](C2)OC(=O)C3=C)C,,,,,,
2724,72725,2-Amino-3H-phenoxazin-3-one,C1=CC=C2C(=C1)N=C3C=C(C(=O)C=C3O2)N,,,,,,
2725,72726,"[(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-1,9-dihydroxy-15-[(2R,3S)-2-hydroxy-3-(2-methylbut-2-enoylamino)-3-phenylpropanoyl]oxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate",CC=C(C)C(=O)N[C@@H](C1=CC=CC=C1)[C@H](C(=O)O[C@H]2C[C@]3([C@H]([C@H]4[C@@]([C@H](C[C@@H]5[C@]4(CO5)OC(=O)C)O)(C(=O)[C@@H](C(=C2C)C3(C)C)OC(=O)C)C)OC(=O)C6=CC=CC=C6)O)O,,,,,,
2726,72727,"1-({[5-(4-Fluorophenyl)furan-2-yl]methylidene}amino)-4-hydroxy-1,5-dihydro-2H-imidazol-2-one",C1C(=O)NC(=O)N1N=CC2=CC=C(O2)C3=CC=C(C=C3)F,,,,,,
2727,72728,"4-Hydroxy-1-[({5-[3-(trifluoromethyl)phenyl]furan-2-yl}methylidene)amino]-1,5-dihydro-2H-imidazol-2-one",C1C(=O)NC(=O)N1N=CC2=CC=C(O2)C3=CC(=CC=C3)C(F)(F)F,,,,,,
2728,72729,"5,7-Dihydro-5,5,7,7-tetramethyl-3-(3-nitrophenyl)furo(3,4-e)-as-triazine 4-oxide",CC1(C2=C(C(O1)(C)C)[N+](=C(N=N2)C3=CC(=CC=C3)[N+](=O)[O-])[O-])C,,,,,,
2729,72730,CID 72730,CC1(C(=C(C(O1)(C)C)N=O)NN)C,,,,,,
2730,72731,"N,N'-(9,10-Dihydro-9,10-dioxoanthracene-1,4-diyl)bisbenzamide",C1=CC=C(C=C1)C(=O)NC2=C3C(=C(C=C2)NC(=O)C4=CC=CC=C4)C(=O)C5=CC=CC=C5C3=O,,,,,,
2731,72732,alpha-Lapachone,CC1(CCC2=C(O1)C(=O)C3=CC=CC=C3C2=O)C,,,['Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)'],,,
2732,72733,Chimyl alcohol,CCCCCCCCCCCCCCCCOCC(CO)O,,,,,,
2733,72734,Xyloidone,CC1(C=CC2=C(O1)C(=O)C3=CC=CC=C3C2=O)C,,,,,,
2734,72735,4-Desmethyllucanthone,CCN(CC)CCNC1=C2C(=CC=C1)SC3=CC=CC=C3C2=O,,,,,,
2735,72736,"1,4-Bis((4-(dimethylamino)butyl)amino)-5,8-dihydroxy-9,10-anthracenedione",CN(C)CCCCNC1=C2C(=C(C=C1)NCCCCN(C)C)C(=O)C3=C(C=CC(=C3C2=O)O)O,,,,,,
2736,72737,"Anthraquinone, 1,4-bis((2-morpholinoethyl)amino)-",C1COCCN1CCNC2=C3C(=C(C=C2)NCCN4CCOCC4)C(=O)C5=CC=CC=C5C3=O,,,,,,
2737,72738,"9,10-Anthracenedione, 1-[[3-(dimethylamino)propyl]amino]-4-hydroxy-, monohydrochloride",CN(C)CCCNC1=C2C(=C(C=C1)O)C(=O)C3=CC=CC=C3C2=O.Cl,,,,,,
2738,72739,1-((3-(Dimethylamino)propyl)amino)-4-hydroxyanthraquinone,CN(C)CCCNC1=C2C(=C(C=C1)O)C(=O)C3=CC=CC=C3C2=O,,,,,,
2739,72740,Juncusol,CC1=C(C=CC2=C1CCC3=CC(=C(C(=C32)C=C)C)O)O,,,,,,
2740,72741,"9,10-Anthracenedione, 1,5-dihydroxy-4,8-bis[(4-methylphenyl)amino]-",CC1=CC=C(C=C1)NC2=C3C(=C(C=C2)O)C(=O)C4=C(C=CC(=C4C3=O)O)NC5=CC=C(C=C5)C,,,,,,
2741,72742,Dermocybin,CC1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C(=C(C(=C3O)O)OC)O,,,,,,
2742,72743,"9,10-Anthracenedione, 1,4-bis((3-((2-hydroxyethyl)amino)propyl)amino)-",C1=CC=C2C(=C1)C(=O)C3=C(C=CC(=C3C2=O)NCCCNCCO)NCCCNCCO,,,,,,
2743,72744,"2-Anthracenesulfonic acid, 1-amino-4-[[4-(ethenylsulfonyl)phenyl]amino]-9,10-dihydro-9,10-dioxo-",C=CS(=O)(=O)C1=CC=C(C=C1)NC2=CC(=C(C3=C2C(=O)C4=CC=CC=C4C3=O)N)S(=O)(=O)O,,,,,,
2744,72745,CID 72745,C1=CC=C2C(=C1)C(=C3C=CC(=C(C3=C2O)N)C(=O)N=C4C=CC(=NC(=O)C5=C(C6=C(C=C5)C(=O)C7=CC=CC=C7C6=O)N)C8=C4C(=O)C9=CC=CC=C9C8=O)O,,,,,,
2745,72746,"7H-Benzo[e]perimidine-4-carboxamide, N-(9,10-dihydro-9,10-dioxo-1-anthracenyl)-7-oxo-",C1=CC=C2C(=C1)C3=NC=NC4=C(C=CC(=C43)C2=O)C(=O)NC5=CC=CC6=C5C(=O)C7=CC=CC=C7C6=O,,,,,,
2746,72747,"9,10-Anthracenedione, 1-hydroxy-4-((2-((2-hydroxyethyl)amino)ethyl)amino)-",C1=CC=C2C(=C1)C(=O)C3=C(C=CC(=C3C2=O)O)NCCNCCO,,,,,,
2747,72748,"Thioxanthen-9-one, 1-((2-(diethylamino)ethyl)amino)-4-methoxy-",CCN(CC)CCNC1=C2C(=C(C=C1)OC)SC3=CC=CC=C3C2=O,,,,,,
2748,72749,"9,10-Anthracenedione, 6,7-dichloro-1,4-bis[(4-methylphenyl)amino]-",CC1=CC=C(C=C1)NC2=C3C(=C(C=C2)NC4=CC=C(C=C4)C)C(=O)C5=CC(=C(C=C5C3=O)Cl)Cl,,,,,,
2749,72750,"1,4-Dihydroxy-5,8-bis((2-(2-hydroxyethoxy)ethyl)amino)-9,10-anthracenedione",C1=CC(=C2C(=C1NCCOCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCOCCO,,,,,,
2750,72751,CID 72751,C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C(=C(C(=C3N)O)S(=O)(=O)[O-])O.[Na+],,,,,,
2751,72752,"4-Amino-1,3-dihydroxy-9,10-dioxo-9,10-dihydroanthracene-2-sulfonic acid",C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C(=C(C(=C3N)O)S(=O)(=O)O)O,,,,,,
2752,72753,"Benzoic acid, 2-(4,5-dibromo-6-hydroxy-3-oxo-3H-xanthen-9-yl)-",C1=CC=C(C(=C1)C2=C3C=CC(=O)C(=C3OC4=C2C=CC(=C4Br)O)Br)C(=O)O,,,,,,
2753,72754,2-Chloro-3-acetamidonaphthoquinone,CC(=O)NC1=C(C(=O)C2=CC=CC=C2C1=O)Cl,,,,,,
2754,72755,"1,3,6,8-Tetranitrocarbazole",C1=C(C=C(C2=C1C3=C(N2)C(=CC(=C3)[N+](=O)[O-])[N+](=O)[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
2755,72756,"2-Heptadecyl-2-oxazoline-4,4-dimethanol",CCCCCCCCCCCCCCCCCC1=NC(CO1)(CO)CO,,,,,,
2756,72757,"2H-1,4-Benzoxazin-3(4H)-one",C1C(=O)NC2=CC=CC=C2O1,,,,,,
2757,72758,2-Hydroxypyrazine,C1=CN=CC(=O)N1,,,,,,
2758,72759,"Furo[3,4-b]quinoxaline-1,3-dione",C1=CC=C2C(=C1)N=C3C(=N2)C(=O)OC3=O,,,,,,
2759,72760,"1,2-Bis(3,5-dioxopiperazin-1-yl)ethane",C1C(=O)NC(=O)CN1CCN2CC(=O)NC(=O)C2,,,,,,
2760,72761,"2,3-Piperazinedione",C1CNC(=O)C(=O)N1,,,,,,
2761,72762,"4-Oxazolecarboxamide, 2-(2-fluorophenyl)-5-methyl-",CC1=C(N=C(O1)C2=CC=CC=C2F)C(=O)N,,,,,,
2762,72763,"5-Oxazolecarboxamide, 4-methyl-2-phenyl-",CC1=C(OC(=N1)C2=CC=CC=C2)C(=O)N,,,,,,
2763,72764,"Oxazole-4-carboxamide, 2-(m-fluorophenyl)-5-methyl-",CC1=C(N=C(O1)C2=CC(=CC=C2)F)C(=O)N,,,,,,
2764,72765,CID 72765,C1=CC=C(C=C1)NC(=O)C2=C(N=C(NC2=O)S)O,,,,,,
2765,72766,Pyrazine diazohydroxide,C1=CN=C(C=N1)NN=O,,,,,,
2766,72767,"2-Chloro-4-(p-dimethylaminophenyl)imino-2,5-cyclohexadiene-1-one",CN(C)C1=CC=C(C=C1)N=C2C=CC(=O)C(=C2)Cl,,,,,,
2767,72768,"Acetamide, 2-(diallylamino)-N-(2,5-dimethylpyrrol-1-yl)-",CC1=CC=C(N1NC(=O)CN(CC=C)CC=C)C,,,,,,
2768,72769,"3,6-Acridinediamine, 2,7,9-trimethyl-, monohydrochloride",CC1=CC2=C(C3=C(C=C(C(=C3)C)N)N=C2C=C1N)C.Cl,,,,,,
2769,72770,"2,7,9-Trimethyl-3,6-acridinediamine",CC1=CC2=C(C3=C(C=C(C(=C3)C)N)N=C2C=C1N)C,,,,,,
2770,72771,Benzyl (hydrazinocarbonylmethyl)carbamate,C1=CC=C(C=C1)COC(=O)NCC(=O)NN,,,,,,
2771,72772,"10H-Pyrido(3,2-b)pyrimido(4,5-e)(1,4)thiazin-4-amine, 8-methyl-",CC1=NC2=C(C=C1)SC3=C(N=CN=C3N2)N,,,,,,
2772,72773,"4-(beta-Diethylaminoethylamino)-1,2-cyclohexenothiaxanthone",CCN(CC)CCNC1=C2C(=C3CCCCC3=C1)C(=O)C4=CC=CC=C4S2,,,,,,
2773,72774,"5,5-Dimethyl-11-oxoisochromeno[4,3-g]chromene-9-carboxylic acid",CC1(C2=CC=CC=C2C3=C(O1)C=C4C(=C3)C(=O)C=C(O4)C(=O)O)C,,,,,,
2774,72775,"10-Chloro-1,4,6,9-tetrahydro-4,6-dioxopyrido(3,2-g)quinoline-2,8-dicarboxylic acid",C1=C2C(=O)C=C(NC2=C(C3=C1C(=O)C=C(N3)C(=O)O)Cl)C(=O)O,,,,,,
2775,72776,"2,6-Dichloro-4-dimethylamino-alpha-methylphenethylamine dihydrochloride",CC(CC1=C(C=C(C=C1Cl)N(C)C)Cl)N.Cl.Cl,,,,,,
2776,72777,"4-(2-aminopropyl)-3,5-dichloro-N,N-dimethylaniline",CC(CC1=C(C=C(C=C1Cl)N(C)C)Cl)N,,,,,,
2777,72778,"N-[4-(benzenesulfonylimino)-3-methylcyclohexa-2,5-dien-1-ylidene]-2-bromoacetamide",CC1=CC(=NC(=O)CBr)C=CC1=NS(=O)(=O)C2=CC=CC=C2,,,,,,
2778,72779,(S)-2-amino-3-(4-hydroxyphenyl)propanehydrazide,C1=CC(=CC=C1C[C@@H](C(=O)NN)N)O,,,,,,
2779,72780,"1-N,4-N-dichloro-2-methylcyclohexa-2,5-diene-1,4-diimine",CC1=CC(=NCl)C=CC1=NCl,,,,,,
2780,72781,"1-N,4-N-dichloro-2-methoxycyclohexa-2,5-diene-1,4-diimine",COC1=CC(=NCl)C=CC1=NCl,,,,,,
2781,72782,"1-N,4-N-dichloro-2-nitrocyclohexa-2,5-diene-1,4-diimine",C1=CC(=NCl)C(=CC1=NCl)[N+](=O)[O-],,,,,,
2782,72783,"N,N'-Dibromo-2,5-cyclohexadiene-1,4-diimine",C1=CC(=NBr)C=CC1=NBr,,,,,,
2783,72784,"1-N,4-N-dibromo-2-methylcyclohexa-2,5-diene-1,4-diimine",CC1=CC(=NBr)C=CC1=NBr,,,,,,
2784,72785,"1-N,4-N-dibromo-2-methoxycyclohexa-2,5-diene-1,4-diimine",COC1=CC(=NBr)C=CC1=NBr,,,,,,
2785,72786,"1-N,4-N-dibromo-2-chlorocyclohexa-2,5-diene-1,4-diimine",C1=CC(=NBr)C(=CC1=NBr)Cl,,,,,,
2786,72787,"1-N,4-N-dibromo-2-nitrocyclohexa-2,5-diene-1,4-diimine",C1=CC(=NBr)C(=CC1=NBr)[N+](=O)[O-],,,,,,
2787,72788,"1-N,4-N,2-trichlorocyclohexa-2,5-diene-1,4-diimine",C1=CC(=NCl)C(=CC1=NCl)Cl,,,,,,
2788,72789,"3-(4-Oxocyclohexa-2,5-dien-1-ylidene)carbazamidine",C1=CC(=CC=C1N=NC(=N)N)O,,,,,,
2789,72790,"5-Nitro-1,10-phenanthroline",C1=CC2=CC(=C3C=CC=NC3=C2N=C1)[N+](=O)[O-],,,,,,
2790,72791,"5-Methyl-1,10-phenanthroline",CC1=CC2=C(C3=C1C=CC=N3)N=CC=C2,,,,,,
2791,72792,"4,7-Dimethyl-1,10-phenanthroline",CC1=C2C=CC3=C(C=CN=C3C2=NC=C1)C,,,,,,
2792,72793,Diazepam N-oxide,CN1C(=O)C[N+](=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3)[O-],,,,,,
2793,72794,Diphenic anhydride,C1=CC=C2C(=C1)C3=CC=CC=C3C(=O)OC2=O,,,,,,
2794,72795,Hexahydro-1-(2-pyridyl)-2H-azepin-2-one,C1CCC(=O)N(CC1)C2=CC=CC=N2,,,,,,
2795,72796,"1,10-Phenanthrolinium, 1,6-dimethyl-, iodide",CC1=CC2=C(C3=C1C=CC=N3)[N+](=CC=C2)C.[I-],,,,,,
2796,72797,"1,6-Dimethyl-1,10-phenanthrolin-1-ium",CC1=CC2=C(C3=C1C=CC=N3)[N+](=CC=C2)C,,,,,,
2797,72798,CID 72798,C1C[C-]=[C-]CC[C-]=[C-]1.C1=CC2=C(C3=C(C=CC=N3)C=C2)N=C1.[Cl-].[Rh],,,,,,
2798,72799,CID 72799,C1C[C-]=[C-]CC[C-]=[C-]1,,,,,,
2799,72800,CID 72800,COC1=CC2=C(C=C1)C(=O)C(=C(O2)O)OC3=CC=CC=C3,,,,,,
2800,72801,"4,7,13,16,21,24-Hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane",C1COCCOCCN2CCOCCOCCN1CCOCCOCC2,,,,,,
2801,72802,"1H-1,2,4-Benzotriazepine-3-carboxamide, 4,5-dihydro-5-oxo-4-phenyl-",C1=CC=C(C=C1)N2C(=O)C3=CC=CC=C3NN=C2C(=O)N,,,,,,
2802,72803,Pyridathion,CCOP(=S)(OC1=C(C(=O)N(N=C1)C)OC)OC(C)C,,,,,,
2803,72804,"1H-Pyridazino(1,2-a)(1,2,5)triazepine-1,5(2H)-dione, hexahydro-3-(4-ethoxyphenyl)-",CCOC1=CC=C(C=C1)N2CC(=O)N3CCCCN3C(=O)C2,,,,,,
2804,72805,"1,4,10,13-Tetraoxa-7,16-diazacyclooctadecane",C1COCCOCCNCCOCCOCCN1,,,,,,
2805,72806,"7,16-Didecyl-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane",CCCCCCCCCCN1CCOCCOCCN(CCOCCOCC1)CCCCCCCCCC,,,,,,
2806,72807,"Tetrahydro-3-(2-methylpropyl)-1H,7H-pyrazolo(1,2-a)(1,2,5)triazepine-1,5(2H)-dione",CC(C)CN1CC(=O)N2CCCN2C(=O)C1,,,,,,
2807,72808,"1H,7H-Pyrazolo(1,2-a)(1,2,5)triazepine-1,5(2H)-dione, tetrahydro-3-((4-chlorophenyl)methyl)-",C1CN2C(=O)CN(CC(=O)N2C1)CC3=CC=C(C=C3)Cl,,,,,,
2808,72809,"Tetrahydro-3-(4-methylphenyl)-1H,7H-pyrazolo(1,2-a)(1,2,5)triazepine-1,5(2H)-dione",CC1=CC=C(C=C1)N2CC(=O)N3CCCN3C(=O)C2,,,,,,
2809,72810,"1,10-Phenanthroline-5,6-dione",C1=CC2=C(C3=C(C=CC=N3)C(=O)C2=O)N=C1,,,,,,
2810,72811,"4-Hydroxy-5-methoxy-1,10-phenanthroline-3-carboxylic acid",COC1=C2C(=C3C(=C1)C=CC=N3)NC=C(C2=O)C(=O)O,,,,,,
2811,72812,"4,7-Diphenyl-1,10-phenanthroline",C1=CC=C(C=C1)C2=C3C=CC4=C(C=CN=C4C3=NC=C2)C5=CC=CC=C5,,,"['Chemical agents that uncouple oxidation from phosphorylation in the metabolic cycle so that ATP synthesis does not occur. Included here are those IONOPHORES that disrupt electron transfer by short-circuiting the proton gradient across mitochondrial membranes. (See all compounds classified as Uncoupling Agents.)', 'Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant and Hackh&apos;s Chemical Dictionary, 5th ed, p301, p499) (See all compounds classified as Indicators and Reagents.)']",,,
2812,72813,"4,5-dichloro-2-phenylpyridazin-3(2H)-one",C1=CC=C(C=C1)N2C(=O)C(=C(C=N2)Cl)Cl,,,,,,
2813,72814,"2H-1,3,5-Thiadiazine-2-thione, tetrahydro-3-(p-chlorophenyl)-5-methyl-",CN1CN(C(=S)SC1)C2=CC=C(C=C2)Cl,,,,,,
2814,72815,"5,6,7,8,3',4',5'-Heptamethoxyflavone",COC1=CC(=CC(=C1OC)OC)C2=CC(=O)C3=C(O2)C(=C(C(=C3OC)OC)OC)OC,,,,,,
2815,72816,"2H-1,3,5-Thiadiazine-2-thione, tetrahydro-3,5-diphenethyl-",C1N(CSC(=S)N1CCC2=CC=CC=C2)CCC3=CC=CC=C3,,,,,,
2816,72817,"2H-1-Benzopyran-2-one, 7-(ethylamino)-6-methyl-4-(trifluoromethyl)-",CCNC1=CC2=C(C=C1C)C(=CC(=O)O2)C(F)(F)F,,,,,,
2817,72818,"2H-Pyrano[3,2-g]quinolin-2-one, 9-ethyl-6,7,8,9-tetrahydro-4-(trifluoromethyl)-",CCN1CCCC2=CC3=C(C=C21)OC(=O)C=C3C(F)(F)F,,,,,,
2818,72819,N-Methylflindersine,CC1(C=CC2=C(O1)C3=CC=CC=C3N(C2=O)C)C,,,,,,
2819,72820,"4-(Aminomethyl)-9-methoxy-7H-furo(3,2-g)(1)benzopyran-7-one hydrochloride",COC1=C2C(=C(C3=C1OC=C3)CN)C=CC(=O)O2.Cl,,,,,,
2820,72821,"4-(Aminomethyl)-9-methoxy-7H-furo[3,2-g]chromen-7-one",COC1=C2C(=C(C3=C1OC=C3)CN)C=CC(=O)O2,,,,,,
2821,72822,"1,3-Oxathiolan-2-one",C1CSC(=O)O1,,,,,,
2822,72823,"1-Aminoimidazolidine-2,4-dione",C1C(=O)NC(=O)N1N,,,,,,
2823,72824,"2,2,3,3-Tetramethylsuccinimide",CC1(C(=O)NC(=O)C1(C)C)C,,,,,,
2824,72825,CID 72825,C1CN(CCN1C2=CC=CC=C2)C3=NC(=O)C=C(N3)N,,,,,,
2825,72826,Benzo[c]cinnoline N-oxide,C1=CC=C2C(=C1)C3=CC=CC=C3[N+](=N2)[O-],,,,,,
2826,72827,"9H-Thioxanthen-9-one, 4-(hydroxymethyl)-1-[[2-(1-piperidinyl)ethyl]amino]-",C1CCN(CC1)CCNC2=C3C(=C(C=C2)CO)SC4=CC=CC=C4C3=O,,,,,,
2827,72828,Cyclopentenyl cytosine,C1=CN(C(=O)N=C1N)[C@@H]2C=C([C@H]([C@H]2O)O)CO,,,"['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)']",,,
2828,72829,"2,3-Pyridinedicarboximide",C1=CC2=C(C(=O)NC2=O)N=C1,,,,,,
2829,72830,"Succinimide, 2-phthalimido-",C1C(C(=O)NC1=O)N2C(=O)C3=CC=CC=C3C2=O,,,,,,
2830,72831,N-[[4-(dimethylamino)phenyl]methylideneamino]-5-nitropyridin-2-amine,CN(C)C1=CC=C(C=C1)C=NNC2=NC=C(C=C2)[N+](=O)[O-],,,,,,
2831,72832,5-nitro-N-[(3-nitrophenyl)methylideneamino]pyridin-2-amine,C1=CC(=CC(=C1)[N+](=O)[O-])C=NNC2=NC=C(C=C2)[N+](=O)[O-],,,,,,
2832,72833,CID 72833,C1=CC(=CN=NC2=NC=C(C=C2)N(O)O)C(=CC1=O)O,,,,,,
2833,72834,"N-[(3,4-dichlorophenyl)methylideneamino]-5-nitropyridin-2-amine",C1=CC(=C(C=C1C=NNC2=NC=C(C=C2)[N+](=O)[O-])Cl)Cl,,,,,,
2834,72835,"Benzaldehyde,4-methyl-, 2-(5-nitro-2-pyridinyl)hydrazone",CC1=CC=C(C=C1)C=NNC2=NC=C(C=C2)[N+](=O)[O-],,,,,,
2835,72836,CID 72836,COC1=CC=CC(=CN=NC2=NC=C(C=C2)N(O)O)C1=O,,,,,,
2836,72837,N-(furan-2-ylmethylideneamino)-5-nitropyridin-2-amine,C1=COC(=C1)C=NNC2=NC=C(C=C2)[N+](=O)[O-],,,,,,
2837,72838,CID 72838,C1OC2=C(O1)C=C(C=C2)C=NNC3=NC=C(C=C3)[N+](=O)[O-],,,,,,
2838,72839,CID 72839,C1=CC=C2C(=C1)C=CC(=O)C2=CN=NC3=NC=C(C=C3)N(O)O,,,,,,
2839,72840,N-(decylideneamino)-5-nitropyridin-2-amine,CCCCCCCCCC=NNC1=NC=C(C=C1)[N+](=O)[O-],,,,,,
2840,72841,N-(dodecylideneamino)-5-nitropyridin-2-amine,CCCCCCCCCCCC=NNC1=NC=C(C=C1)[N+](=O)[O-],,,,,,
2841,72842,CID 72842,CC(=CN=NC1=NC=C(C=C1)[N+](=O)[O-])N=NC2=NC=C(C=C2)N(O)O,,,,,,
2842,72843,"2-(4'-Methylpiperazino-1-methyl)-1,3-diazafluoranthene 1-oxide",CN1CCN(CC1)CC2=NC3=CC=CC4=C3C(=[N+]2[O-])C5=CC=CC=C45,,,,,,
2843,72844,2-(3'-(Methoxycarbonylamino)phenyl)-3-phenyl-6-methoxycarbonylamino-4-(3H)-quinazolone,COC(=O)NC1=CC2=C(C=C1)N=C(N(C2=O)C3=CC=CC=C3)C4=CC(=CC=C4)NC(=O)OC,,,,,,
2844,72845,"6-Amino-10,12-dichloronaphth(2,3-c)acridine-5,8,14(13H)-trione",C1=CC=C2C(=C1)C(=O)C3=C(C=C4C(=C3C2=O)NC5=C(C4=O)C=C(C=C5Cl)Cl)N,,,,,,
2845,72846,Centazolone,C1=CC=C2C=C3C(=CC2=C1)C(=O)N(C=N3)N,,,,,,
2846,72847,3-[C-pyridin-2-yl-N-(pyridin-2-ylamino)carbonimidoyl]benzenesulfonic acid,C1=CC=NC(=C1)C(=NNC2=CC=CC=N2)C3=CC(=CC=C3)S(=O)(=O)O,,,,,,
2847,72848,"Benzamide, 3,5-dichloro-N-(5-nitro-2-thiazolyl)-",C1=C(C=C(C=C1Cl)Cl)C(=O)NC2=NC=C(S2)[N+](=O)[O-],,,,,,
2848,72849,7-Bromobenz[a]anthracene,C1=CC=C2C(=C1)C=CC3=C(C4=CC=CC=C4C=C32)Br,,,,,,
2849,72850,2-Bromobenzyl alcohol,C1=CC=C(C(=C1)CO)Br,,,,,,
2850,72851,2-(4-Bromophenyl)ethanol,C1=CC(=CC=C1CCO)Br,,,,,,
2851,72852,"1,1-Dimethylcyclohexane-2,4,6-trione",CC1(C(=O)CC(=O)CC1=O)C,,,,,,
2852,72853,13-(Cyclopent-2-enyl)tridecanoic acid,C1CC(C=C1)CCCCCCCCCCCCC(=O)O,,,,,,
2853,72854,3-(4-Propan-2-ylphenyl)prop-2-enoic acid,CC(C)C1=CC=C(C=C1)C=CC(=O)O,,,,,,
2854,72855,5-Isopropyl-3-methylphenol,CC1=CC(=CC(=C1)O)C(C)C,,,,,,
2855,72856,"2,6-Diallylphenol",C=CCC1=C(C(=CC=C1)CC=C)O,,,,,,
2856,72857,4-Bromo-3-methylphenol,CC1=C(C=CC(=C1)O)Br,,,,,,
2857,72858,"2,4-Diiodophenol",C1=CC(=C(C=C1I)I)O,,,,,,
2858,72859,"2,5-Diphenylhydroquinone",C1=CC=C(C=C1)C2=CC(=C(C=C2O)C3=CC=CC=C3)O,,,,,,
2859,72860,1-Bromo-2-methoxynaphthalene,COC1=C(C2=CC=CC=C2C=C1)Br,,,,,,
2860,72861,9H-Xanthen-9-ol,C1=CC=C2C(=C1)C(C3=CC=CC=C3O2)O,,,,,,
2861,72862,2-(2-Chlorophenoxy)propanoic acid,CC(C(=O)O)OC1=CC=CC=C1Cl,,,,,,
2862,72863,5-Bromosalicylaldehyde,C1=CC(=C(C=C1Br)C=O)O,,,,,,
2863,72864,2'-Chloroacetophenone,CC(=O)C1=CC=CC=C1Cl,,,,,,
2864,72865,1-(4-Chlorophenyl)-2-methylpropan-1-one,CC(C)C(=O)C1=CC=C(C=C1)Cl,,,,,,
2865,72866,"7H-Benz[de]anthracen-7-one, 3-chloro-",C1=CC=C2C(=C1)C3=C4C(=C(C=C3)Cl)C=CC=C4C2=O,,,,,,
2866,72867,"2,4-Dichlorobenzophenone",C1=CC=C(C=C1)C(=O)C2=C(C=C(C=C2)Cl)Cl,,,,,,
2867,72868,"4,4'-Dibromobenzophenone",C1=CC(=CC=C1C(=O)C2=CC=C(C=C2)Br)Br,,,,,,
2868,72869,4'-Iodoacetophenone,CC(=O)C1=CC=C(C=C1)I,,,,,,
2869,72870,"2,2-Dichloroacetophenone",C1=CC=C(C=C1)C(=O)C(Cl)Cl,,,,,,
2870,72871,3-Benzoylpropionic acid,C1=CC=C(C=C1)C(=O)CCC(=O)O,,,,,,
2871,72872,4'-Ethoxyacetophenone,CCOC1=CC=C(C=C1)C(=O)C,,,,,,
2872,72873,8-Bromo-1-naphthoic acid,C1=CC2=C(C(=C1)C(=O)O)C(=CC=C2)Br,,,,,,
2873,72874,2-Hydroxy-4-iodobenzoic acid,C1=CC(=C(C=C1I)O)C(=O)O,,,,,,
2874,72875,Dodecyl sulfide,CCCCCCCCCCCCSCCCCCCCCCCCC,,,,,,
2875,72876,5-Bromosalicylamide,C1=CC(=C(C=C1Br)C(=O)N)O,,,,,,
2876,72877,"2,5-Dihydroxybenzamide",C1=CC(=C(C=C1O)C(=O)N)O,,,,,,
2877,72878,"3,5-Dimethoxybenzamide",COC1=CC(=CC(=C1)C(=O)N)OC,,,,,,
2878,72879,Methanesulfonamide,CS(=O)(=O)N,,,,,,
2879,72880,2-Thiopheneacetonitrile,C1=CSC(=C1)CC#N,,,,,,
2880,72881,2-Thiophenesulfonamide,C1=CSC(=C1)S(=O)(=O)N,,,,,,
2881,72882,Sebacamide,C(CCCCC(=O)N)CCCC(=O)N,,,,,,
2882,72883,2-Cyanobenzamide,C1=CC=C(C(=C1)C#N)C(=O)N,,,,,,
2883,72884,"N,N'-Diacetylhydrazine",CC(=O)NNC(=O)C,,,,,,
2884,72885,Allylethylamine,CCNCC=C,,,,,,
2885,72886,L-Cysteic acid,C([C@@H](C(=O)O)N)S(=O)(=O)O,,,,,,
2886,72887,1-Piperidinecarboxamide,C1CCN(CC1)C(=O)N,,,,,,
2887,72888,"1,2-Dimorpholinoethane",C1COCCN1CCN2CCOCC2,,,,,,
2888,72889,"1,3-Dibenzylurea",C1=CC=C(C=C1)CNC(=O)NCC2=CC=CC=C2,,,,,,
2889,72890,"1,3-Bis(methoxymethyl)imidazolidin-2-one",COCN1CCN(C1=O)COC,,,,,,
2890,72891,"1,3-Bis(2-hydroxyethyl)imidazolidine-2-thione",C1CN(C(=S)N1CCO)CCO,,,,,,
2891,72892,"N,N'-Ethylenebisbenzenesulfonamide",C1=CC=C(C=C1)S(=O)(=O)NCCNS(=O)(=O)C2=CC=CC=C2,,,,,,
2892,72893,N-(4-Ethylphenyl)acetamide,CCC1=CC=C(C=C1)NC(=O)C,,,,,,
2893,72894,2-Aminobenzenesulfonamide,C1=CC=C(C(=C1)N)S(=O)(=O)N,,,,,,
2894,72895,2-(4-Aminophenyl)ethylamine,C1=CC(=CC=C1CCN)N,,,,,,
2895,72896,3'-Aminobenzanilide,C1=CC=C(C=C1)C(=O)NC2=CC=CC(=C2)N,,,,,,
2896,72897,3-Nitrodibenzofuran,C1=CC=C2C(=C1)C3=C(O2)C=C(C=C3)[N+](=O)[O-],,,,,,
2897,72898,2-Phenyl-1H-pyrrole,C1=CC=C(C=C1)C2=CC=CN2,,,,,,
2898,72899,Indole-2-carboxylic acid,C1=CC=C2C(=C1)C=C(N2)C(=O)O,,,,,,
2899,72900,3-Methylrhodanine,CN1C(=O)CSC1=S,,,,,,
2900,72901,CID 72901,C1=CC=C2C(=C1)NC3=CC(=O)C=CC3=N2,,,,,,
2901,72902,CID 72902,C1=CC=C2C(=C1)NC3=CC(=O)C(=CC3=N2)N,,,,,,
2902,72903,Hydroxyphenylphosphine oxide,C1=CC=C(C=C1)P(O)O,,,,,,
2903,72904,P-Phenylphosphonic diamide,C1=CC=C(C=C1)P(=O)(N)N,,,,,,
2904,72905,3-Nitrophenylarsonic acid,C1=CC(=CC(=C1)[As](=O)(O)O)[N+](=O)[O-],,,,,,
2905,72906,Tetraphenyllead,C1=CC=C(C=C1)[Pb](C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
2906,72907,"Butanamide, N-(4-hydroxyphenyl)-3-oxo-",CC(=O)CC(=O)NC1=CC=C(C=C1)O,,,,,,
2907,72908,"4-Amino-1,2-naphthoquinone",C1=CC=C2C(=C1)C(=CC(=O)C2=O)N,,,,,,
2908,72909,"2-Amino-1,4-naphthoquinone",C1=CC=C2C(=C1)C(=O)C=C(C2=O)N,,,,,,
2909,72910,"9,10-Anthracenedione, 1-amino-2,4-dichloro-",C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C(=C(C=C3Cl)Cl)N,,,,,,
2910,72911,2-Amino-5-iodobenzoic acid,C1=CC(=C(C=C1I)C(=O)O)N,,,,,,
2911,72912,4-Aminophthalic acid,C1=CC(=C(C=C1N)C(=O)O)C(=O)O,,,,,,
2912,72913,2-Aminobenzonitrile,C1=CC=C(C(=C1)C#N)N,,,,,,
2913,72914,3-Aminophthalimide,C1=CC2=C(C(=C1)N)C(=O)NC2=O,,,,,,
2914,72915,4-Aminophthalimide,C1=CC2=C(C=C1N)C(=O)NC2=O,,,,,,
2915,72916,"1,2,4-Triazolidine-3,5-dione",C1(=O)NC(=O)NN1,,,,,,
2916,72917,1H-Benzotriazole-5-carboxylic acid,C1=CC2=NNN=C2C=C1C(=O)O,,,,,,
2917,72918,4-Pentylpyridine,CCCCCC1=CC=NC=C1,,,,,,
2918,72919,2-Heptylpyridine,CCCCCCCC1=CC=CC=N1,,,,,,
2919,72920,"2,6-Diphenylpyridine",C1=CC=C(C=C1)C2=NC(=CC=C2)C3=CC=CC=C3,,,,,,
2920,72921,4-Pyridineethanol,C1=CN=CC=C1CCO,,,,,,
2921,72922,2-Pyridinepropanol,C1=CC=NC(=C1)CCCO,,,,,,
2922,72923,4-Pyridinepropanol,C1=CN=CC=C1CCCO,,,,,,
2923,72924,6-Hydroxynicotinic acid,C1=CC(=O)NC=C1C(=O)O,,,,,,
2924,72925,6-Hydroxynicotinamide,C1=CC(=O)NC=C1C(=O)N,,,,,,
2925,72926,"3,4-Pyridinedicarboximide",C1=CN=CC2=C1C(=O)NC2=O,,,,,,
2926,72927,"Pyridine, 3-(4-aminobutyl)-",C1=CC(=CN=C1)CCCCN,,,,,,
2927,72928,"3-Buten-1-amine, N-methyl-4-(3-pyridinyl)-",CNCCC=CC1=CN=CC=C1,,,,,,
2928,72929,2-Acetamidopyridine,CC(=O)NC1=CC=CC=N1,,,,,,
2929,72930,2-Aminonicotinic acid,C1=CC(=C(N=C1)N)C(=O)O,,,,,,
2930,72931,CID 72931,C1[C@@H](N=C(NC1[C@@H]2C(=O)NC[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)NC(=CNC(=O)N)C(=O)N2)CO)CO)NC(=O)C[C@@H](CCCN)N)N)O.OS(=O)(=O)O,,,,,,
2931,72932,CID 72932,C1[C@@H](N=C(NC1[C@@H]2C(=O)NC[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)NC(=CNC(=O)N)C(=O)N2)CO)CO)NC(=O)C[C@@H](CCCN)N)N)O,,,,,,
2932,72933,2-Chloro-5-nitrobenzaldehyde,C1=CC(=C(C=C1[N+](=O)[O-])C=O)Cl,,,,,,
2933,72934,"5-Methyl-6-[(3,5-dimethoxyphenyl)aminomethyl]pyrido[2,3-d]pyrimidine-2,4-diamine",CC1=C2C(=NC(=NC2=NC=C1CNC3=CC(=CC(=C3)OC)OC)N)N,,,,,,
2934,72935,N-Cyclohexylhydroxylamine,C1CCC(CC1)NO,,,,,,
2935,72936,Sophoraflavanone G,CC(=CC[C@H](CC1=C2C(=C(C=C1O)O)C(=O)C[C@H](O2)C3=C(C=C(C=C3)O)O)C(=C)C)C,,,,,,
2936,72937,Viscosin,CCCCCCC[C@H](CC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@@H]1[C@H](OC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC1=O)C(C)C)CC(C)C)CO)CC(C)C)CO)[C@@H](C)CC)C)O,,,"['Agents that modify interfacial tension of water; usually substances that have one lipophilic and one hydrophilic group in the molecule; includes soaps, detergents, emulsifiers, dispersing and wetting agents, and several groups of antiseptics. (See all compounds classified as Surface-Active Agents.)']",,,
2937,72938,SB-265805S;LB-20304a,CON=C1CN(CC1CN)C2=C(C=C3C(=O)C(=CN(C3=N2)C4CC4)C(=O)O)F,,,"['Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)', 'Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)']","['Gemifloxacin, given as an oral tablet, is rapidly absorbed from the gastrointestinal tract. Peak plasma concentrations of gemifloxacin were observed between 0.5 and 2 hours following oral tablet administration and the absolute bioavailability of the 320 mg tablet averaged approximately 71% (95% CI 60%-84%). Following repeat oral doses of 320 mg to healthy subjects, the mean + or - SD maximal gemifloxacin plasma concentrations (Cmax) and systemic drug exposure (AUC (0-24)) were 1.61 + or - 0.51 ug/mL (range 0.70-2.62 ug/mL) and 9.93 + or - 3.07 ug.hr/mL (range 4.71-20.1 ug.hr/mL), respectively. In patients with respiratory and urinary tract infections (n=1423), similar estimates of systemic drug exposure were determined using a population pharmacokinetics analysis (geometric mean AUC (0-24), 8.36 ug.hr/mL; range 3.2 -47.7 ug.hr/mL).', 'In vitro binding of gemifloxacin to plasma proteins in healthy subjects is approximately 60 to 70% and is concentration independent. After repeated doses, the in vivo plasma protein binding in healthy elderly and young subjects ranged from 55% to 73% and was unaffected by age. Renal impairment does not significantly affect the protein binding of gemifloxacin. The blood-to-plasma concentration ratio of gemifloxacin was 1.2:1. The geometric mean for Vdss/F is 4.18 L/kg (range, 1.66 - 12.12 L/kg).  Gemifloxacin is widely distributed throughout the body after oral administration. Concentrations of gemifloxacin in bronchoalveolar lavage fluid exceed those in the plasma. Gemifloxacin penetrates well into lung tissue and fluids.', 'Gemifloxacin and its metabolites are excreted via dual routes of excretion. Following oral administration of gemifloxacin to healthy subjects, a mean (+ or - SD) of 61 + or - 9.5% of the dose was excreted in the feces and 36 + or - 9.3% in the urine as unchanged drug and metabolites. The mean (+ or - SD) renal clearance following repeat doses of 320 mg was approximately 11.6 + or - 3.9 L/hr (range 4.6-17.6 L/hr), which indicates active secretion is involved in the renal excretion of gemifloxacin. The mean (+ or - SD) plasma elimination half-life at steady state following 320 mg to healthy subjects was approximately 7 + or - 2 hours (range 4-12 hours).']","['Gemifloxacin is metabolized to a limited extent by the liver. The unchanged compound is the predominant drug-related component detected in plasma (approximately 65%) up to 4 hours after dosing. All metabolites formed are minor (<10% of the administered oral dose); the principal ones are N-acetyl gemifloxacin, the E-isomer of gemifloxacin and the carbamyl glucuronide of gemifloxacin. Cytochrome P450 enzymes do not play an important role in gemifloxacin metabolism, and the metabolic activity of these enzymes is not significantly inhibited by gemifloxacin.']",['Gemifloxacin has an elimination half life of about 7 hours.']
2938,72939,CID 72939,C[C@@H]1CO[C@]2(C[C@@H]1OC(=O)C=CC3=CC=CC=C3)[C@]4(CO4)[C@@H]5CC[C@@H](C[C@@H]5O2)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)C)O)OC(=O)C)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)C)O)OC(=O)C)O,,,,,,
2939,72940,"(R)-4-((1R,4Z,8Z,10S,13R,15R)-15-hydroxy-5,10-dimethyl-3-oxo-2,14-dioxabicyclo[11.3.1]heptadeca-4,8-dien-15-yl)thiazolidin-2-one",C[C@H]1CC[C@@H]2C[C@H](C[C@@](O2)([C@@H]3CSC(=O)N3)O)OC(=O)C=C(CCC=C1)C,,,,,,
2940,72941,CID 72941,CC[C@H](C)[C@@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)NC(=CC)C(=O)N[C@H](C(=O)O[C@@H]([C@@H](C(=O)N1)NC(=O)[C@@H]([C@@H](C)CC)NC(=O)[C@H](CCCN)NC(=O)[C@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)NC(=O)CCCC(C)C)C)C(C)C)CC3=CC=CC=C3)C(C)C,,,,,,
2941,72942,Kahalalide A,CCC(C)C(=O)N[C@H](CC1=CC=CC=C1)C(=O)N[C@@H]2[C@@H](OC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC2=O)CC(C)C)CC3=CC=CC=C3)CC(C)C)[C@@H](C)O)CO)C,,,,,,
2942,72943,"[(1S,4S,5aS,5bR,7aS,11aS,11bR,13R,13aR)-1-acetoxy-13-hydroxy-5a,5b,8,8,11a,13a-hexamethyl-4,5,6,7,7a,9,10,11,11b,12,13,13b-dodecahydro-1H-phenanthro[2,1-e]isobenzofuran-4-yl] acetate",CC(=O)O[C@H]1C[C@]2([C@@]3(CC[C@@H]4[C@@]([C@H]3C[C@H]([C@@]2(C5C1=CO[C@H]5OC(=O)C)C)O)(CCCC4(C)C)C)C)C,,,,,,
2943,72944,"(1R,3S,11S,12S,13R,15S,16S,17S,19S,23R,25S,33S,35R,37S,38S,39S,41S)-3,13,15,25,35,37-hexahydroxy-11,33-bis[(2S,3S,4S)-3-hydroxy-6-[(2S,4R,6S)-4-methoxy-6-methyloxan-2-yl]-4-methylhexan-2-yl]-17,39-dimethoxy-6,12,16,28,34,38-hexamethyl-10,32,45,46-tetraoxatricyclo[39.3.1.119,23]hexatetraconta-5,7,21,27,29,43-hexaene-9,31-dione",C[C@H]1C[C@H](C[C@@H](O1)CC[C@H](C)[C@@H]([C@H](C)[C@@H]2[C@H]([C@@H](C[C@@H]([C@@H]([C@H](C[C@@H]3CC=C[C@H](O3)C[C@H](CC=C(C=CC(=O)O[C@@H](C([C@@H](C[C@@H]([C@@H]([C@H](C[C@@H]4CC=C[C@H](O4)C[C@H](CC=C(C=CC(=O)O2)C)O)OC)C)O)O)C)[C@@H](C)[C@H]([C@@H](C)CC[C@H]5C[C@@H](C[C@@H](O5)C)OC)O)C)O)OC)C)O)O)C)O)OC,,,,,,
2944,72945,CID 72945,CC1=C(C(CCC1)(C)C)CCC(=CCC[C@]2(CC[C@H](OO2)[C@@H](C)C(=O)O)C)C,,,,,,
2945,72946,CID 72946,C1=CC=C(C(=C1)C=NN=C(N)S)O,,,,,,
2946,72947,Bafilomycina1,C[C@H]1CC(=CC=C[C@@H]([C@H](OC(=O)C(=CC(=C[C@H]([C@H]1O)C)C)OC)[C@@H](C)[C@H]([C@H](C)[C@]2(C[C@H]([C@@H]([C@H](O2)C(C)C)C)O)O)O)OC)C,,,"['Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)']",,,
2947,72948,CID 72948,CCCCCCCCCCCCCCCC=CC(=O)N(CCCC[C@@H](C(=O)O[C@@H](C)CC(=O)N[C@H]1CCCCN(C1=O)O)NC(=O)[C@@H]2COC(=N2)C3=CC=CC=C3O)O,,,,,,
2948,72949,Miramistin,CCCCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC1=CC=CC=C1.[Cl-],,,,,,
2949,72950,Miramistin ion,CCCCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC1=CC=CC=C1,,,,,,
2950,72951,CID 72951,C1=CC(=C(C=C1C2=C(C(=C3C(=CC(=O)C=C3O2)O)O)O[C@H]4[C@@H]([C@H]([C@H]([C@H](O4)CO)O)O)O)O)O,,,,,,
2951,72952,Yadanzioside B,CC1=C(C(=O)[C@H]([C@]2([C@H]1C[C@@H]3[C@]45[C@@H]2[C@H]([C@@H](C([C@@H]4[C@H](C(=O)O3)OC(=O)CC(C)C)(OC5)C(=O)OC)O)O)C)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O,,,,,,
2952,72953,Bruceoside B,CC1=C(C(=O)C[C@]2([C@H]1C[C@@H]3[C@]45[C@@H]2[C@H]([C@@H](C([C@@H]4[C@H](C(=O)O3)OC(=O)C=C(C)C)(OC5)C(=O)OC)O)O)C)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O,,,,,,
2953,72954,CID 72954,CC1=C(C(=O)C[C@]2([C@H]1C[C@@H]3[C@]45[C@@H]2[C@H]([C@@H](C([C@@H]4[C@H](C(=O)O3)OC(=O)C=C(C)C(C)(C)O)(OC5)C(=O)OC)O)O)C)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O,,,,,,
2954,72955,CID 72955,C[C@H]1[C@@H]2C[C@@H]3[C@@]45COC([C@@H]4[C@H](C(=O)O3)OC(=O)C)([C@H]([C@@H]([C@@H]5[C@]2(C=C(C1=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C)O)O)C(=O)OC,,,,,,
2955,72956,Yadanzioside A,C[C@H]1[C@@H]2C[C@@H]3[C@@]45CO[C@]([C@@H]4[C@H](C(=O)O3)OC(=O)CC(C)C)([C@H]([C@@H]([C@@H]5[C@]2(C=C(C1=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C)O)O)C(=O)OC,,,,,,
2956,72957,"Picras-1-en-21-oic acid, 11,12-dihydroxy-3,16-dioxo-13,20-epoxy-2-(beta-D-glucopyranosyloxy)-15-((3-methyl-1-oxo-2-butenyl)oxy)-, methyl ester, (11-beta,12-alpha,15-beta)-",C[C@H]1[C@@H]2C[C@@H]3[C@@]45COC([C@@H]4[C@H](C(=O)O3)OC(=O)C=C(C)C)([C@H]([C@@H]([C@@H]5[C@]2(C=C(C1=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C)O)O)C(=O)OC,,,,,,
2957,72958,CID 72958,C[C@H]1[C@@H]2C[C@@H]3[C@@]45COC([C@@H]4[C@H](C(=O)O3)OC(=O)C=C(C)C(C)C)([C@H]([C@@H]([C@@H]5[C@]2(C=C(C1=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C)O)O)C(=O)OC,,,,,,
2958,72959,CID 72959,C[C@H]1[C@@H]2C[C@@H]3[C@@]45COC([C@@H]4[C@H](C(=O)O3)OC(=O)C=C(C)C(C)(C)O)([C@H]([C@@H]([C@@H]5[C@]2(C=C(C1=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C)O)O)C(=O)OC,,,,,,
2959,72960,CID 72960,C[C@H]1[C@@H]2C[C@@H]3[C@@]45COC([C@@H]4[C@H](C(=O)O3)OC(=O)C=C(C)C(C)(C)OC(=O)C)([C@H]([C@@H]([C@@H]5[C@]2(C=C(C1=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C)O)O)C(=O)OC,,,,,,
2960,72961,CID 72961,CC1C2CC3C45COC(C4C(C(=O)O3)OC(=O)C6=CC=CC=C6)(C(C(C5C2(C=C(C1=O)OC7C(C(C(C(O7)CO)O)O)O)C)O)O)C(=O)OC,,,,,,
2961,72962,"Methyl 3-(4-acetyloxy-3,4-dimethylpent-2-enoyl)oxy-15,16-dihydroxy-9,13-dimethyl-4,12-dioxo-11-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5,18-dioxapentacyclo[12.5.0.01,6.02,17.08,13]nonadec-10-ene-17-carboxylate",CC1C=C(C(=O)C2(C1CC3C45C2C(C(C(C4C(C(=O)O3)OC(=O)C=C(C)C(C)(C)OC(=O)C)(OC5)C(=O)OC)O)O)C)OC6C(C(C(C(O6)CO)O)O)O,,,,,,
2962,72963,"Methyl 3-(3,4-dimethylpent-2-enoyloxy)-15,16-dihydroxy-9,13-dimethyl-4,12-dioxo-11-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5,18-dioxapentacyclo[12.5.0.01,6.02,17.08,13]nonadec-10-ene-17-carboxylate",CC1C=C(C(=O)C2(C1CC3C45C2C(C(C(C4C(C(=O)O3)OC(=O)C=C(C)C(C)C)(OC5)C(=O)OC)O)O)C)OC6C(C(C(C(O6)CO)O)O)O,,,,,,
2963,72964,Neoquassin,C[C@@H]1C=C(C(=O)[C@]2([C@H]1C[C@@H]3[C@@]4([C@@H]2C(=O)C(=C([C@@H]4CC(O3)O)C)OC)C)C)OC,,,,,,
2964,72965,Ailanthone,CC1=CC(=O)[C@H]([C@]2([C@H]1C[C@@H]3[C@]45[C@@H]2[C@]([C@@H](C(=C)[C@@H]4CC(=O)O3)O)(OC5)O)C)O,,,,,,
2965,72966,Isonicotinamide 1-oxide,C1=C[N+](=CC=C1C(=O)N)[O-],,,,,,
2966,72967,Isonicotinohydroxamic acid,C1=CN=CC=C1C(=O)NO,,,,,,
2967,72968,Neplanocin A,C1=C([C@H]([C@H]([C@@H]1N2C=NC3=C(N=CN=C32)N)O)O)CO,,,"['Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)', 'Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. (See all compounds classified as Antibiotics, Antineoplastic.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)']",,,
2968,72969,"1-[Amino-[3-(2,4,5-trichlorophenoxy)propoxyamino]methylidene]-2-propan-2-ylguanidine;hydrochloride",CC(C)N=C(N)N=C(N)NOCCCOC1=CC(=C(C=C1Cl)Cl)Cl.Cl,,,,,,
2969,72970,"5-[3-(2,4,5-Trichlorophenoxy)propoxy]-1-isopropylbiguanide",CC(C)N=C(N)N=C(N)NOCCCOC1=CC(=C(C=C1Cl)Cl)Cl,,,,,,
2970,72971,4-Butoxybenzoic acid,CCCCOC1=CC=C(C=C1)C(=O)O,,,,,,
2971,72972,4-Isopropoxybenzoic acid,CC(C)OC1=CC=C(C=C1)C(=O)O,,,,,,
2972,72973,Azoxybacilin,CN=[N+](CC[C@@H](C(=O)O)N)[O-],,,,,,
2973,72974,Pneumocandin C(0),CCC(C)CC(C)CCCCCCCCC(=O)NC1C[C@@H]([C@H](NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@@H](NC1=O)[C@@H](C)O)O)C([C@@H](C4=CC=C(C=C4)O)O)O)[C@@H](CC(=O)N)O)O)O)O,,,,,,
2974,72975,Pneumocandin Do,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H]([C@H](NC(=O)[C@@H]2[C@H]([C@H](CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@@H](NC1=O)[C@@H](C)O)O)C([C@@H](C4=CC=C(C=C4)O)O)O)[C@@H](CC(=O)N)O)O)O)O)O,,,,,,
2975,72976,Hyphodontal,CC1(C[C@H]2C[C@]34C[C@]3([C@@H](OC4=O)O)C(=C2C1)C=O)C,,,,,,
2976,72977,CID 72977,CC1=C(OC(=CC(=O)C)C1=O)O,,,,,,
2977,72978,Soulattrolide,C[C@H]1[C@@H](OC2=C([C@H]1O)C3=C(C(=CC(=O)O3)C4=CC=CC=C4)C5=C2C=CC(O5)(C)C)C,,,,,,
2978,72979,CID 72979,[CH3-].CC1=CC2=C(C=C1C)N(C=N2)[C@H]3C(C([C@@H](O3)CO)OP(=O)([O-])OC(C)CNC(=O)CC[C@]4([C@@H](C5[C@@]6([C@]([C@@H](C(=N6)C(=C7[C@@]([C@@H](C(=N7)C=C8C([C@@H](C(=N8)C(=C4[N-]5)C)CCC(=O)N)(C)C)CCC(=O)N)(C)CC(=O)N)C)CCC(=O)N)(C)CC(=O)N)C)CC(=O)N)C)O.[Co+3],,,,,,
2979,72980,"benzyl N-[(1S)-2-[[(1S,2S,4R)-1-benzyl-2-hydroxy-5-[[(1S)-1-[[(1S)-1-(hydroxymethyl)-2-methyl-propyl]carbamoyl]-2-methyl-propyl]amino]-4-methyl-5-oxo-pentyl]amino]-1-methyl-2-oxo-ethyl]carbamate",C[C@H](C[C@@H]([C@H](CC1=CC=CC=C1)NC(=O)[C@H](C)NC(=O)OCC2=CC=CC=C2)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](CO)C(C)C,,,,,,
2980,72981,Palinavir,CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](CN2CC[C@H](C[C@H]2C(=O)NC(C)(C)C)OCC3=CC=NC=C3)O)NC(=O)C4=NC5=CC=CC=C5C=C4,,,,,,
2981,72982,CID 72982,C1=CC=C(C=C1)N=NC2=C(NC(=NC2=O)N)N,,,,,,
2982,72983,CID 72983,CC1=C(N=C2C(=NC=NC2=O)N1)C,,,,,,
2983,72984,CID 72984,CC1=C(N=C2C(=NC(=NC2=O)S)N1)C,,,,,,
2984,72985,Amidino TIC,CN=C(C1=CC=C(C=C1)N=C(C2=CC=C(C=C2)C(=NC3=CC=C(C=C3)C(=NC)N)N)N)N.Cl.Cl.Cl.Cl,,,,,,
2985,72986,"5-(4-Chlorophenoxy)-6-methylpyrimidine-2,4-diamine",CC1=C(C(=NC(=N1)N)N)OC2=CC=C(C=C2)Cl,,,,,,
2986,72987,CID 72987,CC1=NC2=C(NC1=O)NC(=NC2=O)S,,,,,,
2987,72988,CID 72988,C1=CC(=CC=C1C(=O)O)NCCC2=CN=C3C(=N2)C(=O)N=C(N3)N,,,,,,
2988,72989,CID 72989,C1C(NC2=C(N1)NC(=NC2=O)N)CCNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,,,,,,
2989,72990,"2,6-Diamino-5-methyl-4-pyrimidinecarboxylic acid",CC1=C(N=C(N=C1N)N)C(=O)O,,,,,,
2990,72991,CID 72991,CC(C1=CN=C2C(=N1)C(=O)N=C(N2)N)NC3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,,,,,,
2991,72992,"Pyrimidinium, 4,4'-(terephthaloylbis(imino-p-phenyleneimino))bis(2-amino-1-ethyl-, di-p-toluenesulfonate",CC[N+]1=C(N=C(C=C1)NC2=CC=C(C=C2)NC(=O)C3=CC=C(C=C3)C(=O)NC4=CC=C(C=C4)NC5=NC(=[N+](C=C5)CC)N)N.CC1=CC=C(C=C1)S(=O)(=O)[O-].CC1=CC=C(C=C1)S(=O)(=O)[O-],,,,,,
2992,72993,"1-N,4-N-bis[4-[(2-amino-1-ethylpyrimidin-1-ium-4-yl)amino]phenyl]benzene-1,4-dicarboxamide",CC[N+]1=C(N=C(C=C1)NC2=CC=C(C=C2)NC(=O)C3=CC=C(C=C3)C(=O)NC4=CC=C(C=C4)NC5=NC(=[N+](C=C5)CC)N)N,,,,,,
2993,72994,CID 72994,CN1C(CNC2=C1C(=O)N=C(N2)N)CCNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-].[Na+].[Na+],,,,,,
2994,72995,CID 72995,COC1=NC(=C(C=C1)NC2=NC(=NC(=C2)N)N)S,,,,,,
2995,72996,CID 72996,C1=CC(=NC(=C1NC2=NC(=NC(=C2)N)N)S)Cl,,,,,,
2996,72997,"4(1H)-Pyridinone, 3-(acetyloxy)-2-methyl-",CC1=C(C(=O)C=CN1)OC(=O)C,,,,,,
2997,72998,"1-[(4-Fluorophenyl)methyl]-2,3-dihydro-2-(methylamino)quinazolin-4(1H)-one",CNC1NC(=O)C2=CC=CC=C2N1CC3=CC=C(C=C3)F,,,,,,
2998,72999,"5-(4-Chlorophenoxy)pyrimidine-2,4-diamine",C1=CC(=CC=C1OC2=CN=C(N=C2N)N)Cl,,,,,,
2999,73000,CID 73000,C1=CN=C2C(=N1)C(=O)N=C(N2)N,,,,,,
3000,73001,8-Benzyltheophylline,CN1C2=C(C(=O)N(C1=O)C)NC(=N2)CC3=CC=CC=C3,,,,,,
3001,73002,Diethyl N-(4-aminobenzoyl)-L-glutamate,CCOC(=O)CC[C@@H](C(=O)OCC)NC(=O)C1=CC=C(C=C1)N,,,,,,
3002,73003,"4-(2,4,6-Triamino-5-pyrimidinylazo)benzenesulfonamide",C1=CC(=CC=C1N=NC2=C(N=C(N=C2N)N)N)S(=O)(=O)N,,,,,,
3003,73004,"4H-Pyrimido(4,5-e)-1,2,4-thiadiazine, 8-amino-4-methyl-6-(methylthio)-, 1,1-dioxide",CN1C=NS(=O)(=O)C2=C(N=C(N=C21)SC)N,,,,,,
3004,73005,N-(2-Quinoxaloyl)-DL-norleucine,CCCCC(C(=O)O)NC(=O)C1=NC2=CC=CC=C2N=C1,,,,,,
3005,73006,"Glutamine, N-(2-quinoxaloyl)-, l-",C1=CC=C2C(=C1)N=CC(=N2)C(=O)N[C@@H](CCC(=O)N)C(=O)O,,,,,,
3006,73007,"10H-Pyrido(2,3-b)pyrimido(4,5-e)(1,4)thiazine-2,4-diamine, 7-methoxy-",COC1=NC2=C(C=C1)NC3=NC(=NC(=C3S2)N)N,,,,,,
3007,73008,"2-Amino-4-chloro-8-methyl-1,3,9-triazaphenothiazine",CC1=NC2=C(C=C1)SC3=C(N2)N=C(N=C3Cl)N,,,,,,
3008,73009,CID 73009,C1=CC(=CC=C1CNC2=CC3=C(C=C2)NC(=NC3=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O,,,,,,
3009,73010,"6-(3,3,3-Tribromopropyl)-1,3,5-triazine-2,4-diamine",C(CC(Br)(Br)Br)C1=NC(=NC(=N1)N)N,,,,,,
3010,73011,7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(2S)-2-fluorocyclopropyl]-4-oxo-quinoline-3-carboxylic acid,C1CC12CN(C[C@H]2N)C3=C(C=C4C(=C3Cl)N(C=C(C4=O)C(=O)O)C5C[C@@H]5F)F,,,"['Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)', 'Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)']",,,
3011,73012,"(2R)-2-(2,4-difluorophenyl)-1-[3-[2-[4-(2,2,3,3-tetrafluoropropoxy)phenyl]ethenyl]-1,2,4-triazol-1-yl]-3-(1,2,4-triazol-1-yl)propan-2-ol",C1=CC(=CC=C1C=CC2=NN(C=N2)C[C@](CN3C=NC=N3)(C4=C(C=C(C=C4)F)F)O)OCC(C(F)F)(F)F,,,,,,
3012,73013,Cresol red,CC1=C(C=CC(=C1)C2(C3=CC=CC=C3S(=O)(=O)O2)C4=CC(=C(C=C4)O)C)O,,,,,,
3013,73014,"3,3,6,6-Tetramethyl-1,2,4,5-tetrathiane",CC1(SSC(SS1)(C)C)C,,,,,,
3014,73015,Orotic acid butyl ester,CCCCOC(=O)C1=CC(=O)NC(=O)N1,,,,,,
3015,73016,CID 73016,C1=C(NC(=NC1=O)S)C(=O)O,,,,,,
3016,73017,CID 73017,C1=C(NC(=NC1=O)N)C(=O)O,,,,,,
3017,73018,5-Aminoorotic acid,C1(=C(NC(=O)NC1=O)C(=O)O)N,,,,,,
3018,73019,"2-Naphthalenesulfonic acid, 4-hydroxy-7-((((5-hydroxy-7-sulfo-2-naphthalenyl)amino)carbonyl)amino)-3-((6-sulfo-2-naphthalenyl)azo)-, trisodium salt",C1=CC2=C(C=C(C=C2C=C1NC(=O)NC3=CC4=CC(=C(C(=C4C=C3)O)N=NC5=CC6=C(C=C5)C=C(C=C6)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)[O-])O.[Na+].[Na+].[Na+],,,,,,
3019,73020,4-Hydroxy-7-((((5-hydroxy-7-sulfo-2-naphthalenyl)amino)carbonyl)amino)-3-(2-(6-sulfo-2-naphthalenyl)diazenyl)-2-naphthalenesulfonic acid,C1=CC2=C(C=C(C=C2C=C1NC(=O)NC3=CC4=CC(=C(C(=C4C=C3)O)N=NC5=CC6=C(C=C5)C=C(C=C6)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)O,,,,,,
3020,73021,"1-But-2-enyl-3,7-dimethylpurine-2,6-dione",CC=CCN1C(=O)C2=C(N=CN2C)N(C1=O)C,,,,,,
3021,73022,Methyl 6-methylpyridine-2-carboxylate,CC1=NC(=CC=C1)C(=O)OC,,,,,,
3022,73023,"3-Methyl-1,2,3-benzotriazin-4(3H)-one",CN1C(=O)C2=CC=CC=C2N=N1,,,,,,
3023,73024,Methylene violet,CN(C)C1=CC2=C(C=C1)N=C3C=CC(=O)C=C3S2,,,,,,
3024,73025,CID 73025,C1(=C(C(=NC(=C1Cl)Cl)C(=O)[O-])Cl)N.[Na+],,,,,,
3025,73026,"3-Hydroxy-1,2,3-benzotriazin-4(3H)-one",C1=CC=C2C(=C1)C(=O)N(N=N2)O,,,,,,
3026,73027,Maheto,CC1=C[C@@H]2[C@](CC1)([C@]3([C@H]4[C@@]([C@H]([C@@]35CO5)O2)(N=C(O4)C)O)C)COC(=O)C,,,,,,
3027,73028,"5-Chloro-1,3-dimethyl-n-phenyl-1h-pyrazole-4-carboxamide",CC1=NN(C(=C1C(=O)NC2=CC=CC=C2)Cl)C,,,,,,
3028,73029,CID 73029,CC(=CCC1=C(OC2=C3C=CC(OC3=CC(=O)C2=C1O)(C)C)C4=C(C=C(C=C4)O)O)C,,,,,,
3029,73030,m-Cresol purple,CC1=C(C=CC(=C1)O)C2(C3=CC=CC=C3S(=O)(=O)O2)C4=C(C=C(C=C4)O)C,['Vasopressin regulates renal water resorption through the V2 receptor. Inhibition of vasopressin’s effects on V2 receptors enhances water excretion and increases urinary output. M0002 is a Vasopressin 2 antagonis. It is an electrolyte-sparing aquaretic and causes much lower levels of salt excretion.'],,,,,
3030,73031,Trypan red,C1=CC(=CC=C1C2=CC(=C(C=C2)N=NC3=C4C=CC(=CC4=CC(=C3N)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)[O-])N=NC5=C6C=CC(=CC6=CC(=C5N)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+],,,,,,
3031,73032,"2, 4,4'-[(3-Sulfo-4,4'-biphenylylene)bis(azo)]bis[3-amino-, pentasodium salt",C1=CC(=CC=C1C2=CC(=C(C=C2)N=NC3=C4C=CC(=CC4=CC(=C3N)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)N=NC5=C6C=CC(=CC6=CC(=C5N)S(=O)(=O)O)S(=O)(=O)O,,,,,,
3032,73033,Diazanil Orange RR,CC1=C(C=CC(=C1)NC(=O)C2=CC=C(C=C2)N=NC3=C(C=C4C=C(C=CC4=C3O)NC(=O)C5=CC=C(C=C5)N)S(=O)(=O)[O-])N=NC6=CC7=C(C=C(C=C7C=C6)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+],,,,,,
3033,73034,"7-[(E)-[4-[[4-[(E)-[6-[(4-aminobenzoyl)amino]-1-hydroxy-3-sulfo-2-naphthyl]azo]benzoyl]amino]-2-methyl-phenyl]azo]naphthalene-1,3-disulfonic acid",CC1=C(C=CC(=C1)NC(=O)C2=CC=C(C=C2)N=NC3=C(C=C4C=C(C=CC4=C3O)NC(=O)C5=CC=C(C=C5)N)S(=O)(=O)O)N=NC6=CC7=C(C=C(C=C7C=C6)S(=O)(=O)O)S(=O)(=O)O,,,,,,
3034,73035,Direct Red 73,CC1=CC=CC=C1N=NC2=C(C=C3C=C(C=CC3=C2O)NC(=O)NC4=CC5=CC(=C(C(=C5C=C4)O)N=NC6=CC7=C(C=C6)C=C(C=C7)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+],,,,,,
3035,73036,Brilliant Paper Scarlet G,CC1=CC=CC=C1N=NC2=C(C=C3C=C(C=CC3=C2O)NC(=O)NC4=CC5=CC(=C(C(=C5C=C4)O)N=NC6=CC7=C(C=C6)C=C(C=C7)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O,,,,,,
3036,73037,Methylthymol Blue sodium salt,CC1=C(C=C(C(=C1CN(CC(=O)[O-])CC(=O)[O-])O)C(C)C)C2(C3=CC=CC=C3S(=O)(=O)O2)C4=C(C(=C(C(=C4)C(C)C)O)CN(CC(=O)[O-])CC(=O)[O-])C.[Na+].[Na+].[Na+].[Na+],,,,,,
3037,73038,Methylthymol blue,CC1=C(C=C(C(=C1CN(CC(=O)O)CC(=O)O)O)C(C)C)C2(C3=CC=CC=C3S(=O)(=O)O2)C4=C(C(=C(C(=C4)C(C)C)O)CN(CC(=O)O)CC(=O)O)C,,,,,,
3038,73039,"N,N'-Bis(1-methyl-4-phenyl-4-piperidylmethyl)sebacamide",CN1CCC(CC1)(CNC(=O)CCCCCCCCC(=O)NCC2(CCN(CC2)C)C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
3039,73040,"(1R,3aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-1-isopropenyl-3a,5a,5b,8,8,11a-hexamethyl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysen-9-ol",CC(=C)[C@@H]1CC[C@]2([C@H]1[C@H]3CC[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4(C3(CC2)C)C)(C)C)O)C)C,,,,,,
3040,73041,Xylenol orange,CC1=CC(=CC(=C1O)CN(CC(=O)O)CC(=O)O)C2(C3=CC=CC=C3S(=O)(=O)O2)C4=CC(=C(C(=C4)C)O)CN(CC(=O)O)CC(=O)O,,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']",,,
3041,73042,Azodicarboxylic acid dipiperidide,C1CCN(CC1)C(=O)N=NC(=O)N2CCCCC2,,,,,,
3042,73043,Diazenedicarboxylic acid bis(N'-methylpiperazide),CN1CCN(CC1)C(=O)N=NC(=O)N2CCN(CC2)C,,,,,,
3043,73044,Oxocularine,COC1=C2C3=C(C=C1)C=CN=C3C(=O)C4=CC(=C(C=C4O2)OC)OC,,,,,,
3044,73045,CID 73045,COC1=CC(=O)C2=C(C(=C(OC2=C1OC)C3=CC(=C(C=C3)O)OC)OC)O,,,,,,
3045,73046,N2-Methyl-L-arginine,CN[C@@H](CCCN=C(N)N)C(=O)O,,,,,,
3046,73047,Proresidor,COC1=CC(=CC(=C1OC)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@H](C4=CC5=C(C=C24)OCO5)O[C@H]6[C@@H]([C@H]([C@H]7[C@H](O6)COC(O7)C8=CC=CC=C8)O)O,,,,,,
3047,73048,CID 73048,CC1=CC(=C2C3=C1C(=O)C4[C@H]([C@@]3(COC2=O)[C@@H]5C4(C6=C7C(=COC(=C7C(=O)C=C6C)O)C5=O)OC)OC(=O)C)O,,,,,,
3048,73049,"[(1S,2R,9R,10R,11S)-10,11-diacetyloxy-1,5-dimethylspiro[8-oxatricyclo[7.2.1.02,7]dodec-5-ene-12,2'-oxirane]-2-yl]methyl acetate",CC1=CC2[C@](CC1)([C@]3([C@@H]([C@H]([C@H](C34CO4)O2)OC(=O)C)OC(=O)C)C)COC(=O)C,,,,,,
3049,73050,"[(1R,2S,4R,7S,9S,10R,11S,12R)-2-(acetyloxymethyl)-10,11-dihydroxy-1,5-dimethylspiro[8-oxatricyclo[7.2.1.02,7]dodec-5-ene-12,2'-oxirane]-4-yl] 3-methylbutanoate",CC1=C[C@H]2[C@@](C[C@H]1OC(=O)CC(C)C)([C@@]3([C@@H]([C@H]([C@@H]([C@]34CO4)O2)O)O)C)COC(=O)C,,,,,,
3050,73051,"(1R,3S,4S,6R,8R,9S,10S,13S,14R,16S)-5,5,9,14-tetramethyltetracyclo[11.2.1.01,10.04,8]hexadecane-3,4,6,9,14,16-hexol",C[C@]1(C[C@]23C[C@@H]([C@@]4([C@H](C[C@H](C4(C)C)O)[C@@]([C@H]2CC[C@H]1[C@@H]3O)(C)O)O)O)O,,,,,,
3051,73052,"Isoquinolinium, 1-[[4-[5-[(6,7-dimethoxy-2-methyl-1-isoquinoliniumyl)methyl]-2-methoxyphenoxy]phenyl]methyl]-6,7-dimethoxy-2-methyl-, dichloride",C[N+]1=C(C2=CC(=C(C=C2C=C1)OC)OC)CC3=CC=C(C=C3)OC4=C(C=CC(=C4)CC5=[N+](C=CC6=CC(=C(C=C65)OC)OC)C)OC.[Cl-].[Cl-],,,,,,
3052,73053,Phaeantharine,C[N+]1=C(C2=CC(=C(C=C2C=C1)OC)OC)CC3=CC=C(C=C3)OC4=C(C=CC(=C4)CC5=[N+](C=CC6=CC(=C(C=C65)OC)OC)C)OC,,,,,,
3053,73054,Acnistin E,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C4C[C@]5(C[C@@H]4OC(=O)[C@]5(C)O)C)O)C[C@@H]6[C@]7([C@@]3(C(=O)C=C[C@@H]7O)C)O6,,,,,,
3054,73055,"5,6-Epoxy-4-hydroxy-2-hydroxymethylcyclohex-2-en-1-one",C1=C(C(=O)[C@@H]2[C@H]([C@@H]1O)O2)CO,,,,,,
3055,73056,Withaferin-A diacetate,CC1=C(C(=O)O[C@@H](C1)[C@@H](C)[C@H]2CC[C@@H]3[C@@]2(CC[C@H]4[C@H]3C[C@@H]5[C@]6([C@@]4(C(=O)C=C[C@@H]6OC(=O)C)C)O5)C)COC(=O)C,,,,,,
3056,73057,Schisanhenol,C[C@H]1CC2=CC(=C(C(=C2C3=C(C(=C(C=C3C[C@H]1C)OC)OC)OC)O)OC)OC,,,,,,
3057,73058,CID 73058,CC(=CCC1=C2C(=C(C3=C1OC(C=C3)(C)C)OC)C(=O)C(=C(O2)O)C4=CC=C(C=C4)O)C,,,,,,
3058,73059,"3-(3,4-Dihydroxyphenyl)-1-(2,3,4-trihydroxyphenyl)-1-propanone",C1=CC(=C(C=C1CCC(=O)C2=C(C(=C(C=C2)O)O)O)O)O,,,,,,
3059,73060,"(1R,2S,3R,5S,6S,7S,9R,12S)-2-hydroxy-7-methyl-12-prop-1-en-2-ylspiro[4,10-dioxatetracyclo[7.2.1.02,7.03,5]dodecane-6,2'-oxirane]-11-one",CC(=C)[C@H]1[C@H]2C[C@@]3([C@]4(CO4)[C@@H]5[C@H]([C@@]3([C@@H]1C(=O)O2)O)O5)C,,,,,,
3060,73061,Venenatine,COC1=CC=CC2=C1C3=C(N2)[C@H]4C[C@H]5[C@H](CC[C@H]([C@H]5C(=O)OC)O)CN4CC3,,,,,,
3061,73062,Kaurenoic acid,C[C@@]12CCC[C@@]([C@H]1CC[C@]34[C@H]2CC[C@H](C3)C(=C)C4)(C)C(=O)O,,,,,,
3062,73063,CID 73063,CCCC=CC=CC(=O)O[C@H]1[C@@H]([C@]2([C@@H]3C=C(C(=O)[C@H]3CC(=C[C@@H]2[C@@H]4[C@]1(C4(C)C)OC(=O)C)COC(=O)C)C)O)C,,,,,,
3063,73064,3-Aminopentanedioic acid,C(C(CC(=O)O)N)C(=O)O,,,,,,
3064,73065,Lycoricidine,C1OC2=C(O1)C=C3C(=C2)C4=C[C@@H]([C@H]([C@H]([C@@H]4NC3=O)O)O)O,,,,,,
3065,73066,CID 73066,CC[C@H](C[C@H]1[C@H](CC[C@]2(O1)C[C@H]3[C@@H]([C@@H](O2)C[C@]4([C@@H](C[C@@H](CO4)C)C=CCCC[C@@]([C@@H]([C@H]([C@@H]([C@@H]([C@@H]([C@](C=CC(=O)O3)(C)O)O)C)O)O[C@H]5C[C@@H]([C@@H]([C@H](O5)C)O)OC)O)(C)O)O)C)C)O,,,,,,
3066,73067,(+)-Medicarpin,COC1=CC2=C(C=C1)[C@H]3COC4=C([C@H]3O2)C=CC(=C4)O,,,,,,
3067,73068,CID 73068,CC(C)[C@@H]1CC2=C(O1)C=CC3=C2O[C@H]4COC5=CC(=C(C=C5[C@H]4C3=O)OC)OC,,,,,,
3068,73069,CID 73069,C1=NC2=C(N1O)C(=O)N=C(N2)N,,,,,,
3069,73070,"(1R,3S,9S,12R,13S,15R)-13-Hydroxy-3,7,12-trimethyl-13-propan-2-yl-10,14,16-trioxatetracyclo[7.5.1.13,6.012,15]hexadeca-5,7-diene-4,11-dione",CC1=C[C@H]2[C@H]3[C@@H](C[C@]4(C(=O)C=C1O4)C)O[C@]([C@@]3(C(=O)O2)C)(C(C)C)O,,,,,,
3070,73071,Skyrin,CC1=CC2=C(C(=C1)O)C(=O)C3=C(C=C(C(=C3C2=O)C4=C5C(=C(C=C4O)O)C(=O)C6=C(C5=O)C=C(C=C6O)C)O)O,,,,,,
3071,73072,Morindaparvin A,C1OC2=C(O1)C3=C(C=C2)C(=O)C4=CC=CC=C4C3=O,,,,,,
3072,73073,Serpentine (alkaloid),C[C@H]1[C@H]2CN3C=CC4=C5C=CC=CC5=NC4=C3C[C@@H]2C(=CO1)C(=O)OC,,,,,,
3073,73074,Methyl phaeophorbide,CCC1=C(C2=NC1=CC3=C(C4=C(C(C(=C5C(C(C(=CC6=NC(=C2)C(=C6C)C=C)N5)C)CCC(=O)OC)C4=N3)C(=O)OC)O)C)C,,,,,,
3074,73075,Sculponeatin D,CC1([C@H](C[C@H]2[C@]3([C@@H]1[C@H](OC3)O)[C@@H]4CC[C@@H]5C[C@]4(C(=O)C5=C)C(=O)O2)O)C,,,,,,
3075,73076,CID 73076,C1=CN=CC=C1C2=NC(=NN2)S.Cl,,,,,,
3076,73077,CID 73077,C1=CC(=O)C=CC1=NC2=CC(=C(C(=C2)Cl)[O-])Cl.[Na+],,,,,,
3077,73078,Tetrandrine,CN1CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)C[C@H]6C7=C(O3)C(=C(C=C7CCN6C)OC)OC)OC)OC,,,"['Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585) (See all compounds classified as Antimalarials.)', 'Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. (See all compounds classified as Antineoplastic Agents, Phytogenic.)', 'A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)', 'Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. (See all compounds classified as Immunosuppressive Agents.)', 'Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)']",,,
3078,73079,Xylostacin,C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)N)O[C@H]3[C@@H]([C@H]([C@H](O3)CO)O)O)O)N,,,,,,
3079,73080,"1H-Indazole-3-carboxylic acid, 1-(2,4-dibromobenzyl)-",C1=CC=C2C(=C1)C(=NN2CC3=C(C=C(C=C3)Br)Br)C(=O)O,,,,,,
3080,73081,"(1S,3R,4S,5R)-3-[3-(3,4-dihydroxyphenyl)prop-2-enoyloxy]-1,4,5-trihydroxycyclohexane-1-carboxylic acid",C1[C@H]([C@@H]([C@@H](C[C@@]1(C(=O)O)O)OC(=O)C=CC2=CC(=C(C=C2)O)O)O)O,,,,,,
3081,73082,"2,2,4,4,6,6-Hexaamino-2,2,4,4,6,6-hexahydro-1,3,5,2,4,6-triazatriphosphorine",NP1(=NP(=NP(=N1)(N)N)(N)N)N,,,,,,
3082,73083,Sinomenine HCl,CN1CC[C@@]23CC(=O)C(=C[C@@H]2[C@H]1CC4=C3C(=C(C=C4)OC)O)OC.Cl,,,,,,
3083,73084,"(1R,9R,10S)-3-hydroxy-4,12-dimethoxy-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5,11-tetraen-13-one",CN1CC[C@@]23CC(=O)C(=C[C@@H]2[C@H]1CC4=C3C(=C(C=C4)OC)O)OC,,,,,,
3084,73085,CID 73085,CC1=C[C@@H]2[C@@]3(C[C@H]1O)COC(=O)[C@@H]4[C@](O4)([C@H](CO[C@H](C=CC=CC(=O)O[C@H]5[C@]3([C@]6(CO6)[C@@H](C5)O2)C)[C@@H](C)O)O)C,,,,,,
3085,73086,Glycyl-L-serine,C([C@@H](C(=O)O)NC(=O)CN)O,,,,,,
3086,73087,3-Deazaneplanocin,C1=CN=C(C2=C1N(C=N2)[C@@H]3C=C([C@H]([C@H]3O)O)CO)N,,,,,,
3087,73088,"2-Amino-4-(3,5-diacetylphenyl)amino-1,6-dimethylpyrimidinium chloride",CC1=CC(=NC2=CC(=CC(=C2)C(=O)C)C(=O)C)N=C(N1C)N.Cl,,,,,,
3088,73089,"2-Amino-4-(3,5-diacetylphenyl)imino-1,4-dihydro-1,6-dimethylpyrimidine",CC1=CC(=NC2=CC(=CC(=C2)C(=O)C)C(=O)C)N=C(N1C)N,,,,,,
3089,73090,Coly-Mycin S,CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CCN)CC(C)C)CC(C)C)CCN)CCN)[C@@H](C)O.OS(=O)(=O)O,,,,,,
3090,73091,Polymixin E complex,CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CCN)CC(C)C)CC(C)C)CCN)CCN)[C@@H](C)O,,,,,,
3091,73092,CID 73092,COC1=CC(=O)C2=C(C(=C(OC2=C1)C3=CC=C(C=C3)O)OC)O,,,,,,
3092,73093,(S)-N-(7-Amino-1-chloro-2-oxoheptan-3-yl)-4-methylbenzenesulfonamide hydrochloride,CC1=CC=C(C=C1)S(=O)(=O)N[C@@H](CCCCN)C(=O)CCl.Cl,,,"['Exogenous or endogenous compounds which inhibit SERINE ENDOPEPTIDASES. (See all compounds classified as Serine Proteinase Inhibitors.)', 'Highly reactive chemicals that introduce alkyl radicals into biologically active molecules and thereby prevent their proper functioning. Many are used as antineoplastic agents, but most are very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. They have also been used as components in poison gases. (See all compounds classified as Alkylating Agents.)', 'Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. (See all compounds classified as Protein Synthesis Inhibitors.)']",,,
3093,73094,Tosyl-L-lysine chloromethyl ketone,CC1=CC=C(C=C1)S(=O)(=O)N[C@@H](CCCCN)C(=O)CCl,,,"['Exogenous or endogenous compounds which inhibit SERINE ENDOPEPTIDASES. (See all compounds classified as Serine Proteinase Inhibitors.)', 'Highly reactive chemicals that introduce alkyl radicals into biologically active molecules and thereby prevent their proper functioning. Many are used as antineoplastic agents, but most are very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. They have also been used as components in poison gases. (See all compounds classified as Alkylating Agents.)', 'Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. (See all compounds classified as Protein Synthesis Inhibitors.)']",,,
3094,73095,"tert-butyl N-[(3S,5S)-5-benzyl-3-hydroxy-6-[[(2S)-3-methyl-1-[[(2S)-1-morpholin-4-yl-1-oxo-3-phenylpropan-2-yl]amino]-1-oxobutan-2-yl]amino]-6-oxo-1-phenylhexan-2-yl]carbamate",CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCOCC2)NC(=O)[C@@H](CC3=CC=CC=C3)C[C@@H](C(CC4=CC=CC=C4)NC(=O)OC(C)(C)C)O,,,,,,
3095,73096,"tert-butyl N-[(2S,3S,5R)-3-hydroxy-5-[(4-methoxyphenyl)methyl]-6-[[(2S)-3-methyl-1-[[(2S)-1-morpholin-4-yl-1-oxo-3-phenylpropan-2-yl]amino]-1-oxobutan-2-yl]amino]-6-oxo-1-phenylhexan-2-yl]carbamate",CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCOCC2)NC(=O)[C@H](CC3=CC=C(C=C3)OC)C[C@@H]([C@H](CC4=CC=CC=C4)NC(=O)OC(C)(C)C)O,,,,,,
3096,73097,CID 73097,CC1=C(S[C@](C1=O)(C)C=C(C)C=C)O,,,,,,
3097,73098,Thiophene-2-carbohydrazide,C1=CSC(=C1)C(=O)NN,,,,,,
3098,73099,N'-Benzenesulphono-N-nicotinohydrazide,C1=CC=C(C=C1)S(=O)(=O)NNC(=O)C2=CN=CC=C2,,,,,,
3099,73100,"2-Furancarboxamide, N-(aminocarbonyl)-",C1=COC(=C1)C(=O)NC(=O)N,,,,,,
3100,73101,"Picolinic acid, 2-benzylhydrazide",C1=CC=C(C=C1)CNNC(=O)C2=CC=CC=N2,,,,,,
3101,73102,CID 73102,CC(=O)N=C1C=CC(=CN=NC2=NC=C(C=C2)N(O)O)C=C1,,,,,,
3102,73103,Benzo(2'-(1-benzyl-4-piperidyl))hydrazide,C1CN(CCC1NNC(=O)C2=CC=CC=C2)CC3=CC=CC=C3,,,,,,
3103,73104,Lauterine,COC1=CC2=C(C=C1)C(=O)C3=NC=CC4=CC5=C(C2=C43)OCO5,,,,,,
3104,73105,CID 73105,C1=CC=C(C=C1)N2C3C(C(=O)N=NC3=O)N=C2S,,,,,,
3105,73106,Diethyl malonimidate dihydrochloride,CCOC(=N)CC(=N)OCC.Cl.Cl,,,,,,
3106,73107,Diethyl malonimidate,CCOC(=N)CC(=N)OCC,,,,,,
3107,73108,"2(1H)-Quinolinone, 7-(dimethylamino)-4-methyl-",CC1=CC(=O)NC2=C1C=CC(=C2)N(C)C,,,,,,
3108,73109,CID 73109,C1=CN=C(C=N1)C(=N)S,,,,,,
3109,73110,Rebeccamycin,CO[C@@H]1[C@H](O[C@H]([C@@H]([C@H]1O)O)N2C3=C(C=CC=C3Cl)C4=C5C(=C6C7=C(C(=CC=C7)Cl)NC6=C42)C(=O)NC5=O)CO,,,,,,
3110,73111,Sennoside A,C1=CC2=C(C(=C1)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)C(=O)C4=C([C@@H]2[C@@H]5C6=C(C(=CC=C6)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)C(=O)C8=C5C=C(C=C8O)C(=O)O)C=C(C=C4O)C(=O)O,,,"['Agents that produce a soft formed stool, and relax and loosen the bowels, typically used over a protracted period, to relieve CONSTIPATION. (See all compounds classified as Laxatives.)']",,,
3111,73112,CID 73112,C1=CC(=CC=C1C2=CC(=C3C(=CC(=O)C(=C3O)C4=C5C(=C(C=C(O5)C6=CC=C(C=C6)O)O)C(=CC4=O)O)O2)O)O,,,,,,
3112,73113,CID 73113,C1=CC(=CC=C1[C@@H]2[C@H](C(=O)C3=C(C=C(C=C3O2)O)O)C4=C5C(=C(C=C(O5)C6=CC(=C(C=C6)O)O)O)C(=O)C=C4O)O,,,,,,
3113,73114,"(1R,2R,8aS)-1-[(3R)-3-hydroxy-3-methylpent-4-enyl]-2,5,5,8a-tetramethyl-3,4,4a,6,7,8-hexahydro-1H-naphthalen-2-ol",C[C@]12CCCC(C1CC[C@@]([C@@H]2CC[C@](C)(C=C)O)(C)O)(C)C,,,,,,
3114,73115,"1-((2S,3R,4S,5S)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione",CC1=CN(C(=O)NC1=O)[C@@H]2[C@@H]([C@H]([C@@H](O2)CO)O)F,"['Investigated for use/treatment in hepatitis (viral, B).']",,['Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)'],,,
3115,73116,CID 73116,COC1=C([C@@H](C2(CC(=NO2)C(=O)NCCC(=O)CNC(=O)C3=NOC4(C3)C=C(C(=C([C@@H]4O)Br)OC)Br)C=C1Br)O)Br,,,,,,
3116,73117,(+)-Eudesmin,COC1=C(C=C(C=C1)[C@@H]2[C@H]3CO[C@@H]([C@H]3CO2)C4=CC(=C(C=C4)OC)OC)OC,,,,,,
3117,73118,Diasesartemin-(+),COC1=CC(=CC2=C1OCO2)[C@H]3[C@H]4CO[C@H]([C@H]4CO3)C5=CC(=C(C(=C5)OC)OC)OC,,,,,,
3118,73119,"1,3-Dimethyl-8-thiaxanthin",CN1C2=NSN=C2C(=O)N(C1=O)C,,,,,,
3119,73120,Bromochlorophenol blue,C1=CC=C2C(=C1)C(OS2(=O)=O)(C3=CC(=C(C(=C3)Br)O)Cl)C4=CC(=C(C(=C4)Br)O)Cl,,,,,,
3120,73121,"1,3,5-Triazine-1,3,5(2H,4H,6H)-tripropanoic acid, 2,4,6-trioxo-",C(CN1C(=O)N(C(=O)N(C1=O)CCC(=O)O)CCC(=O)O)C(=O)O,,,,,,
3121,73122,Bruceoside C,CC1=C(C(=O)C[C@]2([C@H]1[C@H]([C@@H]3[C@]45[C@@H]2[C@H]([C@@H](C([C@@H]4CC(=O)O3)(OC5)C(=O)OC)O)O)OC(=O)C=C(C)C)C)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O,,,,,,
3122,73123,CID 73123,C1=CC(=CC=C1C2=CC(=C3C(=CC(=CC3=O)O[C@H]4[C@@H]([C@H]([C@H]([C@H](O4)CO)O)O)O)O2)O)O,,,,,,
3123,73124,"(S)-9-(2,3-Dihydroxypropyl)adenine",C1=NC(=C2C(=N1)N(C=N2)C[C@@H](CO)O)N,,,['Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)'],,,
3124,73125,Ethyl indole-2-carboxylate,CCOC(=O)C1=CC2=CC=CC=C2N1,,,,,,
3125,73126,2-Hydroxy-2-phenylacetohydrazide,C1=CC=C(C=C1)C(C(=O)NN)O,,,,,,
3126,73127,"1,9-Heptadecadiene-4,6-diyn-3-ol, (3R,9Z)-",CCCCCCCC=CCC#CC#C[C@@H](C=C)O,,,,,,
3127,73128,"1,9-Heptadecadiene-4,6-diyne-3,8-diol, (3S,8S,9Z)-",CCCCCCCC=C[C@@H](C#CC#C[C@H](C=C)O)O,,,,,,
3128,73129,"(4aS,6aR,6aS,6bR,8aR,9R,10S,12aR,14bS)-10-[(2S,3R,4R,5R)-5-[(2S,3R,4S,5R,6S)-3,4-dihydroxy-6-methyl-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxyoxan-2-yl]oxy-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid",C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2CO[C@H]([C@@H]([C@H]2O)O)O[C@H]3CC[C@]4([C@H]([C@]3(C)CO)CC[C@@]5([C@@H]4CC=C6[C@]5(CC[C@@]7([C@H]6CC(CC7)(C)C)C(=O)O)C)C)C)O)O)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O)O)O)O,,,,,,
3129,73130,Transsylvanoside B,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2CO[C@H]([C@@H]([C@H]2O)O)O[C@H]3CC[C@]4([C@H]([C@]3(C)CO)CC[C@@]5([C@@H]4CC=C6[C@]5(CC[C@@]7([C@H]6CC(CC7)(C)C)C(=O)O)C)C)C)O)O)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O,,,,,,
3130,73131,Xeatobergsterol B,C[C@@H]1C[C@@]([C@@H]2[C@H]1[C@]3(CCC4C([C@H]3C2=O)[C@H]([C@@H]([C@@H]5[C@@]4([C@@H]([C@@H]([C@H](C5)O)O)O)C)O)O)C)(CC(C)C)O,,,,,,
3131,73132,2-[1-Carbamoyl-2-(5-nitrofurfurylidene)hydrazino]acetic acid ethyl ester,CCOC(=O)CN(C(=O)N)N=CC1=CC=C(O1)[N+](=O)[O-],,,,,,
3132,73133,N-(4-Methyl-3-nitrophenyl)acetamide,CC1=C(C=C(C=C1)NC(=O)C)[N+](=O)[O-],,,,,,
3133,73134,"4-Imidazolidinone, 1-ethyl-3-methyl-2-thioxo-",CCN1CC(=O)N(C1=S)C,,,,,,
3134,73135,"5-[[4-[[4-[(3-Carboxy-4-chlorophenyl)amino]phenyl]phenylmethylene]-2,5-cyclohexadien-1-ylidene]amino]-2-chlorobenzoic acid",C1=CC=C(C=C1)C(=C2C=CC(=NC3=CC(=C(C=C3)Cl)C(=O)O)C=C2)C4=CC=C(C=C4)NC5=CC(=C(C=C5)Cl)C(=O)O,,,,,,
3135,73136,"4,5-Diphenyl-2H-imidazol-2-one",C1=CC=C(C=C1)C2=NC(=O)N=C2C3=CC=CC=C3,,,,,,
3136,73137,4-Methyl-3-nitrophenyl isocyanate,CC1=C(C=C(C=C1)N=C=O)[N+](=O)[O-],,,,,,
3137,73138,4-(Acetylamino)-2-nitrobenzoic acid,CC(=O)NC1=CC(=C(C=C1)C(=O)O)[N+](=O)[O-],,,,,,
3138,73139,"1-Imidazolidineacetic acid, 4-oxo-3-phenyl-2-thioxo-",C1C(=O)N(C(=S)N1CC(=O)O)C2=CC=CC=C2,,,,,,
3139,73140,"Rhodanine, 3-(4-chloro-m-tolyl)-",CC1=C(C=CC(=C1)N2C(=O)CSC2=S)Cl,,,,,,
3140,73141,"Benzenesulfonamide, N-(4-chloro-3-(trifluoromethyl)phenyl)-4-fluoro-",C1=CC(=CC=C1F)S(=O)(=O)NC2=CC(=C(C=C2)Cl)C(F)(F)F,,,,,,
3141,73142,"Imidazo[1,2-a]pyridine-3-carboxylic acid",C1=CC2=NC=C(N2C=C1)C(=O)O,,,,,,
3142,73143,Sulfated pentagalloyl glucose,C1=C(C=C(C(=C1OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])C(=O)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC(=O)C3=CC(=C(C(=C3)OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OC(=O)C4=CC(=C(C(=C4)OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OC(=O)C5=CC(=C(C(=C5)OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OC(=O)C6=CC(=C(C(=C6)OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+],,,,,,
3143,73144,"[(2R,3R,4S,5R,6S)-3,4,5,6-tetrakis[(3,4,5-trisulfooxybenzoyl)oxy]tetrahydropyran-2-yl]methyl 3,4,5-trisulfooxybenzoate",C1=C(C=C(C(=C1OS(=O)(=O)O)OS(=O)(=O)O)OS(=O)(=O)O)C(=O)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC(=O)C3=CC(=C(C(=C3)OS(=O)(=O)O)OS(=O)(=O)O)OS(=O)(=O)O)OC(=O)C4=CC(=C(C(=C4)OS(=O)(=O)O)OS(=O)(=O)O)OS(=O)(=O)O)OC(=O)C5=CC(=C(C(=C5)OS(=O)(=O)O)OS(=O)(=O)O)OS(=O)(=O)O)OC(=O)C6=CC(=C(C(=C6)OS(=O)(=O)O)OS(=O)(=O)O)OS(=O)(=O)O,,,,,,
3144,73145,beta-Amyrin,C[C@@]12CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)O)C)C)[C@@H]1CC(CC2)(C)C)C,,,,,,
3145,73146,Aridanin,CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O[C@H]2CC[C@]3([C@H](C2(C)C)CC[C@@]4([C@@H]3CC=C5[C@]4(CC[C@@]6([C@H]5CC(CC6)(C)C)C(=O)O)C)C)C)CO)O)O,,,,,,
3146,73147,22-Hydroxytingenone,C[C@@H]1C[C@@H]2[C@@](CC[C@]3([C@]2(CC[C@@]4(C3=CC=C5C4=CC(=O)C(=C5C)O)C)C)C)([C@@H](C1=O)O)C,,,,,,
3147,73148,Einecs 255-532-8,CC(=CCCC(C)([C@H]1CC[C@@]2([C@@H]1[C@@H](C[C@H]3[C@]2(CC[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C)C)O)C)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)COC8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)O)O)O)C,,,,,,
3148,73149,"(2S,3R,4R,5R,6S)-2-[(2R,3R,4S,5S,6R)-2-[[(3S,5R,6S,8R,10R,12R,13S,14R,17S)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2S)-6-methyl-2-[(2S,3R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-6-yl]oxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-6-methyloxane-3,4,5-triol",C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2O[C@H]3C[C@@]4(C(C[C@H]([C@@H]5[C@]4(CC[C@@H]5[C@](C)(CCC=C(C)C)O[C@H]6[C@@H](C([C@@H]([C@H](O6)CO)O)O)O)C)O)[C@@]7([C@@H]3C([C@H](CC7)O)(C)C)C)C)CO)O)O)O)O)O,,,,,,
3149,73150,CID 73150,CC=C1CN2CC[C@H]1C(=C)C3=C(C2)C=C4C=CNC4=C3,,,,,,
3150,73151,CID 73151,CC=C1CN([C@H]2CC3=C(C(=O)C[C@@H]1[C@H]2C(=O)OC)NC4=CC=CC=C34)C=O,,,,,,
3151,73152,CID 73152,C[C@@H]1[C@H]([C@@H]([C@@H]([C@@H](O1)O[C@@H]2C[C@H]3[C@@H]([C@H](C[C@](O3)(C[C@H](C[C@H](C[C@H](C[C@H](CC(=O)C[C@H](CC(=O)OC(C(C=CC=CC=CC=CC=CC=CC=C2)C)[C@@H](C)CCC(CC(=O)C4=CC=C(C=C4)NC)O)O)O)O)O)O)O)O)C(=O)NCCN(C)C)O)NC(=O)CN(C)C)O.C([C@@H](C(=O)O)N)C(=O)O.C([C@@H](C(=O)O)N)C(=O)O,,,,,,
3152,73153,CID 73153,C[C@@H]1[C@H]([C@@H]([C@@H]([C@@H](O1)O[C@@H]2C[C@H]3[C@@H]([C@H](C[C@](O3)(C[C@H](C[C@H](C[C@H](C[C@H](CC(=O)C[C@H](CC(=O)OC(C(C=CC=CC=CC=CC=CC=CC=C2)C)[C@@H](C)CCC(CC(=O)C4=CC=C(C=C4)NC)O)O)O)O)O)O)O)O)C(=O)NCCN(C)C)O)NC(=O)CN(C)C)O,,,,,,
3153,73154,Chaparrinone,C[C@@H]1[C@@H]2CC(=O)O[C@H]3[C@@]24CO[C@@]([C@@H]1O)([C@@H]4[C@@]5([C@@H](C3)C(=CC(=O)[C@H]5O)C)C)O,,,,,,
3154,73155,CID 73155,C[C@@H]1CC[C@H]2[C@H]([C@H](O[C@H]3[C@@]24[C@H]1CCC(O3)(OO4)C)OCC5=CC=C(C=C5)C(=O)[O-])C.[Na+],,,,,,
3155,73156,Artelinate,C[C@@H]1CC[C@H]2[C@H]([C@H](O[C@H]3[C@@]24[C@H]1CCC(O3)(OO4)C)OCC5=CC=C(C=C5)C(=O)O)C,,,,,,
3156,73157,Lobaric acid,CCCCCC1=C(C(=CC2=C1OC3=CC(=CC(=C3C(=O)O2)C(=O)CCCC)OC)O)C(=O)O,,,,,,
3157,73158,"1,2,11,12-Tetramethoxy-6,7-dimethyl-5,6,7,8-tetrahydrodibenzo[a,c][8]annulene-3,10-diol",CC1CC2=CC(=C(C(=C2C3=C(C(=C(C=C3CC1C)O)OC)OC)OC)OC)O,,,,,,
3158,73159,"(2R,3S)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-2H-chromene-3,5,7-triol;(2S,3R)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-2H-chromene-3,5,7-triol",C1[C@H]([C@@H](OC2=CC(=CC(=C21)O)O)C3=CC(=C(C=C3)O)O)O.C1[C@@H]([C@H](OC2=CC(=CC(=C21)O)O)C3=CC(=C(C=C3)O)O)O,,,,,,
3159,73160,(-)-Catechin,C1[C@H]([C@@H](OC2=CC(=CC(=C21)O)O)C3=CC(=C(C=C3)O)O)O,,,,,,
3160,73161,2-Aminophenylarsonic acid,C1=CC=C(C(=C1)N)[As](=O)(O)O,,,,,,
3161,73162,CID 73162,C[C@@H]1[C@H](C[C@]2(CC[C@@](O2)(C)C3CC[C@@](O3)(C)[C@H]4[C@H]([C@H]([C@@H](O4)[C@@H]5[C@H]([C@@H]([C@H]([C@@](O5)(C)O)C)OC)C)OC)C)O[C@@H]1[C@@H](C)[C@@H]6[C@@H]([C@@H]([C@H]([C@@](O6)([C@H](C)C(=O)[O-])O)C)OC)C)OC.[Na+],,,,,,
3162,73163,CID 73163,C[C@@H]1[C@H]([C@H]([C@](O[C@H]1[C@H](C)[C@H]2[C@@H](C(C[C@@]3(O2)CC[C@](O3)(C)C4CC[C@](O4)(C)[C@H]5[C@H]([C@H]([C@H](O5)[C@H]6[C@H](C([C@H]([C@](O6)(C)O)C)OC)C)OC)C)OC)C)([C@H](C)C(=O)O)O)C)OC,,,,,,
3163,73164,Costunolide,CC1=CCCC(=C[C@@H]2[C@@H](CC1)C(=C)C(=O)O2)C,,,"['Agents that kill parasitic worms. They are used therapeutically in the treatment of HELMINTHIASIS in man and animal. (See all compounds classified as Anthelmintics.)', 'Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)', 'Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. (See all compounds classified as Antineoplastic Agents, Phytogenic.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)']",,,
3164,73165,"4,6-Dimethyl-1,2-oxathiine 2,2-dioxide",CC1=CC(=CS(=O)(=O)O1)C,,,,,,
3165,73166,2-Methylindole-3-carboxaldehyde,CC1=C(C2=CC=CC=C2N1)C=O,,,,,,
3166,73167,"1-Piperazinecarbodithioic acid, 4-methyl-",CN1CCN(CC1)C(=S)S,,,,,,
3167,73168,CID 73168,CN1C=C(N=N1)C=C2[C@@H]3N(C2=O)C(=CS3)C(=O)[O-].[Na+],,,,,,
3168,73169,(5R)-6-[(1-methyltriazol-4-yl)methylidene]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid,CN1C=C(N=N1)C=C2[C@@H]3N(C2=O)C(=CS3)C(=O)O,,,,,,
3169,73170,alpha-Amyrin,C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)O)C)C)[C@@H]2[C@H]1C)C)C,,,,,,
3170,73171,4-(3-Hydroxy-1-propen-1-yl)-2-methoxyphenyl beta-glucopyranoside,COC1=C(C=CC(=C1)C=CCO)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O,,,,,,
3171,73172,Pyrazinecarbonitrile,C1=CN=C(C=N1)C#N,,,,,,
3172,73173,"Pyrazine-2,3-dicarboxamide",C1=CN=C(C(=N1)C(=O)N)C(=O)N,,,,,,
3173,73174,Dehydrocostus lactone,C=C1CC[C@@H]2[C@@H]([C@@H]3[C@H]1CCC3=C)OC(=O)C2=C,,,,,,
3174,73175,CID 73175,C1CCN[C@H](C1)[C@@H](C2=CC(=NC(=C2)C(F)(F)F)C3=CC=C(C=C3)C(F)(F)F)O.C1CCN[C@@H](C1)[C@H](C2=CC(=NC(=C2)C(F)(F)F)C3=CC=C(C=C3)C(F)(F)F)O,,,,,,
3175,73176,CID 73176,C1CCN[C@@H](C1)C(C2=CC(=NC(=C2)C(F)(F)F)C3=CC=C(C=C3)C(F)(F)F)O,,,,,,
3176,73177,(+)-Ganodermanontriol,C[C@H](CC[C@@H](C(C)(CO)O)O)[C@H]1CC[C@@]2([C@@]1(CC=C3C2=CC[C@@H]4[C@@]3(CCC(=O)C4(C)C)C)C)C,,,,,,
3177,73178,"1,2,3,6-Tetrakis-O-galloyl-beta-D-glucose",C1=C(C=C(C(=C1O)O)O)C(=O)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC(=O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O)OC(=O)C5=CC(=C(C(=C5)O)O)O)O,,,,,,
3178,73179,Tellimagradin I,C1[C@H]([C@@H](OC(=O)C2=CC(=C(C(=C2C3=C(C(=C(C=C3C(=O)O1)O)O)O)O)O)O)[C@@H]([C@H](C=O)OC(=O)C4=CC(=C(C(=C4)O)O)O)OC(=O)C5=CC(=C(C(=C5)O)O)O)O,,,,,,
3179,73180,(R)-Linezolid,CC(=O)NC[C@@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,,,,,,
3180,73181,"Isoxazole, 5-[5-[2,6-dichloro-4-(2-oxazolyl)phenoxy]pentyl]-3-methyl-",CC1=NOC(=C1)CCCCCOC2=C(C=C(C=C2Cl)C3=NC=CO3)Cl,,,,,,
3181,73182,Difluoromethylene diphosphonate,C(F)(F)(P(=O)(O)O)P(=O)(O)O,,,,,,
3182,73183,"Phosphinecarboxylic acid, hydroxymethoxy-, oxide, disodium salt",COP(=O)(C(=O)[O-])[O-].[Na+].[Na+],,,,,,
3183,73184,[Hydroxy(methoxy)phosphoryl]formic acid,COP(=O)(C(=O)O)O,,,,,,
3184,73185,Disodium (ethoxycarbonyl)phosphonate,CCOC(=O)P(=O)([O-])[O-].[Na+].[Na+],,,,,,
3185,73186,(Ethoxycarbonyl)phosphonic acid,CCOC(=O)P(=O)(O)O,,,,,,
3186,73187,2-Phosphonopropionic acid,CC(C(=O)O)P(=O)(O)O,,,,,,
3187,73188,Phosphonoacetamide,C(C(=O)N)P(=O)(O)O,,,,,,
3188,73189,"Acetic acid, hydroxyphosphono-",C(C(=O)O)(O)P(=O)(O)O,,,,,,
3189,73190,"(S,Z)-2-(2-oxo-8,9-dihydro-2H-furo[2,3-h]chromen-8-yl)propan-2-yl 2-methylbut-2-enoate",CC=C(C)C(=O)OC(C)(C)[C@@H]1CC2=C(O1)C=CC3=C2OC(=O)C=C3,,,,,,
3190,73191,Nodakenin,CC(C)([C@H]1CC2=C(O1)C=C3C(=C2)C=CC(=O)O3)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O,,,,,,
3191,73192,"(2S,3R,4R,4aS,10bR)-3,4,8,9,10-pentahydroxy-2-(hydroxymethyl)-3,4,4a,10b-tetrahydro-2H-pyrano[3,2-c]isochromen-6-one",C1=C2C(=C(C(=C1O)O)O)[C@@H]3[C@H]([C@@H]([C@H]([C@@H](O3)CO)O)O)OC2=O,,,,,,
3192,73193,Tormentic acid,C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(C[C@H]([C@@H](C5(C)C)O)O)C)C)[C@@H]2[C@]1(C)O)C)C(=O)O,,,,,,
3193,73194,[6-benzyl-2-[bis[(2S)-2-aminopropanoyl]amino]-3-methylphenyl] (2S)-2-[[(2S)-2-(3-hydroxyhexanoylamino)-3-methylbutanoyl]amino]-3-methylbutanoate,CCCC(CC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)OC1=C(C=CC(=C1N(C(=O)[C@H](C)N)C(=O)[C@H](C)N)C)CC2=CC=CC=C2)O,,,,,,
3194,73195,"methyl (2R)-2-[[(2R)-2-[[(4S,5S)-5-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]propanoyl]amino]-4-hydroxy-6-phenyl-hexanoyl]amino]-3-methyl-butanoyl]amino]-3-methyl-butanoate",C[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CCC(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)OC)O)N,,,,,,
3195,73196,2-Quinolinylmethanol,C1=CC=C2C(=C1)C=CC(=N2)CO,,,,,,
3196,73197,CID 73197,C1=CC(=C(C=C1O)O)C=CC2=CC(=CC(=C2)O)O,,,,,,
3197,73198,Marini,CC(=CCC(CC1=C2C(=C(C=C1O)O)C(=O)CC(O2)C3=C(C=C(C=C3)O)O)C(=C)C)C,,,,,,
3198,73199,CID 73199,CC(=CCC1=C(C2=C(C(=COC2=CC1=O)C3=CC=C(C=C3)O)O)O)C,,,,,,
3199,73200,(3R)-Astragaluquinone,COC1=C(C2=C(C[C@@H](CO2)C3=CC(=O)C=C(C3=O)O)C=C1)OC,,,,,,
3200,73201,5-Hydroxy-7-methoxy-2-phenylchroman-4-one,COC1=CC(=C2C(=O)C[C@H](OC2=C1)C3=CC=CC=C3)O,,,,,,
3201,73202,Pinobanksin,C1=CC=C(C=C1)[C@@H]2[C@H](C(=O)C3=C(C=C(C=C3O2)O)O)O,,,,,,
3202,73203,CID 73203,COC1=CC(=O)C2=C(C(=C(OC2=C1)C3=CC=CC=C3)O)O,,,,,,
3203,73204,Sigmoidin A,CC(=CCC1=CC(=C(C(=C1O)O)CC=C(C)C)[C@@H]2CC(=O)C3=C(C=C(C=C3O2)O)O)C,,,,,,
3204,73205,Sigmoidin B,CC(=CCC1=C(C(=CC(=C1)[C@@H]2CC(=O)C3=C(C=C(C=C3O2)O)O)O)O)C,,,,,,
3205,73206,CID 73206,CC(=CCC1=C(C=CC(=C1)C2=CC(=C3C(=CC(=O)C=C3O2)O)O)O)C,,,,,,
3206,73207,Xanthomicrol,COC1=C(C(=C2C(=C1O)C(=O)C=C(O2)C3=CC=C(C=C3)O)OC)OC,,,,,,
3207,73208,CID 73208,COC1=C(C=CC(=C1)C2=C(C(=C3C(=CC(=O)C(=C3O)OC)O2)O)OC)O,,,,,,
3208,73209,"3-Amino-2,6-difluorobenzoicacid",C[C@H]1C[C@@H]([C@@H]([C@H](C=C([C@@H]([C@H](C=CC=C(C(=O)NC2=CC(=O)C=C([C@@H]1OC)C2=O)C)OC)OC(=O)N)C)C)OC)OC,,,"['Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. (See all compounds classified as Antibiotics, Antineoplastic.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)', 'Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)']",,,
3209,73210,Alnetin,COC1=C(C(=C2C(=C1O)C(=O)C=C(O2)C3=CC=CC=C3)OC)OC,,,,,,
3210,73211,"(2S)-2-[[(2S)-2-(tert-butylsulfonylmethyl)-3-naphthalen-1-ylpropanoyl]amino]-N-[(2S,3R,4S,5S)-5-[[(2S)-2-[[(2R)-2-(tert-butylsulfonylmethyl)-3-naphthalen-1-ylpropanoyl]amino]-3-methylbutanoyl]amino]-3,4-dihydroxy-1,6-diphenylhexan-2-yl]-3-methylbutanamide",CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H]([C@H]([C@H](CC2=CC=CC=C2)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](CC3=CC=CC4=CC=CC=C43)CS(=O)(=O)C(C)(C)C)O)O)NC(=O)[C@H](CC5=CC=CC6=CC=CC=C65)CS(=O)(=O)C(C)(C)C,,,,,,
3211,73212,Lead (II) ion,[Pb+2],,,,,,
3212,73213,Vineomycin a1,C[C@H]1[C@H](CC[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@H]2O)C3=C(C4=C(C=C3)C(=O)C5=C(C4=O)C=C[C@]6([C@@]5(C(=O)C[C@](C6)(C)O[C@H]7CC[C@@H]([C@@H](O7)C)O[C@H]8C=CC(=O)[C@@H](O8)C)O)O)O)C)O[C@H]9C=CC(=O)[C@@H](O9)C,,,,,,
3213,73214,Eperezolid,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCN(CC3)C(=O)CO)F,,,['Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. (See all compounds classified as Anti-Infective Agents.)'],,,
3214,73215,"(2r,5r)-5-(6-Amino-9h-purin-9-yl)-3-[(1r)-1-hydroxyethyl]cyclopent-3-ene-1,2-diol",C[C@H](C1=C[C@H](C([C@@H]1O)O)N2C=NC3=C(N=CN=C32)N)O,,,,,,
3215,73216,Ethyl 2-aminothiazole-4-carboxylate,CCOC(=O)C1=CSC(=N1)N,,,,,,
3216,73217,Titan yellow,CC1=C(C2=C(C=C1)N=C(S2)C3=CC=C(C=C3)NN=NC4=CC=C(C=C4)C5=NC6=C(S5)C(=C(C=C6)C)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+],,,,,,
3217,73218,Direct Yellow TZ,CC1=C(C2=C(C=C1)N=C(S2)C3=CC=C(C=C3)NN=NC4=CC=C(C=C4)C5=NC6=C(S5)C(=C(C=C6)C)S(=O)(=O)O)S(=O)(=O)O,,,,,,
3218,73219,"3,5-Di-tert-butyl-4-hydroxybenzaldehyde",CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)C=O,,,,,,
3219,73220,Thianthrene 5-oxide,C1=CC=C2C(=C1)SC3=CC=CC=C3S2=O,,,,,,
3220,73221,"7,8-Dimethyl-10-formylmethylisoalloxazine",CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)CC=O,,,,,,
3221,73222,"2-Amino-4,5-diphenylthiazole",C1=CC=C(C=C1)C2=C(SC(=N2)N)C3=CC=CC=C3,,,,,,
3222,73223,"Imidazo[2,1-b]thiazole, 3-(4-chlorophenyl)-5,6-dihydro-, monohydrobromide",C1CN2C(=CSC2=N1)C3=CC=C(C=C3)Cl.Br,,,,,,
3223,73224,"3-(4-Chlorophenyl)-5,6-dihydroimidazo[2,1-b]thiazole",C1CN2C(=CSC2=N1)C3=CC=C(C=C3)Cl,,,,,,
3224,73225,"1,4-Dihydro-6-methylquinoxaline-2,3-dione",CC1=CC2=C(C=C1)NC(=O)C(=O)N2,,,,,,
3225,73226,"3-[[Ethyl-[4-[[4-[ethyl-[(3-sulfophenyl)methyl]amino]phenyl]-phenylmethylidene]cyclohexa-2,5-dien-1-ylidene]azaniumyl]methyl]benzenesulfonate",CCN(CC1=CC(=CC=C1)S(=O)(=O)[O-])C2=CC=C(C=C2)C(=C3C=CC(=[N+](CC)CC4=CC(=CC=C4)S(=O)(=O)O)C=C3)C5=CC=CC=C5,,,,"['Studies in rats involving oral administration showed that only small amounts of the dye (< 5%) are absorbed and excreted unchanged in the bile. Following its iv injection in rats, about 75% of the dye was excreted in the bile within 4 hr.']",,
3226,73227,Indole-3-glyoxylamide,C1=CC=C2C(=C1)C(=CN2)C(=O)C(=O)N,,,,,,
3227,73228,"2-Thiazolamine, 4-(chloromethyl)-, monohydrochloride",C1=C(N=C(S1)N)CCl.Cl,,,,,,
3228,73229,4-(Chloromethyl)thiazol-2-amine,C1=C(N=C(S1)N)CCl,,,,,,
3229,73230,Micromelin,C[C@@]12[C@@H](O1)[C@@H](OC2=O)C3=C(C=C4C(=C3)C=CC(=O)O4)OC,,,,,,
3230,73231,CID 73231,CC(=CCCC(=CCC1=CC2=CC=C(OC2=CC1=O)O)C)C,,,,,,
3231,73232,"Carbamimidothioic acid, (2-amino-4-thiazolyl)methyl ester, dihydrochloride",C1=C(N=C(S1)N)CSC(=N)N.Cl.Cl,,,,,,
3232,73233,"(2-Amino-1,3-thiazol-4-yl)methyl carbamimidothioate",C1=C(N=C(S1)N)CSC(=N)N,,,,,,
3233,73234,4-Phenyl-5-tetradecylthiazol-2-amine,CCCCCCCCCCCCCCC1=C(N=C(S1)N)C2=CC=CC=C2,,,,,,
3234,73235,"Thiazole, 2-amino-4-(aminooxymethyl)-, dihydrochloride",C1=C(N=C(S1)N)CON.Cl.Cl,,,,,,
3235,73236,4-((Aminooxy)methyl)thiazol-2-amine,C1=C(N=C(S1)N)CON,,,,,,
3236,73237,"2-Amino-4,5-dimethylthiazole hydrobromide",CC1=C(SC(=N1)N)C.Br,,,,,,
3237,73238,"4,5-Dimethyl-1,3-thiazol-2-amine",CC1=C(SC(=N1)N)C,,,,,,
3238,73239,Ethyl 2-amino-4-phenylthiazole-5-carboxylate,CCOC(=O)C1=C(N=C(S1)N)C2=CC=CC=C2,,,,,,
3239,73240,Antibiotic CC 1065,CC1=CNC2=C1C34CC3CN(C4=CC2=O)C(=O)C5=CC6=C7CCN(C7=C(C(=C6N5)OC)O)C(=O)C8=CC9=C1CCN(C1=C(C(=C9N8)OC)O)C(=O)N,,,"['A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026) (See all compounds classified as Antineoplastic Agents, Alkylating.)', 'Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. (See all compounds classified as Antibiotics, Antineoplastic.)']",,,
3240,73241,"4-(4-Chlorophenyl)-1,3-thiazol-2-amine",C1=CC(=CC=C1C2=CSC(=N2)N)Cl,,,,,,
3241,73242,Ethyl 2-amino-4-phenylthiophene-3-carboxylate,CCOC(=O)C1=C(SC=C1C2=CC=CC=C2)N,,,,,,
3242,73243,"N,N-Bis(2-hydroxyethyl)-2-aminoethanesulfonic acid",C(CO)N(CCO)CCS(=O)(=O)O,,,,,,
3243,73244,"1-Phenyl-4-(phenylamino)-2,5-piperazinedione",C1C(=O)N(CC(=O)N1C2=CC=CC=C2)NC3=CC=CC=C3,,,,,,
3244,73245,"2,6,11,15-Tetramethylhexadeca-2,4,6,8,10,12,14-heptaenedioic acid",CC(=CC=CC=C(C)C=CC=C(C)C(=O)O)C=CC=C(C)C(=O)O,,,,,,
3245,73246,Piperacillin hydrate,CCN1CCN(C(=O)C1=O)C(=O)N[C@H](C2=CC=CC=C2)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O.O,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
3246,73247,"4,5-Dichloro-3(2H)-pyridazinone",C1=NNC(=O)C(=C1Cl)Cl,,,,,,
3247,73248,CID 73248,C1=CN=CC=C1CC(=N)S,,,,,,
3248,73249,"1H-Benzimidazol-2-amine, N-(4,6-dimethyl-2-pyrimidinyl)-",CC1=CC(=NC(=N1)NC2=NC3=CC=CC=C3N2)C,,,,,,
3249,73250,"Theophylline, 8-(4-(2-benzimidazolyl)butyl)-",CN1C2=C(C(=O)N(C1=O)C)NC(=N2)CCCCC3=NC4=CC=CC=C4N3,,,,,,
3250,73251,CID 73251,C1=CC2=NC(=NC(=N)N)N=C2C=C1N(O)O,,,,,,
3251,73252,Tetrachloro-O-benzoquinone,C1(=C(C(=O)C(=O)C(=C1Cl)Cl)Cl)Cl,,,,,,
3252,73253,Heraclenol,CC(C)([C@@H](COC1=C2C(=CC3=C1OC=C3)C=CC(=O)O2)O)O,,,,,,
3253,73254,"(2S,6S,8aS)-1-hydroxy-6,8a-dimethyl-5-methylene-decalin-1,2-dicarbaldehyde",C[C@H]1CC[C@]2(C(C1=C)CC[C@@H](C2(C=O)O)C=O)C,,,,,,
3254,73255,Voacangine,CC[C@H]1C[C@H]2C[C@@]3([C@H]1N(C2)CCC4=C3NC5=C4C=C(C=C5)OC)C(=O)OC,,,,,,
3255,73256,Canventol,CC(C)C1=CC(=C(C)C)CCC1O,,,,,,
3256,73257,CID 73257,C1=NC2=C(N1C[C@@H](CO)OCP(=O)(O)O)NC(=NC2=O)N,,,,,,
3257,73258,DihydroCsA,CCCC[C@@H](C)[C@H](C1C(=O)N[C@H](C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C)CC)O,,,,,,
3258,73259,"(3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-1,4,7,10,12,15,19,25,28-nonamethyl-33-[(2R)-2-methylhex-4-enoyl]-6,9,18,24-tetrakis(2-methylpropyl)-3,21,30-tri(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone",CC=CC[C@@H](C)C(=O)[C@H]1C(=O)N[C@H](C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C)C(C)C,,,,,,
3259,73260,CID 73260,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N(C(C(=O)N1)[C@@H]([C@H](C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)C)C)C(C)C)CC(C)C)C)C,,,,,,
3260,73261,CID 73261,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N([C@@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N(C(C(=O)N1)[C@@H]([C@H](C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)C)CC(C)C)C)C,,,,,,
3261,73262,CID 73262,CC=CC[C@@H](C)[C@H](C1C(=O)N[C@H](C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C)C(C)C)O,,,,,,
3262,73263,CID 73263,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N(C(C(=O)N1)[C@@H](C(C)(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,,,,,,
3263,73264,Reactive Red 120,C1=CC=C(C(=C1)N=NC2=C(C3=C(C=C(C=C3C=C2S(=O)(=O)O)S(=O)(=O)O)NC4=NC(=NC(=N4)NC5=CC=C(C=C5)NC6=NC(=NC(=N6)Cl)NC7=C8C(=CC(=C7)S(=O)(=O)O)C=C(C(=C8O)N=NC9=CC=CC=C9S(=O)(=O)O)S(=O)(=O)O)Cl)O)S(=O)(=O)O,,,,,,
3264,73265,3-Butyluracil,CCCCN1C(=O)C=CNC1=O,,,,,,
3265,73266,5-Diazouracil,C1=C(C(=O)NC(=N1)[O-])[N+]#N,,,,,,
3266,73267,5-Ethyluracil,CCC1=CNC(=O)NC1=O,,,,,,
3267,73268,5-Hydroxyuracil,C1=C(C(=O)NC(=O)N1)O,,,,,,
3268,73269,5-Propyluracil,CCCC1=CNC(=O)NC1=O,,,,,,
3269,73270,"5-Pyrimidinesulfonamide, 1,2,3,4-tetrahydro-2,4-dioxo-",C1=C(C(=O)NC(=O)N1)S(=O)(=O)N,,,,,,
3270,73271,6-Carboxymethyluracil,C1=C(NC(=O)NC1=O)CC(=O)O,,,,,,
3271,73272,6-Chlorouracil,C1=C(NC(=O)NC1=O)Cl,,,,,,
3272,73273,6-(Chloromethyl)uracil,C1=C(NC(=O)NC1=O)CCl,,,,,,
3273,73274,CID 73274,C1=CN=C(N=C1)S,,,,,,
3274,73275,CID 73275,C1=CC=C(C=C1)CC2=CC(=O)N=C(N2)S,,,,,,
3275,73276,1-Methyl-5-bromouracil,CN1C=C(C(=O)NC1=O)Br,,,,,,
3276,73277,2-Chloropyrazine,C1=CN=C(C=N1)Cl,,,,,,
3277,73278,3-Oxauracil,C1=CNC(=O)OC1=O,,,,,,
3278,73279,"7-Hydroxy-8-[2-[5-[5-[6-hydroxy-6-(hydroxymethyl)-3,5-dimethyloxan-2-yl]-3-methyloxolan-2-yl]-5-methyloxolan-2-yl]-7-methoxy-2,4,6-trimethyl-1,10-dioxaspiro[4.5]decan-9-yl]-2,4-dimethyloct-2-enoic acid",CC1CC(C(OC1C2CC(C(O2)C3(CCC(O3)C4(CC(C5(O4)C(C(CC(O5)CC(CCC(C)C=C(C)C(=O)O)O)OC)C)C)C)C)C)(CO)O)C,,,,,,
3279,73280,"Nigericin, (28S)-",C[C@H]1CC[C@@H](O[C@H]1[C@@H](C)C(=O)C)C[C@@H]2C[C@H]([C@H](C3(O2)[C@@H](C[C@@](O3)(C)[C@H]4CC[C@@](O4)(C)[C@H]5[C@H](C[C@@H](O5)[C@@H]6[C@H](C[C@@H]([C@@](O6)(CO)O)C)C)C)C)C)OC,,,,,,
3280,73281,Nicosulfuron,CN(C)C(=O)C1=C(N=CC=C1)S(=O)(=O)NC(=O)NC2=NC(=CC(=N2)OC)OC,,,,"['Two female goats weighing 43 kg (#1) and 34 kg (#2) (1.4 and 1.8 mg/kg bodyweight respectively), were dosed daily for 3 consecutive days in feed rations treated with (pyrimidine2-(14)C)nicosulfuron, sp. act., 62.2 uCi/mg, radiochemical purity, >95%, isotopic purity, 97%, and (pyridine-2-(14)C)nicosulfuron, sp. act., 62.9 uCi/mg, radiochemical purity, >95%, isotopic purity, >99%, respectively. Dosing capsules were prepared with the (14)C-labeled materials, 13C-enriched isomers (C2 position of each respective ring), and nonradioactive nicosulfuron. The capsules were analyzed prior to dosing by LSC for total (14)C-activity and by HPLC for chemical analysis. These capsules were imbedded in a larger gelatin capsule containing 6 g of goat chow. Goat #1 was housed for a 9-day acclimation period, while goat #2 was kept for 11 days.  Both goats showed good health and milk production before and during dosing. The dosage represents a daily feeding level of approximately 60 ppm based on the average feed and hay consumption of 1 kg/day. Samples of milk, bile, urine, and feces were collected daily and analyzed by combustion/liquid scintillation counting. A control goat was not used in the study. Milk, bile, urine, and feces were collected at least one day prior to dosing for use as control samples. ... The administered 14C-dosage was excreted in the urine at 46% and 17%, and in the feces at 62% and 32%, respectively for the pyridinyl- and pyrimidinyl-labeled nicosulfuron. Uptake of residues was low for all tissues and organs for either label. The highest level, 0.1 ppm (0.04% of total dose) was in the liver from the goat treated with the pyridinyl label. All other tissues had total readioactive residue (TRR) of approximately 0.07 ppm or less (nicosulfuron equivalents). Radioactivity in the collected bile comprised 0.1% and 0.7% of the total dose, respectively for the pyridinyl- and pyrimidinyl labeled nicosulfuron.  ...', 'The ... /absorption and elimination/ of /nicosulfuron/ (2-(4,6-dimethoxy-2-pyrimidinyl) aminocarbonylaminosulfonyl-N,N-dimethyl-3-pyridinecarboxamide) was studied in male and female Sprague-Dawley Crl:CDBR rats. Pyridine-2-(14)C nicosulfuron was administered orally at 10 mg/kg or 1000 mg/kg, at 10 mg/kg following oral administration of unlabeled nicosulfuron at 10 mg/kg/day for 14 days, and intravenously at 10 mg/kg. Pyrimidine-2-(14)C labeled nicosulfuron was also administered orally at 1000 mg/kg. Total recovery of administered radioactivity 4 days postdosing accounted for 98-109% of the dose. Most of the radioactivity was excreted unchanged within 24 hours post dosing. With oral dosing, there were no apparent differences between sexes or dose groups, although a slightly greater percentage of the administered radioactivity was detected in feces of animals receiving the high dose than in animals receiving the low dose. Following oral dosing, elimination in the feces accounted for 80 to 95% of the dose, and elimination in the urine accounted for 9 to 20%. Elimination of (14)C-CO2 was negligible (<0.01 of the administered dose). ... Following intravenous administration, approximately 76 to 80% of the dose was eliminated in the urine and 27 to 30% in the feces. Residues in tissues accounted for 0.05 to 0.5% of the dose. The major excretion product in urine and feces was unchanged parent compound. In addition, pyridinesulfonamide (N,N-dimethyl-2-sulfonamide pyridine-3-carboxamide) was detected in the urine and accounted for 1.1 to 5.7% of the dose. Pyridine acid sulfonamide (2-sulfonamidepyridine-3-carboxylic acid) was tentatively identified as a minor metabolite in the feces of orally dosed rats and urine of intravenously dosed rats. ...']","['Two female goats weighing 43 kg (#1) and 34 kg (#2) (1.4 and 1.8 mg/kg bodyweight respectively), were dosed daily for 3 consecutive days in feed rations treated with (pyrimidine2-(14)C)nicosulfuron, sp. act., 62.2 uCi/mg, radiochemical purity, >95%, isotopic purity, 97%, and (pyridine-2-(14)C)nicosulfuron, sp. act., 62.9 uCi/mg, radiochemical purity, >95%, isotopic purity, >99%, respectively. Dosing capsules were prepared with the (14)C-labeled materials, 13C-enriched isomers (C2 position of each respective ring), and nonradioactive nicosulfuron. The capsules were analyzed prior to dosing by LSC for total (14)C-activity and by HPLC for chemical analysis. These capsules were imbedded in a larger gelatin capsule containing 6 g of goat chow. Goat #1 was housed for a 9-day acclimation period, while goat #2 was kept for 11 days.  Both goats showed good health and milk production before and during dosing. The dosage represents a daily feeding level of approximately 60 ppm based on the average feed and hay consumption of 1 kg/day. Samples of milk, bile, urine, and feces were collected daily and analyzed by combustion/liquid scintillation counting. A control goat was not used in the study. Milk, bile, urine, and feces were collected at least one day prior to dosing for use as control samples. ... The proposed metabolic pathway for nicosulfuron in the goat showed primarily three mechanisms: 1) hydrolysis of the sulfonylurea bridge to yield pyridine sulfonamide and pyrimidine amine (both of which undergo additional metabolism); 2) N-demethylation and subsequent loss of sulfur dioxide leading to the cyclized compound N2; and 3) oxidation and conjugation at the 5-position of the pyrimidine ring.', 'The metabolism of /nicosulfuron/ (2-(4,6-dimethoxy-2-pyrimidinyl) aminocarbonylaminosulfonyl-N,N-dimethyl-3-pyridinecarboxamide (Accent)) was studied in male and female Sprague-Dawley Crl:CDBR rats. Pyridine-2-(14)C Accent was administered orally at 10 mg/kg or 1000 mg/kg, at 10 mg/kg following oral administration of unlabeled Accent at 10 mg/kg/day for 14 days, and intravenously at 10 mg/kg. Pyrimidine-2-(14)C labeled Accent was also administered orally at 1000 mg/kg. ... Metabolites; / pyridinesulfonamide (N,N-dimethyl-2-sulfonamide pyridine-3-carboxamide) and Pyridine acid sulfonamide (2-sulfonamidepyridine-3-carboxylic acid)/ represent hydrolytic cleavage/oxidation of the parent molecule.']","['The ... /absorption and elimination/ of /nicosulfuron/ (2-(4,6-dimethoxy-2-pyrimidinyl) aminocarbonylaminosulfonyl-N,N-dimethyl-3-pyridinecarboxamide) was studied in male and female Sprague-Dawley Crl:CDBR rats. Pyridine-2-(14)C nicosulfuron was administered orally at 10 mg/kg or 1000 mg/kg, at 10 mg/kg following oral administration of unlabeled nicosulfuron at 10 mg/kg/day for 14 days, and intravenously at 10 mg/kg. Pyrimidine-2-(14)C labeled nicosulfuron was also administered orally at 1000 mg/kg. ... The average total cumulative excretion indicated half-lives between 12 and 24 hours.']"
3281,73282,Triasulfuron,CC1=NC(=NC(=N1)OC)NC(=O)NS(=O)(=O)C2=CC=CC=C2OCCCl,,,"['Pesticides used to destroy unwanted vegetation, especially various types of weeds, grasses (POACEAE), and woody plants. Some plants develop HERBICIDE RESISTANCE. (See all compounds classified as Herbicides.)']",,"['Cytochrome P450 monooxygenases play paramount roles in the detoxification of herbicides as well as in the synthesis of lignins, flavonoids, and phenolic acids. Biochemical analysis of triasulfuron metabolism in maize (Zea mays) seedlings has demonstrated that the P450(s) responsible for detoxification of this herbicide is induced by naphthalic anhydride (NA), a plant safener, and by triasulfuron, the herbicide itself. Induction studies conducted with seedlings of different ages suggest that two separate response pathways modulate this P-450 activity. Induction by NA is independent of the developmental age of the seedlings up to 6.5 d; induction by triasulfuron is tightly modulated with respect to developmental age in that triasulfuron metabolism can be induced by triasulfuron in young (2.5 d) but not older (6.5 d) seedlings. Induction by NA administered in combination with triasulfuron synergistically enhances triasulfuron metabolism in younger seedlings to levels substantially above that obtained with either herbicide or safener treatment alone. In older seedlings, NA plus triasulfuron treatment induces triasulfuron metabolism to only the level of NA treatment alone, indicating again that the induction cascade responding to triasulfuron is nonfunctional in later development. MnCl2 studies indicate that the triasulfuron insensitivity of older seedlings does not result from a general limitation in the inducibility of this P-450 detoxification system but rather from specific limitations in the triasulfuron-response pathway.']",
3282,73283,CID 73283,CC(C)N(C(=O)C(=O)[O-])O.[K+],,,,,,
3283,73284,N-Hydroxy-N-isopropyloxamic acid,CC(C)N(C(=O)C(=O)O)O,,,,,,
3284,73285,Isoalantolactone,C[C@]12CCCC(=C)[C@@H]1C[C@H]3[C@@H](C2)OC(=O)C3=C,,,,,,
3285,73286,Quetiapina fumarato,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O,,,"['Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. (See all compounds classified as Antidepressive Agents.)', 'Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)']",,,
3286,73287,CID 73287,CC=C[C@@H]1C=C[C@@H]2C[C@@H](CC[C@H]2[C@]1(C)C(=O)C3=C(N([C@H](C3=O)CO)C)O)C,,,,,,
3287,73288,"3-[3,4a,6-Trimethyl-2-(4-methylhexa-2,4-dien-2-yl)-2,5,6,7,8,8a-hexahydro-1H-naphthalene-1-carbonyl]-5-benzyl-5-hydroxy-1H-pyrrol-2-one",CC=C(C)C=C(C)C1C(C2CCC(CC2(C=C1C)C)C)C(=O)C3=CC(NC3=O)(CC4=CC=CC=C4)O,,,,,,
3288,73289,"3,5-Dihydroxy-4-[(3,4,5-trihydroxybenzoyl)oxy]benzoic acid",C1=C(C=C(C(=C1O)OC(=O)C2=CC(=C(C(=C2)O)O)O)O)C(=O)O,,,,,,
3289,73290,Kelletinin A,C1=CC(=CC=C1C(=O)OC[C@H](C([C@H](COC(=O)C2=CC=C(C=C2)O)OC(=O)C3=CC=C(C=C3)O)OC(=O)C4=CC=C(C=C4)O)OC(=O)C5=CC=C(C=C5)O)O,,,,,,
3290,73291,Kelletinin I,C1=CC(=CC=C1C(=O)OC[C@H]([C@H](COC(=O)C2=CC=C(C=C2)O)OC(=O)C3=CC=C(C=C3)O)OC(=O)C4=CC=C(C=C4)O)O,,,,,,
3291,73292,Fascaplysine,C1=CC=C2C(=C1)C3=C(N2)C4=[N+](C=C3)C5=CC=CC=C5C4=O.[Cl-],,,,,,
3292,73293,Fascaplysin,C1=CC=C2C(=C1)C3=C(N2)C4=[N+](C=C3)C5=CC=CC=C5C4=O,,,,,,
3293,73294,"(5R,10S,13R,14R,17R)-17-[(2R,5S)-5,6-dihydroxy-6-methylheptan-2-yl]-4,4,10,13,14-pentamethyl-1,2,5,6,12,15,16,17-octahydrocyclopenta[a]phenanthren-3-one",C[C@H](CC[C@@H](C(C)(C)O)O)[C@H]1CC[C@@]2([C@@]1(CC=C3C2=CC[C@@H]4[C@@]3(CCC(=O)C4(C)C)C)C)C,,,,,,
3294,73295,Phthalocyanine nickel(II) salt,C1=CC=C2C(=C1)C3=NC4=C5C=CC=CC5=C([N-]4)N=C6C7=CC=CC=C7C(=N6)N=C8C9=CC=CC=C9C(=N8)N=C2[N-]3.[Ni+2],,,,,,
3295,73296,alpha-Hederin,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@H](CO[C@H]2O[C@H]3CC[C@]4([C@H]([C@]3(C)CO)CC[C@@]5([C@@H]4CC=C6[C@]5(CC[C@@]7([C@H]6CC(CC7)(C)C)C(=O)O)C)C)C)O)O)O)O)O,,,,,,
3296,73297,"Olean-12-en-28-oic acid, 3-[[2-O-(6-deoxy-alpha-L-mannopyranosyl)-alpha-L-arabinopyranosyl]oxy]-23-hydroxy-, O-6-deoxy-alpha-L-mannopyranosyl-(1.fwdarw.4)-O-beta-D-glucopyranosyl-(1.fwdarw.6)-beta-D-glucopyranosyl ester, (3beta,4alpha)-",C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](OC([C@@H]([C@H]2O)O)OC[C@@H]3[C@H]([C@@H]([C@H]([C@@H](O3)OC(=O)[C@@]45CC[C@@]6(C(=CC[C@H]7[C@]6(CC[C@@H]8[C@@]7(CC[C@@H]([C@@]8(C)CO)O[C@H]9C([C@H]([C@H](CO9)O)O)O[C@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)C)O)O)O)C)C)[C@@H]4CC(CC5)(C)C)C)O)O)O)CO)O)O)O,,,,,,
3297,73298,CID 73298,COC1=CC(=CC(=C1O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)OC)C=CCO,,,,,,
3298,73299,Hederagenin,C[C@]12CC[C@@H]([C@@]([C@@H]1CC[C@@]3([C@@H]2CC=C4[C@]3(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)C)C)(C)CO)O,,,,,,
3299,73300,"2-[(4S,5S,6S,8S,9S,10R,13R,14S,16S)-6,16-diacetyloxy-4,8,10,14-tetramethyl-3,7-dioxo-5,6,9,11,12,13,15,16-octahydro-4H-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoic acid",C[C@H]1[C@@H]2[C@@H](C(=O)[C@]3([C@H]([C@]2(C=CC1=O)C)CC[C@@H]4[C@@]3(C[C@@H](C4=C(CCC=C(C)C)C(=O)O)OC(=O)C)C)C)OC(=O)C,,,,,,
3300,73301,CID 73301,CN(C)CC(=O)NC1=CC(=C2C[C@H]3C[C@H]4[C@@H](C(=O)C(=C(N)O)C(=O)[C@]4(C(=O)C3=C(C2=C1O)O)O)N(C)C)N(C)C,,,,,,
3301,73302,Tacapenem,C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@@H]3CC(=O)NC3)C(=O)O)[C@@H](C)O,,,,,,
3302,73303,Doripenem,C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)CNS(=O)(=O)N)C(=O)O)[C@@H](C)O,"['Doripenem is indicated in the treatment of complicated intra-abdominal infections and complicated urinary tract infections, including pyelonephritis, caused by designated susceptible bacteria.']","['Similar to other beta-lactam antimicrobial agents, the time that unbound plasma concentration of doripenem exceeds the MIC (T>MIC) of the infecting organism has been shown to best correlate with efficacy in animal models of infection.']",['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],"['Doripenem is administered intravenously as an infusion. There was no accumulation of doripenem following mulitiple infusions of either 500mg or 1g administered every 8 hours for 7-10 days in subjects with normal renal function.', 'Doripenem is primarily eliminated unchanged by the kidneys and undergoes glomerular filtration and active tubular secretion. A mean of 71% and 15% of the dose was recovered in urine as unchanged drug and the ring-opened metabolite, respectively, within 48 hours of 500 mg dose in healthy adults. Following the administration of a single 500 mg dose of radiolabeled doripenem to healthy adults, less than 1% of the total radioactivity was recovered in feces after one week.', 'The average Vd is 16.8 L (8.09-55.5 L) at steady-state in healthy subjects. Doripenem penetrates into many tissues and fluids, including potential sites of approved indication infections.', '10.3 L/hour.']","['Metabolism of doripenem is via dehydropeptidase-I (also called dipeptidase-1) into a microbiologically inactive ring-opened metabolite, doripenem-M1. Doripenem does not appear to be a substrate of the hepatic CYP450 enzymes.']","['1 hour, in healthy non-elderly adults.']"
3303,73304,"(1S,2R)-2-aminocyclopentane-1-carboxylic acid;(1R,2S)-2-aminocyclopentane-1-carboxylic acid",C1C[C@H]([C@H](C1)N)C(=O)O.C1C[C@@H]([C@@H](C1)N)C(=O)O,,,,,,
3304,73305,"(1r,2s)-2-Aminocyclopentanecarboxylic acid",C1C[C@H]([C@H](C1)N)C(=O)O,,,,,,
3305,73306,"(1S,2R)-2-aminocyclopentanecarboxylic acid",C1C[C@@H]([C@@H](C1)N)C(=O)O,,,,,,
3306,73307,Jacaranone,COC(=O)CC1(C=CC(=O)C=C1)O,,,,,,
3307,73308,CID 73308,COC1=C(C2=C(C=C1)[C@@H]3C[C@H](C[C@H]4C3CCCC4)OC(=O)C=CC5=CC2=C(C=C5)O)OC,,,,,,
3308,73309,Echinocystic acid,C[C@]12CC[C@@H](C([C@@H]1CC[C@@]3([C@@H]2CC=C4[C@]3(C[C@H]([C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)O)C)C)(C)C)O,,,,,,
3309,73310,CID 73310,C1=C2C(=C(N=C1N)S)N=CN2,,,,,,
3310,73311,CID 73311,C1=C(C(=O)NC(=O)N1[C@H]2C(C([C@H](O2)[C@@H](C(=O)O)NC(=O)[C@H]([C@@H]([C@H](COC(=O)N)O)O)N)O)O)CO,,,,,,
3311,73312,"2-[18,21-Bis(2-aminoethyl)-12-benzyl-3-(2-chloro-1-hydroxyethyl)-15-[3-(diaminomethylideneamino)propyl]-24-(hydroxymethyl)-27-(3-hydroxyundecanoylamino)-2,5,8,11,14,17,20,23,26-nonaoxo-9-propylidene-1-oxa-4,7,10,13,16,19,22,25-octazacyclooctacos-6-yl]-2-hydroxyacetic acid",CCCCCCCCC(CC(=O)NC1COC(=O)C(NC(=O)C(NC(=O)C(=CCC)NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CO)CCN)CCN)CCCN=C(N)N)CC2=CC=CC=C2)C(C(=O)O)O)C(CCl)O)O,,,,,,
3312,73313,"3,4,5-Trihydroxybenzamidoxime",C1=C(C=C(C(=C1O)O)O)C(=NO)N,,,"['Substances that eliminate free radicals. Among other effects, they protect PANCREATIC ISLETS against damage by CYTOKINES and prevent myocardial and pulmonary REPERFUSION INJURY. (See all compounds classified as Free Radical Scavengers.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)']",,,
3313,73314,5-(N-Methyl-N-isobutyl)amiloride,CC(C)CN(C)C1=NC(=C(N=C1Cl)C(=O)N=C(N)N)N,,,,,,
3314,73315,CID 73315,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC2=C(OC3=CC(=O)C=C(C3=C2O)O)C4=CC=C(C=C4)O)O)O)O,,,,,,
3315,73316,"3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-6-methoxy-5-methyl-1,6-dihydropyrimidin-2-one",CC1=CN(C(=O)NC1OC)[C@H]2C[C@@H]([C@H](O2)CO)O,,,,,,
3316,73317,O(6)-Methyl-2'-deoxyguanosine,COC1=NC(=NC2=C1N=CN2[C@H]3C[C@@H]([C@H](O3)CO)O)N,,,,,,
3317,73318,CID 73318,C1[C@@H]([C@H](O[C@H]1N2C3=C(C(=O)N=C(N3)N)NC2=O)CO)O,,,,,,
3318,73319,"5-amino-3-[(2R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]imidazo[4,5-d][1,3]oxazin-7-one",C1=NC2=C(N1[C@H]3C(C([C@H](O3)CO)O)O)N=C(OC2=O)N,,,,,,
3319,73320,Wilforine,C[C@H]1CCC2=C(C=CC=N2)C(=O)OC[C@]3([C@@H]4[C@H]([C@H]([C@@]5([C@H]([C@H]([C@@H](C([C@]5([C@@H]4OC(=O)C)O3)(C)O)OC1=O)OC(=O)C6=CC=CC=C6)OC(=O)C)COC(=O)C)OC(=O)C)OC(=O)C)C,,,,,,
3320,73321,CID 73321,CC(=O)OC[C@]12[C@@H]([C@@H]([C@@H]3[C@H]([C@]14C([C@H]([C@@H]([C@@H]2OC(=O)C)OC(=O)C5=COC=C5)OC(=O)C(CCC6=C(C=CC=N6)C(=O)OC[C@@]3(O4)C)(C)O)(C)O)OC(=O)C)OC(=O)C)OC(=O)C,,,,,,
3321,73322,CID 73322,C1=NC2=C(N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)[O-])O)O)NC(=O)NC2=O.[Na+],,,,,,
3322,73323,Xanthosine-5'-monophosphate,C1=NC2=C(N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O)NC(=O)NC2=O,,,,,,
3323,73324,"2,6-Dimethylphenylphthalimide",CC1=C(C(=CC=C1)C)N2C(=O)C3=CC=CC=C3C2=O,,,,,,
3324,73325,"1,4-Phthalazinediol",C1=CC2C(C=C1)C(=O)N=NC2=O,,,,,,
3325,73326,1-(2-Benzimidazolyl)-3-methylurea,CNC(=O)NC1=NC2=CC=CC=C2N1,,,,,,
3326,73327,N-(2-Hydroxyethyl)isonicotinamide,C1=CN=CC=C1C(=O)NCCO,,,,,,
3327,73328,CID 73328,C(CN=C(S)[S-])CN=C(S)[S-].[Na+].[Na+],,,,,,
3328,73329,CID 73329,C(CN=C(S)S)CN=C(S)S,,,,,,
3329,73330,Strictinin,C1[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC(=O)C3=CC(=C(C(=C3)O)O)O)O)O)OC(=O)C4=CC(=C(C(=C4C5=C(C(=C(C=C5C(=O)O1)O)O)O)O)O)O,,,,,,
3330,73331,Promethazine tetraiodomercurate,[H+].[H+].CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C.I[Hg-2](I)(I)I,,,,,,
3331,73332,1-(5-Isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride,CC1CNCCN1S(=O)(=O)C2=CC=CC3=C2C=CN=C3.Cl.Cl,,,,,,
3332,73333,Amperozide,CCNC(=O)N1CCN(CC1)CCCC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F,,,"['Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)', 'Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or SEROTONIN RECEPTOR AGONISTS. (See all compounds classified as Serotonin Antagonists.)', 'A loosely defined grouping of drugs that have effects on psychological function. Here the psychotropic agents include the antidepressive agents, hallucinogens, and tranquilizing agents (including the antipsychotics and anti-anxiety agents). (See all compounds classified as Psychotropic Drugs.)']",,,
3333,73334,Amperozide hydrochloride,CCNC(=O)N1CCN(CC1)CCCC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F.Cl,,,"['Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)', 'A loosely defined grouping of drugs that have effects on psychological function. Here the psychotropic agents include the antidepressive agents, hallucinogens, and tranquilizing agents (including the antipsychotics and anti-anxiety agents). (See all compounds classified as Psychotropic Drugs.)', 'Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or SEROTONIN RECEPTOR AGONISTS. (See all compounds classified as Serotonin Antagonists.)']",,,
3334,73335,5-Chloro-m-phenylenediamine,C1=C(C=C(C=C1N)Cl)N,,,,,,
3335,73336,Phenolphthalexon,C1=CC=C2C(=C1)C(=O)OC2(C3=CC(=C(C=C3)O)CN(CC(=O)O)CC(=O)O)C4=CC(=C(C=C4)O)CN(CC(=O)O)CC(=O)O,,,,,,
3336,73337,Magnoflorine,C[N+]1(CCC2=CC(=C(C3=C2[C@@H]1CC4=C3C(=C(C=C4)OC)O)O)OC)C,,,,,,
3337,73338,"2,7-Naphthalenedisulfonic acid, 4-(acetylamino)-5-hydroxy-, disodium salt",CC(=O)NC1=C2C(=CC(=C1)S(=O)(=O)[O-])C=C(C=C2O)S(=O)(=O)[O-].[Na+].[Na+],,,,,,
3338,73339,"2',3'-Dideoxy-3'-thiacytidine",C1[C@@H](O[C@@H](S1)CO)N2C=CC(=NC2=O)N,,,"['Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. (See all compounds classified as Anti-HIV Agents.)', 'Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. (See all compounds classified as Reverse Transcriptase Inhibitors.)']",,,
3339,73340,"N,N-Diethyl-N'-(6-methoxy-4-methyl-8-quinolyl)hexane-1,6-diamine dihydrochloride",CCN(CC)CCCCCCNC1=CC(=CC2=C(C=CN=C12)C)OC.Cl.Cl,,,,,,
3340,73341,Amprolio,CCCC1=NC=C(C(=N1)N)C[N+]2=CC=CC=C2C.[Cl-],,,['Agents useful in the treatment or prevention of COCCIDIOSIS in man or animals. (See all compounds classified as Coccidiostats.)'],,,
3341,73342,N-methyl-N-(1-naphthalenylmethyl)-3-phenyl-2-propen-1-amine,CN(CC=CC1=CC=CC=C1)CC2=CC=CC3=CC=CC=C32,"['For the topical treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organisms <i>Trichophyton rubrum</i>, <i>Trichophyton mentagrophytes</i>, <i>Trichophyton tonsurans</i> and <i>Epidermophyton floccosum</i>.']","['Naftifine is a synthetic, broad spectrum, antifungal agent and allylamine derivative. The following in vitro data are available, but their clinical significance is unknown. Naftifine has been shown to exhibit fungicidal activity in vitro against a broad spectrum of organisms including <i>Trichophyton rubrum</i>, <i>Trichophyton mentagrophytes</i>, <i>Trichophyton tonsurans</i>, <i>Epidermophyton floccosum</i>, and <i>Microsporum canis</i>, <i>Microsporum audouini</i>, and <i>Microsporum gypseum</i>; and fungistatic activity against <i>Candida</i> species including <i>Candida albicans</i>. However it is only used to treat the organisms listed in the indications.']",,"['Following single topical applications of 3H-labeled naftifine gel 1% to the skin of healthy subjects, up to 4.2% of the applied dose was absorbed.', 'Naftifine and/or its metabolites are excreted via the urine and feces with a half-life of approximately two to three days.']",,['Approximately 2 to 3 days following topical administration.']
3342,73343,Ammonium pyrrolidyldithiocarbamate,C1CCN(C1)C(=S)S.N,,,['Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. (See all compounds classified as Antioxidants.)'],,,
3343,73344,CID 73344,C1(=NC(=O)NC(=O)N1)C(=O)[O-].[K+],,,,,,
3344,73345,beta-Kainic acid,CC(=C)[C@H]1CN[C@H]([C@H]1CC(=O)O)C(=O)O,,,,,,
3345,73346,Befuraline hydrochloride,C1CN(CCN1CC2=CC=CC=C2)C(=O)C3=CC4=CC=CC=C4O3.Cl,,,,,,
3346,73347,CID 73347,CC1=CC=C(C=C1)S(=O)(=O)NC2=CC(=C(C3=C2C(=O)C4=CC=CC=C4C3=O)N)S(=O)(=O)[O-].[Na+],,,,,,
3347,73348,CID 73348,C1=CC(=O)C=CC1=NC2=CC=C(C=C2)[O-].[Na+],,,,,,
3348,73349,Losoxantrone hydrochloride,C1=CC2=C(C(=C1)O)C(=O)C3=C(C=CC4=C3C2=NN4CCNCCO)NCCNCCO.Cl.Cl,,,['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)'],,,
3349,73350,"1,10-Phenanthroline hydrochloride",C1=CC2=C(C3=C(C=CC=N3)C=C2)N=C1.Cl,,,,,,
3350,73351,Pamidronate disodium,C(CN)C(O)(P(=O)(O)[O-])P(=O)(O)[O-].[Na+].[Na+],,,['Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS. (See all compounds classified as Bone Density Conservation Agents.)'],,,
3351,73352,Peptide T,C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C)N)O,,,,,,
3352,73353,CID 73353,CC[C@H](C)C(=O)O[C@@H](C)[C@@]1([C@@H](O[C@H](C[C@H]1OC)O[C@H]2[C@H]([C@@H](O[C@@H]([C@H]2OC(=O)C(=CC)N=C=S)COC(=O)C)[C@]3(CC(=O)C(=C(C3=O)C(=O)O)N)O)O)C)O,,,,,,
3353,73354,(2-Ethoxy-3-hexadecylsulfanylpropyl) 2-(trimethylazaniumyl)ethyl phosphate,CCCCCCCCCCCCCCCCSCC(COP(=O)([O-])OCC[N+](C)(C)C)OCC,,,,,,
3354,73355,2-[(2-Ethoxy-3-hexadecylsulfanylpropoxy)-hydroxyphosphoryl]oxyethyl-trimethylazanium,CCCCCCCCCCCCCCCCSCC(COP(=O)(O)OCC[N+](C)(C)C)OCC,,,,,,
3355,73356,Eprazinone dihydrochloride,CCOC(CN1CCN(CC1)CC(C)C(=O)C2=CC=CC=C2)C3=CC=CC=C3.Cl.Cl,,,"['Agents that increase mucous excretion. Mucolytic agents, that is drugs that liquefy mucous secretions, are also included here. (See all compounds classified as Expectorants.)']",,,
3356,73357,Gramicidin S,CC(C)C[C@H]1C(=O)N[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N3CCC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCN)C(C)C)CC4=CC=CC=C4)CC(C)C)CCCN)C(C)C)CC5=CC=CC=C5,,,"['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)', 'Substances used on humans and other animals that destroy harmful microorganisms or inhibit their activity. They are distinguished from DISINFECTANTS, which are used on inanimate objects. (See all compounds classified as Anti-Infective Agents, Local.)']",,,
3357,73358,"[(1R,2S,3R,5R,6S,8R)-6-hydroxy-8-methyl-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9,10-dioxatetracyclo[4.3.1.02,5.03,8]decan-2-yl]methyl benzoate",C[C@@]12C[C@]3([C@@H]4C[C@]1([C@@]4([C@H](O2)O3)COC(=O)C5=CC=CC=C5)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)O,,,,,,
3358,73359,Alborixin,CC[C@H]1[C@](CC[C@@H](O1)[C@@]2(C[C@H]([C@@](O2)([C@@]3(CC[C@H](O3)[C@H]([C@]4([C@@H](C[C@@H]([C@H](O4)C[C@@]5([C@H](CC[C@@H](O5)[C@@H](C)[C@@H](C[C@H]6[C@@H](C[C@@H]([C@H](O6)[C@@H](C)C(=O)O)C)C)O)C)O)C)C)O)O)C)O)C)C)(C)O,,,,,,
3359,73360,Pretazettine,CN1C[C@H]2[C@]3([C@@H]1C[C@@H](C=C3)OC)C4=CC5=C(C=C4[C@@H](O2)O)OCO5,,,,,,
3360,73361,Halistanol sulfate,C[C@H](CC[C@H](C)C(C)(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C[C@@H]([C@@H]4[C@@]3(C[C@@H]([C@H](C4)OS(=O)(=O)O)OS(=O)(=O)O)C)OS(=O)(=O)O)C,,,,,,
3361,73362,Triterpenoid saponin tub,C[C@H]1[C@H]2[C@H]([C@H]([C@@H](O1)O[C@@H]3[C@H]([C@@H](CO[C@H]3OC(=O)[C@@]45CC[C@@]6(C(=CC[C@]7([C@]6(CC[C@H]8[C@@]7(C[C@@H]([C@@H]([C@@]8(C)CO)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)C(=O)C[C@](CC(=O)O2)(C)O)O)O)O)O)C)C)C)[C@@]4(CC(CC5)(C)C)C)C)O)O)O)O[C@H]1[C@@H]([C@H]([C@@H](CO1)O)O)O,,,,,,
3362,73363,"3-hydroxy-N-[6-hydroxy-9-[8-hydroxy-1-(methoxymethyl)-5,7-dimethyl-3,6-dioxo-2-oxa-5-azaspiro[3.4]octan-8-yl]-9-methoxy-7-methylnona-2,4-dienyl]-2,2,4-trimethyl-10-(2-methyl-1,3-oxazol-5-yl)deca-4,6,8-trienamide",CC1C(=O)N(C2(C1(C(CC(C)C(C=CC=CCNC(=O)C(C)(C)C(C(=CC=CC=CCC3=CN=C(O3)C)C)O)O)OC)O)C(OC2=O)COC)C,,,,,,
3363,73364,Calpeptin,CCCC[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1,,,['Exogenous and endogenous compounds which inhibit CYSTEINE ENDOPEPTIDASES. (See all compounds classified as Cysteine Proteinase Inhibitors.)'],,,
3364,73365,CID 73365,C[C@H]1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)O[C@@](C4=O)(OC=C[C@@H]([C@H]([C@H]([C@H]([C@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C(=C2N5CCN(CC5)CC6=C(C=C(C=C6C)C)C)O)O)C,,,,,,
3365,73366,"1-Cyclopropyl-7-[3-(ethylaminomethyl)pyrrolidin-1-yl]-6,8-difluoro-4-oxoquinoline-3-carboxylic acid",CCNCC1CCN(C1)C2=C(C=C3C(=C2F)N(C=C(C3=O)C(=O)O)C4CC4)F,,,,,,
3366,73367,Dihydromycoplanecin A,CCC1C[C@H](N(C1)C(=O)[C@H](C(C)C)N(C)C(=O)C(CC)O)C(=O)N(C)[C@H]2[C@H](OC(=O)CNC(=O)[C@H](N(C(=O)[C@@H]3CCCN3C(=O)[C@@H](N(C(=O)[C@@H](NC(=O)[C@@H]4CC(CN4C(=O)[C@@H](NC2=O)CC(C)C)C)CCC(C)C)C)C(C)C)C)CC(C)C)C,,,,,,
3367,73368,"(3S)-3-[(2R,3S,5R)-5-[(2R)-3-[(1S,3R,5S,7R,9S,11R,14R,16S,17S,18R,20S,21S,25R,27S,29R,31S,34S,35S,37R,39S,41R)-17,34-dihydroxy-11-[(4R)-5-hydroxy-2,4-dimethylpent-2-enyl]-9,18,21,27,29-pentamethyl-12-methylidene-2,6,10,15,19,26,30,36,40-nonaoxanonacyclo[23.18.0.03,20.05,18.07,16.09,14.027,41.029,39.031,37]tritetracont-22-en-35-yl]-2-hydroxypropyl]-3-methyloxolan-2-yl]butanoic acid",C[C@H]1C[C@@H](O[C@H]1[C@@H](C)CC(=O)O)C[C@H](C[C@H]2[C@H](CC[C@H]3[C@H](O2)C[C@H]4[C@](O3)(C[C@]5([C@H](O4)CC[C@H]6[C@H](O5)CC=C[C@@H]([C@H]7[C@H](O6)C[C@H]8[C@](O7)([C@H]([C@H]9[C@H](O8)C[C@]1([C@H](O9)CC(=C)[C@H](O1)CC(=C[C@@H](C)CO)C)C)O)C)C)C)C)O)O,,,,,,
3368,73369,CID 73369,CCC(C)C=C(C)C=CC=C(C)CC(C)CC(C)CC(CO)C=C(C)C=CC(C(C)(C)C1=CC(=O)C(=C(O1)O)[C@H]2[C@@H]([C@H](C[C@H](O2)CO)O)O)O,,,,,,
3369,73370,CID 73370,C[C@@H]1C=CC=C(C(=O)NC2=C(C(=C3C(=C(C(=C4C3=C(C(=C[C@@H]([C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H](C1O)C)O)C(=O)OC)O)C)O)C)C)OCO4)C)O)C2=O)OC(=O)C)C)C,,,,,,
3370,73371,CID 73371,C[C@H]1CC([C@H]([C@@H](C=C(C([C@H](C=CC=C(C(=O)NC2=CC(=O)C=C([C@@H]1OC)C2=O)C)C)OC(=O)N)C)C)OC)OC,,,,,,
3371,73372,Rhodanile blue,CCN(CC)C1=CC2=C(C=C1)C(=C3C=CC(=[N+](CC)CC)C=C3O2)C4=CC=CC=C4C(=O)N=C5C=C6C(=NC7=C(O6)C=C(C=C7)N(CC)CC)C8=CC=CC=C85.[Cl-],,,,,,
3372,73373,"3,6-Bis(diethylamino)-9-[2-[[[9-(diethylamino)-5H-benzo[a]phenoxazin-5-ylidene]amino]carbonyl]phenyl]xanthylium",CCN(CC)C1=CC2=C(C=C1)N=C3C4=CC=CC=C4C(=NC(=O)C5=CC=CC=C5C6=C7C=CC(=CC7=[O+]C8=C6C=CC(=C8)N(CC)CC)N(CC)CC)C=C3O2,,,,,,
3373,73374,CID 73374,C1=CC(=CC=C1C(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)O)C(=O)O)C(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)N=C(N3)N,,,,,,
3374,73375,"Dodecahydro-1,4,7-tris(phenylcarbamoyl)-1,4,7,9b-tetraazaphenalene",C1CN(C2CCN(C3N2C1N(CC3)C(=O)NC4=CC=CC=C4)C(=O)NC5=CC=CC=C5)C(=O)NC6=CC=CC=C6,,,,,,
3375,73376,(((Diethylamino)thioxomethyl)thio)acetic acid,CCN(CC)C(=S)SCC(=O)O,,,,,,
3376,73377,"1-Piperazinecarbodithioic acid, 2-methyl-",CC1CNCCN1C(=S)S,,,,,,
3377,73378,"trans-2,5-Dimethyl-1-piperazine-carbodithioic acid",C[C@@H]1CN[C@H](CN1C(=S)S)C,,,,,,
3378,73379,CID 73379,CC1C(C(C(OC1O)C(C)C(C(C)C=CC=C(C)C(=O)NC2=C(C(=C3C(=C(C(=C4C3=C(OCO4)C(=CC(=O)C)C)C)O)C2=O)OC(=O)C)C)O)C(=O)OC)O,,,,,,
3379,73380,CID 73380,CC(=C1C=CC=CN1[O-])N=NC(=S)N2CC3CCC(C2)CC3.[Cl-].[Cu+2],,,,,,
3380,73381,CID 73381,CC(=C1C=CC=CN1[O-])N=NC(=S)N2CC3CCC(C2)CC3,,,,,,
3381,73382,"Platinum(3+), hexaamminetri-mu-hydroxytri-, cyclo, trinitrate",N.N.N.N.N.N.[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[OH-].[OH-].[OH-].[Pt+2].[Pt+2].[Pt+2],,,,,,
3382,73383,Adigal,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]4[C@@H]3CC[C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)C)O)O[C@H]7C[C@@H]([C@@H]([C@H](O7)C)O[C@H]8C[C@@H]([C@@H](C(O8)C)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O)OC(=O)C)O,,,,,,
3383,73384,Brazilin,C1C2=CC(=C(C=C2[C@H]3[C@@]1(COC4=C3C=CC(=C4)O)O)O)O,,,,,,
3384,73385,CID 73385,C[C@@H]([C@H]([C@H]1[C@@H]([C@H]([C@@H]([C@@H](O1)SCCOC(=O)C2=CC=CC=C2O)O)O)O)NC(=O)[C@@H]3CCCN3C)OC,,,,,,
3385,73386,Petunidin chloride,COC1=CC(=CC(=C1O)O)C2=[O+]C3=CC(=CC(=C3C=C2O)O)O.[Cl-],,,,,,
3386,73387,"2-(3,4-Dihydroxy-5-methoxyphenyl)-3,5-dihydroxychromen-7-one",COC1=CC(=CC(=C1O)O)C2=C(C=C3C(=CC(=O)C=C3O2)O)O,,,,,,
3387,73388,Atisinium chloride,C[C@@]12CCC[C@@]3([C@@H]1CC[C@]45[C@H]3CC(CC4)C(=C)[C@H]5O)C=[N+](C2)CCO.[Cl-],,,,,,
3388,73389,"(1S,2S,6R,7S,10R,11R)-13-(2-hydroxyethyl)-11-methyl-5-methylidene-13-azoniapentacyclo[9.3.3.24,7.01,10.02,7]nonadec-13-en-6-ol",C[C@@]12CCC[C@@]3([C@@H]1CC[C@]45[C@H]3CC(CC4)C(=C)[C@H]5O)C=[N+](C2)CCO,,,,,,
3389,73390,Serpentine hydrochloride,C[C@H]1[C@H]2C[N+]3=C(C[C@@H]2C(=CO1)C(=O)OC)C4=C(C=C3)C5=CC=CC=C5N4.[Cl-],,,,,,
3390,73391,Serpentine,C[C@H]1[C@H]2C[N+]3=C(C[C@@H]2C(=CO1)C(=O)OC)C4=C(C=C3)C5=CC=CC=C5N4,,,,,,
3391,73392,"(3S,3aR,4R,4aS,8aR,9aS)-4-[2-[(2R,6S)-1,6-dimethylpiperidin-2-yl]ethenyl]-3-methyl-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-3H-benzo[f][2]benzofuran-1-one",C[C@H]1CCC[C@@H](N1C)C=C[C@@H]2[C@H]3CCCC[C@@H]3C[C@H]4[C@@H]2[C@@H](OC4=O)C,,,,,,
3392,73393,Strychnine N-oxide,C1C[N+]2(CC3=CCO[C@H]4CC(=O)N5[C@H]6[C@H]4[C@H]3C[C@H]2[C@@]61C7=CC=CC=C75)[O-],,,,,,
3393,73394,"1,2-Propanediol, 3-(9-octadecenyloxy)-",CCCCCCCCC=CCCCCCCCCOCC(CO)O,,,,,,
3394,73395,"(2S)-7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-2,3-dihydrochromen-4-one",C[C@H]1[C@@H]([C@H]([C@H](C(O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=CC(=C4C(=O)C[C@H](OC4=C3)C5=CC(=C(C=C5)OC)O)O)CO)O)O)O)O)O,,,,,,
3395,73396,Acetoxycycloheximide,C[C@H]1C[C@@](C[C@H](C1=O)[C@@H](CC2CC(=O)NC(=O)C2)O)(C)OC(=O)C,,,,,,
3396,73397,(S)-Laudanosine,CN1CCC2=CC(=C(C=C2[C@@H]1CC3=CC(=C(C=C3)OC)OC)OC)OC,,,"['A class of drugs producing both physiological and psychological effects through a variety of mechanisms. They can be divided into &quot;specific&quot; agents, e.g., affecting an identifiable molecular mechanism unique to target cells bearing receptors for that agent, and &quot;nonspecific&quot; agents, those producing effects on different target cells and acting by diverse molecular mechanisms. Those with nonspecific mechanisms are generally further classed according to whether they produce behavioral depression or stimulation. Those with specific mechanisms are classed by locus of action or specific therapeutic use. (From Gilman AG, et al., Goodman and Gilman&apos;s The Pharmacological Basis of Therapeutics, 8th ed, p252) (See all compounds classified as Central Nervous System Agents.)']",,,
3397,73398,18alpha-Glycyrrhetinic acid,C[C@]12CC[C@](C[C@@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)O)C)(C)C(=O)O,,,,,,
3398,73399,Pinoresinol,COC1=C(C=CC(=C1)[C@@H]2[C@H]3CO[C@@H]([C@H]3CO2)C4=CC(=C(C=C4)O)OC)O,,,,,,
3399,73400,Dauricine,CN1CCC2=CC(=C(C=C2[C@H]1CC3=CC=C(C=C3)OC4=C(C=CC(=C4)C[C@@H]5C6=CC(=C(C=C6CCN5C)OC)OC)O)OC)OC,,,"['Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)', 'Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)', 'Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)']",,,
3400,73401,Marrubiin,C[C@@H]1C[C@@H]2[C@H]3[C@](CCC[C@@]3([C@]1(CCC4=COC=C4)O)C)(C(=O)O2)C,,,,,,
3401,73402,Eburicoic acid,CC(C)C(=C)CC[C@H]([C@H]1CC[C@@]2([C@@]1(CCC3=C2CC[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O)C)C)C)C(=O)O,,,,,,
3402,73403,"(2S,3R,4S,5S,6R)-2-[3-hydroxy-5-[2-(3-hydroxy-4-methoxyphenyl)ethenyl]phenoxy]-6-(hydroxymethyl)oxane-3,4,5-triol",COC1=C(C=C(C=C1)C=CC2=CC(=CC(=C2)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O)O,,,,,,
3403,73404,Hydroxylupanine,C1C[C@@H]2[C@H]3C[C@@H](CN2C(=O)C1)[C@@H]4C[C@H](CCN4C3)O,,,,,,
3404,73405,CID 73405,CC=C1CN2[C@H]3C[C@@H]1[C@@H]4[C@@H]2C[C@@]5([C@H]3N(C6=CC=CC=C65)C)[C@@H]4O,,,,,,
3405,73406,"Methyl (3beta,19alpha,20alpha)-16,17-didehydro-10,11-dimethoxy-19-methyloxayohimban-16-carboxylate, oxalate",C[C@H]1[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2C(=CO1)C(=O)OC)NC5=CC(=C(C=C45)OC)OC.C(=O)(C(=O)O)O,,,,,,
3406,73407,CID 73407,CC=C1C[C@H]([C@@](C(=O)OC[C@H]2CCN3[C@H]2[C@@H](CC3)OC1=O)(C)O)C.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,,,,,,
3407,73408,CID 73408,C/C=C/1\C[C@H]([C@@](C(=O)OCC2CCN3[C@H]2[C@@H](CC3)OC1=O)(C)O)C,,,,,,
3408,73409,Elephantoin,CC(=C)C(=O)O[C@H]1CC2=C[C@@H](C[C@@]3([C@@H](O3)[C@@H]4[C@@H]1C(=C)C(=O)O4)C)OC2=O,,,,,,
3409,73410,Tomatine solaradixine,C[C@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)C[C@@H]4[C@@]3(CC[C@H]5[C@H]4CC=C6[C@@]5(CC[C@@H](C6)O[C@H]7[C@@H]([C@H]([C@H]([C@H](O7)CO)O)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)O[C@H]9[C@@H]([C@@H]([C@H]([C@@H](O9)C)O)O)O)C)C)C)NC1,,,,,,
3410,73411,Flexuosin B,C[C@@H]1C[C@@H]2[C@@H]([C@@H](C(=O)O2)C)[C@@H]([C@]3([C@H]1[C@H](CC3=O)O)C)OC(=O)C=C(C)C,,,,,,
3411,73412,Madecassic acid,C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(C[C@H]([C@@H]5[C@@]4(C[C@H]([C@@H]([C@@]5(C)CO)O)O)C)O)C)[C@@H]2[C@H]1C)C)C(=O)O,,,,,,
3412,73413,Fulvine,C[C@@H]1C(=O)OCC2=CCN3[C@H]2[C@@H](CC3)OC(=O)[C@H]([C@@]1(C)O)C,,,,,,
3413,73414,Spectabiline,C[C@H]1C(=O)O[C@@H]2CCN3[C@@H]2C(=CC3)COC(=O)[C@]([C@]1(C)OC(=O)C)(C)O,,,,,,
3414,73415,N-Methylocoteamine,CN1CCC2=CC(=C(C3=C2[C@@H]1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)C[C@@H]6C7=CC(=C(C=C7CCN6C)OC)OC3)O)O)OC,,,,,,
3415,73416,Evoxine,CC(C)(C(COC1=C(C2=C(C=C1)C(=C3C=COC3=N2)OC)OC)O)O,,,,,,
3416,73417,"[(6R)-6-[(2S,8S,9R,10R,13R,14S,16R,17R)-2,16-dihydroxy-9-(hydroxymethyl)-4,4,13,14-tetramethyl-3,11-dioxo-2,7,8,10,12,15,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-hydroxy-2-methyl-5-oxohept-3-en-2-yl] acetate",CC(=O)OC(C)(C)C=CC(=O)[C@@](C)([C@H]1[C@@H](C[C@@]2([C@@]1(CC(=O)[C@@]3([C@H]2CC=C4[C@H]3C[C@@H](C(=O)C4(C)C)O)CO)C)C)O)O,,,,,,
3417,73418,"(1S,2R,10S,11S)-21,24-dimethyl-3,12,21,24-tetrazahexacyclo[9.7.3.32,10.01,10.04,9.013,18]tetracosa-4,6,8,13,15,17-hexaene",CN1CC[C@@]23[C@H]4NC5=CC=CC=C5[C@@]2([C@@H]1NC6=CC=CC=C36)CCN4C,,,,,,
3418,73419,Solanocapsine,C[C@@H]1C[C@]2([C@@H]([C@H]([C@H]3[C@H](O2)C[C@@H]4[C@@]3(CC[C@H]5[C@H]4CC[C@@H]6[C@@]5(CC[C@@H](C6)N)C)C)C)NC1)O,,,,,,
3419,73420,Althiomycin,COC1=CC(=O)N(C1)C(=O)C2CSC(=N2)C(CO)NC(=O)C3=CSC(=N3)C=NO,,,,,,
3420,73421,Fusarubin,CC1(CC2=C(CO1)C(=C3C(=O)C=C(C(=O)C3=C2O)OC)O)O,,,,,,
3421,73422,Pretazettine hydrochloride,CN1C[C@H]2[C@]3([C@@H]1C[C@@H](C=C3)OC)C4=CC5=C(C=C4[C@@H](O2)O)OCO5.Cl,,,,,,
3422,73423,Furanomycin,C[C@H]1C=C[C@@H](O1)[C@@H](C(=O)O)N,,,,,,
3423,73424,Isariin,CCCCCCCCC[C@@H]1CC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O1)C(C)C)C)CC(C)C)C(C)C,,,,,,
3424,73425,CID 73425,CC=C(C)C(=O)O[C@@H]1C=C([C@H](C[C@@H](C(=C[C@@H]2[C@H]1C(=C)C(=O)O2)C)OC(=O)C)O)C,,,,,,
3425,73426,Glaziovina,CN1CCC2=CC(=C(C3=C2[C@@H]1CC34C=CC(=O)C=C4)O)OC,,,,,,
3426,73427,Geiparvin,CC(=CCOC1=CC2=C(C=C1)C=CC(=O)O2)C3=CC(=O)C(O3)(C)C,,,,,,
3427,73428,CID 73428,CC=C(C)C1=CC(=O)C2=C(O1)C3=C(C=C2C)C(=O)C4=C([C@@]3(OC)OC(=O)C)C(=C(C=C4[C@H]5C[C@H]([C@@H]([C@H](O5)C)OC(=O)C)N(C)C)[C@H]6C[C@]([C@@H]([C@@H](O6)C)OC(=O)C)(C)N(C)C)O,,,,,,
3428,73429,CID 73429,CC=C(C)C1=CC(=O)C2=C(O1)C3=C(C=C2C)C(=O)C4=C(C3=O)C(=C(C=C4[C@H]5C[C@H]([C@@H]([C@H](O5)C)OC(=O)C)N(C)C)[C@H]6C[C@]([C@@H]([C@@H](O6)C)OC(=O)C)(C)N(C)C)O,,,,,,
3429,73430,CID 73430,C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](C[C@](C(=O)C=C[C@H]3[C@@H](O3)[C@@H]([C@H](OC(=O)C=C[C@@H]2C)C)CO[C@H]4[C@@H]([C@@H]([C@@H]([C@H](O4)C)O)OC)OC)(C)O)C)O)OC,,,,,,
3430,73431,Secalonic acid D,C[C@H]1CC(=O)C2=C(C3=C(C=CC(=C3O)C4=C(C5=C(C=C4)O[C@]6([C@@H]([C@H](CC(=O)C6=C5O)C)O)C(=O)OC)O)O[C@]2([C@@H]1O)C(=O)OC)O,,,,,,
3431,73432,Brusatol,CC1=C(C(=O)C[C@]2([C@H]1C[C@@H]3[C@]45[C@@H]2[C@H]([C@@H]([C@]([C@@H]4[C@H](C(=O)O3)OC(=O)C=C(C)C)(OC5)C(=O)OC)O)O)C)O,,,,,,
3432,73433,"2,5-Dimethylpiperazine-1,4-diethanol",CC1CN(C(CN1CCO)C)CCO,,,,,,
3433,73434,C.I. Acid Orange 63,CC1=CC=C(C=C1)S(=O)(=O)OC2=CC=C(C=C2)N=NC3=C(C=C(C=C3)C4=CC=C(C=C4)N=NC5C(=NN(C5=O)C6=CC=C(C=C6)S(=O)(=O)[O-])C)S(=O)(=O)[O-].[Na+].[Na+],,,,,,
3434,73435,Benzyl Fast Yellow 3R,CC1=CC=C(C=C1)S(=O)(=O)OC2=CC=C(C=C2)N=NC3=C(C=C(C=C3)C4=CC=C(C=C4)N=NC5C(=NN(C5=O)C6=CC=C(C=C6)S(=O)(=O)O)C)S(=O)(=O)O,,,,,,
3435,73436,CID 73436,CC1=C(C=CC(=C1)C2=CC(=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)[O-])C)N=NC4C(=NN(C4=O)C5=CC=C(C=C5)S(=O)(=O)[O-])C.[Na+].[Na+],,,,,,
3436,73437,2-Hydroxy-5-[[2-methyl-4-[3-methyl-4-[[3-methyl-5-oxo-1-(4-sulfophenyl)-4H-pyrazol-4-yl]diazenyl]phenyl]phenyl]diazenyl]benzoic acid,CC1=C(C=CC(=C1)C2=CC(=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O)C)N=NC4C(=NN(C4=O)C5=CC=C(C=C5)S(=O)(=O)O)C,,,,,,
3437,73438,(2R)-2-[[(2S)-2-[(2-aminoacetyl)amino]-3-hydroxypropanoyl]amino]propanoic acid,C[C@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)CN,,,,,,
3438,73439,"methyl 2-[(3R)-3-methyl-2,5-dioxopyrrolidin-1-yl]prop-2-enoate",C[C@@H]1CC(=O)N(C1=O)C(=C)C(=O)OC,,,,,,
3439,73440,Dehydroleucodine,CC1=C2[C@@H]([C@@H]3[C@@H](CC1)C(=C)C(=O)O3)C(=CC2=O)C,,,,,,
3440,73441,Aquayamycin,C[C@@H]1[C@H]([C@@H](C[C@@H](O1)C2=C(C3=C(C=C2)C(=O)C4=C(C3=O)C=C[C@]5([C@@]4(C(=O)C[C@](C5)(C)O)O)O)O)O)O,,,,,,
3441,73442,Palmatine chloride,COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC(=C(C=C4CC3)OC)OC)OC.[Cl-],,,,,,
3442,73443,l-alpha-(2-Aminoethoxyvinyl)-glycine,C(COC=C[C@@H](C(=O)O)N)N,,,,,,
3443,73444,CID 73444,CC[C@H](C)[C@H]1C(=O)N([C@H](C(=O)N([C@@H](C(=O)NCCC(=O)O[C@@H](C(=O)N2CCC[C@H]2C(=O)N1)CC(C)C)C)C)C(C)C)C,,,,,,
3444,73445,CID 73445,C[C@@H]1[C@@H]([C@@H](C[C@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=NNC(=O)C6=CC(=C(C=C6)Cl)Cl)CO)O)N)O.Cl,,,,,,
3445,73446,CID 73446,C[C@@H]1[C@@H]([C@@H](C[C@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=NNC(=O)C6=CC(=C(C=C6)Cl)Cl)CO)O)N)O,,,,,,
3446,73447,Uvaretin,COC1=C(C(=C(C(=C1)O)CC2=CC=CC=C2O)O)C(=O)CCC3=CC=CC=C3,,,,,,
3447,73448,Spiculisporic acid,CCCCCCCCCC[C@H](C(=O)O)[C@@]1(CCC(=O)O1)C(=O)O,,,,,,
3448,73449,CID 73449,CCC(=C1C(=O)O[C@@H]([C@@H](C(=O)N[C@H]([C@@H]([C@H](C(=O)O1)C)O)CC2=CN=CC=C2)NC(=O)C3=C(C=CC=N3)O)C)C,,,,,,
3449,73450,6-Chloro-N-(4-(diethylamino)-1-methylbutyl)-3-pyridinecarboxamide,CCN(CC)CCCC(C)NC(=O)C1=CN=C(C=C1)Cl,,,,,,
3450,73451,"2,5-Piperazinedione, 3,6-bis(1-azabicyclo(3.1.0)hex-2-yl)-",C1CC(N2C1C2)C3C(=O)NC(C(=O)N3)C4CCC5N4C5,,,,,,
3451,73452,"2,5-Deoxyfructosazine",C1=C(N=CC(=N1)[C@H]([C@@H]([C@@H](CO)O)O)O)C[C@@H]([C@@H](CO)O)O,,,,,,
3452,73453,Ergocornine,CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=CNC7=CC=CC(=C67)C5=C4)C)O,,,,,,
3453,73454,CID 73454,CC=C1C[C@H]([C@](C(=O)OC[C@H]2[C@@H](CN3[C@H]2[C@@H](CC3)OC1=O)O)(C)O)C,,,,,,
3454,73455,"Manganese, tetracarbonyl(trifluoromethylthio)-, dimer",[C-]#[O+].[C-]#[O+].[C-]#[O+].[C-]#[O+].[C-]#[O+].[C-]#[O+].[C-]#[O+].[C-]#[O+].C(F)(F)(F)[S-].C(F)(F)(F)[S-].[Mn+2].[Mn+2],,,,,,
3455,73456,Unii-dxk68bhz98,C[C@@H]1C(=C)C(=O)O[C@@H]2CCN3[C@@H]2C(=CC3)COC(=O)[C@@]([C@]14CO4)(C)O,,,,,,
3456,73457,CID 73457,CC1=CC(=O)N(CCC[C@@H](C(=O)OCCC(=CC(=O)N(CCC[C@@H](C(=O)OCCC(=CC(=O)N(CCC[C@@H](C(=O)OCC1)NC(=O)C)[O-])C)NC(=O)C)[O-])C)NC(=O)C)[O-].[Fe+3],,,,,,
3457,73458,"N-(15,27-diacetamido-10,22,34-trimethyl-7,19,31-trioxido-2,8,14,20,26,32-hexaoxo-1,13,25-trioxa-7,19,31-triazacyclohexatriaconta-9,21,33-trien-3-yl)acetamide",CC1=CC(=O)N(CCCC(C(=O)OCCC(=CC(=O)N(CCCC(C(=O)OCCC(=CC(=O)N(CCCC(C(=O)OCC1)NC(=O)C)[O-])C)NC(=O)C)[O-])C)NC(=O)C)[O-],,,,,,
3458,73459,CID 73459,CCCCC(CC)CN=C(S)[S-].[Na+],,,,,,
3459,73460,CID 73460,CCCCC(CC)CN=C(S)S,,,,,,
3460,73461,"Cyclo[(2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl],cyclic (3®5)-disulfide",CC=C1C(=O)N[C@H](C(=O)O[C@H]2CC(=O)N[C@@H](C(=O)N[C@H](CSSCCC=C2)C(=O)N1)C(C)C)C(C)C,,,,,,
3461,73462,C.I. Pigment Yellow 13,CC1=CC(=C(C=C1)NC(=O)C(C(=O)C)N=NC2=C(C=C(C=C2)C3=CC(=C(C=C3)N=NC(C(=O)C)C(=O)NC4=C(C=C(C=C4)C)C)Cl)Cl)C,,,,,,
3462,73463,"Butanamide, 2,2'-((3,3'-dimethoxy(1,1'-biphenyl)-4,4'-diyl)bis(azo))bis(N-(2-methylphenyl)-3-oxo-",CC1=CC=CC=C1NC(=O)C(C(=O)C)N=NC2=C(C=C(C=C2)C3=CC(=C(C=C3)N=NC(C(=O)C)C(=O)NC4=CC=CC=C4C)OC)OC,,,,,,
3463,73464,Z-His-NHNH2,C1=CC=C(C=C1)COC(=O)N[C@@H](CC2=CN=CN2)C(=O)NN,,,,,,
3464,73465,Pinnatifidin,CC1=CC(=O)C[C@]2([C@H]1C[C@H]3[C@@H](C2)OC(=O)C3=C)C,,,,,,
3465,73466,Monotropein,C1=C[C@@]([C@@H]2[C@H]1C(=CO[C@H]2O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)C(=O)O)(CO)O,,,,,,
3466,73467,Verbenalin,C[C@H]1CC(=O)[C@H]2[C@@H]1[C@@H](OC=C2C(=O)OC)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O,,,,,,
3467,73468,Chrysomycin A,C[C@@H]1[C@@H]([C@@]([C@H]([C@@H](O1)C2=C3C(=C(C=C2)O)C(=CC4=C3OC(=O)C5=C4C(=CC(=C5)C=C)OC)OC)O)(C)O)O,,,,,,
3468,73469,2-(2-(Dimethylamino)-1-hydroxyethyl)dibenzofuran hydrochloride,CN(C)CC(C1=CC2=C(C=C1)OC3=CC=CC=C32)O.Cl,,,,,,
3469,73470,2-[2-[Dimethylamino]-1-hydroxy]ethyldibenzofuran,CN(C)CC(C1=CC2=C(C=C1)OC3=CC=CC=C32)O,,,,,,
3470,73471,2-(2-Piperidino-1-hydroxyethyl)dibenzofuran hydrochloride,C1CCN(CC1)CC(C2=CC3=C(C=C2)OC4=CC=CC=C43)O.Cl,,,,,,
3471,73472,2-[2-Piperidino-1-hydroxy]ethyl dibenzofuran,C1CCN(CC1)CC(C2=CC3=C(C=C2)OC4=CC=CC=C43)O,,,,,,
3472,73473,CID 73473,C1C[C@H]2[C@@H]3CC4=C5[C@@]2(CCN3CC6=COC=C6)[C@H](C1)OC5=C(C=C4)O.Cl,,,,,,
3473,73474,CID 73474,C1C[C@H]2[C@@H]3CC4=C5[C@@]2(CCN3CC6=COC=C6)[C@H](C1)OC5=C(C=C4)O,,,,,,
3474,73475,CID 73475,CS(=O)(=O)O.C1C[C@]2([C@@H]3CC4=C5[C@@]2(CCN3CC6=COC=C6)[C@H](C1=O)OC5=C(C=C4)O)O,,,,,,
3475,73476,CID 73476,C1C[C@]2([C@@H]3CC4=C5[C@@]2(CCN3CC6=COC=C6)[C@H](C1=O)OC5=C(C=C4)O)O,,,,,,
3476,73477,"2-Phenyl-6-methyl-4-oxo-4,5,6,7-tetrahydrobenzofuran",CC1CC2=C(C=C(O2)C3=CC=CC=C3)C(=O)C1,,,,,,
3477,73478,"3-Ribofuranosyl-1,2,4-triazole-5-carboxamide",C([C@@H]1[C@H]([C@H]([C@@H](O1)C2=NC(=NN2)C(=O)N)O)O)O,,,,,,
3478,73479,4-beta-D-Ribofuranosylthiazole-2-carboxamide,C1=C(N=C(S1)C(=O)N)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O,,,,,,
3479,73480,Nortropine,C1C[C@H]2CC(C[C@@H]1N2)O,,,,,,
3480,73481,Fangchinoline,CN1CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)C[C@H]6C7=C(O3)C(=C(C=C7CCN6C)OC)O)OC)OC,,,,,,
3481,73482,"Ambros-2-en-12-oic acid, 6beta,8alpha-dihydroxy-4-oxo-, 12,8-lactone, acetate, (11R)-",C[C@@H]1C[C@H]2[C@@H]([C@H](C(=O)O2)C)[C@H]([C@]3(C1C=CC3=O)C)OC(=O)C,,,,,,
3482,73483,2-(2-carboxyethenylamino)-N-methoxy-2-oxoethanimine oxide,CO[N+](=CC(=O)NC=CC(=O)O)[O-],,,,,,
3483,73484,Agroclavine,CC1=C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)C,,,,,,
3484,73485,"[(1S,3S,5R,6S,10R,11R)-3-methyl-9-methylidene-8,14-dioxo-4,7,15-trioxatetracyclo[11.2.1.03,5.06,10]hexadec-13(16)-en-11-yl] 3-methylbut-2-enoate",CC(=CC(=O)O[C@@H]1CC2=C[C@H](C[C@]3([C@H](O3)[C@@H]4[C@@H]1C(=C)C(=O)O4)C)OC2=O)C,,,,,,
3485,73486,Ascochitine,CC[C@H](C)C1=C(C2=CC(=O)C(=C(C2=CO1)O)C(=O)O)C,,,,,,
3486,73487,CID 73487,CC[C@@H]1[C@H](CC=CC[C@@H](O1)[C@@H](CC=CC#C)OC(=O)C)Br,,,,,,
3487,73488,Mitomycin derivative T 38,CC1=C(C(=O)C2=C(C1=O)N3C[C@H]4[C@@H]([C@@]3([C@@H]2COC(=O)N)OC)N4)NCCO,,,,,,
3488,73489,Coronaridine,CC[C@H]1C[C@H]2C[C@@]3([C@H]1N(C2)CCC4=C3NC5=CC=CC=C45)C(=O)OC,,,,,,
3489,73490,"N-1-Anthraquinonyl-2,3-dichloropropionamide",C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C(=CC=C3)NC(=O)C(CCl)Cl,,,,,,
3490,73491,Fosfomycin sodium,C[C@H]1[C@H](O1)P(=O)([O-])[O-].[Na+].[Na+],,,,,,
3491,73492,Isoharringtonine,CC(C)CC[C@@]([C@@H](C(=O)OC)O)(C(=O)O[C@H]1[C@H]2C3=CC4=C(C=C3CCN5[C@@]2(CCC5)C=C1OC)OCO4)O,,,,,,
3492,73493,Methyl betulinate,CC(=C)[C@@H]1CC[C@]2([C@H]1[C@H]3CC[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)O)C)C(=O)OC,,,,,,
3493,73494,Polysaccharide Y4113,CC(=O)N[C@@H](C=O)[C@H]([C@@H]([C@@H](C(=O)O)O)O)O,,,,,,
3494,73495,"(1R,2R,7R,9R,10R,11S,12S)-2-(hydroxymethyl)-1,5-dimethylspiro[8-oxatricyclo[7.2.1.02,7]dodec-5-ene-12,2'-oxirane]-10,11-diol",CC1=C[C@@H]2[C@](CC1)([C@@]3([C@@H]([C@H]([C@H]([C@@]34CO4)O2)O)O)C)CO,,,,,,
3495,73496,"[(3Ar,4R,11aR)-6,10-bis(hydroxymethyl)-3-methylidene-2-oxo-3a,4,5,8,9,11a-hexahydrocyclodeca[b]furan-4-yl] 2-methylpropanoate",CC(C)C(=O)O[C@@H]1CC(=CCCC(=C[C@@H]2[C@@H]1C(=C)C(=O)O2)CO)CO,,,,,,
3496,73497,"[(1S,2R,4R,5R,6S,8R,10S,11S,12R,14R,15S,16S,19S,21R)-4,16-diacetyloxy-6-(furan-3-yl)-12,19-dihydroxy-5,11,15-trimethyl-3-oxo-9,17-dioxahexacyclo[13.3.3.01,14.02,11.05,10.08,10]henicosan-21-yl] acetate",CC(=O)O[C@@H]1C[C@@H]([C@@]23CO[C@H]([C@]1([C@@H]2C[C@H]([C@@]4([C@@H]3C(=O)[C@@H]([C@@]5([C@]46[C@H](O6)C[C@H]5C7=COC=C7)C)OC(=O)C)C)O)C)OC(=O)C)O,,,,,,
3497,73498,Panaxadiol,C[C@@]1(CCCC(O1)(C)C)[C@H]2CC[C@@]3([C@@H]2[C@@H](C[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)O)C)C)O)C,,,,,,
3498,73499,alpha-Dihydrograyanotoxin II,C[C@H]1[C@@H]2CC[C@H]3[C@H]([C@@]2(C[C@H]([C@]4([C@H]1C[C@@H](C4(C)C)O)O)O)C[C@@]3(C)O)O,,,,,,
3499,73500,N6-2-Propynylmitomycin C,CC1=C(C(=O)C2=C(C1=O)N3C[C@H]4[C@@H]([C@@]3([C@@H]2COC(=O)N)OC)N4)NCC#C,,,,,,
3500,73501,1-Propylagroclavine tartrate,CCCN1C=C2C[C@@H]3[C@H](C=C(CN3C)C)C4=C2C1=CC=C4.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,,,,,,
3501,73502,CID 73502,CCCN1C=C2C[C@@H]3C(C=C(CN3C)C)C4=C2C1=CC=C4,,,,,,
3502,73503,1-Hydroxymethylfestuclavine,C[C@@H]1C[C@H]2[C@@H](CC3=CN(C4=CC=CC2=C34)CO)N(C1)C,,,,,,
3503,73504,CID 73504,C=CCC(=NOS(=O)(=O)[O-])S[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O.[K+],,,,,,
3504,73505,CID 73505,C=CCC(=NOS(=O)(=O)O)SC1[C@@H]([C@H](C([C@H](O1)CO)O)O)O,,,,,,
3505,73506,"(2S,3R,4S,5R,6R)-6-[[(3S,4aR,6aR,6bS,8aS,12aS,14aR,14bR)-8-hydroxy-8a-(hydroxymethyl)-4,4,6a,6b,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-4-hydroxy-5-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyoxane-2-carboxylic acid",C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@H]([C@H](O[C@H]2O[C@H]3CC[C@]4([C@H](C3(C)C)CC[C@@]5([C@@H]4CC=C6[C@]5(CC([C@@]7([C@H]6CC(CC7)(C)C)CO)O)C)C)C)C(=O)O)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO[C@H]9[C@@H]([C@H]([C@H]([C@H](O9)CO)O)O)O)O)O)O)O)O)O)O,,,,,,
3506,73507,4-Methyl-2-undecyl-2-oxazoline-4-methanol,CCCCCCCCCCCC1=NC(CO1)(C)CO,,,,,,
3507,73508,3-Aminodihydrofuran-2(3H)-one hydrobromide,C1COC(=O)C1N.Br,,,,,,
3508,73509,Homoserine lactone,C1COC(=O)C1N,,,,,,
3509,73510,4-((2-Fluorophenyl)methylene)-2-phenyloxazol-5(4H)-one,C1=CC=C(C=C1)C2=NC(=CC3=CC=CC=C3F)C(=O)O2,,,,,,
3510,73511,"(1R,3S,4S,5S,7R)-6-methyl-2-oxa-6-azatricyclo[3.3.1.03,7]nonan-4-ol",CN1[C@H]2C[C@@H]3C[C@@H]1[C@@H]([C@H]2O)O3,,,,,,
3511,73512,Z-Pro-val-OH,CC(C)[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)OCC2=CC=CC=C2,,,,,,
3512,73513,N-Benzyloxycarbonyl-L-prolyl-L-alanine,C[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)OCC2=CC=CC=C2,,,,,,
3513,73514,Arazide,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)N=[N+]=[N-])N,,,,,,
3514,73515,"3'-Amino-2',3'-dideoxycytidine",C1[C@@H]([C@H](O[C@H]1N2C=CC(=NC2=O)N)CO)N,,,,,,
3515,73516,Bindschedler's green,CN(C)C1=CC=C(C=C1)N=C2C=CC(=[N+](C)C)C=C2.[Cl-],,,,,,
3516,73517,"N-(4-((4-(dimethylamino)phenyl)imino)cyclohexa-2,5-dien-1-ylidene)-N-methylmethanaminium",CN(C)C1=CC=C(C=C1)N=C2C=CC(=[N+](C)C)C=C2,,,,,,
3517,73518,New methylene blue,CCNC1=CC2=C(C=C1C)N=C3C=C(C(=[NH+]CC)C=C3S2)C.[Cl-],,,,,,
3518,73519,"N-Ethyl-3-(ethylimino)-2,8-dimethyl-3H-phenothiazine-7-amine",CCNC1=CC2=C(C=C1C)N=C3C=C(C(=NCC)C=C3S2)C,,,,,,
3519,73520,"4',5'-Dibromo-3',6'-dihydroxy-2',7'-dimethylspiro(isobenzofuran-1(3H),9'-(9H)xanthene)-3-one",CC1=CC2=C(C(=C1O)Br)OC3=C(C24C5=CC=CC=C5C(=O)O4)C=C(C(=C3Br)O)C,,,,,,
3520,73521,Modr kresylova,CC1=CC2=NC3=C(C=C(C=C3)N)OC2=CC1=[N+](C)C.[Cl-],,,,,,
3521,73522,7-(Dimethylamino)-8-methyl-3H-phenoxazine-3-ylideneiminium,CC1=CC2=NC3=C(C=C(C=C3)N)OC2=CC1=[N+](C)C,,,,,,
3522,73523,CID 73523,CC1=C(C2=C(C=C1)C(=O)N3C=C(C[C@H]3[C@H](N2)OC)C=CC(=O)N)O.O,,,,,,
3523,73524,"3-[(6R,6aS)-4-hydroxy-6-methoxy-3-methyl-11-oxo-5,6,6a,7-tetrahydropyrrolo[2,1-c][1,4]benzodiazepin-8-yl]prop-2-enamide",CC1=C(C2=C(C=C1)C(=O)N3C=C(C[C@H]3[C@H](N2)OC)C=CC(=O)N)O,,,,,,
3524,73525,(-)-Cyclopenin,CN1C(=O)C2=CC=CC=C2NC(=O)[C@@]13[C@H](O3)C4=CC=CC=C4,,,,,,
3525,73526,CID 73526,C1=C(N(N=CC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)O,,,,,,
3526,73527,Heteratisine,CCN1C[C@@]2(CC[C@@H]([C@@]34[C@@H]2[C@@H]([C@@H](C31)[C@]5(CC[C@H]6C[C@@H]4[C@@H]5C(=O)O6)O)O)OC)C,,,,,,
3527,73528,"(8S,9R,10R,13R,14S,16R,17R)-17-[(2R)-2,6-dihydroxy-6-methyl-3-oxohept-4-en-2-yl]-2,16-dihydroxy-4,4,9,13,14-pentamethyl-8,10,12,15,16,17-hexahydro-7H-cyclopenta[a]phenanthrene-3,11-dione",C[C@@]12C[C@H]([C@@H]([C@]1(CC(=O)[C@@]3([C@H]2CC=C4[C@H]3C=C(C(=O)C4(C)C)O)C)C)[C@](C)(C(=O)C=CC(C)(C)O)O)O,,,,,,
3528,73529,"4-Methoxy-8-(ribofuranosylamino)pyrimido(5,4-d)pyrimidine",COC1=NC=NC2=C1N=CN=C2N[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O,,,,,,
3529,73530,Tetrahydroharman-3-carboxylic acid,CC1C2=C(CC(N1)C(=O)O)C3=CC=CC=C3N2,,,,,,
3530,73531,"Strychnidin-10-one, 21,22-dihydro-2,3-dimethoxy-",COC1=C(C=C2C(=C1)[C@]34CCN5[C@H]3C[C@@H]6[C@@H]7[C@@H]4N2C(=O)C[C@@H]7OCCC6C5)OC,,,,,,
3531,73532,Methyl reserpate,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)O,,,,,,
3532,73533,(+)-catechin 7-O-beta-D-xyloside,C1[C@@H]([C@H](OC2=CC(=CC(=C21)O)O[C@H]3[C@@H]([C@H]([C@@H](CO3)O)O)O)C4=CC(=C(C=C4)O)O)O,,,,,,
3533,73534,Vobtusine,COC1=CC=CC2=C1N3C[C@]4(C[C@H]5[C@]3([C@]26CCN7[C@H]6[C@@]8(C5)CCO[C@H]8CC7)O)CN9CC[C@@]12[C@@H]9[C@@]3([C@H]4OCC3)CC(=C1NC1=CC=CC=C21)C(=O)OC,,,,,,
3534,73535,"6-[3-[2-[2-[3-(3,8-Diamino-5-methylphenanthridin-5-ium-6-yl)phenoxy]ethoxy]ethoxy]phenyl]-5-methylphenanthridin-5-ium-3,8-diamine;dibromide",C[N+]1=C2C=C(C=CC2=C3C=CC(=CC3=C1C4=CC(=CC=C4)OCCOCCOC5=CC=CC(=C5)C6=C7C=C(C=CC7=C8C=CC(=CC8=[N+]6C)N)N)N)N.[Br-].[Br-],,,,,,
3535,73536,"6-[3-[2-[2-[3-(3,8-Diamino-5-methylphenanthridin-5-ium-6-yl)phenoxy]ethoxy]ethoxy]phenyl]-5-methylphenanthridin-5-ium-3,8-diamine",C[N+]1=C2C=C(C=CC2=C3C=CC(=CC3=C1C4=CC(=CC=C4)OCCOCCOC5=CC=CC(=C5)C6=C7C=C(C=CC7=C8C=CC(=CC8=[N+]6C)N)N)N)N,,,,,,
3536,73537,trans-ACPD,C1C[C@@](C[C@H]1C(=O)O)(C(=O)O)N,,,"['Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids. (See all compounds classified as Neuroprotective Agents.)']",,,
3537,73538,3-amino-1H-pyrazol-5(4H)-one,C1C(=NNC1=O)N,,,,,,
3538,73539,"4,5-Dihydroxy-1,3-dimethylimidazolidin-2-one",CN1C(C(N(C1=O)C)O)O,,,,,,
3539,73540,"4,5-Dihydro-4,5-dihydroxyuric acid",C1(=O)C2(C(NC(=O)N1)(NC(=O)N2)O)O,,,,,,
3540,73541,4-[(3-Fluorophenyl)methylene]-2-phenyl-5(4H)-oxazolone,C1=CC=C(C=C1)C2=NC(=CC3=CC(=CC=C3)F)C(=O)O2,,,,,,
3541,73542,"4-[(4-Fluorophenyl)methylidene]-2-phenyl-1,3-oxazol-5-one",C1=CC=C(C=C1)C2=NC(=CC3=CC=C(C=C3)F)C(=O)O2,,,,,,
3542,73543,Sucrose octapalmitate,CCCCCCCCCCCCCCCC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@]2([C@H]([C@@H]([C@H](O2)COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC,,,,,,
3543,73544,"2,5-Anhydro-D-mannitol",C([C@@H]1[C@H]([C@@H]([C@H](O1)CO)O)O)O,,,,,,
3544,73545,"(4-beta-D-Ribofuranosyl)-1,3-dihydroxybenzene",C1=CC(=C(C=C1O)O)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O,,,,,,
3545,73546,alpha-Phenyl-1-cyclopentene-1-hydracrylic acid 2-(diethylamino)ethyl ester hydrochloride,CCN(CC)CCOC(=O)C(C1=CC=CC=C1)C(C2=CCCC2)O.Cl,,,,,,
3546,73547,2-(Diethylamino)ethyl 3-(cyclopenten-1-yl)-3-hydroxy-2-phenylpropanoate,CCN(CC)CCOC(=O)C(C1=CC=CC=C1)C(C2=CCCC2)O,,,,,,
3547,73548,Licarin A,CC=CC1=CC2=C(C(=C1)OC)OC(C2C)C3=CC(=C(C=C3)O)OC,,,,,,
3548,73549,"Indolo[2,1-b]quinazoline-6,12-dione",C1=CC=C2C(=C1)C(=O)N3C4=CC=CC=C4C(=O)C3=N2,,,,,,
3549,73550,"4-Thiazolidinone, 3-(1,3,4-thiadiazol-2-yl)-2-(2-thienyl)-",C1C(=O)N(C(S1)C2=CC=CS2)C3=NN=CS3,,,,,,
3550,73551,N-Trifluoroacetyladriamycin,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)NC(=O)C(F)(F)F)O,,,,,,
3551,73552,"4-oxo-4-[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-4-[(2R,4S,5S,6S)-5-hydroxy-6-methyl-4-[(2,2,2-trifluoroacetyl)amino]tetrahydropyran-2-yl]oxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethoxy]butanoic acid",C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)COC(=O)CCC(=O)O)O)NC(=O)C(F)(F)F)O,,,,,,
3552,73553,"(9S)-7-[(2R,4S,5S,6S)-4-(benzylamino)-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione",C[C@H]1[C@H]([C@H](C[C@@H](O1)OC2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)NCC6=CC=CC=C6)O,,,,,,
3553,73554,"(3R,4S,6S,8S,10R,12R,14R,15R,16R,27S,28R)-4,6,8,10,12,14,15,16,27-nonahydroxy-3-[(1R)-1-hydroxyhexyl]-17,28-dimethyl-1-oxacyclooctacosa-17,19,21,23,25-pentaen-2-one",CCCCC[C@H]([C@@H]1[C@H](C[C@H](C[C@H](C[C@H](C[C@H](C[C@H]([C@H]([C@@H](C(=CC=CC=CC=CC=C[C@@H]([C@H](OC1=O)C)O)C)O)O)O)O)O)O)O)O)O,,,,,,
3554,73555,"(1R,3R,9S,24S,25S,32R)-20,24,32-Trihydroxy-16-methoxy-29-methyl-6,10,18-trioxa-26,27-dithia-2,29-diazaheptacyclo[23.2.2.11,4.12,25.119,23.03,9.012,17]dotriaconta-4,7,12(17),13,15,19,21,23(31)-octaene-11,28,30-trione",CN1C(=O)[C@]23[C@@H](C4=COC=C[C@H]5[C@@H]4N2C(=O)[C@]1([C@H](C6=CC(=C(C=C6)O)OC7=C(C=CC=C7OC)C(=O)O5)O)SS3)O,,,,,,
3555,73556,Fencholic acid,CC(C)[C@H]1CC[C@@](C1)(C)C(=O)O,,,,,,
3556,73557,Bromosuccinic acid,C(C(C(=O)O)Br)C(=O)O,,,,,,
3557,73558,2-Hydroxy-2-phenylacetamide,C1=CC=C(C=C1)C(C(=O)N)O,,,,,,
3558,73559,"1,2-Cyclohexanedicarboximide",C1CCC2C(C1)C(=O)NC2=O,,,,,,
3559,73560,"1,2-Cyclobutanedicarboxamide",C1CC(C1C(=O)N)C(=O)N,,,,,,
3560,73561,"3-Amino-1,2-propanediol",C(C(CO)O)N,,,,,,
3561,73562,"(2S,3S)-2-amino-3-hydroxy-3-phenylpropanoic acid",C1=CC=C(C=C1)[C@@H]([C@@H](C(=O)O)N)O,,,,,,
3562,73563,2-Amino-2-deoxy-D-gluconic acid,C([C@H]([C@H]([C@@H]([C@H](C(=O)O)N)O)O)O)O,,,,,,
3563,73564,CID 73564,CC1C(=O)N=C(S1)S,,,,,,
3564,73565,5-Benzylhydantoin,C1=CC=C(C=C1)CC2C(=O)NC(=O)N2,,,,,,
3565,73566,"5-[(1R,7S,8S,9R)-7-Acetyloxy-4,9-dimethyl-11-oxo-10-oxatricyclo[6.3.2.01,7]tridec-3-en-9-yl]-2-methylpenta-2,4-dienoic acid",CC1=CC[C@]23CC[C@H]([C@]2(CC1)OC(=O)C)[C@@](OC3=O)(C)C=CC=C(C)C(=O)O,,,,,,
3566,73567,Sarasinoside C1,CC(CC(=O)C=C(C)C)C1CCC2C1(CCC3=C2CCC4C3(CCC(C4(C)C)OC5C(C(C(CO5)OC6C(C(C(C(O6)CO)O)O)NC(=O)C)O)OC7C(C(C(C(O7)COC8C(C(C(CO8)O)O)O)O)O)NC(=O)C)C)C,,,,,,
3567,73568,Corilagin,C1[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC(=O)C3=CC(=C(C(=C3)O)O)O)O)OC(=O)C4=CC(=C(C(=C4C5=C(C(=C(C=C5C(=O)O1)O)O)O)O)O)O)O,,,,,,
3568,73569,4-methyl-3-(8-oxonon-1-enyl)-2H-furan-5-one,CC1=C(COC1=O)C=CCCCCCC(=O)C,,,,,,
3569,73570,4-(8-Hydroxy-1-nonenyl)-3-methyl-2(5h)-furanone,CC1=C(COC1=O)C=CCCCCCC(C)O,,,,,,
3570,73571,Sakuranetin,COC1=CC(=C2C(=O)C[C@H](OC2=C1)C3=CC=C(C=C3)O)O,,,,,,
3571,73572,Pradimicin Q,CC1=CC2=C(C3=C(C[C@H]2O)C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC(=C5)O)O)O)C(=C1C(=O)O)O,,,['Compounds that inhibit or block the activity of GLYCOSIDE HYDROLASES such as ALPHA-AMYLASES and ALPHA-GLUCOSIDASES. (See all compounds classified as Glycoside Hydrolase Inhibitors.)'],,,
3572,73573,CID 73573,CCCC=CC=CC=CC(CC=CC=CC(=O)O[C@@H]1[C@H]([C@]2(C3=C(CO2)C=C(C=C3O)O)OC(C1O[C@H]4[C@@H]([C@H]([C@H](C(O4)COC(=O)C=CC=CC=CCCC)O)O)O)CO)O)O,,,,,,
3573,73574,11-O-Demethylpradinone I,CC1=CC2=C(C3=C(C4=C(C=C3[C@@H]([C@H]2O)O)C(=O)C5=C(C4=O)C=C(C=C5O)O)O)C(=C1C(=O)O)O,,,,,,
3574,73575,Pradimicin N,CC1=CC2=C(C3=C(C(C2O)O)C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC(=C5)OC)O)OC)C(=C1C(=O)N[C@H](C)C(=O)O)O,,,,,,
3575,73576,Pradimicin O,CC1=CC2=C(C3=C(C[C@H]2O)C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC(=C5)OC)O)OC)C(=C1C(=O)N[C@H](C)C(=O)O)O,,,,,,
3576,73577,CID 73577,C1=CC(=CC=C1C(=O)N[C@@H](CCC(=O)O)C(=O)O)NCCC2=CN=C3C(=N2)C(=O)N=C(N3)N,,,,,,
3577,73578,CID 73578,CC1C(NC2=C(N1)C(=O)N=C(N2)N)C.Cl,,,,,,
3578,73579,CID 73579,CC1C(NC2=C(N1)C(=O)N=C(N2)N)C,,,,,,
3579,73580,CID 73580,C1=CC(=CC=C1C(=O)N[C@@H](CCC(=O)O)C(=O)O)N(CC2=CC3=C(C=C2)NC(=NC3=O)N)C=O,,,,,,
3580,73581,Bilobalide,CC(C)(C)[C@@]1(C[C@H]2[C@@]3([C@]14[C@H](C(=O)O[C@H]4OC3=O)O)CC(=O)O2)O,,,,,,
3581,73582,3-Phenyl-5-(2-propynyloxymethyl)-2-oxazolidinone,C#CCOCC1CN(C(=O)O1)C2=CC=CC=C2,,,,,,
3582,73583,Chaetomin,CN1C(=O)[C@]2(N(C(=O)[C@]1(SS2)CC3=CN(C4=CC=CC=C43)[C@]56C[C@]78C(=O)N([C@](C(=O)N7[C@H]5NC9=CC=CC=C69)(SS8)CO)C)C)CO,,,,,,
3583,73584,Furylacryloylglycylleucinamide,CC(C)C[C@@H](C(=O)N)NC(=O)CNC(=O)C=CC1=CC=CO1,,,,,,
3584,73585,"2,5-Diphenyl-3,4-dimethyloxazolidine",C[C@H]1[C@@H](OC(N1C)C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
3585,73586,CID 73586,CC[C@@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N)N,,,,,,
3586,73587,Glycyl-l-histidyl-l-lysine,C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)CN,['Commonly used in cosmetic products for the skin and hair.'],"['Prezatide in complex with copper improve skin elasticity, density, and firmness, reduces fine lines and wrinkles, reduces photodamage, increases keratinocyte proliferation. Prezatide also displays anti-oxidant and angiogenic effects and appears to modulate tissue remodeling in injury.']",,['Prezatide both free and in complex with copper can pass through the stratum corneum. Its absorption is pH dependent with the highest absorption occurring at physiological pH.'],['Prezatide is broken down to histidyl-lysine which is likely further degraded to other metabolites of proteolysis.'],['Prezatide is rapidly eliminated within minutes.']
3587,73588,Taxodione,CC(C)C1=CC2=CC(=O)[C@@H]3[C@@](C2=C(C1=O)O)(CCCC3(C)C)C,,,,,,
3588,73589,Sellowin A,CC(CO)[C@@H]1[C@]23[C@H](O2)[C@@H]4[C@@H]5[C@@](C3=CC(=O)O1)(C[C@H]6[C@@H]([C@@]5(C(=O)O4)C)O6)C,,,,,,
3589,73590,CID 73590,CN1C=NC2=C1C(=O)N(C(=O)N2C)C.C1[C@H]([C@H]([C@@H](C[C@@]1(C(=O)[O-])O)OC(=O)C=CC2=CC(=C(C=C2)O)O)O)O.[K+],,,,,,
3590,73591,CID 73591,C1[C@H](C([C@@H](C[C@@]1(C(=O)O)O)OC(=O)C=CC2=CC(=C(C=C2)O)O)O)O,,,,,,
3591,73592,"beta-D-Glucopyranoside, 2-(3,4-dihydroxyphenyl)ethyl 3-O-(6-deoxy-alpha-L-mannopyranosyl)-, 4-[3-(3,4-dihydroxyphenyl)-2-propenoate]",C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H](O[C@@H]([C@H]2OC(=O)C=CC3=CC(=C(C=C3)O)O)CO)OCCC4=CC(=C(C=C4)O)O)O)O)O)O,,,"['Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. (See all compounds classified as Immunosuppressive Agents.)', 'Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. (See all compounds classified as Antioxidants.)', 'Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. (See all compounds classified as Anti-Infective Agents.)', 'Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. (See all compounds classified as Antineoplastic Agents, Phytogenic.)', 'Chemicals that bind to and remove ions from solutions. Many chelating agents function through the formation of COORDINATION COMPLEXES with METALS. (See all compounds classified as Chelating Agents.)']",,,
3592,73593,Cinerubin B,CC[C@]1(C[C@@H](C2=C(C3=C(C=C2[C@H]1C(=O)OC)C(=O)C4=C(C=CC(=C4C3=O)O)O)O)O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O[C@H]6C[C@H]7[C@@H]([C@@H](O6)C)O[C@H]8[C@@H](O7)CC(=O)[C@@H](O8)C)N(C)C)O,,,,,,
3593,73594,"methyl (1R,11S,17S)-12-ethylidene-4-hydroxy-8,14-diazapentacyclo[9.5.2.01,9.02,7.014,17]octadeca-2(7),3,5,9-tetraene-10-carboxylate",CC=C1CN2CC[C@@]34[C@@H]2C[C@@H]1C(=C3NC5=C4C=C(C=C5)O)C(=O)OC,,,,,,
3594,73595,CID 73595,C[C@@H]1CCCC(=CCC[C@@]([C@H]2C[C@@H]3[C@H]([C@@H]1O2)OC(=O)C3=C)(C)O)C,,,,,,
3595,73596,CID 73596,CC1=C[C@H]2[C@H]([C@H](CC(=C[C@@H](C1)O)CO)OC(=O)C(=C)C)C(=C)C(=O)O2,,,,,,
3596,73597,Paris saponin II,C[C@@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)CC4[C@@]3(CC[C@H]5[C@H]4CC=C6[C@@]5(CC[C@@H](C6)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O[C@H]8[C@@H]([C@@H]([C@H]([C@@H](O8)C)O[C@H]9[C@H]([C@@H]([C@H]([C@@H](O9)C)O)O)O)O)O)O)O[C@H]2[C@@H]([C@@H](C([C@@H](O2)C)O)O)O)C)C)C)OC1,,,,,,
3597,73598,Ginsenoside C2,CC(=CCC[C@@](C)([C@H]1CC[C@@]2([C@@H]1[C@@H](C[C@H]3[C@]2(CC[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C)C)O)C)O[C@H]7[C@@H](C([C@@H]([C@H](O7)CO[C@H]8[C@@H]([C@H]([C@H](CO8)O)O)O)O)O)O)C,,,"['Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS. (See all compounds classified as Hypolipidemic Agents.)', 'Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)']",,,
3598,73599,Panaxatriol,C[C@@]1(CCCC(O1)(C)C)[C@H]2CC[C@@]3([C@@H]2[C@@H](C[C@H]4[C@]3(C[C@H]([C@@H]5[C@@]4(CC[C@@H](C5(C)C)O)C)O)C)O)C,,,,,,
3599,73600,Endosidin 1,CC[C@@H](C)[C@H](C(=O)O[C@H]1[C@@H]([C@H](C(=C)[C@@]2([C@@]1([C@H](CC2=O)C3=COC=C3)C)O)[C@@]4([C@H](CC(=O)O[C@]([C@@H]4CC(=O)OC)(C)COC(=O)C)OC(=O)C)C)OC=O)O,,,,,,
3600,73601,CID 73601,C[C@@](C=C[C@@H]1CC=CC(=O)O1)([C@@H](C[C@H](C=CC=CC=CCO)O)OP(=O)(O)O)O,,,,,,
3601,73602,"[(1S,3R,4R,5R,6R,7S,8R,11S,13R,16R,17R)-6-hydroxy-16-(1-hydroxyethyl)-13-methoxy-5,17,19-trimethyl-14-oxo-2,15-dioxatetracyclo[9.8.0.01,7.03,8]nonadeca-9,18-dien-4-yl] 1H-pyrrole-2-carboxylate",C[C@@H]1C=C([C@]23[C@@H](C[C@H](C(=O)O[C@H]1C(C)O)OC)C=C[C@@H]4[C@H]2[C@@H]([C@H]([C@H]([C@@H]4O3)OC(=O)C5=CC=CN5)C)O)C,,,,,,
3602,73603,Neotenone,COC1=CC2=C(C=C1C3COC4=C(C3=O)C=C5C=COC5=C4)OCO2,,,,,,
3603,73604,Deidaclin,C1C[C@@](C=C1)(C#N)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O,,,,,,
3604,73605,CID 73605,CCC1CC(C(C=CC=CCC(OC(=O)CC(C(C1O[C@H]2[C@@H]([C@@](C[C@H](O2)C)(C(=O)C)O)O)OC)O)C)O)C,,,,,,
3605,73606,L-Rhamnopyranosyl-14-D-glucopyranose solasodine,C[C@@H]1CCC2([C@H]([C@H]3[C@@H](O2)C[C@@H]4[C@@]3(CC[C@H]5[C@H]4CC=C6[C@@]5(CC[C@@H](C6)O[C@H]7[C@@H]([C@@H]([C@H]([C@@H](O7)CO)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)C)O)O)O)O)O)C)C)C)NC1,,,,,,
3606,73607,Sakuranin,COC1=CC2=C(C(=O)C[C@H](O2)C3=CC=C(C=C3)O)C(=C1)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O,,,,,,
3607,73608,"(2S,3R,5S,6R)-2-[7-hydroxy-2-(4-hydroxy-3,5-dimethoxyphenyl)-3-[(2R,3S,4R,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromenylium-5-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol;chloride",COC1=CC(=CC(=C1O)OC)C2=C(C=C3C(=CC(=CC3=[O+]2)O)O[C@H]4[C@@H](C([C@@H]([C@H](O4)CO)O)O)O)O[C@@H]5[C@H]([C@@H]([C@H]([C@@H](O5)CO)O)O)O.[Cl-],,,,,,
3608,73609,"2-(4-hydroxy-3,5-dimethoxyphenyl)-3-[(2R,3S,4R,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-[(2S,3R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-7-one",COC1=CC(=CC(=C1O)OC)C2=C(C=C3C(=CC(=O)C=C3O[C@H]4[C@@H](C([C@@H]([C@H](O4)CO)O)O)O)O2)O[C@@H]5[C@H]([C@@H]([C@H]([C@@H](O5)CO)O)O)O,,,,,,
3609,73610,"(1R,2R,5S,8S,9S,12S,13R,14S,15R,16R,17S,20S,21S,24S)-12,17-dihydroxy-3,8,12,17,21,25-hexamethyl-6,23-dioxaheptacyclo[13.9.2.01,16.02,14.04,13.05,9.020,24]hexacosa-3,25-diene-7,22-dione",C[C@H]1[C@@H]2CC[C@]([C@@H]3[C@H]4[C@@H]5C=C([C@@]6([C@H]4C(=C3[C@H]2OC1=O)C)[C@@H]5[C@@](CC[C@@H]7[C@@H]6OC(=O)[C@H]7C)(C)O)C)(C)O,,,,,,
3610,73611,Solamargine,C[C@@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)C[C@@H]4[C@@]3(CC[C@H]5[C@H]4CC=C6[C@@]5(CC[C@@H](C6)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O[C@H]8[C@@H]([C@@H]([C@H]([C@@H](O8)C)O)O)O)O)O[C@H]9[C@@H]([C@@H]([C@H]([C@@H](O9)C)O)O)O)C)C)C)NC1,,,,,,
3611,73612,"[(2S,3S,6S)-6-[(2R,3R,4R,6S)-6-[(2R,4R,6S)-6-[[(2S,3S)-6-[(2S,4R,5S,6R)-4-acetyloxy-5-[(2R,4R,5R,6R)-4-hydroxy-5-methoxy-6-methyloxan-2-yl]oxy-6-methyloxan-2-yl]oxy-3-[(1S,3S,4R)-3,4-dihydroxy-1-methoxy-2-oxopentyl]-8,9-dihydroxy-1-oxo-3,4-dihydro-2H-anthracen-2-yl]oxy]-3-hydroxy-2-methyloxan-4-yl]oxy-3-hydroxy-2-methyloxan-4-yl]oxy-4-hydroxy-2,4-dimethyloxan-3-yl] 2-methylpropanoate",C[C@@H]1[C@H]([C@@H](C[C@@H](O1)O[C@@H]2C[C@@H](O[C@@H](C2O)C)O[C@H]3[C@@H](CC4=CC5=CC(=CC(=C5C(=C4C3=O)O)O)O[C@H]6C[C@H]([C@H]([C@H](O6)C)O[C@@H]7C[C@H]([C@H]([C@H](O7)C)OC)O)OC(=O)C)[C@@H](C(=O)[C@H]([C@@H](C)O)O)OC)O[C@H]8CC([C@H]([C@@H](O8)C)OC(=O)C(C)C)(C)O)O,,,,,,
3612,73613,CID 73613,C[C@H]1[C@@H]2C(=O)[C@H]3[C@](O3)([C@@](O2)(O[C@@H]1[C@H](C)C=C(C)C=CC(=O)C4=C(NCC4=O)O)C)C,,,,,,
3613,73614,Indicine,C[C@@H]([C@](C(C)C)(C(=O)OCC1=CCN2[C@H]1[C@@H](CC2)O)O)O,,,,,,
3614,73615,Einecs 259-391-3,C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1N)O[C@@H]2[C@@H](C[C@@H]([C@H](O2)CO)O)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O[C@@H]4[C@@H]([C@H]([C@@H]([C@@H](O4)CN)O[C@@H]5[C@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)O)N)O)O)N.OS(=O)(=O)O,,,,,,
3615,73616,"(2R,3S,4S,5S,6R)-2-[(2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(2R,3S,4R,5S)-5-[(1S,2S,3R,5S,6R)-3,5-diamino-2-[(2S,3R,5S,6R)-3-amino-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxy-4-hydroxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol",C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1N)O[C@@H]2[C@@H](C[C@@H]([C@H](O2)CO)O)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O[C@@H]4[C@@H]([C@H]([C@@H]([C@@H](O4)CN)O[C@@H]5[C@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)O)N)O)O)N,,,,,,
3616,73617,CID 73617,C[C@@H]1C=CC=C(C(=O)NC2=C(C(=C3C(=C(C(=C4C3=C(C(=C[C@@]([C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H](C1O)C)O)C(=O)OC)OC(=O)C)C)O)(C)O)C)OCO4)C)O)C2=O)OC(=O)C)C)C,,,,,,
3617,73618,Antibiotic A 32Y2,C[C@H]1[C@H](CC[C@@H](O1)O[C@]23C(=O)C[C@@](C[C@]2(C=CC4=C3C(=O)C5=C(C4=O)C(=C(C=C5)[C@H]6C[C@H]([C@@H]([C@H](O6)C)O)O[C@H]7CC[C@@H]([C@@H](O7)C)O[C@H]8C[C@H]([C@@H]([C@H](O8)C)O)O)O)O)(C)O)O,,,,,,
3618,73619,"(4R,7R,10S,13R,17R,19S)-7-[(2-Bromo-1H-indol-3-yl)methyl]-4-(4-hydroxyphenyl)-8,10,13,15,17,19-hexamethyl-1-oxa-5,8,11-triazacyclononadec-15-ene-2,6,9,12-tetrone",C[C@@H]1C[C@@H](OC(=O)C[C@@H](NC(=O)[C@H](N(C(=O)[C@@H](NC(=O)[C@@H](CC(=C1)C)C)C)C)CC2=C(NC3=CC=CC=C32)Br)C4=CC=C(C=C4)O)C,,,"['Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)', 'Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)', 'Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)']",,,
3619,73620,Crinamin,CO[C@@H]1C[C@H]2[C@@]3(C=C1)[C@H](CN2CC4=CC5=C(C=C34)OCO5)O,,,,,,
3620,73621,4beta-Hydroxywithanolide E,CC1=C(C(=O)O[C@H](C1)[C@@](C)([C@@]2(CC[C@@]3([C@@]2(CC[C@H]4[C@H]3C[C@@H]5[C@]6([C@@]4(C(=O)C=C[C@@H]6O)C)O5)C)O)O)O)C,,,,,,
3621,73622,CID 73622,CC1=CC=C(N1)C(=O)O[C@H]2[C@H]([C@@H](OC([C@@H]2OC)(C)C)OC3=C(C4=C(C=C3)C(=O)C(=C(O4)O)NC(=O)C5=CC(=C(C=C5)O)CC=C(C)C)Cl)O,,,,,,
3622,73623,9-Methylstreptimidone,CC=CC(=CC(C)C(=O)CC(CC1CC(=O)NC(=O)C1)O)C,,,,,,
3623,73624,CID 73624,C[C@H]1C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@@H](C(=O)N([C@@H]2C(C3=CC=C(C=C3)OC4=C(C=CC(=C4)C[C@H](C(=O)N1)N(C2=O)C)O)O)C)C)CC5=CC=C(C=C5)OC)C)C,,,"['Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. (See all compounds classified as Protein Synthesis Inhibitors.)']",,,
3624,73625,CID 73625,CC1=C[C@@H]2[C@@H]([C@@H]([C@H](C(=CCC1)C=O)OC(=O)C(C)C)O)C(=C)C(=O)O2,,,,,,
3625,73626,"(13alpha,17aalpha)-14beta,15beta:21,23-Diepoxy-7alpha-hydroxy-4,4,8-trimethyl-17-oxa-D-homo-24-nor-5alpha-chola-20,22-diene-3,16-dione",C[C@]12CCC(=O)C([C@@H]1C[C@H]([C@@]3([C@@H]2CC[C@@]4([C@]35[C@H](O5)C(=O)O[C@H]4C6=COC=C6)C)C)O)(C)C,,,,,,
3626,73627,2-Demethyl-N-trifluoroacetyl-deacetylcolchicine,COC1=CC=C2C(=CC1=O)[C@H](CCC3=CC(=C(C(=C32)OC)O)OC)NC(=O)C(F)(F)F,,,,,,
3627,73628,Deoxyparguerol,CC(=O)O[C@@H]1C[C@@]2([C@H](C[C@H]([C@H]3C2=CC[C@](C3)(C)[C@H](CO)Br)O)[C@@]4([C@H]1C4)C)C,,,,,,
3628,73629,"(2s,3s)-2,3-Dihydroxybutanedihydrazide",[C@H]([C@@H](C(=O)NN)O)(C(=O)NN)O,,,,,,
3629,73630,"methyl 2-[(1S,2S,5R,6R,13S,16S)-6-(furan-3-yl)-1,5,15,15-tetramethyl-8,14,17-trioxo-7-oxatetracyclo[11.3.1.02,11.05,10]heptadec-10-en-16-yl]acetate",C[C@@]12CC[C@H]3C(=C1CC(=O)O[C@H]2C4=COC=C4)C[C@@H]5C(=O)[C@@]3([C@H](C(C5=O)(C)C)CC(=O)OC)C,,,,,,
3630,73631,"Methyl 2,3:4,6-di-O-benzylidene-alpha-D-mannopyranoside",CO[C@@H]1[C@@H]2[C@H]([C@H]3[C@H](O1)COC(O3)C4=CC=CC=C4)OC(O2)C5=CC=CC=C5,,,,,,
3631,73632,Tetracenomycin C,CC1=C(C(=CC2=CC3=C(C(=C12)O)C(=O)[C@@]4(C(=O)C=C([C@H]([C@@]4(C3=O)O)O)OC)O)OC)C(=O)OC,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
3632,73633,CID 73633,C1=CC(=CC=C1C2=C(C(=C3C(=CC(=O)C=C3O2)O)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O,,,,,,
3633,73634,"1,3-Dibromo-5-ethyl-5-methylhydantoin",CCC1(C(=O)N(C(=O)N1Br)Br)C,,,,,,
3634,73635,Homoeriodictyol,COC1=C(C=CC(=C1)[C@@H]2CC(=O)C3=C(C=C(C=C3O2)O)O)O,,,,,,
3635,73636,"(2S,3R,4S,5S,6R)-2-[4-[6-[3,5-dimethoxy-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan-3-yl]-2,6-dimethoxyphenoxy]-6-(hydroxymethyl)oxane-3,4,5-triol",COC1=CC(=CC(=C1O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)OC)C3C4COC(C4CO3)C5=CC(=C(C(=C5)OC)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)OC,,,,,,
3636,73637,CID 73637,CCC(=C[C@H](C)CC=CC(=C[C@@H](C)C(=O)[C@@H](C)[C@@H]([C@@H](C)CC(=CC(=O)O)C)O)C)C=C[C@@H]1[C@H](C=CC(=O)O1)C,,,,,,
3637,73638,"17-Ethyl-6-hydroxy-9-(hydroxymethyl)-3,5,7,11,15-pentamethyl-19-(3-methyl-6-oxo-3,6-dihydro-2h-pyran-2-yl)-8-oxononadeca-2,10,12,16,18-pentaenoic acid",CCC(=CC(C)CC=CC(=CC(CO)C(=O)C(C)C(C(C)CC(=CC(=O)O)C)O)C)C=CC1C(C=CC(=O)O1)C,,,"['Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. (See all compounds classified as Antibiotics, Antineoplastic.)']",,,
3638,73639,Kazusamycin B;CL 1957E,CC1C=CC(=O)OC1C=CC(=CC(C)CC=CC(=CC(CO)C(=O)C(C)C(C(C)CC(=CC(=O)O)C)O)C)C,,,,,,
3639,73640,"9-Fluoro-8-(1h-imidazol-1-yl)-5-methyl-1-oxo-6,7-dihydro-1h,5h-pyrido[3,2,1-ij]quinoline-2-carboxylic acid",CC1CCC2=C3N1C=C(C(=O)C3=CC(=C2N4C=CN=C4)F)C(=O)O,,,,,,
3640,73641,Arjunolic acid,C[C@@]12CC[C@@H]3[C@@]([C@H]1CC=C4[C@]2(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)C)(C[C@H]([C@@H]([C@@]3(C)CO)O)O)C,,,,,,
3641,73642,"(2S,3R,4S,5S,6R)-2-[3-hydroxy-5-[2-(4-hydroxyphenyl)ethenyl]phenoxy]-6-(hydroxymethyl)oxane-3,4,5-triol",C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O)O,,,,,,
3642,73643,"[(3aR,4R,5R,9aR,9bS)-4,9a-dihydroxy-6,9-dimethyl-3-methylidene-2,7-dioxo-3a,4,5,9b-tetrahydroazuleno[4,5-b]furan-5-yl] 2-methylbut-2-enoate",CC=C(C)C(=O)O[C@H]1[C@@H]([C@@H]2[C@@H]([C@]3(C(=CC(=O)C3=C1C)C)O)OC(=O)C2=C)O,,,,,,
3643,73644,Casuarictin,C1[C@@H]2[C@H]([C@H]3[C@H]([C@@H](O2)OC(=O)C4=CC(=C(C(=C4)O)O)O)OC(=O)C5=CC(=C(C(=C5C6=C(C(=C(C=C6C(=O)O3)O)O)O)O)O)O)OC(=O)C7=CC(=C(C(=C7C8=C(C(=C(C=C8C(=O)O1)O)O)O)O)O)O,,,,,,
3644,73645,"2alpha,3alpha,19 alpha-Trihydroxyurs-12-en-28-oic acid",C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CCC5[C@@]4(C[C@H]([C@H](C5(C)C)O)O)C)C)[C@H]2[C@]1(C)O)C)C(=O)O,,,,,,
3645,73646,CID 73646,CC1=C[C@@H]([C@H]([C@@H](C1)C2=C(C=C(C=C2)O)O)C(=O)C3=C(C(=C(C=C3)O)CC=C(C)C)O)C4=C5C(=C(C(=C(O5)C6=C(C=C(C=C6)OCC=C(C)C)O)CC=C(C)C)O)C(=O)C=C4O,,,,,,
3646,73647,CID 73647,CC1=C[C@@H]([C@H]([C@@H](C1)C2=C(C=C(C=C2)O)O)C(=O)C3=C(C=C(C=C3)O)O)C4=C5C(=C(C(=C(O5)C6=C(C=C(C=C6)O)O)CC=C(C)C)O)C(=O)C=C4O,,,,,,
3647,73648,Umuhengerin,COC1=CC(=CC(=C1OC)OC)C2=CC(=O)C3=C(C(=C(C=C3O2)OC)OC)O,,,,,,
3648,73649,Isoneorautenol,CC1(C=CC2=CC3=C(C=C2O1)OC4C3COC5=C4C=CC(=C5)O)C,,,,,,
3649,73650,CID 73650,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=C(OC4=CC(=CC(=O)C4=C3O)OC)C5=CC(=C(C=C5)O)OC)O)O)O)O)O)O,,,,,,
3650,73651,"(1R,2S,3R)-3-(6-amino-9H-purin-9-yl)cyclopentane-1,2-diol",C1C[C@H]([C@H]([C@@H]1N2C=NC3=C(N=CN=C32)N)O)O,,,,,,
3651,73652,"(1r,2s,3r)-3-(4-Amino-1h-imidazo[4,5-c]pyridin-1-yl)cyclopentane-1,2-diol",C1C[C@H]([C@H]([C@@H]1N2C=NC3=C2C=CN=C3N)O)O,,,,,,
3652,73653,"2-(2-((2,4-Dimethoxyphenyl)amino)ethenyl)-1,3,3-trimethyl-3H-indolium chloride",CC1(C2=CC=CC=C2[N+](=C1C=CNC3=C(C=C(C=C3)OC)OC)C)C.[Cl-],,,,,,
3653,73654,"2-[2-(2,4-Dimethoxyanilino)vinyl]-1,3,3-trimethyl-3H-indolium",CC1(C2=CC=CC=C2[N+](=C1C=CNC3=C(C=C(C=C3)OC)OC)C)C,,,,,,
3654,73655,7-Chlororiboflavin,CC1=CC2=C(C=C1Cl)N=C3C(=O)NC(=O)N=C3N2C[C@@H]([C@@H]([C@@H](CO)O)O)O,,,,,,
3655,73656,CID 73656,CCN1CCN(CC1)NC=C2C(=C3C4=C(C2=NC(=O)C(=CC=C[C@H]([C@H]([C@H]([C@@H]([C@@H]([C@H]([C@H]([C@H](C=CO[C@@]5(C(=O)C3=C(O5)C(=C4O)C)C)OC)C)OC(=O)C)C)O)C)O)C)C)O)O,,,,,,
3656,73657,"(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-4-[(2R,4R,5S,6S)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-7-[(2S,4R,6S)-4-(dimethylamino)-5-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-12,13-dihydroxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione",CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)O)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O[C@H]4C[C@H](C([C@@H](O4)C)O)N(C)C)C)C)O)(C)O,,,,,,
3657,73658,"(1S,2R,5R,7R,8R,9R,11R,13S,14R)-8-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-9-methoxy-1,5,7,9,11,13-hexamethyl-15-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-3,17-dioxa-15-azabicyclo[12.3.0]heptadecane-4,6,12,16-tetrone",CC[C@@H]1[C@@]2([C@@H]([C@@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,,,,"['Telithromycin concentration in white blood cells exceeds the concentration in plasma and is eliminated more slowly from white blood cells than from plasma. Mean white blood cell concentrations of telithromycin peaked at 72.1 ug/mL at 6 hours, and remained at 14.1 ug/mL 24 hours after 5 days of repeated dosing of 600 mg once daily. After 10 days, repeated dosing of 600 mg once daily, white blood cell concentrations remained at 8.9 ug/mL 48 hours after the last dose.', 'Volume of distribution - 2.9 L/kg following an intervenous infusion. Widely distributed throughout the body. Telithromycin is distributed into breast milk of rats.', 'Rapidly absorbed, absolute bioavailability is 57% in both young and elderly patients. The rate and extent of absorption are unaffected by food. The AUC following a single dose is 8.25 ug h/mL and 12.5 ug h/mL following multiple dosing.', 'The systemically available telithromycin is eliminated by multiple pathways as follows: 7% of the dose is excreted unchanged in feces by biliary and/or intestinal secretion; 13% of the dose is excreted unchanged in urine by renal excretion; and 37% of the dose is metabolized by the liver.', 'For more Absorption, Distribution and Excretion (Complete) data for TELITHROMYCIN (11 total), please visit the HSDB record page.']","['About 70% (33% presystemic and 37% systemic) of an oral dose is metabolized about equally by cytochrome P450 (CYP) 3A4 and non-CYP3A4 isoenzymes to 4 major metabolites. The systemically available telithromycin is eliminated in the feces as unchanged drug (7%), in urine as unchanged drug (13%), and 37% is metabolized in the liver.', 'Biotransformation: Hepatic; 37% of the dose is metabolized by the liver. Metabolism accounts for approximately 70% of the dose. The main metabolite represented 12.6% of the AUC while three other metabolites quantified represented 3% or less of the AUC of telithromycin.', 'In total, metabolism accounts for approximately 70% of the dose. In plasma, the main circulating compound after administration of an 800-mg radiolabeled dose was parent compound, representing 56.7% of the total radioactivity. The main metabolite represented 12.6% of the AUC of telithromycin. Three other plasma metabolites were quantified, each representing 3% or less of the AUC of telithromycin. It is estimated that approximately 50% of its metabolism is mediated by CYP 450 3A4 and the remaining 50% is CYP 450-independent.']",['Elimination: 10 hours following oral dosing.']
3658,73659,Maslinic acid,C[C@@]12CC[C@@H]3[C@@]([C@H]1CC=C4[C@]2(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)C)(C[C@H]([C@@H](C3(C)C)O)O)C,,,,,,
3659,73660,CID 73660,CN(C)CC(=O)NC1=C(C2=C(C[C@H]3C[C@H]4[C@@H](C(=O)C(=C(N)O)C(=O)[C@]4(C(=O)C3=C2O)O)N(C)C)C=C1)O,,,,,,
3660,73661,"(2S,3S,4S,5R)-2-(2,6-diaminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol",C1=NC2=C(N=C(N=C2N1[C@@H]3[C@H]([C@@H]([C@H](O3)CO)O)O)N)N,,,,,,
3661,73662,"(2R,3S,4S,5R)-2-(2,6-diaminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol",C1=NC2=C(N=C(N=C2N1[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)O)N)N,,,,,,
3662,73663,CID 73663,CN1CCC2=CC(=C3C=C2[C@H]1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)C[C@@H]6C7=C(O3)C(=C(C=C7CCN6C)OC)OC)OC)OC.CN1CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)C[C@H]6C7=C(O3)C(=C(C=C7CCN6C)OC)OC)OC)OC,,,,,,
3663,73664,Pheanthine,CN1CCC2=CC(=C3C=C2[C@H]1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)C[C@@H]6C7=C(O3)C(=C(C=C7CCN6C)OC)OC)OC)OC,,,"['Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)', 'Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. (See all compounds classified as Immunosuppressive Agents.)', 'Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585) (See all compounds classified as Antimalarials.)', 'Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. (See all compounds classified as Antineoplastic Agents, Phytogenic.)', 'A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)']",,,
3664,73665,Prochloraz,CCCN(CCOC1=C(C=C(C=C1Cl)Cl)Cl)C(=O)N2C=CN=C2,,,"['Chemicals that kill or inhibit the growth of fungi in agricultural applications, on wood, plastics, or other materials, in swimming pools, etc. (See all compounds classified as Fungicides, Industrial.)']",,,
3665,73666,Pentachlorocyclopentadiene,C1(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl,,,,,,
3666,73667,Ammonium methacrylate,CC(=C)C(=O)[O-].[NH4+],,,,,,
3667,73668,Flurprimidol,CC(C)C(C1=CC=C(C=C1)OC(F)(F)F)(C2=CN=CN=C2)O,,,,,,
3668,73669,Tridiphane,C1C(O1)(CC(Cl)(Cl)Cl)C2=CC(=CC(=C2)Cl)Cl,,,,,,
3669,73670,Clofentezine,C1=CC=C(C(=C1)C2=NN=C(N=N2)C3=CC=CC=C3Cl)Cl,,,,,,
3670,73671,Paclobutrazol,CC(C)(C)[C@@H]([C@H](CC1=CC=C(C=C1)Cl)N2C=NC=N2)O,,,,,,
3671,73672,Isoxaben,CCC(C)(CC)C1=NOC(=C1)NC(=O)C2=C(C=CC=C2OC)OC,,,,"['In rats, following oral administration, 90% is excreted in the feces within 48 hours; about 10% of the absorbed isoxaben undergoes conversion into about 15-20 metabolites, which are excreted in the urine. There is no accumulation of either parent or metabolites in cell tissue.']",,
3672,73673,"(4S)-5-(4-chlorophenyl)-N-cyclohexyl-4-methyl-2-oxo-1,3-thiazolidine-3-carboxamide",C[C@H]1C(SC(=O)N1C(=O)NC2CCCCC2)C3=CC=C(C=C3)Cl,,,,,,
3673,73674,Thifensulfuron-methyl,CC1=NC(=NC(=N1)OC)NC(=O)NS(=O)(=O)C2=C(SC=C2)C(=O)OC,,,,"['In mammals, following oral administration of thifensulfuron-methyl, 70-75% of the unchanged material is excreted in the urine and feces.']","['In the rat metabolism study, ...of the radioactivity eliminated in the urine and feces, most was parent compound with 5 minor metabolites. /from table/', 'The primary degradation mechanism involves hydrolysis of the methoxycarbonyl group, O-demethylation of the heterocyclic ring, and hydrolysis of the sulfonylurea group.']",
3674,73675,Flusilazole,C[Si](CN1C=NC=N1)(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F,,,"['Chemicals that kill or inhibit the growth of fungi in agricultural applications, on wood, plastics, or other materials, in swimming pools, etc. (See all compounds classified as Fungicides, Industrial.)']",,,
3675,73676,CID 73676,CC1=CC(=O)C(=CO)C2=C1C(=O)OC3=C(C(=O)C4=C(OC(C4=C3O2)O)O)CO,,,,,,
3676,73677,Stictic acid,CC1=CC(=C(C2=C1C(=O)OC3=C(O2)C4=C(C(=C3C)O)C(=O)OC4O)C=O)OC,,,,,,
3677,73678,CID 73678,CC(=C)C(=O)O[C@H]1C[C@]23[C@H](O2)CCC(=C[C@@H]4[C@@H]1C(=C)C(=O)O4)CO[C@@H]3O,,,,,,
3678,73679,Hydroxyaspergillic acid,CCC(C)(C1=CN=C(C(=O)N1O)CC(C)C)O,,,,,,
3679,73680,Tiazofurin adenine dinucleotide,C1=C(N=C(S1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O)O)O)C(=O)N,,,['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)'],,,
3680,73681,"7-Oxabicyclo(2.2.1)heptane-2,3-dicarboxylic anhydride, 5,6-dibromo-, (E)-",C12C(C3C(C(C1O3)Br)Br)C(=O)OC2=O,,,,,,
3681,73682,11-Ketotigogenin,C[C@@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)C[C@@H]4[C@@]3(CC(=O)[C@H]5[C@H]4CC[C@@H]6[C@@]5(CC[C@@H](C6)O)C)C)C)OC1,,,,,,
3682,73683,"4-Hydroxy-5-chloro-3,6-endoxo-hexahydrophthalic acid lactone",C12C(C3C(C(C1O3)OC2=O)Cl)C(=O)O,,,,,,
3683,73684,"3-(2,2-Diethoxyethylaminomethyl)-1,4-dimethyl-carbazole",CCOC(CNCC1=C(C2=C(C(=C1)C)NC3=CC=CC=C32)C)OCC,,,,,,
3684,73685,Gallein,C1=CC=C2C(=C1)C(=O)OC23C4=C(C(=C(C=C4)O)O)OC5=C3C=CC(=C5O)O,,,,,,
3685,73686,"(3S)-3-[(2R,3S,5R)-5-[(2R)-3-[(1S,3R,5S,7R,9S,11R,14R,16S,17S,18R,20S,21S,25R,27S,29R,31S,34S,35S,37R,39S,41R)-17,34-dihydroxy-11-[(4R)-5-hydroxy-2,4-dimethylpent-2-enyl]-9,18,21,27,29,34-hexamethyl-12-methylidene-2,6,10,15,19,26,30,36,40-nonaoxanonacyclo[23.18.0.03,20.05,18.07,16.09,14.027,41.029,39.031,37]tritetracont-22-en-35-yl]-2-hydroxypropyl]-3-methyloxolan-2-yl]butanoic acid",C[C@H]1C[C@@H](O[C@H]1[C@@H](C)CC(=O)O)C[C@H](C[C@H]2[C@@](CC[C@H]3[C@H](O2)C[C@H]4[C@](O3)(C[C@]5([C@H](O4)CC[C@H]6[C@H](O5)CC=C[C@@H]([C@H]7[C@H](O6)C[C@H]8[C@](O7)([C@H]([C@H]9[C@H](O8)C[C@]1([C@H](O9)CC(=C)[C@H](O1)CC(=C[C@@H](C)CO)C)C)O)C)C)C)C)(C)O)O,,,,,,
3686,73687,"5,5,8a-Trimethyl-1,4,4a,5,6,7,8,8a-octahydronaphthalene-1,2-dicarbaldehyde",C[C@@]12CCCC([C@H]1CC=C([C@H]2C=O)C=O)(C)C,,,,,,
3687,73688,Methyl butadienecarboxylate,COC(=O)C=CC=C,,,,,,
3688,73689,p-(Methoxymethyl)anisole,COCC1=CC=C(C=C1)OC,,,,,,
3689,73690,1-Ethyl-4-methoxybenzene,CCC1=CC=C(C=C1)OC,,,,,,
3690,73691,CID 73691,CCCCN=C(N)S,,,,,,
3691,73692,CID 73692,COC1=CC=CC=C1N=C(N)S,,,,,,
3692,73693,2-Nitrophenyl azide,C1=CC=C(C(=C1)N=[N+]=[N-])[N+](=O)[O-],,,,,,
3693,73694,1-(Diazonioamino)-2-nitrobenzene,C1=CC=C(C(=C1)N[N+]#N)[N+](=O)[O-],,,,,,
3694,73695,Ethoxytriphenylsilane,CCO[Si](C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
3695,73696,"1,4-Bis(dicyanomethylene)cyclohexane",C1CC(=C(C#N)C#N)CCC1=C(C#N)C#N,,,,,,
3696,73697,"7,7,8,8-Tetracyanoquinodimethane",C1=CC(=C(C#N)C#N)C=CC1=C(C#N)C#N,,,,,,
3697,73698,"1,4-Dimethylanthraquinone",CC1=C2C(=C(C=C1)C)C(=O)C3=CC=CC=C3C2=O,,,,,,
3698,73699,CID 73699,CC1=C(C=C(C=C1)N=C(N)S)N=C(N)S,,,,,,
3699,73700,4-Vinylaniline,C=CC1=CC=C(C=C1)N,,,,,,
3700,73701,CID 73701,C1=CC(=CC=C1N=C(N)S)O,,,,,,
3701,73702,Ethanesulfonamide,CCS(=O)(=O)N,,,,,,
3702,73703,Tripropyl lead chloride,CCC[Pb](CCC)(CCC)Cl,,,,,,
3703,73704,"Plumbane, dichlorodimethyl-",C[Pb](C)(Cl)Cl,,,,,,
3704,73705,"3,4-Dimethoxybenzamide",COC1=C(C=C(C=C1)C(=O)N)OC,,,,,,
3705,73706,Hexafluoroacetylacetone,C(C(=O)C(F)(F)F)C(=O)C(F)(F)F,,,,,,
3706,73707,"1,3-Diiodo-2,2-bis(iodomethyl)propane",C(C(CI)(CI)CI)I,,,,,,
3707,73708,(Morpholin-4-yl)methyl acetate,CC(=O)OCN1CCOCC1,,,,,,
3708,73709,2-Naphthyl acetate,CC(=O)OC1=CC2=CC=CC=C2C=C1,,,,,,
3709,73710,2-Fluoro-6-nitrophenol,C1=CC(=C(C(=C1)F)O)[N+](=O)[O-],,,,,,
3710,73711,"2-Chloro-3-hydroxy-1,4-naphthoquinone",C1=CC=C2C(=C1)C(=C(C(=O)C2=O)Cl)O,,,,,,
3711,73712,3-Methoxybenzonitrile,COC1=CC=CC(=C1)C#N,,,,,,
3712,73713,3-Ethyl-4-heptanone,CCCC(=O)C(CC)CC,,,,,,
3713,73714,Methylenecyclopentane,C=C1CCCC1,,,,,,
3714,73715,N'-Propionylpropionohydrazide,CCC(=O)NNC(=O)CC,,,,,,
3715,73716,Ethyl 4-acetylphenylacetate,CCOC(=O)CC1=CC=C(C=C1)C(=O)C,,,,,,
3716,73717,"Triheptyl benzene-1,2,4-tricarboxylate",CCCCCCCOC(=O)C1=CC(=C(C=C1)C(=O)OCCCCCCC)C(=O)OCCCCCCC,,,,,,
3717,73718,"Trihexyl benzene-1,2,4-tricarboxylate",CCCCCCOC(=O)C1=CC(=C(C=C1)C(=O)OCCCCCC)C(=O)OCCCCCC,,,,,,
3718,73719,"Triisobutyl benzene-1,2,4-tricarboxylate",CC(C)COC(=O)C1=CC(=C(C=C1)C(=O)OCC(C)C)C(=O)OCC(C)C,,,,,,
3719,73720,"Silane, trimethylphenoxy-",C[Si](C)(C)OC1=CC=CC=C1,,,,,,
3720,73721,9H-Fluorene-9-carbonitrile,C1=CC=C2C(=C1)C(C3=CC=CC=C32)C#N,,,,,,
3721,73722,3-Chlorobenzyl cyanide,C1=CC(=CC(=C1)Cl)CC#N,,,,,,
3722,73723,Chlorotrimethylgermane,C[Ge](C)(C)Cl,,,,,,
3723,73724,Dimethylgermanium dichloride,C[Ge](C)(Cl)Cl,,,,,,
3724,73725,"1,1,3,5,5-Pentamethyl-1,3,5-trivinyltrisiloxane",C[Si](C)(C=C)O[Si](C)(C=C)O[Si](C)(C)C=C,,,,,,
3725,73726,"1,1-Diphenylpropane",CCC(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
3726,73727,Ethyltriphenylphosphonium bromide,CC[P+](C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3.[Br-],,,,,,
3727,73728,Ethyl(triphenyl)phosphonium,CC[P+](C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
3728,73729,"Phosphonium, triphenyl(3-phenyl-2-propen-1-yl)-, chloride (1:1)",C1=CC=C(C=C1)C=CC[P+](C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4.[Cl-],,,,,,
3729,73730,Cinnamyl-triphenyl-phosphanium,C1=CC=C(C=C1)C=CC[P+](C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
3730,73731,(Ethoxycarbonylmethyl)triphenylphosphonium bromide,CCOC(=O)C[P+](C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3.[Br-],,,,,,
3731,73732,Ethoxycarbonylmethyl-triphenyl-phosphonium,CCOC(=O)C[P+](C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
3732,73733,Allyltributylphosphonium chloride,CCCC[P+](CCCC)(CCCC)CC=C.[Cl-],,,,,,
3733,73734,Allyltributylphosphonium,CCCC[P+](CCCC)(CCCC)CC=C,,,,,,
3734,73735,Di-p-toluohydrazide,CC1=CC=C(C=C1)C(=O)NNC(=O)C2=CC=C(C=C2)C,,,,,,
3735,73736,1-Piperidinecarbonitrile,C1CCN(CC1)C#N,,,,,,
3736,73737,Pyrrolidine-1-carbonitrile,C1CCN(C1)C#N,,,,,,
3737,73738,4-Morpholinecarbonitrile,C1COCCN1C#N,,,,,,
3738,73739,2-Ethylisonicotinonitrile,CCC1=NC=CC(=C1)C#N,,,,,,
3739,73740,"3,4-Dimethyl-8-nitroquinoline",CC1=CN=C2C(=C1C)C=CC=C2[N+](=O)[O-],,,,,,
3740,73741,"Dibenzo[b,e]thiepin-11(6H)-one",C1C2=CC=CC=C2C(=O)C3=CC=CC=C3S1,,,,,,
3741,73742,1-Aminoisoquinoline,C1=CC=C2C(=C1)C=CN=C2N,,,,,,
3742,73743,4-Bromoisoquinoline,C1=CC=C2C(=C1)C=NC=C2Br,,,,,,
3743,73744,"Benzoxazole, 2,2'-(1,2-ethenediyldi-4,1-phenylene)bis-",C1=CC=C2C(=C1)N=C(O2)C3=CC=C(C=C3)C=CC4=CC=C(C=C4)C5=NC6=CC=CC=C6O5,,,,,,
3744,73745,"2-Naphthalenol, 1-(3-pyridinylazo)-",C1=CC=C2C(=C1)C=CC(=C2N=NC3=CN=CC=C3)O,,,,,,
3745,73746,"2,2'-[[3-Acetamido-4-[(4-nitrophenyl)azo]phenyl]imino]diethyl diacetate",CC(=O)NC1=C(C=CC(=C1)N(CCOC(=O)C)CCOC(=O)C)N=NC2=CC=C(C=C2)[N+](=O)[O-],,,,,,
3746,73747,"Propanamide, N-[5-[bis[2-(acetyloxy)ethyl]amino]-2-[(4-nitrophenyl)azo]phenyl]-",CCC(=O)NC1=C(C=CC(=C1)N(CCOC(=O)C)CCOC(=O)C)N=NC2=CC=C(C=C2)[N+](=O)[O-],,,,,,
3747,73748,"Acetamide, N-[5-[bis[2-(acetyloxy)ethyl]amino]-2-[(2-methoxy-4-nitrophenyl)azo]phenyl]-",CC(=O)NC1=C(C=CC(=C1)N(CCOC(=O)C)CCOC(=O)C)N=NC2=C(C=C(C=C2)[N+](=O)[O-])OC,,,,,,
3748,73749,"Acetamide, N-[5-[bis[2-(acetyloxy)ethyl]amino]-2-[(2-chloro-4-nitrophenyl)azo]phenyl]-",CC(=O)NC1=C(C=CC(=C1)N(CCOC(=O)C)CCOC(=O)C)N=NC2=C(C=C(C=C2)[N+](=O)[O-])Cl,,,,,,
3749,73750,S-Methyl thioacetate,CC(=O)SC,,,,,,
3750,73751,3-Tridecanone,CCCCCCCCCCC(=O)CC,,,,,,
3751,73752,[(Difluoromethyl)thio]benzene,C1=CC=C(C=C1)SC(F)F,,,,,,
3752,73753,3-(Trifluoromethoxy)aniline,C1=CC(=CC(=C1)OC(F)(F)F)N,,,,,,
3753,73754,2-(Trifluoromethoxy)aniline,C1=CC=C(C(=C1)N)OC(F)(F)F,,,,,,
3754,73755,"2,3,4,5,6-Pentafluorobenzophenone",C1=CC=C(C=C1)C(=O)C2=C(C(=C(C(=C2F)F)F)F)F,,,,,,
3755,73756,Acetic acid;triphenylstibane,CC(=O)O.CC(=O)O.C1=CC=C(C=C1)[Sb](C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
3756,73757,Diphenyl terephthalate,C1=CC=C(C=C1)OC(=O)C2=CC=C(C=C2)C(=O)OC3=CC=CC=C3,,,,,,
3757,73758,4-Acetamido-3-nitrobenzoic acid,CC(=O)NC1=C(C=C(C=C1)C(=O)O)[N+](=O)[O-],,,,,,
3758,73759,"2,2'-Dipicolylamine",C1=CC=NC(=C1)CNCC2=CC=CC=N2,,,,,,
3759,73760,Ethyl 3-(1-methylethoxy)-2-butenoate,CCOC(=O)C=C(C)OC(C)C,,,,,,
3760,73761,"3-Ethyl-2,4-pentanedione",CCC(C(=O)C)C(=O)C,,,,,,
3761,73762,"3-Propylpentane-2,4-dione",CCCC(C(=O)C)C(=O)C,,,,,,
3762,73763,"3-Butylpentane-2,4-dione",CCCCC(C(=O)C)C(=O)C,,,,,,
3763,73764,4-Dodecylmorpholine,CCCCCCCCCCCCN1CCOCC1,,,,,,
3764,73765,"1,1'-Isopropylidenebis(4-(1,1,2,2-tetrafluoroethoxy)benzene)",CC(C)(C1=CC=C(C=C1)OC(C(F)F)(F)F)C2=CC=C(C=C2)OC(C(F)F)(F)F,,,,,,
3765,73766,Fluoroacetaldehyde,C(C=O)F,,,,,,
3766,73767,1-(Trifluoroacetyl)imidazole,C1=CN(C=N1)C(=O)C(F)(F)F,,,,,,
3767,73768,4-(Trifluoromethyl)phenyl isocyanate,C1=CC(=CC=C1C(F)(F)F)N=C=O,,,,,,
3768,73769,"4-Amino-2,3,5,6-tetrafluorobenzamide",C1(=C(C(=C(C(=C1F)F)N)F)F)C(=O)N,,,,,,
3769,73770,"2,4-Difluorobenzaldehyde",C1=CC(=C(C=C1F)F)C=O,,,,,,
3770,73771,2-Propylthiophene,CCCC1=CC=CS1,,,,,,
3771,73772,Cyclohexyl pentanoate,CCCCC(=O)OC1CCCCC1,,,,,,
3772,73773,Crystal violet lactone,CN(C)C1=CC=C(C=C1)C2(C3=C(C=C(C=C3)N(C)C)C(=O)O2)C4=CC=C(C=C4)N(C)C,,,,,,
3773,73774,"5-Methyl-2-[4-[2-(5-methyl-1,3-benzoxazol-2-yl)ethenyl]phenyl]-1,3-benzoxazole",CC1=CC2=C(C=C1)OC(=N2)C=CC3=CC=C(C=C3)C4=NC5=C(O4)C=CC(=C5)C,,,,,,
3774,73775,CID 73775,CC(C)C1=CC2=C(C=C1)OC(=N2)C=CC3=CC=C(C=C3)C4=NC5=C(O4)C=CC(=C5)C(C)C,,,,,,
3775,73776,Ethyl cyclohexylideneacetate,CCOC(=O)C=C1CCCCC1,,,,,,
3776,73777,Cinnamalacetic acid,C1=CC=C(C=C1)C=CC=CC(=O)O,,,,,,
3777,73778,"4-(N,N-dimethylamino) cinnamic acid",CN(C)C1=CC=C(C=C1)C=CC(=O)O,,,,,,
3778,73779,"Propanenitrile, 3,3'-(methylimino)bis-",CN(CCC#N)CCC#N,,,,,,
3779,73780,"N,N-Bis(cyanoethyl)aniline",C1=CC=C(C=C1)N(CCC#N)CCC#N,,,,,,
3780,73781,8-Ethoxyquinoline,CCOC1=CC=CC2=C1N=CC=C2,,,,,,
3781,73782,Chlorocyclooctane,C1CCCC(CCC1)Cl,,,,,,
3782,73783,Bromocyclooctane,C1CCCC(CCC1)Br,,,,,,
3783,73784,Iodocyclopentane,C1CCC(C1)I,,,,,,
3784,73785,CID 73785,C1=CC(=CN=C1)C(=O)OC2=C(OC3=CC(=O)C=C(C3=C2O)O)C4=CC(=C(C=C4)O)O,,,,,,
3785,73786,Trichloro(dichloromethyl)silane,C([Si](Cl)(Cl)Cl)(Cl)Cl,,,,,,
3786,73787,"Silane, dichloro(dichloromethyl)methyl-",C[Si](C(Cl)Cl)(Cl)Cl,,,,,,
3787,73788,Dichloro(chloromethyl)methylsilane,C[Si](CCl)(Cl)Cl,,,,,,
3788,73789,Diethyl [2-(phenylthio)ethyl]malonate,CCOC(=O)C(CCSC1=CC=CC=C1)C(=O)OCC,,,,,,
3789,73790,"Diethyl 1,1-cyclopropanedicarboxylate",CCOC(=O)C1(CC1)C(=O)OCC,,,,,,
3790,73791,"3,6,9,12-Tetraoxahexadecan-1-OL",CCCCOCCOCCOCCOCCO,,,,,,
3791,73792,"2-Bromo-1,3,4,5-tetrafluorobenzene",C1=C(C(=C(C(=C1F)Br)F)F)F,,,,,,
3792,73793,"1,3-Dibromotetrafluorobenzene",C1(=C(C(=C(C(=C1F)Br)F)Br)F)F,,,,,,
3793,73794,"1-Bromo-2,3,5,6-tetrafluorobenzene",C1=C(C(=C(C(=C1F)F)Br)F)F,,,,,,
3794,73795,Chloropentamethyldisilane,C[Si](C)(C)[Si](C)(C)Cl,,,,,,
3795,73796,2-Methyltriacontane,CCCCCCCCCCCCCCCCCCCCCCCCCCCCC(C)C,,,,,,
3796,73797,Dicyclohexyl peroxydicarbonate,C1CCC(CC1)OC(=O)OOC(=O)OC2CCCCC2,,,,,,
3797,73798,"Disulfide, dihexadecyl",CCCCCCCCCCCCCCCCSSCCCCCCCCCCCCCCCC,,,,,,
3798,73799,CID 73799,CC(=C)CS(=O)(=O)[O-].[Na+],,,,,,
3799,73800,2-Methylprop-2-ene-1-sulfonic acid,CC(=C)CS(=O)(=O)O,,,,,,
3800,73801,Gallocyanine,CN(C)C1=CC2=C(C=C1)[NH+]=C3C(=CC(=O)C(=C3O2)O)C(=O)O.[Cl-],,,['Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. (See all compounds classified as Coloring Agents.)'],,,
3801,73802,Callocyanine,CN(C)C1=CC2=C(C=C1)NC3=C(O2)C(=O)C(=O)C=C3C(=O)O,,,,,,
3802,73803,CID 73803,CCN(CC)C1=CC2=C(C=C1)NC3=C(O2)C(=O)C(=O)C=C3C(=[NH2+])O.[Cl-],,,,,,
3803,73804,"7-(diethylamino)-3,4-dioxo-10H-phenoxazine-1-carboxamide",CCN(CC)C1=CC2=C(C=C1)NC3=C(O2)C(=O)C(=O)C=C3C(=O)N,,,,,,
3804,73805,Bis(2-pyridyl) ketone oxime,C1=CC=NC(=C1)C(=NO)C2=CC=CC=N2,,,,,,
3805,73806,"Benzenesulfonic acid, 3-((4-(diethylamino)-2-hydroxyphenyl)azo)-4-hydroxy-",CCN(CC)C1=CC(=C(C=C1)N=NC2=C(C=CC(=C2)S(=O)(=O)O)O)O,,,,,,
3806,73807,2-(2-Amino-5-bromobenzoyl)pyridine,C1=CC=NC(=C1)C(=O)C2=C(C=CC(=C2)Br)N,,,,,,
3807,73808,N-Acetyl-N-ethylacetamide,CCN(C(=O)C)C(=O)C,,,,,,
3808,73809,N-Acetyl-N-(1-methylethyl)acetamide,CC(C)N(C(=O)C)C(=O)C,,,,,,
3809,73810,N-Acetyl-N-butylacetamide,CCCCN(C(=O)C)C(=O)C,,,,,,
3810,73811,"N,N-Dibutylacetamide",CCCCN(CCCC)C(=O)C,,,,,,
3811,73812,N-Butylphthalimide,CCCCN1C(=O)C2=CC=CC=C2C1=O,,,,,,
3812,73813,1-Methylcycloheptene,CC1=CCCCCC1,,,,,,
3813,73814,5-Benzyloxygramine,CN(C)CC1=CNC2=C1C=C(C=C2)OCC3=CC=CC=C3,,,,,,
3814,73815,"2-(beta,beta-Diethoxycarbonylphenethyl)pyridinium chloride",CCOC(=O)C(CC1=CC=CC=N1)(C2=CC=CC=C2)C(=O)OCC.Cl,,,,,,
3815,73816,2-Phenyl-2-(2-pyridylmethyl)malonic acid diethyl ester,CCOC(=O)C(CC1=CC=CC=N1)(C2=CC=CC=C2)C(=O)OCC,,,,,,
3816,73817,3-Methylbenzo[b]thiophene,CC1=CSC2=CC=CC=C12,,,,,,
3817,73818,2-Butylthiophene,CCCCC1=CC=CS1,,,,,,
3818,73819,CID 73819,C1=CC=C(C=C1)C2=NC(=O)ON2,,,,,,
3819,73820,"2,4-Pentanedione, 3-(8-quinolinylazo)-",CC(=O)C(C(=O)C)N=NC1=CC=CC2=C1N=CC=C2,,,,,,
3820,73821,CID 73821,COCCCNC(=O)C1=CC(=[N+](O)[O-])C2=C(C1=N)C(=O)C3=CC=CC=C3C2=O,,,,,,
3821,73822,3-Phenylrhodanine,C1C(=O)N(C(=S)S1)C2=CC=CC=C2,,,,,,
3822,73823,3-Allylrhodanine,C=CCN1C(=O)CSC1=S,,,,,,
3823,73824,2-Methyl-1H-imidazole-4-carboxylic acid,CC1=NC=C(N1)C(=O)O,,,,,,
3824,73825,4-Methyl-1H-imidazole-5-carboxylic acid,CC1=C(N=CN1)C(=O)O,,,,,,
3825,73826,Ethyl oxanilate,CCOC(=O)C(=O)NC1=CC=CC=C1,,,,,,
3826,73827,"Methyl 3,5-diamino-6-chloropyrazine-2-carboxylate",COC(=O)C1=C(N=C(C(=N1)Cl)N)N,,,,,,
3827,73828,"Methyl 3-amino-5,6-dichloropyrazine-2-carboxylate",COC(=O)C1=C(N=C(C(=N1)Cl)Cl)N,,,,,,
3828,73829,"3h-Pyrazol-3-one, 4,4'-butylidenebis[1,2-dihydro-1,5-dimethyl-2-phenyl-",CCCC(C1=C(N(N(C1=O)C2=CC=CC=C2)C)C)C3=C(N(N(C3=O)C4=CC=CC=C4)C)C,,,,,,
3829,73830,1-Methylcyclopentanol,CC1(CCCC1)O,,,,,,
3830,73831,Diethyl ethylidenemalonate,CCOC(=O)C(=CC)C(=O)OCC,,,,,,
3831,73832,1-Cyclohexylbutan-1-one,CCCC(=O)C1CCCCC1,,,,,,
3832,73833,((2-Bromoethoxy)methyl)benzene,C1=CC=C(C=C1)COCCBr,,,,,,
3833,73834,3-(Dodecylthio)propionic acid,CCCCCCCCCCCCSCCC(=O)O,,,,,,
3834,73835,"Ethanol, 2-(dodecylthio)-",CCCCCCCCCCCCSCCO,,,,,,
3835,73836,3-Aminopicolinic acid,C1=CC(=C(N=C1)C(=O)O)N,,,,,,
3836,73837,"6-Ethyl-2,3-dimethylpyridine",CCC1=NC(=C(C=C1)C)C,,,,,,
3837,73838,1-(4-Bromophenyl)-2-methylpropan-2-amine hydrochloride,CC(C)(CC1=CC=C(C=C1)Br)N.Cl,,,,,,
3838,73839,1-(4-Bromophenyl)-2-methylpropan-2-amine,CC(C)(CC1=CC=C(C=C1)Br)N,,,,,,
3839,73840,1-tert-Butyl-piperidin-4-one,CC(C)(C)N1CCC(=O)CC1,,,,,,
3840,73841,4-(2-Cyanoethyl)-4-nitroheptanedinitrile,C(CC(CCC#N)(CCC#N)[N+](=O)[O-])C#N,,,,,,
3841,73842,CID 73842,C1=CC=C(C(=C1)C=CC=O)[N+](=O)[O-],,,,,,
3842,73843,4-Ethylbenzyl chloride,CCC1=CC=C(C=C1)CCl,,,,,,
3843,73844,"2,3,4-Trimethylaniline",CC1=C(C(=C(C=C1)N)C)C,,,,,,
3844,73845,"1,5-Diphenylpentane-1,3,5-trione",C1=CC=C(C=C1)C(=O)CC(=O)CC(=O)C2=CC=CC=C2,,,,,,
3845,73846,2-(Furan-2-yl)-2-oxoacetic acid,C1=COC(=C1)C(=O)C(=O)O,,,,,,
3846,73847,Isovaleric anhydride,CC(C)CC(=O)OC(=O)CC(C)C,,,,,,
3847,73848,9-Anthracenemethanol,C1=CC=C2C(=C1)C=C3C=CC=CC3=C2CO,,,,,,
3848,73849,"1-(2-Hydroxyphenyl)-3-phenylpropane-1,3-dione",C1=CC=C(C=C1)C(=O)CC(=O)C2=CC=CC=C2O,,,,,,
3849,73850,"2-Octenoic acid, (Z)-",CCCCCC=CC(=O)O,,,,,,
3850,73851,2-Hydroxy-5-methylbenzophenone,CC1=CC(=C(C=C1)O)C(=O)C2=CC=CC=C2,,,,,,
3851,73852,"2,4,4'-Trihydroxybenzophenone",C1=CC(=CC=C1C(=O)C2=C(C=C(C=C2)O)O)O,,,,,,
3852,73853,"1,4-Bis(allyloxy)butane",C=CCOCCCCOCC=C,,,,,,
3853,73854,Pentaerythritol triallyl ether,C=CCOCC(CO)(COCC=C)COCC=C,,,,,,
3854,73855,"3,3'-((2,2-Bis((allyloxy)methyl)-1,3-propanediyl)bis(oxy))dipropene",C=CCOCC(COCC=C)(COCC=C)COCC=C,,,,,,
3855,73856,"1,3-Propanediol, 2-butyl-2-ethyl-, dicarbamate",CCCCC(CC)(COC(=O)N)COC(=O)N,,,,,,
3856,73857,"1,3-Propanediol, 2,2-dimethyl-, dicarbamate",CC(C)(COC(=O)N)COC(=O)N,,,,,,
3857,73858,"Butanamide, N,N'-1,2-ethanediylbis[3-oxo-",CC(=O)CC(=O)NCCNC(=O)CC(=O)C,,,,,,
3858,73859,N-[4-(1-benzylpiperidin-4-yl)phenyl]propanamide,CCC(=O)NC1=CC=C(C=C1)C2CCN(CC2)CC3=CC=CC=C3,,,,,,
3859,73860,Dimethyl diethyl pyrophosphate,CCOP(=O)(OCC)OP(=O)(OC)OC,,,,,,
3860,73861,"Diphosphoric acid, tetrabutyl ester",CCCCOP(=O)(OCCCC)OP(=O)(OCCCC)OCCCC,,,,,,
3861,73862,"P,P-Diamidodiphosphoric acid, N,N,N',N'-tetramethyl-, diethyl ester",CCOP(=O)(OCC)OP(=O)(N(C)C)N(C)C,,,,,,
3862,73863,3-Indoleglyoxylic acid,C1=CC=C2C(=C1)C(=CN2)C(=O)C(=O)O,,,,,,
3863,73864,Bisphenol AF,C1=CC(=CC=C1C(C2=CC=C(C=C2)O)(C(F)(F)F)C(F)(F)F)O,,,"['Exogenous agents, synthetic and naturally occurring, which are capable of disrupting the functions of the ENDOCRINE SYSTEM including the maintenance of HOMEOSTASIS and the regulation of developmental processes. Endocrine disruptors are compounds that can mimic HORMONES, or enhance or block the binding of hormones to their receptors, or otherwise lead to activating or inhibiting the endocrine signaling pathways and hormone metabolism. (See all compounds classified as Endocrine Disruptors.)']",,,
3864,73865,2-Amino-5-bromo-2'-fluorobenzophenone,C1=CC=C(C(=C1)C(=O)C2=C(C=CC(=C2)Br)N)F,,,,,,
3865,73866,"Silane, chlorodimethyl(3,3,3-trifluoropropyl)-",C[Si](C)(CCC(F)(F)F)Cl,,,,,,
3866,73867,"1-Chloro-2,4-difluoro-5-nitrobenzene",C1=C(C(=CC(=C1Cl)F)F)[N+](=O)[O-],,,,,,
3867,73868,2-Amino-3-trifluoromethylbenzonitrile,C1=CC(=C(C(=C1)C(F)(F)F)N)C#N,,,,,,
3868,73869,2-Heptynoic acid,CCCCC#CC(=O)O,,,,,,
3869,73870,Diphenyliodonium chloride,C1=CC=C(C=C1)[I+]C2=CC=CC=C2.[Cl-],,,['Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. (See all compounds classified as Anti-Infective Agents.)'],,,
3870,73871,Diphenyliodonium bromide,C1=CC=C(C=C1)[I+]C2=CC=CC=C2.[Br-],,,['Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. (See all compounds classified as Anti-Infective Agents.)'],,,
3871,73872,9-Butyl-9H-carbazole,CCCCN1C2=CC=CC=C2C3=CC=CC=C31,,,,,,
3872,73873,9-Isopropyl-9H-carbazole,CC(C)N1C2=CC=CC=C2C3=CC=CC=C31,,,,,,
3873,73874,"3,4-Methylenedioxyphenethylamine",C1OC2=C(O1)C=C(C=C2)CCN,,,,,,
3874,73875,"2,4,6-Triphenylpyrylium perchlorate",C1=CC=C(C=C1)C2=CC(=[O+]C(=C2)C3=CC=CC=C3)C4=CC=CC=C4.[O-]Cl(=O)(=O)=O,,,,,,
3875,73876,"2,4,6-Triphenylpyrylium",C1=CC=C(C=C1)C2=CC(=[O+]C(=C2)C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
3876,73877,2-Naphthaleneethanol,C1=CC=C2C=C(C=CC2=C1)CCO,,,,,,
3877,73878,N-Benzylbenzamide,C1=CC=C(C=C1)CNC(=O)C2=CC=CC=C2,,,,,,
3878,73879,Methyldiphenylphosphine,CP(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
3879,73880,4-Benzyloxybenzoic acid,C1=CC=C(C=C1)COC2=CC=C(C=C2)C(=O)O,,,,,,
3880,73881,"Furan, 2-ethenyl-",C=CC1=CC=CO1,,,,,,
3881,73882,"(R)-1-(3-Hydroxy-7-methyl-2,4-dioxa-7-aza-3-phosphaoct-1-yl)ethylene dipalmitate P-oxide",CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCCN(C)C)OC(=O)CCCCCCCCCCCCCCC,,,,,,
3882,73883,Diphenyliodonium-2-carboxylate,C1=CC=C(C=C1)[I+]C2=CC=CC=C2C(=O)[O-],,,,,,
3883,73884,(2-Carboxylatophenyl)phenyliodonium,C1=CC=C(C=C1)[I+]C2=CC=CC=C2C(=O)O,,,,,,
3884,73885,"2-Methyl-1,3-cyclohexadiene",CC1=CCCC=C1,,,,,,
3885,73886,(4-Bromo-1-buten-1-yl)cyclopropane,C1CC1C=CCCBr,,,,,,
3886,73887,"1-Propanol, 2,2'-azobis[2-methyl-, diacetate (ester)",CC(=O)OCC(C)(C)N=NC(C)(C)COC(=O)C,,,,,,
3887,73888,Methyl 4-chloro-4-oxobutanoate,COC(=O)CCC(=O)Cl,,,,,,
3888,73889,"Benzo[h][1]benzothieno[3,2-b]quinoline",C1=CC=C2C(=C1)C=CC3=CC4=C(C5=CC=CC=C5S4)N=C32,,,,,,
3889,73890,"Benzo[f][1]benzothieno[3,2-b]quinoline",C1=CC=C2C(=C1)C=CC3=NC4=C(C=C32)SC5=CC=CC=C54,,,,,,
3890,73891,4-Nitrophenyl palmitate,CCCCCCCCCCCCCCCC(=O)OC1=CC=C(C=C1)[N+](=O)[O-],,,,,,
3891,73892,"Benzo(a)phenaleno(1,9-hi)acridine, 7-methyl-",CC1=C2C=C3C=CC4=C5C3=C(C2=NC6=C1C7=CC=CC=C7C=C6)C=CC5=CC=C4,,,,,,
3892,73893,"2-Propenoic acid, 4-[methyl[(nonafluorobutyl)sulfonyl]amino]butyl ester",CN(CCCCOC(=O)C=C)S(=O)(=O)C(C(C(C(F)(F)F)(F)F)(F)F)(F)F,,,,,,
3893,73894,Trifluoromethanol,C(O)(F)(F)F,,,,,,
3894,73895,1-Fluoro-2-nitrobenzene,C1=CC=C(C(=C1)[N+](=O)[O-])F,,,,,,
3895,73896,"1,3-Propanedione, 1,3-bis(4-fluorophenyl)-",C1=CC(=CC=C1C(=O)CC(=O)C2=CC=C(C=C2)F)F,,,,,,
3896,73897,Diphenylamine compd. with boron trifluoride,B(F)(F)F.C1=CC=C(C=C1)NC2=CC=CC=C2,,,,,,
3897,73898,Tripropylphosphine oxide,CCCP(=O)(CCC)CCC,,,,,,
3898,73899,"3-Methyl-3-propylpyrrolidine-2,5-dione",CCCC1(CC(=O)NC1=O)C,,,,,,
3899,73900,"Thiobenzoic acid, anhydrosulphide with O,O-diethyl dithiophosphorate",CCOP(=S)(OCC)SC(=O)C1=CC=CC=C1,,,,,,
3900,73901,O-(4-Chlorophenyl) O-ethyl ethylphosphonothioate,CCOP(=S)(CC)OC1=CC=C(C=C1)Cl,,,,,,
3901,73902,Glutaconaldehyde dianilide hydrochloride,C1=CC=C(C=C1)NC=CC=CC=NC2=CC=CC=C2.Cl,,,,,,
3902,73903,"N-[5-(Phenylimino)-1,3-pentadien-1-yl]aniline",C1=CC=C(C=C1)NC=CC=CC=NC2=CC=CC=C2,,,,,,
3903,73904,1-(Methoxymethyl)aziridine,COCN1CC1,,,,,,
3904,73905,Ethyl dichlorophosphite,CCOP(Cl)Cl,,,,,,
3905,73906,Diethylphosphoramidic dichloride,CCN(CC)P(=O)(Cl)Cl,,,,,,
3906,73907,Ethyl dichlorothiophosphate,CCOP(=S)(Cl)Cl,,,,,,
3907,73908,9-Butylanthracene,CCCCC1=C2C=CC=CC2=CC3=CC=CC=C31,,,,,,
3908,73909,"1,3,2-Benzodioxaphosphole, 2-chloro-, 2-oxide",C1=CC=C2C(=C1)OP(=O)(O2)Cl,,,,,,
3909,73910,Diphenylphosphinic chloride,C1=CC=C(C=C1)P(=O)(C2=CC=CC=C2)Cl,,,,,,
3910,73911,Methyltriphenylarsonium iodide,C[As+](C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3.[I-],,,,,,
3911,73912,Methyltriphenylarsonium,C[As+](C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
3912,73913,5-Methyl DL-glutamate,COC(=O)CCC(C(=O)O)N,,,,,,
3913,73914,4-Benzoylbutyric acid,C1=CC=C(C=C1)C(=O)CCCC(=O)O,,,,,,
3914,73915,Diethyl 2-acetylglutarate,CCOC(=O)CCC(C(=O)C)C(=O)OCC,,,,,,
3915,73916,Methyl 5-chloro-5-oxopentanoate,COC(=O)CCCC(=O)Cl,,,,,,
3916,73917,5-Methoxy-5-oxopentanoic acid,COC(=O)CCCC(=O)O,,,,,,
3917,73918,Cyclodecanone,C1CCCCC(=O)CCCC1,,,,,,
3918,73919,Melem,C1(=NC2=NC(=N)N=C3N2C(=NC(=N3)N)N1)N,,,,,,
3919,73920,"QUINO[2,3-b]ACRIDINE-6,7,13,14(5H,12H)-TETRONE",C1=CC=C2C(=C1)C(=O)C3=C(N2)C(=O)C4=C(C3=O)NC5=CC=CC=C5C4=O,,,,,,
3920,73921,4-Benzoylbenzonitrile,C1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)C#N,,,,,,
3921,73922,2-(Acetyloxy)-5-bromobenzoic acid,CC(=O)OC1=C(C=C(C=C1)Br)C(=O)O,,,,,,
3922,73923,2-(Acetyloxy)-5-iodobenzoic acid,CC(=O)OC1=C(C=C(C=C1)I)C(=O)O,,,,,,
3923,73924,"3-(3,4,5-Trimethoxyphenyl)-2-propen-1-ol",COC1=CC(=CC(=C1OC)OC)C=CCO,,,,,,
3924,73925,"2-Propen-1-ol, 3-(4-nitrophenyl)-",C1=CC(=CC=C1C=CCO)[N+](=O)[O-],,,,,,
3925,73926,CID 73926,CCOC1=CC=C(C=C1)C=CC(=O)OCC,,,,,,
3926,73927,3-(p-Tolyl)propionic acid,CC1=CC=C(C=C1)CCC(=O)O,,,,,,
3927,73928,"1,2,3,4,5,6-Hexachloro-7-methoxynaphthalene",COC1=C(C(=C2C(=C1)C(=C(C(=C2Cl)Cl)Cl)Cl)Cl)Cl,,,,,,
3928,73929,N-Dodecylacrylamide,CCCCCCCCCCCCNC(=O)C=C,,,,,,
3929,73930,N-Octadecylacrylamide,CCCCCCCCCCCCCCCCCCNC(=O)C=C,,,,,,
3930,73931,4-Isothiocyanatobiphenyl,C1=CC=C(C=C1)C2=CC=C(C=C2)N=C=S,,,,,,
3931,73932,Difluoromethanesulfonyl chloride,C(F)(F)S(=O)(=O)Cl,,,,,,
3932,73933,"3-Amino-alpha,alpha,alpha-trifluorotoluene-4-sulphonic acid",C1=CC(=C(C=C1C(F)(F)F)N)S(=O)(=O)O,,,,,,
3933,73934,"2,6-Difluoropyridine",C1=CC(=NC(=C1)F)F,,,,,,
3934,73935,Methyl chlorodifluoroacetate,COC(=O)C(F)(F)Cl,,,,,,
3935,73936,"1,1,1,3,3,3-Hexafluoro-2-methylpropan-2-ol",CC(C(F)(F)F)(C(F)(F)F)O,,,,,,
3936,73937,1-Ethylcyclohexene,CCC1=CCCCC1,,,,,,
3937,73938,[2-(N-Ethylanilino)ethyl]trimethylammonium chloride,CCN(CC[N+](C)(C)C)C1=CC=CC=C1.[Cl-],,,,,,
3938,73939,[2-(N-Ethylanilino)ethyl]trimethylaminium,CCN(CC[N+](C)(C)C)C1=CC=CC=C1,,,,,,
3939,73940,CID 73940,C1=CC2=NC(=O)N=C2C=C1N(O)O,,,,,,
3940,73941,4-(Methylsulfonyl)-2-nitrophenol,CS(=O)(=O)C1=CC(=C(C=C1)O)[N+](=O)[O-],,,,,,
3941,73942,4-Acetamidobenzaldehyde,CC(=O)NC1=CC=C(C=C1)C=O,,,,,,
3942,73943,"1,1,1-Trifluoro-2,4-pentanedione",CC(=O)CC(=O)C(F)(F)F,,,,,,
3943,73944,"2,4-Dinitro-5-fluoroaniline",C1=C(C(=CC(=C1F)[N+](=O)[O-])[N+](=O)[O-])N,,,,,,
3944,73945,Dimethyl difluoromalonate,COC(=O)C(C(=O)OC)(F)F,,,,,,
3945,73946,1-(4-Fluorophenyl)ethanol,CC(C1=CC=C(C=C1)F)O,,,,,,
3946,73947,"Methane, trifluoromethoxy-",COC(F)(F)F,,,,,,
3947,73948,Carbohydrazide,C(=O)(NN)NN,,,,,,
3948,73949,2-Oxazolidinone,C1COC(=O)N1,,,"['Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. (See all compounds classified as Anti-Infective Agents.)', 'Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. (See all compounds classified as Protein Synthesis Inhibitors.)']",,,
3949,73950,CID 73950,C1=CC(=CC=C1NN=C(N)N)N=NC(=N)S,,,,,,
3950,73951,"1,1-Dimethylhydrazine hydrochloride",CN(C)N.Cl,,,,,,
3951,73952,Dicyclohexyl but-2-enedioate,C1CCC(CC1)OC(=O)C=CC(=O)OC2CCCCC2,,,,,,
3952,73953,4-Piperidineethanol,C1CNCCC1CCO,,,,,,
3953,73954,N-Benzylidenemethylamine,CN=CC1=CC=CC=C1,,,,,,
3954,73955,4-Methylphenetole,CCOC1=CC=C(C=C1)C,,,,,,
3955,73956,Bis(2-ethoxyethyl)sebacate,CCOCCOC(=O)CCCCCCCCC(=O)OCCOCC,,,,,,
3956,73957,Pramoxine hydrochloride,CCCCOC1=CC=C(C=C1)OCCCN2CCOCC2.Cl,,,"['Drugs that block nerve conduction when applied locally to nerve tissue in appropriate concentrations. They act on any part of the nervous system and on every type of nerve fiber. In contact with a nerve trunk, these anesthetics can cause both sensory and motor paralysis in the innervated area. Their action is completely reversible. (From Gilman AG, et. al., Goodman and Gilman&apos;s The Pharmacological Basis of Therapeutics, 8th ed) Nearly all local anesthetics act by reducing the tendency of voltage-dependent sodium channels to activate. (See all compounds classified as Anesthetics, Local.)']","['... These agents are readily absorbed through mucous membranes into the systemic circulation. The rate of absorption is influenced by the vascularity or rate of blood flow at the site of application, the total dosage (concentration and volume) administered, and the duration of exposure. ... /Local anesthetics/']",,
3957,73958,"3,5-Dimethylcyclopent-2-en-1-one",CC1CC(=CC1=O)C,,,,,,
3958,73959,Dibutyltin;methanol,CCCC[Sn]CCCC.CO.CO,,,,,,
3959,73960,Diethyl L-glutamate hydrochloride,CCOC(=O)CC[C@@H](C(=O)OCC)N.Cl,,,"['Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)', 'Drugs that bind to but do not activate excitatory amino acid receptors, thereby blocking the actions of agonists. (See all compounds classified as Excitatory Amino Acid Antagonists.)', 'A loosely defined grouping of drugs that have effects on psychological function. Here the psychotropic agents include the antidepressive agents, hallucinogens, and tranquilizing agents (including the antipsychotics and anti-anxiety agents). (See all compounds classified as Psychotropic Drugs.)']",,,
3960,73961,Glutamic acid diethyl ester,CCOC(=O)CC[C@@H](C(=O)OCC)N,,,"['Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)', 'Drugs that bind to but do not activate excitatory amino acid receptors, thereby blocking the actions of agonists. (See all compounds classified as Excitatory Amino Acid Antagonists.)', 'A loosely defined grouping of drugs that have effects on psychological function. Here the psychotropic agents include the antidepressive agents, hallucinogens, and tranquilizing agents (including the antipsychotics and anti-anxiety agents). (See all compounds classified as Psychotropic Drugs.)']",,,
3961,73962,Tris(cyclopentadienyl)lanthanum(III),[CH-]1C=CC=C1.[CH-]1C=CC=C1.[CH-]1C=CC=C1.[La+3],,,,,,
3962,73963,Cerium dioxide,O=[Ce]=O,,,,,,
3963,73964,Iron(III) hydroxide,[OH-].[OH-].[OH-].[Fe+3],,,,,,
3964,73965,Manganese hydroxide,[OH-].[OH-].[Mn+2],,,,,,
3965,73966,Thulium hydroxide,[OH-].[OH-].[OH-].[Tm+3],,,,,,
3966,73967,CID 73967,[In+3].[SbH3],,,,,,
3967,73968,Dipotassium selenide,[K+].[K+].[Se-2],,,,,,
3968,73969,Magnesium selenide,[Mg+2].[Se-2],,,,,,
3969,73970,Manganese monoselenide,[Mn+2].[Se-2],,,,,,
3970,73971,Sodium oxide,[O-2].[Na+].[Na+],,,,,,
3971,73972,Disodium sulfide nonahydrate,O.O.O.O.O.O.O.O.O.[Na+].[Na+].[S-2],,,,,,
3972,73973,Sodium selenide,[Na+].[Na+].[Se-2],,,,,,
3973,73974,Oxygen(2-); palladium(2+),[O-2].[Pd+2],,,,,,
3974,73975,Strontium monoxide,[O-2].[Sr+2],,,,,,
3975,73976,Einecs 234-379-0,[O-2].[O-2].[Pt+4],,,,,,
3976,73977,Tin disulphide,[S-2].[S-2].[Sn+4],,,,,,
3977,73978,Einecs 215-258-1,[Se-2].[Sr+2],,,,,,
3978,73979,ZINC selenide [MI],[Zn].[Se-2],,,,,,
3979,73980,Copper selenide (CuSe),[Cu+2].[Se-2],,,,,,
3980,73981,Milk of magnesia,[OH-].[OH-].[Mg+2],"['Magnesium hydroxide can be used as an antacid or a laxative depending on the administered dose.  As an antacid, it is used for the temporary relief of heartburn, upset stomach, sour stomach or acid indigestion.  As a laxative, it is used for the relief of occasional constipation by promoting bowel movements for 30 minutes and up to 6 hours.']","['As an antacid, magnesium hydroxide suspension neutralizes gastric acid by reacting with hydrochloric acid in the stomach to form magnesium chloride and water. It is practically insoluble in water and does not have any effect until it reacts with the hydrochloric acid in the stomach. There, it decreases the direct acid irritant effect and increases the pH in the stomach leading to inactivation of pepsin. Magnesium hydroxide enhances the integrity of the mucosal barrier of the stomach as well as improving the tone of both the gastric and esophageal sphincters.   As a laxative, the magnesium hydroxide works by increasing the osmotic effect in the intestinal tract and drawing water in. This creates distension of the colon which results in an increase in peristaltic movement and bowel evacuation.']",['Substances that counteract or neutralize acidity of the GASTROINTESTINAL TRACT. (See all compounds classified as Antacids.)'],"['About 15%-50% of magnesium hydroxide is absorbed very slowly through the small intestine.', 'After oral administration, up to 50% of the magnesium hydroxide suspension may be absorbed as magnesium ions through the small intestines and then rapidly excreted in the urine through the kidneys. The unabsorbed drug is mainly excreted in the feces and saliva.', 'The peak action and distribution of magnesium hydroxide are variable.', 'Magnesium hydroxide is mainly excreted in the urine by the kidneys. Since the kidneys play a major role in its clearance, individuals with renal failure are at risk of hypermagnesemia with long term consumption as the appropriate amounts of magnesium may not be excreted.']","['Unless a patient is deficient in magnesium, very little is absorbed by the intestine. Overall, about 15%-50% of the magnesium hydroxide suspension is absorbed systemically. However, it does not undergo any metabolism as it is rapidly excreted in the urine.']",['N/A']
3981,73982,Boehmite (Al(OH)O),[OH-].[O-2].[Al+3],,,,,,
3982,73983,Octachlorocamphene,CC1(C(=C)C2(C(C1(C(C2(Cl)Cl)(Cl)Cl)Cl)(Cl)Cl)Cl)C,,,,,,
3983,73984,"Urea, (2-hydroxyethyl)-",C(CO)NC(=O)N,,,,,,
3984,73985,6-Methylheptan-1-amine,CC(C)CCCCCN,,,,,,
3985,73986,"Phenol, 3-methyl(1-methylethyl)-",CC1=C(C(=CC=C1)O)C(C)C,,,,,,
3986,73987,"3-Penten-2-one, 4-(methoxyphenyl)-",CC(=CC(=O)C)C1=CC=C(C=C1)OC,,,,,,
3987,73988,"1,2-Benzenedicarboxylic acid, mono(dimethylcyclohexyl) ester",CC1(CCC(CC1)OC(=O)C2=CC=CC=C2C(=O)O)C,,,,,,
3988,73989,"Dibromodibenzo(b,def)chrysene-7,14-dione",C1=CC=C2C(=C1)C3=C4C(=CC=C5C4=C(C=C3)C(=O)C6=C(C=CC(=C56)Br)Br)C2=O,,,,,,
3989,73990,"Benzo(rst)phenanthro(10,1,2-cde)pentaphene-9,18-dione, bromo-",C1=CC=C2C(=C1)C3=C4C(=CC=C5C4=C(C=C3)C6=CC=C7C8=C(C=CC5=C68)C9=C(C7=O)C=CC(=C9)Br)C2=O,,,,,,
3990,73991,C.I. Mordant Black 13,C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C(=C(C=C3NC4=CC=C(C=C4)S(=O)(=O)[O-])NC5=CC=C(C=C5)S(=O)(=O)[O-])O.[Na+].[Na+],,,,,,
3991,73992,"4,4'-((9,10-Dihydro-4-hydroxy-9,10-dioxo-1,3-anthrylene)diimino)bis(benzenesulphonic) acid",C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C(=C(C=C3NC4=CC=C(C=C4)S(=O)(=O)O)NC5=CC=C(C=C5)S(=O)(=O)O)O,,,,,,
3992,73993,Pigment Red 60,C1=CC=C(C(=C1)C(=O)[O-])N=NC2=C3C=CC(=CC3=CC(=C2[O-])S(=O)(=O)[O-])S(=O)(=O)[O-].[Ba+2].[Ba+2],,,,,,
3993,73994,"1-Naphthalenemethanol, alpha,alpha-bis(4-(diethylamino)phenyl)-4-(ethylamino)-",CCNC1=CC=C(C2=CC=CC=C21)C(C3=CC=C(C=C3)N(CC)CC)(C4=CC=C(C=C4)N(CC)CC)O,,,,,,
3994,73995,C.I. Vat blue 43,C1=CC=C2C(=C1)C3=C(N2)C=CC(=C3)N=C4C=CC(=O)C=C4,,,,,,
3995,73996,"4-Methoxy-2,6-dimethylphenol",CC1=CC(=CC(=C1O)C)OC,,,,,,
3996,73997,Bis(6-methylheptyl) but-2-enedioate,CC(C)CCCCCOC(=O)C=CC(=O)OCCCCCC(C)C,,,,,,
3997,73998,4-Isopropylmorpholine,CC(C)N1CCOCC1,,,,,,
3998,73999,3-(2-Diethylaminohydrazinyl)propan-1-ol,CCN(CC)NNCCCO,,,,,,
3999,74000,"(2,2-Dichloroethyl)benzene",C1=CC=C(C=C1)CC(Cl)Cl,,,,,,
4000,74001,"2,4,6-Trimethylcyclohexan-1-ol",CC1CC(C(C(C1)C)O)C,,,,,,
4001,74002,Antimony oxide (Sb2O4),O=[Sb]O[Sb](=O)=O,,,,,,
4002,74003,Tris(dinonylphenyl) phosphite,CCCCCCCCCC1=CC(=CC(=C1)OP(OC2=CC(=CC(=C2)CCCCCCCCC)CCCCCCCCC)OC3=CC(=CC(=C3)CCCCCCCCC)CCCCCCCCC)CCCCCCCCC,,,,,,
4003,74004,"Quinoline, (1-methylethyl)-",CC(C)C1=CC=NC2=CC=CC=C12,,,,,,
4004,74005,4-Isobutylquinoline,CC(C)CC1=CC=NC2=CC=CC=C12,,,,,,
4005,74006,"[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl] octadec-9-enoate",CCCCCCCCC=CCCCCCCCC(=O)OC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O,,,,,,
4006,74007,CID 74007,CCCCCCCCC=CCCCCCCCC(=O)OC[C@@H]([C@H]([C@@H]([C@@H](COC(=O)CCCCCCCC=CCCCCCCCC)OC(=O)CCCCCCCC=CCCCCCCCC)O)O)O,,,,,,
4007,74008,Amyl 2-furoate,CCCCCOC(=O)C1=CC=CO1,,,,,,
4008,74009,"1,4-Butanediol monostearate",CCCCCCCCCCCCCCCCCC(=O)OCCCCO,,,,,,
4009,74010,ar-Isopropylphenylacetaldehyde,CC(C)C1=CC=CC(=C1)CC=O,,,,,,
4010,74011,CID 74011,C1=CC(=CC=C1N)[SbH](=O)O.C(=O)(N)NO,,,,,,
4011,74012,CID 74012,C1=CC(=CC=C1N)[SbH2]=O.O,,,,,,
4012,74013,Uranium trioxide,O=[U](=O)=O,,,,,,
4013,74014,Decamethonium iodide,C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C.[I-].[I-],,,['Drugs that interrupt transmission at the skeletal neuromuscular junction by causing sustained depolarization of the motor end plate. These agents are primarily used as adjuvants in surgical anesthesia to cause skeletal muscle relaxation. (See all compounds classified as Neuromuscular Depolarizing Agents.)'],,,
4014,74015,4-((2-Bromoethyl)(2-bromopropyl)amino)benzenesulfonamide,C1=CC(=CC=C1N(CCCBr)CCBr)S(=O)(=O)N,,,,,,
4015,74016,2-Bromo-4-fluorotoluene,CC1=C(C=C(C=C1)F)Br,,,,,,
4016,74017,Pentafluoronitrosobenzene,C1(=C(C(=C(C(=C1F)F)F)F)F)N=O,,,,,,
4017,74018,CID 74018,C1=CC=C(C=C1)CNC(=NCC2=CC=CC=C2)S,,,,,,
4018,74019,1-Cyclohexenyl acetate,CC(=O)OC1=CCCCC1,,,,,,
4019,74020,3-(Phenylsulfonyl)prop-2-enenitrile,C1=CC=C(C=C1)S(=O)(=O)C=CC#N,,,,,,
4020,74021,2-Chloro-4-(dimethylamino)benzaldehyde,CN(C)C1=CC(=C(C=C1)C=O)Cl,,,,,,
4021,74022,"1,2,4-Trichloro-3-(chloromethyl)benzene",C1=CC(=C(C(=C1Cl)CCl)Cl)Cl,,,,,,
4022,74023,"2,4-Diamino-6,7-dimethylpteridine",CC1=C(N=C2C(=N1)C(=NC(=N2)N)N)C,,,,,,
4023,74024,"6-Quinolinecarboxylic acid, 4-nitro-, 1-oxide",C1=CC2=[N+](C=CC(=C2C=C1C(=O)O)[N+](=O)[O-])[O-],,,,,,
4024,74025,2-Fluoro-4-nitrotoluene,CC1=C(C=C(C=C1)[N+](=O)[O-])F,,,,,,
4025,74026,"Allyl 1,1,2,2-tetrafluoroethyl ether",C=CCOC(C(F)F)(F)F,,,,,,
4026,74027,Trimethylolpropane tris((3-isocyanato-4-methylphenyl)carbamate),CCC(COC(=O)NC1=CC(=C(C=C1)C)N=C=O)(COC(=O)NC2=CC(=C(C=C2)C)N=C=O)COC(=O)NC3=CC(=C(C=C3)C)N=C=O,,,,,,
4027,74028,"1,2-Dichloro-4-fluorobenzene",C1=CC(=C(C=C1F)Cl)Cl,,,,,,
4028,74029,2-[(o-Nitrophenyl)azo]-p-cresol,CC1=CC(=C(C=C1)O)N=NC2=CC=CC=C2[N+](=O)[O-],,,,,,
4029,74030,"Phenol, 3-methyl-4-(phenylazo)-",CC1=C(C=CC(=C1)O)N=NC2=CC=CC=C2,,,,,,
4030,74031,Quinoline-2-carbonitrile,C1=CC=C2C(=C1)C=CC(=N2)C#N,,,,,,
4031,74032,"Pyridine, (1,2-ethenediyl)bis-",C1=CC=NC(=C1)C=CC2=CC=CC=N2,,,,,,
4032,74033,N-Aminorhodanine,C1C(=O)N(C(=S)S1)N,,,,,,
4033,74034,"Rhodanine, 3-indolylacetylamino-",C1C(=O)N(C(=S)S1)NC(=O)CC2=CNC3=CC=CC=C32,,,,,,
4034,74035,Vinylphosphonic dichloride,C=CP(=O)(Cl)Cl,,,,,,
4035,74036,"Disiloxane, ethenylpentamethyl-",C[Si](C)(C)O[Si](C)(C)C=C,,,,,,
4036,74037,"1,1,3,3,3-Pentamethyldisiloxane",C[SiH](C)O[Si](C)(C)C,,,,,,
4037,74038,"1-(2-Furyl)propane-1,2-dione",CC(=O)C(=O)C1=CC=CO1,,,,,,
4038,74039,Tris(2-cyanoethyl)phosphine oxide,C(CP(=O)(CCC#N)CCC#N)C#N,,,,,,
4039,74040,4-(Chloroacetyl)morpholine,C1COCCN1C(=O)CCl,,,,,,
4040,74041,Salicyloyl chloride,C1=CC=C(C(=C1)C(=O)Cl)O,,,,,,
4041,74042,4-(Methylthio)benzoyl chloride,CSC1=CC=C(C=C1)C(=O)Cl,,,,,,
4042,74043,"3,5-Dimethoxy-4-hydroxybenzhydrazide",COC1=CC(=CC(=C1O)OC)C(=O)NN,,,,,,
4043,74044,4-Acetylbenzonitrile,CC(=O)C1=CC=C(C=C1)C#N,,,,,,
4044,74045,1-(Piperidyl)-3-(4-tolylsulfonyl)urea,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CCCCC2,,,,,,
4045,74046,Diethyl bis(2-cyanoethyl)malonate,CCOC(=O)C(CCC#N)(CCC#N)C(=O)OCC,,,,,,
4046,74047,CID 74047,CN(C)C1=NC(=O)C2=C(N1)N=CN2,,,,,,
4047,74048,"3,4-Xylenol, 6-tert-butyl-",CC1=CC(=C(C=C1C)O)C(C)(C)C,,,,,,
4048,74049,1-Methyl-4-piperidone,CN1CCC(=O)CC1,,,,,,
4049,74050,"2,5-Diphenylthiophene",C1=CC=C(C=C1)C2=CC=C(S2)C3=CC=CC=C3,,,,,,
4050,74051,"Methyl 2,2-dichloro-1-methylcyclopropanecarboxylate",CC1(CC1(Cl)Cl)C(=O)OC,,,,,,
4051,74052,CID 74052,COC1=C(C2=C(C=C(OC2=CC1=O)C3=CC=C(C=C3)O)O)O,,,,,,
4052,74053,"Diethyl 4,4'-[hexamethylenebis(oxy)]dibenzimidate",CCOC(=N)C1=CC=C(C=C1)OCCCCCCOC2=CC=C(C=C2)C(=N)OCC,,,,,,
4053,74054,2-Chloroquinazoline,C1=CC=C2C(=C1)C=NC(=N2)Cl,,,,,,
4054,74055,"Acetamide, N-(aminocarbonyl)-2-cyano-",C(C#N)C(=O)NC(=O)N,,,,,,
4055,74056,Tetracyclohexylstannane,C1CCC(CC1)[Sn](C2CCCCC2)(C3CCCCC3)C4CCCCC4,,,,,,
4056,74057,Hexamethyldisilane,C[Si](C)(C)[Si](C)(C)C,,,,,,
4057,74058,"1,1,1-Trimethyl-2,2,2-triphenyldisilane",C[Si](C)(C)[Si](C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
4058,74059,Hexaphenyldisilane,C1=CC=C(C=C1)[Si](C2=CC=CC=C2)(C3=CC=CC=C3)[Si](C4=CC=CC=C4)(C5=CC=CC=C5)C6=CC=CC=C6,,,,,,
4059,74060,"1,1,4,4-Tetraphenyl-1,3-butadiene",C1=CC=C(C=C1)C(=CC=C(C2=CC=CC=C2)C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
4060,74061,5'-Chloro-2'-hydroxyacetophenone,CC(=O)C1=C(C=CC(=C1)Cl)O,,,,,,
4061,74062,9-Bromoanthracene,C1=CC=C2C(=C1)C=C3C=CC=CC3=C2Br,,,,,,
4062,74063,1-Amino-2-bromo-4-o-toluidinoanthraquinone,CC1=CC=CC=C1NC2=CC(=C(C3=C2C(=O)C4=CC=CC=C4C3=O)N)Br,,,,,,
4063,74064,1-Amino-4-anilino-2-bromoanthraquinone,C1=CC=C(C=C1)NC2=CC(=C(C3=C2C(=O)C4=CC=CC=C4C3=O)N)Br,,,,,,
4064,74065,4-Acetylbenzenesulfonamide,CC(=O)C1=CC=C(C=C1)S(=O)(=O)N,,,,,,
4065,74066,4-Methoxyphenylurea,COC1=CC=C(C=C1)NC(=O)N,,,,,,
4066,74067,Methyl 1-methylcyclopropyl ketone,CC(=O)C1(CC1)C,,,,,,
4067,74068,Methyl cyanocycloheptylideneacetate,COC(=O)C(=C1CCCCCC1)C#N,,,,,,
4068,74069,"2-Propanone, (2,4-dinitrophenyl)hydrazone",CC(=NNC1=C(C=C(C=C1)[N+](=O)[O-])[N+](=O)[O-])C,,,,,,
4069,74070,3-Phenyl-2-propenal 2-(3-phenyl-2-propen-1-ylidene)hydrazone,C1=CC=C(C=C1)C=CC=NN=CC=CC2=CC=CC=C2,,,,,,
4070,74071,"3,3,3',3'-Tetramethyl-2,2',3,3'-tetrahydro-1,1'-spirobi[indene]-6,6'-diol",CC1(CC2(CC(C3=C2C=C(C=C3)O)(C)C)C4=C1C=CC(=C4)O)C,,,,,,
4071,74072,CID 74072,CC1=CC(=O)N=C2C1=CC=C(N2)N,,,,,,
4072,74073,"2-Methyl-[1,8]naphthyridine",CC1=NC2=C(C=CC=N2)C=C1,,,,,,
4073,74074,3-Propionylpyridine,CCC(=O)C1=CN=CC=C1,,,,,,
4074,74075,"4-Chloro-2,3-dimethylphenol",CC1=C(C=CC(=C1C)Cl)O,,,,,,
4075,74076,1-((p-Tolyl)methyl)cyclopropanecarbonyl chloride,CC1=CC=C(C=C1)CC2(CC2)C(=O)Cl,,,,,,
4076,74077,"3,4,5,6-Tetrachlorophthalimide",C12=C(C(=C(C(=C1Cl)Cl)Cl)Cl)C(=O)NC2=O,,,,,,
4077,74078,"1H-Isoindole-1,3(2H)-dione, 4,5,6,7-tetrachloro-2-dodecyl-",CCCCCCCCCCCCN1C(=O)C2=C(C1=O)C(=C(C(=C2Cl)Cl)Cl)Cl,,,,,,
4078,74079,8-Hydroxyquinoline-2-carboxylic acid,C1=CC2=C(C(=C1)O)N=C(C=C2)C(=O)O,,,,,,
4079,74080,2-Methyleneglutaronitrile,C=C(CCC#N)C#N,,,,,,
4080,74081,"1,4-Diacetoxy-2-butyne",CC(=O)OCC#CCOC(=O)C,,,,,,
4081,74082,4-((1H-Imidazol-2-yl)azo)aniline,C1=CC(=CC=C1N)N=NC2=NC=CN2,,,,,,
4082,74083,9-oxo-9H-fluorene-1-carboxylic acid,C1=CC=C2C(=C1)C3=C(C2=O)C(=CC=C3)C(=O)O,,,,,,
4083,74084,2-(Phenylmethylene)-1-hydrazinecarboxamide,C1=CC=C(C=C1)C=NNC(=O)N,,,,,,
4084,74085,"5,8-Dichloro-1-naphthol",C1=CC2=C(C=CC(=C2C(=C1)O)Cl)Cl,,,,,,
4085,74086,"3-Penten-1-yne, 3-methyl-",CC=C(C)C#C,,,,,,
4086,74087,3-Methylenepent-1-yne,CCC(=C)C#C,,,,,,
4087,74088,beta-Formylacrylic acid,C(=CC(=O)O)C=O,,,,,,
4088,74089,5-Chlorovaleryl chloride,C(CCCl)CC(=O)Cl,,,,,,
4089,74090,N-Acetylbenzamide,CC(=O)NC(=O)C1=CC=CC=C1,,,,,,
4090,74091,2-Methyl-1-naphthoic acid,CC1=C(C2=CC=CC=C2C=C1)C(=O)O,,,,,,
4091,74092,1-Methoxy-1-methyl-3-phenylurea,CN(C(=O)NC1=CC=CC=C1)OC,,,,,,
4092,74093,4-Hydroxybenzenesulfonamide,C1=CC(=CC=C1O)S(=O)(=O)N,,,,,,
4093,74094,Hept-3-en-1-yl acetate,CCCC=CCCOC(=O)C,,,,,,
4094,74095,3-Butenyl acetate,CC(=O)OCCC=C,,,,,,
4095,74096,4-Pentenyl acetate,CC(=O)OCCCC=C,,,,,,
4096,74097,CID 74097,CCCCCCC(CC=CCCCCCCCCO)O,,,,,,
4097,74098,p-Tolyl ether,CC1=CC=C(C=C1)OC2=CC=C(C=C2)C,,,,,,
4098,74099,3-(4-Fluorophenoxy)propionic acid,C1=CC(=CC=C1OCCC(=O)O)F,,,,,,
4099,74100,"2-(4-Fluorophenyl)-5-phenyl-1,3,4-oxadiazole",C1=CC=C(C=C1)C2=NN=C(O2)C3=CC=C(C=C3)F,,,,,,
4100,74101,2-Amino-2'-fluorobenzophenone,C1=CC=C(C(=C1)C(=O)C2=CC=CC=C2F)N,,,,,,
4101,74102,"2,4-Difluorobenzoic acid",C1=CC(=C(C=C1F)F)C(=O)O,,,,,,
4102,74103,"2,2-Difluoro-1,3-benzodioxole",C1=CC=C2C(=C1)OC(O2)(F)F,,,,,,
4103,74104,1-(Difluoromethoxy)-4-methylbenzene,CC1=CC=C(C=C1)OC(F)F,,,,,,
4104,74105,Perfluoro-2-methyl-2-pentene,C(=C(C(C(F)(F)F)(F)F)F)(C(F)(F)F)C(F)(F)F,,,,,,
4105,74106,2-Bromo-4'-chloro-2'-(o-fluorobenzoyl)acetanilide,C1=CC=C(C(=C1)C(=O)C2=C(C=CC(=C2)Cl)NC(=O)CBr)F,,,,,,
4106,74107,4-Ethylphenetole,CCC1=CC=C(C=C1)OCC,,,,,,
4107,74108,"2,4,6-Trimethylbenzyl chloride",CC1=CC(=C(C(=C1)C)CCl)C,,,,,,
4108,74109,2-Benzylbenzyl alcohol,C1=CC=C(C=C1)CC2=CC=CC=C2CO,,,,,,
4109,74110,Tris(trimethylsilyl)amine,C[Si](C)(C)N([Si](C)(C)C)[Si](C)(C)C,,,,,,
4110,74111,CID 74111,C[CH2-].C[CH2-].CCO.[AlH+2],,,,,,
4111,74112,Trimethyl citrate,COC(=O)CC(CC(=O)OC)(C(=O)OC)O,,,,,,
4112,74113,Tripropyl citrate,CCCOC(=O)CC(CC(=O)OCCC)(C(=O)OCCC)O,,,,,,
4113,74114,"3,3-Dichlorodihydrofuran-2(3H)-one",C1COC(=O)C1(Cl)Cl,,,,,,
4114,74115,4-Amino-3-nitrobenzoic acid,C1=CC(=C(C=C1C(=O)O)[N+](=O)[O-])N,,,,,,
4115,74116,3-Methoxy-1-propanol,COCCCO,,,,,,
4116,74117,"Cyclohexanone 2,4-dinitrophenylhydrazone",C1CCC(=NNC2=C(C=C(C=C2)[N+](=O)[O-])[N+](=O)[O-])CC1,,,,,,
4117,74118,Benzylbromomagnesium,[CH2-]C1=CC=CC=C1.[Mg+2].[Br-],,,,,,
4118,74119,"2-Methylpropane-1,2,3-tricarboxylic acid",CC(CC(=O)O)(CC(=O)O)C(=O)O,,,,,,
4119,74120,N-(2-Hydroxyethyl)-N-methylformamide,CN(CCO)C=O,,,,,,
4120,74121,(4-(Hexadecylsulphonyl)phenyl)hydrazine,CCCCCCCCCCCCCCCCS(=O)(=O)C1=CC=C(C=C1)NN,,,,,,
4121,74122,"1,4-Benzenediamine, N-octyl-N'-phenyl-",CCCCCCCCNC1=CC=C(C=C1)NC2=CC=CC=C2,,,,,,
4122,74123,Silylsilane,[SiH3][SiH3],,,,,,
4123,74124,Dibutoxy(dimethyl)silane,CCCCO[Si](C)(C)OCCCC,,,,,,
4124,74125,Pentafluorophenyl isocyanate,C(=NC1=C(C(=C(C(=C1F)F)F)F)F)=O,,,,,,
4125,74126,1-(Chloromethyl)-4-vinylbenzene,C=CC1=CC=C(C=C1)CCl,,,,,,
4126,74127,"1,4-Bis(dibromomethyl)benzene",C1=CC(=CC=C1C(Br)Br)C(Br)Br,,,,,,
4127,74128,2-Naphthalenemethanol,C1=CC=C2C=C(C=CC2=C1)CO,,,,,,
4128,74129,CID 74129,COC1=C(OC2=CC(=O)C=C(C2=C1O)O)C3=CC=C(C=C3)O,,,,,,
4129,74130,"Phosphorothioic acid, O,O-dimethyl O-(3-isopropyl-4-nitrophenyl) ester",CC(C)C1=C(C=CC(=C1)OP(=S)(OC)OC)[N+](=O)[O-],,,,,,
4130,74131,"O-(2,4-Dichlorophenyl) O-ethyl ethylphosphonothioate",CCOP(=S)(CC)OC1=C(C=C(C=C1)Cl)Cl,,,,,,
4131,74132,"9,10-Anthracenedione, 1-hydroxy-4-[[4-[(methylsulfonyl)oxy]phenyl]amino]-",CS(=O)(=O)OC1=CC=C(C=C1)NC2=C3C(=C(C=C2)O)C(=O)C4=CC=CC=C4C3=O,,,,,,
4132,74133,CID 74133,C1=CC(=O)C(=CN=O)C=C1N(O)O,,,,,,
4133,74134,2-Cyclohexyl-4-methylphenol,CC1=CC(=C(C=C1)O)C2CCCCC2,,,,,,
4134,74135,6-Cyclopentyl-o-cresol,CC1=C(C(=CC=C1)C2CCCC2)O,,,,,,
4135,74136,Naphthol AS-MX phosphate,CC1=CC(=C(C=C1)NC(=O)C2=CC3=CC=CC=C3C=C2OP(=O)(O)O)C,,,,,,
4136,74137,"1,1-Dimethoxyhexane",CCCCCC(OC)OC,,,,,,
4137,74138,1-Docosene,CCCCCCCCCCCCCCCCCCCCC=C,,,,,,
4138,74139,CID 74139,CN1C(=O)N=C(N1)C2=CC=C(O2)[N+](=O)[O-],,,,,,
4139,74140,"1,3-Diethyl-2-(2-aminoethyl)-isothiouronium dibromide",CCNC(=NCC)SCCN.Br.Br,,,,,,
4140,74141,"2-aminoethyl N,N'-diethylcarbamimidothioate",CCNC(=NCC)SCCN,,,,,,
4141,74142,"2,5,6-Triaminopyrimidin-4-yl hydrogen sulfate",C1(=C(N=C(N=C1OS(=O)(=O)O)N)N)N,,,,,,
4142,74143,2-Amino-4-methylthiazole,CC1=CSC(=N1)N,,,,,,
4143,74144,2-Methylbut-3-yn-2-yl acetate,CC(=O)OC(C)(C)C#C,,,,,,
4144,74145,"2,6-Dinitroanthraquinone",C1=CC2=C(C=C1[N+](=O)[O-])C(=O)C3=C(C2=O)C=C(C=C3)[N+](=O)[O-],,,,,,
4145,74146,"1,6-Dinitroanthraquinone",C1=CC2=C(C(=C1)[N+](=O)[O-])C(=O)C3=C(C2=O)C=C(C=C3)[N+](=O)[O-],,,,,,
4146,74147,"1,7-Dinitroanthraquinone",C1=CC2=C(C(=C1)[N+](=O)[O-])C(=O)C3=C(C2=O)C=CC(=C3)[N+](=O)[O-],,,,,,
4147,74148,"1,4-Diisopropenylbenzene",CC(=C)C1=CC=C(C=C1)C(=C)C,,,,,,
4148,74149,Diethylphenylphosphine,CCP(CC)C1=CC=CC=C1,,,,,,
4149,74150,Bis(dimethylamino)phosphoryl Chloride,CN(C)P(=O)(N(C)C)Cl,,,,,,
4150,74151,"N,N-Diethylglycine",CCN(CC)CC(=O)O,,,,,,
4151,74152,"1-Penten-3-one, 4-methyl-",CC(C)C(=O)C=C,,,,,,
4152,74153,2-Nitrothiazole,C1=CSC(=N1)[N+](=O)[O-],,,,,,
4153,74154,"5-Oxa-2-heptyne-1,7-diol",C(COCC#CCO)O,,,,,,
4154,74155,Triisobutyl phosphite,CC(C)COP(OCC(C)C)OCC(C)C,,,,,,
4155,74156,N-Phenyl-N-4-piperidinylacetamide,CC(=O)N(C1CCNCC1)C2=CC=CC=C2,,,,,,
4156,74157,Tetramethyloxamide,CN(C)C(=O)C(=O)N(C)C,,,,,,
4157,74158,3-Methoxy-2-(methoxymethyl)-2-propenenitrile,COCC(=COC)C#N,,,,,,
4158,74159,1-Decylpyridinium chloride,CCCCCCCCCC[N+]1=CC=CC=C1.[Cl-],,,,,,
4159,74160,1-Decylpyridinium,CCCCCCCCCC[N+]1=CC=CC=C1,,,,,,
4160,74161,"Diethyl 3,3'-dithiodipropionate",CCOC(=O)CCSSCCC(=O)OCC,,,,,,
4161,74162,Diisopropylphosphate,CC(C)OP(=O)(O)OC(C)C,,,,,,
4162,74163,11-Bromo-1-undecanol,C(CCCCCO)CCCCCBr,,,,,,
4163,74164,N-Phenylmethacrylamide,CC(=C)C(=O)NC1=CC=CC=C1,,,,,,
4164,74165,2-[p-(Dimethylamino)styryl]quinoline,CN(C)C1=CC=C(C=C1)C=CC2=NC3=CC=CC=C3C=C2,,,,,,
4165,74166,2-Propylquinoline,CCCC1=NC2=CC=CC=C2C=C1,,,,,"['2-propylquinoline has known human metabolites that include 2-Quinolinemethanol, alpha-ethyl-, 3-(Quinolin-2-yl)propan-1-ol, 5-propyl-1a,7b-dihydrooxireno[2,3-f]quinoline, and 6-propyl-1a,7b-dihydrooxireno[2,3-h]quinoline.']",
4166,74167,Diphenyldichlorogermane,C1=CC=C(C=C1)[Ge](C2=CC=CC=C2)(Cl)Cl,,,,,,
4167,74168,2-(1H-Imidazol-1-yl)ethanol,C1=CN(C=N1)CCO,,,,,,
4168,74169,2-(2-Methyl-1H-imidazol-1-yl)ethanol,CC1=NC=CN1CCO,,,,,,
4169,74170,"2,4-Pentadienenitrile",C=CC=CC#N,,,,,,
4170,74171,"1,2-Dipropylhydrazine",CCCNNCCC,,,,,,
4171,74172,"3-Butenoic acid, ethyl ester",CCOC(=O)CC=C,,,,,,
4172,74173,Ethyl cyclohexenecarboxylate,CCOC(=O)C1=CCCCC1,,,,,,
4173,74174,2-Methyl-pentenoic acid ethyl ester,CCC=C(C)C(=O)OCC,,,,,,
4174,74175,Ethyl 2-cyano-2-ethylbutanoate,CCC(CC)(C#N)C(=O)OCC,,,,,,
4175,74176,(Diethylamino)acetone,CCN(CC)CC(=O)C,,,,,,
4176,74177,alpha-(4-Pyridyl)benzhydrol,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=NC=C3)O,,,,,,
4177,74178,"2,6-Di-tert-butyl-alpha-mercapto-p-cresol",CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)CS,,,,,,
4178,74179,1-Phenyl-2-(pyridin-2-yl)ethan-1-one,C1=CC=C(C=C1)C(=O)CC2=CC=CC=N2,,,,,,
4179,74180,"Benzoic acid, 3,5-bis(1,1-dimethylethyl)-4-hydroxy-, ethyl ester",CCOC(=O)C1=CC(=C(C(=C1)C(C)(C)C)O)C(C)(C)C,,,,,,
4180,74181,"2,6-Bis[(2-hydroxy-5-methylphenyl)methyl]-4-methylphenol",CC1=CC(=C(C=C1)O)CC2=CC(=CC(=C2O)CC3=C(C=CC(=C3)C)O)C,,,,,,
4181,74182,6-Methylpyridine-2-carbonitrile,CC1=NC(=CC=C1)C#N,,,,,,
4182,74183,5-Methylpyridine-2-carbonitrile,CC1=CN=C(C=C1)C#N,,,,,,
4183,74184,"alpha,alpha'-Thiobis(2,6-di-tert-butyl-p-cresol)",CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)CSCC2=CC(=C(C(=C2)C(C)(C)C)O)C(C)(C)C,,,,,,
4184,74185,Ethyl 1-(p-methylbenzyl)cyclopropanecarboxylate,CCOC(=O)C1(CC1)CC2=CC=C(C=C2)C,,,,,,
4185,74186,2-[2-(2-Thienyl)ethyl]benzoic acid,C1=CC=C(C(=C1)CCC2=CC=CS2)C(=O)O,,,,,,
4186,74187,2-Amino-1-methylbenzimidazole,CN1C2=CC=CC=C2N=C1N,,,,,,
4187,74188,"Phosphoric acid, monopropyl ester",CCCOP(=O)(O)O,,,,,,
4188,74189,Dibenzyl phosphate,C1=CC=C(C=C1)COP(=O)(O)OCC2=CC=CC=C2,,,,,,
4189,74190,Ethyl dihydrogen phosphate,CCOP(=O)(O)O,,,,,,
4190,74191,5-Chloromethylfurfural,C1=C(OC(=C1)C=O)CCl,,,,,,
4191,74192,4-Biphenylsulfonyl Chloride,C1=CC=C(C=C1)C2=CC=C(C=C2)S(=O)(=O)Cl,,,,,,
4192,74193,4-Phenoxybenzoyl chloride,C1=CC=C(C=C1)OC2=CC=C(C=C2)C(=O)Cl,,,,,,
4193,74194,Tetrakis(dimethylamino)silane,CN(C)[Si](N(C)C)(N(C)C)N(C)C,,,,,,
4194,74195,"4,4'-di-tert-Butylbiphenyl",CC(C)(C)C1=CC=C(C=C1)C2=CC=C(C=C2)C(C)(C)C,,,,,,
4195,74196,"2,7-Octanedione",CC(=O)CCCCC(=O)C,,,,,,
4196,74197,Triphenylgermanium chloride,C1=CC=C(C=C1)[Ge](C2=CC=CC=C2)(C3=CC=CC=C3)Cl,,,,,,
4197,74198,CID 74198,C1=CC=C(C=C1)C=NN=C(N)S,,,,,,
4198,74199,2-(Triethoxysilyl)butyronitrile,CCC(C#N)[Si](OCC)(OCC)OCC,,,,,,
4199,74200,10-Acetylphenothiazine,CC(=O)N1C2=CC=CC=C2SC3=CC=CC=C31,,,,,,
4200,74201,2-Methoxypyridine,COC1=CC=CC=N1,,,,,,
4201,74202,"1,1-Dimethylcyclopropane",CC1(CC1)C,,,,,,
4202,74203,N-Cyclohexylmaleimide,C1CCC(CC1)N2C(=O)C=CC2=O,,,,,,
4203,74204,N-Benzylmaleimide,C1=CC=C(C=C1)CN2C(=O)C=CC2=O,,,,,,
4204,74205,Benzyl(dimethyl)silane,C[SiH](C)CC1=CC=CC=C1,,,,,,
4205,74206,Hexanoic-D11acid,C1=CC=C(C=C1)[SiH](C2=CC=CC=C2)Cl,,,,,,
4206,74207,Dichloro(phenyl)silane,C1=CC=C(C=C1)[SiH](Cl)Cl,,,,,,
4207,74208,3-Methylpyridazine,CC1=NN=CC=C1,,,,,,
4208,74209,"1,6-Diaminohexane-N,N,N',N'-tetraacetic acid",C(CCCN(CC(=O)O)CC(=O)O)CCN(CC(=O)O)CC(=O)O,,,,,,
4209,74210,[2.2]Paracyclophane,C1CC2=CC=C(CCC3=CC=C1C=C3)C=C2,,,,,,
4210,74211,"Pyridine-3,4-dicarbonitrile",C1=CN=CC(=C1C#N)C#N,,,,,,
4211,74212,4-Chloro-1-butylsulfonyl chloride,C(CCCl)CS(=O)(=O)Cl,,,,,,
4212,74213,2-Methylpentane-2-thiol,CCCC(C)(C)S,,,,,,
4213,74214,2-Ethyl-2-(hydroxymethyl)butyraldehyde,CCC(CC)(CO)C=O,,,,,,
4214,74215,2-(4-Hydroxyphenylazo)benzoic acid,C1=CC=C(C(=C1)C(=O)O)N=NC2=CC=C(C=C2)O,,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']",,,
4215,74216,N-Dodecyl-p-toluenesulphonamide,CCCCCCCCCCCCNS(=O)(=O)C1=CC=C(C=C1)C,,,,,,
4216,74217,3-Aminocoumarin,C1=CC=C2C(=C1)C=C(C(=O)O2)N,,,,,,
4217,74218,5-Chloro-2-nitroaniline,C1=CC(=C(C=C1Cl)N)[N+](=O)[O-],,,,,,
4218,74219,"2,4-Dimethyl-6-nitroaniline",CC1=CC(=C(C(=C1)[N+](=O)[O-])N)C,,,,,,
4219,74220,Ethylphenylmalonic acid,CCC(C1=CC=CC=C1)(C(=O)O)C(=O)O,,,,,,
4220,74221,Dipropylmalonic acid,CCCC(CCC)(C(=O)O)C(=O)O,,,,,,
4221,74222,2-Isothiocyanatonaphthalene,C1=CC=C2C=C(C=CC2=C1)N=C=S,,,,,,
4222,74223,"1,3-Bis(4-phenoxyphenoxy)benzene",C1=CC=C(C=C1)OC2=CC=C(C=C2)OC3=CC(=CC=C3)OC4=CC=C(C=C4)OC5=CC=CC=C5,,,,,,
4223,74224,"Phosphine oxide, (chloromethyl)dimethyl-",CP(=O)(C)CCl,,,,,,
4224,74225,Diethyl phenylphosphonite,CCOP(C1=CC=CC=C1)OCC,,,,,,
4225,74226,3-Methylpentane-3-thiol,CCC(C)(CC)S,,,,,,
4226,74227,"3,4,5-Trimethylaniline",CC1=CC(=CC(=C1C)C)N,,,,,,
4227,74228,"Propiophenone, 3-dimethylamino-2'-hydroxy-, hydrochloride",CN(C)CCC(=O)C1=CC=CC=C1O.Cl,,,,,,
4228,74229,3-(Dimethylamino)-1-(2-hydroxyphenyl)propan-1-one,CN(C)CCC(=O)C1=CC=CC=C1O,,,,,,
4229,74230,Ethyl alpha-oxofuran-2-acetate,CCOC(=O)C(=O)C1=CC=CO1,,,,,,
4230,74231,Thiophene-3-carbonitrile,C1=CSC=C1C#N,,,,,,
4231,74232,o-Phenylene phosphorochloridite,C1=CC=C2C(=C1)OP(O2)Cl,,,,,,
4232,74233,4-Indanol,C1CC2=C(C1)C(=CC=C2)O,,,,,,
4233,74234,4-(Chloromethyl)benzoic acid,C1=CC(=CC=C1CCl)C(=O)O,,,,,,
4234,74235,3-Methylphenoxyacetic acid,CC1=CC(=CC=C1)OCC(=O)O,,,,,,
4235,74236,Tetrabutylammonium bromide,CCCC[N+](CCCC)(CCCC)CCCC.[Br-],,,"['Purifying or cleansing agents, usually salts of long-chain aliphatic bases or acids, that exert cleansing (oil-dissolving) and antimicrobial effects through a surface action that depends on possessing both hydrophilic and hydrophobic properties. (See all compounds classified as Detergents.)']",,,
4236,74237,p-Fluorophenyl-p-tolylsulfone,CC1=CC=C(C=C1)S(=O)(=O)C2=CC=C(C=C2)F,,,,,,
4237,74238,"1-Nitro-3-(1,1,2,2-tetrafluoroethoxy)benzene",C1=CC(=CC(=C1)OC(C(F)F)(F)F)[N+](=O)[O-],,,,,,
4238,74239,"2-Propanimine, 1,1,1,3,3,3-hexafluoro-",C(=N)(C(F)(F)F)C(F)(F)F,,,,,,
4239,74240,"3-Bromo-1,2,4,5-tetramethylbenzene",CC1=CC(=C(C(=C1C)Br)C)C,,,,,,
4240,74241,"1,4-Dibromo-2,3,5,6-tetramethylbenzene",CC1=C(C(=C(C(=C1Br)C)C)Br)C,,,,,,
4241,74242,"2,2,2-Trifluoroethanesulfonyl chloride",C(C(F)(F)F)S(=O)(=O)Cl,,,,,,
4242,74243,"2,2-Dichloro-1,1,1,3,3,3-hexafluoropropane",C(C(F)(F)F)(C(F)(F)F)(Cl)Cl,,,,,,
4243,74244,"1,1,3-Trichloro-1,2,2,3,3-pentafluoropropane",C(C(F)(F)Cl)(C(F)(Cl)Cl)(F)F,,,,,,
4244,74245,Pentadecan-8-ol,CCCCCCCC(CCCCCCC)O,,,,,,
4245,74246,"3,4-Methylenedioxyphenethylamine hydrochloride",C1OC2=C(O1)C=C(C=C2)CCN.Cl,,,,,,
4246,74247,Decyl decanoate,CCCCCCCCCCOC(=O)CCCCCCCCC,,,,,,
4247,74248,"Disodium 1,5-naphthalenedisulfonate",C1=CC2=C(C=CC=C2S(=O)(=O)[O-])C(=C1)S(=O)(=O)[O-].[Na+].[Na+],,,,,,
4248,74249,"2,7-Naphthalenedisulfonic acid, disodium salt",C1=CC(=CC2=C1C=CC(=C2)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+],,,,,,
4249,74250,"1,6-Naphthalenedisulfonic acid, disodium salt",C1=CC2=C(C=CC(=C2)S(=O)(=O)[O-])C(=C1)S(=O)(=O)[O-].[Na+].[Na+],,,,,,
4250,74251,"(S)-2-((2,4-Dinitrophenyl)amino)propanoic acid",C[C@H](C(=O)O)NC1=C(C=C(C=C1)[N+](=O)[O-])[N+](=O)[O-],,,,,,
4251,74252,1-Methoxy-3-phenoxybenzene,COC1=CC(=CC=C1)OC2=CC=CC=C2,,,,,,
4252,74253,"Benzene, 1-methoxy-4-phenoxy-",COC1=CC=C(C=C1)OC2=CC=CC=C2,,,,,,
4253,74254,"Benzene, 1,1'-oxybis[4-methoxy-",COC1=CC=C(C=C1)OC2=CC=C(C=C2)OC,,,,,,
4254,74255,"2,4-Dinitrobenzenesulfonyl chloride",C1=CC(=C(C=C1[N+](=O)[O-])[N+](=O)[O-])S(=O)(=O)Cl,,,,,,
4255,74256,Trilauryl trithiophosphite,CCCCCCCCCCCCSP(SCCCCCCCCCCCC)SCCCCCCCCCCCC,,,,,,
4256,74257,Bis((3-pyridyl)methyl)amine,C1=CC(=CN=C1)CNCC2=CN=CC=C2,,,,,,
4257,74258,2-[(p-Nitrophenyl)azo]acetoacetanilide,CC(=O)C(C(=O)NC1=CC=CC=C1)N=NC2=CC=C(C=C2)[N+](=O)[O-],,,,,,
4258,74259,2-[(p-Methoxyphenyl)azo]acetoacetanilide,CC(=O)C(C(=O)NC1=CC=CC=C1)N=NC2=CC=C(C=C2)OC,,,,,,
4259,74260,3-Oxo-N-2-pyridylbutyramide,CC(=O)CC(=O)NC1=CC=CC=N1,,,,,,
4260,74261,"4,4'-Dimethoxybibenzyl",COC1=CC=C(C=C1)CCC2=CC=C(C=C2)OC,,,,,,
4261,74262,"(E)-1,2-di(biphenyl-4-yl)ethene",C1=CC=C(C=C1)C2=CC=C(C=C2)C=CC3=CC=C(C=C3)C4=CC=CC=C4,,,,,,
4262,74263,"1,2,3,4,5,6,7,8-Octahydroacridine",C1CCC2=NC3=C(CCCC3)C=C2C1,,,,,,
4263,74264,Methyl 2-pyridylacetate,COC(=O)CC1=CC=CC=N1,,,,,,
4264,74265,"3,4,7,8-Tetramethyl-1,10-phenanthroline",CC1=CN=C2C(=C1C)C=CC3=C(C(=CN=C32)C)C,,,,,,
4265,74266,Tetraisopropyl methylenediphosphonate,CC(C)OP(=O)(CP(=O)(OC(C)C)OC(C)C)OC(C)C,,,,,,
4266,74267,"1,2-Bis(diphenylphosphino)ethane",C1=CC=C(C=C1)P(CCP(C2=CC=CC=C2)C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
4267,74268,(Triethoxymethyl)benzene,CCOC(C1=CC=CC=C1)(OCC)OCC,,,,,,
4268,74269,Malonyl chloride,C(C(=O)Cl)C(=O)Cl,,,,,,
4269,74270,N-Phenylethylenediamine,C1=CC=C(C=C1)NCCN,,,,,,
4270,74271,"N,N-Diethyl-N'-phenylethylenediamine",CCN(CC)CCNC1=CC=CC=C1,,,,,,
4271,74272,"1,3,2-Dioxaphosphole, 2,2-dihydro-2,2,2-trimethoxy-4,5-dimethyl-",CC1=C(OP(O1)(OC)(OC)OC)C,,,,,,
4272,74273,o-(Allyloxy)phenetole,CCOC1=CC=CC=C1OCC=C,,,,,,
4273,74274,Cyclopropylphenylmethane,C1CC1CC2=CC=CC=C2,,,,,,
4274,74275,"4,4'-Bis(chloromethyl)-1,1'-biphenyl",C1=CC(=CC=C1CCl)C2=CC=C(C=C2)CCl,,,,,,
4275,74276,"1,3-Benzenediol, 4-[4,6-bis(2,4-dimethylphenyl)-1,3,5-triazin-2-yl]-",CC1=CC(=C(C=C1)C2=NC(=NC(=N2)C3=C(C=C(C=C3)O)O)C4=C(C=C(C=C4)C)C)C,,,,,,
4276,74277,4-[Bis(2-iodoethyl)amino]benzenesulfonamide,C1=CC(=CC=C1N(CCI)CCI)S(=O)(=O)N,,,,,,
4277,74278,N-[2-(1H-imidazol-5-yl)ethyl]-9H-purin-6-amine,C1=C(NC=N1)CCNC2=NC=NC3=C2NC=N3,,,,,,
4278,74279,"1,1-Diethoxycyclohexane",CCOC1(CCCCC1)OCC,,,,,,
4279,74280,Indole-5-carboxylic acid,C1=CC2=C(C=CN2)C=C1C(=O)O,,,,,,
4280,74281,1H-Indole-7-carboxylic acid,C1=CC2=C(C(=C1)C(=O)O)NC=C2,,,,,,
4281,74282,Heptanophenone,CCCCCCC(=O)C1=CC=CC=C1,,,,,,
4282,74283,1-(4-Methoxyphenyl)pentan-1-one,CCCCC(=O)C1=CC=C(C=C1)OC,,,,,,
4283,74284,4'-Methylvalerophenone,CCCCC(=O)C1=CC=C(C=C1)C,,,,,,
4284,74285,"1,2,3,6-Tetrahydro-1,3-dimethyl-2,6-dioxo-7H-purine-7-propanesulphonic acid",CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CCCS(=O)(=O)O,,,,,,
4285,74286,CID 74286,C1(=C(NC(=NC1=O)S)N)N=O,,,,,,
4286,74287,CID 74287,C1=NC(=O)C(=C(N1)N)N,,,,,,
4287,74288,Cyclohexyl palmitate,CCCCCCCCCCCCCCCC(=O)OC1CCCCC1,,,,,,
4288,74289,3-Chlorobenzhydrazide,C1=CC(=CC(=C1)Cl)C(=O)NN,,,,,,
4289,74290,Tetraphenylallene,C1=CC=C(C=C1)C(=C=C(C2=CC=CC=C2)C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
4290,74291,Octanophenone,CCCCCCCC(=O)C1=CC=CC=C1,,,,,,
4291,74292,Dodecanophenone,CCCCCCCCCCCC(=O)C1=CC=CC=C1,,,,,,
4292,74293,CID 74293,C(CCCCCF)CCCCC=CC(=O)O,,,,,,
4293,74294,10-(3-Chloropropyl)-2-(trifluoromethyl)-10H-phenothiazine,C1=CC=C2C(=C1)N(C3=C(S2)C=CC(=C3)C(F)(F)F)CCCCl,,,,,,
4294,74295,Azelanitrile,C(CCCC#N)CCCC#N,,,,,,
4295,74296,N-Phenylbenzenesulfonamide,C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC=C2,,,,,,
4296,74297,"Dodecanoic acid, 2-hydroxy-1-(hydroxymethyl)ethyl ester",CCCCCCCCCCCC(=O)OC(CO)CO,,,,,,
4297,74298,"2,2-Dimethylpropanethiol",CC(C)(C)CS,,,,,,
4298,74299,4-Chlorophenylboronic acid,B(C1=CC=C(C=C1)Cl)(O)O,,,,,,
4299,74300,10-Hydroxydecanoic acid,C(CCCCC(=O)O)CCCCO,,,,,,
4300,74301,"2,5-Bis(4-diethylaminophenyl)-1,3,4-oxadiazole",CCN(CC)C1=CC=C(C=C1)C2=NN=C(O2)C3=CC=C(C=C3)N(CC)CC,,,,,,
4301,74302,CID 74302,CCCCOC(=O)CN=C(N1C2=CC=CC=C2N=C1N[N+]#N)[O-],,,,,,
4302,74303,CID 74303,CCCCOC(=O)CNC(=O)N1C2=CC=CC=C2N=C1N[N+]#N,,,,,,
4303,74304,Nonanoic anhydride,CCCCCCCCC(=O)OC(=O)CCCCCCCC,,,,,,
4304,74305,CID 74305,CC1=C2C(=NC=N2)N=C(N1)N,,,,,,
4305,74306,Dibromoacetyl bromide,C(C(=O)Br)(Br)Br,,,,,,
4306,74307,"2,7-Naphthalenedisulfonic acid, 3-[(4-aminophenyl)azo]-4,5-dihydroxy-, disodium salt",C1=CC(=CC=C1N)N=NC2=C(C3=C(C=C(C=C3C=C2S(=O)(=O)[O-])S(=O)(=O)[O-])O)O.[Na+].[Na+],,,,,,
4307,74308,"3-[(4-Aminophenyl)azo]-4,5-dihydroxynaphthalene-2,7-disulphonic acid",C1=CC(=CC=C1N)N=NC2=C(C3=C(C=C(C=C3C=C2S(=O)(=O)O)S(=O)(=O)O)O)O,,,,,,
4308,74309,"1,1,1,2,2,3,3,4,4,5,5-Undecafluoro-7-iodoheptane",C(CI)C(C(C(C(C(F)(F)F)(F)F)(F)F)(F)F)(F)F,,,,,,
4309,74310,2-Amino-5-fluoropyrimidin-4(1h)-one,C1=C(C(=O)NC(=N1)N)F,,,,,,
4310,74311,"2,3-Diphenylquinoxaline",C1=CC=C(C=C1)C2=NC3=CC=CC=C3N=C2C4=CC=CC=C4,,,,,,
4311,74312,"Vanadium, triethoxyoxo-, (T-4)-",CCO.CCO.CCO.O=[V],,,,,,
4312,74313,Oxotripropoxyvanadium,CCCO.CCCO.CCCO.O=[V],,,,,,
4313,74314,5-Amino-2-methoxyphenol,COC1=C(C=C(C=C1)N)O,,,,,,
4314,74315,"Ethanediamide, N,N'-dihydroxy-",C(=O)(C(=O)NO)NO,,,,,,
4315,74316,5-Ethyl-o-cresol,CCC1=CC(=C(C=C1)C)O,,,,,,
4316,74317,"3,3-Dimethyl-2-benzofuran-1(3H)-one",CC1(C2=CC=CC=C2C(=O)O1)C,,,,,,
4317,74318,9H-Fluoren-9-ol,C1=CC=C2C(=C1)C(C3=CC=CC=C32)O,,,,,,
4318,74319,"Phenol, 4-[(phenylimino)methyl]-",C1=CC=C(C=C1)N=CC2=CC=C(C=C2)O,,,,,,
4319,74320,"alpha-Cyano-4-hydroxy-3,5-diiodobenzyl acetate",CC(=O)OC1=C(C=C(C=C1I)C#N)I,,,,,,
4320,74321,"Methane, oxybis(difluoro-",C(OC(F)F)(F)F,,,,,,
4321,74322,"N-ethyl-1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluoro-N-(2-hydroxyethyl)octane-1-sulfonamide",CCN(CCO)S(=O)(=O)C(C(C(C(C(C(C(C(F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F,,,,,,
4322,74323,"Dichloromethyl[3-(1,1,2,2-tetrafluoroethoxy)propyl]silane",C[Si](CCCOC(C(F)F)(F)F)(Cl)Cl,,,,,,
4323,74324,2-(Trifluoromethyl)thioxanthen-9-one,C1=CC=C2C(=C1)C(=O)C3=C(S2)C=CC(=C3)C(F)(F)F,,,,,,
4324,74325,Parapropamol,CCC(=O)NC1=CC=C(C=C1)O,,,,,,
4325,74326,"2,2,4,4,6,6-Hexamethyl-8,8-diphenylcyclotetrasiloxane",C[Si]1(O[Si](O[Si](O[Si](O1)(C)C)(C2=CC=CC=C2)C3=CC=CC=C3)(C)C)C,,,,,,
4326,74327,4-Methylphenylsulfonylurea,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)N,,,,,,
4327,74328,"3-Chloropentane-2,4-dione",CC(=O)C(C(=O)C)Cl,,,,,,
4328,74329,2-Bromo-n-[4-bromo-2-(pyridin-2-ylcarbonyl)phenyl]acetamide,C1=CC=NC(=C1)C(=O)C2=C(C=CC(=C2)Br)NC(=O)CBr,,,,,,
4329,74330,"cis-1,2,3,6-Tetrahydro-4-methylphthalic anhydride",CC1=CC[C@@H]2[C@H](C1)C(=O)OC2=O,,,,,,
4330,74331,"4,4'-(Hydrazine-1,2-diylidenebis(methanylylidene))bis(2-methoxyphenol)",COC1=C(C=CC(=C1)C=NN=CC2=CC(=C(C=C2)O)OC)O,,,,,,
4331,74332,Dodecyl 5-methyl-8-quinolyl sulphate,CCCCCCCCCCCCOS(=O)(=O)OC1=C2C(=C(C=C1)C)C=CC=N2,,,,,,
4332,74333,6-hydroxy-2-phenylpyridazin-3(2H)-one,C1=CC=C(C=C1)N2C(=O)C=CC(=O)N2,,,,,,
4333,74334,"4-Chloro-1,2-dihydro-1-phenylpyridazine-3,6-dione",C1=CC=C(C=C1)N2C(=O)C=C(C(=O)N2)Cl,,,,,,
4334,74335,4-Chloro-5-(methylamino)-2-phenyl-3(2H)-pyridazinone,CNC1=C(C(=O)N(N=C1)C2=CC=CC=C2)Cl,,,,,,
4335,74336,5-Bromo-4-chloro-2-phenylpyridazin-3(2H)-one,C1=CC=C(C=C1)N2C(=O)C(=C(C=N2)Br)Cl,,,,,,
4336,74337,2-((Phenylthio)methyl)benzoic acid,C1=CC=C(C=C1)SCC2=CC=CC=C2C(=O)O,,,,,,
4337,74338,"3,4-Bis(benzyloxy)benzyl alcohol",C1=CC=C(C=C1)COC2=C(C=C(C=C2)CO)OCC3=CC=CC=C3,,,,,,
4338,74339,"3,4-Dibenzyloxybenzyl chloride",C1=CC=C(C=C1)COC2=C(C=C(C=C2)CCl)OCC3=CC=CC=C3,,,,,,
4339,74340,Bis(2-hydroxyethyl) adipate,C(CCC(=O)OCCO)CC(=O)OCCO,,,,,,
4340,74341,3-Benzyloxybenzyl alcohol,C1=CC=C(C=C1)COC2=CC=CC(=C2)CO,,,,,,
4341,74342,3-Benzyloxybenzaldehyde,C1=CC=C(C=C1)COC2=CC=CC(=C2)C=O,,,,,,
4342,74343,4-Propionylpyridine,CCC(=O)C1=CC=NC=C1,,,,,,
4343,74344,1-(Pyridin-4-yl)pentan-1-one,CCCCC(=O)C1=CC=NC=C1,,,,,,
4344,74345,Silver isothiocyanate,C(#N)[S-].[Ag+],,,,,,
4345,74346,2-Ethyl-5-methylfuran,CCC1=CC=C(O1)C,,,,,,
4346,74347,"4'-tert-Butyl-2',6'-dimethylbutyrophenone",CCCC(=O)C1=C(C=C(C=C1C)C(C)(C)C)C,,,,,,
4347,74348,2-[2-(Dimethylamino)ethoxy]ethanol,CN(C)CCOCCO,,,,,,
4348,74349,CID 74349,CC(C)(C)OOC1CCC(CC1)C(C)(C)C2CCC(CC2)(OOC(C)(C)C)OOC(C)(C)C,,,,,,
4349,74350,"2,5-Dimethylanisole",CC1=CC(=C(C=C1)C)OC,,,,,,
4350,74351,1-Methyl-4-phenoxybenzene,CC1=CC=C(C=C1)OC2=CC=CC=C2,,,,,,
4351,74352,"1,4-Benzenediol, 2-octyl-",CCCCCCCCC1=C(C=CC(=C1)O)O,,,,,,
4352,74353,"1,4-Benzenediol, 2-octadecyl-",CCCCCCCCCCCCCCCCCCC1=C(C=CC(=C1)O)O,,,,,,
4353,74354,"1,4-Benzenediol, 2-(phenylmethyl)-",C1=CC=C(C=C1)CC2=C(C=CC(=C2)O)O,,,,,,
4354,74355,beta-Styrenephosphonic acid,C1=CC=C(C=C1)C=CP(=O)(O)O,,,,,,
4355,74356,"2-(2-Chlorophenyl)-4,5-diphenyl-1H-imidazole",C1=CC=C(C=C1)C2=C(N=C(N2)C3=CC=CC=C3Cl)C4=CC=CC=C4,,,,,,
4356,74357,"1,1'-Bi-1H-imidazole, 2,2'-bis(2-chlorophenyl)-4,4',5,5'-tetraphenyl-",C1=CC=C(C=C1)C2=C(N(C(=N2)C3=CC=CC=C3Cl)N4C(=C(N=C4C5=CC=CC=C5Cl)C6=CC=CC=C6)C7=CC=CC=C7)C8=CC=CC=C8,,,,,,
4357,74358,"1,1-Diphenyl-2-picrylhydrazine",C1=CC=C(C=C1)N(C2=CC=CC=C2)NC3=C(C=C(C=C3[N+](=O)[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
4358,74359,Tribenzyl phosphate,C1=CC=C(C=C1)COP(=O)(OCC2=CC=CC=C2)OCC3=CC=CC=C3,,,,,,
4359,74360,"2-Hexyl-1,3-dioxolane",CCCCCCC1OCCO1,,,,,,
4360,74361,"2-Hexyl-1,3-dioxan-5-ol",CCCCCCC1OCC(CO1)O,,,,,,
4361,74362,"2-Phenyl-1,3-dioxan-5-ol",C1C(COC(O1)C2=CC=CC=C2)O,,,,,,
4362,74363,Hept-3-en-1-ol,CCCC=CCCO,,,,,,
4363,74364,"3-Penten-1-ol, 3-methyl-, acetate",CC=C(C)CCOC(=O)C,,,,,,
4364,74365,"3-Penten-1-ol, 3-methyl-",CC=C(C)CCO,,,,,,
4365,74366,3-Aminobenzaldehyde,C1=CC(=CC(=C1)N)C=O,,,,,,
4366,74367,"N,N-Diethylbenzenesulfonamide",CCN(CC)S(=O)(=O)C1=CC=CC=C1,,,,,,
4367,74368,4-Amino-N-methylbenzenesulfonamide,CNS(=O)(=O)C1=CC=C(C=C1)N,,,,,,
4368,74369,"4-Amino-N,N-dimethylbenzenesulfonamide",CN(C)S(=O)(=O)C1=CC=C(C=C1)N,,,,,,
4369,74370,"1,3,5-Trimethyl-2,4,6-tris(3,5-di-tert-butyl-4-hydroxybenzyl)benzene",CC1=C(C(=C(C(=C1CC2=CC(=C(C(=C2)C(C)(C)C)O)C(C)(C)C)C)CC3=CC(=C(C(=C3)C(C)(C)C)O)C(C)(C)C)C)CC4=CC(=C(C(=C4)C(C)(C)C)O)C(C)(C)C,,,,,,
4370,74371,"2,3-Dihydro-5-methoxy-1,4-benzodioxin",COC1=CC=CC2=C1OCCO2,,,,,,
4371,74372,4-tert-Butylbenzoyl chloride,CC(C)(C)C1=CC=C(C=C1)C(=O)Cl,,,,,,
4372,74373,4-Iodobenzoyl chloride,C1=CC(=CC=C1C(=O)Cl)I,,,,,,
4373,74374,3-Methoxybenzoyl chloride,COC1=CC=CC(=C1)C(=O)Cl,,,,,,
4374,74375,3-Methylbenzoyl chloride,CC1=CC(=CC=C1)C(=O)Cl,,,,,,
4375,74376,3-Fluorobenzoyl chloride,C1=CC(=CC(=C1)F)C(=O)Cl,,,,,,
4376,74377,3-Bromobenzoyl chloride,C1=CC(=CC(=C1)Br)C(=O)Cl,,,,,,
4377,74378,3-Iodobenzoyl chloride,C1=CC(=CC(=C1)I)C(=O)Cl,,,,,,
4378,74379,p-tert-Butylperbenzoic acid,CC(C)(C)C1=CC=C(C=C1)C(=O)OO,,,,,,
4379,74380,2-Nitroperbenzoic acid,C1=CC=C(C(=C1)C(=O)OO)[N+](=O)[O-],,,,,,
4380,74381,4-Chloro-alpha-methylstyrene,CC(=C)C1=CC=C(C=C1)Cl,,,,,,
4381,74382,m-Isopropenylchlorobenzene,CC(=C)C1=CC(=CC=C1)Cl,,,,,,
4382,74383,Cumyl ethyl ether,CCOC(C)(C)C1=CC=CC=C1,,,,,,
4383,74384,O-(4-(((1-Methylethyl)amino)sulfonyl)phenyl) phosphorothioate,CC(C)NS(=O)(=O)C1=CC=C(C=C1)OP(=S)(OC)OC,,,,,,
4384,74385,"Phosphorothioic acid, O-(4-((ethylamino)sulfonyl)phenyl) O,O-dimethyl ester",CCNS(=O)(=O)C1=CC=C(C=C1)OP(=S)(OC)OC,,,,,,
4385,74386,"Phosphonodithioic acid, chloromethyl-, S-(p-chlorophenyl) O-isopropyl ester",CC(C)OP(=S)(CCl)SC1=CC=C(C=C1)Cl,,,,,,
4386,74387,S-(4-Chlorophenyl) O-propyl (chloromethyl)phosphonodithioate,CCCOP(=S)(CCl)SC1=CC=C(C=C1)Cl,,,,,,
4387,74388,"Phosphonodithioic acid, chloromethyl-, S-(p-fluorophenyl) O-isopropyl ester",CC(C)OP(=S)(CCl)SC1=CC=C(C=C1)F,,,,,,
4388,74389,"4,4'-Dichlorobenzophenone oxime",C1=CC(=CC=C1C(=NO)C2=CC=C(C=C2)Cl)Cl,,,,,,
4389,74390,Fenthion-ethyl,CCOP(=S)(OCC)OC1=CC(=C(C=C1)SC)C,,,,,,
4390,74391,1-(3-Chloropropoxy)-4-fluorobenzene,C1=CC(=CC=C1OCCCCl)F,,,,,,
4391,74392,"2,2,4,4-Tetrafluoro-1,3-dithietane",C1(SC(S1)(F)F)(F)F,,,,,,
4392,74393,Chloro(chloromethyl)dimethylsilane,C[Si](C)(CCl)Cl,,,,,,
4393,74394,Chloro-ethenyl-dimethylstannane,C[Sn](C)(C=C)Cl,,,,,,
4394,74395,Tetrazolium violet,C1=CC=C(C=C1)C2=NN([N+](=N2)C3=CC=CC4=CC=CC=C43)C5=CC=CC=C5.[Cl-],,,,,,
4395,74396,Tetrazolium violet(1+),C1=CC=C(C=C1)C2=NN([N+](=N2)C3=CC=CC4=CC=CC=C43)C5=CC=CC=C5,,,,,,
4396,74397,CID 74397,CC(C)N=C(N)S,,,,,,
4397,74398,"3,4,5-Trimethoxybenzoic Anhydride",COC1=CC(=CC(=C1OC)OC)C(=O)OC(=O)C2=CC(=C(C(=C2)OC)OC)OC,,,,,,
4398,74399,2-Methyldotriacontane,CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC(C)C,,,,,,
4399,74400,"1,9-Decadiyne",C#CCCCCCCC#C,,,,,,
4400,74401,Ethyl 2-methylnicotinate,CCOC(=O)C1=C(N=CC=C1)C,,,,,,
4401,74402,"1,3-Dimethylisoquinoline",CC1=CC2=CC=CC=C2C(=N1)C,,,,,,
4402,74403,3-Chloro-6-methoxypyridazine,COC1=NN=C(C=C1)Cl,,,,,,
4403,74404,2-Chloropyrimidine,C1=CN=C(N=C1)Cl,,,,,,
4404,74405,"4,6-Dichloro-N,N-diethyl-1,3,5-triazin-2-amine",CCN(CC)C1=NC(=NC(=N1)Cl)Cl,,,,,,
4405,74406,Pentenedioic acid,C(C=CC(=O)O)C(=O)O,,,,,,
4406,74407,Dipropyl glutarate,CCCOC(=O)CCCC(=O)OCCC,,,,,,
4407,74408,"1,8-Dioxacycloheptadecan-9-one",C1CCCCOCCCCCCOC(=O)CCC1,,,,,,
4408,74409,Oxacyclododecan-2-one,C1CCCCCOC(=O)CCCC1,,,,,,
4409,74410,3-Iodo-2-propynol,C(C#CI)O,,,,,,
4410,74411,Trimellitic acid tri-n-butyl ester,CCCCOC(=O)C1=CC(=C(C=C1)C(=O)OCCCC)C(=O)OCCCC,,,,,,
4411,74412,"2,3,3-Trimethylcyclopent-1-enylacetonitrile",CC1=C(CCC1(C)C)CC#N,,,,,,
4412,74413,Allylmagnesium bromide,[CH2-]C=C.[Mg+2].[Br-],,,,,,
4413,74414,"6-Methoxy-1,2,3,4-tetrahydronaphthalene",COC1=CC2=C(CCCC2)C=C1,,,,,,
4414,74415,Dimethyl dodecanedioate,COC(=O)CCCCCCCCCCC(=O)OC,,,,,,
4415,74416,Dimethyl pimelate,COC(=O)CCCCCC(=O)OC,,,,,,
4416,74417,"1,2,3,6,7,8-Hexahydropyrene",C1CC2=C3C(=CC=C4C3=C(CCC4)C=C2)C1,,,,,,
4417,74418,N-Pyren-2-ylacetamide,CC(=O)NC1=CC2=C3C(=C1)C=CC4=C3C(=CC=C4)C=C2,,,,,,
4418,74419,"Phosphine, dibutyl-",CCCCPCCCC,,,,,,
4419,74420,"Ethane-1,2-diyl bis(1,3-dioxo-1,3-dihydroisobenzofuran-5-carboxylate)",C1=CC2=C(C=C1C(=O)OCCOC(=O)C3=CC4=C(C=C3)C(=O)OC4=O)C(=O)OC2=O,,,,,,
4420,74421,"5-Isobenzofurancarboxylic acid, 1,3-dihydro-1,3-dioxo-, 2-(acetyloxy)-1,3-propanediyl ester",CC(=O)OC(COC(=O)C1=CC2=C(C=C1)C(=O)OC2=O)COC(=O)C3=CC4=C(C=C3)C(=O)OC4=O,,,,,,
4421,74422,"1,1,3-Propanetricarboxylic acid, trimethyl ester",COC(=O)CCC(C(=O)OC)C(=O)OC,,,,,,
4422,74423,Ethyldiphenylphosphine oxide,CCP(=O)(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
4423,74424,"1,5-Bis(chloromethyl)naphthalene",C1=CC(=C2C=CC=C(C2=C1)CCl)CCl,,,,,,
4424,74425,CID 74425,C1=CC=C(C=C1)OS(=O)(=O)[O-].[K+],,,,,,
4425,74426,Phenyl hydrogen sulfate,C1=CC=C(C=C1)OS(=O)(=O)O,,,,,,
4426,74427,CID 74427,C1=CC=C2C=C(C=CC2=C1)OS(=O)(=O)[O-].[K+],,,,,,
4427,74428,2-Naphthyl sulfate,C1=CC=C2C=C(C=CC2=C1)OS(=O)(=O)O,,,,,,
4428,74429,"2,2'-((2-(Dodecyloxy)ethyl)imino)bisethanol",CCCCCCCCCCCCOCCN(CCO)CCO,,,,,,
4429,74430,2-(2-Biphenylyloxy)triethylamine hydrochloride,CCN(CC)CCOC1=CC=CC=C1C2=CC=CC=C2.Cl,,,,,,
4430,74431,2-(2-Biphenylyloxy)triethylamine,CCN(CC)CCOC1=CC=CC=C1C2=CC=CC=C2,,,,,,
4431,74432,Bis[4-(trifluoromethoxy)phenyl] sulphone,C1=CC(=CC=C1OC(F)(F)F)S(=O)(=O)C2=CC=C(C=C2)OC(F)(F)F,,,,,,
4432,74433,2-Nitro-4-(trifluoromethyl)phenylacetic acid,C1=CC(=C(C=C1C(F)(F)F)[N+](=O)[O-])CC(=O)O,,,,,,
4433,74434,"1H-Benzimidazole, 6-chloro-1-ethyl-2-methyl-5-(trifluoromethyl)-",CCN1C(=NC2=C1C=C(C(=C2)C(F)(F)F)Cl)C,,,,,,
4434,74435,Allylpentafluorobenzene,C=CCC1=C(C(=C(C(=C1F)F)F)F)F,,,,,,
4435,74436,CID 74436,C1=CC=C(C(=C1)C(F)(F)F)N=C(N)S,,,,,,
4436,74437,4'-(Trifluoromethoxy)acetanilide,CC(=O)NC1=CC=C(C=C1)OC(F)(F)F,,,,,,
4437,74438,"3-(1,1,2,2-Tetrafluoroethoxy)toluene",CC1=CC(=CC=C1)OC(C(F)F)(F)F,,,,,,
4438,74439,"4-(1,1,2,2-Tetrafluoroethoxy)toluene",CC1=CC=C(C=C1)OC(C(F)F)(F)F,,,,,,
4439,74440,"Urea, 1-(fluoroacetyl)-3-phenyl-",C1=CC=C(C=C1)NC(=O)NC(=O)CF,,,,,,
4440,74441,"2,2-Diaminohexafluoropropane",C(C(F)(F)F)(C(F)(F)F)(N)N,,,,,,
4441,74442,Methoxyacetonitrile,COCC#N,,,,,,
4442,74443,"Benzeneethanamine, N-phenyl-",C1=CC=C(C=C1)CCNC2=CC=CC=C2,,,,,,
4443,74444,"1,2,4,5-Tetramethyl-1H-imidazole",CC1=C(N(C(=N1)C)C)C,,,,,,
4444,74445,Isophthalamide,C1=CC(=CC(=C1)C(=O)N)C(=O)N,,,,,,
4445,74446,4-Isopropyl-2-methylphenol,CC1=C(C=CC(=C1)C(C)C)O,,,,,,
4446,74447,"Phosphorodithioic acid, S-hydroxymethyl O,O-dimethyl ester, acetate",CC(=O)OCSP(=S)(OC)OC,,,,,,
4447,74448,"1,1-Bis(3,4-dimethylphenyl)ethane",CC1=C(C=C(C=C1)C(C)C2=CC(=C(C=C2)C)C)C,,,,,,
4448,74449,"Naphtho[1,2-d]thiazolium, 1-methyl-2-[2-[(1-methylnaphtho[1,2-d]thiazol-2(1H)-ylidene)methyl]-1-butenyl]-, chloride",CCC(=CC1=[N+](C2=C(S1)C=CC3=CC=CC=C32)C)C=C4N(C5=C(S4)C=CC6=CC=CC=C65)C.[Cl-],,,,,,
4449,74450,"1-Methyl-2-[2-[(1-methylnaphtho[1,2-d]thiazol-2(1H)-ylidene)methyl]-1-butenyl]naphtho[1,2-d]thiazol-3-ium",CCC(=CC1=[N+](C2=C(S1)C=CC3=CC=CC=C32)C)C=C4N(C5=C(S4)C=CC6=CC=CC=C65)C,,,,,,
4450,74451,Tetraformaltrisazine,C1NNCN2N1CNNC2,,,,,,
4451,74452,Isobutylidene(ethyl)amine,CCN=CC(C)C,,,,,,
4452,74453,"1-(2,2-Diethoxyethyl)-4-fluorobenzene",CCOC(CC1=CC=C(C=C1)F)OCC,,,,,,
4453,74454,"1,2-Dibutylhydrazine",CCCCNNCCCC,,,,,,
4454,74455,"Benzothiazolium, 3-ethyl-2-[3-(3-ethyl-2(3H)-benzothiazolylidene)-2-methyl-1-propen-1-yl]-, bromide (1:1)",CCN1C2=CC=CC=C2SC1=CC(=CC3=[N+](C4=CC=CC=C4S3)CC)C.[Br-],,,,,,
4455,74456,Dichlorodivinylsilane,C=C[Si](C=C)(Cl)Cl,,,,,,
4456,74457,"Phenol, 4,4'-(1-methylethylidene)bis[2-(2-propenyl)-",CC(C)(C1=CC(=C(C=C1)O)CC=C)C2=CC(=C(C=C2)O)CC=C,,,,,,
4457,74458,Allyl phenyl ether,C=CCOC1=CC=CC=C1,,,,,,
4458,74459,"2,4,5-Triiodoimidazole",C1(=C(N=C(N1)I)I)I,,,,,,
4459,74460,CID 74460,C1(=NN=C(N1N)S)NN,,,,,,
4460,74461,"4,4'-Iminodiphenol",C1=CC(=CC=C1NC2=CC=C(C=C2)O)O,,,,,,
4461,74462,CID 74462,CCC(=NN=C(N)S)C,,,,,,
4462,74463,N-Phenylnicotinamide,C1=CC=C(C=C1)NC(=O)C2=CN=CC=C2,,,,,,
4463,74464,"2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-[[4-(dimethylamino)phenyl]methylene]-",CN(C)C1=CC=C(C=C1)C=C2C(=O)NC(=O)NC2=O,,,,,,
4464,74465,"Ethyl 2,4,6-trimethylbenzoate",CCOC(=O)C1=C(C=C(C=C1C)C)C,,,,,,
4465,74466,"Bis(2,4-dimethoxyphenyl)(2-methoxyphenyl)methanol",COC1=CC(=C(C=C1)C(C2=C(C=C(C=C2)OC)OC)(C3=CC=CC=C3OC)O)OC,,,,,,
4466,74467,2-Ethoxy-4-prop-1-enylphenol,CCOC1=C(C=CC(=C1)C=CC)O,,,,,,
4467,74468,1-Methyl-2-phenyl-1H-indole-3-carbaldehyde,CN1C2=CC=CC=C2C(=C1C3=CC=CC=C3)C=O,,,,,,
4468,74469,"2,5-Dimethoxyphenylacetic acid",COC1=CC(=C(C=C1)OC)CC(=O)O,,,,,,
4469,74470,"Bis[P-(1,1,3,3-tetramethylbutyl)phenyl] hydrogen phosphate",CC(C)(C)CC(C)(C)C1=CC=C(C=C1)OP(=O)(O)OC2=CC=C(C=C2)C(C)(C)CC(C)(C)C,,,,,,
4470,74471,o-Phenylenediarsonic acid,C1=CC=C(C(=C1)[As](=O)(O)O)[As](=O)(O)O,,,,,,
4471,74472,Dicyclohexyl peroxide,C1CCC(CC1)OOC2CCCCC2,,,,,,
4472,74473,"9,10-Anthracenedione, 1,6-diamino-",C1=CC2=C(C(=C1)N)C(=O)C3=C(C2=O)C=C(C=C3)N,,,,,,
4473,74474,p-Chlorophenyl 1-pyrrolidinecarboxylate,C1CCN(C1)C(=O)OC2=CC=C(C=C2)Cl,,,,,,
4474,74475,Bis(4-chloro-3-nitrophenyl) sulphone,C1=CC(=C(C=C1S(=O)(=O)C2=CC(=C(C=C2)Cl)[N+](=O)[O-])[N+](=O)[O-])Cl,,,,,,
4475,74476,"Cyclopentene, 1-methoxyheptafluoro-",COC1=C(C(C(C1(F)F)(F)F)(F)F)F,,,,,,
4476,74477,Oroselone,CC(=C)C1=CC2=C(O1)C=CC3=C2OC(=O)C=C3,,,,,,
4477,74478,4-Chloro-6-nitro-o-cresol,CC1=CC(=CC(=C1O)[N+](=O)[O-])Cl,,,,,,
4478,74479,2-Salicylideneaminophenol,C1=CC=C(C(=C1)C=NC2=CC=CC=C2O)O,,,,,,
4479,74480,"1'-(Phenylmethyl)-[1,4'-bipiperidine]-4'-carboxamide",C1CCN(CC1)C2(CCN(CC2)CC3=CC=CC=C3)C(=O)N,,,,,,
4480,74481,1-Benzyl-4-(dimethylamino)piperidine-4-carboxamide,CN(C)C1(CCN(CC1)CC2=CC=CC=C2)C(=O)N,,,,,,
4481,74482,"3,3,4,4-Tetrafluorohexa-1,5-diene",C=CC(C(C=C)(F)F)(F)F,,,,,,
4482,74483,Perfluorooctanesulfonic acid,C(C(C(C(C(F)(F)S(=O)(=O)O)(F)F)(F)F)(F)F)(C(C(C(F)(F)F)(F)F)(F)F)(F)F,,,,"['Tissue specific uptake and elimination of perfluoroalkyl acids (PFAAs) were studied in rainbow trout (Oncorhynchus mykiss). Adult trout were exposed to perfluorobutane sulfonic acid (PFBS), perfluorohexane sulfonic acid (PFHxS), perfluorooctane sulfonic acid (PFOS), perfluorooctanoic acid (PFOA) and perfluorononanoic acid (PFNA) via food over a time period of 28 d. In the following 28-d depuration period the fish were fed PFAA-free food. At defined sampling times four animals were removed from the experimental tank, euthanized and dissected. Muscle, liver, kidneys, gills, blood, skin and carcass were examined individually. At the end of the accumulation phase between 0.63% (PFOA) and 15.5% (PFOS) of the absolute, applied quantity of PFAAs was recovered in the whole fish. The main target organ was the liver with recovery rates between 0.11% (PFBS) and 4.01% (PFOS) of the total amount of ingested PFAAs. Perfluoroalkyl sulfonic acids were taken up more readily and had longer estimated elimination half-lives than perfluoroalkyl carboxylic acids of the same chain length. The longest estimated elimination half-lives were found to be for PFOS between 8.4 d in muscle tissue and 20.4 d in the liver and for PFNA between 8.2 d in the blood and 11.6 d in the liver.', 'Perfluorinated alkyl acids (PFAAs) have been detected in serum at low concentrations in background populations. Higher concentrations have been observed in adult males compared to females, with a possible explanation that menstruation offers females an additional elimination route. In this study, we examined the significance of blood loss as an elimination route of PFAAs. Pooled serum samples were collected from individuals undergoing a medical procedure involving ongoing blood withdrawal called venesection. Concentrations from male venesection patients were approximately 40% lower than males in the general population for perfluorohexane sulfonate (PFHxS), perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA). A simple pharmacokinetic model was used to test the hypothesis that blood loss could explain why adult males have higher concentrations of PFAAs than females, and why males undergoing venesections had lower concentrations compared to males in the general population. The model application generally supported these hypotheses showing that venesection might reduce blood serum concentrations by 37% (PFOA) and 53% (PFOS) compared to the observed difference of 44% and 37%. Menstruation was modeled to show a 22% reduction in PFOA serum concentrations compared to a 24% difference in concentrations between males and females in the background population. Uncertainties in the modeling and the data are identified and discussed.', ""... In this study, PFOS and PFOA were analyzed in 81 whole blood-urine paired samples from general adults and pregnant women in Tianjin, China. PFOS and PFOA were detected in 48 and 76% of adult urine (AU) samples, with geometric mean (GM) concentrations of 0.011 and 0.008 ng/mL, respectively; whereas relatively low PFOS and PFOA concentrations were found in maternal urine (MU) samples, with GM concentrations of 0.006 and 0.003 ng/mL, respectively. For PFOA, the coefficients of Pearson's correlation between whole blood concentrations and creatinine-adjusted and creatinine-unadjusted urinary concentrations were 0.348 (p=0.013) and 0.417 (p=0.002), respectively. The GM urinary elimination rates of PFOS (PFOSUER) and PFOA (PFOAUER) were 16 and 25%, respectively, for adults. These results indicate that urine is an important pathway of excretion of perfluoroalkyl substances (PFASs). The partitioning ratios of PFAS concentration between urine and whole blood (PFASU/B) in pregnant women (PFOSU/B, 0.0004; PFOAU/B, 0.0011) were significantly lower (p=0.025 for PFOSU/B, p=0.017 for PFOAU/B) than the ratios found in non-pregnant women (PFOSU/B, 0.0013; PFOAU/B, 0.0028). Furthermore, our results suggest a clear gender difference in the urinary elimination of PFOA, with male adults (31%) having significantly higher PFOAUER than that of female adults (19%). PFOSUER was significantly inversely correlated with age (r=-0.334, p=0.015); these findings suggest that urinary elimination of PFOS is faster in young adults than in the elderly."", 'Prenatal exposure to perfluoroalkyl substances (PFAS) has been associated with lower birth weight in epidemiologic studies. This association could be attributable to glomerular filtration rate (GFR), which is related to PFAS concentration and birth weight. We used a physiologically based pharmacokinetic (PBPK) model of pregnancy to assess how much of the PFAS-birth weight association observed in epidemiologic studies might be attributable to GFR. We modified a PBPK model to reflect the association of GFR with birth weight (estimated from three studies of GFR and birth weight) and used it to simulate PFAS concentrations in maternal and cord plasma. The model was run 250,000 times, with variation in parameters, to simulate a population. Simulated data were analyzed to evaluate the association between PFAS levels and birth weight due to GFR. We compared simulated estimates with those from a meta-analysis of epidemiologic data. The reduction in birth weight for each 1-ng/mL increase in simulated cord plasma for perfluorooctane sulfonate (PFOS) was 2.72 g (95% CI: -3.40, -2.04), and for perfluorooctanoic acid (PFOA) was 7.13 g (95% CI: -8.46, -5.80); results based on maternal plasma at term were similar. Results were sensitive to variations in PFAS level distributions and the strength of the GFR-birth weight association. In comparison, our meta-analysis of epidemiologic studies suggested that each 1-ng/mL increase in prenatal PFOS and PFOA levels was associated with 5.00 g (95% CI: -21.66, -7.78) and 14.72 g (95% CI: -8.92, -1.09) reductions in birth weight, respectively. Results of our simulations suggest that a substantial proportion of the association between prenatal PFAS and birth weight may be attributable to confounding by GFR and that confounding by GFR may be more important in studies with sample collection later in pregnancy.', 'For more Absorption, Distribution and Excretion (Complete) data for Perfluorooctane sulfonic acid (16 total), please visit the HSDB record page.']","['Female Sprague-Dawley rats were treated orally with N-ethyl perfluorooctanesulfonamidoethanol (N-EtFOSE), ciprofibrate or corn oil (vehicle) for 21 days, and levels of N-EtFOSE and its metabolites as well as markers of peroxisome proliferation and oxidative stress were assessed in serum, liver and/or uterus. The N-EtFOSE metabolite profile in liver and serum was in good agreement with reported in vitro biotransformation pathways in rats and the metabolite levels decreasing in the order perfluorooctanesulfonate >> perfluorooctanesulfonamide ~ N-ethyl perfluorooctanesulfonamidoacetate >> perfluorooctanesulfonamidoethanol approximately N-EtFOSE. Although N-EtFOSE treatment significantly decreased the growth rate, increased relative liver weight and activity of superoxide dismutases (SOD) in liver and uterus (total SOD, CuZnSOD and MnSOD), a metabolic  study revealed no differences in the metabolome in serum from N-EtFOSE-treated and control animals. Ciprofibrate treatment increased liver weight and peroxisomal acyl Co-A oxidase activity in the liver and altered antioxidant enzyme activities in the uterus and liver. According to NMR metabolomic studies, ciprofibrate treated animals had altered serum lipid profiles compared to N-EtFOSE-treated and control animals, whereas putative markers of peroxisome proliferation in serum were not affected. ... /Perfluorooctane sulfonate/', 'PFOS can also be formed as a metabolite of other perfluorinated sulfonates. It does not appear to be further metabolized. /Perfluorooctyl sulfonates/']","['... Adult trout were exposed to ... perfluorooctane sulfonic acid (PFOS) ... via food over a time period of 28 d ... The ... estimated elimination half-lives were found to be ... between 8.4 d in muscle tissue and 20.4 d in the liver ...', 'There are species differences in the elimination half-life of PFOS. The half-life in serum is 7.5 days in adult rats and 200 days in Cynomolgus monkeys. In humans, it appears to be quite longer. A recent halflife analysis was conducted on 9 retired 3M chemical workers. PFOS samples were collected over 4 time periods spanning 180 days, measured in triplicate with all time points from each subject analyzed in the same analytical run. The mean half-life for PFOS was 8.67 years (range 2.29 - 21.3 years, SD = 6.12).', 'Serum PFOS levels in 3 retired male 3M chemical workers have been followed for 5 1/2 yr and suggest a mean elim half-life (t 1/2) of 1,428 days (approx 4 yr). /Perfluorooctyl sulfonates/']"
4483,74484,"2,3,4,5,6-Pentafluorobenzyl bromide",C(C1=C(C(=C(C(=C1F)F)F)F)F)Br,,,,,,
4484,74485,Bis(pentafluorophenyl)methanol,C1(=C(C(=C(C(=C1F)F)F)F)F)C(C2=C(C(=C(C(=C2F)F)F)F)F)O,,,,,,
4485,74486,"Acetamide, N-[4-(1H-imidazol-2-ylazo)phenyl]-",CC(=O)NC1=CC=C(C=C1)N=NC2=NC=CN2,,,,,,
4486,74487,CID 74487,C1=CC=C(C=C1)NNC(=NC2=CC=CC=C2)S,,,,,,
4487,74488,CID 74488,C1=CC=C(C=C1)NC(=CN=O)O,,,,,,
4488,74489,"Tetrahydro-5-propyl-1,3,5-triazin-2(1H)-one",CCCN1CNC(=O)NC1,,,,,,
4489,74490,2-Methoxy-10H-phenothiazine,COC1=CC2=C(C=C1)SC3=CC=CC=C3N2,,,,,,
4490,74491,3-Methoxy-10H-phenothiazine,COC1=CC2=C(C=C1)NC3=CC=CC=C3S2,,,,,,
4491,74492,2-Methyl-4-oxo-4-phenylbutanoic acid,CC(CC(=O)C1=CC=CC=C1)C(=O)O,,,,,,
4492,74493,D-Galactosamine hydrochloride,C([C@H]([C@@H]([C@@H]([C@H](C=O)N)O)O)O)O.Cl,,,,,,
4493,74494,CID 74494,C(C([C@@H]([C@@H]([C@H](C=O)N)O)O)O)O,,,,,,
4494,74495,5-Nitro-2-(4-nitrophenyl)-1H-benzimidazole,C1=CC(=CC=C1C2=NC3=C(N2)C=C(C=C3)[N+](=O)[O-])[N+](=O)[O-],,,,,,
4495,74496,"2,4,4-Trimethyl-2-oxazoline",CC1=NC(CO1)(C)C,,,,,,
4496,74497,"Phenol, 4,4'-sulfinylbis-",C1=CC(=CC=C1O)S(=O)C2=CC=C(C=C2)O,,,,,,
4497,74498,Trimethylsulfoxonium iodide,C[S+](=O)(C)C.[I-],,,,,,
4498,74499,"Sulfoxonium, trimethyl-",C[S+](=O)(C)C,,,,,,
4499,74500,"2-hydroxy-N,N-dimethylbenzamide",CN(C)C(=O)C1=CC=CC=C1O,,,,,,
4500,74501,4'-(Methylthio)acetophenone,CC(=O)C1=CC=C(C=C1)SC,,,,,,
4501,74502,"4,7-Dibromo-3-hydroxy-2-naphthoic acid",C1=CC2=C(C(=C(C=C2C=C1Br)C(=O)O)O)Br,,,,,,
4502,74503,7-Bromo-3-hydroxy-2-naphthoic acid,C1=CC(=CC2=CC(=C(C=C21)O)C(=O)O)Br,,,,,,
4503,74504,"1,3-Isobenzofurandione, 5,5'-(1-methylethylidene)bis-",CC(C)(C1=CC2=C(C=C1)C(=O)OC2=O)C3=CC4=C(C=C3)C(=O)OC4=O,,,,,,
4504,74505,Methyltriphenylphosphonium bromide,C[P+](C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3.[Br-],,,"['Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant and Hackh&apos;s Chemical Dictionary, 5th ed, p301, p499) (See all compounds classified as Indicators and Reagents.)']",,,
4505,74506,Methyltriphenylphosphonium,C[P+](C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3,,,"['Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant and Hackh&apos;s Chemical Dictionary, 5th ed, p301, p499) (See all compounds classified as Indicators and Reagents.)']",,,
4506,74507,Propyl acetoacetate,CCCOC(=O)CC(=O)C,,,,,,
4507,74508,"2,4-Dichloro-5-methylpyrimidine",CC1=CN=C(N=C1Cl)Cl,,,,,,
4508,74509,2-Sulphopalmitic acid,CCCCCCCCCCCCCCC(C(=O)O)S(=O)(=O)O,,,,,,
4509,74510,3-(Ethylthio)aniline,CCSC1=CC=CC(=C1)N,,,,,,
4510,74511,"7-Chloro-5-cyclohexyl-1,3-dihydro-1-methyl-2H-1,4-benzodiazepin-2-one",CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3CCCCC3,,,,,,
4511,74512,"Mercury, chloro(ethanethiolato)-",CCS[Hg]Cl,,,,,,
4512,74513,"2-Acetoxy-1,4-naphthoquinone",CC(=O)OC1=CC(=O)C2=CC=CC=C2C1=O,,,,,,
4513,74514,"Naphthalene-1,2,4-triyl triacetate",CC(=O)OC1=CC(=C(C2=CC=CC=C21)OC(=O)C)OC(=O)C,,,,,,
4514,74515,"1,3-Benzenedicarboperoxoic acid",C1=CC(=CC(=C1)C(=O)OO)C(=O)OO,,,,,,
4515,74516,"3,6,9,12,15-Pentaoxanonadecan-1-ol",CCCCOCCOCCOCCOCCOCCO,,,,,,
4516,74517,N-Acetyl-N-(2-methylpropyl)acetamide,CC(C)CN(C(=O)C)C(=O)C,,,,,,
4517,74518,"1,3-Diphenylacetone oxime",C1=CC=C(C=C1)CC(=NO)CC2=CC=CC=C2,,,,,,
4518,74519,2-Amino-5-chlorophenyl cyclohexyl ketone,C1CCC(CC1)C(=O)C2=C(C=CC(=C2)Cl)N,,,,,,
4519,74520,CID 74520,C1CCC(CC1)C2=C3C=C(C=CC3=NC(=O)CN2)Cl,,,,,,
4520,74521,"2,3-Dihydro-7-(trifluoromethyl)-4H-1,2,4-benzothiadiazine-4-ethanol 1,1-dioxide",C1NS(=O)(=O)C2=C(N1CCO)C=CC(=C2)C(F)(F)F,,,,,,
4521,74522,"Titanium, dibutoxydichloro-, (T-4)-",CCCCO.CCCCO.Cl[Ti]Cl,,,,,,
4522,74523,"N,N'-Dibutylurea",CCCCNC(=O)NCCCC,,,,,,
4523,74524,2-Methyl-5-nitrobenzimidazole,CC1=NC2=C(N1)C=C(C=C2)[N+](=O)[O-],,,,,,
4524,74525,"2,5-Dimethyl-1H-benzimidazole",CC1=CC2=C(C=C1)N=C(N2)C,,,,,,
4525,74526,Triisopentyl citrate,CC(C)CCOC(=O)CC(CC(=O)OCCC(C)C)(C(=O)OCCC(C)C)O,,,,,,
4526,74527,"Dodecanoic acid, 2-[bis(2-hydroxyethyl)amino]ethyl ester",CCCCCCCCCCCC(=O)OCCN(CCO)CCO,,,,,,
4527,74528,Bis(diethylamino)phosphoryl chloride,CCN(CC)P(=O)(N(CC)CC)Cl,,,,,,
4528,74529,Chloronitromethane,C([N+](=O)[O-])Cl,,,,,,
4529,74530,3-Ethylthiophene,CCC1=CSC=C1,,,,,,
4530,74531,"2,3,5-Trimethylthiophene",CC1=CC(=C(S1)C)C,,,,,,
4531,74532,CID 74532,CC1=CC(=CC(=C1O)C(=O)[O-])C(=C2C=C(C(=O)C(=C2)C(=O)[O-])C)C3=C(C=CC=C3Cl)Cl.[Na+].[Na+],,,,,,
4532,74533,"5-[(Z)-(3-Carboxy-5-methyl-4-oxocyclohexa-2,5-dien-1-ylidene)(2,6-dichlorophenyl)methyl]-2-hydroxy-3-methylbenzoic acid",CC1=CC(=CC(=C1O)C(=O)O)C(=C2C=C(C(=O)C(=C2)C(=O)O)C)C3=C(C=CC=C3Cl)Cl,,,,,,
4533,74534,"3,3,4,4,5,5,6,6,6-Nonafluorohexyl methacrylate",CC(=C)C(=O)OCCC(C(C(C(F)(F)F)(F)F)(F)F)(F)F,,,,,,
4534,74535,3-(Trifluoromethyl)benzamide,C1=CC(=CC(=C1)C(F)(F)F)C(=O)N,,,,,,
4535,74536,"2,3-Diphenyl-1H-inden-1-one",C1=CC=C(C=C1)C2=C(C(=O)C3=CC=CC=C32)C4=CC=CC=C4,,,,,,
4536,74537,"1,3-Diallylurea",C=CCNC(=O)NCC=C,,,,,,
4537,74538,Tributoxyoxovanadium,CCCCO.CCCCO.CCCCO.O=[V],,,,,,
4538,74539,3-(3-Phenylpropyl)pyridine,C1=CC=C(C=C1)CCCC2=CN=CC=C2,,,,,,
4539,74540,CID 74540,CC(=CN=O)NO,,,,,,
4540,74541,1-(p-Methylbenzyl)cyclopropanecarboxylic acid,CC1=CC=C(C=C1)CC2(CC2)C(=O)O,,,,,,
4541,74542,CID 74542,CC(=C)C(=O)OCCS(=O)(=O)[O-].[Na+],,,,,,
4542,74543,2-Sulfoethyl methacrylate,CC(=C)C(=O)OCCS(=O)(=O)O,,,,,,
4543,74544,Dipropyl hydrogen phosphate,CCCOP(=O)(O)OCCC,,,,,,
4544,74545,2-Amino-5-methoxy-1-methylbenzimidazole,CN1C2=C(C=C(C=C2)OC)N=C1N,,,,,,
4545,74546,Perfluoromethylcyclopentane,C1(C(C(C(C1(F)F)(F)F)(F)F)(F)F)(C(F)(F)F)F,,,,,,
4546,74547,2-Chloro-4'-fluorobenzophenone,C1=CC=C(C(=C1)C(=O)C2=CC=C(C=C2)F)Cl,,,,,,
4547,74548,"2,4-Dioctylphenol",CCCCCCCCC1=CC(=C(C=C1)O)CCCCCCCC,,,,,,
4548,74549,3-Iodopentane,CCC(CC)I,,,,,,
4549,74550,Phosphonic acid dioctyl ester,CCCCCCCCOP(=O)OCCCCCCCC,,,,,,
4550,74551,"Quinoline, 1,2-dihydro-2,2,4,7-tetramethyl-",CC1=CC2=C(C=C1)C(=CC(N2)(C)C)C,,,,,,
4551,74552,2-Methylhexane-2-thiol,CCCCC(C)(C)S,,,,,,
4552,74553,"2-(p-Tolyl-2,5-xylylsulfone)",CC1=CC=C(C=C1)S(=O)(=O)C2=C(C=CC(=C2)C)C,,,,,,
4553,74554,"3,6-Dichloro-2-(trichloromethyl)pyridine",C1=CC(=NC(=C1Cl)C(Cl)(Cl)Cl)Cl,,,,,,
4554,74555,4-Phenyl-3-butyn-2-one,CC(=O)C#CC1=CC=CC=C1,,,,,,
4555,74556,"Benzene, (2-ethoxyethyl)-",CCOCCC1=CC=CC=C1,,,,,,
4556,74557,"1,4-Benzenedicarboxylic acid, monobutyl ester",CCCCOC(=O)C1=CC=C(C=C1)C(=O)O,,,,,,
4557,74558,Octyl phenyl ether,CCCCCCCCOC1=CC=CC=C1,,,,,,
4558,74559,"1-(2,4,5-Trihydroxyphenyl)ethanone",CC(=O)C1=CC(=C(C=C1O)O)O,,,,,"['5-hydroxy-resacetophenone has known human metabolites that include (5-Acetyl-2,4-dihydroxyphenyl) hydrogen sulfate.']",
4559,74560,"Ethanone, 1-(2,4,5-trimethoxyphenyl)-",CC(=O)C1=CC(=C(C=C1OC)OC)OC,,,,,,
4560,74561,3-Aminopyrazole,C1=C(NN=C1)N,,,,,,
4561,74562,"Benzoic acid, 3,3'-thiobis[6-hydroxy-",C1=CC(=C(C=C1SC2=CC(=C(C=C2)O)C(=O)O)C(=O)O)O,,,,,,
4562,74563,2-Oxopentanoic acid,CCCC(=O)C(=O)O,,,,,,
4563,74564,CID 74564,CC(C1=C(OC2=CC=CC=C2C1=O)O)C3=C(OC4=CC=CC=C4C3=O)O,,,,,,
4564,74565,CID 74565,CCOC(=O)C1=C(OC2=CC=CC=C2C1=O)O,,,,,,
4565,74566,N-Benzoyl-N'-phenylurea,C1=CC=C(C=C1)C(=O)NC(=O)NC2=CC=CC=C2,,,,,,
4566,74567,N-Cyclohexylaniline,C1CCC(CC1)NC2=CC=CC=C2,,,,,,
4567,74568,N-Ethyl-4-methyl-N-phenylbenzenesulfonamide,CCN(C1=CC=CC=C1)S(=O)(=O)C2=CC=C(C=C2)C,,,,,,
4568,74569,"N,N'-Bis(trimethylsilyl)ethylenediamine",C[Si](C)(C)NCCN[Si](C)(C)C,,,,,,
4569,74570,4-(Chloromethyl)pyridine hydrochloride,C1=CN=CC=C1CCl.Cl,,,,,,
4570,74571,4-(Chloromethyl)pyridine,C1=CN=CC=C1CCl,,,,,,
4571,74572,Phenyl vinyl sulfide,C=CSC1=CC=CC=C1,,,,,,
4572,74573,5-Phenyl-1-pentyne,C#CCCCC1=CC=CC=C1,,,,,,
4573,74574,"4,4'-Oxydiphthalic anhydride",C1=CC2=C(C=C1OC3=CC4=C(C=C3)C(=O)OC4=O)C(=O)OC2=O,,,,,,
4574,74575,3-Amino-3-phenylprop-2-enenitrile,C1=CC=C(C=C1)C(=CC#N)N,,,,,,
4575,74576,Ethoxy(methyl)diphenylsilane,CCO[Si](C)(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
4576,74577,"Silane, trimethylpropoxy-",CCCO[Si](C)(C)C,,,,,,
4577,74578,Isopropoxytrimethylsilane,CC(C)O[Si](C)(C)C,,,,,,
4578,74579,Dimethylmethoxychlorosilane,CO[Si](C)(C)Cl,,,,,,
4579,74580,Dichloro(methoxy)methylsilane,CO[Si](C)(Cl)Cl,,,,,,
4580,74581,4-Phenylthiazole,C1=CC=C(C=C1)C2=CSC=N2,,,,,,
4581,74582,Phenyl 2-pyridyl ketone oxime,C1=CC=C(C=C1)C(=NO)C2=CC=CC=N2,,,,,,
4582,74583,"Acetamide, N-ethyl-N-(4-nitrophenyl)-",CCN(C1=CC=C(C=C1)[N+](=O)[O-])C(=O)C,,,,,,
4583,74584,Vinylmagnesium bromide,C=[CH-].[Mg+2].[Br-],,,,,,
4584,74585,3-Chlorosalicylic acid,C1=CC(=C(C(=C1)Cl)O)C(=O)O,,,,,,
4585,74586,o-Bromophenyl acetate,CC(=O)OC1=CC=CC=C1Br,,,,,,
4586,74587,Hexaphenyldisiloxane,C1=CC=C(C=C1)[Si](C2=CC=CC=C2)(C3=CC=CC=C3)O[Si](C4=CC=CC=C4)(C5=CC=CC=C5)C6=CC=CC=C6,,,,,,
4587,74588,Methoxytriphenylsilane,CO[Si](C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
4588,74589,Triethylsulfonium iodide,CC[S+](CC)CC.[I-],,,,,,
4589,74590,Triethylsulfonium,CC[S+](CC)CC,,,,,,
4590,74591,Dimethyl 3-oxopentanedioate,COC(=O)CC(=O)CC(=O)OC,,,,,,
4591,74592,1-Ethylbenz(cd)indol-2(1H)-one,CCN1C2=CC=CC3=C2C(=CC=C3)C1=O,,,,,,
4592,74593,"2-Anthracenecarboxamide, 3-hydroxy-N-(2-methylphenyl)-",CC1=CC=CC=C1NC(=O)C2=CC3=CC4=CC=CC=C4C=C3C=C2O,,,,,,
4593,74594,"Glycerol 1,3-Dimethacrylate",CC(=C)C(=O)OCC(COC(=O)C(=C)C)O,,,,,,
4594,74595,p-Benzoquinone O-(phenylsulfonyl)oxime,C1=CC=C(C=C1)S(=O)(=O)ON=C2C=CC(=O)C=C2,,,,,,
4595,74596,Phosphonitrile chloride,N#P(Cl)Cl,,,,,,
4596,74597,"1,3-Dibenzyltetramethyldisiloxane",C[Si](C)(CC1=CC=CC=C1)O[Si](C)(C)CC2=CC=CC=C2,,,,,,
4597,74598,(Chloromethyl)dimethylphenylsilane,C[Si](C)(CCl)C1=CC=CC=C1,,,,,,
4598,74599,"Silane, trimethyl[(1-methylethenyl)oxy]-",CC(=C)O[Si](C)(C)C,,,,,,
4599,74600,Tetrafluorophthalonitrile,C(#N)C1=C(C(=C(C(=C1F)F)F)F)C#N,,,,,,
4600,74601,Benzyltriethylammonium hydroxide,CC[N+](CC)(CC)CC1=CC=CC=C1.[OH-],,,,,,
4601,74602,3-Chloro-2-(4-nitrophenoxy)toluene,CC1=C(C(=CC=C1)Cl)OC2=CC=C(C=C2)[N+](=O)[O-],,,,,,
4602,74603,"1,2,3,4,5,6-Hexabromocyclohexane",C1(C(C(C(C(C1Br)Br)Br)Br)Br)Br,,,,,,
4603,74604,"N,N-Dimethylboranamine",BN(C)C,,,,,,
4604,74605,Ethyl 4-(ethoxycarbonyl)piperidine-1-acetate,CCOC(=O)CN1CCC(CC1)C(=O)OCC,,,,,,
4605,74606,"2-Penten-1-ol, 2-methyl-, 1-acetate",CCC=C(C)COC(=O)C,,,,,,
4606,74607,"9E,11E-octadecadienoic acid",CCCCCCC=CC=CCCCCCCCC(=O)O,,,,,,
4607,74608,CID 74608,C(C[S-])O.C(C[S-])O.[SbH3],,,,,,
4608,74609,Octadecyl sulfide,CCCCCCCCCCCCCCCCCCSCCCCCCCCCCCCCCCCCC,,,,,,
4609,74610,Oct-2-ynal,CCCCCC#CC=O,,,,,,
4610,74611,2-Nonynoic acid,CCCCCCC#CC(=O)O,,,,,,
4611,74612,"Carbonic acid, ethyl 2-methoxyphenyl ester",CCOC(=O)OC1=CC=CC=C1OC,,,,,,
4612,74613,Tetramethoxymethane,COC(OC)(OC)OC,,,,,,
4613,74614,Ethylenediurea,C(CNC(=O)N)NC(=O)N,,,,,,
4614,74615,Tetrahydro-2(1H)-pyrimidinone,C1CNC(=O)NC1,,,,,,
4615,74616,Tetrahydro-5-hydroxy-1H-pyrimidin-2-one,C1C(CNC(=O)N1)O,,,,,,
4616,74617,"1,3,5-Triazin-2(1H)-one, tetrahydro-5-(2-hydroxyethyl)-1,3-bis(hydroxymethyl)-",C1N(CN(C(=O)N1CO)CO)CCO,,,,,,
4617,74618,5-Cyclohexylsalicylic acid,C1CCC(CC1)C2=CC(=C(C=C2)O)C(=O)O,,,,,,
4618,74619,Cyclohexenecarbonitrile,C1CCC(=CC1)C#N,,,,,,
4619,74620,Dichloroisothiocyanatophosphine,C(=NP(=O)(Cl)Cl)=S,,,,,,
4620,74621,1-Hydroxy-2-phenylindole,C1=CC=C(C=C1)C2=CC3=CC=CC=C3N2O,,,,,,
4621,74622,(3-(Benzyloxy)-4-methoxyphenyl)methanol,COC1=C(C=C(C=C1)CO)OCC2=CC=CC=C2,,,,,,
4622,74623,"1-Hexanol, 6-(dimethylamino)-",CN(C)CCCCCCO,,,,,,
4623,74624,N-Methylsalicylamide,CNC(=O)C1=CC=CC=C1O,,,,,,
4624,74625,"3-Ethoxy-N,N-diethylaniline",CCN(CC)C1=CC(=CC=C1)OCC,,,,,,
4625,74626,Phenyl formate,C1=CC=C(C=C1)OC=O,,,,,,
4626,74627,"Formic acid, 4-methylphenyl ester",CC1=CC=C(C=C1)OC=O,,,,,,
4627,74628,4-Nitrophenyl formate,C1=CC(=CC=C1[N+](=O)[O-])OC=O,,,,,,
4628,74629,Acetylthiocholine iodide,CC(=O)SCC[N+](C)(C)C.[I-],,,,,,
4629,74630,Butyrylthiocholine iodide,CCCC(=O)SCC[N+](C)(C)C.[I-],,,,,,
4630,74631,3-(3-Chlorophenyl)prop-2-enoic acid,C1=CC(=CC(=C1)Cl)C=CC(=O)O,,,,,,
4631,74632,Propionylthiocholine iodide,CCC(=O)SCC[N+](C)(C)C.[I-],,,,,,
4632,74633,Propionylthiocholine,CCC(=O)SCC[N+](C)(C)C,,,,,,
4633,74634,4-Naphthalen-1-yl-4-oxo-butyricacid,COC1=C(C=CC(=C1)C2=CC(=C(C=C2)N3NC(=NN3C4=CC=CC=C4)C5=CC=CC=C5)OC)N6NC(=NN6C7=CC=CC=C7)C8=CC=CC=C8.Cl.Cl,,,,,,
4634,74635,"2-[4-[4-(3,5-diphenyl-1H-tetrazol-2-yl)-3-methoxyphenyl]-2-methoxyphenyl]-3,5-diphenyl-1H-tetrazole",COC1=C(C=CC(=C1)C2=CC(=C(C=C2)N3NC(=NN3C4=CC=CC=C4)C5=CC=CC=C5)OC)N6NC(=NN6C7=CC=CC=C7)C8=CC=CC=C8,,,,,,
4635,74636,"1,2,3-Trichloro-2-methylpropane",CC(CCl)(CCl)Cl,,,,,,
4636,74637,Diphenylacetyl chloride,C1=CC=C(C=C1)C(C2=CC=CC=C2)C(=O)Cl,,,,,,
4637,74638,"N,N'-Bis(2-hydroxyethyl)oxamide",C(CO)NC(=O)C(=O)NCCO,,,,,,
4638,74639,Sebaconitrile,C(CCCCC#N)CCCC#N,,,,,,
4639,74640,"1,1,1,3,5,5,5-Heptamethyl trisiloxane",C[SiH](O[Si](C)(C)C)O[Si](C)(C)C,,,,,,
4640,74641,Allyldichloromethylsilane,C[Si](CC=C)(Cl)Cl,,,,,,
4641,74642,"2-(3-Methoxyphenyl)-5-phenyl-1,3,4-oxadiazole",COC1=CC=CC(=C1)C2=NN=C(O2)C3=CC=CC=C3,,,,,,
4642,74643,"2-(2-Methoxyphenyl)-5-phenyl-1,3,4-oxadiazole",COC1=CC=CC=C1C2=NN=C(O2)C3=CC=CC=C3,,,,,,
4643,74644,6-Benzylthioguanine,C1=CC=C(C=C1)CSC2=NC(=NC3=C2NC=N3)N,,,,,,
4644,74645,N-aminophthalimide,C1=CC=C2C(=C1)C(=O)N(C2=O)N,,,,,,
4645,74646,"2,3-Dinitronaphthalene",C1=CC=C2C=C(C(=CC2=C1)[N+](=O)[O-])[N+](=O)[O-],,,,,,
4646,74647,2-(4-Chlorophenyl)ethanol,C1=CC(=CC=C1CCO)Cl,,,,,,
4647,74648,2-(3-Methylphenyl)ethanol,CC1=CC(=CC=C1)CCO,,,,,,
4648,74649,2-(4-Methoxyphenoxy)acetic acid,COC1=CC=C(C=C1)OCC(=O)O,,,,,,
4649,74650,CID 74650,CCOC(=O)C=CC1=CC(=C(C(=C1)OC)OC)OC,,,,,,
4650,74651,2-(2-Methylphenoxy)acetic acid,CC1=CC=CC=C1OCC(=O)O,,,,,,
4651,74652,"[3-(1,1-Dimethylethyl)phenoxy]acetic acid",CC(C)(C)C1=CC(=CC=C1)OCC(=O)O,,,,,,
4652,74653,3-Bromophenylacetic acid,C1=CC(=CC(=C1)Br)CC(=O)O,,,,,,
4653,74654,4-Bromophenylacetic acid,C1=CC(=CC=C1CC(=O)O)Br,,,,,,
4654,74655,4-Acetylphenoxyacetic acid,CC(=O)C1=CC=C(C=C1)OCC(=O)O,,,,,,
4655,74656,(3-Nitrophenoxy)acetic acid,C1=CC(=CC(=C1)OCC(=O)O)[N+](=O)[O-],,,,,,
4656,74657,(4-Bromophenoxy)acetic acid,C1=CC(=CC=C1OCC(=O)O)Br,,,,,,
4657,74658,4-Iodophenoxyacetic acid,C1=CC(=CC=C1OCC(=O)O)I,,,,,,
4658,74659,"Benz(a)anthracene, 9-fluoro-7-methyl-",CC1=C2C=C(C=CC2=CC3=C1C=CC4=CC=CC=C43)F,,,,,,
4659,74660,"Benz(a)anthracene, 10-fluoro-7-methyl-",CC1=C2C=CC(=CC2=CC3=C1C=CC4=CC=CC=C43)F,,,,,,
4660,74661,4-tert-Butylpiperidine,CC(C)(C)C1CCNCC1,,,,,,
4661,74662,"2,2-Diphenylethanol",C1=CC=C(C=C1)C(CO)C2=CC=CC=C2,,,,,,
4662,74663,"2,5-Furandimethanol",C1=C(OC(=C1)CO)CO,,,,,,
4663,74664,Tetraphenylthiophene,C1=CC=C(C=C1)C2=C(SC(=C2C3=CC=CC=C3)C4=CC=CC=C4)C5=CC=CC=C5,,,,,,
4664,74665,4-Methoxyphthalic acid,COC1=CC(=C(C=C1)C(=O)O)C(=O)O,,,,,,
4665,74666,Dibromomalononitrile,C(#N)C(C#N)(Br)Br,,,,,,
4666,74667,"2-Propenenitrile, 3-phenyl-",C1=CC=C(C=C1)C=CC#N,,,,,,
4667,74668,"2-(Difluoromethoxy)-1,1,1-trifluoroethane",C(C(F)(F)F)OC(F)F,,,,,,
4668,74669,2-Methyl-6-nitrobenzonitrile,CC1=C(C(=CC=C1)[N+](=O)[O-])C#N,,,,,,
4669,74670,1-Chloro-4-isocyanobenzene,[C-]#[N+]C1=CC=C(C=C1)Cl,,,,,,
4670,74671,CID 74671,CCOP(=O)(OCC)SC(=CCl)Cl,,,,,,
4671,74672,"Phosphorothioic acid, S-(2,2-dichlorovinyl) O,O-diethyl ester",CCOP(=O)(OCC)SC=C(Cl)Cl,,,,,,
4672,74673,"O,O-Dimethyl S-(2,2,2-trichloroethyl) phosphorothioate",COP(=O)(OC)SCC(Cl)(Cl)Cl,,,,,,
4673,74674,1-tert-Butyl-2-nitrobenzene,CC(C)(C)C1=CC=CC=C1[N+](=O)[O-],,,,,,
4674,74675,"2,5-Cyclohexadiene-1,4-dione, 2,3,5,6-tetrahydroxy-, disodium salt",C1(=C(C(=O)C(=C(C1=O)O)[O-])[O-])O.[Na+].[Na+],,,,,,
4675,74676,CID 74676,C1=CC=C(C=C1)S(=O)(=S)[O-].[Na+],,,,,,
4676,74677,CID 74677,C1=CC=C(C=C1)S(=O)(=O)S,,,,,,
4677,74678,Isopropyllithium,[Li+].C[CH-]C,,,,,,
4678,74679,"Aluminum, dichloro(2-methylpropyl)-",CC(C)C[Al](Cl)Cl,,,,,,
4679,74680,Ethyl vinyl sulfone,CCS(=O)(=O)C=C,,,,,,
4680,74681,"2,3-Dimethyl-2,3-diphenylbutane",CC(C)(C1=CC=CC=C1)C(C)(C)C2=CC=CC=C2,,,,,,
4681,74682,"2,3-Dihydroxy-4,4,5,5-tetramethylcyclopent-2-en-1-one",CC1(C(=C(C(=O)C1(C)C)O)O)C,,,,,,
4682,74683,"3-Bromo-2-hydroxy-4,4,5,5-tetramethylcyclopent-2-en-1-one",CC1(C(=C(C(=O)C1(C)C)O)Br)C,,,,,,
4683,74684,4-(Trifluoromethyl)benzamide,C1=CC(=CC=C1C(=O)N)C(F)(F)F,,,,,,
4684,74685,"3,5-Dichloro-4-hydroxybenzonitrile",C1=C(C=C(C(=C1Cl)O)Cl)C#N,,,,,,
4685,74686,Cyclododecylmethanol,C1CCCCCC(CCCCC1)CO,,,,,,
4686,74687,(4-Chloroanilino)phosphonic acid,C1=CC(=CC=C1NP(=O)(O)O)Cl,,,,,,
4687,74688,5-Hydroxyindole-3-acetaldehyde,C1=CC2=C(C=C1O)C(=CN2)CC=O,,,,,,
4688,74689,2-Hydroxyethyl phosphate,C(COP(=O)(O)O)O,,,,,,
4689,74690,Propanethioic acid,CCC(=O)S,,,,,,
4690,74691,3-Phenanthrylamine,C1=CC=C2C(=C1)C=CC3=C2C=C(C=C3)N,,,,,,
4691,74692,"2-Propenoic acid, 2-[ethyl[(tridecafluorohexyl)sulfonyl]amino]ethyl ester",CCN(CCOC(=O)C=C)S(=O)(=O)C(C(C(C(C(C(F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F,,,,,,
4692,74693,CID 74693,C(=O)(C(F)(F)Cl)[O-].[Na+],,,,,,
4693,74694,Tetrachloroterephthalonitrile,C(#N)C1=C(C(=C(C(=C1Cl)Cl)C#N)Cl)Cl,,,,,,
4694,74695,"2,6-Difluorobenzonitrile",C1=CC(=C(C(=C1)F)C#N)F,,,,,,
4695,74696,"5,6,7,8-Tetrahydroquinazoline-2,4-diamine",C1CCC2=C(C1)C(=NC(=N2)N)N,,,,,,
4696,74697,3-Methylbenzenesulfonamide,CC1=CC(=CC=C1)S(=O)(=O)N,,,,,,
4697,74698,4-Diethoxyphosphinothioyloxybenzenesulfonamide,CCOP(=S)(OCC)OC1=CC=C(C=C1)S(=O)(=O)N,,,,,,
4698,74699,Ethyl cyclopentylideneacetate,CCOC(=O)C=C1CCCC1,,,,,,
4699,74700,CID 74700,CCOC(=O)C(=O)[O-].[K+],,,,,,
4700,74701,2-Ethoxy-2-oxoacetic acid,CCOC(=O)C(=O)O,,,,,,
4701,74702,Ethyl acetamidoacetate,CCOC(=O)CNC(=O)C,,,,,,
4702,74703,3-Methylthiazolidine-2-thione,CN1CCSC1=S,,,,,,
4703,74704,Ethyl ethanesulfonate,CCOS(=O)(=O)CC,,,,,,
4704,74705,Propyl methanesulfonate,CCCOS(=O)(=O)C,,,,,,
4705,74706,methyl 2-(1H-indol-3-yl)acetate,COC(=O)CC1=CNC2=CC=CC=C21,,,,,,
4706,74707,CID 74707,C1=CC(=C(C=C1Cl)P(=O)(O)O)NN=C2C(=CC3=C(C2=O)C(=O)C(=NNC4=C(C=C(C=C4)Cl)P(=O)(O)O)C(=C3)S(=O)(=O)O)S(=O)(=O)O,,,,,,
4707,74708,2-Hydroxyxanthone,C1=CC=C2C(=C1)C(=O)C3=C(O2)C=CC(=C3)O,,,,,,
4708,74709,"3-Hydroxy-4,5-dimethoxybenzoic acid",COC1=CC(=CC(=C1OC)O)C(=O)O,,,,,,
4709,74710,5-Methylfuran-2-carboxylic acid,CC1=CC=C(O1)C(=O)O,,,,,,
4710,74711,5-(Methoxymethyl)-2-furaldehyde,COCC1=CC=C(O1)C=O,,,,,,
4711,74712,"Heptyl 2,4-dichlorophenoxyacetate",CCCCCCCOC(=O)COC1=C(C=C(C=C1)Cl)Cl,,,,,,
4712,74713,5-Methyl-2-thiophenecarboxylic acid,CC1=CC=C(S1)C(=O)O,,,,,,
4713,74714,"2,3-Dichloroquinoxaline-6-carbonyl chloride",C1=CC2=C(C=C1C(=O)Cl)N=C(C(=N2)Cl)Cl,,,,,,
4714,74715,"2-Naphthalenecarboxamide, 7-bromo-N-(2-methoxyphenyl)-3-(phosphonooxy)-",COC1=CC=CC=C1NC(=O)C2=C(C=C3C=CC(=CC3=C2)Br)OP(=O)(O)O,,,,,,
4715,74716,2-Chloro-5-nitropyrimidin-4-amine,C1=C(C(=NC(=N1)Cl)N)[N+](=O)[O-],,,,,,
4716,74717,1-(2-Sulfosulfanylethylamino)hexane,CCCCCCNCCSS(=O)(=O)O,,,,,,
4717,74718,1-(2-Sulfosulfanylethylamino)octane,CCCCCCCCNCCSS(=O)(=O)O,,,,,,
4718,74719,1-(2-Sulfosulfanylethylamino)nonane,CCCCCCCCCNCCSS(=O)(=O)O,,,,,,
4719,74720,1-Benzyl-4-benzylaminopiperidine dihydrochloride,C1CN(CCC1NCC2=CC=CC=C2)CC3=CC=CC=C3.Cl.Cl,,,,,,
4720,74721,"N,1-dibenzylpiperidin-4-amine",C1CN(CCC1NCC2=CC=CC=C2)CC3=CC=CC=C3,,,,,,
4721,74722,Bis(trichlorosilyl)benzylmethane,C1=CC=C(C=C1)CC([Si](Cl)(Cl)Cl)[Si](Cl)(Cl)Cl,,,,,,
4722,74723,Tetrabutylammonium perchlorate,CCCC[N+](CCCC)(CCCC)CCCC.[O-]Cl(=O)(=O)=O,,,"['Purifying or cleansing agents, usually salts of long-chain aliphatic bases or acids, that exert cleansing (oil-dissolving) and antimicrobial effects through a surface action that depends on possessing both hydrophilic and hydrophobic properties. (See all compounds classified as Detergents.)']",,,
4723,74724,Choline Bromide,C[N+](C)(C)CCO.[Br-],,,,,,
4724,74725,10H-Phenothiazin-3-ol,C1=CC=C2C(=C1)NC3=C(S2)C=C(C=C3)O,,,,,,
4725,74726,4-Bromophenyl acetate,CC(=O)OC1=CC=C(C=C1)Br,,,,,,
4726,74727,"Propyl 2,4,5-trichlorophenoxyacetate",CCCOC(=O)COC1=CC(=C(C=C1Cl)Cl)Cl,,,,,,
4727,74728,Ethyl 3-(4-methoxyphenyl)prop-2-enoate,CCOC(=O)C=CC1=CC=C(C=C1)OC,,,,,,
4728,74729,"1H-Pyrazole-3-carboxylic acid, 4-((4-chloro-2-nitrophenyl)azo)-4,5-dihydro-5-oxo-1-phenyl-, ethyl ester",CCOC(=O)C1=NN(C(=O)C1N=NC2=C(C=C(C=C2)Cl)[N+](=O)[O-])C3=CC=CC=C3,,,,,,
4729,74730,CID 74730,C1=CC(=O)N=C2C1=CC=C(N2)N,,,,,,
4730,74731,Itaconyl chloride,C=C(CC(=O)Cl)C(=O)Cl,,,,,,
4731,74732,Methyl 9-oxononanoate,COC(=O)CCCCCCCC=O,,,,,,
4732,74733,"1,2-Dipiperidinoethane",C1CCN(CC1)CCN2CCCCC2,,,,,,
4733,74734,Dibenzyl azelate,C1=CC=C(C=C1)COC(=O)CCCCCCCC(=O)OCC2=CC=CC=C2,,,,,,
4734,74735,Propargyl propionate,CCC(=O)OCC#C,,,,,,
4735,74736,N-Methyl-N-phenylbenzamide,CN(C1=CC=CC=C1)C(=O)C2=CC=CC=C2,,,,,,
4736,74737,p-(Methylamino)phenol sulphate,CNC1=CC=C(C=C1)O.OS(=O)(=O)O,,,,,,
4737,74738,11-Octadecenoic acid methyl ester,CCCCCCC=CCCCCCCCCCC(=O)OC,,,,,,
4738,74739,"5-(Chloromethyl)-6-propyl-1,3-benzodioxole",CCCC1=CC2=C(C=C1CCl)OCO2,,,,,,
4739,74740,Phenylmethanesulfonyl chloride,C1=CC=C(C=C1)CS(=O)(=O)Cl,,,,,,
4740,74741,1-Vinylcyclohexanol,C=CC1(CCCCC1)O,,,,,,
4741,74742,"Phenol, 2,3,4-trichloro-6-[(2,3,5-trichloro-6-hydroxyphenyl)methyl]-",C1=C(C(=C(C(=C1Cl)Cl)Cl)O)CC2=C(C(=CC(=C2Cl)Cl)Cl)O,,,,,,
4742,74743,Tetramethylammonium nitrate,C[N+](C)(C)C.[N+](=O)([O-])[O-],,,['Agents that mimic neural transmission by stimulation of the nicotinic receptors on postganglionic autonomic neurons. Drugs that indirectly augment ganglionic transmission by increasing the release or slowing the breakdown of acetylcholine or by non-nicotinic effects on postganglionic neurons are not included here nor are the nonspecific cholinergic agonists. (See all compounds classified as Ganglionic Stimulants.)'],,,
4743,74744,Tetraethylammonium nitrate,CC[N+](CC)(CC)CC.[N+](=O)([O-])[O-],,,,,,
4744,74745,Tetrapropylammonium bromide,CCC[N+](CCC)(CCC)CCC.[Br-],,,,,,
4745,74746,Nonanediperoxoic acid,C(CCCC(=O)OO)CCCC(=O)OO,,,,,,
4746,74747,"Diazene, (4-isocyanatophenyl)phenyl-",C1=CC=C(C=C1)N=NC2=CC=C(C=C2)N=C=O,,,,,,
4747,74748,S-(4-Chloro-3-methylphenyl) O-ethyl ethylphosphonodithioate,CCOP(=S)(CC)SC1=CC(=C(C=C1)Cl)C,,,,,,
4748,74749,S-(4-Chloro-3-methylphenyl) O-methyl phosphonodithioate,CCP(=S)(OC)SC1=CC(=C(C=C1)Cl)C,,,,,,
4749,74750,Trimethylnonylammonium bromide,CCCCCCCCC[N+](C)(C)C.[Br-],,,,,,
4750,74751,Hexadecyl isocyanate,CCCCCCCCCCCCCCCCN=C=O,,,,,,
4751,74752,Methyl (4-nitrophenyl)carbamate,COC(=O)NC1=CC=C(C=C1)[N+](=O)[O-],,,,,,
4752,74753,1-Benzylcyclohexan-1-ol,C1CCC(CC1)(CC2=CC=CC=C2)O,,,,,,
4753,74754,"1-Naphthaleneacetamide, alpha,alpha-bis(2-(dimethylamino)ethyl)-",CN(C)CCC(CCN(C)C)(C1=CC=CC2=CC=CC=C21)C(=O)N,,,,,,
4754,74755,"Benzothiazole, 2,2'-methylenebis-",C1=CC=C2C(=C1)N=C(S2)CC3=NC4=CC=CC=C4S3,,,,,,
4755,74756,3-Acetyloxyprop-2-enyl acetate,CC(=O)OCC=COC(=O)C,,,,,,
4756,74757,"2-(2,4-Dinitroanilino)ethanol",C1=CC(=C(C=C1[N+](=O)[O-])[N+](=O)[O-])NCCO,,,,,,
4757,74758,N-Benzyloxycarbonyl-6-aminocaproic acid,C1=CC=C(C=C1)COC(=O)NCCCCCC(=O)O,,,,,,
4758,74759,"4-Hydroxy-3,5-diiodophenylacetic acid",C1=C(C=C(C(=C1I)O)I)CC(=O)O,,,,,,
4759,74760,"4-Hydroxy-3,5-diiodobenzaldehyde",C1=C(C=C(C(=C1I)O)I)C=O,,,,,,
4760,74761,"1-Propanesulfinothioic acid, S-propyl ester",CCCSS(=O)CCC,,,,,,
4761,74762,4-((4-Nitrophenyl)sulfonyl)aniline,C1=CC(=CC=C1N)S(=O)(=O)C2=CC=C(C=C2)[N+](=O)[O-],,,,,,
4762,74763,Hetolin hydrochloride,CN1CCN(CC1)C(=O)CC(C2=CC=C(C=C2)Cl)(C3=CC=C(C=C3)Cl)C4=CC=C(C=C4)Cl.Cl,,,,,,
4763,74764,Hetolin,CN1CCN(CC1)C(=O)CC(C2=CC=C(C=C2)Cl)(C3=CC=C(C=C3)Cl)C4=CC=C(C=C4)Cl,,,,,,
4764,74765,"Ethyl 3,5-diaminobenzoate",CCOC(=O)C1=CC(=CC(=C1)N)N,,,,,,
4765,74766,4-Methoxybenzenesulfonohydrazide,COC1=CC=C(C=C1)S(=O)(=O)NN,,,,,,
4766,74767,CID 74767,CS(=O)(=S)[O-].[Na+],,,,,,
4767,74768,CID 74768,CS(=O)(=O)S,,,,,,
4768,74769,"2-Butyl-3-(3,5-diiodo-4-hydroxy benzoyl) benzofuran",CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)O)I,,,,,,
4769,74770,2-((p-Methoxybenzylidene)amino)ethanol,COC1=CC=C(C=C1)C=NCCO,,,,,,
4770,74771,5-Butylbarbituric acid,CCCCC1C(=O)NC(=O)NC1=O,,,,,,
4771,74772,3-Amino-5-[(methylamino)carbonyl]benzoic acid,CNC(=O)C1=CC(=CC(=C1)N)C(=O)O,,,,,,
4772,74773,3-[(Methylamino)carbonyl]-5-nitrobenzoic acid,CNC(=O)C1=CC(=CC(=C1)[N+](=O)[O-])C(=O)O,,,,,,
4773,74774,Methyl 3-(chlorocarbonyl)-5-nitrobenzoate,COC(=O)C1=CC(=CC(=C1)[N+](=O)[O-])C(=O)Cl,,,,,,
4774,74775,"2,6-Diiodohydroquinone",C1=C(C=C(C(=C1I)O)I)O,,,,,,
4775,74776,3-(Methoxycarbonyl)-5-nitrobenzoic acid,COC(=O)C1=CC(=CC(=C1)C(=O)O)[N+](=O)[O-],,,,,,
4776,74777,4-Nitrophenyl propionate,CCC(=O)OC1=CC=C(C=C1)[N+](=O)[O-],,,,,,
4777,74778,4-Nitrophenyl laurate,CCCCCCCCCCCC(=O)OC1=CC=C(C=C1)[N+](=O)[O-],,,,,,
4778,74779,2-(Bromomethyl)-1-fluoro-3-nitrobenzene,C1=CC(=C(C(=C1)F)CBr)[N+](=O)[O-],,,,,,
4779,74780,"2,6,11,15-Tetramethyl-17-(2,6,6-trimethylcyclohex-1-en-1-yl)heptadeca-2,4,6,8,10,12,14,16-octaenoic acid",CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)C(=O)O)C)C,,,,,,
4780,74781,CID 74781,C1=CC(=C(C=C1[N+](=O)[O-])S(=O)(=O)O)NN=C2C(=CC3=C(C2=O)C(=O)C(=NNC4=C(C=C(C=C4)[N+](=O)[O-])S(=O)(=O)O)C(=C3)S(=O)(=O)O)S(=O)(=O)O,,,,,,
4781,74782,"2-(2-methoxyphenyl)-4,5-diphenyl-1H-imidazole",COC1=CC=CC=C1C2=NC(=C(N2)C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
4782,74783,"9,10-Anthracenedione, 1,1'-[(6-phenoxy-1,3,5-triazine-2,4-diyl)diimino]bis-",C1=CC=C(C=C1)OC2=NC(=NC(=N2)NC3=CC=CC4=C3C(=O)C5=CC=CC=C5C4=O)NC6=CC=CC7=C6C(=O)C8=CC=CC=C8C7=O,,,,,,
4783,74784,"9,10-Anthracenedione, 1-[(4,6-diphenoxy-1,3,5-triazin-2-yl)amino]-",C1=CC=C(C=C1)OC2=NC(=NC(=N2)NC3=CC=CC4=C3C(=O)C5=CC=CC=C5C4=O)OC6=CC=CC=C6,,,,,,
4784,74785,2-Chloroterephthalic acid,C1=CC(=C(C=C1C(=O)O)Cl)C(=O)O,,,,,,
4785,74786,Ethyl 4-pentenoate,CCOC(=O)CCC=C,,,,,,
4786,74787,2-Phenylisatogen,C1=CC=C(C=C1)C2=[N+](C3=CC=CC=C3C2=O)[O-],,,,,,
4787,74788,"1,2,3-Trimethyl-1H-indole",CC1=C(N(C2=CC=CC=C12)C)C,,,,,,
4788,74789,(Acetyloxymethyldiazenyl)methyl acetate,CC(=O)OCN=NCOC(=O)C,,,,,,
4789,74790,2-Methyl-4-nitrobenzoic acid,CC1=C(C=CC(=C1)[N+](=O)[O-])C(=O)O,,,,,,
4790,74791,Decanenitrile,CCCCCCCCCC#N,,,,,,
4791,74792,"2-Bromo-N,N-dimethylbenzylamine",CN(C)CC1=CC=CC=C1Br,,,,,,
4792,74793,CID 74793,C1=CC=C(C(=C1)C(=O)[O-])NC2=CC=CC(=C2)C(F)(F)F.[Na+],,,,,,
4793,74794,"2',5'-Difluoroacetophenone",CC(=O)C1=C(C=CC(=C1)F)F,,,,,,
4794,74795,"4,6-Dihydroxy-2-methylthiopyrimidine",CSC1=NC(=CC(=O)N1)O,,,,,,
4795,74796,"Phenol, 4-[2-(3,3-dimethyl-3H-indol-2-yl)ethenyl]-",CC1(C2=CC=CC=C2N=C1C=CC3=CC=C(C=C3)O)C,,,,,,
4796,74797,Diethyl (4-sulfamoylphenyl) phosphate,CCOP(=O)(OCC)OC1=CC=C(C=C1)S(=O)(=O)N,,,,,,
4797,74798,"2-(2,4-Dichlorophenoxy)acetamide",C1=CC(=C(C=C1Cl)Cl)OCC(=O)N,,,,,,
4798,74799,"Phosphonic dichloride, (chloromethyl)-",C(P(=O)(Cl)Cl)Cl,,,,,,
4799,74800,"2,4,6(1H,3H,5H)-Pyrimidinetrione, 1-(3-chlorophenyl)-3-methyl-",CN1C(=O)CC(=O)N(C1=O)C2=CC(=CC=C2)Cl,,,,,,
4800,74801,CID 74801,C1=CC2=C(C=C(OC2=CC1=O)O)O,,,,,,
4801,74802,1-Isocyano-4-nitrobenzene,[C-]#[N+]C1=CC=C(C=C1)[N+](=O)[O-],,,,,,
4802,74803,4-Bromo-N-ethylbenzenesulfonamide,CCNS(=O)(=O)C1=CC=C(C=C1)Br,,,,,,
4803,74804,2-Hydroxyethyl phenoxyacetate,C1=CC=C(C=C1)OCC(=O)OCCO,,,,,,
4804,74805,Octyl sulfoxide,CCCCCCCCS(=O)CCCCCCCC,,,,,,
4805,74806,Dipentyl sulfoxide,CCCCCS(=O)CCCCC,,,,,,
4806,74807,2-Naphthyl formate,C1=CC=C2C=C(C=CC2=C1)OC=O,,,,,,
4807,74808,2-(4-Chlorophenyl)propan-2-ol,CC(C)(C1=CC=C(C=C1)Cl)O,,,,,,
4808,74809,9H-Fluorene-9-carboxylic acid,C1=CC=C2C(=C1)C(C3=CC=CC=C32)C(=O)O,,,,,,
4809,74810,"2,6-Dimethoxybenzoyl chloride",COC1=C(C(=CC=C1)OC)C(=O)Cl,,,,,,
4810,74811,4-Amino-3-methylpyridine,CC1=C(C=CN=C1)N,,,,,,
4811,74812,"2,5-Di-tert-butyl-4-methoxyphenol",CC(C)(C)C1=CC(=C(C=C1OC)C(C)(C)C)O,,,,,,
4812,74813,Tetraisopropyl orthosilicate,CC(C)O[Si](OC(C)C)(OC(C)C)OC(C)C,,,,,,
4813,74814,2-Chloro-4-fluorophenol,C1=CC(=C(C=C1F)Cl)O,,,,,,
4814,74815,"1,1'-((1,1,2,2-Tetrafluoroethylene)bis(oxy))bis(1,2,2-trifluoroethylene)",C(=C(F)F)(OC(C(OC(=C(F)F)F)(F)F)(F)F)F,,,,,,
4815,74816,"alpha,alpha'-Dihydroxy-1,3-diisopropylbenzene",CC(C)(C1=CC(=CC=C1)C(C)(C)O)O,,,,,,
4816,74817,"1-[1,1'-Biphenyl]-4-yl-2-phenylethan-1-one",C1=CC=C(C=C1)CC(=O)C2=CC=C(C=C2)C3=CC=CC=C3,,,,,,
4817,74818,3-(2-Nitrophenyl)propanoic acid,C1=CC=C(C(=C1)CCC(=O)O)[N+](=O)[O-],,,,,,
4818,74819,2-Aminoethanol hydrochloride,C(CO)N.Cl,,,,,,
4819,74820,CID 74820,CC1=C2C(=NC=N2)N=CN1,,,,,,
4820,74821,Lithium trimethylsilanolate,[Li+].C[Si](C)(C)[O-],,,,,,
4821,74822,1-Heptacosanol,CCCCCCCCCCCCCCCCCCCCCCCCCCCO,,,,,,
4822,74823,4-Chlorobenzyl benzoate,C1=CC=C(C=C1)C(=O)OCC2=CC=C(C=C2)Cl,,,,,,
4823,74824,"6,6-Dimethoxy-2-methylhex-2-ene",CC(=CCCC(OC)OC)C,,,,,,
4824,74825,"2,2,2-Trichloro-2,2-dihydro-1,3,2-benzodioxaphosphole",C1=CC=C2C(=C1)OP(O2)(Cl)(Cl)Cl,,,,,,
4825,74826,1-(2-Chloroethyl)piperidine hydrochloride,C1CCN(CC1)CCCl.Cl,,,,,,
4826,74827,1-(2-Chloroethyl)piperidine,C1CCN(CC1)CCCl,,,,,,
4827,74828,6-Chloro-1-hexanol,C(CCCCl)CCO,,,,,,
4828,74829,"Benzenemethanol, 4-methyl-alpha,alpha-bis(trifluoromethyl)-",CC1=CC=C(C=C1)C(C(F)(F)F)(C(F)(F)F)O,,,,,,
4829,74830,2-Amino-2'-chloro-5-nitrobenzophenone,C1=CC=C(C(=C1)C(=O)C2=C(C=CC(=C2)[N+](=O)[O-])N)Cl,,,,,,
4830,74831,CID 74831,C1=CC=C(C=C1)C(=O)C2=C(C=CC(=C2)[N+](=O)[O-])NOCBr,,,,,,
4831,74832,"2,6-Dichlorobenzyl chloride",C1=CC(=C(C(=C1)Cl)CCl)Cl,,,,,,
4832,74833,N-[(4-sulfamoylphenyl)methyl]acetamide,CC(=O)NCC1=CC=C(C=C1)S(=O)(=O)N,,,,,,
4833,74834,5-Amino-2-chlorobenzenesulfonamide,C1=CC(=C(C=C1N)S(=O)(=O)N)Cl,,,,,,
4834,74835,Perphenazine dihydrochloride,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO.Cl.Cl,,,,,,
4835,74836,Diphenyl phosphoramidate,C1=CC=C(C=C1)OP(=O)(N)OC2=CC=CC=C2,,,,,,
4836,74837,"Methanamine, N,N-dimethyl-1,1-bis(phenylmethoxy)-",CN(C)C(OCC1=CC=CC=C1)OCC2=CC=CC=C2,,,,,,
4837,74838,"N,N-Dimethylformamide dicyclohexyl acetal",CN(C)C(OC1CCCCC1)OC2CCCCC2,,,,,,
4838,74839,N-Acetyl-L-phenylalanine,CC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O,,,,,,
4839,74840,N-Benzyloxycarbonyl-L-leucine,CC(C)C[C@@H](C(=O)O)NC(=O)OCC1=CC=CC=C1,,,,,,
4840,74841,"Benz(a)anthracene, 7,12-dimethyl-11-fluoro-",CC1=C2C=CC=C(C2=C(C3=C1C=CC4=CC=CC=C43)C)F,,,,,,
4841,74842,"3,4-Dimethoxybenzonitrile",COC1=C(C=C(C=C1)C#N)OC,,,,,,
4842,74843,Bisphenol A bis(chloroformate),CC(C)(C1=CC=C(C=C1)OC(=O)Cl)C2=CC=C(C=C2)OC(=O)Cl,,,,,,
4843,74844,"Pyridine, 5-ethyl-2-methyl-, hydrochloride",CCC1=CN=C(C=C1)C.Cl,,,,,,
4844,74845,Benzylidenecyanoacetic acid ethyl ester,CCOC(=O)C(=CC1=CC=CC=C1)C#N,,,,,,
4845,74846,"1,8-Naphthalenedimethanol",C1=CC2=C(C(=C1)CO)C(=CC=C2)CO,,,,,,
4846,74847,"3,4-Diethoxybenzaldehyde",CCOC1=C(C=C(C=C1)C=O)OCC,,,,,,
4847,74848,Diethoxy-methyl-silane,CCO[SiH](C)OCC,,,,,,
4848,74849,Hexaethylcyclotrisiloxane,CC[Si]1(O[Si](O[Si](O1)(CC)CC)(CC)CC)CC,,,,,,
4849,74850,"Benzenemethanamine, N-propyl-",CCCNCC1=CC=CC=C1,,,,,,
4850,74851,"3,3-Diethoxypropanenitrile",CCOC(CC#N)OCC,,,,,,
4851,74852,Bromoacetaldehyde diethyl acetal,CCOC(CBr)OCC,,,,,,
4852,74853,"5,6-Dimethyl-1H-benzo[d]imidazol-2(3H)-one",CC1=CC2=C(C=C1C)NC(=O)N2,,,,,,
4853,74854,1-(2-Bromoethoxy)-4-chlorobenzene,C1=CC(=CC=C1OCCBr)Cl,,,,,,
4854,74855,Palladium(II) cyanide,[C-]#N.[C-]#N.[Pd+2],,,,,,
4855,74856,4-Benzoyl-3-hydroxyphenyl methacrylate,CC(=C)C(=O)OC1=CC(=C(C=C1)C(=O)C2=CC=CC=C2)O,,,,,,
4856,74857,Dimethylmethylenehydrazine,CN(C)N=C,,,,,,
4857,74858,6-Cyanopurine,C1=NC2=NC=NC(=C2N1)C#N,,,,,,
4858,74859,5-Methylpyrimidine,CC1=CN=CN=C1,,,,,,
4859,74860,Dicyclohexyl diperoxycarbonate,C1CCC(CC1)OOC(=O)OOC2CCCCC2,,,,,,
4860,74861,Toluene-D8,[2H]C1=C(C(=C(C(=C1[2H])[2H])C([2H])([2H])[2H])[2H])[2H],,,,,,
4861,74862,CID 74862,C(=C(N=O)Cl)(NO)Cl,,,,,,
4862,74863,CID 74863,C1=CC=C(C=C1)C=CS(=O)(=O)[O-].[Na+],,,,,,
4863,74864,2-Phenylethenesulfonic acid,C1=CC=C(C=C1)C=CS(=O)(=O)O,,,,,,
4864,74865,2-(2-Aminoethyl)phenol,C1=CC=C(C(=C1)CCN)O,,,,,,
4865,74866,3-Methoxyphenethylamine,COC1=CC=CC(=C1)CCN,,,,,,
4866,74867,3-Acetylphenanthrene,CC(=O)C1=CC2=C(C=CC3=CC=CC=C32)C=C1,,,,,,
4867,74868,9-Acetylphenanthrene,CC(=O)C1=CC2=CC=CC=C2C3=CC=CC=C31,,,,,,
4868,74869,"3,4-Dichlorostyrene",C=CC1=CC(=C(C=C1)Cl)Cl,,,,,,
4869,74870,3-Bromostyrene,C=CC1=CC(=CC=C1)Br,,,,,,
4870,74871,"Benzene, (1-methylenepropyl)-",CCC(=C)C1=CC=CC=C1,,,,,,
4871,74872,CID 74872,C[Si](C)(C)CCCS(=O)(=O)[O-].[Na+],,,,,,
4872,74873,3-(Trimethylsilyl)propane-1-sulfonic acid,C[Si](C)(C)CCCS(=O)(=O)O,,,,,,
4873,74874,"Aluminum, diethyliodo-",CC[Al](CC)I,,,,,,
4874,74875,Iodoalumane,[AlH2]I,,,,,,
4875,74876,1-(Pentamethylphenyl)ethan-1-one,CC1=C(C(=C(C(=C1C)C)C(=O)C)C)C,,,,,,
4876,74877,"1-(2,6-Dichlorophenyl)ethanone",CC(=O)C1=C(C=CC=C1Cl)Cl,,,,,,
4877,74878,"2',4',5'-Trimethylacetophenone",CC1=CC(=C(C=C1C)C(=O)C)C,,,,,,
4878,74879,"4'-tert-Butyl-2',6'-dimethylacetophenone",CC1=CC(=CC(=C1C(=O)C)C)C(C)(C)C,,,,,,
4879,74880,Thorium oxalate,C(=O)(C(=O)O)O.C(=O)(C(=O)O)O.[Th],,,,,,
4880,74881,Lauryl myristate,CCCCCCCCCCCCCC(=O)OCCCCCCCCCCCC,,,,,,
4881,74882,1-Methyl-5-thioxopyrrolidin-2-one,CN1C(=O)CCC1=S,,,,,,
4882,74883,"1-Hexanol, 3,3,4,4,5,5,6,6,6-nonafluoro-",C(CO)C(C(C(C(F)(F)F)(F)F)(F)F)(F)F,,,,,,
4883,74884,"1,1,1,2,2,3,3,4,4,5,5,6,6,7,7-Pentadecafluoro-9-iodononane",C(CI)C(C(C(C(C(C(C(F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F,,,,,,
4884,74885,"1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8-Heptadecafluoro-10-iododecane",C(CI)C(C(C(C(C(C(C(C(F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F,,,,,,
4885,74886,"1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10-Henicosafluoro-12-iodododecane",C(CI)C(C(C(C(C(C(C(C(C(C(F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F,,,,,,
4886,74887,"1,1,1,2,2,3,3,4,4-Nonafluoro-6-iodohexane",C(CI)C(C(C(C(F)(F)F)(F)F)(F)F)(F)F,,,,,,
4887,74888,"1,1,1,2,2,3,3,4,4,5,5,6,6-Tridecafluoro-8-iodooctane",C(CI)C(C(C(C(C(C(F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F,,,,,,
4888,74889,CID 74889,[Li+].CCCCCCCCCCCCOS(=O)(=O)[O-],,,,,,
4889,74890,"2',5'-Dichloroacetoacetanilide",CC(=O)CC(=O)NC1=C(C=CC(=C1)Cl)Cl,,,,,,
4890,74891,"N-Methyl-2,4-dinitroaniline",CNC1=C(C=C(C=C1)[N+](=O)[O-])[N+](=O)[O-],,,,,,
4891,74892,"Sulfanilamide, N(sup 4)-(2-iodoethyl)-N(sup 4)-(2-iodopropyl)-",C1=CC(=CC=C1N(CCCI)CCI)S(=O)(=O)N,,,,,,
4892,74893,4-[Bis(2-chloroethyl)amino]benzenesulfonamide,C1=CC(=CC=C1N(CCCl)CCCl)S(=O)(=O)N,,,,,,
4893,74894,4-[Bis(2-chloroethyl)amino]benzamide,C1=CC(=CC=C1C(=O)N)N(CCCl)CCCl,,,,,,
4894,74895,"2-Amino-3,5-dinitrothiophene",C1=C(SC(=C1[N+](=O)[O-])N)[N+](=O)[O-],,,,,,
4895,74896,2-Methoxyphenethylamine,COC1=CC=CC=C1CCN,,,,,,
4896,74897,4-Phenylbutyronitrile,C1=CC=C(C=C1)CCCC#N,,,,,,
4897,74898,"2-Pentenedioic acid, diethyl ester",CCOC(=O)CC=CC(=O)OCC,,,,,,
4898,74899,"1,3-Diethoxybenzene",CCOC1=CC(=CC=C1)OCC,,,,,,
4899,74900,Diethyl allylmalonate,CCOC(=O)C(CC=C)C(=O)OCC,,,,,,
4900,74901,3-Methylbutyl pentanoate,CCCCC(=O)OCCC(C)C,,,,,,
4901,74902,"2,2'-Dihydroxyazobenzene",C1=CC=C(C(=C1)N=NC2=CC=CC=C2O)O,,,,,,
4902,74903,"N-(3,5-Dimethylphenyl)acetamide",CC1=CC(=CC(=C1)NC(=O)C)C,,,,,,
4903,74904,"1,2-Diethoxybenzene",CCOC1=CC=CC=C1OCC,,,,,,
4904,74905,"1-Propanol, 3-(dibutylamino)-",CCCCN(CCCC)CCCO,,,,,,
4905,74906,Dibutylcyanamide,CCCCN(CCCC)C#N,,,,,,
4906,74907,"Disulfide, bis(4-chloro-2-nitrophenyl)",C1=CC(=C(C=C1Cl)[N+](=O)[O-])SSC2=C(C=C(C=C2)Cl)[N+](=O)[O-],,,,,,
4907,74908,"1,6-Dichloronaphthalene",C1=CC2=C(C=CC(=C2)Cl)C(=C1)Cl,,,,,,
4908,74909,Decyl nitrate,CCCCCCCCCCO[N+](=O)[O-],,,,,,
4909,74910,"3-Heptene, 3,5,5-trimethyl-",CCC(=CC(C)(C)CC)C,,,,,,
4910,74911,"N,N'-(1,2-Phenylene)diacetamide",CC(=O)NC1=CC=CC=C1NC(=O)C,,,,,,
4911,74912,"[1,1'-Biphenyl]-3,3'-diamine",C1=CC(=CC(=C1)N)C2=CC(=CC=C2)N,,,,,,
4912,74913,Diisopentyl carbonate,CC(C)CCOC(=O)OCCC(C)C,,,,,,
4913,74914,Diisopentyl oxalate,CC(C)CCOC(=O)C(=O)OCCC(C)C,,,,,,
4914,74915,Diisoamyl disulfide,CC(C)CCSSCCC(C)C,,,,,,
4915,74916,4-Isopropylbenzyl chloride,CC(C)C1=CC=C(C=C1)CCl,,,,,,
4916,74917,3-Ethyloctan-3-ol,CCCCCC(CC)(CC)O,,,,,,
4917,74918,Hexanoic anhydride,CCCCCC(=O)OC(=O)CCCCC,,,,,,
4918,74919,Acrylic anhydride,C=CC(=O)OC(=O)C=C,,,,,,
4919,74920,"N5,N5-Diethyltoluene-2,5-diamine monohydrochloride",CC[NH+](CC)C1=CC(=C(C=C1)N)C.[Cl-],,,,,,
4920,74921,"Acetamide, N-(4-aminophenyl)-N-ethyl-",CCN(C1=CC=C(C=C1)N)C(=O)C,,,,,,
4921,74922,1-Benzylpyrrole,C1=CC=C(C=C1)CN2C=CC=C2,,,,,,
4922,74923,5-Bromoacenaphthene,C1CC2=CC=C(C3=CC=CC1=C23)Br,,,,,,
4923,74924,2-Bromo-2-methylpropanoic acid,CC(C)(C(=O)O)Br,,,,,,
4924,74925,Papaverine sulfate,COC1=C(C=C(C=C1)CC2=NC=CC3=CC(=C(C=C32)OC)OC)OC.OS(=O)(=O)O,,,,,,
4925,74926,"1,2-Ethanediyl dimethyl phthalate",COC(=O)C1=CC=CC=C1C(=O)OCCOC(=O)C2=CC=CC=C2C(=O)OC,,,,,,
4926,74927,"Pyridine, 3-((diethylamino)methyl)-",CCN(CC)CC1=CN=CC=C1,,,,,,
4927,74928,4-Isopropyl styrene,CC(C)C1=CC=C(C=C1)C=C,,,,,,
4928,74929,"Trimethylenediamine, N,N'-bis(o-chlorobenzyl)-, dihydrochloride",C1=CC=C(C(=C1)CNCCCNCC2=CC=CC=C2Cl)Cl.Cl.Cl,,,,,,
4929,74930,"N,N'-Bis(o-chlorobenzyl)-1,3-propanediamine",C1=CC=C(C(=C1)CNCCCNCC2=CC=CC=C2Cl)Cl,,,,,,
4930,74931,"Tetramethylenediamine, N,N'-bis(o-chlorobenzyl)-, dihydrochloride",C1=CC=C(C(=C1)CNCCCCNCC2=CC=CC=C2Cl)Cl.Cl.Cl,,,,,,
4931,74932,"N,N'-bis[(2-chlorophenyl)methyl]butane-1,4-diamine",C1=CC=C(C(=C1)CNCCCCNCC2=CC=CC=C2Cl)Cl,,,,,,
4932,74933,"Pyridine, 4-[1-(2-butenyl)-3-pentenyl]-",CC=CCC(CC=CC)C1=CC=NC=C1,,,,,,
4933,74934,2-[1-(2-Butenyl)-3-pentenyl]pyridine,CC=CCC(CC=CC)C1=CC=CC=N1,,,,,,
4934,74935,2-Pent-3-enylpyridine,CC=CCCC1=CC=CC=N1,,,,,,
4935,74936,4-[3-Phenyl-1-(2-phenylethyl)propyl]pyridine,C1=CC=C(C=C1)CCC(CCC2=CC=CC=C2)C3=CC=NC=C3,,,,,,
4936,74937,4-(3-Phenylpropyl)pyridine,C1=CC=C(C=C1)CCCC2=CC=NC=C2,,,,,,
4937,74938,4-Iodophenyl isothiocyanate,C1=CC(=CC=C1N=C=S)I,,,,,,
4938,74939,"2-Propenoic acid, 3-[2-(trifluoromethyl)phenyl]-",C1=CC=C(C(=C1)C=CC(=O)O)C(F)(F)F,,,,,,
4939,74940,3-[4-(Trifluoromethyl)phenyl]prop-2-enoic acid,C1=CC(=CC=C1C=CC(=O)O)C(F)(F)F,,,,,,
4940,74941,CID 74941,CN(C)CCC=C1C2=CC=CC=C2SC3=CC=CC(=C31)C(F)(F)F.Cl,,,,,,
4941,74942,CID 74942,CN(C)CCC=C1C2=CC=CC=C2SC3=CC=CC(=C31)C(F)(F)F,,,,,,
4942,74943,Dioctyl azelate,CCCCCCCCOC(=O)CCCCCCCC(=O)OCCCCCCCC,,,,,,
4943,74944,"2-Bromo-1,4-naphthoquinone",C1=CC=C2C(=C1)C(=O)C=C(C2=O)Br,,,,,,
4944,74945,2-Bromomalonaldehyde,C(=O)C(C=O)Br,,,,,,
4945,74946,Phenylenediamine mustard,C1=CC(=CC=C1N)N(CCCl)CCCl,,,,,,
4946,74947,"1,4-Dihydropyrido[2,3-b]pyrazine-2,3-dione",C1=CC2=C(NC(=O)C(=O)N2)N=C1,,,,,,
4947,74948,CID 74948,COC1=CC(=O)C2=C(C(=C(OC2=C1)C3=CC(=C(C=C3)O)O)OC)O,,,,,,
4948,74949,"Acetic acid, 2,2'-[methylenebis(thio)]bis-",C(C(=O)O)SCSCC(=O)O,,,,,,
4949,74950,CID 74950,C1=CC2=C(C=C1C(F)(F)F)N=C3C=CC(=[N+](O)[O-])C=C3S2,,,,,,
4950,74951,4-Bromo-4'-fluorobenzophenone,C1=CC(=CC=C1C(=O)C2=CC=C(C=C2)Br)F,,,,,,
4951,74952,Bis(diphenylphosphino)methane,C1=CC=C(C=C1)P(CP(C2=CC=CC=C2)C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
4952,74953,Methyl 3-methyl-2-benzofurancarboxylate,CC1=C(OC2=CC=CC=C12)C(=O)OC,,,,,,
4953,74954,"3,4-Dichlorocumene",CC(C)C1=CC(=C(C=C1)Cl)Cl,,,,,,
4954,74955,Trimethylsilyl benzoate,C[Si](C)(C)OC(=O)C1=CC=CC=C1,,,,,,
4955,74956,Tetrahydro-2H-pyran-4-ol,C1COCCC1O,,,,,,
4956,74957,Butanilicaine phosphate,CCCCNCC(=O)NC1=C(C=CC=C1Cl)C.OP(=O)(O)O,,,,,,
4957,74958,[1-(2-Bromo-4-chlorophenyl)-2-chloroethenoxy]-diethoxy-sulfanylidene-lambda5-phosphane,CCOP(=S)(OCC)OC(=CCl)C1=C(C=C(C=C1)Cl)Br,,,,,,
4958,74959,Valeric anhydride,CCCCC(=O)OC(=O)CCCC,,,,,,
4959,74960,Decanoic anhydride,CCCCCCCCCC(=O)OC(=O)CCCCCCCCC,,,,,,
4960,74961,Undecanoic anhydride,CCCCCCCCCCC(=O)OC(=O)CCCCCCCCCC,,,,,,
4961,74962,Trioctadecyl phosphate,CCCCCCCCCCCCCCCCCCOP(=O)(OCCCCCCCCCCCCCCCCCC)OCCCCCCCCCCCCCCCCCC,,,,,,
4962,74963,"Thiophene, 2,5-dihydro-3-(4-methyl-3-pentenyl)-, 1,1-dioxide",CC(=CCCC1=CCS(=O)(=O)C1)C,,,,,,
4963,74964,n-Octyltrimethylammonium bromide,CCCCCCCC[N+](C)(C)C.[Br-],,,,,,
4964,74965,"N,N-Dimethyltrimethylsilylamine",CN(C)[Si](C)(C)C,,,,,,
4965,74966,CID 74966,C1=CC2=C(C(=C1)O)N=CC=C2.C1=CC2=C(C(=C1)O)N=CC=C2.C1=CC2=C(C(=C1)O)N=CC=C2.[AlH3],,,,,,
4966,74967,O-(4-Nitrobenzyl)hydroxylamine hydrochloride,C1=CC(=CC=C1CON)[N+](=O)[O-].Cl,,,,,,
4967,74968,O-(4-nitrobenzyl)hydroxylamine,C1=CC(=CC=C1CON)[N+](=O)[O-],,,,,,
4968,74969,3-Methoxyphenoxyacetic acid,COC1=CC(=CC=C1)OCC(=O)O,,,,,,
4969,74970,"1,1-Dichlorocyclopropane",C1CC1(Cl)Cl,,,,,,
4970,74971,"1,2-Naphthalenedicarboxylic acid",C1=CC=C2C(=C1)C=CC(=C2C(=O)O)C(=O)O,,,,,,
4971,74972,"2,6-Bis(1-piperidylmethyl)-4-(alpha,alpha-dimethylbenzyl)phenol dihydrobromide",CC(C)(C1=CC=CC=C1)C2=CC(=C(C(=C2)CN3CCCCC3)O)CN4CCCCC4.Br.Br,,,,,,
4972,74973,"4-(2-Phenylpropan-2-yl)-2,6-bis(piperidin-1-ylmethyl)phenol",CC(C)(C1=CC=CC=C1)C2=CC(=C(C(=C2)CN3CCCCC3)O)CN4CCCCC4,,,,,,
4973,74974,"1,6-Naphthalenedicarboxylic acid",C1=CC2=C(C=CC(=C2)C(=O)O)C(=C1)C(=O)O,,,,,,
4974,74975,Phenolphthalein diphosphate,C1=CC=C2C(=C1)C(=O)OC2(C3=CC=C(C=C3)OP(=O)(O)O)C4=CC=C(C=C4)OP(=O)(O)O,,,,,,
4975,74976,2-(2-Hydroxyethoxy)ethyl acetate,CC(=O)OCCOCCO,,,,,,
4976,74977,"Propanoic acid, 2,2-dimethyl-, phenylmethyl ester",CC(C)(C)C(=O)OCC1=CC=CC=C1,,,,,,
4977,74978,"1,1'-Azobis(cyclohexanecarbonitrile)",C1CCC(CC1)(C#N)N=NC2(CCCCC2)C#N,,,,,,
4978,74979,"1,3-Benzenediamine, 4,6-diethyl-2-methyl-",CCC1=CC(=C(C(=C1N)C)N)CC,,,,,,
4979,74980,"1,3-Benzenediamine, 2,4-diethyl-6-methyl-",CCC1=C(C(=C(C(=C1)C)N)CC)N,,,,,,
4980,74981,Didemethylchlorpromazine,C1=CC=C2C(=C1)N(C3=C(S2)C=CC(=C3)Cl)CCCN,,,,,,
4981,74982,"5H-Dibenz(b,f)azepine, 5-(2-(diethylamino)ethyl)-10,11-dihydro-",CCN(CC)CCN1C2=CC=CC=C2CCC3=CC=CC=C31,,,,,,
4982,74983,"2,8,9-Trioxa-5-aza-1-silabicyclo[3.3.3]undecane, 1-ethyl-",CC[Si]12OCCN(CCO1)CCO2,,,,,,
4983,74984,1-Vinylsilatrane,C=C[Si]12OCCN(CCO1)CCO2,,,,,,
4984,74985,"Benzoic acid, 2-amino-, hydrochloride",C1=CC=C(C(=C1)C(=O)O)N.Cl,,,,,,
4985,74986,"2-[3-(Diethylamino)-6-diethylazaniumylidenexanthen-9-yl]-5-[2-[2,3-di(hexadecanoyloxy)propoxy-hydroxyphosphoryl]oxyethylsulfamoyl]benzenesulfonate",CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCCNS(=O)(=O)C1=CC(=C(C=C1)C2=C3C=CC(=[N+](CC)CC)C=C3OC4=C2C=CC(=C4)N(CC)CC)S(=O)(=O)[O-])OC(=O)CCCCCCCCCCCCCCC,,,,,,
4986,74987,"N-[2-[2,3-Di(hexadecanoyloxy)propoxy(oxylato)phosphinyloxy]ethyl]-4-[6-(diethylamino)-3-(diethyliminio)-3H-xanthen-9-yl]-3-sulfonatobenzenesulfonamide",CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCCNS(=O)(=O)C1=CC(=C(C=C1)C2=C3C=CC(=[N+](CC)CC)C=C3OC4=C2C=CC(=C4)N(CC)CC)S(=O)(=O)O)OC(=O)CCCCCCCCCCCCCCC,,,,,,
4987,74988,Hexachlorofulvene,C1(=C(C(=C(Cl)Cl)C(=C1Cl)Cl)Cl)Cl,,,,,,
4988,74989,Atovaquone,C1CC(CCC1C2=CC=C(C=C2)Cl)C3=C(C4=CC=CC=C4C(=O)C3=O)O,['For the treatment or prevention of <i>Pneumocystis carinii</i> pneumonia in patients who are intolerant to trimethoprim-sulfamethoxazole (TMP-SMX). Also indicated for the acute oral treatment of mild to moderate PCP in patients who are intolerant to TMP-SMX.'],"['Atovaquone is a highly lipophilic drug that closely resembles the structure [ubiquinone]. Its inhibitory effect being comparable to ubiquinone, atovaquone can act by selectively affecting mitochondrial electron transport and parallel processes such as ATP and pyrimidine biosynthesis in atovaquone-responsive parasites. Cytochrome bc1 complex (complex III) seems to serve as a highly discriminating molecular target for atovaquone in Plasmodia. There is no significant risk for myelosuppression associated with atovaquone, making this drug a beneficial therapeutic agent for recipients of bone marrow transplantation.']","['Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. (See all compounds classified as Anti-Infective Agents.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)', 'Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585) (See all compounds classified as Antimalarials.)']","['The bioavailability of atovaquone is low and variable and is highly dependent on formulation and diet. Bioavailability of the suspension increases two-fold when administered with meals. When administered with food, bioavailability is approximately 47%. Without food, the bioavailability is 23%.', 'The half-life of atovaquone is long due to presumed enterohepatic cycling and eventual fecal elimination. There was little or no excretion of atovaquone in the urine (less than 0.6%).', '0.60 ± 0.17 L/kg', '10.4 +/- 5.5 ml/min [HIV-infected patients receiving IV administration]', 'Drug absorption after a single oral dose is slow, erratic and variable; increased by 2- to 3-fold by fatty food; and dose-limited above 750 mg. More than 99% of the drug is bound to plasma protein, so its concentration in cerebrospinal fluid is less than 1% of that in plasma.', 'The bioavailability of atovaquone is low and variable, and decreases significantly with single doses greater than 750 mg. A standard breakfast containing 23 g of fat has been shown to enhance absorption significantly. Oral suspension: The oral suspension provides a two-fold increase in bioavailability in fasting or fed conditions compared to the tablets. Bioavailability of the suspension increases two-fold when administered with meals; when administered with food, bioavailability is approximately 47%. Tablets: Bioavailability increases three-fold when administered with meals; bioavailability of the tablets when administered with food is approximately 23%.', 'Fecal; > 94% of atovaquone was recovered in the feces over 21 days; < 0.6% was excreted in the urine.', 'Bioavailability is increased with meals. Time to peak blood level is 1 to 8 hours, with a second peak in 24 to 96 hours.', 'For more Absorption, Distribution and Excretion (Complete) data for ATOVAQUONE (8 total), please visit the HSDB record page.']","['Some evidence suggests limited metabolism (although no metabolites have been identified).', 'Atovaquone is not significantly metabolized by human beings. It is excreted in bile and more than 94% of the drug is recovered unchanged in feces; only traces appear in the urine.', 'Atovaquone is an antiprotozoal compound with good in vitro stability against metabolic inactivation. Previous human studies which did not involve radiolabelling had not accounted for a substantial proportion of the dose. The possible metabolism of atovaquone in men was examined in a radiolabelling study involving four healthy male volunteers. Radioactivity was eliminated almost exclusively via the feces. All radioactivity in plasma, urine, and feces was accounted for by atovaquone, with no evidence of metabolites. Radiolabelled atovaquone was administered to a patient with an indwelling biliary tube after surgery. Biliary radioactivity was approximately 10- to 40-fold higher than that in plasma and was accounted for by atovaquone. Atovaquone is not significantly metabolized in humans but is excreted into bile against a high concentration gradient.']","['2.2 to 3.2 days', 'Atovaquone has a half-life averaging 1.5 to 3 days', '2.2 to 3.2 days in adult patients with acquired immunodeficiency syndrome (AIDS), adult healthy volunteers, and immunocompromised children (ages 5 months to 13 years).']"
4989,74990,Irinotecan hydrochloride,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl,,,['Compounds that inhibit the activity of DNA TOPOISOMERASE I. (See all compounds classified as Topoisomerase I Inhibitors.)'],,,
4990,74991,CID 74991,CCN(CC)C1=CC2=C(C=C1)C(=C3C=CC(=[N+](CC)CC)C=C3O2)C4=C(C=CC(=C4)C(=O)[O-])C(=O)O.[Na+],,,,,,
4991,74992,"9-(2,5-Dicarboxyphenyl)-3,6-bis(diethylamino)xanthylium",CCN(CC)C1=CC2=C(C=C1)C(=C3C=CC(=[N+](CC)CC)C=C3O2)C4=C(C=CC(=C4)C(=O)O)C(=O)O,,,,,,
4992,74993,"Xanthylium, 9-(2,5-dicarboxyphenyl)-3,6-bis(diethylamino)-, inner salt",CCN(CC)C1=CC2=C(C=C1)C(=C3C=CC(=[N+](CC)CC)C=C3O2)C4=C(C=CC(=C4)C(=O)[O-])C(=O)O,,,,,,
4993,74994,"3,6-Diaminoxanthylium",C1=CC(=[NH2+])C=C2C1=CC3=C(O2)C=C(C=C3)N,,,,,,
4994,74995,"3H-Xanthen-6-amine, 3-imino-",C1=CC(=N)C=C2C1=CC3=C(O2)C=C(C=C3)N,,,,,,
4995,74996,"Bis(9-(o-carboxyphenyl)-3,6-bis(diethylamino)xanthylium) dicopper(1+) hexa(cyano-C)ferrate(4-)",CCN(CC)C1=CC2=C(C=C1)C(=C3C=CC(=[N+](CC)CC)C=C3O2)C4=CC=CC=C4C(=O)O.CCN(CC)C1=CC2=C(C=C1)C(=C3C=CC(=[N+](CC)CC)C=C3O2)C4=CC=CC=C4C(=O)O.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[Fe+2].[Cu+].[Cu+],,,,,,
4996,74997,Tmria,CN(C)C1=CC(=C2C(=C1)OC3=CC(=[N+](C)C)C=CC3=C2C4=CC=CC=C4C(=O)O)NC(=O)CI.[Cl-],,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']",,,
4997,74998,[9-(2-Carboxyphenyl)-6-(dimethylamino)-8-[(2-iodoacetyl)amino]xanthen-3-ylidene]-dimethylazanium,CN(C)C1=CC(=C2C(=C1)OC3=CC(=[N+](C)C)C=CC3=C2C4=CC=CC=C4C(=O)O)NC(=O)CI,,,,,,
4998,74999,Tetrabromorhodamine 123,COC(=O)C1=CC=CC=C1C2=C3C=C(C(=[NH2+])C(=C3OC4=C(C(=C(C=C24)Br)N)Br)Br)Br.[Cl-],,,,,,
4999,75000,"Methyl 2-(3-amino-2,4,5,7-tetrabromo-6-iminoxanthen-9-yl)benzoate",COC(=O)C1=CC=CC=C1C2=C3C=C(C(=N)C(=C3OC4=C(C(=C(C=C24)Br)N)Br)Br)Br,,,,,,
